IL-2	B-DNA
gene	I-DNA
expression	O
and	O
NF-kappa	B-protein
B	I-protein
activation	O
through	O
CD28	B-protein
requires	O
reactive	O
oxygen	O
production	O
by	O
5-lipoxygenase	B-protein
.	O

Activation	O
of	O
the	O
CD28	B-protein
surface	I-protein
receptor	I-protein
provides	O
a	O
major	O
costimulatory	O
signal	O
for	O
T	O
cell	O
activation	O
resulting	O
in	O
enhanced	O
production	O
of	O
interleukin-2	B-protein
(	O
IL-2	B-protein
)	O
and	O
cell	O
proliferation	O
.	O

In	O
primary	B-cell_type
T	I-cell_type
lymphocytes	I-cell_type
we	O
show	O
that	O
CD28	B-protein
ligation	O
leads	O
to	O
the	O
rapid	O
intracellular	O
formation	O
of	O
reactive	O
oxygen	O
intermediates	O
(	O
ROIs	O
)	O
which	O
are	O
required	O
for	O
CD28	B-protein
-mediated	O
activation	O
of	O
the	O
NF-kappa	B-protein
B	I-protein
/	O
CD28-responsive	B-protein
complex	I-protein
and	O
IL-2	B-protein
expression	O
.	O

Delineation	O
of	O
the	O
CD28	B-protein
signaling	O
cascade	O
was	O
found	O
to	O
involve	O
protein	B-protein
tyrosine	I-protein
kinase	I-protein
activity	O
,	O
followed	O
by	O
the	O
activation	O
of	O
phospholipase	B-protein
A2	I-protein
and	O
5-lipoxygenase	B-protein
.	O

Our	O
data	O
suggest	O
that	O
lipoxygenase	B-protein
metabolites	I-protein
activate	O
ROI	O
formation	O
which	O
then	O
induce	O
IL-2	B-protein
expression	O
via	O
NF-kappa	B-protein
B	I-protein
activation	O
.	O

These	O
findings	O
should	O
be	O
useful	O
for	O
therapeutic	O
strategies	O
and	O
the	O
development	O
of	O
immunosuppressants	O
targeting	O
the	O
CD28	B-protein
costimulatory	O
pathway	O
.	O

The	O
peri-kappa	B-DNA
B	I-DNA
site	I-DNA
mediates	O
human	B-DNA
immunodeficiency	I-DNA
virus	I-DNA
type	I-DNA
2	I-DNA
enhancer	I-DNA
activation	O
in	O
monocytes	B-cell_type
but	O
not	O
in	O
T	B-cell_type
cells	I-cell_type
.	O

Human	O
immunodeficiency	O
virus	O
type	O
2	O
(	O
HIV-2	O
)	O
,	O
like	O
HIV-1	O
,	O
causes	O
AIDS	O
and	O
is	O
associated	O
with	O
AIDS	O
cases	O
primarily	O
in	O
West	O
Africa	O
.	O

HIV-1	O
and	O
HIV-2	O
display	O
significant	O
differences	O
in	O
nucleic	O
acid	O
sequence	O
and	O
in	O
the	O
natural	O
history	O
of	O
clinical	O
disease	O
.	O

Consistent	O
with	O
these	O
differences	O
,	O
we	O
have	O
previously	O
demonstrated	O
that	O
the	O
enhancer/promoter	B-DNA
region	I-DNA
of	O
HIV-2	O
functions	O
quite	O
differently	O
from	O
that	O
of	O
HIV-1	O
.	O

Whereas	O
activation	O
of	O
the	O
HIV-1	B-DNA
enhancer	I-DNA
following	O
T-cell	O
stimulation	O
is	O
mediated	O
largely	O
through	O
binding	O
of	O
the	O
transcription	B-protein
factor	I-protein
NF-kappa	B-protein
B	I-protein
to	O
two	O
adjacent	O
kappa	B-DNA
B	I-DNA
sites	I-DNA
in	O
the	O
HIV-1	B-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
,	O
activation	O
of	O
the	O
HIV-2	B-DNA
enhancer	I-DNA
in	O
monocytes	B-cell_type
and	O
T	B-cell_type
cells	I-cell_type
is	O
dependent	O
on	O
four	O
cis-acting	B-DNA
elements	I-DNA
:	O
a	O
single	O
kappa	B-DNA
B	I-DNA
site	I-DNA
,	O
two	O
purine-rich	B-DNA
binding	I-DNA
sites	I-DNA
,	O
PuB1	B-DNA
and	O
PuB2	B-DNA
,	O
and	O
a	O
pets	B-DNA
site	I-DNA
.	O

We	O
have	O
now	O
identified	O
a	O
novel	O
cis-acting	B-DNA
element	I-DNA
within	O
the	O
HIV-2	B-DNA
enhancer	I-DNA
,	O
immediately	O
upstream	O
of	O
the	O
kappa	B-DNA
B	I-DNA
site	I-DNA
,	O
designated	O
peri-kappa	B-DNA
B	I-DNA
.	O

This	O
site	O
is	O
conserved	O
among	O
isolates	O
of	O
HIV-2	O
and	O
the	O
closely	O
related	O
simian	O
immunodeficiency	O
virus	O
,	O
and	O
transfection	O
assays	O
show	O
this	O
site	O
to	O
mediate	O
HIV-2	B-DNA
enhancer	I-DNA
activation	O
following	O
stimulation	O
of	O
monocytic	B-cell_line
but	O
not	O
T-cell	B-cell_line
lines	I-cell_line
.	O

This	O
is	O
the	O
first	O
description	O
of	O
an	O
HIV-2	B-DNA
enhancer	I-DNA
element	I-DNA
which	O
displays	O
such	O
monocyte	O
specificity	O
,	O
and	O
no	O
comparable	O
enhancer	B-DNA
element	I-DNA
has	O
been	O
clearly	O
defined	O
for	O
HIV-1	O
.	O

While	O
a	O
nuclear	B-protein
factor	I-protein
(	O
s	O
)	O
from	O
both	O
peripheral	B-cell_type
blood	I-cell_type
monocytes	I-cell_type
and	O
T	B-cell_type
cells	I-cell_type
binds	O
the	O
peri-kappa	B-DNA
B	I-DNA
site	I-DNA
,	O
electrophoretic	O
mobility	O
shift	O
assays	O
suggest	O
that	O
either	O
a	O
different	O
protein	O
binds	O
to	O
this	O
site	O
in	O
monocytes	B-cell_type
versus	O
T	B-cell_type
cells	I-cell_type
or	O
that	O
the	O
protein	O
recognizing	O
this	O
enhancer	B-DNA
element	I-DNA
undergoes	O
differential	O
modification	O
in	O
monocytes	B-cell_type
and	O
T	B-cell_type
cells	I-cell_type
,	O
thus	O
supporting	O
the	O
transfection	O
data	O
.	O

Further	O
,	O
while	O
specific	O
constitutive	O
binding	O
to	O
the	O
peri-kappa	B-DNA
B	I-DNA
site	I-DNA
is	O
seen	O
in	O
monocytes	B-cell_type
,	O
stimulation	O
with	O
phorbol	O
esters	O
induces	O
additional	O
,	O
specific	O
binding	O
.	O

Understanding	O
the	O
monocyte-specific	O
function	O
of	O
the	O
peri-kappa	B-protein
B	I-protein
factor	I-protein
may	O
ultimately	O
provide	O
insight	O
into	O
the	O
different	O
role	O
monocytes	B-cell_type
and	O
T	B-cell_type
cells	I-cell_type
play	O
in	O
HIV	O
pathogenesis	O
.	O

E1A	B-DNA
gene	I-DNA
expression	O
induces	O
susceptibility	O
to	O
killing	O
by	O
NK	B-cell_type
cells	I-cell_type
following	O
immortalization	O
but	O
not	O
adenovirus	O
infection	O
of	O
human	B-cell_type
cells	I-cell_type
.	O

Adenovirus	O
(	O
Ad	O
)	O
infection	O
and	O
E1A	B-protein
transfection	O
were	O
used	O
to	O
model	O
changes	O
in	O
susceptibility	O
to	O
NK	O
cell	O
killing	O
caused	O
by	O
transient	O
vs	O
stable	O
E1A	B-protein
expression	O
in	O
human	B-cell_type
cells	I-cell_type
.	O

Only	O
stably	O
transfected	B-cell_line
target	I-cell_line
cells	I-cell_line
exhibited	O
cytolytic	O
susceptibility	O
,	O
despite	O
expression	O
of	O
equivalent	O
levels	O
of	O
E1A	B-protein
proteins	I-protein
in	O
Ad-infected	B-cell_line
targets	I-cell_line
.	O

The	O
inability	O
of	O
E1A	B-DNA
gene	I-DNA
products	O
to	O
induce	O
cytolytic	O
susceptibility	O
during	O
infection	O
was	O
not	O
explained	O
by	O
an	O
inhibitory	O
effect	O
of	O
viral	O
infection	O
on	O
otherwise	O
susceptible	O
target	B-cell_type
cells	I-cell_type
or	O
by	O
viral	B-DNA
gene	I-DNA
effects	O
on	O
class	B-protein
I	I-protein
MHC	I-protein
antigen	I-protein
expression	O
on	O
target	B-cell_type
cells	I-cell_type
.	O

This	O
differential	O
effect	O
of	O
E1A	B-protein
expression	O
on	O
the	O
cytolytic	O
phenotypes	O
of	O
infected	O
and	O
stably	O
transfected	O
human	B-cell_type
cells	I-cell_type
suggests	O
that	O
human	B-cell_type
NK	I-cell_type
cells	I-cell_type
provide	O
an	O
effective	O
immunologic	O
barrier	O
against	O
the	O
in	O
vivo	O
survival	O
and	O
neoplastic	O
progression	O
of	O
E1A-immortalized	B-cell_line
cells	I-cell_line
that	O
may	O
emerge	O
from	O
the	O
reservoir	O
of	O
persistently	B-cell_type
infected	I-cell_type
cells	I-cell_type
in	O
the	O
human	O
host	O
.	O

Distinct	O
signaling	O
properties	O
identify	O
functionally	O
different	O
CD4	B-protein
epitopes	I-protein
.	O

The	O
CD4	B-protein
coreceptor	I-protein
interacts	O
with	O
non-polymorphic	B-protein
regions	I-protein
of	O
major	B-protein
histocompatibility	I-protein
complex	I-protein
class	I-protein
II	I-protein
molecules	I-protein
on	O
antigen-presenting	B-cell_type
cells	I-cell_type
and	O
contributes	O
to	O
T	O
cell	O
activation	O
.	O

We	O
have	O
investigated	O
the	O
effect	O
of	O
CD4	B-protein
triggering	O
on	O
T	O
cell	O
activating	O
signals	O
in	O
a	O
lymphoma	O
model	O
using	O
monoclonal	B-protein
antibodies	I-protein
(	O
mAb	B-protein
)	O
which	O
recognize	O
different	O
CD4	B-protein
epitopes	I-protein
.	O

We	O
demonstrate	O
that	O
CD4	B-protein
triggering	O
delivers	O
signals	O
capable	O
of	O
activating	O
the	O
NF-AT	B-protein
transcription	I-protein
factor	I-protein
which	O
is	O
required	O
for	O
interleukin-2	B-protein
gene	O
expression	O
.	O

Whereas	O
different	O
anti-CD4	B-protein
mAb	I-protein
or	O
HIV-1	B-protein
gp120	I-protein
could	O
all	O
trigger	O
activation	O
of	O
the	O
protein	B-protein
tyrosine	I-protein
kinases	I-protein
p56lck	B-protein
and	O
p59fyn	B-protein
and	O
phosphorylation	O
of	O
the	O
Shc	B-protein
adaptor	I-protein
protein	I-protein
,	O
which	O
mediates	O
signals	O
to	O
Ras	B-protein
,	O
they	O
differed	O
significantly	O
in	O
their	O
ability	O
to	O
activate	O
NF-AT	B-protein
.	O

Lack	O
of	O
full	O
activation	O
of	O
NF-AT	B-protein
could	O
be	O
correlated	O
to	O
a	O
dramatically	O
reduced	O
capacity	O
to	O
induce	O
calcium	O
flux	O
and	O
could	O
be	O
complemented	O
with	O
a	O
calcium	O
ionophore	O
.	O

The	O
results	O
identify	O
functionally	O
distinct	O
epitopes	B-protein
on	O
the	O
CD4	B-protein
coreceptor	I-protein
involved	O
in	O
activation	O
of	O
the	O
Ras/protein	B-protein
kinase	I-protein
C	I-protein
and	O
calcium	O
pathways	O
.	O

Ligand-dependent	O
repression	O
of	O
the	O
erythroid	B-protein
transcription	I-protein
factor	I-protein
GATA-1	B-protein
by	O
the	O
estrogen	B-protein
receptor	I-protein
.	O

High-dose	O
estrogen	O
administration	O
induces	O
anemia	O
in	O
mammals	O
.	O

In	O
chickens	O
,	O
estrogens	O
stimulate	O
outgrowth	O
of	O
bone	B-cell_type
marrow-derived	I-cell_type
erythroid	I-cell_type
progenitor	I-cell_type
cells	I-cell_type
and	O
delay	O
their	O
maturation	O
.	O

This	O
delay	O
is	O
associated	O
with	O
down-regulation	O
of	O
many	O
erythroid	B-DNA
cell-specific	I-DNA
genes	I-DNA
,	O
including	O
alpha-	B-DNA
and	I-DNA
beta-globin	I-DNA
,	O
band	O
3	O
,	O
band	O
4.1	O
,	O
and	O
the	O
erythroid	B-protein
cell-specific	I-protein
histone	I-protein
H5	B-protein
.	O

We	O
show	O
here	O
that	O
estrogens	O
also	O
reduce	O
the	O
number	O
of	O
erythroid	B-cell_type
progenitor	I-cell_type
cells	I-cell_type
in	O
primary	B-cell_line
human	I-cell_line
bone	I-cell_line
marrow	I-cell_line
cultures	I-cell_line
.	O

To	O
address	O
potential	O
mechanisms	O
by	O
which	O
estrogens	O
suppress	O
erythropoiesis	O
,	O
we	O
have	O
examined	O
their	O
effects	O
on	O
GATA-1	B-protein
,	O
an	O
erythroid	B-protein
transcription	I-protein
factor	I-protein
that	O
participates	O
in	O
the	O
regulation	O
of	O
the	O
majority	O
of	O
erythroid	B-DNA
cell-specific	I-DNA
genes	I-DNA
and	O
is	O
necessary	O
for	O
full	O
maturation	O
of	O
erythrocytes	B-cell_type
.	O

We	O
demonstrate	O
that	O
the	O
transcriptional	O
activity	O
of	O
GATA-1	B-protein
is	O
strongly	O
repressed	O
by	O
the	O
estrogen	B-protein
receptor	I-protein
(	O
ER	B-protein
)	O
in	O
a	O
ligand-dependent	O
manner	O
and	O
that	O
this	O
repression	O
is	O
reversible	O
in	O
the	O
presence	O
of	O
4-hydroxytamoxifen	O
.	O

ER	B-protein
-mediated	O
repression	O
of	O
GATA-1	B-protein
activity	O
occurs	O
on	O
an	O
artificial	B-DNA
promoter	I-DNA
containing	O
a	O
single	O
GATA-binding	B-DNA
site	I-DNA
,	O
as	O
well	O
as	O
in	O
the	O
context	O
of	O
an	O
intact	B-DNA
promoter	I-DNA
which	O
is	O
normally	O
regulated	O
by	O
GATA-1	B-protein
.	O

GATA-1	B-protein
and	O
ER	B-protein
bind	O
to	O
each	O
other	O
in	O
vitro	O
in	O
the	O
absence	O
of	O
DNA	O
.	O

In	O
coimmunoprecipitation	O
experiments	O
using	O
transfected	O
COS	B-cell_line
cells	I-cell_line
,	O
GATA-1	B-protein
and	O
ER	B-protein
associate	O
in	O
a	O
ligand-dependent	O
manner	O
.	O

Mapping	O
experiments	O
indicate	O
that	O
GATA-1	B-protein
and	O
the	O
ER	B-protein
form	O
at	O
least	O
two	O
contacts	O
,	O
which	O
involve	O
the	O
finger	O
region	O
and	O
the	O
N-terminal	B-protein
activation	I-protein
domain	I-protein
of	O
GATA-1	B-protein
.	O

We	O
speculate	O
that	O
estrogens	O
exert	O
effects	O
on	O
erythropoiesis	O
by	O
modulating	O
GATA-1	B-protein
activity	O
through	O
protein-protein	O
interaction	O
with	O
the	O
ER	B-protein
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Mouse	B-DNA
interleukin-2	I-DNA
receptor	I-DNA
alpha	I-DNA
gene	I-DNA
expression	O
.	O

Interleukin-1	B-protein
and	O
interleukin-2	B-protein
control	O
transcription	O
via	O
distinct	O
cis-acting	B-DNA
elements	I-DNA
.	O

We	O
have	O
shown	O
that	O
interleukin-1	B-protein
(	O
IL-1	B-protein
)	O
and	O
IL-2	B-protein
control	O
IL-2	B-DNA
receptor	I-DNA
alpha	I-DNA
(	I-DNA
IL-2R	I-DNA
alpha	I-DNA
)	I-DNA
gene	I-DNA
transcription	O
in	O
CD4-CD8-	B-cell_line
murine	I-cell_line
T	I-cell_line
lymphocyte	I-cell_line
precursors	I-cell_line
.	O

Here	O
we	O
map	O
the	O
cis-acting	B-DNA
elements	I-DNA
that	O
mediate	O
interleukin	O
responsiveness	O
of	O
the	O
mouse	B-DNA
IL-2R	I-DNA
alpha	I-DNA
gene	I-DNA
using	O
a	O
thymic	B-cell_line
lymphoma-derived	I-cell_line
hybridoma	I-cell_line
(	O
PC60	B-cell_line
)	O
.	O

The	O
transcriptional	O
response	O
of	O
the	O
IL-2R	B-DNA
alpha	I-DNA
gene	I-DNA
to	O
stimulation	O
by	O
IL-1	B-protein
+	O
IL-2	B-protein
is	O
biphasic	O
.	O

IL-1	B-protein
induces	O
a	O
rapid	O
,	O
protein	O
synthesis-independent	O
appearance	O
of	O
IL-2R	B-RNA
alpha	I-RNA
mRNA	I-RNA
that	O
is	O
blocked	O
by	O
inhibitors	O
of	O
NF-kappa	B-protein
B	I-protein
activation	O
.	O

It	O
also	O
primes	O
cells	O
to	O
become	O
IL-2	B-protein
responsive	O
and	O
thereby	O
prepares	O
the	O
second	O
phase	O
,	O
in	O
which	O
IL-2	B-protein
induces	O
a	O
100-fold	O
further	O
increase	O
in	O
IL-2R	B-RNA
alpha	I-RNA
transcripts	I-RNA
.	O

Transient	O
transfection	O
experiments	O
show	O
that	O
several	O
elements	O
in	O
the	O
promoter-proximal	B-DNA
region	I-DNA
of	O
the	O
IL-2R	B-DNA
alpha	I-DNA
gene	I-DNA
contribute	O
to	O
IL-1	B-protein
responsiveness	O
,	O
most	O
importantly	O
an	O
NF-kappa	B-DNA
B	I-DNA
site	I-DNA
conserved	O
in	O
the	O
human	B-DNA
and	I-DNA
mouse	I-DNA
gene	I-DNA
.	O

IL-2	B-protein
responsiveness	O
,	O
on	O
the	O
other	O
hand	O
,	O
depends	O
on	O
a	O
78-nucleotide	B-DNA
segment	I-DNA
1.3	O
kilobases	O
upstream	O
of	O
the	O
major	B-DNA
transcription	I-DNA
start	I-DNA
site	I-DNA
.	O

This	O
segment	O
functions	O
as	O
an	O
IL-2-inducible	B-DNA
enhancer	I-DNA
and	O
lies	O
within	O
a	O
region	O
that	O
becomes	O
DNase	B-protein
I	I-protein
hypersensitive	O
in	O
normal	O
T	B-cell_type
cells	I-cell_type
in	O
which	O
IL-2R	B-protein
alpha	I-protein
expression	O
has	O
been	O
induced	O
.	O

IL-2	B-protein
responsiveness	O
requires	O
three	O
distinct	O
elements	B-DNA
within	O
the	O
enhancer	B-DNA
.	O

Two	O
of	O
these	O
are	O
potential	O
binding	O
sites	O
for	O
STAT	B-protein
proteins	I-protein
.	O

Hematopoietic	B-cell_type
lineage	I-cell_type
commitment	O
:	O
role	O
of	O
transcription	B-protein
factors	I-protein
.	O

This	O
review	O
focuses	O
on	O
the	O
roles	O
of	O
transcription	B-protein
factors	I-protein
in	O
hematopoietic	O
lineage	O
commitment	O
.	O

A	O
brief	O
introduction	O
to	O
lineage	O
commitment	O
and	O
asymmetric	O
cell	O
division	O
is	O
followed	O
by	O
a	O
discussion	O
of	O
several	O
methods	O
used	O
to	O
identify	O
transcription	B-protein
factors	I-protein
important	O
in	O
specifying	O
hematopoietic	B-cell_type
cell	I-cell_type
types	I-cell_type
.	O

Next	O
is	O
presented	O
a	O
discussion	O
of	O
the	O
use	O
of	O
embryonic	B-cell_type
stem	I-cell_type
cells	I-cell_type
in	O
the	O
analysis	O
of	O
hematopoietic	B-DNA
gene	I-DNA
expression	O
and	O
the	O
use	O
of	O
targeted	O
gene	O
disruption	O
to	O
analyze	O
the	O
role	O
of	O
transcription	B-protein
factors	I-protein
in	O
hematopoiesis	O
.	O

Finally	O
,	O
the	O
status	O
of	O
our	O
current	O
knowledge	O
concerning	O
the	O
roles	O
of	O
transcription	B-protein
factors	I-protein
in	O
the	O
commitment	O
to	O
erythroid	B-cell_type
,	I-cell_type
myeloid	I-cell_type
and	I-cell_type
lymphoid	I-cell_type
cell	I-cell_type
types	I-cell_type
is	O
summarized	O
.	O

Epstein-Barr	O
virus	O
replicative	O
gene	O
transcription	O
during	O
de	O
novo	O
infection	O
of	O
human	B-cell_type
thymocytes	I-cell_type
:	O
simultaneous	O
early	O
expression	O
of	O
BZLF-1	B-protein
and	O
its	O
repressor	O
RAZ	B-protein
.	O

Epstein-Barr	O
virus	O
(	O
EBV	O
)	O
is	O
known	O
to	O
infect	O
B	B-cell_type
cells	I-cell_type
and	O
epithelial	B-cell_type
cells	I-cell_type
.	O

We	O
and	O
others	O
have	O
shown	O
that	O
EBV	O
can	O
also	O
infect	O
a	O
subset	O
of	O
thymocytes	B-cell_type
.	O

Infection	O
of	O
thymocytes	B-cell_type
was	O
accompanied	O
by	O
the	O
appearance	O
of	O
linear	B-DNA
EBV	I-DNA
genome	I-DNA
within	O
8	O
hr	O
of	O
infection	O
.	O

Circularization	O
of	O
the	O
EBV	B-DNA
genome	I-DNA
was	O
not	O
detected	O
.	O

This	O
is	O
in	O
contrast	O
to	O
the	O
infection	O
in	O
B	B-cell_type
cells	I-cell_type
where	O
the	O
genome	O
can	O
circularize	O
within	O
24	O
hr	O
of	O
infection	O
.	O

The	O
appearance	O
of	O
the	O
BamHI	B-protein
ZLF-1	I-protein
gene	I-protein
product	I-protein
,	O
ZEBRA	B-protein
,	O
by	O
RT-PCR	O
,	O
was	O
observed	O
within	O
8	O
hr	O
of	O
infection	O
.	O

The	O
appearance	O
of	O
a	O
novel	O
fusion	B-protein
transcript	I-protein
(	O
RAZ	B-protein
)	O
,	O
which	O
comprised	O
regions	O
of	O
the	O
BZLF-1	B-DNA
locus	I-DNA
and	O
the	O
adjacent	O
BRLF-1	B-DNA
locus	I-DNA
,	O
was	O
detected	O
by	O
RT-PCR	O
.	O

ZEBRA	B-protein
protein	I-protein
was	O
also	O
identified	O
in	O
infected	O
thymocytes	B-cell_type
by	O
immunoprecipitation	O
.	O

In	O
addition	O
,	O
we	O
demonstrated	O
that	O
the	O
EBNA-1	B-DNA
gene	I-DNA
in	O
infected	O
thymocytes	B-cell_type
was	O
transcribed	O
from	O
the	O
Fp	B-DNA
promoter	I-DNA
,	O
rather	O
than	O
from	O
the	O
Cp/Wp	B-DNA
promoter	I-DNA
which	O
is	O
used	O
in	O
latently	B-cell_type
infected	I-cell_type
B	I-cell_type
cells	I-cell_type
.	O

Transcripts	O
encoding	O
gp350/220	B-protein
,	O
the	O
major	B-protein
coat	I-protein
protein	I-protein
of	O
EBV	O
,	O
were	O
identified	O
,	O
but	O
we	O
did	O
not	O
find	O
any	O
evidence	O
of	O
transcription	O
from	O
the	O
LMP-2A	B-DNA
or	O
EBER-1	B-DNA
loci	I-DNA
in	O
infected	O
thymocytes	B-cell_type
.	O

These	O
observations	O
suggest	O
that	O
de	O
novo	O
EBV	O
infection	O
of	O
thymocytes	B-cell_type
differs	O
from	O
infection	O
of	O
B	B-cell_type
cells	I-cell_type
.	O

The	O
main	O
difference	O
is	O
that	O
with	O
thymocytes	B-cell_type
,	O
no	O
evidence	O
could	O
be	O
found	O
that	O
the	O
virus	O
ever	O
circularizes	O
.	O

Rather	O
,	O
EBV	O
remains	O
in	O
a	O
linear	O
configuration	O
from	O
which	O
replicative	B-DNA
genes	I-DNA
are	O
transcribed	O
.	O

Identification	O
and	O
purification	O
of	O
human	B-protein
Stat	I-protein
proteins	I-protein
activated	O
in	O
response	O
to	O
interleukin-2	B-protein
.	O

A	O
key	O
cytokine	B-protein
induced	O
during	O
the	O
immune	O
response	O
is	O
IL-2	B-protein
.	O

Following	O
T	O
cell	O
activation	O
,	O
the	O
genes	O
encoding	O
IL-2	B-protein
and	O
the	O
various	O
chains	O
of	O
its	O
receptor	O
are	O
transcriptionally	O
induced	O
.	O

In	O
turn	O
,	O
secreted	O
IL-2	B-protein
serves	O
to	O
stimulate	O
the	O
proliferation	O
and	O
differentiation	O
of	O
T	B-cell_type
lymphocytes	I-cell_type
.	O

Several	O
recent	O
studies	O
have	O
implicated	O
Jak	O
kinases	O
in	O
the	O
signaling	O
pathway	O
induced	O
by	O
IL-2	B-protein
.	O

Following	O
this	O
lead	O
,	O
we	O
set	O
out	O
to	O
identify	O
transcription	B-protein
factors	I-protein
induced	O
in	O
response	O
to	O
IL-2	B-protein
.	O

Human	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
lymphocytes	I-cell_type
were	O
observed	O
to	O
contain	O
several	O
IL-2	B-protein
-inducible	O
DNA	O
binding	O
activities	O
.	O

Similar	O
activities	O
were	O
also	O
observed	O
in	O
a	O
transformed	B-cell_line
human	I-cell_line
lymphocyte	I-cell_line
line	I-cell_line
,	O
termed	O
YT	B-cell_line
.	O

We	O
have	O
purified	O
these	O
activities	O
and	O
found	O
that	O
the	O
principal	O
IL-2-inducible	B-protein
component	I-protein
bears	O
significant	O
relatedness	O
to	O
a	O
prolactin-induced	B-protein
transcription	I-protein
factor	I-protein
first	O
identified	O
in	O
sheep	B-cell_type
mammary	I-cell_type
gland	I-cell_type
tissue	I-cell_type
.	O

We	O
hypothesize	O
that	O
activation	O
of	O
this	O
protein	O
,	O
designated	O
hStat5	B-protein
,	O
helps	O
govern	O
the	O
biological	O
effects	O
of	O
IL-2	B-protein
during	O
the	O
immune	O
response	O
.	O

E2F-1	B-protein
and	O
a	O
cyclin-like	B-protein
DNA	I-protein
repair	I-protein
enzyme	I-protein
,	O
uracil-DNA	B-protein
glycosylase	I-protein
,	O
provide	O
evidence	O
for	O
an	O
autoregulatory	O
mechanism	O
for	O
transcription	O
.	O

The	O
cell	B-protein
cycle-dependent	I-protein
transcription	I-protein
factor	I-protein
,	O
E2F-1	B-protein
,	O
regulates	O
the	O
cyclin	B-protein
-like	O
species	O
of	O
the	O
DNA	B-protein
repair	I-protein
enzyme	I-protein
uracil-DNA	B-DNA
glycosylase	I-DNA
(	I-DNA
UDG	I-DNA
)	I-DNA
gene	I-DNA
in	O
human	B-cell_line
osteosarcoma	I-cell_line
(	I-cell_line
Saos-2	I-cell_line
)	I-cell_line
cells	I-cell_line
.	O

We	O
demonstrate	O
,	O
through	O
the	O
deletion	O
of	O
the	O
human	B-DNA
UDG	I-DNA
promoter	I-DNA
sequences	I-DNA
,	O
that	O
expression	O
of	O
E2F-1	B-protein
activates	O
the	O
UDG	B-DNA
promoter	I-DNA
through	O
several	O
E2F	B-DNA
sites	I-DNA
.	O

The	O
major	B-DNA
putative	I-DNA
downstream	I-DNA
site	I-DNA
for	O
E2F	B-protein
,	O
located	O
in	O
the	O
first	B-DNA
exon	I-DNA
,	O
serves	O
as	O
a	O
target	O
for	O
E2F-1/DP1	B-protein
complex	I-protein
binding	O
in	O
vitro	O
.	O

We	O
also	O
provide	O
evidence	O
for	O
the	O
functional	O
relationship	O
between	O
the	O
cyclin-like	B-protein
UDG	I-protein
gene	I-protein
product	I-protein
and	O
E2F	B-protein
.	O

High	O
levels	O
of	O
UDG	B-protein
expression	O
in	O
a	O
transient	O
transfection	O
assay	O
result	O
in	O
the	O
down-regulation	O
of	O
transcriptional	O
activity	O
through	O
elements	B-DNA
specific	O
for	O
E2F	B-protein
-mediated	O
transcription	O
.	O

Overexpression	O
of	O
UDG	B-protein
in	O
Saos	B-cell_line
2	I-cell_line
cells	I-cell_line
was	O
observed	O
to	O
delay	O
growth	O
late	O
in	O
G1	O
phase	O
and	O
transiently	O
arrest	O
these	O
cells	O
from	O
progressing	O
into	O
the	O
S	O
phase	O
.	O

This	O
hypothetical	O
model	O
integrates	O
one	O
mechanism	O
of	O
DNA	O
repair	O
with	O
the	O
cell	O
cycle	O
control	O
of	O
gene	O
transcription	O
,	O
likely	O
through	O
E2F	B-protein
.	O

This	O
implicates	O
E2F	B-protein
as	O
a	O
multifunctional	O
target	O
for	O
proteins	O
and	O
enzymes	O
,	O
possibly	O
,	O
responsive	O
to	O
DNA	O
damage	O
through	O
the	O
negative	O
effect	O
of	O
UDG	B-protein
on	O
E2F	B-protein
-mediated	O
transcriptional	O
activity	O
.	O

Cellular	O
and	O
molecular	O
mechanisms	O
of	O
IFN-gamma	B-protein
production	O
induced	O
by	O
IL-2	B-protein
and	O
IL-12	B-protein
in	O
a	O
human	B-cell_line
NK	I-cell_line
cell	I-cell_line
line	I-cell_line
.	O

Interferon-gamma	B-protein
(	O
IFN-gamma	B-protein
)	O
is	O
an	O
important	O
immunoregulatory	B-protein
protein	I-protein
produced	O
predominantly	O
by	O
T	B-cell_type
cells	I-cell_type
and	O
large	B-cell_type
granular	I-cell_type
lymphocytes	I-cell_type
(	O
LGL	B-cell_type
)	O
in	O
response	O
to	O
different	O
extracellular	O
signals	O
.	O

In	O
particular	O
,	O
two	O
interleukins	B-protein
(	O
ILs	B-protein
)	O
,	O
IL-2	B-protein
and	O
IL-12	B-protein
,	O
have	O
been	O
shown	O
to	O
be	O
potent	O
inducers	O
of	O
IFN-gamma	B-protein
gene	O
expression	O
in	O
both	O
T	B-cell_type
cells	I-cell_type
and	O
LGL	B-cell_type
.	O

Although	O
it	O
has	O
been	O
reported	O
that	O
there	O
are	O
some	O
T	B-cell_line
cell	I-cell_line
lines	I-cell_line
that	O
produce	O
IFN-gamma	B-protein
in	O
response	O
to	O
IL-2	O
and	O
IL-12	O
stimulation	O
,	O
there	O
has	O
as	O
yet	O
been	O
no	O
report	O
of	O
a	O
natural	B-cell_line
killer	I-cell_line
(	I-cell_line
NK	I-cell_line
)	I-cell_line
cell	I-cell_line
line	I-cell_line
that	O
responds	O
in	O
a	O
similar	O
manner	O
.	O

In	O
this	O
report	O
we	O
present	O
evidence	O
that	O
the	O
cell	B-cell_line
line	I-cell_line
NK3.3	I-cell_line
derived	O
from	O
human	B-cell_type
NK	I-cell_type
cells	I-cell_type
,	O
responds	O
to	O
both	O
IL-2	B-protein
and	O
IL-12	B-protein
,	O
as	O
measured	O
by	O
increases	O
in	O
IFN-gamma	B-protein
and	O
granulocyte-macrophage	B-protein
colony-stimulating	I-protein
factor	I-protein
(	O
GM-CSF	B-protein
)	O
cytoplasmic	O
mRNA	O
and	O
protein	O
expression	O
.	O

In	O
addition	O
,	O
when	O
used	O
together	O
IL-2	B-protein
and	O
IL-12	B-protein
synergized	O
in	O
the	O
induction	O
of	O
IFN-gamma	B-protein
and	O
GM-CSF	B-protein
and	O
this	O
synergy	O
was	O
attributed	O
to	O
an	O
increased	O
accumulation	O
and	O
stability	O
of	O
the	O
IFN-gamma	B-RNA
and	I-RNA
GM-CSF	I-RNA
mRNAs	I-RNA
.	O

To	O
investigate	O
the	O
signaling	O
pathways	O
involved	O
in	O
the	O
gene	O
induction	O
,	O
five	O
inhibitors	O
,	O
cyclosporin	O
A	O
(	O
CsA	O
)	O
,	O
transforming	B-protein
growth	I-protein
factor-beta	I-protein
,	O
cycloheximide	O
,	O
genistein	O
,	O
and	O
staurosporine	O
A	O
,	O
were	O
used	O
in	O
analyzing	O
the	O
effects	O
of	O
IL-2	B-protein
and	O
IL-12	B-protein
on	O
NK3.3	B-cell_line
cells	I-cell_line
.	O

The	O
results	O
suggest	O
that	O
activation	O
of	O
protein	B-protein
kinase	I-protein
C	I-protein
,	O
but	O
not	O
new	O
protein	O
synthesis	O
,	O
is	O
required	O
for	O
IL-2	B-protein
induction	O
of	O
IFN-gamma	B-RNA
and	I-RNA
GM-CSF	I-RNA
cytoplasmic	I-RNA
mRNA	I-RNA
.	O

In	O
contrast	O
,	O
IL-12	B-protein
induction	O
of	O
IFN-gamma	B-RNA
cytoplasmic	I-RNA
mRNA	I-RNA
appears	O
to	O
only	O
partially	O
depend	O
on	O
activation	O
of	O
protein	B-protein
kinase	I-protein
C	I-protein
.	O

Furthermore	O
,	O
both	O
transforming	B-protein
growth	I-protein
factor-beta	I-protein
and	O
genistein	O
,	O
a	O
tyrosine	O
kinase	O
inhibitor	O
,	O
could	O
suppress	O
IL-2	B-protein
and	O
IL-12	B-protein
signaling	O
but	O
CsA	O
was	O
generally	O
inactive	O
.	O

It	O
also	O
was	O
observed	O
that	O
suppression	O
of	O
cytokine	B-DNA
gene	I-DNA
expression	O
by	O
these	O
agents	O
was	O
independent	O
of	O
the	O
inhibition	O
of	O
proliferation	O
.	O

In	O
addition	O
,	O
IL-2	B-protein
but	O
not	O
IL-12	B-protein
induced	O
nuclear	B-protein
factors	I-protein
NF-kappa	B-protein
B	I-protein
and	O
AP1	B-protein
,	O
and	O
regulation	O
of	O
the	O
nuclear	O
levels	O
of	O
these	O
two	O
DNA	B-protein
binding	I-protein
protein	I-protein
complexes	I-protein
is	O
correlated	O
with	O
IFN-gamma	O
and	O
GM-CSF	O
gene	O
expression	O
.	O

These	O
data	O
indicate	O
that	O
IL-2	B-protein
and	O
IL-12	B-protein
may	O
have	O
distinct	O
signaling	O
pathways	O
leading	O
to	O
the	O
induction	O
of	O
IFN-gamma	B-protein
and	O
GM-CSF	B-protein
gene	O
expression	O
,	O
and	O
that	O
the	O
NK3.3	B-cell_line
cell	I-cell_line
line	I-cell_line
may	O
serve	O
as	O
a	O
novel	O
model	O
for	O
dissecting	O
the	O
biochemical	O
and	O
molecular	O
events	O
involved	O
in	O
these	O
pathways	O
.	O

A	O
functional	O
T-cell	B-protein
receptor	I-protein
signaling	O
pathway	O
is	O
required	O
for	O
p95vav	B-protein
activity	O
.	O

Stimulation	O
of	O
the	O
T-cell	B-protein
antigen	I-protein
receptor	I-protein
(	O
TCR	B-protein
)	O
induces	O
activation	O
of	O
multiple	O
tyrosine	B-protein
kinases	I-protein
,	O
resulting	O
in	O
phosphorylation	O
of	O
numerous	O
intracellular	O
substrates	O
.	O

One	O
substrate	O
is	O
p95vav	B-protein
,	O
which	O
is	O
expressed	O
exclusively	O
in	O
hematopoietic	B-cell_type
and	I-cell_type
trophoblast	I-cell_type
cells	I-cell_type
.	O

It	O
contains	O
a	O
number	O
of	O
structural	B-protein
motifs	I-protein
,	O
including	O
Src	B-protein
homology	I-protein
2	I-protein
,	I-protein
Src	I-protein
homology	I-protein
3	I-protein
,	I-protein
and	I-protein
pleckstrin	I-protein
homology	I-protein
domains	I-protein
and	O
a	O
putative	B-protein
guanine	I-protein
nucleotide	I-protein
exchange	I-protein
domain	I-protein
.	O

The	O
role	O
of	O
p95vav	B-protein
in	O
TCR	B-protein
-mediated	O
signaling	O
processes	O
is	O
unclear	O
.	O

Here	O
,	O
we	O
show	O
that	O
overexpression	O
of	O
p95vav	B-protein
alone	O
in	O
Jurkat	O
T	B-cell_type
cells	I-cell_type
leads	O
to	O
activation	O
of	O
the	O
nuclear	B-protein
factors	I-protein
,	O
including	O
NFAT	B-protein
,	O
involved	O
in	O
interleukin-2	B-protein
expression	O
.	O

Furthermore	O
,	O
p95vav	B-protein
synergizes	O
with	O
TCR	B-protein
stimulation	O
in	O
inducing	O
NFAT-	O
and	O
interleukin-2-dependent	O
transcription	O
.	O

In	O
contrast	O
,	O
NFAT	B-protein
activation	O
by	O
a	O
G-protein-coupled	B-protein
receptor	I-protein
is	O
not	O
modulated	O
by	O
p95vav	B-protein
overexpression	O
,	O
suggesting	O
that	O
the	O
effect	O
is	O
specific	O
to	O
the	O
TCR	B-protein
signaling	O
pathways	O
.	O

Although	O
removal	O
of	O
the	O
first	B-protein
67	I-protein
amino	I-protein
acids	I-protein
of	O
p95vav	B-protein
activates	O
its	O
transforming	O
potential	O
in	O
NIH	B-cell_line
3T3	I-cell_line
cells	I-cell_line
,	O
this	O
region	O
appears	O
to	O
be	O
required	O
for	O
its	O
function	O
in	O
T	B-cell_type
cells	I-cell_type
.	O

We	O
further	O
demonstrate	O
that	O
the	O
p95vav	B-protein
-induced	O
NFAT	B-protein
activation	O
is	O
not	O
mimicked	O
by	O
Ras	B-protein
activation	O
,	O
though	O
its	O
function	O
is	O
dependent	O
upon	O
Ras	B-protein
and	O
Raf	B-protein
.	O

Furthermore	O
,	O
the	O
activating	O
function	O
of	O
p95vav	B-protein
is	O
blocked	O
by	O
FK506	O
,	O
suggesting	O
that	O
its	O
activity	O
also	O
depends	O
on	O
calcineurin	B-protein
.	O

To	O
further	O
dissect	O
p95vav	B-protein
involvement	O
in	O
TCR	B-protein
signaling	O
,	O
we	O
analyzed	O
various	O
Jurkat	B-cell_line
mutants	I-cell_line
deficient	O
in	O
TCR	B-protein
signaling	O
function	O
or	O
TCR	B-protein
expression	O
and	O
showed	O
that	O
an	O
intact	O
TCR	B-protein
signaling	O
pathway	O
is	O
required	O
for	O
p95vav	B-protein
to	O
function	O
.	O

However	O
,	O
overexpression	O
of	O
p95vav	B-protein
does	O
not	O
appear	O
to	O
influence	O
TCR	B-protein
-induced	O
protein	O
tyrosine	O
phosphorylation	O
or	O
increases	O
in	O
cytoplasmic	O
free	O
calcium	O
.	O

Taken	O
together	O
,	O
our	O
data	O
suggest	O
that	O
p95vav	B-protein
plays	O
an	O
important	O
role	O
at	O
an	O
yet	O
unidentified	O
proximal	O
position	O
in	O
the	O
TCR	B-protein
signaling	O
cascade	O
.	O

Positive	O
and	O
negative	O
regulation	O
of	O
granulocyte-macrophage	B-protein
colony-stimulating	I-protein
factor	I-protein
promoter	O
activity	O
by	O
AML1-related	B-protein
transcription	I-protein
factor	I-protein
,	O
PEBP2	B-protein
.	O

The	O
granulocyte-macrophage	B-DNA
colony-stimulating	I-DNA
factor	I-DNA
(	I-DNA
GM-CSF	I-DNA
)	I-DNA
gene	I-DNA
promoter	I-DNA
contains	O
a	O
consensus	O
sequence	O
for	O
the	O
polyomavirus	B-protein
enhancer	I-protein
binding-protein	I-protein
2	I-protein
(	I-protein
PEBP2	I-protein
)	I-protein
transcription	I-protein
factor	I-protein
,	O
which	O
consists	O
of	O
alpha	B-protein
and	I-protein
beta	I-protein
subunits	I-protein
.	O

There	O
are	O
at	O
least	O
two	O
genes	O
,	O
alpha	B-DNA
A	I-DNA
and	O
alpha	B-DNA
B	I-DNA
,	O
encoding	O
the	O
alpha	B-protein
subunit	I-protein
.	O

alpha	B-DNA
B	I-DNA
is	O
the	O
mouse	B-DNA
homologue	I-DNA
of	O
human	B-DNA
AML1	I-DNA
gene	I-DNA
detected	O
at	O
the	O
breakpoints	O
of	O
t	O
(	O
8	O
;	O
21	O
)	O
and	O
t	O
(	O
3	O
;	O
21	O
)	O
myeloid	O
leukemias	O
.	O

We	O
examined	O
alpha	B-protein
A1	I-protein
(	O
an	O
alpha	B-protein
A-gene	I-protein
product	I-protein
)	O
and	O
alpha	B-protein
B1	I-protein
and	O
alpha	B-protein
B2	I-protein
(	O
two	O
alpha	B-protein
B-encoded	I-protein
isomers	I-protein
)	O
for	O
their	O
effects	O
on	O
the	O
GM-CSF	B-DNA
promoter	I-DNA
.	O

PEBP2	B-protein
alpha	I-protein
A1	I-protein
,	O
alpha	B-protein
B1	I-protein
,	O
and	O
alpha	B-protein
B2	I-protein
proteins	I-protein
bound	O
the	O
PEBP2	B-DNA
site	I-DNA
within	O
the	O
mouse	B-DNA
GM-CSF	I-DNA
promoter	I-DNA
.	O

PEBP2	B-protein
alpha	I-protein
A1	I-protein
and	O
alpha	B-protein
B1	I-protein
enhanced	O
the	O
expression	O
of	O
the	O
GM-CSF	B-DNA
promoter-driven	I-DNA
reporter	I-DNA
plasmid	I-DNA
in	O
unstimulated	B-cell_line
and	I-cell_line
12-O-tetradecanoylphorbol	I-cell_line
13-acetate/phytohemagglutinin-stimulated	I-cell_line
human	I-cell_line
Jurkat	I-cell_line
T	I-cell_line
cells	I-cell_line
.	O

In	O
contrast	O
,	O
the	O
promoter	O
activity	O
was	O
suppressed	O
by	O
alpha	B-protein
B2	I-protein
.	O

Coexpression	O
of	O
alpha	B-protein
B1	I-protein
and	O
alpha	B-protein
B2	I-protein
showed	O
that	O
the	O
promoter	O
activity	O
could	O
be	O
determined	O
by	O
the	O
alpha	B-protein
B1	I-protein
/alpha	B-protein
B2	I-protein
ratio	O
.	O

Jurkat	O
cell	O
extract	O
contained	O
PEBP2	B-protein
site-binding	I-protein
protein	I-protein
(	O
s	O
)	O
that	O
cross-reacted	O
with	O
antimouse	B-protein
alpha	I-protein
A1	I-protein
antibodies	I-protein
.	O

Northern	O
blot	O
analysis	O
indicated	O
the	O
expression	O
of	O
human	O
PEBP2	B-protein
alpha	I-protein
A	I-protein
,	O
alpha	B-DNA
B	I-DNA
(	O
AML1	B-DNA
)	O
,	O
and	O
beta	B-DNA
genes	I-DNA
in	O
Jurkat	B-cell_line
cells	I-cell_line
.	O

Although	O
further	O
studies	O
are	O
required	O
to	O
determine	O
the	O
precise	O
role	O
of	O
PEBP2	B-protein
in	O
the	O
GM-CSF	B-protein
promoter	O
activity	O
,	O
the	O
present	O
findings	O
suggested	O
the	O
importance	O
of	O
the	O
relative	O
ratio	O
of	O
different	O
PEBP2	B-protein
isoforms	I-protein
in	O
regulating	O
the	O
levels	O
of	O
the	O
promoter	O
activity	O
.	O

IFN-gamma	B-protein
priming	O
of	O
monocytes	B-cell_type
enhances	O
LPS-induced	O
TNF	B-protein
production	O
by	O
augmenting	O
both	O
transcription	O
and	O
MRNA	O
stability	O
.	O

The	O
induction	O
of	O
cytokine	B-protein
expression	O
in	O
monocytes	B-cell_type
/	O
macrophages	B-cell_type
by	O
bacterial	B-protein
endotoxin	I-protein
or	O
lipopolysaccharide	O
is	O
a	O
critical	O
,	O
highly	O
regulated	O
host	O
defence	O
response	O
.	O

The	O
augmentation	O
of	O
LPS	O
responses	O
by	O
interferon	B-protein
gamma	I-protein
(	O
IFN-gamma	B-protein
)	O
,	O
referred	O
to	O
as	O
priming	O
,	O
is	O
well	O
established	O
.	O

However	O
,	O
the	O
mechanism	O
(	O
s	O
)	O
by	O
which	O
priming	O
occurs	O
is	O
poorly	O
defined	O
.	O

Using	O
tumour	B-protein
necrosis	I-protein
factor	I-protein
(	O
TNF	B-protein
)	O
induction	O
as	O
a	O
model	O
,	O
experiments	O
were	O
designed	O
to	O
analyse	O
in	O
detail	O
the	O
priming	O
effect	O
on	O
the	O
LPS	O
response	O
in	O
human	B-cell_type
monocytes	I-cell_type
.	O

Priming	O
by	O
IFN-gamma	B-protein
was	O
primarily	O
manifested	O
at	O
the	O
level	O
of	O
TNF	B-RNA
mRNA	I-RNA
accumulation	O
.	O

IFN-gamma	B-protein
pre-treatment	O
affected	O
the	O
magnitude	O
rather	O
than	O
the	O
sensitivity	O
of	O
the	O
LPS	O
response	O
.	O

Priming	O
occurred	O
after	O
several	O
hours	O
of	O
treatment	O
,	O
and	O
the	O
primed	O
state	O
was	O
induced	O
by	O
either	O
IFN-gamma	B-protein
or	O
GM-CSF	B-protein
,	O
but	O
not	O
M-CSF	B-protein
.	O

Primed	O
monocytes	B-cell_type
transcribed	O
TNF	B-RNA
mRNA	I-RNA
at	O
a	O
higher	O
rate	O
than	O
freshly	O
isolated	O
monocytes	B-cell_type
upon	O
activation	O
with	O
LPS	O
.	O

The	O
increased	O
transcriptional	O
rate	O
correlated	O
with	O
a	O
marked	O
increase	O
in	O
nuclear	B-protein
factor-kappa	I-protein
B	I-protein
activity	O
in	O
these	O
cells	O
as	O
determined	O
by	O
electrophoretic	O
mobility	O
shift	O
assay	O
using	O
a	O
consensus	B-DNA
NF-kappa	I-DNA
B	I-DNA
oligonucleotide	I-DNA
.	O

An	O
additional	O
significant	O
finding	O
was	O
than	O
TNF	B-RNA
mRNA	I-RNA
induced	O
in	O
primed	B-cell_line
cells	I-cell_line
was	O
much	O
more	O
stable	O
than	O
in	O
unprimed	B-cell_line
cells	I-cell_line
(	O
T1/2	O
increased	O
6-8-fold	O
)	O
.	O

Consistent	O
with	O
the	O
increased	O
mRNA	B-RNA
stability	O
,	O
the	O
duration	O
of	O
mRNA	B-RNA
accumulation	O
was	O
longer	O
following	O
LPS	O
stimulation	O
in	O
primed	O
monocytes	B-cell_type
,	O
in	O
addition	O
to	O
being	O
of	O
greater	O
magnitude	O
.	O

Finally	O
,	O
primed	O
and	O
unprimed	O
cells	O
possessed	O
a	O
differential	O
sensitivity	O
to	O
the	O
kinase	O
inhibitor	O
H-89	O
.	O

H-89	O
substantially	O
suppressed	O
LPS-induced	O
TNF	B-RNA
mRNA	I-RNA
accumulation	O
in	O
unprimed	B-cell_line
cells	I-cell_line
,	O
but	O
had	O
no	O
effect	O
on	O
primed	B-cell_line
monocytes	I-cell_line
following	O
LPS	O
stimulation	O
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

A	O
Myc-associated	B-DNA
zinc	I-DNA
finger	I-DNA
protein	I-DNA
binding	I-DNA
site	I-DNA
is	O
one	O
of	O
four	O
important	O
functional	B-DNA
regions	I-DNA
in	O
the	O
CD4	B-DNA
promoter	I-DNA
.	O

The	O
CD4	B-DNA
promoter	I-DNA
plays	O
an	O
important	O
role	O
in	O
the	O
developmental	O
control	O
of	O
CD4	B-protein
transcription	O
.	O

In	O
this	O
report	O
,	O
we	O
show	O
that	O
the	O
minimal	O
CD4	B-DNA
promoter	I-DNA
has	O
four	O
factor	B-DNA
binding	I-DNA
sites	I-DNA
,	O
each	O
of	O
which	O
is	O
required	O
for	O
full	O
function	O
.	O

Using	O
biochemical	O
and	O
mutagenesis	O
analyses	O
,	O
we	O
determined	O
that	O
multiple	O
nuclear	B-protein
factors	I-protein
bind	O
to	O
these	O
independent	O
sites	O
.	O

We	O
determined	O
that	O
an	O
initiator-like	B-DNA
sequence	I-DNA
present	O
at	O
the	O
cap	B-DNA
site	I-DNA
and	O
an	O
Ets	B-DNA
consensus	I-DNA
sequence	I-DNA
are	O
required	O
for	O
full	O
promoter	B-DNA
function	O
.	O

We	O
also	O
demonstrate	O
that	O
the	O
Myc-associated	B-protein
zinc	I-protein
finger	I-protein
protein	I-protein
(	O
MAZ	B-protein
)	O
appears	O
to	O
be	O
the	O
predominant	B-protein
factor	I-protein
binding	O
to	O
one	O
of	O
these	O
sites	O
.	O

This	O
last	O
site	O
closely	O
resembles	O
the	O
ME1a1	B-DNA
G3AG4AG3	I-DNA
motif	I-DNA
previously	O
shown	O
to	O
be	O
a	O
critical	O
element	O
in	O
the	O
P2	B-DNA
promoter	I-DNA
of	O
the	O
c-myc	B-DNA
gene	I-DNA
.	O

We	O
therefore	O
believe	O
that	O
the	O
MAZ	B-protein
transcription	I-protein
factor	I-protein
is	O
also	O
likely	O
to	O
play	O
an	O
important	O
role	O
in	O
the	O
control	O
of	O
developmental	O
expression	O
of	O
the	O
CD4	B-DNA
gene	I-DNA
.	O

Erythropoietin	B-protein
stimulates	O
transcription	O
of	O
the	O
TAL1/SCL	B-DNA
gene	I-DNA
and	O
phosphorylation	O
of	O
its	O
protein	B-protein
products	I-protein
.	O

Activation	O
of	O
the	O
TAL1	B-DNA
(	I-DNA
or	I-DNA
SCL	I-DNA
)	I-DNA
gene	I-DNA
,	O
originally	O
identified	O
through	O
its	O
involvement	O
by	O
a	O
recurrent	O
chromosomal	O
translocation	O
,	O
is	O
the	O
most	O
frequent	O
molecular	O
lesion	O
recognized	O
in	O
T-cell	O
acute	O
lymphoblastic	O
leukemia	O
.	O

The	O
protein	B-protein
products	I-protein
of	O
this	O
gene	O
contain	O
the	O
basic-helix-loop-helix	B-protein
motif	I-protein
characteristic	O
of	O
a	O
large	O
family	O
of	O
transcription	B-protein
factors	I-protein
that	O
bind	O
to	O
the	O
canonical	B-DNA
DNA	I-DNA
sequence	I-DNA
CANNTG	I-DNA
as	O
protein	B-protein
heterodimers	I-protein
.	O

TAL1	B-protein
expression	O
by	O
erythroid	B-cell_type
cells	I-cell_type
in	O
vivo	O
and	O
in	O
chemical-induced	B-cell_line
erythroleukemia	I-cell_line
cell	I-cell_line
lines	I-cell_line
in	O
vivo	O
suggested	O
the	O
gene	O
might	O
regulate	O
aspects	O
of	O
erythroid	O
differentiation	O
.	O

Since	O
the	O
terminal	O
events	O
of	O
erythropoiesis	O
are	O
controlled	O
by	O
the	O
glycoprotein	B-protein
hormone	I-protein
erythropoietin	I-protein
(	O
Epo	B-protein
)	O
,	O
we	O
investigated	O
whether	O
the	O
expression	O
or	O
activity	O
of	O
the	O
TAL1	B-DNA
gene	I-DNA
and	O
its	O
protein	B-protein
products	I-protein
were	O
affected	O
by	O
Epo	B-protein
in	O
splenic	B-cell_type
erythroblasts	I-cell_type
from	O
mice	O
infected	O
with	O
an	O
anemia-inducing	O
strain	O
of	O
Friend	O
virus	O
(	O
FVA	O
cells	O
)	O
.	O

Epo	B-protein
elicited	O
a	O
rapid	O
,	O
dose-related	O
increase	O
in	O
TAL1	B-RNA
mRNA	I-RNA
by	O
increasing	O
transcription	O
of	O
the	O
gene	O
and	O
stabilizing	O
one	O
of	O
its	O
mRNAs	B-RNA
.	O

An	O
Epo	B-protein
-inducible	O
TAL1	B-protein
DNA	O
binding	O
activity	O
was	O
identified	O
in	O
FVA	O
cell	O
nuclear	O
extracts	O
that	O
subsequently	O
decayed	O
despite	O
accumulating	O
mRNA	B-RNA
and	O
protein	O
.	O

Induction	O
of	O
DNA	O
binding	O
activity	O
was	O
associated	O
temporally	O
with	O
Epo	B-protein
-induced	O
phosphorylation	O
of	O
nuclear	B-protein
TAL1	I-protein
protein	I-protein
.	O

These	O
results	O
indicate	O
that	O
Epo	B-protein
acts	O
at	O
both	O
transcriptional	O
and	O
posttranscriptional	O
levels	O
on	O
the	O
TAL1	B-protein
locus	O
in	O
Friend	B-cell_line
virus-induced	I-cell_line
erythroblasts	I-cell_line
and	O
establish	O
a	O
link	O
between	O
Epo	B-protein
signaling	O
mechanisms	O
and	O
a	O
member	O
of	O
a	O
family	O
of	O
transcription	B-protein
factors	I-protein
involved	O
in	O
the	O
differentiation	O
of	O
diverse	B-cell_type
cell	I-cell_type
lineages	I-cell_type
.	O

Nonradioactive	O
quantification	O
of	O
glucocorticoid	B-protein
receptor	I-protein
expression	O
during	O
differentiation	O
of	O
human	O
monocytic	B-cell_type
cells	I-cell_type
(	O
U937	B-cell_line
)	O
.	O

We	O
describe	O
a	O
method	O
for	O
relative	O
quantification	O
of	O
specific	O
mRNA	B-RNA
using	O
a	O
nonradioactive	O
assay	O
based	O
on	O
DNA	O
strand	O
competition	O
between	O
identical	O
sequences	O
of	O
biotin-	O
and	O
fluorescein-labeled	O
amplicon	O
(	O
probe	O
)	O
and	O
unlabeled	O
amplicon	O
(	O
target	O
)	O
during	O
hybridization	O
.	O

As	O
the	O
target	O
quantity	O
increased	O
,	O
that	O
of	O
the	O
double-labeled	O
probe	O
decreased	O
in	O
accordance	O
with	O
the	O
mass	O
action	O
law	O
.	O

This	O
technique	O
was	O
successfully	O
applied	O
to	O
evaluate	O
differences	O
in	O
glucocorticoid	B-protein
receptor	I-protein
expression	O
in	O
U937	B-cell_line
cells	I-cell_line
before	O
and	O
after	O
the	O
addition	O
of	O
potent	O
differentiation	O
inducers	O
:	O
12-O-tetradecanoylphorbol	O
13-acetate	O
(	O
TPA	O
)	O
and	O
a	O
combination	O
of	O
all-trans	O
retinoic	O
acid	O
(	O
RA	O
)	O
and	O
1	O
,	O
25-dihydroxyvitamin	O
D2	O
(	O
VD	O
)	O
.	O

We	O
observed	O
that	O
TPA	O
treatment	O
was	O
associated	O
with	O
an	O
increase	O
in	O
specific	O
binding	O
of	O
[	O
3H	O
]	O
dexamethasone	O
and	O
up-regulation	O
of	O
GR	B-RNA
mRNA	I-RNA
while	O
no	O
enhanced	O
GR	B-protein
expression	O
was	O
perceived	O
with	O
RA/VD	O
treatment	O
.	O

Induction	O
of	O
Sp1	B-protein
phosphorylation	O
and	O
NF-kappa	B-DNA
B-independent	I-DNA
HIV	I-DNA
promoter	I-DNA
domain	O
activity	O
in	O
T	B-cell_type
lymphocytes	I-cell_type
stimulated	O
by	O
okadaic	O
acid	O
.	O

In	O
contrast	O
to	O
the	O
purely	O
enhancer-dependent	O
effect	O
of	O
cytokines	B-protein
such	O
as	O
TNF	B-protein
on	O
the	O
activity	O
of	O
the	O
HIV	B-DNA
regulatory	I-DNA
region	I-DNA
(	O
LTR	B-DNA
)	O
,	O
we	O
observed	O
that	O
okadaic	O
acid	O
(	O
OKA	O
)	O
activates	O
HIV	O
transcription	O
through	O
both	O
the	O
enhancer	O
,	O
responding	O
to	O
the	O
factor	O
NF-kappa	B-protein
B	I-protein
,	O
and	O
the	O
promoter	B-DNA
domain	I-DNA
of	O
the	O
LTR	B-DNA
.	O

The	O
inducibility	O
of	O
HIV	B-DNA
LTR-driven	I-DNA
luciferase	I-DNA
expression	I-DNA
constructs	I-DNA
in	O
lymphoblastoid	B-cell_type
cells	I-cell_type
stimulated	O
by	O
OKA	O
depended	O
on	O
both	O
functional	B-DNA
Sp1	I-DNA
binding	I-DNA
elements	I-DNA
and	O
the	O
ability	O
of	O
the	O
TATA	B-DNA
box	I-DNA
to	O
bind	O
the	O
protein	O
TBP	B-protein
.	O

In	O
both	O
transformed	B-cell_type
and	I-cell_type
normal	I-cell_type
lymphocytes	I-cell_type
,	O
OKA	O
stimulation	O
induced	O
intense	O
phosphorylation	O
of	O
the	O
constitutively	O
expressed	O
Sp1	B-protein
protein	I-protein
in	O
the	O
nucleus	O
,	O
a	O
property	O
of	O
OKA	O
not	O
shared	O
by	O
TNF	B-protein
,	O
phorbol	O
ester	O
,	O
or	O
PHA	B-protein
and	O
interleukin	B-protein
2	I-protein
.	O

Responsiveness	O
of	O
LTR	B-DNA
constructs	I-DNA
deleted	O
of	O
kappa	B-DNA
B	I-DNA
elements	I-DNA
to	O
HIV	B-protein
Tat	I-protein
expression	O
was	O
increased	O
upon	O
OKA	O
but	O
not	O
TNF	B-protein
stimulation	O
.	O

Our	O
results	O
suggest	O
that	O
SP1	B-protein
phosphorylation	O
induced	O
by	O
OKA	O
,	O
a	O
selective	O
inhibitor	O
of	O
the	O
serine-threonine	B-protein
phosphatase	I-protein
PP2A	B-protein
,	O
facilitates	O
the	O
formation	O
of	O
a	O
transcription	B-protein
complex	I-protein
involving	O
general	O
transcription	B-protein
factors	I-protein
,	O
HIV	B-protein
Tat	I-protein
,	O
and	O
Sp1	B-protein
proteins	I-protein
.	O

The	O
formation	O
of	O
this	O
complex	O
would	O
increase	O
,	O
independently	O
of	O
an	O
in	O
synergy	O
with	O
NF-kappa	B-protein
B	I-protein
,	O
the	O
low	O
basal	O
activity	O
of	O
the	O
HIV	B-DNA
LTR	I-DNA
observed	O
in	O
normal	B-cell_type
T	I-cell_type
lymphocytes	I-cell_type
.	O

The	O
role	O
of	O
shared	B-protein
receptor	I-protein
motifs	I-protein
and	O
common	B-protein
Stat	I-protein
proteins	I-protein
in	O
the	O
generation	O
of	O
cytokine	B-protein
pleiotropy	O
and	O
redundancy	O
by	O
IL-2	B-protein
,	O
IL-4	B-protein
,	O
IL-7	B-protein
,	O
IL-13	B-protein
,	O
and	O
IL-15	B-protein
.	O

To	O
understand	O
the	O
molecular	O
bases	O
for	O
cytokine	O
redundancy	O
and	O
pleiotropy	O
,	O
we	O
have	O
compared	O
the	O
Stat	B-protein
proteins	I-protein
activated	O
in	O
peripheral	B-cell_type
blood	I-cell_type
lymphocytes	I-cell_type
(	O
PBLs	B-cell_type
)	O
by	O
cytokines	B-protein
with	O
shared	O
and	O
distinct	O
actions	O
.	O

Interleukin-2	B-protein
(	O
IL-2	B-protein
)	O
rapidly	O
activated	O
Stat5	B-protein
in	O
fresh	O
PBL	B-cell_type
,	O
and	O
Stat3	B-protein
and	O
Stat5	B-protein
in	O
preactivated	B-cell_type
PBL	I-cell_type
.	O

IL-7	B-protein
and	O
IL-15	B-protein
induced	O
the	O
same	O
complexes	O
as	O
IL-2	B-protein
,	O
a	O
feature	O
explained	O
by	O
the	O
existence	O
of	O
similar	O
tyrosine-phosphorylated	B-protein
motifs	I-protein
in	O
the	O
cytoplasmic	B-protein
domains	I-protein
of	O
IL-2R	B-protein
beta	I-protein
and	O
IL-7R	B-protein
that	O
can	O
serve	O
as	O
docking	O
sites	O
for	O
Stat	B-protein
proteins	I-protein
.	O

IL-13	B-protein
Induced	O
the	O
same	O
complexes	O
as	O
IL-4	B-protein
,	O
a	O
finding	O
explained	O
by	O
our	O
studies	O
implicating	O
IL-4R	B-protein
as	O
a	O
shared	O
component	O
of	O
the	O
receptors	B-protein
.	O

These	O
studies	O
demonstrate	O
that	O
a	O
single	O
cytokine	B-protein
can	O
activate	O
different	O
combinations	O
of	O
Stat	B-protein
proteins	I-protein
under	O
different	O
physiological	O
conditions	O
,	O
and	O
also	O
indicate	O
two	O
mechanisms	O
by	O
which	O
distinct	O
cytokines	B-protein
can	O
activate	O
the	O
same	O
Stat	B-protein
protein	I-protein
.	O

Control	O
of	O
I	B-protein
kappa	I-protein
B-alpha	I-protein
proteolysis	O
by	O
site-specific	O
,	O
signal-induced	O
phosphorylation	O
.	O

I	B-protein
kappa	I-protein
B-alpha	I-protein
inhibits	O
transcription	B-protein
factor	I-protein
NF-kappa	B-protein
B	I-protein
by	O
retaining	O
it	O
in	O
the	O
cytoplasm	O
.	O

Various	O
stimuli	O
,	O
typically	O
those	O
associated	O
with	O
stress	O
or	O
pathogens	O
,	O
rapidly	O
inactivate	O
I	B-protein
kappa	I-protein
B-alpha	I-protein
.	O

This	O
liberates	O
NF-kappa	B-protein
B	I-protein
to	O
translocate	O
to	O
the	O
nucleus	O
and	O
initiate	O
transcription	O
of	O
genes	B-DNA
important	O
for	O
the	O
defense	O
of	O
the	O
organism	O
.	O

Activation	O
of	O
NF-kappa	B-protein
B	I-protein
correlates	O
with	O
phosphorylation	O
of	O
I	B-protein
kappa	I-protein
B-alpha	I-protein
and	O
requires	O
the	O
proteolysis	O
of	O
this	O
inhibitor	O
.	O

When	O
either	O
serine-32	O
or	O
serine-36	O
of	O
I	B-protein
kappa	I-protein
B-alpha	I-protein
was	O
mutated	O
,	O
the	O
protein	O
did	O
not	O
undergo	O
signal-induced	O
phosphorylation	O
or	O
degradation	O
,	O
and	O
NF-kappa	B-protein
B	I-protein
could	O
not	O
be	O
activated	O
.	O

These	O
results	O
suggest	O
that	O
phosphorylation	O
at	O
one	O
or	O
both	O
of	O
these	O
residues	O
is	O
critical	O
for	O
activation	O
of	O
NF-kappa	B-protein
B	I-protein
.	O

Regulation	O
of	O
transcription	O
of	O
the	O
human	B-DNA
erythropoietin	I-DNA
receptor	I-DNA
gene	I-DNA
by	O
proteins	O
binding	O
to	O
GATA-1	B-DNA
and	I-DNA
Sp1	I-DNA
motifs	I-DNA
.	O

Erythropoietin	B-protein
(	O
Epo	B-protein
)	O
,	O
the	O
primary	O
regulator	O
of	O
the	O
production	O
of	O
erythroid	B-cell_type
cells	I-cell_type
,	O
acts	O
by	O
binding	O
to	O
a	O
cell	B-protein
surface	I-protein
receptor	I-protein
(	O
EpoR	B-protein
)	O
on	O
erythroid	B-cell_type
progenitors	I-cell_type
.	O

We	O
used	O
deletion	O
analysis	O
and	O
transfection	O
assays	O
with	O
reporter	B-DNA
gene	I-DNA
constructs	I-DNA
to	O
examine	O
the	O
transcription	B-DNA
control	I-DNA
elements	I-DNA
in	O
the	O
5	B-DNA
'	I-DNA
flanking	I-DNA
region	I-DNA
of	O
the	O
human	B-DNA
EpoR	I-DNA
gene	I-DNA
.	O

In	O
erythroid	B-cell_type
cells	I-cell_type
most	O
of	O
the	O
transcription	O
activity	O
was	O
contained	O
in	O
a	O
150	B-DNA
bp	I-DNA
promoter	I-DNA
fragment	O
with	O
binding	B-DNA
sites	I-DNA
for	O
transcription	B-protein
factors	I-protein
AP2	B-protein
,	O
Sp1	B-protein
and	O
the	O
erythroid-specific	B-protein
GATA-1	I-protein
.	O

The	O
150	B-DNA
bp	I-DNA
hEpoR	I-DNA
promoter	I-DNA
exhibited	O
high	O
and	O
low	O
activity	O
in	O
erythroid	O
OCIM1	B-cell_line
and	O
K562	B-cell_line
cells	I-cell_line
,	O
respectively	O
,	O
reflecting	O
the	O
high	O
and	O
low	O
levels	O
of	O
constitutive	O
hEpoR	B-protein
expression	O
.	O

The	O
GATA-1	B-DNA
and	I-DNA
Sp1	I-DNA
binding	I-DNA
sites	I-DNA
in	O
this	O
promoter	O
lacking	O
a	O
TATA	B-DNA
sequence	I-DNA
were	O
necessary	O
for	O
a	O
high	O
level	O
of	O
transcription	O
activation	O
.	O

Protein-DNA	O
binding	O
studies	O
suggested	O
that	O
Sp1	B-protein
and	O
two	O
other	O
CCGCCC	B-protein
binding	I-protein
proteins	I-protein
from	O
erythroid	B-cell_type
and	I-cell_type
non-erythroid	I-cell_type
cells	I-cell_type
could	O
bind	O
to	O
the	O
Sp1	B-DNA
binding	I-DNA
motif	I-DNA
.	O

By	O
increasing	O
GATA-1	B-protein
levels	O
via	O
co-transfection	O
,	O
we	O
were	O
able	O
to	O
transactivate	O
the	O
hEpoR	B-DNA
promoter	I-DNA
in	O
K562	B-cell_line
cells	I-cell_line
and	O
non-erythroid	B-cell_type
cells	I-cell_type
,	O
but	O
not	O
in	O
the	O
highly	O
active	O
OCIM1	B-cell_type
cells	I-cell_type
,	O
although	O
GATA-1	B-RNA
mRNA	I-RNA
levels	O
were	O
comparable	O
in	O
OCIM1	B-cell_line
and	O
K562	B-cell_line
.	O

Interestingly	O
,	O
when	O
we	O
mutated	O
the	O
Sp1	B-DNA
site	I-DNA
,	O
resulting	O
in	O
a	O
marked	O
decrease	O
in	O
hEpoR	B-DNA
promoter	I-DNA
activity	O
,	O
we	O
could	O
restore	O
transactivation	O
by	O
increasing	O
GATA-1	B-protein
levels	O
in	O
OCIM1	B-cell_type
cells	I-cell_type
.	O

These	O
data	O
suggest	O
that	O
while	O
GATA-1	B-protein
can	O
transactivate	O
the	O
EpoR	B-DNA
promoter	I-DNA
,	O
the	O
level	O
of	O
hEpoR	B-DNA
gene	I-DNA
expression	O
does	O
not	O
depend	O
on	O
GATA-1	B-protein
alone	O
.	O

Rather	O
,	O
hEpoR	B-protein
transcription	O
activity	O
depends	O
on	O
coordination	O
between	O
Sp1	B-protein
and	O
GATA-1	B-protein
with	O
other	O
cell-specific	B-protein
factors	I-protein
,	O
including	O
possibly	O
other	O
Sp1-like	B-protein
binding	I-protein
proteins	I-protein
,	O
to	O
provide	O
high	O
level	O
,	O
tissue-specific	O
expression	O
.	O

Overexpression	O
of	O
DR-nm23	B-protein
,	O
a	O
protein	O
encoded	O
by	O
a	O
member	O
of	O
the	O
nm23	B-DNA
gene	I-DNA
family	I-DNA
,	O
inhibits	O
granulocyte	B-cell_type
differentiation	O
and	O
induces	O
apoptosis	O
in	O
32Dc13	B-cell_line
myeloid	I-cell_line
cells	I-cell_line
.	O

Chronic	O
myelogenous	O
leukemia	O
evolves	O
in	O
two	O
clinically	O
distinct	O
stages	O
:	O
a	O
chronic	O
and	O
a	O
blast	O
crisis	O
phase	O
.	O

The	O
molecular	O
changes	O
associated	O
with	O
chronic	O
phase	O
to	O
blast	O
crisis	O
transition	O
are	O
largely	O
unknown	O
.	O

We	O
have	O
identified	O
a	O
cDNA	B-DNA
clone	I-DNA
,	O
DR-nm23	B-protein
,	O
differentially	O
expressed	O
in	O
a	O
blast-crisis	B-DNA
cDNA	I-DNA
library	I-DNA
,	I-DNA
which	O
has	O
approximately	O
70	O
%	O
sequence	O
similarity	O
to	O
the	O
putative	B-DNA
metastatic	I-DNA
suppressor	I-DNA
genes	I-DNA
,	O
nm23-H1	B-DNA
and	O
nm23-H2	B-DNA
.	O

The	O
deduced	O
amino	O
acid	O
sequence	O
similarity	O
to	O
the	O
proteins	O
encoded	O
by	O
these	O
two	O
latter	O
genes	O
is	O
approximately	O
65	O
%	O
and	O
includes	O
domains	O
and	O
amino	O
acid	O
residues	O
(	O
the	O
leucine	B-protein
zipper-like	I-protein
and	O
the	O
RGD	B-protein
domain	I-protein
,	O
a	O
serine	O
and	O
a	O
histidine	O
residue	O
in	O
the	O
NH2-	B-protein
and	O
in	O
the	O
COOH-terminal	B-protein
portion	I-protein
of	O
the	O
protein	O
,	O
respectively	O
)	O
postulated	O
to	O
be	O
important	O
for	O
nm23	B-protein
function	O
.	O

DR-nm23	B-RNA
mRNA	I-RNA
is	O
preferentially	O
expressed	O
at	O
early	O
stages	O
of	O
myeloid	O
differentiation	O
of	O
highly	B-cell_line
purified	I-cell_line
CD34+	I-cell_line
cells	I-cell_line
.	O

Its	O
constitutive	O
expression	O
in	O
the	O
myeloid	B-cell_line
precursor	I-cell_line
32Dc13	I-cell_line
cell	I-cell_line
line	I-cell_line
,	O
which	O
is	O
growth-factor	O
dependent	O
for	O
both	O
proliferation	O
and	O
differentiation	O
,	O
results	O
in	O
inhibition	O
of	O
granulocytic	O
differentiation	O
induced	O
by	O
granulocyte	B-protein
colony-stimulating	I-protein
factor	I-protein
and	O
causes	O
apoptotic	O
cell	O
death	O
.	O

These	O
results	O
are	O
consistent	O
with	O
a	O
role	O
for	O
DR-nm23	B-protein
in	O
normal	O
hematopoiesis	O
and	O
raise	O
the	O
possibility	O
that	O
its	O
overexpression	O
contributes	O
to	O
differentiation	O
arrest	O
,	O
a	O
feature	O
of	O
blastic	O
transformation	O
in	O
chronic	O
myelogenous	O
leukemia	O
.	O

An	O
interferon-gamma	B-DNA
activation	I-DNA
sequence	I-DNA
mediates	O
the	O
transcriptional	O
regulation	O
of	O
the	O
IgG	B-DNA
Fc	I-DNA
receptor	I-DNA
type	I-DNA
IC	I-DNA
gene	I-DNA
by	O
interferon-gamma	B-protein
.	O

Expression	O
of	O
the	O
IgG	B-protein
Fc	I-protein
receptor	I-protein
type	I-protein
I	I-protein
(	O
Fc	B-protein
gamma	I-protein
RI	I-protein
)	O
on	O
myeloid	B-cell_type
cells	I-cell_type
is	O
dramatically	O
increased	O
by	O
treatment	O
with	O
interferon-gamma	B-protein
(	O
IFN-gamma	B-protein
)	O
.	O

We	O
observed	O
that	O
Fc	B-protein
gamma	I-protein
RI	I-protein
transcript	O
levels	O
in	O
monoblast-like	B-cell_line
U937	I-cell_line
cells	I-cell_line
were	O
elevated	O
within	O
3	O
hr	O
and	O
peaked	O
12	O
hr	O
after	O
exposure	O
to	O
IFN-gamma	B-protein
.	O

Treatment	O
of	O
U937	B-cell_line
with	O
IFN-gamma	B-protein
for	O
9	O
hr	O
in	O
the	O
presence	O
of	O
cycloheximide	O
led	O
to	O
super-induction	O
of	O
Fc	B-protein
gamma	I-protein
RI	I-protein
expression	O
.	O

Nuclear	O
run-on	O
analysis	O
revealed	O
that	O
the	O
rate	O
of	O
Fc	B-protein
gamma	I-protein
RI	I-protein
transcription	O
was	O
increased	O
by	O
IFN-gamma	B-protein
.	O

Genomic	O
sequence	O
upstream	O
of	O
the	O
Fc	B-DNA
gamma	I-DNA
RIC	I-DNA
gene	I-DNA
was	O
cloned	O
and	O
subjected	O
to	O
primer	O
extension	O
analysis	O
,	O
which	O
demonstrated	O
a	O
single	O
transcription	B-DNA
initiation	I-DNA
site	I-DNA
without	O
a	O
TATA	B-DNA
box	I-DNA
.	O

Transient	O
transfections	O
of	O
CAT	B-DNA
reporter	I-DNA
gene	I-DNA
constructs	I-DNA
containing	O
various	O
Fc	B-DNA
gamma	I-DNA
RIC	I-DNA
promoter	I-DNA
sequences	I-DNA
into	O
U937	B-cell_line
cells	I-cell_line
revealed	O
that	O
a	O
20-bp	B-DNA
region	I-DNA
surrounding	O
the	O
transcription	B-DNA
start	I-DNA
site	I-DNA
(	O
-7	O
to	O
+13	O
)	O
was	O
capable	O
of	O
mediating	O
transcription	O
initiation	O
and	O
that	O
an	O
IFN-gamma	B-DNA
responsive	I-DNA
element	I-DNA
(	O
GIRE	B-DNA
)	O
was	O
present	O
within	O
74	B-DNA
bp	I-DNA
upstream	I-DNA
of	O
the	O
transcription	B-DNA
initiation	I-DNA
site	I-DNA
.	O

A	O
17-bp	B-DNA
sequence	I-DNA
between	O
positions	O
-51	O
and	O
-35	O
conferred	O
IFN-gamma	B-protein
responsiveness	O
on	O
a	O
heterologous	B-DNA
promoter	I-DNA
.	O

Double-stranded	B-DNA
GIRE	I-DNA
sequence	I-DNA
,	O
but	O
not	O
a	O
scrambled	B-DNA
sequence	I-DNA
,	O
was	O
specifically	O
bound	O
by	O
nuclear	B-protein
proteins	I-protein
from	O
IFN-gamma	B-cell_line
treated	I-cell_line
U937	I-cell_line
cells	I-cell_line
.	O

Gel	O
shift	O
experiments	O
further	O
showed	O
that	O
the	O
STAT1	B-protein
alpha	I-protein
protein	I-protein
bound	O
to	O
the	O
Fc	B-DNA
gamma	I-DNA
RIC	I-DNA
GIRE	I-DNA
in	O
response	O
to	O
IFN-gamma	B-protein
treatment	O
of	O
U937	B-cell_line
cells	I-cell_line
.	O

The	O
Fc	B-DNA
gamma	I-DNA
RIC	I-DNA
GIRE	I-DNA
is	O
homologous	O
to	O
the	O
IFN-gamma	B-DNA
activation	I-DNA
sequence	I-DNA
(	O
GAS	B-DNA
)	O
of	O
the	O
guanylate	B-protein
binding	I-protein
protein	I-protein
and	O
to	O
X	B-DNA
box	I-DNA
elements	I-DNA
of	O
class	B-DNA
II	I-DNA
MHC	I-DNA
genes	I-DNA
.	O

Our	O
results	O
demonstrate	O
that	O
transcriptional	O
regulation	O
of	O
the	O
Fc	B-DNA
gamma	I-DNA
RIC	I-DNA
gene	I-DNA
by	O
IFN-gamma	B-protein
involves	O
the	O
binding	O
of	O
STAT1	B-protein
alpha	I-protein
to	O
a	O
17-bp	B-DNA
GAS	I-DNA
homology	I-DNA
in	O
the	O
proximal	B-DNA
promoter	I-DNA
.	O

Constitutively	O
activated	O
Jak	B-protein
-STAT	B-protein
pathway	O
in	O
T	B-cell_type
cells	I-cell_type
transformed	O
with	O
HTLV-I	O
.	O

Human	O
T	O
cell	O
lymphotropic	O
virus	O
I	O
(	O
HTLV-I	O
)	O
is	O
the	O
etiological	O
agent	O
for	O
adult	O
T	O
cell	O
leukemia	O
and	O
tropical	O
spastic	O
paraparesis	O
(	O
also	O
termed	O
HTLV-I-associated	O
myelopathy	O
)	O
.	O

HTLV-I-infected	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
T	I-cell_type
cells	I-cell_type
exhibit	O
an	O
initial	O
phase	O
of	O
interleukin-2	B-protein
(	O
IL-2	B-protein
)	O
-dependent	O
growth	O
;	O
over	O
time	O
,	O
by	O
an	O
unknown	O
mechanism	O
,	O
the	O
cells	O
become	O
IL-2	B-protein
-independent	O
.	O

Whereas	O
the	O
Jak	B-protein
kinases	I-protein
Jak1	B-protein
and	O
Jak3	B-protein
and	O
the	O
signal	O
transducer	O
and	O
activator	O
of	O
transcription	B-protein
proteins	I-protein
Stat3	B-protein
and	O
Stat5	B-protein
are	O
activated	O
in	O
normal	B-cell_type
T	I-cell_type
cells	I-cell_type
in	O
response	O
to	O
IL-2	B-protein
,	O
this	O
signaling	O
pathway	O
was	O
constitutively	O
activated	O
in	O
HTLV-I-transformed	B-cell_line
cells	I-cell_line
.	O

In	O
HTLV-I-infected	B-cell_line
cord	I-cell_line
blood	I-cell_line
lymphocytes	I-cell_line
,	O
the	O
transition	O
from	O
IL-2	B-protein
-dependent	O
to	O
IL-2	B-protein
-independent	O
growth	O
correlated	O
with	O
the	O
acquisition	O
of	O
a	O
constitutively	O
activated	O
Jak	B-protein
-STAT	B-protein
pathway	O
,	O
which	O
suggests	O
that	O
this	O
pathway	O
participates	O
in	O
HTLV-I-mediated	O
T	O
cell	O
transformation	O
.	O

Nitric	O
oxide	O
decreases	O
cytokine	B-protein
-induced	O
endothelial	O
activation	O
.	O

Nitric	O
oxide	O
selectively	O
reduces	O
endothelial	O
expression	O
of	O
adhesion	B-protein
molecules	I-protein
and	O
proinflammatory	B-protein
cytokines	I-protein
.	O

To	O
test	O
the	O
hypothesis	O
that	O
nitric	O
oxide	O
(	O
NO	O
)	O
limits	O
endothelial	O
activation	O
,	O
we	O
treated	O
cytokine-stimulated	B-cell_line
human	I-cell_line
saphenous	I-cell_line
vein	I-cell_line
endothelial	I-cell_line
cells	I-cell_line
with	O
several	O
NO	O
donors	O
and	O
assessed	O
their	O
effects	O
on	O
the	O
inducible	O
expression	O
of	O
vascular	B-protein
cell	I-protein
adhesion	I-protein
molecule-1	I-protein
(	O
VCAM-1	B-protein
)	O
.	O

In	O
a	O
concentration-dependent	O
manner	O
,	O
NO	O
inhibited	O
interleukin	B-protein
(	I-protein
IL	I-protein
)	I-protein
-1	I-protein
alpha-stimulated	O
VCAM-1	B-protein
expression	O
by	O
35-55	O
%	O
as	O
determined	O
by	O
cell	O
surface	O
enzyme	O
immunoassays	O
and	O
flow	O
cytometry	O
.	O

This	O
inhibition	O
was	O
paralleled	O
by	O
reduced	O
monocyte	O
adhesion	O
to	O
endothelial	O
monolayers	O
in	O
nonstatic	O
assays	O
,	O
was	O
unaffected	O
by	O
cGMP	O
analogues	O
,	O
and	O
was	O
quantitatively	O
similar	O
after	O
stimulation	O
by	O
either	O
IL-1	B-protein
alpha	I-protein
,	O
IL-1	B-protein
beta	I-protein
,	O
IL-4	B-protein
,	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
(	O
TNF	B-protein
alpha	I-protein
)	O
,	O
or	O
bacterial	O
lipopolysaccharide	O
.	O

NO	O
also	O
decreased	O
the	O
endothelial	O
expression	O
of	O
other	O
leukocyte	B-protein
adhesion	I-protein
molecules	I-protein
(	O
E-selectin	B-protein
and	O
to	O
a	O
lesser	O
extent	O
,	O
intercellular	B-protein
adhesion	I-protein
molecule-1	I-protein
)	O
and	O
secretable	O
cytokines	B-protein
(	O
IL-6	B-protein
and	O
IL-8	B-protein
)	O
.	O

Inhibition	O
of	O
endogenous	O
NO	O
production	O
by	O
L-N-monomethyl-arginine	O
also	O
induced	O
the	O
expression	O
of	O
VCAM-1	B-protein
,	O
but	O
did	O
not	O
augment	O
cytokine-induced	O
VCAM-1	B-protein
expression	O
.	O

Nuclear	O
run-on	O
assays	O
,	O
transfection	O
studies	O
using	O
various	O
VCAM-1	B-DNA
promoter	I-DNA
reporter	I-DNA
gene	I-DNA
constructs	I-DNA
,	O
and	O
electrophoretic	O
mobility	O
shift	O
assays	O
indicated	O
that	O
NO	O
represses	O
VCAM-1	B-protein
gene	O
transcription	O
,	O
in	O
part	O
,	O
by	O
inhibiting	O
NF-kappa	B-protein
B	I-protein
.	O

We	O
propose	O
that	O
NO	O
's	O
ability	O
to	O
limit	O
endothelial	O
activation	O
and	O
inhibit	O
monocyte	O
adhesion	O
may	O
contribute	O
to	O
some	O
of	O
its	O
antiatherogenic	O
and	O
antiinflammatory	O
properties	O
within	O
the	O
vessel	O
wall	O
.	O

MIP1	B-protein
alpha	I-protein
nuclear	I-protein
protein	I-protein
(	O
MNP	B-protein
)	O
,	O
a	O
novel	O
transcription	B-protein
factor	I-protein
expressed	O
in	O
hematopoietic	O
cells	O
that	O
is	O
crucial	O
for	O
transcription	O
of	O
the	O
human	B-DNA
MIP-1	I-DNA
alpha	I-DNA
gene	I-DNA
.	O

Murine	B-protein
macrophage	I-protein
inflammatory	I-protein
protein	I-protein
1	I-protein
alpha	I-protein
(	O
MIP-1	B-protein
alpha	I-protein
)	O
and	O
its	O
human	B-protein
equivalent	I-protein
(	O
GOS19	B-protein
,	O
LD78	B-protein
,	O
or	O
AT464	B-protein
)	O
are	O
members	O
of	O
the	O
-C-C	B-protein
family	I-protein
of	O
low-molecular-weight	B-protein
chemokines	I-protein
.	O

Secreted	O
from	O
activated	B-cell_type
T	I-cell_type
cells	I-cell_type
and	O
macrophages	B-cell_type
,	O
bone	O
marrow-derived	B-protein
MIP-1	I-protein
alpha/GOS19	I-protein
inhibits	O
primitive	B-cell_type
hematopoietic	I-cell_type
stem	I-cell_type
cells	I-cell_type
and	O
appears	O
to	O
be	O
involved	O
in	O
the	O
homeostatic	O
control	O
of	O
stem	B-cell_type
cell	I-cell_type
proliferation	O
.	O

It	O
also	O
induces	O
chemotaxis	O
and	O
inflammatory	O
responses	O
in	O
mature	B-cell_type
cell	I-cell_type
types	I-cell_type
.	O

Therefore	O
,	O
it	O
is	O
important	O
to	O
understand	O
the	O
mechanisms	O
which	O
control	O
the	O
expression	O
of	O
MIP-1	B-protein
alpha	I-protein
/GOS19	B-protein
.	O

Previous	O
work	O
has	O
shown	O
that	O
in	O
Jurkat	B-cell_line
T	I-cell_line
cells	I-cell_line
,	O
a	O
set	O
of	O
widely	O
expressed	O
transcription	B-protein
factors	I-protein
(	O
the	O
ICK-1	B-protein
family	I-protein
)	O
affect	O
the	O
GOS19	B-DNA
promoter	I-DNA
.	O

One	O
member	O
,	O
ICK-1A	B-protein
,	O
behaves	O
as	O
a	O
strong	B-protein
negative	I-protein
regulator	I-protein
.	O

In	O
this	O
communication	O
,	O
we	O
provide	O
evidence	O
that	O
the	O
pathway	O
of	O
induction	O
in	O
the	O
macrophage	B-cell_line
cell	I-cell_line
line	I-cell_line
U937	B-cell_line
is	O
different	O
from	O
that	O
in	O
Jurkat	B-cell_line
cells	I-cell_line
.	O

Furthermore	O
,	O
we	O
show	O
that	O
the	O
ICK-1	B-DNA
binding	I-DNA
site	I-DNA
does	O
not	O
confer	O
negative	O
regulation	O
in	O
U937	B-cell_line
cells	I-cell_line
.	O

We	O
provide	O
evidence	O
for	O
an	O
additional	O
binding	B-DNA
site	I-DNA
,	O
the	O
MIP-1	B-DNA
alpha	I-DNA
nuclear	I-DNA
protein	I-DNA
(	I-DNA
MNP	I-DNA
)	I-DNA
site	I-DNA
,	O
which	O
overlaps	O
the	O
ICK-1	B-DNA
site	I-DNA
.	O

Interaction	O
of	O
nuclear	O
extracts	O
from	O
various	B-cell_line
cell	I-cell_line
lines	I-cell_line
and	O
tissue	O
with	O
the	O
MNP	B-DNA
site	I-DNA
leads	O
to	O
the	O
formation	O
of	O
fast-migrating	B-protein
protein-DNA	I-protein
complexes	I-protein
with	O
similar	O
but	O
distinct	O
electrophoretic	O
mobilities	O
.	O

A	O
mutation	O
of	O
the	O
MNP	B-DNA
site	I-DNA
which	O
does	O
not	O
abrogate	O
ICK-1	O
binding	O
inactivates	O
the	O
GOS19.1	B-DNA
promoter	I-DNA
in	O
U937	B-cell_line
cells	I-cell_line
and	O
reduces	O
its	O
activity	O
by	O
fourfold	O
in	O
Jurkat	B-cell_line
cells	I-cell_line
.	O

We	O
propose	O
that	O
the	O
MNP	B-protein
protein	I-protein
(	O
s	O
)	O
binding	O
at	O
the	O
MNP	B-DNA
site	I-DNA
constitutes	O
a	O
novel	O
transcription	B-protein
factor	I-protein
(	O
s	O
)	O
expressed	O
in	O
hematopoietic	B-cell_type
cells	I-cell_type
.	O

The	O
effect	O
of	O
Toremifene	O
on	O
the	O
expression	O
of	O
some	O
genes	O
in	O
human	B-cell_type
mononuclear	I-cell_type
cells	I-cell_type
.	O

Toremifene	O
exerts	O
multiple	O
and	O
varied	O
effects	O
on	O
the	O
gene	O
expression	O
of	O
human	B-cell_type
peripheral	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
.	O

After	O
short-term	O
,	O
in	O
vitro	O
exposure	O
to	O
therapeutical	O
levels	O
,	O
distinct	O
changes	O
in	O
P-glycoprotein	O
,	O
steroid	O
receptors	O
,	O
p53	O
and	O
Bcl-2	O
expression	O
take	O
place	O
.	O

In	O
view	O
of	O
the	O
increasing	O
use	O
of	O
antiestrogens	O
in	O
cancer	O
therapy	O
and	O
prevention	O
,	O
there	O
is	O
obvious	O
merit	O
in	O
long-term	O
in	O
vivo	O
studies	O
to	O
be	O
conducted	O
.	O

The	O
interleukin-5	B-protein
/receptor	O
interaction	O
activates	O
Lyn	B-protein
and	I-protein
Jak2	I-protein
tyrosine	I-protein
kinases	I-protein
and	O
propagates	O
signals	O
via	O
the	O
Ras-Raf-1-MAP	B-protein
kinase	I-protein
and	O
the	O
Jak	B-protein
-STAT	B-protein
pathways	O
in	O
eosinophils	B-cell_type
.	O

We	O
have	O
shown	O
that	O
the	O
interaction	O
of	O
interleukin	B-protein
(	I-protein
IL	I-protein
)	I-protein
-5	I-protein
with	O
the	O
receptor	O
activates	O
Lyn	B-protein
tyrosine	I-protein
kinase	I-protein
within	O
1	O
min	O
and	O
Jak2	B-protein
tyrosine	I-protein
kinase	I-protein
within	O
1-3	O
min	O
.	O

IL-5	B-protein
also	O
stimulates	O
GTP	O
binding	O
to	O
p21ras	B-protein
.	O

The	O
signal	O
is	O
subsequently	O
propagated	O
through	O
the	O
activation	O
of	O
Raf-1	B-protein
,	O
MEK	B-protein
,	O
and	O
MAP	B-protein
kinases	I-protein
as	O
shown	O
by	O
their	O
increased	O
autophosphorylation	O
in	O
vitro	O
and	O
phosphorylation	O
in	O
situ	O
.	O

Jak2	B-protein
kinase	I-protein
has	O
been	O
shown	O
to	O
phosphorylate	O
STAT	B-protein
nuclear	I-protein
proteins	I-protein
.	O

The	O
activation	O
of	O
STAT	B-protein
nuclear	I-protein
factors	I-protein
was	O
studied	O
by	O
electrophoretic	O
mobility	O
shift	O
assay	O
using	O
a	O
gamma	B-DNA
activation	I-DNA
site	I-DNA
(	O
GAS	B-DNA
)	O
probe	O
.	O

We	O
found	O
that	O
IL-5	B-protein
induces	O
two	O
GAS-binding	B-protein
proteins	I-protein
in	O
eosinophils	B-cell_type
,	O
one	O
of	O
which	O
is	O
STAT1	B-protein
.	O

We	O
conclude	O
that	O
IL-5	B-protein
induced	O
signals	O
are	O
propagated	O
through	O
two	O
distinct	O
pathways	O
:	O
(	O
1	O
)	O
Lyn	B-protein
--	O
>	O
Ras	B-protein
--	O
>	O
Raf-1	B-protein
--	O
>	O
MEK	B-protein
--	O
>	O
MAP	B-protein
kinase	I-protein
and	O
(	O
2	O
)	O
Jak2	B-protein
--	O
>	O
STAT1	B-protein
.	O

The	O
retinoblastoma	B-protein
gene	I-protein
product	I-protein
negatively	O
regulates	O
transcriptional	O
activation	O
mediated	O
by	O
the	O
human	B-protein
cytomegalovirus	I-protein
IE2	I-protein
protein	I-protein
.	O

The	O
IE2	B-protein
gene	I-protein
product	I-protein
of	O
human	O
cytomegalovirus	O
(	O
HCMV	O
)	O
is	O
one	O
of	O
a	O
few	O
viral	B-protein
regulatory	I-protein
proteins	I-protein
expressed	O
immediately	O
upon	O
infection	O
of	O
the	O
host	B-cell_type
cell	I-cell_type
.	O

It	O
is	O
a	O
potent	O
transcriptional	B-protein
activator	I-protein
of	O
many	O
viral	B-DNA
and	I-DNA
cellular	I-DNA
promoters	I-DNA
.	O

We	O
found	O
that	O
the	O
retinoblastoma	B-protein
susceptibility	I-protein
gene	I-protein
product	I-protein
(	O
Rb	B-protein
)	O
dramatically	O
suppressed	O
this	O
IE2	B-protein
transactivation	O
of	O
various	B-DNA
promoters	I-DNA
.	O

However	O
,	O
unlike	O
another	O
tumor	B-protein
suppressor	I-protein
protein	I-protein
,	O
p53	B-protein
,	O
Rb	B-protein
did	O
not	O
have	O
any	O
significant	O
effect	O
on	O
basal	O
levels	O
of	O
transcription	O
,	O
suggesting	O
that	O
Rb	B-protein
specifically	O
interacts	O
with	O
IE2	B-protein
rather	O
than	O
other	O
cellular	B-protein
factors	I-protein
involved	O
in	O
the	O
general	O
transcription	O
machinery	O
.	O

We	O
found	O
by	O
protein-affinity	O
chromatography	O
that	O
Rb	B-protein
in	O
nuclear	O
extracts	O
or	O
produced	O
by	O
in	O
vitro	O
translation	O
directly	O
bound	O
to	O
IE2	B-protein
.	O

Our	O
results	O
suggest	O
that	O
Rb	B-protein
may	O
regulate	O
the	O
life	O
cycle	O
of	O
HCMV	O
,	O
which	O
is	O
endemic	O
in	O
the	O
human	O
population	O
.	O

Furthermore	O
,	O
these	O
data	O
may	O
provide	O
new	O
insights	O
into	O
the	O
slow	O
rate	O
of	O
HCMV	O
DNA	O
replication	O
in	O
cells	O
and	O
the	O
possible	O
involvement	O
of	O
HCMV	O
in	O
tumorigenesis	O
.	O

Expression	O
of	O
the	O
nucleoside	B-protein
diphosphate	I-protein
kinase	I-protein
in	O
human	O
skin	O
cancers	O
:	O
an	O
immunohistochemical	O
study	O
.	O

Expression	O
of	O
nucleoside	B-protein
diphosphate	I-protein
(	I-protein
NDP	I-protein
)	I-protein
kinase	I-protein
,	O
which	O
is	O
homologous	O
to	O
the	O
nm23	B-protein
gene	I-protein
product	I-protein
in	O
a	O
variety	O
of	O
species	O
,	O
has	O
been	O
found	O
to	O
be	O
inversely	O
associated	O
with	O
metastatic	O
potential	O
.	O

However	O
,	O
the	O
relationship	O
remains	O
controversial	O
according	O
to	O
the	O
tumor	B-cell_type
cell	I-cell_type
types	I-cell_type
and	O
experimental	O
system	O
,	O
with	O
conflicting	O
results	O
from	O
different	O
research	O
groups	O
.	O

In	O
order	O
to	O
determine	O
whether	O
NDP	B-protein
kinase	I-protein
expression	O
serves	O
as	O
a	O
marker	O
for	O
metastatic	O
potential	O
in	O
human	O
skin	O
cancer	O
,	O
we	O
assessed	O
the	O
levels	O
of	O
NDP	B-protein
kinase	I-protein
expression	O
in	O
9	O
keratoacanthomas	O
(	O
KAs	O
)	O
,	O
26	O
squamous	O
cell	O
carcinomas	O
(	O
SCCs	O
)	O
,	O
and	O
25	O
basal	O
cell	O
carcinomas	O
(	O
BCCs	O
)	O
using	O
immunohistochemistry	O
.	O

The	O
expression	O
of	O
NDP	B-protein
kinase	I-protein
was	O
intense	O
in	O
KA	O
and	O
SCC	O
compared	O
with	O
BCC	O
.	O

However	O
,	O
the	O
difference	O
of	O
NDP	B-protein
kinase	I-protein
expression	O
between	O
KA	O
and	O
SCC	O
was	O
not	O
statistically	O
significant	O
.	O

And	O
there	O
was	O
no	O
statistically	O
significant	O
difference	O
in	O
NDP	B-protein
kinase	I-protein
expression	O
between	O
SCC	O
with	O
metastasis	O
and	O
SCC	O
without	O
metastasis	O
.	O

Our	O
results	O
contradict	O
the	O
hypothesis	O
concerning	O
the	O
possible	O
role	O
of	O
nm23	B-DNA
gene	I-DNA
as	O
a	O
metastatic	O
suppressor	O
gene	O
in	O
human	O
skin	O
cancer	O
.	O

The	O
mechanism	O
of	O
overexpression	O
in	O
various	O
tumor	B-cell_type
cell	I-cell_type
types	I-cell_type
and	O
its	O
biological	O
significance	O
in	O
cutaneous	O
carcinogenesis	O
remain	O
to	O
be	O
determined	O
.	O

RB	B-protein
and	O
a	O
novel	O
E2F-1	B-protein
binding	I-protein
protein	I-protein
in	O
MHC	B-cell_line
class	I-cell_line
II	I-cell_line
deficient	I-cell_line
B-cell	I-cell_line
lines	I-cell_line
and	O
normal	O
IFN-gamma	B-protein
induction	O
of	O
the	O
class	B-DNA
IL	I-DNA
transactivator	I-DNA
CIITA	B-DNA
in	O
class	B-cell_line
II	I-cell_line
non-inducible	I-cell_line
RB-defective	I-cell_line
tumor	I-cell_line
lines	I-cell_line
.	O

The	O
major	B-DNA
histocompatibility	I-DNA
(	I-DNA
MHC	I-DNA
)	I-DNA
class	I-DNA
II	I-DNA
genes	I-DNA
encode	O
cell	B-protein
surface	I-protein
proteins	I-protein
that	O
bind	O
antigenic	O
peptide	O
for	O
presentation	O
to	O
T-cells	B-cell_type
.	O

The	O
class	B-protein
II	I-protein
proteins	I-protein
are	O
expressed	O
constitutively	O
on	O
B-cells	B-cell_type
and	O
EBV-transformed	B-cell_line
B-cells	I-cell_line
,	I-cell_line
and	O
are	O
inducible	O
by	O
IFN-gamma	B-protein
on	O
a	O
wide	O
variety	O
of	O
cell	B-cell_type
types	I-cell_type
.	O

Retinoblastoma	B-protein
protein	I-protein
(	O
RB	B-protein
)	O
is	O
a	O
tumor	O
suppressor	O
and	O
functions	O
as	O
a	O
transcriptional	B-protein
repressor	I-protein
by	O
binding	O
and	O
inactivating	O
the	O
transactivator	B-DNA
E2F-I	I-DNA
.	O

RB-defective	B-cell_line
tumor	I-cell_line
lines	I-cell_line
are	O
non-inducible	O
for	O
MHC	B-protein
class	I-protein
II	I-protein
by	O
IFN-gamma	B-protein
,	O
or	O
very	O
weakly	O
inducible	O
,	O
but	O
transfection	O
of	O
2	O
different	O
lines	O
with	O
RB	B-DNA
expression	I-DNA
vectors	I-DNA
re-establishes	O
or	O
substantially	O
enhances	O
class	O
II	O
inducibility	O
.	O

Therefore	O
,	O
we	O
examined	O
the	O
RB	B-protein
status	O
of	O
a	O
series	O
of	O
B-cell	O
mutants	O
that	O
are	O
defective	O
in	O
class	O
II	O
expression	O
,	O
generated	O
either	O
in	O
vitro	O
or	O
derived	O
from	O
Bare	O
Lymphocyte	O
Syndrome	O
(	O
BLS	O
)	O
patients	O
.	O

Nuclear	O
matrix-bound	O
RB	B-protein
was	O
detectable	O
in	O
all	O
cases	O
,	O
indicating	O
that	O
loss	O
of	O
RB	B-protein
is	O
not	O
responsible	O
for	O
decreased	O
class	O
II	O
expression	O
in	O
these	O
lines	O
.	O

A	O
second	O
E2F-I	O
binding	O
protein	O
,	O
most	O
likely	O
DP-I	O
,	O
was	O
also	O
apparently	O
normal	O
in	O
both	O
class	O
II-positive	O
and	O
-negative	O
B-cell	O
lines	O
.	O

We	O
also	O
examined	O
the	O
IFN-gamma	B-protein
induction	O
of	O
CIITA	B-DNA
in	O
RB	B-protein
-defective	O
lines	O
.	O

CIITA	B-DNA
is	O
a	O
class	B-DNA
II	I-DNA
gene	I-DNA
transactivator	I-DNA
known	O
to	O
be	O
defective	O
in	O
one	O
form	O
of	O
BLS	O
and	O
to	O
be	O
required	O
for	O
the	O
induction	O
of	O
MHC	B-protein
class	I-protein
II	I-protein
by	O
IFN-gamma	B-protein
.	O

CIITA	B-RNA
mRNA	I-RNA
is	O
normally	O
inducible	O
by	O
IFN-gamma	B-protein
in	O
class	B-cell_line
II	I-cell_line
non-inducible	I-cell_line
,	I-cell_line
RB-defective	I-cell_line
lines	I-cell_line
,	O
and	O
in	O
one	O
line	O
,	O
re-expression	O
of	O
RB	B-protein
has	O
no	O
effect	O
on	O
CIITA	B-RNA
mRNA	I-RNA
induction	O
levels	O
.	O

Thus	O
,	O
the	O
block	O
in	O
MHC	O
class	O
II	O
inducibility	O
in	O
RB-defective	B-cell_line
cells	I-cell_line
is	O
not	O
due	O
to	O
a	O
block	O
in	O
CIITA	B-DNA
inducibility	O
.	O

Interleukin	B-protein
12	I-protein
induces	O
tyrosine	O
phosphorylation	O
and	O
activation	O
of	O
STAT4	B-protein
in	O
human	B-cell_type
lymphocytes	I-cell_type
.	O

Interleukin	B-protein
12	I-protein
(	O
IL-12	B-protein
)	O
is	O
an	O
important	O
immunoregulatory	B-protein
cytokine	I-protein
whose	O
receptor	O
is	O
a	O
member	O
of	O
the	O
hematopoietin	B-protein
receptor	I-protein
superfamily	I-protein
.	O

We	O
have	O
recently	O
demonstrated	O
that	O
stimulation	O
of	O
human	B-cell_type
T	I-cell_type
and	I-cell_type
natural	I-cell_type
killer	I-cell_type
cells	I-cell_type
with	O
IL-12	B-protein
induces	O
tyrosine	O
phosphorylation	O
of	O
the	O
Janus	B-protein
family	I-protein
tyrosine	I-protein
kinase	I-protein
JAK2	B-protein
and	O
Tyk2	B-protein
,	O
implicating	O
these	O
kinases	B-protein
in	O
the	O
immediate	O
biochemical	O
response	O
to	O
IL-12	B-protein
.	O

Recently	O
,	O
transcription	B-protein
factors	I-protein
known	O
as	O
STATs	B-protein
(	O
signal	B-protein
transducers	I-protein
and	I-protein
activators	I-protein
of	I-protein
transcription	I-protein
)	O
have	O
been	O
shown	O
to	O
be	O
tyrosine	O
phosphorylated	O
and	O
activated	O
in	O
response	O
to	O
a	O
number	O
of	O
cytokines	B-protein
that	O
bind	O
hematopoietin	B-protein
receptors	I-protein
and	O
activate	O
JAK	B-protein
kinases	I-protein
.	O

In	O
this	O
report	O
we	O
demonstrate	O
that	O
IL-12	B-protein
induces	O
tyrosine	O
phosphorylation	O
of	O
a	O
recently	O
identified	O
STAT	B-protein
family	I-protein
member	I-protein
,	O
STAT4	B-protein
,	O
and	O
show	O
that	O
STAT4	B-protein
expression	O
is	O
regulated	O
by	O
T-cell	O
activation	O
.	O

Furthermore	O
,	O
we	O
show	O
that	O
IL-12	B-protein
stimulates	O
formation	O
of	O
a	O
DNA-binding	B-protein
complex	I-protein
that	O
recognizes	O
a	O
DNA	O
sequence	O
previously	O
shown	O
to	O
bind	O
STAT	B-protein
proteins	I-protein
and	O
that	O
this	O
complex	O
contains	O
STAT4	B-protein
.	O

These	O
data	O
,	O
and	O
the	O
recent	O
demonstration	O
of	O
JAK	B-protein
phosphorylation	O
by	O
IL-12	B-protein
,	O
identify	O
a	O
rapid	O
signal-transduction	O
pathway	O
likely	O
to	O
mediate	O
IL-12	B-protein
-induced	O
gene	O
expression	O
.	O

Temperature-induced	O
down-regulation	O
of	O
the	O
glucocorticoid	B-protein
receptor	I-protein
in	O
peripheral	B-cell_type
blood	I-cell_type
mononuclear	I-cell_type
leucocyte	I-cell_type
in	O
patients	O
with	O
sepsis	O
or	O
septic	O
shock	O
.	O

OBJECTIVE	O
:	O
Activation	O
of	O
the	O
hypothalamic-pituitary-adrenal	O
axis	O
is	O
of	O
vital	O
importance	O
during	O
critical	O
illness	O
.	O

We	O
have	O
studied	O
the	O
adaptive	O
mechanisms	O
which	O
occur	O
at	O
the	O
level	O
of	O
the	O
glucocorticoid	B-protein
receptor	I-protein
in	O
glucocorticoid	O
target	O
tissues	O
in	O
patients	O
with	O
sepsis	O
or	O
septic	O
shock	O
.	O

DESIGN	O
:	O
The	O
effects	O
of	O
hypercortisolaemia	O
,	O
hyperthermia	O
and	O
cellular	O
composition	O
on	O
number	O
of	O
glucocorticoid	B-protein
receptors	I-protein
per	O
cell	O
and	O
their	O
affinity	O
were	O
evaluated	O
,	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
,	O
in	O
peripheral	B-cell_type
blood	I-cell_type
mononuclear	I-cell_type
leucocytes	I-cell_type
of	O
control	O
subjects	O
and	O
in	O
patients	O
with	O
sepsis	O
or	O
septic	O
shock	O
.	O

SUBJECTS	O
:	O
Fifteen	O
patients	O
(	O
age	O
25-79	O
)	O
with	O
sepsis	O
or	O
septic	O
shock	O
who	O
were	O
admitted	O
to	O
an	O
intensive	O
care	O
unit	O
were	O
studied	O
.	O

The	O
control	O
group	O
consisted	O
of	O
24	O
healthy	O
laboratory	O
employees	O
.	O

MEASUREMENTS	O
:	O
The	O
binding	O
capacity	O
and	O
affinity	O
of	O
the	O
glucocorticoid	B-protein
receptors	I-protein
were	O
measured	O
and	O
compared	O
to	O
clinical	O
data	O
and	O
the	O
plasma	O
cortisol	O
concentrations	O
.	O

RESULTS	O
:	O
Hypercortisolaemia	O
,	O
in	O
vitro	O
,	O
resulted	O
in	O
a	O
decreased	O
affinity	O
and	O
a	O
decreased	O
binding	O
capacity	O
of	O
the	O
glucocorticoid	B-protein
receptor	I-protein
.	O

In	O
vitro	O
,	O
hyperthermia	O
as	O
well	O
as	O
variations	O
in	O
the	O
cellular	O
composition	O
did	O
not	O
influence	O
the	O
glucocorticoid	O
receptor	O
.	O

In	O
vivo	O
,	O
there	O
was	O
no	O
change	O
in	O
the	O
number	O
of	O
receptors	O
per	O
cell	O
in	O
patients	O
with	O
sepsis	O
or	O
septic	O
shock	O
as	O
compared	O
to	O
healthy	O
controls	O
.	O

However	O
,	O
a	O
decreased	O
affinity	O
of	O
the	O
glucocorticoid	B-protein
receptor	I-protein
was	O
observed	O
.	O

There	O
was	O
a	O
weak	O
but	O
significant	O
negative	O
correlation	O
between	O
body	O
temperature	O
and	O
the	O
number	O
of	O
glucocorticoid	B-protein
receptors	I-protein
in	O
the	O
patient	O
group	O
.	O

There	O
was	O
no	O
relation	O
between	O
circulating	O
cortisol	O
concentrations	O
and	O
glucocorticoid	B-protein
receptor	I-protein
affinity	O
and	O
number	O
.	O

CONCLUSIONS	O
:	O
There	O
is	O
no	O
obvious	O
regulation	O
of	O
the	O
number	O
of	O
glucocorticoid	B-protein
receptors	I-protein
by	O
plasma	O
cortisol	O
concentrations	O
in	O
vivo	O
.	O

The	O
decreased	O
affinity	O
of	O
the	O
glucocorticoid	B-protein
receptor	I-protein
together	O
with	O
the	O
negative	O
correlation	O
between	O
hyperthermia	O
and	O
the	O
number	O
of	O
glucocorticoid	B-protein
receptors	I-protein
in	O
patients	O
with	O
sepsis	O
or	O
septic	O
shock	O
suggest	O
that	O
hypothalamic-pituitary-adrenal	O
axis	O
activation	O
during	O
critical	O
illness	O
is	O
accompanied	O
by	O
peripheral	O
adaptation	O
in	O
glucocorticoid	B-protein
receptor	I-protein
number	O
and	O
affinity	O
.	O

Integrin-mediated	O
tyrosine	O
phosphorylation	O
and	O
cytokine	B-protein
message	O
induction	O
in	O
monocytic	B-cell_type
cells	I-cell_type
.	O

A	O
possible	O
signaling	O
role	O
for	O
the	O
Syk	B-protein
tyrosine	I-protein
kinase	I-protein
.	O

Activation	O
of	O
cytoplasmic	B-protein
tyrosine	I-protein
kinases	I-protein
is	O
an	O
important	O
aspect	O
of	O
signal	O
transduction	O
mediated	O
by	O
integrins	B-protein
.	O

In	O
the	O
human	B-cell_line
monocytic	I-cell_line
cell	I-cell_line
line	I-cell_line
THP-1	I-cell_line
,	O
either	O
integrin	B-protein
-dependent	O
cell	O
adhesion	O
to	O
fibronectin	B-protein
or	O
ligation	O
of	O
beta	O
1	O
integrins	O
with	O
antibodies	B-protein
causes	O
a	O
rapid	O
and	O
intense	O
tyrosine	O
phosphorylation	O
of	O
two	O
sets	O
of	O
proteins	O
of	O
about	O
65-75	B-protein
and	I-protein
120-125	I-protein
kDa	I-protein
.	O

In	O
addition	O
,	O
integrin	B-protein
ligation	O
leads	O
to	O
nuclear	O
translocation	O
of	O
the	O
p50	B-protein
and	O
p65	B-protein
subunits	I-protein
of	O
the	O
NF-kappa	B-protein
B	I-protein
transcription	I-protein
factor	I-protein
,	O
to	O
activation	O
of	O
a	O
reporter	B-DNA
gene	I-DNA
driven	O
by	O
a	O
promoter	B-DNA
containing	O
NF-kappa	B-DNA
B	I-DNA
sites	I-DNA
,	O
and	O
to	O
increased	O
levels	O
of	O
mRNAs	B-RNA
for	O
immediate-early	B-DNA
genes	I-DNA
,	O
including	O
the	O
cytokine	B-protein
interleukin	I-protein
(	I-protein
IL	I-protein
)	I-protein
-1	I-protein
beta	I-protein
.	O

The	O
tyrosine	O
kinase	O
inhibitors	O
genistein	O
and	O
herbimycin	O
A	O
block	O
both	O
integrin	B-protein
-mediated	O
tyrosine	O
phosphorylation	O
and	O
increases	O
in	O
IL-1	B-protein
beta	I-protein
message	O
levels	O
,	O
indicating	O
a	O
causal	O
relationship	O
between	O
the	O
two	O
events	O
.	O

The	O
components	O
tyrosine	O
phosphorylated	O
subsequent	O
to	O
cell	O
adhesion	O
include	O
paxillin	B-protein
,	O
pp125FAK	B-protein
,	O
and	O
the	O
SH2	B-protein
domain	I-protein
containing	I-protein
tyrosine	I-protein
kinase	I-protein
Syk	I-protein
.	O

In	O
contrast	O
,	O
integrin	B-protein
ligation	O
with	O
antibodies	B-protein
induces	O
tyrosine	O
phosphorylation	O
of	O
Syk	B-protein
but	O
not	O
of	O
FAK	B-protein
or	O
paxillin	B-protein
.	O

In	O
adhering	B-cell_type
cells	I-cell_type
,	O
pre-treatment	O
with	O
cytochalasin	O
D	O
suppresses	O
tyrosine	O
phosphorylation	O
of	O
FAK	B-protein
and	O
paxillin	B-protein
but	O
not	O
of	O
Syk	B-protein
,	O
while	O
IL-1	B-protein
beta	I-protein
message	O
induction	O
is	O
unaffected	O
.	O

These	O
observations	O
indicate	O
that	O
the	O
Syk	B-protein
tyrosine	O
kinase	O
may	O
be	O
an	O
important	O
component	O
of	O
an	O
integrin	B-protein
signaling	O
pathway	O
in	O
monocytic	B-cell_type
cells	I-cell_type
,	O
leading	O
to	O
activation	O
of	O
NF-kappa	B-protein
B	I-protein
and	O
to	O
increased	O
levels	O
of	O
cytokine	B-protein
messages	O
.	O

Inhibition	O
of	O
dexamethasone	O
binding	O
to	O
human	B-protein
glucocorticoid	I-protein
receptor	I-protein
by	O
New	O
World	O
primate	O
cell	O
extracts	O
.	O

To	O
determine	O
if	O
New	O
World	O
primates	O
express	O
an	O
inhibitor	O
that	O
influences	O
glucocorticoid	B-protein
receptor	I-protein
(	O
GR	B-protein
)	O
binding	O
characteristics	O
,	O
we	O
examined	O
[	O
3H	O
]	O
dexamethasone	O
binding	O
in	O
cytosol	O
prepared	O
from	O
B95-8	B-cell_line
lymphoid	I-cell_line
cells	I-cell_line
,	O
derived	O
from	O
the	O
cotton	O
top	O
tamarin	O
(	O
Saguinus	O
oedipus	O
)	O
,	O
in	O
combination	O
with	O
cytosol	O
prepared	O
from	O
human	O
or	O
rat	O
tissues	O
.	O

B95-8	O
cytosol	O
inhibited	O
specific	O
binding	O
of	O
[	O
3H	O
]	O
dexamethasone	O
(	O
P	O
<	O
0.01	O
)	O
when	O
mixed	O
with	O
cytosol	O
prepared	O
from	O
either	O
a	O
human	B-cell_line
lymphoid	I-cell_line
cell	I-cell_line
line	I-cell_line
(	O
HL	B-cell_line
)	O
or	O
rat	O
thymus	O
.	O

The	O
inhibitory	O
activity	O
was	O
heat	O
labile	O
and	O
trypsin	B-protein
sensitive	O
.	O

Peak	O
inhibitory	O
activity	O
was	O
found	O
in	O
the	O
150-200	O
kd	O
fractions	O
after	O
Sephacryl	O
G-200	O
ultrafiltration	O
.	O

Scatchard	O
analysis	O
of	O
[	O
3H	O
]	O
dexamethasone	O
binding	O
using	O
mixed	O
cytosol	O
showed	O
a	O
diminished	O
GR	B-protein
apparent	O
binding	O
affinity	O
when	O
compared	O
to	O
HL	O
cytosol	O
.	O

Kinetic	O
studies	O
using	O
mixed	O
cytosol	O
indicated	O
that	O
B95-8	O
cytosol	O
did	O
not	O
affect	O
the	O
apparent	O
dissociation	O
rate	O
of	O
[	O
3H	O
]	O
dexamethasone	O
.	O

These	O
data	O
demonstrate	O
that	O
B95-8	B-cell_type
cells	I-cell_type
contain	O
a	O
competitive	O
inhibitor	O
that	O
prevents	O
binding	O
of	O
dexamethasone	O
to	O
its	O
cognate	B-protein
receptor	I-protein
.	O

Disruption	O
of	O
a	O
GATA	B-DNA
motif	I-DNA
in	O
the	O
Duffy	B-DNA
gene	I-DNA
promoter	I-DNA
abolishes	O
erythroid	B-DNA
gene	I-DNA
expression	O
in	O
Duffy-negative	O
individuals	O
.	O

The	O
mRNA	B-RNA
for	O
the	O
Duffy	B-protein
blood	I-protein
group	I-protein
antigen	I-protein
,	O
the	O
erythrocyte	B-protein
receptor	I-protein
for	O
the	O
Plasmodium	O
vivax	O
malaria	O
parasite	O
,	O
has	O
recently	O
been	O
cloned	O
and	O
shown	O
to	O
encode	O
a	O
widely	O
expressed	O
chemokine	B-protein
receptor	I-protein
.	O

Here	O
,	O
we	O
show	O
that	O
the	O
Duffy	B-DNA
antigen/chemokine	I-DNA
receptor	I-DNA
gene	I-DNA
(	O
DARC	B-DNA
)	O
is	O
composed	O
of	O
a	O
single	O
exon	B-DNA
and	O
that	O
most	O
Duffy-negative	O
blacks	O
carry	O
a	O
silent	B-DNA
FY*B	I-DNA
allele	I-DNA
with	O
a	O
single	O
T	O
to	O
C	O
substitution	O
at	O
nucleotide	O
-46	O
.	O

This	O
mutation	O
impairs	O
the	O
promoter	O
activity	O
in	O
erythroid	B-cell_type
cells	I-cell_type
by	O
disrupting	O
a	O
binding	B-DNA
site	I-DNA
for	O
the	O
GATA1	B-protein
erythroid	I-protein
transcription	I-protein
factor	I-protein
.	O

With	O
the	O
recent	O
characterization	O
of	O
the	O
FY*A	B-DNA
and	I-DNA
FY*B	I-DNA
alleles	I-DNA
,	O
these	O
findings	O
provide	O
the	O
molecular	O
basis	O
of	O
the	O
Duffy	O
blood	O
group	O
system	O
and	O
an	O
explanation	O
for	O
the	O
erythroid-specific	O
repression	O
of	O
the	O
DARC	B-DNA
gene	I-DNA
in	O
Duffy-negative	O
individuals	O
.	O

Activation	O
of	O
pp90rsk	B-protein
and	O
early	B-DNA
growth	I-DNA
response-1	I-DNA
gene	I-DNA
expression	O
by	O
pokeweed	B-protein
mitogen	I-protein
in	O
human	B-cell_type
B	I-cell_type
cells	I-cell_type
.	O

The	O
present	O
studies	O
have	O
examined	O
the	O
effects	O
of	O
pokeweed	B-protein
mitogen	I-protein
(	O
PWM	B-protein
)	O
on	O
the	O
induction	O
of	O
early	B-DNA
growth	I-DNA
response-1	I-DNA
gene	I-DNA
(	O
EGR-1	B-DNA
)	O
in	O
normal	B-cell_type
human	I-cell_type
B	I-cell_type
cells	I-cell_type
.	O

PWM	B-protein
regulates	O
EGR-1	B-DNA
gene	O
expression	O
by	O
both	O
transcriptional	O
and	O
post-transcriptional	O
mechanisms	O
.	O

Transient	O
transfection	O
assays	O
with	O
EGR-1	B-DNA
promoter	I-DNA
fragments	I-DNA
linked	O
to	O
the	O
chloramphenicol	B-DNA
acetyltransferase	I-DNA
(	I-DNA
CAT	I-DNA
)	I-DNA
gene	I-DNA
demonstrated	O
that	O
PWM	B-protein
induced	O
EGR-1	B-DNA
transcription	O
is	O
conferred	O
by	O
the	O
CArG	B-DNA
motif	I-DNA
(	O
C	B-DNA
C	I-DNA
[	I-DNA
AT	I-DNA
]	I-DNA
6GG	I-DNA
)	O
in	O
the	O
EGR-1	B-DNA
promoter	I-DNA
.	O

The	O
results	O
further	O
demonstrated	O
the	O
activation	O
of	O
S6	B-protein
kinase	I-protein
(	O
pp90rsk	B-protein
)	O
,	O
evidenced	O
by	O
phosphorylation	O
of	O
S6	B-protein
and	O
serum	O
response	O
factor	O
(	O
SRF	O
)	O
peptides	O
,	O
in	O
PWM	B-cell_line
treated	I-cell_line
B	I-cell_line
cells	I-cell_line
.	O

Taken	O
together	O
,	O
these	O
findings	O
suggest	O
that	O
PWM	B-protein
is	O
able	O
to	O
initiate	O
an	O
intracytoplasmic	O
signalling	O
cascade	O
and	O
EGR-1	B-DNA
induction	O
in	O
normal	B-cell_type
human	I-cell_type
B	I-cell_type
cells	I-cell_type
.	O

A	O
conserved	B-DNA
motif	I-DNA
in	O
the	O
promoters	B-DNA
of	O
several	O
cytokines	B-protein
expressed	O
by	O
human	B-cell_line
Th2-type	I-cell_line
lymphocytes	I-cell_line
.	O

We	O
have	O
recently	O
found	O
a	O
novel	O
conserved	B-DNA
motif	I-DNA
in	O
the	O
promoters	B-DNA
of	O
several	O
T-cell-expressed	B-protein
cytokines	I-protein
[	O
human	B-protein
interleukin-2	I-protein
,	I-protein
-4	I-protein
,	I-protein
-5	I-protein
and	I-protein
-13	I-protein
and	O
human	B-protein
and	I-protein
mouse	I-protein
granulocyte/macrophage-colony	I-protein
stimulating	I-protein
factor	I-protein
(	O
GM-CSF	B-protein
)	O
]	O
.	O

It	O
contains	O
a	O
core	B-DNA
sequence	I-DNA
CTTGG	O
...	O
CCAAG	O
which	O
is	O
present	O
as	O
part	O
of	O
larger	O
palindromic	B-DNA
sequences	I-DNA
in	O
each	O
gene	O
.	O

This	O
suggest	O
that	O
they	O
may	O
interact	O
with	O
a	O
new	O
family	O
of	O
trans-acting	B-protein
factors	I-protein
.	O

In	O
transfection	O
assays	O
,	O
the	O
human	B-DNA
GM-CSF	I-DNA
element	I-DNA
has	O
a	O
strong	O
positive	O
effect	O
on	O
the	O
expression	O
of	O
a	O
reporter	B-DNA
gene	I-DNA
by	O
the	O
human	B-cell_line
T	I-cell_line
cell	I-cell_line
line	I-cell_line
Jurkat	B-cell_line
J6	I-cell_line
upon	O
stimulation	O
.	O

In	O
DNA	O
mobility	O
shift	O
assays	O
,	O
this	O
sequence	O
can	O
give	O
either	O
six	O
different	O
specific	O
bands	O
which	O
are	O
competed	O
out	O
by	O
different	O
parts	O
of	O
the	O
sequence	O
or	O
one	O
specific	O
band	O
which	O
is	O
competed	O
out	O
by	O
each	O
of	O
the	O
inverted	O
repeats	O
,	O
depending	O
on	O
the	O
reconstitution	O
conditions	O
.	O

In	O
different	O
genes	B-DNA
,	O
the	O
core	B-DNA
sequences	I-DNA
are	O
separated	O
by	O
integer	O
numbers	O
of	O
helical	O
turns	O
.	O

Considering	O
the	O
strong	O
positive	O
regulatory	O
effect	O
of	O
this	O
element	B-DNA
and	O
its	O
presence	O
in	O
several	O
T-cell-expressed	B-DNA
cytokine	I-DNA
genes	I-DNA
,	O
it	O
may	O
be	O
crucial	O
to	O
the	O
coordinated	O
expression	O
of	O
these	O
cytokines	B-protein
in	O
T	B-cell_type
helper	I-cell_type
cells	I-cell_type
.	O

cDNA	B-DNA
cloning	O
of	O
a	O
NGFI-B/nur77-related	B-protein
transcription	I-protein
factor	I-protein
from	O
an	O
apoptotic	B-cell_line
human	I-cell_line
T	I-cell_line
cell	I-cell_line
line	I-cell_line
.	O

A	O
human	B-cell_line
T	I-cell_line
lymphoid	I-cell_line
cell	I-cell_line
line	I-cell_line
,	O
PEER	B-cell_line
,	O
dies	O
by	O
apoptosis	O
in	O
the	O
presence	O
of	O
PMA	O
and	O
calcium	O
ionophore	O
.	O

A	O
new	O
gene	B-DNA
,	O
TINUR	B-DNA
,	O
was	O
cloned	O
from	O
apoptotic	B-cell_line
PEER	I-cell_line
cells	I-cell_line
.	O

The	O
expression	O
of	O
the	O
TINUR	B-DNA
gene	I-DNA
is	O
induced	O
within	O
1	O
h	O
after	O
the	O
cross-linking	O
of	O
the	O
T	B-protein
cell	I-protein
Ag	I-protein
receptor	I-protein
complex	I-protein
.	O

TINUR	B-DNA
belongs	O
to	O
the	O
NGFI-B/nur77	B-protein
family	I-protein
of	O
the	O
steroid	B-protein
receptor	I-protein
superfamily	I-protein
and	O
is	O
an	O
orphan	B-protein
receptor	I-protein
.	O

TINUR	B-DNA
binds	O
to	O
the	O
same	O
DNA	B-DNA
sequence	I-DNA
as	O
NGFI-B/nur77	B-protein
.	O

We	O
also	O
propose	O
that	O
the	O
NGFI-B/nur77	B-protein
family	I-protein
can	O
be	O
classified	O
into	O
two	O
subtypes	O
.	O

Aspirin	O
inhibits	O
nuclear	B-protein
factor-kappa	I-protein
B	I-protein
mobilization	O
and	O
monocyte	O
adhesion	O
in	O
stimulated	B-cell_line
human	I-cell_line
endothelial	I-cell_line
cells	I-cell_line
.	O

BACKGROUND	O
:	O
The	O
induction	O
of	O
vascular	B-protein
cell	I-protein
adhesion	I-protein
molecule-1	I-protein
(	O
VCAM-1	B-protein
)	O
and	O
E-selectin	B-protein
by	O
tumor	B-protein
necrosis	I-protein
factor-alpha	I-protein
(	O
TNF	B-protein
)	O
is	O
mediated	O
by	O
mobilization	O
of	O
the	O
transcription	B-protein
factor	I-protein
nuclear	B-protein
factor-kappa	I-protein
B	I-protein
(	O
NF-kappa	B-protein
B	I-protein
)	O
.	O

Since	O
salicylates	O
have	O
been	O
reported	O
to	O
inhibit	O
NF-kappa	B-protein
B	I-protein
activation	O
by	O
preventing	O
the	O
degradation	O
of	O
its	O
inhibitor	O
I	B-protein
kappa	I-protein
B	I-protein
,	O
we	O
studied	O
a	O
potential	O
inhibition	O
of	O
this	O
pathway	O
by	O
acetylsalicylate	O
(	O
aspirin	O
)	O
in	O
human	B-cell_line
umbilical	I-cell_line
vein	I-cell_line
endothelial	I-cell_line
cells	I-cell_line
(	O
HUVECs	B-cell_line
)	O
.	O

METHODS	O
AND	O
RESULTS	O
:	O
Gel-shift	O
analyses	O
demonstrated	O
dose-dependent	O
inhibition	O
of	O
TNF	B-protein
-induced	O
NF-kappa	B-protein
B	I-protein
mobilization	O
by	O
aspirin	O
at	O
concentrations	O
ranging	O
from	O
1	O
to	O
10	O
mmol/L	O
.	O

Induction	O
of	O
VCAM-1	B-protein
and	O
E-selectin	B-protein
surface	O
expression	O
by	O
TNF	B-protein
was	O
dose-dependently	O
reduced	O
by	O
aspirin	O
over	O
the	O
same	O
range	O
,	O
while	O
induction	O
of	O
intercellular	B-protein
adhesion	I-protein
molecule-1	I-protein
(	O
ICAM-1	B-protein
)	O
was	O
hardly	O
affected	O
.	O

Aspirin	O
appeared	O
to	O
prevent	O
VCAM-1	B-protein
transcription	O
,	O
since	O
it	O
dose-dependently	O
inhibited	O
induction	O
of	O
VCAM-1	B-RNA
mRNA	I-RNA
by	O
TNF	B-protein
.	O

As	O
a	O
functional	O
consequence	O
,	O
adhesion	O
of	O
U937	B-cell_line
monocytes	I-cell_line
to	O
TNF-stimulated	B-cell_line
HUVECs	I-cell_line
was	O
markedly	O
reduced	O
by	O
aspirin	O
due	O
to	O
suppression	O
of	O
VCAM-1	B-protein
and	O
E-selectin	B-protein
upregulation	O
.	O

These	O
effects	O
of	O
aspirin	O
were	O
not	O
related	O
to	O
the	O
inhibition	O
of	O
cyclooxygenase	B-protein
activity	O
,	O
since	O
indomethacin	O
was	O
ineffective	O
.	O

CONCLUSIONS	O
:	O
Our	O
data	O
suggest	O
that	O
aspirin	O
inhibits	O
NF-kappa	B-protein
B	I-protein
mobilization	O
,	O
induction	O
of	O
VCAM-1	B-protein
and	O
E-selectin	B-protein
,	O
and	O
subsequent	O
monocyte	O
adhesion	O
in	O
endothelial	B-cell_type
cells	I-cell_type
stimulated	O
by	O
TNF	B-protein
,	O
thereby	O
providing	O
an	O
additional	O
mechanism	O
for	O
therapeutic	O
effects	O
of	O
aspirin	O
.	O

Activation	O
of	O
NF-kappa	B-protein
B	I-protein
by	O
phosphatase	B-protein
inhibitors	O
involves	O
the	O
phosphorylation	O
of	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
at	O
phosphatase	B-protein
2A-sensitive	I-protein
sites	I-protein
.	O

Activation	O
of	O
NF-kappa	B-protein
B	I-protein
by	O
various	O
cellular	O
stimuli	O
involves	O
the	O
phosphorylation	O
and	O
subsequent	O
degradation	O
of	O
its	O
inhibitor	O
,	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
,	O
although	O
the	O
underlying	O
mechanism	O
remains	O
unclear	O
.	O

In	O
the	O
present	O
study	O
,	O
the	O
role	O
of	O
serine/threonine	B-protein
phosphatases	I-protein
in	O
the	O
regulation	O
of	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
phosphorylation	O
was	O
investigated	O
.	O

Our	O
studies	O
demonstrate	O
that	O
incubation	O
of	O
human	B-cell_type
T	I-cell_type
cells	I-cell_type
with	O
low	O
concentrations	O
(	O
approximately	O
1-5	O
nM	O
)	O
of	O
calyculin	O
A	O
or	O
okadaic	O
acid	O
,	O
potent	O
inhibitors	O
of	O
protein	B-protein
phosphatase	I-protein
type	I-protein
1	I-protein
(	I-protein
PP-1	I-protein
)	I-protein
and	I-protein
type	I-protein
2A	I-protein
(	O
PP-2A	B-protein
)	O
,	O
induces	O
the	O
phosphorylation	O
of	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
even	O
in	O
the	O
absence	O
of	O
any	O
cellular	O
stimulus	O
.	O

This	O
action	O
of	O
the	O
phosphatase	O
inhibitors	O
,	O
which	O
is	O
associated	O
with	O
the	O
activation	O
of	O
the	O
RelA.p50	B-protein
NF-kappa	I-protein
B	I-protein
heterodimer	I-protein
,	O
is	O
not	O
affected	O
by	O
agents	O
that	O
block	O
the	O
induction	O
of	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
phosphorylation	O
by	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
alpha	I-protein
(	O
TNF-alpha	B-protein
)	O
.	O

Furthermore	O
,	O
the	O
phosphorylated	B-protein
I	I-protein
kappa	I-protein
B	I-protein
alpha	I-protein
from	O
calyculin	B-cell_line
A-treated	I-cell_line
cells	I-cell_line
,	O
but	O
not	O
that	O
from	O
TNF-alpha-stimulated	B-cell_line
cells	I-cell_line
,	O
is	O
sensitive	O
to	O
PP-2A	B-protein
in	O
vitro	O
,	O
suggesting	O
the	O
existence	O
of	O
fundamental	O
differences	O
in	O
the	O
phosphorylation	O
of	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
induced	O
by	O
the	O
two	O
different	O
NF-kappa	B-protein
B	I-protein
inducers	O
.	O

However	O
,	O
induction	O
of	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
phosphorylation	O
by	O
both	O
TNF-alpha	B-protein
and	O
the	O
phosphatase	O
inhibitors	O
is	O
associated	O
with	O
the	O
subsequent	O
degradation	O
of	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
.	O

We	O
further	O
demonstrate	O
that	O
TNF-alpha-	O
and	O
calyculin	O
A-induced	O
I	O
kappa	O
B	O
alpha	O
degradation	O
exhibits	O
similar	O
but	O
not	O
identical	O
sensitivities	O
to	O
a	O
proteasome	O
inhibitor	O
.	O

Together	O
,	O
these	O
results	O
suggest	O
that	O
phosphorylation	O
of	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
,	O
mediated	O
through	O
both	O
the	O
TNF-alpha	B-protein
-inducible	O
and	O
the	O
PP-2A-opposing	B-protein
kinases	I-protein
,	O
may	O
serve	O
to	O
target	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
for	O
proteasome	B-protein
-mediated	O
degradation	O
.	O

Sp1	B-protein
functions	O
in	O
a	O
chromatin	B-DNA
-dependent	O
manner	O
to	O
augment	O
human	B-DNA
alpha-globin	I-DNA
promoter	I-DNA
activity	O
.	O

The	O
5	B-DNA
'	I-DNA
flanking	I-DNA
region	I-DNA
of	O
the	O
human	B-DNA
alpha-globin	I-DNA
gene	I-DNA
is	O
highly	O
G	O
+	O
C	O
rich	O
and	O
contains	O
multiple	O
copies	O
of	O
the	O
consensus	B-DNA
sequence	I-DNA
for	O
the	O
Sp1	B-DNA
binding	I-DNA
site	I-DNA
.	O

We	O
investigated	O
the	O
role	O
of	O
this	O
G	B-DNA
+	I-DNA
C-rich	I-DNA
region	I-DNA
in	O
augmenting	O
alpha-globin	B-DNA
promoter	I-DNA
activity	O
in	O
the	O
presence	O
of	O
the	O
far-upstream	B-DNA
alpha-globin	I-DNA
enhancer	I-DNA
,	O
HS-40	B-DNA
.	O

We	O
show	O
that	O
in	O
transiently	B-cell_line
transfected	I-cell_line
erythroid	I-cell_line
cells	I-cell_line
,	O
deletion	O
of	O
the	O
alpha-globin	B-DNA
G	I-DNA
+	I-DNA
C-rich	I-DNA
5	I-DNA
'	I-DNA
flanking	I-DNA
region	I-DNA
has	O
no	O
effect	O
on	O
alpha-globin	B-DNA
promoter	I-DNA
activity	O
.	O

However	O
,	O
upon	O
stable	O
integration	O
into	O
chromatin	B-DNA
,	O
deletion	O
of	O
this	O
region	O
causes	O
a	O
nearly	O
90	O
%	O
decrease	O
in	O
promoter	O
activity	O
compared	O
with	O
expression	O
from	O
an	O
alpha-globin	B-DNA
promoter	I-DNA
retaining	O
this	O
region	O
.	O

These	O
results	O
suggest	O
that	O
the	O
alpha-globin	B-DNA
G	I-DNA
+	I-DNA
C-rich	I-DNA
5	I-DNA
'	I-DNA
flanking	I-DNA
region	I-DNA
augments	O
alpha-globin	B-DNA
promoter	I-DNA
activity	O
in	O
a	O
chromatin	B-DNA
-dependent	O
manner	O
.	O

We	O
further	O
show	O
that	O
this	O
G	B-DNA
+	I-DNA
C-rich	I-DNA
region	I-DNA
is	O
required	O
for	O
the	O
activation	O
of	O
alpha-globin	B-DNA
gene	I-DNA
expression	O
during	O
erythroid	O
differentiation	O
.	O

Finally	O
,	O
we	O
show	O
by	O
both	O
footprint	O
analysis	O
and	O
functional	O
assays	O
that	O
the	O
ability	O
of	O
the	O
G	B-DNA
+	I-DNA
C-rich	I-DNA
region	I-DNA
to	O
increase	O
alpha-globin	B-DNA
promoter	I-DNA
activity	O
from	O
a	O
stably	O
integrated	O
alpha-globin	B-DNA
gene	I-DNA
is	O
mediated	O
by	O
its	O
multiple	B-DNA
binding	I-DNA
sites	I-DNA
for	O
the	O
transcription	B-protein
factor	I-protein
Sp1	B-protein
.	O

Costimulation	O
of	O
human	B-cell_line
CD4+	I-cell_line
T	I-cell_line
cells	I-cell_line
with	O
LFA-3	B-protein
and	O
B7	B-protein
induce	O
distinct	O
effects	O
on	O
AP-1	O
and	O
NF-kappa	B-protein
B	I-protein
transcription	B-protein
factors	I-protein
.	O

We	O
have	O
earlier	O
shown	O
that	O
stimulation	O
of	O
human	B-cell_line
CD4+	I-cell_line
T	I-cell_line
cells	I-cell_line
with	O
SEA	O
presented	O
on	O
Chinese	B-cell_line
hamster	I-cell_line
ovary	I-cell_line
(	I-cell_line
CHO	I-cell_line
)	I-cell_line
-DR	I-cell_line
transfectants	I-cell_line
coexpressing	O
either	O
B7	B-protein
or	O
LFA-3	B-protein
resulted	O
in	O
distinct	O
cytokine	B-protein
profiles	O
.	O

We	O
now	O
demonstrate	O
that	O
B7	B-protein
,	O
but	O
not	O
LFA-3	B-protein
,	O
strongly	O
costimulated	O
IL-2	B-protein
transcription	O
and	O
mRNA	O
expression	O
in	O
CD4+	B-cell_line
T	I-cell_line
cells	I-cell_line
.	O

Maximal	O
increase	O
in	O
IL-2	B-protein
transcription	O
was	O
recorded	O
with	O
CHO-DR/B7/LFA-3	B-protein
,	O
suggesting	O
a	O
cooperative	O
effect	O
of	O
B7	B-protein
and	O
LFA-3	B-protein
at	O
the	O
transcriptional	O
level	O
.	O

Gel-shift	O
analysis	O
demonstrated	O
that	O
stimulation	O
of	O
CD4+	B-cell_line
T	I-cell_line
cells	I-cell_line
with	O
CHO-DR	B-protein
and	O
staphylococcal	O
enterotoxin	O
A	O
was	O
sufficient	O
to	O
induce	O
significant	O
amounts	O
of	O
NF-kappa	B-protein
B	I-protein
binding	O
proteins	O
,	O
whereas	O
induction	O
of	O
AP-1	B-protein
binding	I-protein
proteins	I-protein
required	O
costimulation	O
.	O

LFA-3	B-protein
induced	O
moderate	O
levels	O
of	O
AP-1	B-protein
,	O
but	O
did	O
not	O
influence	O
the	O
levels	O
of	O
NF-kappa	B-protein
B	I-protein
,	O
while	O
B7	B-protein
costimulation	O
strongly	O
induced	O
both	O
AP-1	B-protein
and	O
substantially	O
enhanced	O
NF-kappa	B-protein
B	I-protein
binding	I-protein
proteins	I-protein
.	O

The	O
CHO-DR/B7/LFA-3	B-cell_line
triple	I-cell_line
transfectant	I-cell_line
induced	O
a	O
further	O
increase	O
in	O
AP-1	B-protein
and	O
NF-kappa	B-protein
B	I-protein
binding	B-protein
proteins	I-protein
compared	O
with	O
the	O
double	B-cell_line
transfectants	I-cell_line
.	O

The	O
level	O
of	O
Oct-1	B-protein
binding	I-protein
proteins	I-protein
remained	O
similar	O
in	O
all	O
samples	O
.	O

Super-shift	O
analysis	O
revealed	O
that	O
the	O
NF-kappa	B-protein
B	I-protein
complex	I-protein
of	O
costimulated	B-cell_line
CD4+	I-cell_line
T	I-cell_line
cells	I-cell_line
contained	O
large	O
amounts	O
of	O
p50	B-protein
,	O
substantial	O
amounts	O
of	O
p65	B-protein
,	O
and	O
marginal	O
levels	O
of	O
c-Rel	B-protein
proteins	I-protein
.	O

The	O
AP-1	B-protein
binding	I-protein
proteins	I-protein
contained	O
c-Jun	B-protein
,	O
Jun-D	B-protein
,	O
and	O
Fra-1	B-protein
,	O
but	O
marginal	O
amounts	O
of	O
Jun-B	B-protein
and	O
c-Fos	B-protein
.	O

Our	O
results	O
indicate	O
distinct	O
effects	O
of	O
B7	B-protein
and	O
LFA-3	B-protein
costimulation	O
on	O
the	O
activity	O
of	O
AP-1	B-protein
and	O
NF-kappa	B-protein
B	I-protein
.	O

These	O
may	O
partly	O
account	O
for	O
the	O
differential	O
effects	O
of	O
B7	B-protein
and	O
LFA-3	B-protein
costimulation	O
on	O
IL-2	B-protein
expression	O
.	O

The	O
Ah	B-protein
receptor	I-protein
recognizes	O
DNA	B-DNA
binding	I-DNA
sites	I-DNA
for	O
the	O
B	B-protein
cell	I-protein
transcription	I-protein
factor	I-protein
,	O
BSAP	B-protein
:	O
a	O
possible	O
mechanism	O
for	O
dioxin-mediated	O
alteration	O
of	O
CD19	B-DNA
gene	I-DNA
expression	O
in	O
human	B-cell_type
B	I-cell_type
lymphocytes	I-cell_type
.	O

2	O
,	O
3	O
,	O
7	O
,	O
8-tetrachlorodibenzo-p-dioxin	O
(	O
TCDD	O
)	O
inhibits	O
murine	O
and	O
human	O
B	O
lymphocyte	O
immunoglobulin	O
production	O
through	O
an	O
unknown	O
mechanism	O
.	O

This	O
study	O
investigated	O
the	O
effect	O
of	O
TCDD	O
on	O
expression	O
of	O
the	O
CD19	B-DNA
gene	I-DNA
in	O
a	O
human	B-cell_line
B	I-cell_line
lymphocyte	I-cell_line
cell	I-cell_line
line	I-cell_line
.	O

Northern	O
blot	O
analysis	O
showed	O
that	O
TCDD	O
treatment	O
decreased	O
steady	O
state	O
levels	O
of	O
CD19	B-RNA
mRNA	I-RNA
by	O
67	O
%	O
in	O
the	O
IM-9	B-cell_line
cell	I-cell_line
line	I-cell_line
.	O

Using	O
a	O
gel	O
mobility	O
shift	O
assay	O
,	O
we	O
identified	O
a	O
DNA-binding	B-protein
complex	I-protein
in	O
IM-9	O
nuclear	O
extracts	O
that	O
by	O
several	O
criteria	O
appears	O
to	O
be	O
the	O
Ah	B-protein
receptor	I-protein
.	O

In	O
addition	O
,	O
the	O
Ah	B-protein
receptor	I-protein
complex	I-protein
recognized	O
a	O
DNA	B-DNA
binding	I-DNA
site	I-DNA
for	O
B	B-protein
cell	I-protein
lineage-specific	I-protein
activator	I-protein
protein	I-protein
(	O
BSAP	B-protein
)	O
in	O
the	O
promoter	B-DNA
region	I-DNA
of	O
the	O
human	O
CD19	B-DNA
gene	I-DNA
which	O
is	O
similar	O
to	O
the	O
consensus	B-DNA
Ah	I-DNA
receptor	I-DNA
DNA	I-DNA
binding	I-DNA
site	I-DNA
.	O

These	O
results	O
suggest	O
that	O
the	O
AhR	B-protein
could	O
interfere	O
with	O
BSAP	B-protein
-stimulated	O
CD19	B-DNA
gene	I-DNA
transcription	O
by	O
competition	O
for	O
a	O
common	O
DNA	B-DNA
binding	I-DNA
site	I-DNA
.	O

Inhibitory	O
action	O
of	O
nm23	B-protein
proteins	I-protein
on	O
induction	O
of	O
erythroid	O
differentiation	O
of	O
human	B-cell_type
leukemia	I-cell_type
cells	I-cell_type
.	O

We	O
recently	O
identified	O
a	O
differentiation	B-protein
inhibitory	I-protein
factor	I-protein
(	O
I-factor	B-protein
)	O
in	O
mouse	B-cell_line
myeloid	I-cell_line
leukemia	I-cell_line
M1	I-cell_line
cells	I-cell_line
as	O
a	O
murine	B-protein
homolog	I-protein
of	O
the	O
human	B-protein
nm23-H2	I-protein
gene	I-protein
product	I-protein
.	O

nm23	B-DNA
genes	I-DNA
encode	O
proteins	O
that	O
participate	O
in	O
tumor	O
metastasis	O
regulation	O
and	O
in	O
various	O
fundamental	O
cellular	O
processes	O
,	O
although	O
their	O
mechanisms	O
of	O
action	O
are	O
still	O
unknown	O
.	O

Although	O
all	O
nm23	B-protein
proteins	I-protein
contain	O
nucleoside	B-protein
diphosphate	I-protein
(	I-protein
NDP	I-protein
)	I-protein
kinase	I-protein
activity	O
,	O
it	O
has	O
not	O
been	O
established	O
that	O
the	O
enzyme	O
activity	O
mediated	O
the	O
various	O
functions	O
of	O
nm23	B-protein
proteins	I-protein
.	O

In	O
the	O
present	O
experiment	O
,	O
we	O
examined	O
the	O
effect	O
of	O
nm23	B-protein
proteins	I-protein
on	O
various	O
differentiation	O
induction	O
systems	O
of	O
human	B-cell_type
leukemic	I-cell_type
cells	I-cell_type
including	O
HL-60	B-cell_line
,	I-cell_line
U937	I-cell_line
,	I-cell_line
HEL/S	I-cell_line
,	I-cell_line
KU812F	I-cell_line
,	I-cell_line
K562	I-cell_line
,	I-cell_line
and	I-cell_line
HEL	I-cell_line
cells	I-cell_line
.	O

Native	B-protein
human	I-protein
erythrocyte	I-protein
NDP	I-protein
kinase	I-protein
protein	I-protein
inhibited	O
the	O
induction	O
of	O
erythroid	O
differentiation	O
of	O
HEL	B-cell_line
,	I-cell_line
KU812	I-cell_line
and	I-cell_line
K562	I-cell_line
cells	I-cell_line
,	O
but	O
not	O
the	O
induction	O
of	O
monocytic	O
or	O
granulocytic	O
differentiation	O
of	O
HL-60	B-cell_line
,	I-cell_line
U937	I-cell_line
and	I-cell_line
HEL/S	I-cell_line
cells	I-cell_line
.	O

The	O
erythroid	O
differentiation	O
of	O
HEL	B-cell_line
cells	I-cell_line
was	O
inhibited	O
by	O
recombinant	B-protein
human	I-protein
nm23-H1	I-protein
,	I-protein
-H2	I-protein
,	I-protein
mouse	I-protein
nm23-M1	I-protein
,	I-protein
and	I-protein
-M2	I-protein
proteins	I-protein
.	O

Moreover	O
,	O
both	O
the	O
mutant	B-protein
nm23-H2His	I-protein
protein	I-protein
and	O
truncated	B-protein
nm23-H2	I-protein
protein	I-protein
containing	O
N-terminal	B-protein
(	I-protein
1-60	I-protein
)	I-protein
peptide	I-protein
,	O
which	O
do	O
not	O
have	O
NDP	B-protein
kinase	I-protein
activity	O
,	O
also	O
inhibited	O
erythroid	O
differentiation	O
of	O
HEL	B-cell_line
cells	I-cell_line
.	O

These	O
results	O
suggest	O
that	O
(	O
1	O
)	O
the	O
differentiation	O
inhibitory	O
activity	O
of	O
I-factor/nm23	B-protein
protein	I-protein
is	O
not	O
restricted	O
to	O
monocytic	O
differentiation	O
of	O
M1	B-cell_line
cells	I-cell_line
,	O
(	O
2	O
)	O
the	O
inhibitory	O
activity	O
is	O
exhibited	O
without	O
species	O
specificity	O
,	O
and	O
(	O
3	O
)	O
the	O
differentiation	O
inhibitory	O
activity	O
of	O
the	O
nm23/NDP	B-protein
kinase	I-protein
protein	I-protein
is	O
independent	O
of	O
its	O
enzyme	O
activity	O
and	O
requires	O
the	O
presence	O
of	O
N-terminal	O
peptides	O
.	O

Lipopolysaccharide-induced	O
E-selectin	B-protein
expression	O
requires	O
continuous	O
presence	O
of	O
LPS	O
and	O
is	O
inhibited	O
by	O
bactericidal/permeability-increasing	B-protein
protein	I-protein
.	O

Endothelial	B-cell_type
cells	I-cell_type
stimulated	O
by	O
LPS	O
express	O
E-selectin	B-protein
,	O
which	O
plays	O
an	O
important	O
role	O
in	O
mediating	O
neutrophil	B-cell_type
adhesion	O
during	O
inflammation	O
.	O

E-selectin	B-protein
is	O
induced	O
within	O
1-2	O
h	O
,	O
peaks	O
at	O
4-6	O
h	O
,	O
and	O
gradually	O
returns	O
to	O
basal	O
level	O
by	O
24	O
h	O
.	O

rBPI21	B-protein
,	O
a	O
recombinant	B-protein
N-terminal	I-protein
fragment	I-protein
of	O
human	B-protein
bactericidal/permeability-increasing	I-protein
protein	I-protein
(	O
BPI	B-protein
)	O
,	O
inhibited	O
LPS-induced	O
E-selectin	B-protein
expression	O
when	O
added	O
at	O
the	O
same	O
time	O
as	O
,	O
and	O
up	O
to	O
6	O
h	O
after	O
,	O
LPS	O
.	O

Delayed	O
administration	O
of	O
rBPI21	B-protein
also	O
affected	O
LPS-mediated	O
activation	O
of	O
the	O
nuclear	B-protein
factor	I-protein
,	O
NF-kappa	B-protein
B	I-protein
.	O

Two	O
to	O
4	O
h	O
following	O
LPS	O
addition	O
to	O
endothelial	B-cell_type
cells	I-cell_type
,	O
when	O
NF-kappa	B-protein
B	I-protein
was	O
already	O
activated	O
,	O
addition	O
of	O
rBPI21	B-protein
resulted	O
in	O
marked	O
reduction	O
of	O
NF-kappa	B-protein
B	I-protein
detectable	O
at	O
4	O
or	O
6	O
h	O
.	O

These	O
results	O
indicate	O
that	O
endothelial	O
activation	O
requires	O
continuous	O
presence	O
of	O
LPS	O
,	O
and	O
rBPI21	B-protein
acts	O
to	O
reverse	O
LPS-mediated	O
endothelial	O
activation	O
by	O
interrupting	O
the	O
on-going	O
LPS	O
signal	O
.	O

GM-CSF	B-protein
and	O
IL-2	B-protein
share	O
common	O
control	O
mechanisms	O
in	O
response	O
to	O
costimulatory	O
signals	O
in	O
T	B-cell_type
cells	I-cell_type
.	O

Antigen	O
complexed	O
with	O
major	B-protein
histocompatibility	I-protein
complex	I-protein
class	I-protein
I	I-protein
or	I-protein
II	I-protein
molecules	I-protein
on	O
the	O
surface	O
of	O
antigen	B-cell_type
presenting	I-cell_type
cells	I-cell_type
interacts	O
with	O
the	O
T	B-protein
cell	I-protein
receptor	I-protein
(	O
TCR	B-protein
)	O
on	O
the	O
surface	O
of	O
T	B-cell_type
cells	I-cell_type
and	O
initiates	O
an	O
activation	O
cascade	O
.	O

So	O
called	O
costimulatory	O
signals	O
,	O
mediated	O
by	O
other	O
cell	O
surface	O
interactions	O
or	O
soluble	B-protein
cytokines	I-protein
produced	O
by	O
antigen	B-cell_type
presenting	I-cell_type
cells	I-cell_type
,	O
are	O
also	O
required	O
for	O
complete	O
T	O
cell	O
activation	O
.	O

High	O
levels	O
of	O
cytokine	B-protein
gene	O
expression	O
in	O
T	B-cell_type
cells	I-cell_type
also	O
required	O
both	O
TCR	B-protein
and	O
costimulatory	O
signals	O
.	O

The	O
granulocyte-macrophage	B-protein
colony-stimulating	I-protein
factor	I-protein
requires	O
sequences	O
in	O
the	O
promoter	B-DNA
as	O
well	O
as	O
a	O
powerful	O
enhancer	B-DNA
located	O
3kb	O
upstream	O
to	O
respond	O
to	O
TCR	B-protein
-like	O
signals	O
.	O

These	O
promoter	B-DNA
and	I-DNA
enhancer	I-DNA
regions	I-DNA
are	O
mainly	O
activated	O
by	O
the	O
transcription	B-protein
factor	I-protein
nuclear	I-protein
factor	I-protein
of	I-protein
activated	I-protein
T	I-protein
cells	I-protein
(	O
NFAT	B-protein
)	O
.	O

The	O
activation	O
of	O
NFAT	B-protein
by	O
TCR	B-protein
signals	O
has	O
been	O
well	O
described	O
for	O
interleukin-2	O
(	O
IL-2	B-protein
)	O
and	O
IL-4	O
gene	O
transcription	O
in	O
T	B-cell_type
cells	I-cell_type
.	O

Costimulatory	O
signals	O
,	O
such	O
as	O
activation	O
of	O
the	O
CD28	B-protein
cell	I-protein
surface	I-protein
molecule	I-protein
on	O
T	B-cell_type
cells	I-cell_type
,	O
lead	O
to	O
activation	O
through	O
a	O
distinct	O
region	O
of	O
the	O
granulocyte-macrophage	B-DNA
colony-stimulating	I-DNA
factor	I-DNA
(	I-DNA
GM-CSF	I-DNA
)	I-DNA
promoter	I-DNA
.	O

This	O
region	O
is	O
termed	O
the	O
CK-1	B-DNA
or	O
CD28RE	B-DNA
and	O
appears	O
to	O
bind	O
specific	O
members	O
of	O
the	O
NF-kappa	B-protein
B	I-protein
family	I-protein
of	O
transcription	B-protein
factors	I-protein
.	O

Human	O
T	O
leukemia	O
virus	O
type	O
1	O
(	O
HTLV-1	O
)	O
infects	O
T	B-cell_type
cells	I-cell_type
and	O
can	O
lead	O
to	O
increase	O
GM-CSF	B-protein
expression	O
.	O

We	O
have	O
found	O
that	O
the	O
HTLV-1	B-protein
transactivator	I-protein
protein	I-protein
,	O
tax	B-protein
,	O
acts	O
as	O
a	O
costimulatory	O
signal	O
for	O
GM-CSF	O
and	O
IL-2	O
gene	O
transcription	O
,	O
in	O
that	O
it	O
can	O
cooperate	O
with	O
TCR	B-protein
signals	O
to	O
mediate	O
high	O
level	O
gene	O
expression	O
.	O

Tax	O
activates	O
the	O
GM-CSF	B-DNA
promoter	I-DNA
through	O
the	O
CK-1	B-DNA
/CD28RE	B-DNA
region	O
and	O
also	O
activates	O
nuclear	B-protein
factor-kappa	I-protein
B	I-protein
binding	O
to	O
this	O
region	O
.	O

However	O
,	O
other	O
transcription	B-protein
factors	I-protein
or	O
coactivators	O
of	O
NF-kappa	B-protein
B	I-protein
are	O
required	O
for	O
tax	B-protein
activation	O
but	O
these	O
remain	O
to	O
be	O
identified	O
.	O

The	O
CK-1	B-DNA
/CD28RE	B-DNA
of	O
GM-CSF	B-protein
shows	O
a	O
high	O
degree	O
of	O
similarity	O
to	O
the	O
IL-2	B-protein
CD28RE	B-DNA
and	O
the	O
IL-3	B-DNA
gene	I-DNA
also	O
contains	O
a	O
related	O
region	O
.	O

This	O
observation	O
,	O
together	O
with	O
the	O
fact	O
that	O
both	O
GM-CSF	B-protein
and	O
IL-2	B-protein
respond	O
to	O
TCR	B-protein
signals	O
via	O
NFAT	B-protein
,	O
implies	O
a	O
high	O
degree	O
of	O
conservation	O
in	O
the	O
regulation	O
of	O
cytokine	B-protein
gene	O
expression	O
in	O
T	B-cell_type
cells	I-cell_type
.	O

Danazol	O
decreases	O
transcription	O
of	O
estrogen	B-DNA
receptor	I-DNA
gene	I-DNA
in	O
human	B-cell_type
monocytes	I-cell_type
.	O

1.	O
Administration	O
of	O
danazol	O
for	O
over	O
one	O
month	O
reduced	O
the	O
levels	O
of	O
estrogen	B-protein
receptor	I-protein
(	O
ER	B-protein
)	O
and	O
its	O
mRNA	B-RNA
to	O
approximately	O
50	O
and	O
20	O
%	O
,	O
respectively	O
in	O
monocytes	B-cell_type
.	O

2.	O
Danazol	O
did	O
not	O
alter	O
the	O
degradation	O
rate	O
of	O
ER	B-RNA
mRNA	I-RNA
in	O
monocytes	B-cell_type
.	O

3.	O
Danazol	O
decreased	O
the	O
transcription	O
rate	O
of	O
ER	B-DNA
gene	I-DNA
to	O
approximately	O
50	O
%	O
in	O
monocytes	B-cell_type
in	O
a	O
run-on	O
assay	O
.	O

4.	O
Danazol	O
may	O
release	O
estrogen	O
predominance	O
via	O
the	O
reduction	O
of	O
transcription	O
for	O
ER	B-DNA
gene	I-DNA
,	O
which	O
leads	O
to	O
the	O
reduction	O
of	O
ER	B-RNA
mRNA	I-RNA
and	O
ER	B-protein
expressions	O
in	O
monocytes	B-cell_type
.	O

Functional	O
characterization	O
of	O
novel	O
IL-2	B-protein
transcriptional	O
inhibitors	O
.	O

IL-2	B-protein
-mediated	O
T	B-cell_type
cell	I-cell_type
proliferation	O
is	O
a	O
critical	O
early	O
event	O
in	O
the	O
inflammatory	O
process	O
.	O

Formation	O
of	O
the	O
NFAT-1	B-protein
transcriptional	I-protein
complex	I-protein
on	O
the	O
IL-2	B-DNA
promoter	I-DNA
is	O
essential	O
for	O
IL-2	B-protein
transcription	O
.	O

Using	O
a	O
cell	O
line	O
that	O
is	O
stably	O
transfected	O
with	O
a	O
trimer	O
of	O
the	O
NFAT-1	B-DNA
regulatory	I-DNA
element	I-DNA
linked	O
to	O
a	O
lac-Z	B-DNA
reporter	I-DNA
gene	I-DNA
,	O
we	O
screened	O
for	O
inhibitors	O
of	O
NFAT	B-protein
-1-mediated	O
beta-galactosidase	B-protein
activity	O
.	O

WIN	O
61058	O
and	O
WIN	O
53071	O
were	O
identified	O
as	O
microM	O
inhibitors	O
.	O

These	O
compounds	O
also	O
inhibited	O
beta-galactosidase	B-RNA
mRNA	I-RNA
levels	O
.	O

Similar	O
inhibition	O
of	O
NFAT	B-protein
-1-mediated	O
gene	O
expression	O
was	O
observed	O
in	O
a	O
second	O
cell	B-cell_line
line	I-cell_line
,	O
which	O
is	O
stably	O
transfected	O
with	O
NFAT-1	B-DNA
regulatory	I-DNA
elements	I-DNA
linked	O
to	O
the	O
reporter	B-DNA
gene	I-DNA
for	I-DNA
sCD8	I-DNA
.	O

At	O
10	O
microM	O
,	O
both	O
compounds	O
inhibited	O
IL-2	O
mRNA	O
and	O
protein	O
levels	O
in	O
the	O
NFAT-1-linked	B-cell_line
lac-Z	I-cell_line
transfectants	I-cell_line
,	O
and	O
in	O
human	B-cell_type
lymphocytes	I-cell_type
.	O

Both	O
compounds	O
inhibited	O
the	O
mixed	O
lymphocyte	O
reaction	O
,	O
and	O
this	O
inhibition	O
was	O
reversed	O
by	O
exogenous	O
IL-2	B-protein
.	O

WIN	O
53071	O
inhibited	O
IL-2	B-protein
production	O
induced	O
in	O
the	O
calcium-dependent	O
PMA	O
and	O
ionomycin	O
pathway	O
.	O

Conversely	O
,	O
calcium-independent	B-protein
anti-CD28	I-protein
Ab	I-protein
and	O
PMA-induced	O
IL-2	B-protein
production	O
was	O
resistant	O
.	O

Both	O
compounds	O
altered	O
the	O
NFAT-1	B-protein
transcriptional	I-protein
complex	I-protein
,	O
causing	O
its	O
retarded	O
mobility	O
on	O
gels	O
.	O

By	O
these	O
functional	O
criteria	O
,	O
we	O
believe	O
we	O
have	O
identified	O
two	O
structurally	O
distinct	O
,	O
novel	O
inhibitors	O
of	O
NFAT	B-protein
-1-mediated	O
transcription	O
.	O

Transcriptional	O
regulation	O
of	O
the	O
vacuolar	B-DNA
H	I-DNA
(	I-DNA
+	I-DNA
)	I-DNA
-ATPase	I-DNA
B2	I-DNA
subunit	I-DNA
gene	I-DNA
in	O
differentiating	B-cell_line
THP-1	I-cell_line
cells	I-cell_line
.	O

Monocyte-macrophage	O
differentiation	O
was	O
used	O
as	O
a	O
model	O
system	O
for	O
studying	O
gene	O
regulation	O
of	O
the	O
human	B-protein
vacuolar	I-protein
H	I-protein
(	I-protein
+	I-protein
)	I-protein
-ATPase	I-protein
(	O
V-ATPase	B-protein
)	O
.	O

We	O
examined	O
mRNA	B-RNA
levels	O
of	O
various	O
V-ATPase	B-protein
subunits	O
during	O
differentiation	O
of	O
both	O
native	B-cell_type
monocytes	I-cell_type
and	O
the	O
cell	B-cell_line
line	I-cell_line
THP-1	B-cell_line
,	O
and	O
found	O
that	O
transcriptional	O
and	O
post-transcriptional	O
mechanisms	O
could	O
account	O
for	O
increases	O
in	O
cell	O
V-ATPase	B-protein
content	O
.	O

From	O
nuclear	O
runoff	O
experiments	O
,	O
we	O
found	O
that	O
one	O
subunit	O
in	O
particular	O
,	O
the	O
B2	B-protein
isoform	I-protein
(	O
Mr	O
=	O
56	O
,	O
000	O
)	O
,	O
was	O
amplified	O
primarily	O
by	O
transcriptional	O
means	O
.	O

We	O
have	O
begun	O
to	O
examine	O
the	O
structure	O
of	O
the	O
B2	B-DNA
subunit	I-DNA
promoter	I-DNA
region	I-DNA
.	O

Isolation	O
and	O
sequencing	O
of	O
the	O
first	B-DNA
exon	I-DNA
and	O
5'-flanking	B-DNA
region	I-DNA
of	O
this	O
gene	O
reveal	O
a	O
TATA-less	B-DNA
promoter	I-DNA
with	O
a	O
high	O
G	O
+	O
C	O
content	O
.	O

Primer	O
extension	O
and	O
ribonuclease	B-protein
protection	O
analyses	O
indicate	O
a	O
single	O
major	B-DNA
transcriptional	I-DNA
start	I-DNA
site	I-DNA
.	O

We	O
transfected	O
promoter-luciferase	B-DNA
reporter	I-DNA
plasmids	I-DNA
into	O
THP-1	B-cell_line
cells	I-cell_line
to	O
define	O
sequences	O
that	O
mediate	O
transcriptional	O
control	O
during	O
monocyte	O
differentiation	O
.	O

We	O
found	O
that	O
sequences	O
downstream	O
from	O
the	O
transcriptional	O
start	O
site	O
were	O
sufficient	O
to	O
confer	O
increased	O
expression	O
during	O
THP-1	B-cell_line
differentiation	O
.	O

DNase	B-protein
I	I-protein
footprinting	O
and	O
sequence	O
analysis	O
revealed	O
the	O
existence	O
of	O
multiple	O
AP2	B-DNA
and	I-DNA
Sp1	I-DNA
binding	I-DNA
sites	I-DNA
in	O
the	O
5'-untranslated	B-DNA
and	I-DNA
proximal	I-DNA
coding	I-DNA
regions	I-DNA
.	O

Synergy	O
between	O
signal	O
transduction	O
pathways	O
is	O
obligatory	O
for	O
expression	O
of	O
c-fos	B-DNA
in	O
B	B-cell_line
and	I-cell_line
T	I-cell_line
cell	I-cell_line
lines	I-cell_line
:	O
implication	O
for	O
c-fos	B-DNA
control	O
via	O
surface	B-protein
immunoglobulin	I-protein
and	O
T	B-protein
cell	I-protein
antigen	I-protein
receptors	I-protein
.	O

Expression	O
of	O
the	O
protooncogene	B-DNA
c-fos	I-DNA
is	O
controlled	O
by	O
three	O
main	O
regulatory	O
pathways	O
involving	O
kinase	B-protein
C	I-protein
,	O
cAMP	O
,	O
and	O
calcium	O
.	O

Kinase	B-protein
C	I-protein
mediates	O
its	O
effects	O
via	O
phosphorylation	O
of	O
serum	B-protein
response	I-protein
factor	I-protein
(	O
SRF	B-protein
)	O
which	O
interacts	O
with	O
the	O
serum	B-DNA
response	I-DNA
element	I-DNA
(	O
SRE	B-DNA
)	O
;	O
cAMP	O
and	O
calcium	O
mediate	O
their	O
effects	O
via	O
phosphorylation	O
of	O
CREB	B-protein
(	O
cAMP	B-protein
regulatory	I-protein
element	I-protein
binding	I-protein
protein	I-protein
)	O
presumably	O
by	O
activation	O
of	O
a	O
protein	B-protein
kinase	I-protein
A	I-protein
or	O
calmodulin-regulated	B-protein
kinase	I-protein
.	O

We	O
have	O
examined	O
the	O
function	O
of	O
these	O
elements	O
in	O
Burkitt	B-cell_line
's	I-cell_line
lymphoma	I-cell_line
cells	I-cell_line
(	O
Ramos	B-cell_line
and	O
Daudi	B-cell_line
)	O
as	O
well	O
as	O
a	O
T	B-cell_line
lymphocytic	I-cell_line
cell	I-cell_line
line	I-cell_line
(	O
Jurkat	B-cell_line
)	O
.	O

We	O
have	O
found	O
that	O
stimulation	O
of	O
any	O
one	O
of	O
these	O
pathways	O
alone	O
has	O
little	O
or	O
no	O
effect	O
on	O
c-fos	B-DNA
induction	O
.	O

However	O
,	O
kinase	B-protein
C	I-protein
activation	O
(	O
PMA	O
stimulation	O
)	O
combined	O
with	O
either	O
cAMP	O
(	O
forskolin	O
plus	O
MIX	O
)	O
or	O
calcium	O
stimulation	O
(	O
ionophore	O
)	O
leads	O
to	O
greatly	O
enhanced	O
c-fos	B-DNA
induction	O
.	O

By	O
contrast	O
,	O
cAMP	O
in	O
the	O
presence	O
of	O
calcium	O
shows	O
no	O
synergy	O
in	O
c-fos	B-DNA
induction	O
.	O

Okadaic	O
acid	O
augments	O
PMA-	O
as	O
well	O
as	O
calcium-mediated	O
activation	O
of	O
c-fos	B-DNA
,	O
and	O
has	O
little	O
or	O
no	O
effect	O
when	O
combined	O
with	O
cAMP	O
.	O

The	O
main	O
difference	O
between	O
Ramos	B-cell_line
(	O
B	B-cell_type
cells	I-cell_type
)	O
and	O
Jurkat	B-cell_line
(	O
T	B-cell_type
cells	I-cell_type
)	O
in	O
the	O
regulation	O
of	O
c-fos	B-DNA
is	O
that	O
cAMP	O
plus	O
calcium	O
is	O
strongly	O
synergistic	O
in	O
Jurkat	B-cell_line
and	O
is	O
without	O
effect	O
in	O
Ramos	B-cell_line
.	O

Analysis	O
of	O
AP-1	B-protein
activity	O
using	O
gel	O
mobility	O
shift	O
assays	O
confirms	O
that	O
the	O
requirements	O
for	O
synergy	O
in	O
c-fos	B-RNA
mRNA	I-RNA
induction	O
are	O
paralleled	O
by	O
requirements	O
for	O
synergy	O
in	O
induction	O
of	O
AP-1	B-protein
activity	O
.	O

Signaling	O
in	O
B	B-cell_type
cells	I-cell_type
due	O
to	O
anti-Ig	B-protein
stimulation	O
involves	O
both	O
kinase	B-protein
C	I-protein
activation	O
and	O
release	O
of	O
intracellular	O
calcium	O
,	O
and	O
results	O
in	O
c-fos	B-RNA
mRNA	I-RNA
induction	O
.	O

Our	O
results	O
indicate	O
that	O
synergy	O
between	O
the	O
kinase	B-protein
C	I-protein
activation	O
and	O
calcium	O
is	O
needed	O
for	O
efficient	O
c-fos	B-DNA
induction	O
since	O
neither	O
of	O
these	O
two	O
alone	O
induces	O
c-fos	B-DNA
well	O
.	O

That	O
synergy	O
of	O
signaling	O
pathways	O
is	O
relevant	O
for	O
the	O
anti-Ig	B-protein
induction	O
of	O
c-fos	B-DNA
is	O
supported	O
by	O
the	O
fact	O
that	O
cAMP-inducing	O
agents	O
and	O
okadaic	O
acid	O
further	O
enhance	O
anti-Ig	B-protein
induction	O
of	O
c-fos	B-DNA
.	O

These	O
results	O
suggest	O
that	O
cell-specific	O
patterns	O
of	O
synergy	O
are	O
an	O
essential	O
feature	O
for	O
c-fos	B-DNA
induction	O
and	O
may	O
be	O
relevant	O
for	O
c-fos	B-DNA
control	O
through	O
B	B-protein
and	I-protein
T	I-protein
cell	I-protein
antigen	I-protein
receptors	I-protein
.	O

Multiple	O
signals	O
are	O
required	O
for	O
function	O
of	O
the	O
human	B-DNA
granulocyte-macrophage	I-DNA
colony-stimulating	I-DNA
factor	I-DNA
gene	I-DNA
promoter	I-DNA
in	O
T	B-cell_type
cells	I-cell_type
.	O

The	O
human	B-DNA
granulocyte-macrophage	I-DNA
CSF	I-DNA
(	I-DNA
GM-CSF	I-DNA
)	I-DNA
gene	I-DNA
is	O
expressed	O
in	O
T	B-cell_type
cells	I-cell_type
in	O
response	O
to	O
TCR	B-protein
activation	O
that	O
can	O
be	O
mimicked	O
by	O
treatment	O
of	O
the	O
cells	O
with	O
PMA	O
and	O
Ca2+	O
ionophore	O
.	O

The	O
gene	O
contains	O
a	O
proximal	B-DNA
functional	I-DNA
promoter	I-DNA
region	I-DNA
(	O
-620	B-DNA
to	I-DNA
+34	I-DNA
)	O
,	O
as	O
well	O
as	O
a	O
powerful	O
enhancer	B-DNA
located	O
3	O
kb	O
upstream	O
,	O
both	O
of	O
which	O
are	O
involved	O
in	O
the	O
response	O
of	O
the	O
gene	O
to	O
TCR	B-protein
activation	O
.	O

The	O
proximal	B-DNA
promoter	I-DNA
contains	O
a	O
region	O
termed	O
CLEO	B-DNA
(	O
-54	B-DNA
to	I-DNA
-31	I-DNA
)	O
that	O
consists	O
of	O
a	O
purine-rich	B-DNA
element	I-DNA
abutting	O
an	O
activator	B-DNA
protein-1	I-DNA
(	I-DNA
AP-1	I-DNA
)	I-DNA
-like	I-DNA
site	I-DNA
,	O
as	O
well	O
as	O
an	O
upstream	B-DNA
nuclear	I-DNA
factor-kappa	I-DNA
B	I-DNA
(	I-DNA
NF-kappa	I-DNA
B	I-DNA
)	I-DNA
site	I-DNA
(	O
-85	B-DNA
to	I-DNA
-76	I-DNA
)	O
and	O
a	O
CK-1	B-DNA
element	I-DNA
(	O
-101	B-DNA
to	I-DNA
-92	I-DNA
)	O
.	O

We	O
show	O
in	O
this	O
work	O
that	O
mutations	O
in	O
either	O
the	O
purine-rich	B-DNA
region	I-DNA
of	O
the	O
CLEO	B-DNA
element	I-DNA
or	O
the	O
NF-kappa	B-DNA
B	I-DNA
site	I-DNA
result	O
in	O
reduced	O
PMA/Ca2+	O
activation	O
of	O
a	O
620-bp	B-DNA
human	I-DNA
GM-CSF	I-DNA
promoter-luciferase	I-DNA
reporter	I-DNA
construct	I-DNA
in	O
Jurkat	B-cell_line
T	I-cell_line
cells	I-cell_line
by	O
65	O
%	O
and	O
50	O
%	O
,	O
respectively	O
.	O

The	O
major	O
inducible	B-protein
protein	I-protein
complex	I-protein
that	O
binds	O
to	O
the	O
human	B-DNA
CLEO	I-DNA
(	I-DNA
hCLEO	I-DNA
)	I-DNA
element	I-DNA
is	O
an	O
AP-1-like	B-protein
complex	I-protein
that	O
is	O
inducible	O
by	O
PMA	O
alone	O
,	O
but	O
shows	O
increased	O
binding	O
in	O
response	O
to	O
PMA	O
together	O
with	O
Ca2+	O
ionophore	O
.	O

Although	O
the	O
binding	O
of	O
this	O
complex	O
is	O
not	O
cyclosporin-sensitive	O
,	O
promoter	O
induction	O
is	O
inhibited	O
by	O
cyclosporin	O
treatment	O
.	O

A	O
second	O
weak	O
inducible	O
complex	O
resembling	O
nuclear	B-protein
factor	I-protein
of	I-protein
activated	I-protein
T	I-protein
cells	I-protein
(	O
NF-AT	B-protein
)	O
was	O
also	O
observed	O
binding	O
to	O
the	O
hCLEO	B-DNA
region	I-DNA
.	O

By	O
using	O
recombinant	B-protein
proteins	I-protein
,	O
we	O
confirmed	O
that	O
AP-1	B-protein
,	O
NF-ATp	B-protein
,	O
and	O
a	O
higher	O
order	O
NF-ATp/AP-1	B-protein
complex	I-protein
could	O
all	O
form	O
with	O
the	O
hCLEO	B-DNA
element	I-DNA
,	O
and	O
we	O
have	O
also	O
defined	O
the	O
sequence	O
requirements	O
for	O
binding	O
of	O
each	O
of	O
these	O
complexes	O
.	O

We	O
found	O
that	O
expression	O
of	O
a	O
constitutively	O
active	O
form	O
of	O
calcineurin	B-protein
could	O
substitute	O
for	O
Ca2+	O
ionophore	O
and	O
synergize	O
with	O
PMA	O
to	O
activate	O
the	O
GM-CSF	B-DNA
promoter	I-DNA
,	O
and	O
conversely	O
that	O
mutant-activated	B-protein
Ras	I-protein
could	O
substitute	O
for	O
PMA	O
and	O
cooperate	O
with	O
Ca2+	O
ionophore	O
.	O

Co-expression	O
of	O
Ras	B-protein
and	O
calcineurin	B-protein
,	O
however	O
,	O
did	O
not	O
activate	O
the	O
GM-CSF	B-DNA
promoter	I-DNA
,	O
but	O
required	O
the	O
additional	O
expression	O
of	O
NF-kappa	B-protein
B	I-protein
p65	I-protein
.	O

These	O
results	O
imply	O
that	O
at	O
least	O
three	O
signals	O
are	O
required	O
to	O
activate	O
the	O
GM-CSF	B-DNA
proximal	I-DNA
promoter	I-DNA
,	O
and	O
that	O
the	O
signals	O
impinge	O
on	O
distinct	O
transcription	B-protein
factors	I-protein
that	O
bind	O
to	O
the	O
hCLEO	B-DNA
and	I-DNA
NF-kappa	I-DNA
B	I-DNA
regions	I-DNA
of	O
the	O
promoter	B-DNA
.	O

IL-10	O
induces	O
the	O
tyrosine	O
phosphorylation	O
of	O
tyk2	B-protein
and	O
Jak1	B-protein
and	O
the	O
differential	O
assembly	O
of	O
STAT1	B-protein
alpha	I-protein
and	O
STAT3	B-protein
complexes	I-protein
in	O
human	B-cell_type
T	I-cell_type
cells	I-cell_type
and	O
monocytes	B-cell_type
.	O

IL-10	B-protein
affects	O
monocytes	B-cell_type
and	O
T	B-cell_type
cells	I-cell_type
by	O
driving	O
the	O
progression	O
of	O
immune	O
responsiveness	O
such	O
that	O
Th2	O
lymphocyte-mediated	O
effects	O
predominate	O
.	O

In	O
this	O
report	O
,	O
we	O
show	O
that	O
in	O
monocytes	B-cell_type
and	O
T	B-cell_type
cells	I-cell_type
IL-10	B-protein
stimulates	O
tyrosine	O
phosphorylation	O
of	O
the	O
signal	B-protein
transducers	I-protein
and	O
activators	B-protein
of	I-protein
transcription	I-protein
,	O
STAT1	B-protein
alpha	I-protein
and	O
STAT3	B-protein
,	O
in	O
a	O
differential	O
manner	O
such	O
that	O
the	O
relative	O
formation	O
of	O
homo-	B-protein
and	I-protein
heterodimers	I-protein
varies	O
between	O
the	O
two	O
cell	O
types	O
.	O

Moreover	O
,	O
monocytes	B-cell_type
express	O
a	O
novel	O
IL-10-stimulated	B-protein
STAT	I-protein
protein	I-protein
with	O
an	O
M	O
(	O
r	O
)	O
of	O
70	B-protein
kDa	I-protein
that	O
is	O
recognized	O
by	O
the	O
anti-STAT3	B-protein
Ab	I-protein
but	O
is	O
not	O
observed	O
in	O
T	B-cell_type
cells	I-cell_type
.	O

IL-10	B-protein
treatment	O
of	O
both	O
T	B-cell_type
cells	I-cell_type
and	O
monocytes	B-cell_type
results	O
in	O
the	O
ligand-induced	O
tyrosine	O
phosphorylation	O
of	O
tyk2	B-protein
and	O
Jak1	B-protein
,	O
but	O
not	O
Jak2	B-protein
or	O
Jak3	B-protein
.	O

Selective	O
modulation	O
of	O
immune	O
responsiveness	O
by	O
IL-10	B-protein
in	O
cells	O
such	O
as	O
monocytes	B-cell_type
and	O
T	B-cell_type
cells	I-cell_type
may	O
result	O
in	O
part	O
from	O
the	O
differential	O
activation	O
of	O
STAT	B-protein
protein	I-protein
pairs	I-protein
.	O

Use	O
of	O
new	O
biologic	O
markers	O
in	O
the	O
ovulation	O
induction	O
.	O

Biological	O
markers	O
of	O
ovulation	O
,	O
after	O
a	O
great	O
in	O
the	O
past	O
,	O
have	O
been	O
fallen	O
into	O
disuse	O
for	O
the	O
large	O
diffusion	O
of	O
biochemical	O
and	O
biophysical	O
ones	O
.	O

However	O
,	O
the	O
real	O
effect	O
of	O
hormones	O
involved	O
in	O
ovulation	O
is	O
expressed	O
by	O
biological	O
modifications	O
on	O
target	B-cell_type
tissues	I-cell_type
.	O

To	O
explore	O
the	O
modifications	O
of	O
not	O
reproductive	O
target	O
tissues	O
as	O
ovulation	O
markers	O
we	O
studied	O
the	O
behaviour	O
of	O
Albuminemia	O
,	O
Platelet	B-protein
Factor	I-protein
IV	I-protein
(	O
as	O
indicator	O
of	O
Platelet	O
Aggregation	O
)	O
,	O
Type	B-protein
II	I-protein
estrogenic	I-protein
receptors	I-protein
in	O
42	O
ovulation	O
induced	O
women	O
,	O
undergoing	O
our	O
observation	O
.	O

33	O
of	O
them	O
had	O
ovulation	O
and	O
9	O
developed	O
a	O
LUF	O
syndrome	O
,	O
constituting	O
two	O
biological	O
models	O
of	O
an	O
opposite	O
situation	O
for	O
the	O
three	O
markers	O
observed	O
.	O

All	O
the	O
markers	O
considered	O
were	O
sufficiently	O
sensitive	O
,	O
but	O
among	O
them	O
,	O
Platelet	B-protein
Factor	I-protein
IV	I-protein
was	O
the	O
most	O
reliable	O
to	O
the	O
hormonal	O
ovulatory	O
situation	O
.	O

Abnormal	O
regulation	O
of	O
the	O
IL-2	B-DNA
promoter	I-DNA
in	O
lpr	O
CD4-CD8-	B-cell_line
T	I-cell_line
lymphocytes	I-cell_line
results	O
in	O
constitutive	O
expression	O
of	O
a	O
novel	B-protein
nuclear	I-protein
factor	I-protein
of	I-protein
activated	I-protein
T	I-protein
cells-binding	I-protein
factor	I-protein
.	O

The	O
inert	O
quality	O
of	O
MRL-Ipr/Ipr	B-cell_line
(	I-cell_line
Ipr	I-cell_line
)	I-cell_line
peripheral	I-cell_line
CD4-CD8-	I-cell_line
(	I-cell_line
CD4-8-	I-cell_line
)	I-cell_line
T	I-cell_line
cells	I-cell_line
manifests	O
primarily	O
as	O
an	O
inability	O
to	O
proliferate	O
or	O
produce	O
IL-2	B-protein
in	O
response	O
to	O
TCR	B-protein
or	O
mitogenic	O
stimulation	O
.	O

Yet	O
these	O
same	O
cells	O
do	O
initiate	O
early	O
TCR	B-protein
-mediated	O
signaling	O
events	O
,	O
such	O
as	O
generation	O
of	O
inositol	O
phosphates	O
and	O
increased	O
intracellular	O
calcium	O
.	O

They	O
also	O
display	O
constitutively	O
high	O
levels	O
of	O
p59fyn	B-protein
and	O
CD3	B-protein
zeta	I-protein
tyrosine	O
phosphorylation	O
.	O

The	O
generation	O
of	O
second	O
messengers	O
in	O
T	B-cell_type
cells	I-cell_type
normally	O
leads	O
to	O
downstream	O
signaling	O
that	O
results	O
in	O
transcriptional	O
activation	O
of	O
the	O
IL-2	B-DNA
gene	I-DNA
.	O

We	O
,	O
therefore	O
,	O
compared	O
the	O
activation	O
state	O
of	O
the	O
IL-2	B-DNA
gene	I-DNA
promoter	I-DNA
region	I-DNA
in	O
freshly	O
isolated	O
and	O
stimulated	O
Ipr	B-cell_line
CD4-8-	I-cell_line
T	I-cell_line
cells	I-cell_line
with	O
that	O
of	O
normal	B-cell_type
T	I-cell_type
lymphocytes	I-cell_type
.	O

Levels	O
of	O
the	O
octamer	O
,	O
NF-kappa	B-protein
B	I-protein
(	O
p50-p65	B-protein
heterodimer	I-protein
)	O
,	O
and	O
AP-1	B-protein
transcriptional	I-protein
factors	I-protein
are	O
constitutively	O
elevated	O
in	O
freshly	O
isolated	O
Ipr	B-cell_line
CD4-8-	I-cell_line
T	I-cell_line
cells	I-cell_line
,	O
consistent	O
with	O
the	O
activated	O
phenotype	O
of	O
these	O
cells	O
.	O

Upon	O
stimulation	O
with	O
mitogens	O
,	O
formation	O
of	O
the	O
transactivating	O
complex	O
,	O
nuclear	B-protein
factor	I-protein
of	I-protein
activated	I-protein
T	I-protein
cells	I-protein
(	O
NF-AT	B-protein
)	O
,	O
occurs	O
with	O
normal	O
kinetics	O
in	O
Ipr	B-cell_line
CD4-8-	I-cell_line
T	I-cell_line
cells	I-cell_line
.	O

Yet	O
,	O
the	O
levels	O
of	O
the	O
activating	O
NF-AT	B-protein
complex	I-protein
never	O
reach	O
those	O
observed	O
in	O
similarly	O
stimulated	O
normal	O
T	B-cell_type
cells	I-cell_type
.	O

Furthermore	O
,	O
nuclear	O
extracts	O
from	O
Ipr	B-cell_line
CD4-8-	I-cell_line
T	I-cell_line
cells	I-cell_line
display	O
high	O
levels	O
of	O
a	O
novel	O
specific	O
binding	O
activity	O
at	O
the	O
NF-AT	B-DNA
site	I-DNA
,	O
which	O
is	O
present	O
at	O
much	O
lower	O
levels	O
in	O
freshly	O
isolated	O
normal	B-cell_type
T	I-cell_type
lymphocytes	I-cell_type
.	O

Upon	O
mitogenic	O
stimulation	O
,	O
the	O
binding	O
activity	O
of	O
the	O
novel	O
NF-AT-binding	B-protein
factor	I-protein
is	O
rapidly	O
down-regulated	O
in	O
normal	O
T	B-cell_type
cells	I-cell_type
,	O
but	O
persists	O
at	O
high	O
levels	O
in	O
Ipr	B-cell_line
CD4-8-	I-cell_line
T	I-cell_line
cells	I-cell_line
.	O

These	O
two	O
abnormalities	O
at	O
the	O
NF-AT	B-DNA
site	I-DNA
provide	O
a	O
potential	O
mechanism	O
to	O
account	O
for	O
the	O
defect	O
in	O
IL-2	B-protein
production	O
from	O
Ipr	B-cell_line
CD4-8-	I-cell_line
T	I-cell_line
cells	I-cell_line
.	O

Cross-linking	O
of	O
CD30	B-protein
induces	O
HIV	O
expression	O
in	O
chronically	O
infected	O
T	B-cell_type
cells	I-cell_type
.	O

CD30	B-protein
,	O
a	O
member	O
of	O
the	O
tumor	O
necrosis	O
factor	O
(	O
TNF	O
)	O
receptor	O
family	O
,	O
is	O
expressed	O
constitutively	O
on	O
the	O
surface	O
of	O
the	O
human	O
T	O
cell	O
line	O
ACH-2	O
,	O
which	O
is	O
chronically	O
infected	O
with	O
human	O
immunodeficiency	O
virus	O
type-1	O
(	O
HIV	O
)	O
-1	O
.	O

We	O
demonstrate	O
that	O
cross-linking	O
CD30	B-protein
with	O
an	O
anti-	O
CD30	B-protein
-specific	O
monoclonal	O
antibody	O
,	O
which	O
mimics	O
the	O
described	O
biological	O
activities	O
of	O
the	O
CD30	B-protein
ligand	I-protein
(	O
CD30L	B-protein
)	O
,	O
results	O
in	O
HIV	O
expression	O
.	O

CD30	B-protein
cross-linking	O
does	O
not	O
alter	O
proliferation	O
of	O
ACH-2	B-cell_line
cells	I-cell_line
and	O
the	O
induction	O
of	O
HIV	O
expression	O
is	O
not	O
mediated	O
by	O
endogenous	O
TNF	B-protein
alpha/beta	I-protein
.	O

Furthermore	O
,	O
cross-linking	O
of	O
CD30	B-protein
leads	O
to	O
NF-kappa	B-protein
B	I-protein
activation	O
and	O
enhanced	O
HIV	O
transcription	O
.	O

Thus	O
,	O
CD30	B-protein
-CD30L	B-protein
interactions	O
mediate	O
the	O
induction	O
of	O
HIV	O
expression	O
by	O
a	O
kappa	O
B-dependent	O
pathway	O
that	O
is	O
independent	O
of	O
TNF	B-protein
.	O

This	O
mechanism	O
may	O
be	O
important	O
in	O
the	O
activation	O
of	O
HIV	O
expression	O
from	O
latently	O
infected	O
CD4+	B-cell_line
T	I-cell_line
cells	I-cell_line
,	O
especially	O
in	O
lymphoid	O
organs	O
where	O
cell	O
to	O
cell	O
contact	O
is	O
conducive	O
to	O
receptor-ligand	O
interactions	O
.	O

Human	O
MHC	B-DNA
class	I-DNA
II	I-DNA
gene	I-DNA
transcription	O
directed	O
by	O
the	O
carboxyl	B-protein
terminus	I-protein
of	O
CIITA	B-DNA
,	O
one	O
of	O
the	O
defective	B-DNA
genes	I-DNA
in	O
type	O
II	O
MHC	B-protein
combined	O
immune	O
deficiency	O
.	O

Type	B-protein
II	I-protein
major	I-protein
histocompatibility	I-protein
complex	I-protein
combined	O
immune	O
deficiency	O
(	O
type	O
II	O
MHC	B-protein
CID	O
or	O
bare	O
lymphocyte	O
syndrome	O
)	O
is	O
a	O
congenital	O
immunodeficiency	O
disease	O
characterized	O
by	O
absent	O
MHC	B-protein
class	I-protein
II	I-protein
expression	O
.	O

Four	O
distinct	O
complementation	O
groups	O
have	O
been	O
identified	O
.	O

Recently	O
,	O
the	O
defective	B-DNA
gene	I-DNA
in	O
group	O
II	O
type	O
II	O
MHC	B-protein
CID	O
has	O
been	O
isolated	O
and	O
termed	O
CIITA	B-DNA
.	O

Here	O
,	O
we	O
demonstrate	O
that	O
CIITA	B-DNA
is	O
an	O
MHC	B-DNA
class	I-DNA
II	I-DNA
gene-specific	I-DNA
transcription	I-DNA
activator	I-DNA
.	O

The	O
transcription	O
activation	O
function	O
is	O
provided	O
by	O
the	O
N-terminal	B-protein
acidic	I-protein
domain	I-protein
(	O
amino	B-protein
acids	I-protein
26-137	I-protein
)	O
,	O
which	O
is	O
experimentally	O
exchangeable	O
with	O
a	O
heterologous	B-protein
viral	I-protein
transcription-activating	I-protein
domain	I-protein
.	O

The	O
specificity	O
of	O
CIITA	B-protein
for	O
three	O
major	O
MHC	B-DNA
class	I-DNA
II	I-DNA
genes	I-DNA
,	O
DR	B-DNA
,	O
DQ	B-DNA
and	O
DP	B-DNA
,	O
is	O
mediated	O
by	O
its	O
remaining	O
C-terminal	B-protein
residues	I-protein
(	O
amino	B-protein
acids	I-protein
317-1130	I-protein
)	O
.	O

The	O
transactivation	O
of	O
multiple	B-DNA
cis	I-DNA
elements	I-DNA
,	O
especially	O
S	B-DNA
and	O
X2	B-DNA
,	O
of	O
the	O
DR	B-DNA
alpha	I-DNA
proximal	I-DNA
promoter	I-DNA
in	O
group	B-cell_line
II	I-cell_line
CID	I-cell_line
cells	I-cell_line
is	O
CIITA	B-protein
dependent	O
.	O

Since	O
CIITA	B-protein
overexpression	O
in	O
normal	B-cell_type
cells	I-cell_type
did	O
not	O
increase	O
class	O
II	O
expression	O
,	O
we	O
propose	O
that	O
initiation	O
of	O
CIITA	B-protein
expression	O
serves	O
as	O
the	O
on-off	O
switch	O
,	O
while	O
availability	O
of	O
downstream	O
interactor	O
(	O
s	O
)	O
limits	O
transcription	O
.	O

Monocyte	O
tethering	O
by	O
P-selectin	B-protein
regulates	O
monocyte	B-protein
chemotactic	I-protein
protein-1	I-protein
and	O
tumor	B-protein
necrosis	I-protein
factor-alpha	I-protein
secretion	O
.	O

Signal	O
integration	O
and	O
NF-kappa	B-protein
B	I-protein
translocation	O
[	O
see	O
comments	O
]	O

Adhesion	B-protein
molecules	I-protein
that	O
tether	O
circulating	B-cell_type
leukocytes	I-cell_type
to	O
endothelial	B-cell_type
cells	I-cell_type
may	O
also	O
transduce	O
or	O
modulate	O
outside-in	O
signals	O
for	O
cellular	O
activation	O
,	O
providing	O
an	O
initial	O
regulatory	O
point	O
in	O
the	O
inflammatory	O
response	O
.	O

Adhesion	O
of	O
human	B-cell_type
monocytes	I-cell_type
to	O
P-selectin	B-protein
,	O
the	O
most	O
rapidly	O
expressed	O
endothelial	B-protein
tethering	I-protein
factor	I-protein
,	O
increased	O
the	O
secretion	O
of	O
monocyte	B-protein
chemotactic	I-protein
protein-1	I-protein
(	O
MCP-1	B-protein
)	O
and	O
tumor	B-protein
necrosis	I-protein
factor-alpha	I-protein
(	O
TNF-alpha	B-protein
)	O
by	O
the	O
leukocytes	B-cell_type
when	O
they	O
were	O
stimulated	O
with	O
platelet-activating	B-protein
factor	I-protein
.	O

Increased	O
cytokine	O
secretion	O
was	O
specifically	O
inhibited	O
by	O
G1	B-protein
,	O
an	O
anti-P-selectin	B-protein
mAb	I-protein
that	O
prevents	O
P-selectin	B-protein
from	O
binding	O
to	O
its	O
ligand	O
(	O
P-selectin	B-protein
glycoprotein	I-protein
ligand-1	I-protein
)	O
on	O
myeloid	B-cell_type
cells	I-cell_type
.	O

Moreover	O
,	O
tethering	O
by	O
P-selectin	B-protein
specifically	O
enhanced	O
nuclear	O
translocation	O
of	O
nuclear	B-protein
factor-kappa	I-protein
B	I-protein
(	O
NF-kappa	B-protein
B	I-protein
)	O
,	O
a	O
transcription	B-protein
factor	I-protein
required	O
for	O
expression	O
of	O
MCP-1	B-protein
,	O
TNF-alpha	B-protein
,	O
and	O
other	O
immediate-early	B-DNA
genes	I-DNA
.	O

These	O
results	O
demonstrate	O
that	O
P-selectin	B-protein
,	O
through	O
its	O
ligands	O
on	O
monocytes	B-cell_type
,	O
may	O
locally	O
regulate	O
cytokine	B-protein
secretion	O
in	O
inflamed	O
tissues	O
.	O

Functional	O
roles	O
of	O
in	B-DNA
vivo	I-DNA
footprinted	I-DNA
DNA	I-DNA
motifs	I-DNA
within	O
an	O
alpha-globin	B-DNA
enhancer	I-DNA
.	O

Erythroid	O
lineage	O
and	O
developmental	O
stage	O
specificities	O
.	O

Transcriptional	O
regulation	O
of	O
the	O
human	B-DNA
alpha-like	I-DNA
globin	I-DNA
genes	I-DNA
,	O
embryonic	B-DNA
zeta	I-DNA
2	I-DNA
and	O
adult	B-DNA
alpha	I-DNA
,	O
during	O
erythroid	O
development	O
is	O
mediated	O
by	O
a	O
distal	B-DNA
enhancer	I-DNA
,	O
HS-40	B-DNA
.	O

Previous	O
protein-DNA	O
binding	O
studies	O
have	O
shown	O
that	O
HS-40	B-DNA
consists	O
of	O
multiple	O
nuclear	B-DNA
factor	I-DNA
binding	I-DNA
motifs	I-DNA
that	O
are	O
occupied	O
in	O
vivo	O
in	O
an	O
erythroid	O
lineage-	O
and	O
developmental	O
stage-specific	O
manner	O
.	O

We	O
have	O
systematically	O
analyzed	O
the	O
functional	O
roles	O
of	O
these	O
factor	B-DNA
binding	I-DNA
motifs	I-DNA
of	O
HS-40	B-DNA
by	O
site-directed	O
mutagenesis	O
and	O
transient	O
expression	O
assay	O
in	O
erythroid	B-cell_line
cell	I-cell_line
cultures	I-cell_line
.	O

Three	O
of	O
these	O
HS-40	B-DNA
enhancer	I-DNA
motifs	I-DNA
,	O
5'NF-E2/AP1	B-DNA
,	O
GT	B-DNA
II	I-DNA
,	O
and	O
GATA-1	B-DNA
(	I-DNA
c	I-DNA
)	I-DNA
,	O
positively	O
regulate	O
the	O
zeta	B-DNA
2-globin	I-DNA
promoter	I-DNA
activity	O
in	O
embryonic/fetal	B-cell_line
erythroid	I-cell_line
K562	I-cell_line
cells	I-cell_line
and	O
the	O
adult	B-DNA
alpha-globin	I-DNA
promoter	I-DNA
activity	O
in	O
adult	B-cell_line
erythroid	I-cell_line
MEL	I-cell_line
cells	I-cell_line
.	O

On	O
the	O
other	O
hand	O
,	O
the	O
3'NF-E2/AP1	B-DNA
motif	I-DNA
is	O
able	O
to	O
exert	O
both	O
positive	O
and	O
negative	O
regulatory	O
effects	O
on	O
the	O
zeta	B-DNA
2-globin	I-DNA
promoter	I-DNA
activity	O
in	O
K562	B-cell_line
cells	I-cell_line
,	O
and	O
this	O
dual	O
function	O
appears	O
to	O
be	O
modulated	O
through	O
differential	O
binding	O
of	O
the	O
ubiquitous	B-protein
AP1	I-protein
factors	I-protein
and	O
the	O
erythroid-enriched	B-protein
NF-E2	I-protein
factor	I-protein
.	O

Mutation	O
in	O
the	O
GATA-1	B-DNA
(	I-DNA
d	I-DNA
)	I-DNA
motif	I-DNA
,	O
which	O
exhibits	O
an	O
adult	B-DNA
erythroid-specific	I-DNA
genomic	I-DNA
footprint	I-DNA
,	O
decreases	O
the	O
HS-40	B-DNA
enhancer	I-DNA
function	O
in	O
dimethyl	B-cell_line
sulfoxide-induced	I-cell_line
MEL	I-cell_line
cells	I-cell_line
but	O
not	O
in	O
K562	B-cell_line
cells	I-cell_line
.	O

These	O
studies	O
have	O
defined	O
the	O
regulatory	O
roles	O
of	O
the	O
different	O
HS-40	B-DNA
motifs	I-DNA
.	O

The	O
remarkable	O
correlation	O
between	O
genomic	O
footprinting	O
data	O
and	O
the	O
mutagenesis	O
results	O
also	O
suggests	O
that	O
the	O
erythroid	O
lineage-	O
and	O
developmental	O
stage-specific	O
regulation	O
of	O
human	B-DNA
alpha-like	I-DNA
globin	I-DNA
promoters	I-DNA
is	O
indeed	O
modulated	O
by	O
stable	O
binding	O
of	O
specific	B-protein
nuclear	I-protein
factors	I-protein
in	O
vivo	O
.	O

Nitric	O
oxide-stimulated	O
guanine	O
nucleotide	O
exchange	O
on	O
p21ras	B-protein
.	O

The	O
protooncogene	B-DNA
p21ras	I-DNA
,	O
a	O
monomeric	B-protein
G	I-protein
protein	I-protein
family	I-protein
member	I-protein
,	O
plays	O
a	O
critical	O
role	O
in	O
converting	O
extracellular	O
signals	O
into	O
intracellular	O
biochemical	O
events	O
.	O

Here	O
,	O
we	O
report	O
that	O
nitric	O
oxide	O
(	O
NO	O
)	O
activates	O
p21ras	B-DNA
in	O
human	B-cell_type
T	I-cell_type
cells	I-cell_type
as	O
evidenced	O
by	O
an	O
increase	O
in	O
GTP-bound	B-protein
p21ras	I-protein
.	O

In	O
vitro	O
studies	O
using	O
pure	B-protein
recombinant	I-protein
p21ras	I-protein
demonstrate	O
that	O
the	O
activation	O
is	O
direct	O
and	O
reversible	O
.	O

Circular	O
dichroism	O
analysis	O
reveals	O
that	O
NO	O
induces	O
a	O
profound	O
conformational	O
change	O
in	O
p21ras	B-DNA
in	O
association	O
with	O
GDP/GTP	O
exchange	O
.	O

The	O
mechanism	O
of	O
activation	O
is	O
due	O
to	O
S-nitrosylation	O
of	O
a	O
critical	O
cysteine	O
residue	O
which	O
stimulates	O
guanine	O
nucleotide	O
exchange	O
.	O

Furthermore	O
,	O
we	O
demonstrate	O
that	O
p21ras	B-protein
is	O
essential	O
for	O
NO-induced	O
downstream	O
signaling	O
,	O
such	O
as	O
NF-kappa	B-protein
B	I-protein
activation	O
,	O
and	O
that	O
endogenous	O
NO	O
can	O
activate	O
p21ras	B-protein
in	O
the	O
same	O
cell	O
.	O

These	O
studies	O
identify	O
p21ras	B-DNA
as	O
a	O
target	O
of	O
the	O
same	O
cell	O
.	O

These	O
studies	O
identify	O
p21ras	B-DNA
as	O
a	O
target	O
of	O
NO	O
in	O
T	B-cell_type
cells	I-cell_type
and	O
suggest	O
that	O
NO	O
activates	O
p21ras	B-DNA
by	O
an	O
action	O
which	O
mimics	O
that	O
of	O
guanine	B-protein
nucleotide	I-protein
exchange	I-protein
factors	I-protein
.	O

Interleukin-2	B-DNA
promoter	I-DNA
activity	O
in	O
Epstein-Barr	B-cell_line
virus-transformed	I-cell_line
B	I-cell_line
lymphocytes	I-cell_line
is	O
controlled	O
by	O
nuclear	B-protein
factor-chi	I-protein
B	I-protein
.	O

The	O
regulation	O
of	O
interleukin	B-DNA
(	I-DNA
IL	I-DNA
)	I-DNA
-2	I-DNA
gene	I-DNA
expression	O
has	O
been	O
investigated	O
mainly	O
in	O
T	B-cell_type
lymphocytes	I-cell_type
,	O
the	O
predominant	O
producers	O
of	O
IL-2	B-protein
.	O

However	O
,	O
B	B-cell_type
cells	I-cell_type
can	O
also	O
synthesize	O
IL-2	B-protein
.	O

In	O
the	O
present	O
study	O
we	O
analyzed	O
the	O
control	O
of	O
IL-2	B-DNA
promoter	I-DNA
activity	O
in	O
Epstein-Barr	B-cell_line
virus	I-cell_line
(	I-cell_line
EBV	I-cell_line
)	I-cell_line
-transformed	I-cell_line
B	I-cell_line
cell	I-cell_line
clones	I-cell_line
which	O
are	O
capable	O
of	O
secreting	O
IL-2	B-protein
at	O
a	O
low	O
level	O
after	O
stimulation	O
with	O
phorbol	O
12-myristate	O
13-acetate	O
and	O
the	O
Ca2+	O
ionophore	O
ionomycin	O
.	O

Transient	O
transfections	O
using	O
reporter	B-DNA
constructs	I-DNA
with	O
multiples	O
of	O
transcription	B-DNA
factor	I-DNA
binding	I-DNA
sites	I-DNA
from	O
the	O
IL-2	B-DNA
promoter	I-DNA
[	O
distal	B-protein
nuclear	I-protein
factor	I-protein
(	I-protein
NF	I-protein
)	I-protein
-AT	I-protein
,	O
proximal	B-protein
NF-AT	I-protein
,	O
AP-1/Octamer	B-protein
(	O
UPS	B-protein
)	O
or	O
NF-chi	B-protein
B	I-protein
(	O
TCEd	B-protein
)	O
sites	O
]	O
were	O
performed	O
.	O

In	O
EBV-transformed	B-cell_line
B	I-cell_line
clones	I-cell_line
,	O
the	O
chi	B-DNA
B	I-DNA
site	I-DNA
exerted	O
the	O
strongest	O
inducible	O
activity	O
;	O
the	O
NF-AT	B-DNA
binding	I-DNA
sites	I-DNA
showed	O
either	O
no	O
or	O
only	O
weak	O
activity	O
compared	O
to	O
Jurkat	B-cell_line
T	I-cell_line
cells	I-cell_line
.	O

An	O
IL-2	B-DNA
promoter	I-DNA
bearing	O
a	O
defective	O
NF-chi	B-DNA
B	I-DNA
site	I-DNA
was	O
completely	O
inactive	O
in	O
EBV-transformed	B-cell_line
B	I-cell_line
cells	I-cell_line
,	O
while	O
it	O
still	O
had	O
activity	O
in	O
Jurkat	B-cell_line
T	I-cell_line
cells	I-cell_line
.	O

In	O
seven	O
EBV-B	B-cell_line
cell	I-cell_line
clones	I-cell_line
or	O
lines	O
differing	O
in	O
their	O
capacity	O
to	O
secrete	O
IL-2	B-protein
,	O
the	O
activity	O
of	O
the	O
IL-2	B-DNA
promoter	I-DNA
correlated	O
well	O
with	O
the	O
status	O
of	O
IL-2	B-protein
secretion	O
.	O

Similarly	O
,	O
a	O
human	B-DNA
immunodeficiency	I-DNA
virus	I-DNA
promoter	I-DNA
,	O
whose	O
activity	O
is	O
controlled	O
through	O
chi	B-protein
B	I-protein
factors	I-protein
,	O
was	O
found	O
to	O
be	O
active	O
in	O
the	O
IL-2	B-cell_line
producing	I-cell_line
EBV-B	I-cell_line
cells	I-cell_line
,	O
but	O
inactive	O
in	O
the	O
non-IL-2-producing	B-cell_line
cells	I-cell_line
.	O

Electrophoretic	O
mobility	O
shift	O
assays	O
using	O
protein	O
extracts	O
from	O
EBV-B	B-cell_line
cells	I-cell_line
and	O
the	O
IL-2	B-protein
NF-chi	B-protein
B	I-protein
probe	O
revealed	O
the	O
constitutive	O
generation	O
of	O
chi	B-protein
B	I-protein
complexes	I-protein
in	O
IL-2-secreting	B-cell_line
cells	I-cell_line
consisting	O
mainly	O
of	O
heterodimeric	B-protein
p50/p65	I-protein
complexes	I-protein
.	O

A	O
weaker	O
chi	B-DNA
B	I-DNA
complex	O
formation	O
and	O
faster-migrating	O
complexes	O
were	O
detected	O
in	O
non-IL-2-secreting	B-cell_line
cells	I-cell_line
.	O

These	O
results	O
demonstrate	O
that	O
the	O
IL-2	B-DNA
NF-chi	I-DNA
B	I-DNA
site	I-DNA
is	O
indispensable	O
for	O
the	O
activity	O
of	O
the	O
IL-2	B-DNA
promoter	I-DNA
in	O
EBV-transformed	B-cell_line
B	I-cell_line
cells	I-cell_line
,	O
whereas	O
other	O
transcription	B-protein
factors	I-protein
appear	O
to	O
be	O
less	O
important	O
for	O
IL-2	B-protein
expression	O
in	O
these	O
cells	O
.	O

Latent	B-protein
membrane	I-protein
protein-1	I-protein
induces	O
cyclin	B-protein
D2	I-protein
expression	O
,	O
pRb	B-protein
hyperphosphorylation	O
,	O
and	O
loss	O
of	O
TGF-beta	B-protein
1	I-protein
-mediated	O
growth	O
inhibition	O
in	O
EBV-positive	B-cell_type
B	I-cell_type
cells	I-cell_type
.	O

The	O
normal	O
cell	O
cycle	O
is	O
regulated	O
by	O
several	O
molecules	O
,	O
such	O
as	O
the	O
tumor-suppressor	B-protein
protein	I-protein
pRb	I-protein
,	O
the	O
G1	B-protein
cyclins	I-protein
,	O
the	O
cyclin-dependent	B-protein
kinases	I-protein
,	O
and	O
their	O
inhibitors	O
.	O

These	O
regulators	O
are	O
targeted	O
by	O
negative	O
growth	O
regulatory	O
signals	O
,	O
such	O
as	O
that	O
provided	O
by	O
TGF-beta	B-protein
.	O

Here	O
,	O
we	O
show	O
that	O
the	O
presence	O
of	O
either	O
wild-type	O
EBV	O
or	O
its	O
transforming	B-protein
latent	I-protein
membrane	I-protein
protein-1	I-protein
(	O
LMP-1	B-protein
)	O
results	O
in	O
the	O
loss	O
of	O
TGF-beta	B-protein
1	I-protein
-mediated	O
growth	O
inhibition	O
in	O
human	B-cell_type
B	I-cell_type
cells	I-cell_type
.	O

Chemical	O
cross-linking	O
with	O
125I-labeled	B-protein
TGF-beta	I-protein
1	I-protein
showed	O
an	O
essentially	O
normal	O
TGF-beta	B-protein
receptor	I-protein
profile	O
in	O
EBV-positive	B-cell_line
and	I-cell_line
EBV-negative	I-cell_line
Burkitt	I-cell_line
's	I-cell_line
lymphoma	I-cell_line
cell	I-cell_line
lines	I-cell_line
,	O
and	O
these	O
receptors	O
were	O
shown	O
to	O
be	O
functional	O
in	O
transducing	O
signals	O
,	O
as	O
evidenced	O
by	O
the	O
TGF-beta	B-protein
1	I-protein
-mediated	O
modulation	O
of	O
junB	B-DNA
gene	I-DNA
expression	O
.	O

However	O
,	O
TGF-beta	B-protein
1	I-protein
did	O
not	O
induce	O
dephosphorylation	O
of	O
pRb	B-protein
in	O
EBV	B-cell_line
(	I-cell_line
or	I-cell_line
LMP-1	I-cell_line
)	I-cell_line
-positive	I-cell_line
cells	I-cell_line
as	O
opposed	O
to	O
EBV-negative	B-cell_line
cells	I-cell_line
,	O
suggesting	O
a	O
dichotomy	O
in	O
the	O
TGF-beta	B-protein
1	I-protein
signaling	O
pathway	O
leading	O
to	O
separable	O
gene	O
regulatory	O
and	O
growth	O
inhibitory	O
responses	O
.	O

Furthermore	O
,	O
LMP-1	B-protein
was	O
found	O
to	O
induce	O
the	O
expression	O
of	O
cyclin	B-protein
D2	I-protein
;	O
normal	O
B	B-cell_type
cells	I-cell_type
or	O
EBV-negative	B-cell_line
Burkitt	I-cell_line
's	I-cell_line
lymphoma	I-cell_line
cells	I-cell_line
do	O
not	O
express	O
D-type	B-protein
cyclins	I-protein
.	O

Taken	O
together	O
,	O
these	O
data	O
point	O
to	O
a	O
potential	O
mechanism	O
underlying	O
EBV-mediated	O
B	O
cell	O
transformation	O
whereby	O
constitutive	O
induction	O
of	O
key	B-protein
cell	I-protein
cycle	I-protein
regulators	I-protein
by	O
LMP-1	B-protein
can	O
lead	O
to	O
pRb	B-protein
hyperphosphorylation	O
and	O
uncontrolled	O
cell	O
proliferation	O
.	O

Does	O
thyroidectomy	O
,	O
radioactive	O
iodine	O
therapy	O
,	O
or	O
antithyroid	O
drug	O
treatment	O
alter	O
reactivity	O
of	O
patients	O
'	O
T	B-cell_type
cells	I-cell_type
to	O
epitopes	O
of	O
thyrotropin	B-protein
receptor	I-protein
in	O
autoimmune	O
thyroid	O
diseases	O
?	O

The	O
effect	O
of	O
treatment	O
on	O
thyroid	O
antibody	O
production	O
and	O
T	O
cell	O
reactivity	O
to	O
thyroid	O
antigens	O
was	O
studied	O
in	O
15	O
patients	O
with	O
Graves	O
'	O
disease	O
(	O
GD	O
)	O
before	O
and	O
after	O
thyroidectomy	O
,	O
19	O
patients	O
with	O
GD	O
before	O
and	O
after	O
radioactive	O
iodine	O
(	O
RAI	O
)	O
therapy	O
,	O
and	O
9	O
patients	O
maintained	O
euthyroid	O
on	O
antithyroid	O
drugs	O
(	O
ATD	O
)	O
.	O

Twenty	O
subjects	O
matched	O
for	O
age	O
and	O
sex	O
without	O
known	O
thyroid	O
disease	O
served	O
as	O
controls	O
.	O

In	O
GD	O
patients	O
,	O
the	O
responses	O
of	O
peripheral	B-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
(	O
PBMC	B-cell_type
)	O
and	O
TSH	B-cell_line
receptor	I-cell_line
(	I-cell_line
TSHR	I-cell_line
)	I-cell_line
-specific	I-cell_line
T	I-cell_line
cell	I-cell_line
lines	I-cell_line
to	O
recombinant	B-protein
human	I-protein
TSHR	I-protein
extracellular	I-protein
domain	I-protein
,	O
thyroglobulin	B-protein
,	O
and	O
TSHR	B-protein
peptides	O
were	O
examined	O
on	O
the	O
day	O
of	O
surgery	O
or	O
RAI	O
therapy	O
(	O
day	O
0	O
)	O
and	O
also	O
6-8	O
weeks	O
and	O
3-6	O
months	O
thereafter	O
.	O

Reactivity	O
to	O
TSHR	B-protein
peptides	O
before	O
surgery	O
was	O
heterogeneous	O
and	O
spanned	O
the	O
entire	O
extracellular	B-protein
domain	I-protein
.	O

Six	O
to	O
8	O
weeks	O
after	O
subtotal	O
thyroidectomy	O
,	O
the	O
number	O
of	O
patients	O
'	O
PBMC	B-cell_type
responding	O
to	O
any	O
peptide	O
and	O
the	O
average	O
number	O
of	O
recognized	O
peptides	O
decreased	O
.	O

A	O
further	O
decrease	O
in	O
the	O
T	O
cell	O
reactivity	O
to	O
TSHR	B-protein
peptides	O
was	O
observed	O
3-6	O
months	O
after	O
surgery	O
.	O

The	O
responses	O
of	O
PBMC	B-cell_type
from	O
Graves	O
'	O
patients	O
before	O
RAI	O
therapy	O
were	O
less	O
than	O
those	O
in	O
the	O
presurgical	O
group	O
.	O

Six	O
to	O
8	O
weeks	O
after	O
RAI	O
therapy	O
,	O
the	O
number	O
of	O
patients	O
responding	O
to	O
any	O
peptide	O
and	O
the	O
average	O
number	O
of	O
recognized	O
peptides	O
increased	O
.	O

Three	O
to	O
6	O
months	O
after	O
RAI	O
,	O
T	O
cell	O
responses	O
to	O
TSHR	B-protein
peptides	O
were	O
less	O
than	O
those	O
6-8	O
weeks	O
after	O
RAI	O
therapy	O
,	O
but	O
still	O
higher	O
than	O
the	O
values	O
on	O
day	O
0	O
.	O

Responses	O
of	O
PBMC	B-cell_type
from	O
patients	O
with	O
GD	O
,	O
maintained	O
euthyroid	O
on	O
ATD	O
,	O
were	O
lower	O
than	O
those	O
before	O
surgery	O
or	O
RAI	O
therapy	O
.	O

The	O
reactivity	O
of	O
T	B-cell_line
cell	I-cell_line
lines	I-cell_line
in	O
different	O
groups	O
reflected	O
a	O
pattern	O
similar	O
to	O
PBMC	B-cell_type
after	O
treatment	O
.	O

TSHR	B-protein
antibody	I-protein
and	O
microsomal	B-protein
antibody	I-protein
levels	O
decreased	O
after	O
surgery	O
,	O
but	O
increased	O
after	O
RAI	O
therapy	O
.	O

The	O
difference	O
in	O
the	O
number	O
of	O
recognized	O
peptides	O
by	O
patients	O
'	O
PBMC	B-cell_type
before	O
RAI	O
and	O
surgery	O
may	O
reflect	O
the	O
effect	O
of	O
long	O
term	O
therapy	O
with	O
ATD	O
in	O
the	O
patients	O
before	O
RAI	O
vs.	O
the	O
shorter	O
period	O
in	O
patients	O
before	O
surgery	O
.	O

The	O
decreased	O
T	O
cell	O
reactivity	O
to	O
thyroid	B-protein
antigens	I-protein
after	O
thyroidectomy	O
could	O
be	O
the	O
result	O
of	O
removal	O
of	O
a	O
major	O
part	O
of	O
the	O
thyroid	O
gland	O
or	O
redistribution	O
of	O
suppressor-inducer	O
T	B-cell_type
cells	I-cell_type
.	O

The	O
increased	O
T	O
cell	O
response	O
after	O
RAI	O
therapy	O
is	O
probably	O
epitope	O
specific	O
,	O
rather	O
than	O
a	O
response	O
to	O
the	O
whole	O
TSHR	B-protein
molecule	O
.	O

Synchronous	O
recognition	O
of	O
peptides	O
158-176	O
and	O
248-263	O
is	O
important	O
for	O
the	O
development	O
of	O
GD	O
,	O
and	O
the	O
loss	O
of	O
recognition	O
of	O
one	O
of	O
these	O
epitopes	B-protein
may	O
be	O
an	O
early	O
sign	O
of	O
immune	O
remission	O
and	O
a	O
predictor	O
of	O
euthyroidism	O
.	O

Circumvention	O
of	O
tolerance	O
for	O
the	O
nuclear	B-protein
T	I-protein
cell	I-protein
protein	I-protein
TCF-1	B-protein
by	O
immunization	O
of	O
TCF-1	B-protein
knock-out	O
mice	O
.	O

Molecular	O
events	O
that	O
underlie	O
the	O
well-defined	O
phenotypic	O
changes	O
of	O
the	O
differentiating	B-cell_type
thymocyte	I-cell_type
are	O
poorly	O
understood	O
.	O

A	O
candidate	O
gene	O
to	O
control	O
thymocyte	B-cell_type
differentiation	O
,	O
T	B-protein
cell	I-protein
factor-1	I-protein
(	O
TCF-1	B-protein
)	O
*	O
encodes	O
a	O
DNA-binding	B-protein
protein	I-protein
.	O

Its	O
mRNA	O
expression	O
pattern	O
is	O
complex	O
during	O
embryogenesis	O
,	O
yet	O
restricted	O
to	O
lymphocytes	B-cell_type
postnatally	O
.	O

Expression	O
studies	O
on	O
TCF-1	B-protein
protein	I-protein
have	O
been	O
hampered	O
by	O
the	O
difficulty	O
to	O
raise	O
antibodies	B-protein
due	O
to	O
extreme	O
evolutionary	O
conservation	O
.	O

TCF-1	B-protein
knock-out	O
mice	O
,	O
generated	O
recently	O
in	O
our	O
laboratory	O
,	O
have	O
strongly	O
decreased	O
numbers	O
of	O
thymocytes	B-cell_type
,	O
but	O
are	O
otherwise	O
normal	O
.	O

We	O
have	O
used	O
these	O
mice	O
to	O
generate	O
anti-TCF-1	B-protein
antibodies	I-protein
.	O

By	O
immunization	O
with	O
a	O
recombinant	B-protein
fusion	I-protein
protein	I-protein
,	O
we	O
show	O
that	O
TCF-1	B-protein
knock-out	O
mice	O
readily	O
yield	O
antiserum	O
titers	O
against	O
human	O
and	O
mouse	O
TCF-1	O
protein	O
.	O

Wild-type	O
littermates	O
remain	O
unresponsive	O
to	O
TCF-1	B-protein
while	O
they	O
mount	O
a	O
high-titer	O
antibody	O
response	O
to	O
the	O
fusion	B-protein
protein	I-protein
,	O
Maltose	B-protein
Binding	I-protein
Protein	I-protein
(	O
MBP	B-protein
)	O
.	O

Subsequently	O
,	O
TCF-1-specific	B-cell_line
hybridomas	I-cell_line
could	O
be	O
prepared	O
from	O
the	O
spleens	O
of	O
immunized	O
knock-out	O
mice	O
.	O

This	O
study	O
illustrates	O
the	O
almost	O
complete	O
tolerance	O
of	O
mice	O
for	O
human	B-protein
TCF-1	I-protein
and	O
demonstrates	O
that	O
this	O
tolerance	O
is	O
readily	O
broken	O
by	O
gene	O
knock-out	O
.	O

Furthermore	O
,	O
the	O
usefulness	O
of	O
knock-out	O
mice	O
for	O
the	O
generation	O
of	O
monoclonal	B-protein
antibodies	I-protein
against	O
the	O
gene	O
product	O
of	O
interest	O
is	O
underscored	O
.	O

The	O
transcription	B-protein
factor	I-protein
,	O
Nm23H2	B-protein
,	O
binds	O
to	O
and	O
activates	O
the	O
translocated	O
c-myc	B-DNA
allele	I-DNA
in	O
Burkitt	O
's	O
lymphoma	O
.	O

We	O
have	O
identified	O
an	O
in	O
vivo	O
footprint	O
over	O
the	O
PuF	B-DNA
site	I-DNA
on	O
the	O
translocated	O
c-myc	B-DNA
allele	I-DNA
in	O
Burkitt	O
's	O
lymphoma	O
cells	O
.	O

The	O
PuF	B-DNA
site	I-DNA
on	O
the	O
silent	B-DNA
normal	I-DNA
c-myc	I-DNA
allele	I-DNA
was	O
unoccupied	O
.	O

We	O
demonstrated	O
by	O
electrophoretic	O
mobility	O
shift	O
assay	O
,	O
electrophoretic	O
mobility	O
shift	O
assay	O
with	O
antibody	O
,	O
UV	O
cross-linking	O
followed	O
by	O
SDS-gel	O
electrophoresis	O
,	O
and	O
Western	O
analysis	O
that	O
Nm23H2	B-protein
in	O
B	O
cell	O
nuclear	O
extracts	O
bound	O
to	O
the	O
c-myc	O
PuF	B-DNA
site	I-DNA
.	O

Transfection	O
experiments	O
with	O
c-myc	B-DNA
promoter	I-DNA
constructs	I-DNA
in	O
both	O
DHL-9	B-cell_line
and	O
Raji	B-cell_line
cells	I-cell_line
revealed	O
that	O
the	O
PuF	B-DNA
site	I-DNA
functioned	O
as	O
a	O
positive	B-DNA
regulatory	I-DNA
element	I-DNA
in	O
B	B-cell_type
cells	I-cell_type
with	O
a	O
drop	O
in	O
activity	O
with	O
mutation	O
of	O
this	O
site	O
.	O

Access	O
to	O
this	O
site	O
is	O
blocked	O
in	O
the	O
normal	B-DNA
silent	I-DNA
c-myc	I-DNA
allele	I-DNA
;	O
these	O
data	O
suggest	O
that	O
the	O
Nm23H2	B-protein
protein	O
is	O
involved	O
in	O
deregulation	O
of	O
the	O
translocated	O
c-myc	B-DNA
allele	I-DNA
in	O
Burkitt	B-cell_line
's	I-cell_line
lymphoma	I-cell_line
cells	I-cell_line
.	O

Identification	O
of	O
two	O
novel	O
regulatory	B-DNA
elements	I-DNA
within	O
the	O
5'-untranslated	B-DNA
region	I-DNA
of	O
the	O
human	B-DNA
A	I-DNA
gamma-globin	I-DNA
gene	I-DNA
.	O

Interaction	O
between	O
the	O
stage	B-DNA
selector	I-DNA
element	I-DNA
(	O
SSE	O
)	O
in	O
the	O
proximal	B-DNA
gamma-globin	I-DNA
promoter	I-DNA
and	O
hypersensitivity	B-DNA
site	I-DNA
2	I-DNA
in	O
the	O
locus	B-DNA
control	I-DNA
region	I-DNA
partly	O
mediates	O
the	O
competitive	O
silencing	O
of	O
the	O
beta-globin	B-DNA
promoter	I-DNA
in	O
the	O
fetal	O
developmental	O
stage	O
.	O

We	O
have	O
now	O
demonstrated	O
that	O
a	O
second	O
SSE-like	B-DNA
element	I-DNA
in	O
the	O
5'-untranslated	B-DNA
region	I-DNA
of	O
the	O
gamma-gene	B-DNA
also	O
contributes	O
to	O
this	O
competitive	O
silencing	O
of	O
the	O
beta-gene	B-DNA
.	O

Utilizing	O
transient	O
transfection	O
assays	O
in	O
the	O
fetal	B-cell_line
erythroid	I-cell_line
cell	I-cell_line
line	I-cell_line
,	O
K562	B-cell_line
,	O
we	O
have	O
shown	O
that	O
the	O
core	B-DNA
enhancer	I-DNA
of	O
hypersensitivity	B-DNA
site	I-DNA
2	I-DNA
can	O
preferentially	O
interact	O
with	O
the	O
proximal	B-DNA
gamma-promoter	I-DNA
in	O
the	O
absence	O
of	O
the	O
SSE	B-DNA
,	O
completely	O
silencing	O
a	O
linked	B-DNA
beta-promoter	I-DNA
.	O

Mutation	O
of	O
a	O
20-base	O
pair	O
sequence	O
of	O
the	O
gamma-gene	B-DNA
5'-untranslated	I-DNA
region	I-DNA
(	O
UTR	B-DNA
)	O
led	O
to	O
derepression	O
of	O
beta-promoter	B-DNA
activity	O
.	O

A	O
marked	O
activation	O
of	O
gamma-promoter	B-DNA
activity	O
was	O
also	O
observed	O
with	O
this	O
mutation	O
,	O
suggesting	O
the	O
presence	O
of	O
a	O
repressor	O
.	O

Fine	O
mutagenesis	O
dissected	O
these	O
activities	O
to	O
different	O
regions	O
of	O
the	O
5'-UTR	B-DNA
.	O

The	O
stage	O
selector	O
activity	O
was	O
localized	O
to	O
a	O
region	O
centered	O
on	O
nucleotides	B-DNA
+13	I-DNA
to	I-DNA
+15	I-DNA
.	O

Electromobility	O
shift	O
assays	O
utilizing	O
this	O
sequence	O
demonstrated	O
binding	O
of	O
a	O
fetal	B-protein
and	I-protein
erythroid-specific	I-protein
protein	I-protein
.	O

The	O
repressor	O
activity	O
of	O
the	O
5'-UTR	B-DNA
was	O
localized	O
to	O
tandem	O
GATA-like	B-DNA
sites	I-DNA
,	O
which	O
appear	O
to	O
bind	O
a	O
complex	O
of	O
two	O
proteins	O
,	O
one	O
of	O
which	O
is	O
the	O
erythroid	B-protein
transcription	I-protein
factor	I-protein
GATA-1	B-protein
.	O

These	O
results	O
indicate	O
that	O
the	O
5'-UTR	B-DNA
of	O
the	O
gamma-gene	B-DNA
contains	O
sequences	O
that	O
may	O
be	O
important	O
for	O
its	O
transcriptional	O
and	O
developmental	O
regulation	O
.	O

Coupling	O
of	O
a	O
signal	B-protein
response	I-protein
domain	I-protein
in	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
to	O
multiple	O
pathways	O
for	O
NF-kappa	B-protein
B	I-protein
activation	O
.	O

The	O
eukaryotic	B-protein
transcription	I-protein
factor	I-protein
NF-kappa	B-protein
B	I-protein
plays	O
a	O
central	O
role	O
in	O
the	O
induced	O
expression	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
and	O
in	O
many	O
aspects	O
of	O
the	O
genetic	O
program	O
mediating	O
normal	O
T-cell	O
activation	O
and	O
growth	O
.	O

The	O
nuclear	O
activity	O
of	O
NF-kappa	B-protein
B	I-protein
is	O
tightly	O
regulated	O
from	O
the	O
cytoplasmic	O
compartment	O
by	O
an	O
inhibitory	B-protein
subunit	I-protein
called	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
.	O

This	O
cytoplasmic	O
inhibitor	O
is	O
rapidly	O
phosphorylated	O
and	O
degraded	O
in	O
response	O
to	O
a	O
diverse	O
set	O
of	O
NF-kappa	B-protein
B-inducing	I-protein
agents	I-protein
,	O
including	O
T-cell	B-protein
mitogens	I-protein
,	I-protein
proinflammatory	B-protein
cytokines	I-protein
,	O
and	O
viral	B-protein
transactivators	I-protein
such	O
as	O
the	O
Tax	B-protein
protein	I-protein
of	O
human	O
T-cell	O
leukemia	O
virus	O
type	O
1	O
.	O

To	O
explore	O
these	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
-dependent	O
mechanisms	O
for	O
NF-kappa	B-protein
B	I-protein
induction	O
,	O
we	O
identified	O
novel	O
mutants	O
of	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
that	O
uncouple	O
its	O
inhibitory	O
and	O
signal-transducing	O
functions	O
in	O
human	B-cell_type
T	I-cell_type
lymphocytes	I-cell_type
.	O

Specifically	O
,	O
removal	O
of	O
the	O
N-terminal	B-protein
36	I-protein
amino	I-protein
acids	I-protein
of	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
failed	O
to	O
disrupt	O
its	O
ability	O
to	O
form	O
latent	O
complexes	O
with	O
NF-kappa	B-protein
B	I-protein
in	O
the	O
cytoplasm	O
.	O

However	O
,	O
this	O
deletion	O
mutation	O
prevented	O
the	O
induced	O
phosphorylation	O
,	O
degradative	O
loss	O
,	O
and	O
functional	O
release	O
of	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
from	O
NF-kappa	B-protein
B	I-protein
in	O
Tax-expressing	B-cell_line
cells	I-cell_line
.	O

Alanine	O
substitutions	O
introduced	O
at	O
two	O
serine	O
residues	O
positioned	O
within	O
this	O
N-terminal	B-protein
regulatory	I-protein
region	I-protein
of	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
also	O
yielded	O
constitutive	O
repressors	O
that	O
escaped	O
from	O
Tax	B-protein
-induced	O
turnover	O
and	O
that	O
potently	O
inhibited	O
immune	O
activation	O
pathways	O
for	O
NF-kappa	B-protein
B	I-protein
induction	O
,	O
including	O
those	O
initiated	O
from	O
antigen	B-protein
and	I-protein
cytokine	I-protein
receptors	I-protein
.	O

In	O
contrast	O
,	O
introduction	O
of	O
a	O
phosphoserine	O
mimetic	O
at	O
these	O
sites	O
rectified	O
this	O
functional	O
defect	O
,	O
a	O
finding	O
consistent	O
with	O
a	O
causal	O
linkage	O
between	O
the	O
phosphorylation	O
status	O
and	O
proteolytic	O
stability	O
of	O
this	O
cytoplasmic	B-protein
inhibitor	I-protein
.	O

Together	O
,	O
these	O
in	O
vivo	O
studies	O
define	O
a	O
critical	O
signal	O
response	O
domain	O
in	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
that	O
coordinately	O
controls	O
the	O
biologic	O
activities	O
of	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
and	O
NF-kappa	B-protein
B	I-protein
in	O
response	O
to	O
viral	O
and	O
immune	O
stimuli	O
.	O

Growth	O
regulation	O
and	O
cellular	O
changes	O
during	O
differentiation	O
of	O
human	B-cell_line
prostatic	I-cell_line
cancer	I-cell_line
LNCaP	I-cell_line
cells	I-cell_line
as	O
induced	O
by	O
T	O
lymphocyte-conditioned	O
medium	O
.	O

Human	B-cell_line
prostatic	I-cell_line
epithelial	I-cell_line
cells	I-cell_line
from	O
an	O
androgen-dependent	B-cell_line
LNCaP	I-cell_line
cell	I-cell_line
line	I-cell_line
were	O
examined	O
in	O
response	O
to	O
conditioned	O
medium	O
(	O
CM	O
)	O
derived	O
from	O
phytohemagglutinin	B-cell_line
(	I-cell_line
PHA	I-cell_line
)	I-cell_line
-stimulated	I-cell_line
lymphocytes	I-cell_line
.	O

Addition	O
of	O
CM	O
caused	O
a	O
greater	O
than	O
70	O
%	O
reduction	O
of	O
cell	O
proliferation	O
by	O
cell	O
counting	O
and	O
cell	O
cycle	O
.	O

These	O
cells	O
showed	O
G1	O
phase	O
arrest	O
and	O
the	O
clonogenicity	O
was	O
reduced	O
.	O

The	O
growth-modulating	O
effect	O
was	O
dose-dependent	O
and	O
not	O
due	O
to	O
cell	O
lysis	O
or	O
apoptosis	O
.	O

The	O
binding	O
of	O
androgen	O
to	O
androgen	B-protein
receptor	I-protein
on	O
these	O
cells	O
showed	O
approximately	O
50	O
%	O
reduction	O
,	O
underlining	O
a	O
proliferation	O
reduction	O
mechanism	O
.	O

The	O
prostate-specific	B-protein
antigen	I-protein
(	O
PSA	B-protein
)	O
was	O
downregulated	O
to	O
approximately	O
75	O
%	O
during	O
the	O
process	O
.	O

Cell	O
morphology	O
showed	O
dendritic	O
processes	O
extending	O
from	O
cytoplasm	O
and	O
other	O
neuroendocrine	B-cell_type
cell	I-cell_type
characteristics	O
.	O

The	O
expression	O
of	O
several	O
cytoskeleton	B-protein
and	I-protein
intracellular	I-protein
proteins	I-protein
increased	O
as	O
determined	O
by	O
immunostaining	O
on	O
slides	O
and	O
by	O
ELISA	O
procedures	O
.	O

These	O
included	O
vimentin	B-protein
,	O
correlating	O
to	O
cell	O
shape	O
changes	O
,	O
cytokeratins	B-protein
8	I-protein
and	I-protein
18	I-protein
,	O
associated	O
with	O
differentiated	B-cell_type
cell	I-cell_type
types	I-cell_type
of	O
prostate	O
epithelia	O
,	O
and	O
neuron-specific	B-protein
enolase	I-protein
and	O
serotonin	O
,	O
associated	O
with	O
neuroendocrine	B-cell_type
cells	I-cell_type
.	O

From	O
these	O
cellular	O
changes	O
,	O
we	O
can	O
infer	O
that	O
the	O
cell	O
growth	O
was	O
modulated	O
along	O
with	O
induction	O
of	O
terminal	O
differentiation	O
.	O

Activated	O
T	B-cell_type
cells	I-cell_type
were	O
demonstrated	O
to	O
be	O
important	O
in	O
providing	O
the	O
modulating	O
activity	O
.	O

This	O
growth	B-protein
modulator	I-protein
was	O
semipurified	O
and	O
had	O
an	O
estimated	O
molecular	O
weight	O
13	O
,	O
000	O
to	O
24	O
,	O
000	O
Da	O
.	O

The	O
activity	O
was	O
determined	O
to	O
be	O
distinct	O
from	O
TGF	B-protein
,	O
TNF	B-protein
,	O
and	O
some	O
commonly	O
known	O
lymphokines	B-protein
.	O

The	O
interaction	O
between	O
lymphoid	B-cell_type
and	I-cell_type
prostatic	I-cell_type
cells	I-cell_type
in	O
growth	O
and	O
development	O
is	O
described	O
.	O

Platelet-activating	B-protein
factor	I-protein
stimulates	O
transcription	O
of	O
the	O
heparin-binding	B-protein
epidermal	I-protein
growth	I-protein
factor-like	I-protein
growth	I-protein
factor	I-protein
in	O
monocytes	B-cell_type
.	O

Correlation	O
with	O
an	O
increased	O
kappa	O
B	O
binding	O
activity	O
.	O

Human	O
peripheral	O
blood	O
monocytes	B-cell_type
responded	O
to	O
stimulation	O
of	O
platelet-activating	B-protein
factor	I-protein
(	O
PAF	B-protein
)	O
with	O
up-regulation	O
of	O
the	O
transcript	O
for	O
heparin-binding	B-protein
epidermal	I-protein
growth	I-protein
factor-like	I-protein
growth	I-protein
factor	I-protein
(	O
HB-EGF	B-protein
)	O
,	O
a	O
potent	B-protein
mitogen	I-protein
for	O
vascular	B-cell_type
smooth	I-cell_type
muscle	I-cell_type
cells	I-cell_type
.	O

This	O
function	O
of	O
PAF	B-protein
was	O
observed	O
at	O
nanomolar	O
concentrations	O
of	O
the	O
ligand	O
,	O
starting	O
at	O
30	O
min	O
after	O
stimulation	O
.	O

The	O
PAF	B-protein
-induced	O
up-regulation	O
of	O
HB-EGF	B-RNA
mRNA	I-RNA
was	O
accompanied	O
by	O
an	O
increase	O
in	O
kappa	O
B	O
binding	O
activity	O
.	O

These	O
functions	O
of	O
PAF	B-protein
appeared	O
to	O
be	O
mediated	O
through	O
the	O
cell	B-protein
surface	I-protein
PAF	I-protein
receptors	I-protein
,	O
as	O
two	O
PAF	B-protein
receptor	O
antagonists	O
,	O
WEB	O
2086	O
and	O
L-659	O
,	O
989	O
,	O
blocked	O
both	O
the	O
up-regulation	O
of	O
HB-EGF	B-RNA
mRNA	I-RNA
and	O
kappa	O
B	O
binding	O
activity	O
induced	O
by	O
PAF	B-protein
.	O

The	O
antagonists	O
,	O
however	O
,	O
had	O
no	O
effect	O
on	O
phorbol	O
ester-induced	O
up-regulation	O
of	O
HB-EGF	B-RNA
mRNA	I-RNA
and	O
kappa	O
B	O
binding	O
activity	O
.	O

Pretreatment	O
of	O
monocytes	B-cell_type
with	O
pertussis	O
toxin	O
inhibited	O
these	O
functions	O
of	O
PAF	B-protein
,	O
whereas	O
cholera	O
toxin	O
had	O
no	O
inhibitory	O
effect	O
.	O

Pyrrolidine	O
dithiocarbamate	O
,	O
an	O
inhibitor	O
for	O
NF-kappa	B-protein
B	I-protein
activation	O
,	O
markedly	O
reduced	O
PAF	B-protein
-stimulated	O
kappa	O
B	O
binding	O
activity	O
as	O
well	O
as	O
up-regulation	O
of	O
HB-EGF	B-RNA
mRNA	I-RNA
.	O

These	O
results	O
suggest	O
a	O
potential	O
role	O
of	O
PAF	B-protein
in	O
HB-EGF	B-protein
expression	O
and	O
provide	O
evidence	O
that	O
this	O
stimulation	O
may	O
occur	O
through	O
increased	O
kappa	O
B	O
binding	O
activity	O
.	O

Mapping	O
of	O
the	O
interaction	B-protein
site	I-protein
of	O
the	O
defective	B-protein
transcription	I-protein
factor	I-protein
in	O
the	O
class	B-cell_line
II	I-cell_line
major	I-cell_line
histocompatibility	I-cell_line
complex	I-cell_line
mutant	I-cell_line
cell	I-cell_line
line	I-cell_line
clone-13	I-cell_line
to	O
the	O
divergent	B-DNA
X2-box	I-DNA
.	O

We	O
have	O
previously	O
described	O
a	O
mutant	B-cell_line
B	I-cell_line
lymphoblastoid	I-cell_line
cell	I-cell_line
line	I-cell_line
,	O
Clone-13	B-cell_line
,	I-cell_line
that	O
expresses	O
HLA-DQ	B-protein
in	O
the	O
absence	O
of	O
HLA-DR	B-protein
and	I-protein
-DP	I-protein
.	O

Several	O
criteria	O
indicated	O
that	O
the	O
defect	O
in	O
this	O
cell	O
line	O
influences	O
the	O
activity	O
of	O
an	O
isotype-specific	B-protein
transcription	I-protein
factor	I-protein
.	O

Indeed	O
,	O
transient	O
transfection	O
of	O
HLA-DRA	B-DNA
and	I-DNA
DQB	I-DNA
reporter	I-DNA
constructs	I-DNA
indicated	O
that	O
the	O
affected	O
factor	O
operates	O
via	O
cis-elements	B-DNA
located	O
between	O
-141	B-DNA
base	I-DNA
pairs	I-DNA
and	O
the	O
transcription	B-DNA
initiation	I-DNA
site	I-DNA
.	O

A	O
series	O
of	O
hybrid	B-DNA
DRA/DQB	I-DNA
reporter	I-DNA
constructs	I-DNA
was	O
generated	O
to	O
further	O
map	O
the	O
relevant	O
cis-elements	B-DNA
in	O
this	O
system	O
.	O

Insertion	O
of	O
oligonucleotides	O
spanning	O
the	O
DQB	B-DNA
X-box	I-DNA
(	O
but	O
not	O
the	O
DQB-W	B-DNA
region	I-DNA
or	O
the	O
DQB	B-DNA
Y-box	I-DNA
)	O
upstream	B-DNA
of	I-DNA
-141	I-DNA
in	O
a	O
DRA	B-DNA
reporter	I-DNA
plasmid	I-DNA
rescued	O
expression	O
to	O
nearly	O
wild-type	O
levels	O
.	O

Substitution	O
promoters	O
were	O
then	O
generated	O
where	O
the	O
entire	O
X-box	B-DNA
,	O
or	O
only	O
the	O
X1-	B-DNA
or	I-DNA
X2-boxes	I-DNA
of	O
HLA-DRA	B-DNA
were	O
replaced	O
with	O
the	O
analogous	O
regions	O
of	O
HLA-DQB	B-DNA
.	O

The	O
DQB	B-DNA
X2-box	I-DNA
was	O
able	O
to	O
restore	O
expression	O
to	O
the	O
silent	B-DNA
DRA	I-DNA
reporter	I-DNA
construct	I-DNA
.	O

Moreover	O
,	O
replacement	O
of	O
the	O
DQB	B-DNA
X2-box	I-DNA
with	O
the	O
DRA	B-DNA
X2-box	I-DNA
markedly	O
diminished	O
the	O
activity	O
of	O
the	O
DQB	B-DNA
promoter	I-DNA
in	O
the	O
mutant	B-cell_line
cell	I-cell_line
.	O

None	O
of	O
the	O
hybrid	B-DNA
reporter	I-DNA
constructs	I-DNA
were	O
defective	O
when	O
transfected	O
into	O
the	O
wild-type	B-protein
,	O
HLA-DR/-DQ	B-cell_line
positive	I-cell_line
parental	I-cell_line
cell	I-cell_line
line	I-cell_line
,	O
Jijoye	B-cell_line
.	O

These	O
studies	O
suggest	O
that	O
the	O
divergent	B-DNA
X2-box	I-DNA
of	O
the	O
class	B-DNA
II	I-DNA
major	I-DNA
histocompatibility	I-DNA
complex	I-DNA
promoters	I-DNA
plays	O
an	O
important	O
role	O
in	O
influencing	O
differential	O
expression	O
of	O
the	O
human	B-DNA
class	I-DNA
II	I-DNA
isotypes	I-DNA
.	O

Restoration	O
of	O
the	O
Epstein-Barr	B-protein
virus	I-protein
ZEBRA	I-protein
protein	I-protein
's	O
capacity	O
to	O
disrupt	O
latency	O
by	O
the	O
addition	O
of	O
heterologous	B-protein
activation	I-protein
regions	I-protein
.	O

The	O
ZEBRA	B-protein
protein	I-protein
has	O
a	O
unique	O
biological	O
function	O
among	O
herpesviral	B-protein
proteins	I-protein
.	O

It	O
is	O
responsible	O
for	O
the	O
disruption	O
of	O
Epstein-Barr	O
virus	O
(	O
EBV	O
)	O
latency	O
and	O
the	O
induction	O
of	O
the	O
lytic	O
cycle	O
.	O

ZEBRA	B-protein
is	O
a	O
bZIP	B-protein
transcriptional	I-protein
activator	I-protein
which	O
binds	O
as	O
a	O
dimer	O
to	O
7-bp	B-DNA
response	I-DNA
elements	I-DNA
within	O
EBV	B-DNA
promoters	I-DNA
and	O
is	O
directly	O
involved	O
in	O
the	O
stimulation	O
of	O
virus	O
replication	O
at	O
the	O
EBV	B-DNA
lytic	I-DNA
origin	I-DNA
.	O

We	O
have	O
employed	O
the	O
ZEBRA	B-protein
/EBV	O
biological	O
system	O
to	O
test	O
whether	O
a	O
heterologous	B-protein
activation	I-protein
domain	I-protein
can	O
substitute	O
for	O
another	O
activation	O
domain	O
(	O
the	O
ZEBRA	B-protein
domain	I-protein
)	O
.	O

The	O
ZEBRA	B-protein
activation	I-protein
region	I-protein
was	O
replaced	O
with	O
the	O
potent	O
acid	B-protein
activation	I-protein
region	I-protein
from	O
the	O
herpes	B-protein
simplex	I-protein
virus	I-protein
VP16	I-protein
protein	I-protein
or	O
with	O
the	O
activation	B-protein
region	I-protein
of	O
the	O
EBV	B-protein
R	I-protein
protein	I-protein
.	O

Both	O
chimeras	O
were	O
found	O
to	O
transactivate	O
model	O
and	O
native	O
promoters	O
at	O
equivalent	O
or	O
better	O
levels	O
than	O
ZEBRA	B-protein
itself	O
.	O

Activation	O
was	O
not	O
target-	O
or	O
cell-type	O
dependent	O
,	O
nor	O
was	O
it	O
dependent	O
on	O
the	O
presence	O
of	O
virus	O
.	O

These	O
activation	O
domains	O
restored	O
ZEBRA	B-protein
's	O
ability	O
to	O
induce	O
early	B-protein
antigen	I-protein
and	O
to	O
stimulate	O
origin	O
replication	O
to	O
levels	O
that	O
were	O
equal	O
to	O
or	O
greater	O
than	O
those	O
of	O
wild	O
type	O
.	O

These	O
studies	O
suggest	O
that	O
the	O
specificities	O
of	O
some	O
of	O
the	O
known	O
biological	O
functions	O
of	O
ZEBRA	B-protein
are	O
not	O
dependent	O
upon	O
the	O
nature	O
of	O
the	O
activation	B-protein
domain	I-protein
present	I-protein
within	O
ZEBRA	B-protein
.	O

Interleukin	B-protein
4	I-protein
activates	O
a	O
signal	O
transducer	O
and	O
activator	O
of	O
transcription	B-protein
(	I-protein
Stat	I-protein
)	I-protein
protein	I-protein
which	O
interacts	O
with	O
an	O
interferon-gamma	B-DNA
activation	I-DNA
site-like	I-DNA
sequence	I-DNA
upstream	O
of	O
the	O
I	B-DNA
epsilon	I-DNA
exon	I-DNA
in	O
a	O
human	B-cell_line
B	I-cell_line
cell	I-cell_line
line	I-cell_line
.	O

Evidence	O
for	O
the	O
involvement	O
of	O
Janus	B-protein
kinase	I-protein
3	I-protein
and	O
interleukin-4	B-protein
Stat	I-protein
.	O

Germ	B-RNA
line	I-RNA
C	I-RNA
transcripts	I-RNA
can	O
be	O
induced	O
by	O
IL-4	B-protein
in	O
the	O
human	B-cell_line
B	I-cell_line
cell	I-cell_line
line	I-cell_line
,	O
BL-2	B-cell_line
.	O

Utilizing	O
a	O
IFN-gamma	B-DNA
activation	I-DNA
site-like	I-DNA
DNA	I-DNA
sequence	I-DNA
element	I-DNA
located	O
upstream	O
of	O
the	O
I	B-DNA
epsilon	I-DNA
exon	I-DNA
,	O
we	O
demonstrated	O
by	O
gel	O
mobility	O
shift	O
assays	O
that	O
IL-4	B-protein
induced	O
a	O
binding	O
activity	O
in	O
the	O
cytosol	O
and	O
nucleus	O
of	O
BL-2	B-cell_line
cells	I-cell_line
.	O

This	O
factor	O
was	O
designated	O
IL-4	B-protein
NAF	I-protein
(	O
IL-4-induced	B-protein
nuclear-activating	I-protein
factors	I-protein
)	O
and	O
was	O
identified	O
as	O
a	O
tyrosine	B-protein
phosphoprotein	I-protein
,	O
which	O
translocates	O
from	O
the	O
cytosol	O
to	O
the	O
nucleus	O
upon	O
IL-4	B-protein
treatment	O
.	O

Because	O
these	O
are	O
the	O
characteristics	O
of	O
a	O
signal	B-protein
transducer	I-protein
and	I-protein
activator	I-protein
of	I-protein
transcription	I-protein
(	I-protein
Stat	I-protein
)	I-protein
protein	I-protein
,	O
we	O
determined	O
whether	O
antibodies	B-protein
to	I-protein
Stat	I-protein
proteins	I-protein
will	O
interfere	O
with	O
gel	O
mobility	O
shift	O
and	O
found	O
that	O
antibodies	B-protein
to	I-protein
IL-4	I-protein
Stat	I-protein
,	O
also	O
known	O
as	O
Stat6	B-protein
,	O
but	O
not	O
antibodies	B-protein
to	O
other	O
Stat	B-protein
proteins	I-protein
,	O
interfere	O
with	O
the	O
formation	O
of	O
the	O
IL-4	B-protein
NAF	I-protein
complex	I-protein
.	O

Congruous	O
with	O
the	O
involvement	O
of	O
a	O
Stat	B-protein
protein	I-protein
,	O
IL-4	B-protein
induced	O
robust	O
Janus	B-protein
kinase	I-protein
3	I-protein
(	O
JAK3	B-protein
)	O
activity	O
in	O
BL-2	B-cell_line
cells	I-cell_line
.	O

Cotransfection	O
of	O
JAK3	B-protein
with	O
IL-4	B-protein
Stat	I-protein
into	O
COS-7	B-cell_line
cells	I-cell_line
produced	O
an	O
intracellular	O
activity	O
which	O
bound	O
the	O
same	O
IFN-gamma	B-DNA
activation	I-DNA
site-like	I-DNA
sequence	I-DNA
and	O
comigrated	O
with	O
IL-4	B-protein
NAF	I-protein
in	O
electrophoretic	O
mobility	O
shift	O
assay	O
.	O

These	O
results	O
show	O
that	O
IL-4	B-protein
NAF	I-protein
is	O
IL-4	B-protein
Stat	I-protein
,	O
which	O
is	O
activated	O
by	O
JAK3	B-protein
in	O
response	O
to	O
IL-4	B-protein
receptor	O
engagement	O
.	O

Does	O
activation	O
of	O
the	O
TAL1	B-DNA
gene	I-DNA
occur	O
in	O
a	O
majority	O
of	O
patients	O
with	O
T-cell	O
acute	O
lymphoblastic	O
leukemia	O
?	O
A	O
pediatric	O
oncology	O
group	O
study	O
.	O

Almost	O
25	O
%	O
of	O
patients	O
with	O
T-cell	O
acute	O
lymphoblastic	O
leukemia	O
(	O
T-ALL	O
)	O
have	O
tumor-specific	O
rearrangements	O
of	O
the	O
TAL1	B-DNA
gene	I-DNA
.	O

Although	O
TAL1	B-protein
expression	O
has	O
not	O
been	O
observed	O
in	O
normal	B-cell_type
lymphocytes	I-cell_type
,	O
TAL1	B-protein
gene	I-protein
products	I-protein
are	O
readily	O
detected	O
in	O
leukemic	B-cell_type
cells	I-cell_type
that	O
harbor	O
a	O
rearranged	B-DNA
TAL1	I-DNA
allele	I-DNA
.	O

Hence	O
,	O
it	O
has	O
been	O
proposed	O
that	O
ectopic	O
expression	O
of	O
TAL1	B-protein
promotes	O
the	O
development	O
of	O
T-ALL	O
.	O

In	O
this	O
report	O
,	O
we	O
show	O
that	O
TAL1	B-protein
is	O
expressed	O
in	O
the	O
leukemic	B-cell_type
cells	I-cell_type
of	O
most	O
patients	O
with	O
T-ALL	O
,	O
including	O
many	O
that	O
do	O
not	O
display	O
an	O
apparent	O
TAL1	B-DNA
gene	I-DNA
alteration	O
.	O

A	O
polymorphic	O
dinucleotide	O
repeat	O
in	O
the	O
transcribed	O
sequences	O
of	O
TAL1	B-protein
was	O
used	O
to	O
determine	O
the	O
allele	O
specificity	O
of	O
TAL1	B-protein
transcription	O
in	O
primary	B-cell_type
T-ALL	I-cell_type
cells	I-cell_type
.	O

Monoallelic	O
expression	O
of	O
TAL1	B-protein
was	O
observed	O
in	O
the	O
leukemic	B-cell_type
cells	I-cell_type
of	O
all	O
patients	O
(	O
8	O
of	O
8	O
)	O
bearing	O
a	O
TAL1	B-DNA
gene	I-DNA
rearrangement	O
.	O

In	O
the	O
leukemic	B-cell_type
cells	I-cell_type
of	O
patients	O
without	O
detectable	O
TAL1	B-protein
rearrangements	O
,	O
TAL1	B-protein
transcription	O
occurred	O
in	O
either	O
a	O
monoallelic	O
(	O
3	O
of	O
7	O
patients	O
)	O
or	O
a	O
biallelic	O
(	O
4	O
of	O
7	O
patients	O
)	O
fashion	O
.	O

Thus	O
,	O
TAL1	B-protein
activation	O
in	O
these	O
patients	O
may	O
result	O
from	O
subtle	O
alterations	O
in	O
cis-acting	B-DNA
regulatory	I-DNA
sequences	I-DNA
(	O
affecting	O
expression	O
of	O
a	O
single	B-DNA
TAL1	I-DNA
allele	I-DNA
)	O
or	O
changes	O
in	O
trans-acting	O
factors	O
that	O
control	O
TAL1	B-protein
transcription	O
(	O
affecting	O
expression	O
of	O
both	O
TAL1	B-DNA
alleles	I-DNA
)	O
.	O

Expression	O
of	O
erythroid-specific	B-DNA
genes	I-DNA
in	O
acute	O
megakaryoblastic	O
leukaemia	O
and	O
transient	O
myeloproliferative	O
disorder	O
in	O
Down	O
's	O
syndrome	O
.	O

Acute	O
megakaryoblastic	O
leukaemia	O
(	O
M7	O
)	O
and	O
transient	O
myeloproliferative	O
disorder	O
in	O
Down	O
's	O
syndrome	O
(	O
TMD	O
)	O
are	O
characterized	O
by	O
rapid	O
growth	O
of	O
abnormal	B-cell_type
blast	I-cell_type
cells	I-cell_type
which	O
express	O
megakaryocytic	B-protein
markers	I-protein
.	O

To	O
clarify	O
properties	O
of	O
the	O
blast	B-cell_type
cells	I-cell_type
in	O
M7	O
and	O
TMD	O
cases	O
,	O
we	O
examined	O
erythroid	O
markers	O
expression	O
in	O
blasts	B-cell_type
from	O
six	O
cases	O
with	O
M7	O
and	O
seven	O
cases	O
with	O
TMD	O
in	O
this	O
study	O
.	O

Erythroid-specific	B-RNA
mRNAs	I-RNA
encoding	O
gamma-globin	B-protein
and	O
erythroid	B-protein
delta-aminolevulinate	I-protein
synthase	I-protein
were	O
found	O
to	O
be	O
expressed	O
in	O
blasts	B-cell_type
from	O
most	O
of	O
these	O
cases	O
,	O
indicating	O
that	O
majorities	O
of	O
the	O
blasts	B-cell_type
in	O
M7	O
and	O
TMD	O
cases	O
have	O
erythroid	O
and	O
megakaryocytic	O
phenotypes	O
.	O

We	O
also	O
found	O
that	O
mRNAs	B-RNA
encoding	O
GATA-1	B-protein
and	O
GATA-2	B-protein
are	O
expressed	O
in	O
all	O
these	O
cases	O
.	O

These	O
results	O
suggest	O
that	O
M7	B-cell_type
blasts	I-cell_type
and	O
TMD	B-cell_type
blasts	I-cell_type
correspond	O
to	O
the	O
erythroid/megakaryocytic	B-cell_type
bipotential	I-cell_type
progenitor	I-cell_type
cells	I-cell_type
.	O

Expression	O
of	O
Ah	B-protein
receptor	I-protein
(	O
TCDD	B-protein
receptor	I-protein
)	O
during	O
human	O
monocytic	O
differentiation	O
.	O

We	O
have	O
previously	O
found	O
a	O
high	O
expression	O
of	O
human	B-RNA
Ah	I-RNA
receptor	I-RNA
(	I-RNA
TCDD	I-RNA
receptor	I-RNA
)	I-RNA
mRNA	I-RNA
in	O
peripheral	B-cell_type
blood	I-cell_type
cells	I-cell_type
of	O
individuals	O
.	O

In	O
this	O
paper	O
,	O
the	O
expression	O
of	O
this	O
gene	O
in	O
blood	B-cell_type
cells	I-cell_type
was	O
first	O
investigated	O
in	O
fractions	O
of	O
nucleated	B-cell_type
cells	I-cell_type
,	O
revealing	O
predominant	O
expression	O
of	O
the	O
Ah	B-DNA
receptor	I-DNA
gene	I-DNA
in	O
the	O
monocyte	B-cell_type
fraction	I-cell_type
.	O

Then	O
the	O
expression	O
levels	O
of	O
AhR	B-RNA
mRNA	I-RNA
in	O
various	O
hematopoietic	B-cell_line
cell	I-cell_line
lines	I-cell_line
were	O
examined	O
together	O
with	O
those	O
of	O
Arnt	B-protein
and	O
P450IA1	B-protein
.	O

AhR	B-protein
was	O
expressed	O
at	O
high	O
levels	O
in	O
monocytoid	B-cell_line
U937	I-cell_line
,	O
THP1	B-cell_line
,	O
and	O
HEL/S	B-cell_line
cells	I-cell_line
,	O
and	O
at	O
moderate	O
levels	O
in	O
promyelocytic	B-cell_line
HL60	I-cell_line
cells	I-cell_line
and	O
erythroblastic	B-cell_line
HEL	I-cell_line
cells	I-cell_line
.	O

However	O
,	O
it	O
was	O
not	O
detected	O
in	O
lymphoid	B-cell_type
cells	I-cell_type
MOLT4	B-cell_line
(	O
T	B-cell_type
cell	I-cell_type
)	O
and	O
BALL1	B-cell_line
(	O
B	B-cell_type
cell	I-cell_type
)	O
,	O
nor	O
in	O
K562	B-cell_line
erythroblasts	I-cell_line
.	O

Furthermore	O
,	O
a	O
specific	O
induction	O
of	O
AhR	B-protein
during	O
monocytic	O
differentiation	O
was	O
investigated	O
in	O
HL60	B-cell_line
and	O
HEL	B-cell_line
cells	I-cell_line
.	O

HL60	B-cell_line
cells	I-cell_line
were	O
induced	O
to	O
differentiate	O
toward	O
monocytes-macrophages	B-cell_type
by	O
incubation	O
with	O
phorbol	O
ester	O
,	O
showing	O
a	O
5-	O
to	O
2-fold	O
increase	O
of	O
AhR	B-RNA
mRNA	I-RNA
.	O

The	O
incubation	O
with	O
transforming	B-protein
growth	I-protein
factor	I-protein
beta	I-protein
1	I-protein
and	O
1	O
alpha	O
,	O
25-dihydroxyvitamin	O
D3	O
resulted	O
in	O
a	O
5-	O
to	O
7-fold	O
increase	O
of	O
AhR	B-RNA
mRNA	I-RNA
.	O

The	O
HEL	B-cell_line
cells	I-cell_line
also	O
exhibited	O
a	O
similar	O
elevation	O
of	O
AhR	B-RNA
mRNA	I-RNA
level	O
,	O
when	O
they	O
had	O
differentiated	O
toward	O
monocyte-macrophage	B-cell_type
cells	I-cell_type
by	O
these	O
combined	O
inducers	O
,	O
but	O
little	O
change	O
in	O
the	O
mRNA	O
level	O
was	O
observed	O
when	O
the	O
cells	O
were	O
induced	O
to	O
differentiate	O
into	O
other	O
cell	O
types	O
.	O

Treatment	O
of	O
the	O
differentiated	B-cell_line
HL60	I-cell_line
cells	I-cell_line
with	O
3-methylcholanthrene	O
,	O
a	O
ligand	O
of	O
AhR	B-protein
,	O
induced	O
the	O
expression	O
of	O
the	O
P450IA1	B-protein
gene	O
.	O

These	O
results	O
indicated	O
that	O
expression	O
of	O
AhR	B-RNA
mRNA	I-RNA
was	O
significantly	O
induced	O
during	O
monocytic	O
differentiation	O
and	O
that	O
the	O
differentiated	B-cell_type
cells	I-cell_type
were	O
responsive	O
to	O
xenobiotics	O
.	O

Our	O
results	O
suggest	O
that	O
AhR	B-protein
may	O
play	O
an	O
important	O
role	O
in	O
the	O
function	O
of	O
monocytes	B-cell_type
and	O
also	O
in	O
the	O
eventual	O
activation	O
of	O
environmental	O
carcinogens	O
.	O

Neutrophils	B-cell_type
and	O
monocytes	B-cell_type
express	O
high	O
levels	O
of	O
PU.1	B-protein
(	O
Spi-1	B-protein
)	O
but	O
not	O
Spi-B	B-protein
.	O

PU.1	B-protein
(	O
the	O
Spi-1	B-DNA
oncogene	I-DNA
)	O
and	O
Spi-B	B-protein
are	O
closely	O
related	O
members	O
of	O
the	O
ets	B-protein
transcription	I-protein
factor	I-protein
family	I-protein
,	O
sharing	O
similar	O
DNA	O
binding	O
specificities	O
mediated	O
by	O
similar	O
DNA	B-protein
binding	I-protein
domains	I-protein
.	O

PU.1	B-protein
and	O
Spi-B	B-protein
have	O
been	O
previously	O
described	O
as	O
being	O
predominantly	O
expressed	O
coordinately	O
in	O
macrophages	B-cell_type
and	O
B	B-cell_type
cells	I-cell_type
,	O
but	O
their	O
expression	O
in	O
early	O
hematopoietic	O
stages	O
and	O
during	O
the	O
course	O
of	O
myeloid	O
differentiation	O
to	O
monocytes	B-cell_type
and	O
macrophages	B-cell_type
or	O
to	O
neutrophils	B-cell_type
has	O
not	O
been	O
extensively	O
investigated	O
.	O

Here	O
,	O
we	O
report	O
that	O
PU.1	B-RNA
mRNA	I-RNA
is	O
upregulated	O
during	O
myeloid	O
differentiation	O
of	O
human	B-cell_line
purified	I-cell_line
CD34+	I-cell_line
cells	I-cell_line
and	O
murine	B-cell_line
multipotential	I-cell_line
FDCP-mix	I-cell_line
A4	I-cell_line
cells	I-cell_line
,	O
suggesting	O
that	O
PU.1	B-protein
is	O
upregulated	O
as	O
an	O
early	O
event	O
during	O
differentiation	O
of	O
multipotential	B-cell_type
progenitor	I-cell_type
cells	I-cell_type
.	O

PU.1	B-protein
expression	O
is	O
maintained	O
at	O
stable	O
levels	O
during	O
differentiation	O
of	O
myeloid	B-cell_line
cell	I-cell_line
lines	I-cell_line
U937	B-cell_line
and	O
HL-60	B-cell_line
to	O
monocytic	B-cell_type
and	I-cell_type
neutrophilic	I-cell_type
cells	I-cell_type
.	O

PU.1	B-protein
is	O
expressed	O
at	O
highest	O
levels	O
in	O
mature	B-cell_type
human	I-cell_type
monocytes	I-cell_type
and	O
human	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
neutrophils	I-cell_type
.	O

In	O
contrast	O
to	O
PU.1	B-protein
,	O
significant	O
levels	O
of	O
Spi-B	B-RNA
mRNA	I-RNA
and	O
protein	O
are	O
found	O
only	O
in	O
some	O
B-cell	B-cell_line
lines	I-cell_line
and	O
spleen	O
but	O
are	O
not	O
found	O
in	O
myeloid	B-cell_line
cell	I-cell_line
lines	I-cell_line
,	O
neutrophils	B-cell_type
,	O
or	O
macrophages	B-cell_type
.	O

In	O
vitro	O
translated	O
Spi-B	B-protein
protein	I-protein
can	O
bind	O
to	O
PU.1	B-DNA
binding	I-DNA
sites	I-DNA
in	O
myeloid	B-DNA
promoters	I-DNA
and	O
transactivate	O
these	O
promoters	B-DNA
in	O
nonmyeloid	B-cell_type
cells	I-cell_type
.	O

Therefore	O
,	O
although	O
PU.1	B-protein
and	O
Spi-B	B-protein
may	O
bind	O
to	O
similar	O
DNA	O
control	O
elements	O
and	O
have	O
redundancy	O
of	O
transactivation	O
function	O
in	O
vitro	O
,	O
the	O
lack	O
of	O
significant	O
levels	O
of	O
Spi-B	B-protein
in	O
myeloid	B-cell_type
cells	I-cell_type
makes	O
it	O
unlikely	O
that	O
Spi-B	B-protein
plays	O
a	O
significant	O
role	O
in	O
myeloid	O
lineage	O
development	O
and	O
gene	O
expression	O
.	O

In	O
contrast	O
,	O
PU.1	B-protein
is	O
expressed	O
at	O
high	O
levels	O
not	O
only	O
in	O
monocytes	B-cell_type
and	O
macrophages	B-cell_type
but	O
also	O
in	O
neutrophils	B-cell_type
,	O
indicating	O
that	O
PU.1	B-protein
can	O
activate	O
gene	O
expression	O
in	O
both	O
major	B-cell_type
myeloid	I-cell_type
lineages	I-cell_type
.	O

Identification	O
of	O
a	O
major	O
positive	B-DNA
regulatory	I-DNA
element	I-DNA
located	O
5	O
'	O
to	O
the	O
human	B-DNA
zeta-globin	I-DNA
gene	I-DNA
.	O

The	O
function	O
of	O
the	O
zeta-globin	B-DNA
promoter	I-DNA
was	O
studied	O
using	O
a	O
series	O
of	O
zeta-globin	B-DNA
promoter	I-DNA
deletion	I-DNA
constructs	I-DNA
to	O
drive	O
luciferase	B-protein
expression	O
in	O
transiently	B-cell_line
transfected	I-cell_line
human	I-cell_line
erythroleukemia	I-cell_line
cells	I-cell_line
.	O

The	O
promoters	B-DNA
were	O
used	O
without	O
enhancers	B-DNA
,	O
or	O
with	O
enhancers	B-DNA
derived	O
from	O
the	O
beta-globin	B-DNA
locus	I-DNA
control	I-DNA
region	I-DNA
and	O
the	O
alpha-globin	B-DNA
HS-40	I-DNA
enhancer	I-DNA
.	O

When	O
transfected	O
into	O
K562	B-cell_line
cells	I-cell_line
,	O
which	O
express	O
zeta-globin	B-protein
,	O
comparable	O
amounts	O
of	O
activity	O
were	O
obtained	O
from	O
the	O
-557	B-DNA
and	I-DNA
-417	I-DNA
zeta-luciferase	I-DNA
constructs	I-DNA
and	O
the	O
alpha-luciferase	B-DNA
constructs	I-DNA
when	O
no	O
enhancers	B-DNA
or	O
the	O
alpha-globin	B-DNA
locus	I-DNA
enhancers	I-DNA
were	O
used	O
.	O

When	O
the	O
constructs	O
were	O
transfected	O
into	O
OCIM1	B-cell_line
cells	I-cell_line
,	O
which	O
do	O
not	O
express	O
zeta-globin	B-protein
,	O
the	O
zeta-globin	B-DNA
promoters	I-DNA
were	O
at	O
best	O
20	O
%	O
as	O
active	O
as	O
the	O
alpha-globin	B-DNA
promoters	I-DNA
.	O

When	O
sequences	B-DNA
from	I-DNA
-417	I-DNA
to	I-DNA
-207	I-DNA
5	I-DNA
'	I-DNA
to	O
the	O
zeta-globin	B-RNA
mRNA	I-RNA
cap	I-RNA
site	I-RNA
were	O
deleted	O
,	O
up	O
to	O
95	O
%	O
of	O
the	O
zeta-globin	B-DNA
promoter	I-DNA
activity	O
was	O
lost	O
in	O
K562	B-cell_line
cells	I-cell_line
.	O

Reinsertion	O
of	O
these	O
sequences	O
into	O
zeta-luciferase	B-DNA
constructs	I-DNA
missing	O
the	O
-417	O
to	O
-207	O
region	O
showed	O
that	O
the	O
sequences	O
lack	O
classical	O
enhancer	O
activity	O
.	O

Point	O
mutation	O
of	O
a	O
GATA-1	B-DNA
site	I-DNA
at	O
-230	O
reduced	O
promoter	O
activity	O
by	O
37	O
%	O
.	O

Point	O
mutation	O
of	O
a	O
CCACC	B-DNA
site	I-DNA
at	O
-240	O
had	O
no	O
effect	O
.	O

Electrophoretic	O
mobility	O
shift	O
assays	O
indicated	O
that	O
the	O
-230	B-DNA
GATA-1	I-DNA
site	I-DNA
has	O
a	O
relatively	O
low	O
affinity	O
for	O
GATA-1	B-protein
.	O

These	O
experiments	O
show	O
the	O
presence	O
of	O
a	O
strong	O
positive-acting	B-DNA
element	I-DNA
,	O
located	O
between	O
-417	B-DNA
and	I-DNA
-207	I-DNA
bp	I-DNA
5	I-DNA
'	I-DNA
to	O
the	O
zeta-globin	B-DNA
mRNA	I-DNA
cap	I-DNA
site	I-DNA
,	O
is	O
necessary	O
for	O
high-level	O
promoter	O
activity	O
in	O
K562	B-cell_line
cells	I-cell_line
.	O

This	O
element	O
requires	O
GATA-1	B-protein
and	O
additional	B-protein
unknown	I-protein
factors	I-protein
for	O
maximal	O
activity	O
.	O

Analysis	O
of	O
the	O
role	O
of	O
protein	B-protein
kinase	I-protein
C-alpha	I-protein
,	I-protein
-epsilon	I-protein
,	I-protein
and	I-protein
-zeta	I-protein
in	O
T	O
cell	O
activation	O
.	O

T	B-cell_type
cells	I-cell_type
express	O
multiple	O
isotypes	O
of	O
protein	B-protein
kinase	I-protein
C	I-protein
(	O
PKC	B-protein
)	O
and	O
although	O
it	O
is	O
well	O
accepted	O
that	O
PKCs	B-protein
have	O
an	O
important	O
role	O
in	O
T	O
cell	O
activation	O
,	O
little	O
is	O
known	O
about	O
the	O
function	O
of	O
individual	O
PKC	B-protein
isotypes	I-protein
.	O

To	O
address	O
this	O
issue	O
,	O
mutationally	O
active	O
PKC-alpha	B-protein
,	I-protein
-epsilon	I-protein
,	I-protein
or	I-protein
-zeta	I-protein
have	O
been	O
transfected	O
into	O
T	B-cell_type
cells	I-cell_type
and	O
the	O
consequences	O
for	O
T	O
cell	O
activation	O
determined	O
.	O

p21ras	B-protein
plays	O
an	O
essential	O
role	O
in	O
T	O
cell	O
activation	O
.	O

Accordingly	O
,	O
the	O
effects	O
of	O
the	O
constitutively	B-protein
active	I-protein
PKCs	I-protein
were	O
compared	O
to	O
the	O
effects	O
of	O
mutationally	O
activated	O
p21ras	B-protein
.	O

The	O
data	O
indicate	O
that	O
PKC-epsilon	B-protein
and	O
,	O
to	O
a	O
lesser	O
extent	O
PKC-alpha	B-protein
but	O
not	O
-zeta	B-protein
,	O
can	O
regulate	O
the	O
transcription	B-protein
factors	I-protein
AP-1	B-protein
and	O
nuclear	O
factor	B-protein
of	I-protein
activated	I-protein
T	I-protein
cells	I-protein
(	O
NF-AT-1	B-protein
)	O
.	O

The	O
ability	O
of	O
PKC-epsilon	B-protein
to	O
induce	O
transactivation	O
of	O
NF-AT-1	B-protein
and	O
AP-1	B-protein
was	O
similar	O
to	O
the	O
stimulatory	O
effect	O
of	O
a	O
constitutively	B-protein
activated	I-protein
p21ras	I-protein
.	O

PKC-epsilon	B-protein
,	O
but	O
not	O
PKC-alpha	B-protein
nor	O
activated	O
p21ras	B-protein
,	O
was	O
able	O
to	O
induce	O
NF-KB	B-protein
activity	O
.	O

Phorbol	O
esters	O
induce	O
expression	O
of	O
CD69	B-protein
whereas	O
none	O
of	O
the	O
activated	B-protein
PKC	I-protein
isotypes	I-protein
tested	O
were	O
able	O
to	O
have	O
this	O
effect	O
.	O

Activated	O
Src	B-protein
and	O
p21ras	B-protein
were	O
able	O
to	O
induce	O
CD69	B-protein
expression	O
.	O

These	O
results	O
indicate	O
selective	O
functions	O
for	O
different	O
PKC	B-protein
isotypes	I-protein
in	O
T	B-cell_type
cells	I-cell_type
.	O

Moreover	O
,	O
the	O
data	O
comparing	O
the	O
effects	O
of	O
activated	B-protein
Ras	I-protein
and	O
PKC	B-protein
mutants	I-protein
suggest	O
that	O
PKC-alpha	B-protein
,	O
p21ras	B-protein
,	O
and	O
PKC-epsilon	B-protein
are	O
not	O
positioned	O
linearly	O
on	O
a	O
single	O
signal	O
transduction	O
pathway	O
.	O

Differences	O
in	O
binding	O
of	O
glucocorticoid	B-protein
receptor	I-protein
to	O
DNA	O
in	O
steroid-resistant	O
asthma	O
.	O

Although	O
glucocorticosteroids	O
are	O
a	O
very	O
effective	O
treatment	O
for	O
asthma	O
and	O
other	O
chronic	O
inflammatory	O
diseases	O
,	O
a	O
small	O
proportion	O
of	O
patients	O
are	O
resistant	O
to	O
their	O
therapeutic	O
effects	O
.	O

The	O
molecular	O
mechanism	O
for	O
this	O
steroid	O
resistance	O
is	O
unclear	O
.	O

Steroid	O
resistance	O
can	O
not	O
be	O
explained	O
by	O
pharmacokinetic	O
mechanisms	O
,	O
by	O
a	O
defect	O
in	O
the	O
binding	O
of	O
steroids	O
to	O
glucocorticoid	B-protein
receptors	I-protein
,	O
nor	O
by	O
defective	O
nuclear	O
translocation	O
of	O
this	O
receptor	O
,	O
thereby	O
suggesting	O
that	O
the	O
molecular	O
abnormality	O
lies	O
distal	O
to	O
nuclear	O
translocation	O
.	O

We	O
examined	O
the	O
ability	O
of	O
nuclear	O
translocated	O
glucocorticoid	B-protein
receptors	I-protein
to	O
bind	O
to	O
their	O
DNA	B-DNA
binding	I-DNA
sites	I-DNA
(	O
GRE	B-DNA
)	O
using	O
electrophoretic	O
mobility	O
shift	O
assays	O
in	O
PBMC	B-cell_type
from	O
patients	O
with	O
steroid-sensitive	O
and	O
steroid-resistant	O
asthma	O
.	O

The	O
binding	O
of	O
the	O
glucocorticoid	B-protein
receptor	I-protein
to	O
DNA	O
in	O
these	O
patients	O
was	O
also	O
studied	O
using	O
Scatchard	O
analysis	O
.	O

Dexamethasone	O
induced	O
a	O
significant	O
rapid	O
and	O
sustained	O
twofold	O
increase	O
in	O
GRE	B-DNA
binding	O
in	O
PBMCs	B-cell_type
from	O
steroid-sensitive	O
asthmatic	O
patients	O
and	O
nonasthmatic	O
individuals	O
,	O
but	O
this	O
was	O
markedly	O
reduced	O
in	O
steroid-resistant	O
asthmatic	O
patients	O
.	O

Scatchard	O
analysis	O
of	O
glucocorticoid	B-protein
receptor	I-protein
-	O
GRE	B-DNA
binding	O
showed	O
no	O
change	O
in	O
binding	O
affinity	O
but	O
did	O
show	O
a	O
reduced	O
number	O
of	O
receptors	B-protein
available	O
for	O
DNA	O
binding	O
in	O
the	O
steroid-resistant	O
patients	O
.	O

These	O
results	O
suggest	O
that	O
the	O
ability	O
of	O
the	O
glucocorticoid	B-protein
receptor	I-protein
to	O
bind	O
to	O
GRE	B-DNA
is	O
impaired	O
in	O
steroid-resistant	O
patients	O
because	O
of	O
a	O
reduced	O
number	O
of	O
receptors	B-protein
available	O
for	O
binding	O
to	O
DNA	O
.	O

Interleukin-5	B-protein
signaling	O
in	O
human	B-cell_type
eosinophils	I-cell_type
involves	O
JAK2	B-protein
tyrosine	I-protein
kinase	I-protein
and	O
Stat1	B-protein
alpha	I-protein
.	O

Signaling	O
by	O
a	O
wide	O
variety	O
of	O
cytokines	B-protein
,	O
including	O
interferons	B-protein
,	O
interleukins	B-protein
,	O
and	O
growth	B-protein
factors	I-protein
,	O
involves	O
activation	O
of	O
JAK	B-protein
kinases	I-protein
and	O
Stat	B-protein
(	I-protein
Signal	I-protein
transducers	I-protein
and	I-protein
activators	I-protein
of	I-protein
transcription	I-protein
)	I-protein
proteins	I-protein
.	O

At	O
present	O
,	O
not	O
much	O
is	O
known	O
about	O
the	O
molecular	O
mechanisms	O
by	O
which	O
interleukin-5	B-protein
(	O
IL-5	B-protein
)	O
exerts	O
its	O
diverse	O
biologic	O
effects	O
.	O

Human	B-cell_type
eosinophils	I-cell_type
are	O
one	O
of	O
the	O
most	O
important	O
target	B-cell_type
cells	I-cell_type
for	O
IL-5	B-protein
and	O
were	O
used	O
here	O
to	O
study	O
IL-5	B-protein
signaling	O
in	O
a	O
primary	B-cell_type
human	I-cell_type
cell	I-cell_type
.	O

IL-5	B-protein
induced	O
rapid	O
and	O
transient	O
tyrosine	O
phosphorylation	O
of	O
JAK2	B-protein
.	O

Moreover	O
,	O
IL-5	B-protein
induced	O
at	O
least	O
two	O
DNA-binding	B-protein
complexes	I-protein
,	O
using	O
nuclear	O
extracts	O
from	O
normal	O
human	B-cell_type
eosinophils	I-cell_type
and	O
the	O
IL-6/interferon-gamma	B-DNA
response	I-DNA
element	I-DNA
of	O
the	O
ICAM-1	B-DNA
promoter	I-DNA
(	O
ICAM-1	B-DNA
pIRE	I-DNA
)	O
in	O
an	O
electromobility	O
shift	O
assay	O
.	O

From	O
supershift	O
experiments	O
it	O
was	O
concluded	O
that	O
one	O
DNA-binding	B-protein
complex	I-protein
contained	O
Stat1	B-protein
alpha	I-protein
,	O
probably	O
as	O
a	O
homodimer	O
.	O

Both	O
DNA-binding	B-protein
complexes	I-protein
were	O
inhibited	O
by	O
a	O
phosphotyrosine	B-protein
antibody	I-protein
(	O
4G10	B-protein
)	O
,	O
suggesting	O
that	O
tyrosine	O
phosphorylation	O
is	O
required	O
for	O
complex	O
formation	O
.	O

IL-3	B-protein
and	O
granulocyte-macrophage	B-protein
colony-stimulating	I-protein
factor	I-protein
induced	O
,	O
similar	O
to	O
IL-5	B-protein
,	O
two	O
DNA-binding	B-protein
complexes	I-protein
in	O
human	B-cell_type
eosinophils	I-cell_type
,	O
including	O
Stat1	B-protein
alpha	I-protein
.	O

These	O
data	O
show	O
for	O
the	O
first	O
time	O
that	O
molecular	O
mechanisms	O
of	O
IL-5	B-protein
signaling	O
in	O
human	B-cell_type
eosinophils	I-cell_type
involve	O
members	O
of	O
the	O
JAK	B-protein
kinase	I-protein
family	I-protein
as	O
well	O
as	O
members	O
of	O
the	O
Stat	B-protein
family	I-protein
.	O

Infection	O
and	O
replication	O
of	O
Tat-	O
human	O
immunodeficiency	O
viruses	O
:	O
genetic	O
analyses	O
of	O
LTR	B-DNA
and	O
tat	B-protein
mutations	I-protein
in	O
primary	B-cell_type
and	I-cell_type
long-term	I-cell_type
human	I-cell_type
lymphoid	I-cell_type
cells	I-cell_type
.	O

Tat	B-protein
is	O
an	O
essential	O
regulatory	B-protein
protein	I-protein
for	O
the	O
replication	O
of	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
.	O

Mutations	O
in	O
the	O
tat	B-DNA
gene	I-DNA
have	O
been	O
shown	O
to	O
block	O
HIV	O
replication	O
in	O
human	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O

Several	O
studies	O
have	O
established	O
that	O
Tat	B-protein
releases	O
an	O
elongation	B-protein
block	I-protein
to	O
the	O
transcription	O
of	O
HIV	B-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
(	O
LTR	B-DNA
)	O
;	O
however	O
,	O
it	O
is	O
not	O
known	O
whether	O
this	O
mechanism	O
alone	O
is	O
sufficient	O
to	O
explain	O
the	O
block	O
to	O
HIV	O
replication	O
in	O
human	B-cell_type
T	I-cell_type
cells	I-cell_type
when	O
Tat	B-protein
is	O
absent	O
.	O

It	O
is	O
possible	O
that	O
Tat	B-protein
is	O
also	O
needed	O
for	O
other	O
functions	O
during	O
HIV	O
replication	O
.	O

To	O
test	O
these	O
hypotheses	O
,	O
we	O
studied	O
several	O
tat	B-protein
mutants	I-protein
,	O
including	O
two	O
stop	B-protein
codon	I-protein
mutants	I-protein
and	O
one	O
deletion	B-protein
mutant	I-protein
using	O
replication-competent	B-DNA
HIV-1	I-DNA
constructs	I-DNA
carrying	O
wild-type	B-DNA
or	I-DNA
mutant	I-DNA
LTRs	I-DNA
with	O
modifications	O
in	O
the	O
NF-kappa	B-DNA
B	I-DNA
and/or	I-DNA
Sp1	I-DNA
binding	I-DNA
sites	I-DNA
.	O

In	O
this	O
study	O
,	O
we	O
show	O
that	O
Tat-	O
HIV-1	O
with	O
wild-type	B-DNA
LTRs	I-DNA
can	O
replicate	O
in	O
HeLa	B-cell_line
cells	I-cell_line
,	O
and	O
the	O
virus	O
produced	O
from	O
HeLa	B-cell_line
cells	I-cell_line
can	O
infect	O
primary	O
peripheral	B-cell_type
blood	I-cell_type
lymphocytes	I-cell_type
and	O
macrophages	B-cell_type
.	O

It	O
was	O
found	O
that	O
the	O
propagation	O
of	O
the	O
Tat	B-protein
mutants	I-protein
containing	O
wild-type	B-DNA
LTRs	I-DNA
was	O
less	O
efficient	O
than	O
that	O
of	O
the	O
LTR-modified	B-protein
Tat	I-protein
mutants	I-protein
.	O

Large	O
amounts	O
of	O
viral	B-RNA
RNA	I-RNA
and	O
particles	O
were	O
synthesized	O
in	O
infections	O
established	O
using	O
the	O
tat	B-protein
mutants	I-protein
that	O
contain	O
modified	B-DNA
LTRs	I-DNA
.	O

However	O
,	O
this	O
efficient	O
propagation	O
of	O
the	O
LTR-modified	B-protein
tat	I-protein
mutants	I-protein
was	O
restricted	O
to	O
some	O
lymphoid	B-cell_line
cell	I-cell_line
lines	I-cell_line
that	O
have	O
been	O
transformed	O
with	O
other	O
viruses	O
.	O

Thus	O
,	O
despite	O
its	O
essential	O
role	O
for	O
releasing	O
an	O
elongation	B-protein
block	I-protein
,	O
Tat	B-protein
is	O
not	O
otherwise	O
absolutely	O
required	O
for	O
synthesis	O
of	O
full-length	B-RNA
HIV	I-RNA
transcripts	I-RNA
and	O
assembly	O
of	O
virus	O
particles	O
.	O

Direct	O
sequencing	O
of	O
the	O
viral	B-DNA
genomes	I-DNA
and	O
reinfection	O
kinetics	O
showed	O
no	O
evidence	O
of	O
wild-type	O
reversion	O
even	O
after	O
prolonged	O
infection	O
with	O
the	O
Tat	B-protein
-virus	O
.	O

The	O
implications	O
for	O
in	O
vivo	O
HIV-1	O
replication	O
and	O
potential	O
application	O
of	O
this	O
system	O
to	O
the	O
study	O
of	O
alternative	O
Tat	B-protein
function	O
are	O
discussed	O
.	O

Functional	O
roles	O
of	O
the	O
transcription	B-protein
factor	I-protein
Oct-2A	I-protein
and	O
the	O
high	B-protein
mobility	I-protein
group	I-protein
protein	I-protein
I/Y	B-protein
in	O
HLA-DRA	B-DNA
gene	I-DNA
expression	O
.	O

The	O
class	B-DNA
II	I-DNA
major	I-DNA
histocompatibility	I-DNA
complex	I-DNA
gene	I-DNA
HLA-DRA	B-DNA
is	O
expressed	O
in	O
B	B-cell_type
cells	I-cell_type
,	O
activated	O
T	B-cell_type
lymphocytes	I-cell_type
,	O
and	O
in	O
antigen-presenting	B-cell_type
cells	I-cell_type
.	O

In	O
addition	O
,	O
HLA-DRA	B-DNA
gene	I-DNA
expression	O
is	O
inducible	O
in	O
a	O
variety	O
of	O
cell	O
types	O
by	O
interferon-gamma	B-protein
(	O
IFN-gamma	B-protein
)	O
.	O

Here	O
we	O
show	O
that	O
the	O
lymphoid-specific	B-protein
transcription	I-protein
factor	I-protein
Oct-2A	I-protein
plays	O
a	O
critical	O
role	O
in	O
HLA-DRA	B-DNA
gene	I-DNA
expression	O
in	O
class	B-cell_line
II-positive	I-cell_line
B	I-cell_line
cell	I-cell_line
lines	I-cell_line
,	O
and	O
that	O
the	O
high	B-protein
mobility	I-protein
group	I-protein
protein	I-protein
(	O
HMG	B-protein
)	O
I/Y	B-protein
binds	O
to	O
multiple	O
sites	O
within	O
the	O
DRA	B-DNA
promoter	I-DNA
,	O
including	O
the	O
Oct-2A	B-DNA
binding	I-DNA
site	I-DNA
.	O

Coexpression	O
of	O
HMG	B-protein
I/Y	I-protein
and	O
Oct-2	B-protein
in	O
cell	B-cell_line
lines	I-cell_line
lacking	O
Oct-2	B-protein
results	O
in	O
high	O
levels	O
of	O
HLA-DRA	B-DNA
gene	I-DNA
expression	O
,	O
and	O
in	O
vitro	O
DNA-binding	O
studies	O
reveal	O
that	O
HMG	O
I/Y	B-protein
stimulates	O
Oct-2A	B-protein
binding	O
to	O
the	O
HLA-DRA	B-DNA
promoter	I-DNA
.	O

Thus	O
,	O
Oct-2A	B-protein
and	O
HMG	B-protein
I/Y	I-protein
may	O
synergize	O
to	O
activate	O
HLA-DRA	B-DNA
expression	O
in	O
B	B-cell_type
cells	I-cell_type
.	O

By	O
contrast	O
,	O
Oct-2A	B-protein
is	O
not	O
involved	O
in	O
the	O
IFN-gamma	B-protein
induction	O
of	O
the	O
HLA-DRA	B-DNA
gene	I-DNA
in	O
HeLa	B-cell_line
cells	I-cell_line
,	O
but	O
antisense	B-DNA
HMG	I-DNA
I/Y	I-DNA
dramatically	O
decreases	O
the	O
level	O
of	O
induction	O
.	O

We	O
conclude	O
that	O
distinct	O
sets	O
of	O
transcription	B-protein
factors	I-protein
are	O
involved	O
in	O
the	O
two	O
modes	O
of	O
HLA-DRA	B-DNA
expression	O
,	O
and	O
that	O
HMG	B-protein
I/Y	I-protein
may	O
be	O
important	O
for	O
B	O
cell-specific	O
expression	O
,	O
and	O
is	O
essential	O
for	O
IFN-gamma	B-protein
induction	O
.	O

Heterogeneous	O
expression	O
of	O
Epstein-Barr	B-protein
virus	I-protein
latent	I-protein
proteins	I-protein
in	O
endemic	O
Burkitt	O
's	O
lymphoma	O
.	O

Epstein-Barr	B-cell_type
virus	I-cell_type
(	I-cell_type
EBV	I-cell_type
)	I-cell_type
-infected	I-cell_type
cells	I-cell_type
may	O
sustain	O
three	O
distinct	O
forms	O
of	O
virus	O
latency	O
.	O

In	O
lymphoblastoid	B-cell_line
cell	I-cell_line
lines	I-cell_line
,	O
six	O
EBV-encoded	B-protein
nuclear	I-protein
antigens	I-protein
(	O
EBNA1	B-protein
,	I-protein
2	I-protein
,	I-protein
3A	I-protein
,	I-protein
3B	I-protein
,	I-protein
3C	I-protein
,	I-protein
-LP	I-protein
)	O
,	O
three	O
latent	B-protein
membrane	I-protein
proteins	I-protein
(	O
LMP1	B-protein
,	O
2A	B-protein
,	O
2B	B-protein
)	O
,	O
and	O
two	O
nuclear	B-RNA
RNAs	I-RNA
(	O
EBERs	B-RNA
)	O
are	O
expressed	O
.	O

This	O
form	O
of	O
latency	O
,	O
termed	O
latency	O
III	O
,	O
is	O
also	O
encountered	O
in	O
some	O
posttransplant	O
lymphoproliferative	O
disorders	O
.	O

In	O
EBV-positive	O
cases	O
of	O
Hodgkin	O
's	O
disease	O
,	O
the	O
EBERs	B-RNA
,	O
EBNA1	B-protein
,	O
and	O
the	O
LMPs	B-protein
are	O
expressed	O
(	O
latency	O
II	O
)	O
,	O
whereas	O
in	O
Burkitt	O
's	O
lymphoma	O
(	O
BL	O
)	O
only	O
the	O
EBERs	B-RNA
and	O
EBNA1	B-protein
have	O
been	O
detected	O
(	O
latency	O
I	O
)	O
.	O

We	O
have	O
studied	O
the	O
expression	O
of	O
EBV	B-protein
proteins	I-protein
in	O
17	O
cases	O
of	O
EBV-positive	O
endemic	O
BL	O
by	O
immunohistology	O
.	O

Expression	O
of	O
LMP1	B-protein
was	O
seen	O
in	O
variable	O
proportions	O
of	O
tumor	B-cell_type
cells	I-cell_type
in	O
two	O
cases	O
and	O
EBNA2	B-protein
was	O
detected	O
in	O
some	O
tumor	B-cell_type
cells	I-cell_type
in	O
three	O
other	O
cases	O
.	O

Also	O
,	O
the	O
BZLF1	B-protein
trans-activator	I-protein
protein	I-protein
was	O
expressed	O
in	O
a	O
few	O
tumor	B-cell_type
cells	I-cell_type
in	O
6	O
cases	O
,	O
indicating	O
entry	O
into	O
the	O
lytic	O
cycle	O
.	O

A	O
phenotypic	O
drift	O
from	O
latency	O
I	O
to	O
latency	O
III	O
has	O
been	O
observed	O
previously	O
in	O
some	O
BL	B-cell_line
cell	I-cell_line
lines	I-cell_line
.	O

Our	O
results	O
suggest	O
that	O
a	O
similar	O
phenomenon	O
may	O
occur	O
in	O
BL	O
in	O
vivo	O
and	O
indicate	O
that	O
the	O
operational	O
definition	O
of	O
EBV	O
latencies	O
is	O
not	O
easily	O
applied	O
to	O
human	O
tumors	O
.	O

The	O
activation	O
of	O
the	O
Jak	B-protein
-STAT	B-protein
1	I-protein
signaling	O
pathway	O
by	O
IL-5	B-protein
in	O
eosinophils	B-cell_type
.	O

The	O
intracellular	O
signal	O
transduction	O
of	O
IL-5	B-protein
in	O
eosinophils	B-cell_type
is	O
unknown	O
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
involvement	O
of	O
the	O
newly	O
discovered	O
Jak	B-protein
-STAT	B-protein
pathway	O
in	O
the	O
IL-5	B-protein
signal	O
transduction	O
mechanism	O
.	O

Eosinophils	B-cell_type
were	O
purified	O
from	O
peripheral	O
blood	O
by	O
discontinuous	O
Percoll	O
gradients	O
and	O
stimulated	O
with	O
IL-5	B-protein
.	O

The	O
involvement	O
of	O
Jak	B-protein
2	I-protein
was	O
investigated	O
by	O
immunoprecipitation	O
followed	O
by	O
immunoblotting	O
for	O
tyrosine	O
phosphorylation	O
.	O

The	O
activation	O
of	O
Jak	B-protein
2	I-protein
was	O
studied	O
by	O
autophosphorylation	O
of	O
the	O
immunoprecipitated	B-protein
kinase	I-protein
.	O

Jak	B-protein
2	I-protein
was	O
tyrosine	O
phosphorylated	O
within	O
1	O
to	O
3	O
min	O
after	O
stimulation	O
of	O
eosinophils	B-cell_type
with	O
IL-5	B-protein
.	O

Further	O
,	O
the	O
immunoprecipitated	B-protein
Jak	I-protein
2	I-protein
obtained	O
from	O
IL-5-stimulated	B-cell_line
cells	I-cell_line
underwent	O
autophosphorylation	O
.	O

Jak	B-protein
2	I-protein
coprecipitated	O
with	O
the	O
beta-subunit	O
of	O
the	O
IL-5	B-protein
receptor	I-protein
,	O
suggesting	O
a	O
physical	O
association	O
of	O
the	O
kinase	B-protein
with	O
the	O
receptor	O
.	O

The	O
nuclear	B-protein
factor	I-protein
STAT-1	I-protein
(	O
p91	B-protein
)	O
was	O
investigated	O
by	O
immunoprecipitation	O
followed	O
by	O
immunoblotting	O
for	O
tyrosine	O
phosphorylation	O
.	O

STAT-1	B-protein
was	O
tyrosine	O
phosphorylated	O
within	O
15	O
min	O
of	O
IL-5	B-protein
stimulation	O
.	O

The	O
presence	O
of	O
STAT-1	B-protein
in	O
the	O
nuclear	O
extract	O
was	O
studied	O
by	O
electrophoretic	O
mobility	O
shift	O
assay	O
.	O

IL-5	B-protein
induced	O
two	O
proteins	O
that	O
bound	O
to	O
the	O
gamma-activating	B-DNA
sequence	I-DNA
.	O

In	O
the	O
presence	O
of	O
an	O
anti-STAT-1	B-protein
Ab	I-protein
,	O
the	O
band	O
was	O
supershifted	O
.	O

Thus	O
,	O
we	O
demonstrated	O
that	O
IL-5	B-protein
activated	O
the	O
Jak	B-protein
2	I-protein
-STAT	B-protein
1	I-protein
signaling	O
pathway	O
in	O
eosinophils	B-cell_type
.	O

We	O
speculate	O
that	O
the	O
Jak	B-protein
2	I-protein
-STAT	B-protein
1	I-protein
pathway	O
may	O
be	O
involved	O
in	O
the	O
activation	O
of	O
IL-5-inducible	B-DNA
genes	I-DNA
in	O
eosinophils	B-cell_type
.	O

Reduced	O
mitogenic	O
stimulation	O
of	O
peripheral	B-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
as	O
a	O
prognostic	O
parameter	O
for	O
the	O
course	O
of	O
breast	O
cancer	O
:	O
a	O
prospective	O
longitudinal	O
study	O
.	O

Immunosuppression	O
has	O
been	O
often	O
associated	O
with	O
the	O
course	O
of	O
malignant	O
diseases	O
.	O

In	O
the	O
present	O
study	O
,	O
the	O
proliferation	O
of	O
peripheral	B-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
(	O
PBMCs	B-cell_type
)	O
in	O
response	O
to	O
mitogenic	O
stimulation	O
with	O
phytohaemagglutinin	B-protein
(	O
PHA	B-protein
)	O
was	O
assessed	O
prospectively	O
in	O
90	O
patients	O
with	O
stage	O
I-III	O
breast	O
cancer	O
.	O

Whereas	O
PHA	B-protein
-induced	O
proliferation	O
of	O
PBMCs	B-cell_type
derived	O
from	O
patients	O
with	O
breast	O
cancer	O
preoperatively	O
was	O
significantly	O
decreased	O
when	O
compared	O
with	O
data	O
obtained	O
in	O
healthy	O
control	O
individuals	O
(	O
P	O
<	O
0.001	O
)	O
,	O
the	O
degree	O
of	O
the	O
defect	O
in	O
PHA	B-protein
-induced	O
proliferation	O
of	O
PBMCs	B-cell_type
depended	O
upon	O
the	O
tumour	O
burden	O
as	O
manifested	O
by	O
tumour	O
size	O
and	O
axillary	O
lymph	O
node	O
involvement	O
(	O
P	O
<	O
0.003	O
in	O
each	O
case	O
)	O
.	O

PHA	B-protein
-induced	O
proliferation	O
of	O
PBMCs	B-cell_type
dropped	O
significantly	O
in	O
patients	O
who	O
received	O
adjuvant	O
chemotherapy	O
consisting	O
of	O
cyclophosphamide	O
,	O
methotrexate	O
and	O
fluorouracil	O
(	O
CMF	O
)	O
after	O
an	O
observation	O
period	O
of	O
6	O
months	O
(	O
P	O
<	O
0.01	O
)	O
,	O
but	O
not	O
in	O
patients	O
under	O
adjuvant	O
treatment	O
with	O
tamoxifen	O
only	O
.	O

After	O
an	O
additional	O
6	O
months	O
(	O
i.e.	O
12	O
months	O
after	O
surgery	O
)	O
,	O
PHA	B-protein
-induced	O
proliferation	O
of	O
PBMCs	B-cell_type
was	O
similar	O
in	O
patients	O
after	O
adjuvant	O
chemotherapy	O
with	O
CMF	O
and	O
in	O
those	O
receiving	O
continued	O
adjuvant	O
tamoxifen	O
treatment	O
(	O
P	O
>	O
0.1	O
)	O
,	O
but	O
in	O
all	O
patients	O
still	O
significantly	O
decreased	O
as	O
compared	O
with	O
healthy	O
controls	O
(	O
P	O
<	O
0.001	O
)	O
.	O

When	O
data	O
obtained	O
preoperatively	O
and	O
after	O
12	O
months	O
were	O
compared	O
,	O
it	O
was	O
found	O
that	O
out	O
of	O
23	O
patients	O
whose	O
PBMCs	B-cell_type
had	O
experienced	O
a	O
drop	O
in	O
their	O
PHA	B-protein
-induced	O
proliferation	O
,	O
14	O
(	O
61	O
%	O
)	O
had	O
developed	O
metastatic	O
disease	O
within	O
the	O
subsequent	O
24	O
months	O
(	O
i.e.	O
36	O
months	O
after	O
surgery	O
)	O
.	O

In	O
contrast	O
,	O
out	O
of	O
59	O
patients	O
whose	O
PBMCs	B-cell_type
showed	O
an	O
increase	O
in	O
their	O
PHA	B-protein
-induced	O
proliferation	O
within	O
the	O
first	O
12	O
months	O
after	O
surgery	O
,	O
only	O
one	O
(	O
2	O
%	O
)	O
presented	O
with	O
disease	O
progression	O
.	O

We	O
thus	O
conclude	O
that	O
PHA	B-protein
-induced	O
proliferation	O
of	O
PBMCs	B-cell_type
derived	O
from	O
patients	O
with	O
breast	O
cancer	O
depends	O
upon	O
the	O
tumour	O
load	O
and	O
is	O
a	O
good	O
clinical	O
predictor	O
for	O
the	O
further	O
course	O
of	O
the	O
disease	O
.	O

Activation	O
of	O
transcription	O
by	O
binding	O
of	O
NF-E1	B-protein
(	O
YY1	B-protein
)	O
to	O
a	O
newly	O
identified	O
element	O
in	O
the	O
first	O
exon	O
of	O
the	O
human	B-DNA
DR	I-DNA
alpha	I-DNA
gene	I-DNA
.	O

A	O
previously	O
unrecognized	O
element	O
,	O
located	O
downstream	O
of	O
the	O
start	B-DNA
site	I-DNA
of	I-DNA
transcription	I-DNA
in	O
the	O
first	O
exon	B-DNA
of	O
the	O
DR	B-DNA
alpha	I-DNA
gene	I-DNA
,	O
has	O
been	O
defined	O
that	O
enhances	O
promoter	O
activity	O
up	O
to	O
eightfold	O
in	O
a	O
position-dependent	O
manner	O
.	O

Mutations	O
in	O
this	O
DNA-binding	B-DNA
site	I-DNA
abolished	O
binding	O
of	O
a	O
nuclear	B-protein
factor	I-protein
in	O
human	O
B	O
cell	O
nuclear	O
extract	O
and	O
decreased	O
the	O
activity	O
of	O
the	O
DR	B-DNA
alpha	I-DNA
promoter	I-DNA
to	O
a	O
basal	O
level	O
.	O

Significant	O
sequence	O
homology	O
of	O
this	O
element	B-DNA
was	O
found	O
in	O
the	O
DNA	O
of	O
the	O
DR	B-DNA
beta	I-DNA
,	I-DNA
DP	I-DNA
alpha	I-DNA
and	I-DNA
-beta	I-DNA
,	I-DNA
and	I-DNA
DQ	I-DNA
alpha	I-DNA
genes	I-DNA
,	O
always	O
located	O
downstream	O
of	O
the	O
transcriptional	B-DNA
start	I-DNA
site	I-DNA
.	O

The	O
nuclear	O
factor	O
binds	O
to	O
the	O
DR	B-DNA
alpha	I-DNA
and	I-DNA
DP	I-DNA
alpha	I-DNA
element	I-DNA
but	O
not	O
to	O
the	O
element	O
in	O
the	O
DQ	B-DNA
alpha	I-DNA
gene	I-DNA
.	O

It	O
was	O
identified	O
as	O
NF-E1	B-protein
(	O
YY1	B-protein
)	O
.	O

This	O
protein	O
,	O
previously	O
identified	O
by	O
its	O
binding	O
to	O
the	O
Ig	B-DNA
kappa	I-DNA
3	I-DNA
'	I-DNA
enhancer	I-DNA
and	O
the	O
Ig	B-DNA
heavy	I-DNA
chain	I-DNA
mu	I-DNA
E1	I-DNA
site	I-DNA
,	O
thus	O
also	O
appears	O
to	O
be	O
quite	O
important	O
in	O
the	O
regulation	O
of	O
MHC	B-DNA
class	I-DNA
II	I-DNA
gene	I-DNA
expression	O
.	O

Transcriptional	O
activity	O
of	O
core	B-protein
binding	I-protein
factor-alpha	I-protein
(	I-protein
AML1	I-protein
)	I-protein
and	I-protein
beta	I-protein
subunits	O
on	O
murine	B-DNA
leukemia	I-DNA
virus	I-DNA
enhancer	I-DNA
cores	I-DNA
.	O

Core	B-protein
binding	I-protein
factor	I-protein
(	O
CBF	B-protein
)	O
,	O
also	O
known	O
as	O
polyomavirus	B-protein
enhancer-binding	I-protein
protein	I-protein
2	I-protein
and	O
SL3	B-protein
enhancer	I-protein
factor	I-protein
1	I-protein
,	O
is	O
a	O
mammalian	B-protein
transcription	I-protein
factor	I-protein
that	O
binds	O
to	O
an	O
element	O
termed	O
the	O
core	O
within	O
the	O
enhancers	B-DNA
of	O
the	O
murine	O
leukemia	O
virus	O
family	O
of	O
retroviruses	O
.	O

The	O
core	B-DNA
elements	I-DNA
of	O
the	O
SL3	O
virus	O
are	O
important	O
genetic	O
determinants	O
of	O
the	O
ability	O
of	O
this	O
virus	O
to	O
induce	O
T-cell	O
lymphomas	O
and	O
the	O
transcriptional	O
activity	O
of	O
the	O
viral	B-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
in	O
T	B-cell_type
lymphocytes	I-cell_type
.	O

CBF	B-protein
consists	O
of	O
two	O
subunits	O
,	O
a	O
DNA	B-protein
binding	I-protein
subunit	I-protein
,	O
CBF	B-protein
alpha	I-protein
,	O
and	O
a	O
second	O
subunit	O
,	O
CBF	B-protein
beta	I-protein
,	O
that	O
stimulates	O
the	O
DNA	O
binding	O
activity	O
of	O
CBF	B-protein
alpha	I-protein
.	O

One	O
of	O
the	O
genes	O
that	O
encodes	O
a	O
CBF	B-protein
alpha	I-protein
subunit	I-protein
is	O
AML1	B-protein
,	O
also	O
called	O
Cbf	B-protein
alpha	I-protein
2	I-protein
.	O

This	O
locus	O
is	O
rearranged	O
by	O
chromosomal	O
translocations	O
in	O
human	O
myeloproliferative	O
disorders	O
and	O
leukemias	O
.	O

An	O
exogenously	O
expressed	O
Cbf	B-protein
alpha	I-protein
2-encoded	I-protein
subunit	I-protein
(	O
CBF	B-protein
alpha	I-protein
2-451	I-protein
)	O
stimulated	O
transcription	O
from	O
the	O
SL3	B-DNA
enhancer	I-DNA
in	O
P19	B-protein
and	O
HeLa	B-cell_line
cells	I-cell_line
.	O

Activity	O
was	O
mediated	O
through	O
the	O
core	B-DNA
elements	I-DNA
.	O

Three	O
different	O
isoforms	O
of	O
CBF	B-protein
beta	I-protein
were	O
also	O
tested	O
for	O
transcriptional	O
activity	O
on	O
the	O
SL3	B-DNA
enhancer	I-DNA
.	O

The	O
longest	O
form	O
,	O
CBF	B-protein
beta-187	I-protein
,	O
increased	O
the	O
transcriptional	O
stimulation	O
by	O
CBF	B-protein
alpha	I-protein
2-451	I-protein
twofold	O
in	O
HeLa	B-cell_line
cells	I-cell_line
,	O
although	O
it	O
had	O
no	O
effect	O
in	O
P19	B-cell_line
cells	I-cell_line
.	O

Transcriptional	O
activation	O
by	O
CBF	B-protein
beta	I-protein
required	O
binding	O
to	O
the	O
CBF	B-protein
alpha	I-protein
subunit	I-protein
,	O
as	O
a	O
form	O
of	O
CBF	B-protein
beta	I-protein
that	O
lacked	O
binding	O
ability	O
,	O
CBF	B-protein
beta-148	I-protein
,	O
failed	O
to	O
increase	O
activity	O
.	O

These	O
results	O
indicated	O
that	O
at	O
least	O
in	O
certain	O
cell	O
types	O
,	O
the	O
maximum	O
activity	O
of	O
CBF	B-protein
required	O
both	O
subunits	O
.	O

They	O
also	O
provided	O
support	O
for	O
the	O
hypothesis	O
that	O
CBF	B-protein
is	O
a	O
factor	O
in	O
T	B-cell_type
lymphocytes	I-cell_type
that	O
is	O
responsible	O
for	O
recognition	O
of	O
the	O
SL3	B-DNA
cores	I-DNA
.	O

We	O
also	O
examined	O
whether	O
CBF	B-protein
could	O
distinguish	O
a	O
1-bp	O
difference	O
between	O
the	O
enhancer	O
core	O
of	O
SL3	O
and	O
the	O
core	O
of	O
the	O
nonleukemogenic	O
virus	O
,	O
Akv	O
.	O

This	O
difference	O
strongly	O
affects	O
transcription	O
in	O
T	O
cells	O
and	O
leukemogenicity	O
of	O
SL3	B-DNA
.	O

However	O
,	O
no	O
combination	O
of	O
CBF	B-protein
alpha	I-protein
and	O
CBF	B-protein
beta	I-protein
subunits	O
that	O
we	O
tested	O
was	O
able	O
to	O
distinguish	O
the	O
1-bp	O
difference	O
in	O
transcription	O
assays	O
.	O

Thus	O
,	O
a	O
complete	O
understanding	O
of	O
how	O
T	B-cell_type
cells	I-cell_type
recognize	O
the	O
SL3	B-DNA
core	I-DNA
remains	O
to	O
be	O
elucidated	O
.	O

Interleukin	B-protein
(	I-protein
IL	I-protein
)	I-protein
-10	I-protein
inhibits	O
nuclear	B-protein
factor	I-protein
kappa	I-protein
B	I-protein
(	O
NF	B-protein
kappa	I-protein
B	I-protein
)	O
activation	O
in	O
human	B-cell_type
monocytes	I-cell_type
.	O

IL-10	B-protein
and	O
IL-4	B-protein
suppress	O
cytokine	B-protein
synthesis	O
by	O
different	O
mechanisms	O
.	O

Our	O
previous	O
studies	O
in	O
human	B-cell_type
monocytes	I-cell_type
have	O
demonstrated	O
that	O
interleukin	B-protein
(	I-protein
IL	I-protein
)	I-protein
-10	I-protein
inhibits	O
lipopolysaccharide	O
(	O
LPS	O
)	O
-stimulated	O
production	O
of	O
inflammatory	B-protein
cytokines	I-protein
,	O
IL-1	B-protein
beta	I-protein
,	O
IL-6	B-protein
,	O
IL-8	B-protein
,	O
and	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
(	I-protein
TNF	I-protein
)	I-protein
-alpha	I-protein
by	O
blocking	O
gene	O
transcription	O
.	O

Using	O
electrophoretic	O
mobility	O
shift	O
assays	O
(	O
EMSA	O
)	O
,	O
we	O
now	O
show	O
that	O
,	O
in	O
monocytes	O
stimulated	O
with	O
LPS	O
or	O
TNF	B-protein
alpha	I-protein
,	O
IL-10	B-protein
inhibits	O
nuclear	O
stimulation	O
of	O
nuclear	B-protein
factor	I-protein
kappa	I-protein
B	I-protein
(	O
NF	B-protein
kappa	I-protein
B	I-protein
)	O
,	O
a	O
transcription	B-protein
factor	I-protein
involved	O
in	O
the	O
expression	O
of	O
inflammatory	B-DNA
cytokine	I-DNA
genes	I-DNA
.	O
Several	O
other	O
transcription	B-protein
factors	I-protein
including	O
NF-	O
IL-6	B-protein
,	O
AP-1	B-protein
,	O
AP-2	B-protein
,	O
GR	B-protein
,	O
CREB	B-protein
,	O
Oct-1	B-protein
,	O
and	O
Sp-1	B-protein
are	O
not	O
affected	O
by	O
IL-10	B-protein
.	O

This	O
selective	O
inhibition	O
by	O
IL-10	B-protein
of	O
NF	B-protein
kappa	I-protein
B	I-protein
activation	O
occurs	O
rapidly	O
and	O
in	O
a	O
dose-dependent	O
manner	O
and	O
correlates	O
well	O
with	O
IL-10	B-protein
's	O
cytokine	B-protein
synthesis	O
inhibitory	O
activity	O
in	O
terms	O
of	O
both	O
kinetics	O
and	O
dose	O
responsiveness	O
.	O

Furthermore	O
,	O
compounds	O
such	O
as	O
tosylphenylalanyl	O
chloromethyl	O
ketone	O
and	O
pyrrolidinedithiocarbamate	O
that	O
are	O
known	O
to	O
selectively	O
inhibit	O
NF	B-protein
kappa	I-protein
B	I-protein
activation	O
block	O
cytokine	O
gene	O
transcription	O
in	O
LPS-stimulated	B-cell_line
monocytes	I-cell_line
.	O

Taken	O
together	O
,	O
these	O
results	O
suggest	O
that	O
inhibition	O
of	O
NF	B-protein
kappa	I-protein
B	I-protein
activation	O
may	O
be	O
an	O
important	O
mechanism	O
for	O
IL-10	B-protein
suppression	O
of	O
cytokine	O
gene	O
transcription	O
in	O
human	B-cell_type
monocytes	I-cell_type
.	O

IL-4	B-protein
,	O
another	O
cytokine	B-protein
that	O
inhibits	O
cytokine	B-RNA
mRNA	I-RNA
accumulation	O
in	O
monocytes	B-cell_type
,	O
shows	O
little	O
inhibitory	O
effect	O
on	O
LPS-induced	O
NF	B-protein
kappa	I-protein
B	I-protein
activation	O
.	O

Further	O
examination	O
reveals	O
that	O
,	O
unlike	O
IL-10	B-protein
,	O
IL-4	B-protein
enhances	O
mRNA	B-RNA
degradation	O
and	O
does	O
not	O
suppress	O
cytokine	O
gene	O
transcription	O
.	O

These	O
data	O
indicate	O
that	O
IL-10	B-protein
and	O
IL-4	B-protein
inhibit	O
cytokine	B-protein
production	O
by	O
different	O
mechanisms	O
.	O

LMP-1	B-protein
activates	O
NF-kappa	B-protein
B	I-protein
by	O
targeting	O
the	O
inhibitory	B-protein
molecule	I-protein
I	I-protein
kappa	I-protein
B	I-protein
alpha	I-protein
.	O

LMP-1	B-protein
,	O
an	O
Epstein-Barr	B-protein
virus	I-protein
membrane	I-protein
protein	I-protein
expressed	O
during	O
latent	O
infection	O
,	O
has	O
oncogenic	O
properties	O
,	O
as	O
judged	O
from	O
its	O
ability	O
to	O
transform	O
B	O
lymphocytes	B-cell_type
and	O
rodent	B-cell_type
fibroblasts	I-cell_type
.	O

LMP-1	B-protein
induces	O
the	O
expression	O
of	O
bcl2	B-DNA
,	O
an	O
oncogene	B-DNA
which	O
protects	O
cells	O
from	O
apoptosis	O
,	O
as	O
well	O
as	O
of	O
genes	O
encoding	O
other	O
proteins	O
involved	O
in	O
cell	O
regulation	O
and	O
growth	O
control	O
.	O

The	O
mechanisms	O
by	O
which	O
LMP-1	B-protein
upregulates	O
these	O
proteins	O
is	O
unknown	O
,	O
but	O
it	O
is	O
plausible	O
that	O
LMP-1	B-protein
modifies	O
signal	O
transduction	O
pathways	O
that	O
result	O
in	O
the	O
activation	O
of	O
one	O
or	O
more	O
transcription	B-protein
factors	I-protein
that	O
ultimately	O
regulate	O
transcription	O
of	O
oncogenic	B-DNA
genes	I-DNA
.	O

NF-kappa	B-protein
B	I-protein
,	O
a	O
transcription	B-protein
factor	I-protein
controlling	O
the	O
expression	O
of	O
genes	B-DNA
involved	O
in	O
cell	O
activation	O
and	O
growth	O
control	O
,	O
has	O
been	O
shown	O
to	O
be	O
activated	O
by	O
LMP-1	B-protein
.	O

The	O
mechanism	O
(	O
s	O
)	O
regulating	O
this	O
activation	O
remains	O
unknown	O
.	O

Our	O
data	O
indicate	O
that	O
increased	O
NF-kappa	B-protein
B	I-protein
DNA	O
binding	O
and	O
functional	O
activity	O
are	O
present	O
in	O
B-lymphoid	B-cell_type
cells	I-cell_type
stably	O
or	O
transiently	O
expressing	O
LMP-1	B-protein
.	O

I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
is	O
selectively	O
modified	O
in	O
LMP-1-expressing	B-cell_line
B	I-cell_line
cells	I-cell_line
.	O

A	O
phosphorylated	O
form	O
of	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
and	O
increased	O
protein	O
turnover-degradation	O
correlate	O
with	O
increased	O
NF-kappa	B-protein
B	I-protein
nuclear	O
translocation	O
.	O

This	O
results	O
in	O
increased	O
transcription	O
of	O
NF-kappa	B-DNA
B-dependent-genes	I-DNA
,	O
including	O
those	O
encoding	O
p105	B-protein
and	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
(	O
MAD3	B-DNA
)	O
.	O

These	O
results	O
indicate	O
that	O
LMP-1	B-protein
activates	O
NF-kappa	B-protein
B	I-protein
in	O
B-cell	B-cell_line
lines	I-cell_line
by	O
targeting	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
.	O

Identification	O
of	O
the	O
pathways	O
activated	O
by	O
LMP-1	B-protein
to	O
result	O
in	O
posttranslational	O
modifications	O
of	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
will	O
aid	O
in	O
determining	O
the	O
role	O
of	O
this	O
virus-host	O
cell	O
protein	O
interaction	O
in	O
Epstein-Barr	O
virus-mediated	O
oncogenesis	O
.	O

Identification	O
of	O
human	B-DNA
TR2	I-DNA
orphan	I-DNA
receptor	I-DNA
response	I-DNA
element	I-DNA
in	O
the	O
transcriptional	B-DNA
initiation	I-DNA
site	I-DNA
of	O
the	O
simian	B-DNA
virus	I-DNA
40	I-DNA
major	I-DNA
late	I-DNA
promoter	I-DNA
[	O
published	O
erratum	O
appears	O
in	O
J	O
Biol	O
Chem	O
1995	O
Nov	O
3	O
;	O
270	O
(	O
44	O
)	O
:	O
26721	O
]	O

A	O
DNA	B-DNA
response	I-DNA
element	I-DNA
(	O
TR2RE-SV40	B-DNA
)	O
for	O
the	O
TR2	B-protein
orphan	I-protein
receptor	I-protein
,	O
a	O
member	O
of	O
the	O
steroid-thyroid	B-protein
hormone	I-protein
receptor	I-protein
superfamily	I-protein
,	O
has	O
been	O
identified	O
in	O
the	O
simian	B-DNA
virus	I-DNA
40	I-DNA
(	I-DNA
SV40	I-DNA
)	I-DNA
+55	I-DNA
region	I-DNA
(	O
nucleotide	B-DNA
numbers	I-DNA
368-389	I-DNA
,	O
5'-GTTAAGGTTCGTAGGTCATGGA-3	O
'	O
)	O
.	O

Electrophoretic	O
mobility	O
shift	O
assay	O
,	O
using	O
in	O
vitro	O
translated	O
TR2	B-protein
orphan	I-protein
receptor	I-protein
with	O
a	O
molecular	O
mass	O
of	O
67	B-protein
kilodaltons	I-protein
,	O
showed	O
a	O
specific	O
binding	O
with	O
high	O
affinity	O
(	O
dissociation	O
constant	O
=	O
9	O
nM	O
)	O
for	O
this	O
DNA	O
sequence	O
.	O

DNA-swap	O
experiments	O
using	O
chloramphenicol	B-protein
acetyl-transferase	I-protein
assay	O
demonstrated	O
that	O
androgen	O
can	O
suppress	O
the	O
transcriptional	O
activities	O
of	O
SV40	B-DNA
early	I-DNA
promoter	I-DNA
via	O
the	O
interaction	O
between	O
this	O
TR2RE-SV40	B-DNA
and	O
the	O
chimeric	B-protein
receptor	I-protein
AR/TR2/AR	I-protein
with	O
the	O
DNA-binding	B-protein
domain	I-protein
of	O
the	O
TR2	B-protein
orphan	I-protein
receptor	I-protein
flanked	O
by	O
the	O
N-terminal	B-protein
and	I-protein
androgen-binding	I-protein
domains	I-protein
of	O
the	O
androgen	B-protein
receptor	I-protein
.	O

In	O
addition	O
,	O
this	O
TR2RE-SV40	B-DNA
can	O
function	O
as	O
a	O
repressor	O
to	O
suppress	O
the	O
transcriptional	O
activities	O
of	O
both	O
SV40	B-DNA
early	I-DNA
and	I-DNA
late	I-DNA
promoters	I-DNA
.	O

Together	O
,	O
these	O
data	O
suggest	O
the	O
TR2RE-SV40	B-DNA
may	O
represent	O
the	O
first	O
identified	O
natural	O
DNA	B-DNA
response	I-DNA
element	I-DNA
for	O
the	O
TR2	B-protein
orphan	I-protein
receptor	I-protein
that	O
may	O
function	O
as	O
a	O
repressor	O
for	O
the	O
SV40	O
gene	O
expression	O
.	O

Detection	O
of	O
the	O
chromosome	B-RNA
16	I-RNA
CBF	I-RNA
beta-MYH11	I-RNA
fusion	I-RNA
transcript	I-RNA
in	O
myelomonocytic	O
leukemias	O
.	O

Karyotypic	O
detection	O
of	O
chromosomal	O
16	O
abnormalities	O
classically	O
associated	O
with	O
AML	O
M4Eo	O
can	O
be	O
difficult	O
.	O

Characterization	O
of	O
the	O
two	O
genes	O
involved	O
in	O
the	O
inv	O
(	O
16	O
)	O
(	O
p13q22	O
)	O
,	O
CBF	B-DNA
beta	I-DNA
and	O
MYH11	B-DNA
,	O
has	O
allowed	O
the	O
detection	O
of	O
fusion	B-RNA
transcripts	I-RNA
by	O
reverse-transcriptase	O
polymerase	O
chain	O
reaction	O
(	O
RT-PCR	O
)	O
.	O

We	O
have	O
analyzed	O
CBF	B-RNA
beta-MYH11	I-RNA
fusion	I-RNA
transcripts	I-RNA
by	O
RT-PCR	O
in	O
myelomonocytic	O
leukemias	O
,	O
with	O
or	O
without	O
eosinophilia	O
,	O
to	O
determine	O
whether	O
their	O
presence	O
correlates	O
with	O
morphology	O
.	O

Fifty-three	O
cases	O
(	O
11	O
AML	O
M4Eo	O
;	O
1	O
AML	O
M4	O
with	O
atypical	B-cell_type
abnormal	I-cell_type
eosinophils	I-cell_type
(	O
AML	O
M4	O
``	O
Eo	O
''	O
)	O
;	O
29	O
AML	O
M4	O
;	O
8	O
AML	O
M5	O
;	O
3	O
CMML	O
;	O
and	O
1	O
AML	O
M2	O
with	O
eosinophilia	O
)	O
were	O
analyzed	O
.	O

All	O
11	O
typical	O
AML	O
M4Eo	O
were	O
CBF	B-DNA
beta	I-DNA
-MYH11	B-DNA
positive	O
.	O

The	O
single	O
case	O
of	O
AML	O
M4	O
with	O
distinctive	O
eosinophil	O
abnormalities	O
was	O
negative	O
by	O
karyotype	O
,	O
RT-PCR	O
and	O
fluorescent	O
in	O
situ	O
hybridization	O
(	O
FISH	O
)	O
.	O

Three	O
of	O
29	O
(	O
10	O
%	O
)	O
AML	O
M4	O
without	O
abnormal	B-cell_type
eosinophils	I-cell_type
were	O
CBF	B-DNA
beta	I-DNA
-MYH11	B-DNA
positive	O
,	O
1	O
of	O
which	O
did	O
not	O
show	O
any	O
apparent	O
chromosome	B-DNA
16	I-DNA
abnormalities	O
by	O
classical	O
metaphase	O
analysis	O
(	O
2	O
not	O
tested	O
)	O
.	O

Both	O
cases	O
tested	O
also	O
showed	O
MYH11	B-DNA
genomic	O
rearrangement	O
.	O

None	O
of	O
the	O
other	O
leukemias	O
were	O
RT-PCR	O
positive	O
.	O

Follow-up	O
of	O
three	O
patient	O
showed	O
residual	O
positivity	O
in	O
apparent	O
complete	O
remission	O
.	O

These	O
data	O
show	O
that	O
CBF	B-RNA
beta-MYH11	I-RNA
fusion	I-RNA
transcripts	I-RNA
occur	O
not	O
only	O
in	O
the	O
vast	O
majority	O
of	O
typical	O
AML	O
M4Eo	O
,	O
but	O
also	O
in	O
approximately	O
10	O
%	O
of	O
AML	O
M4	O
without	O
eosinophilic	O
abnormalities	O
,	O
a	O
much	O
higher	O
incidence	O
than	O
the	O
sporadic	O
reports	O
of	O
chromosome	B-DNA
16	I-DNA
abnormalities	O
in	O
AML	O
M4	O
would	O
suggest	O
.	O

Taken	O
together	O
with	O
the	O
detection	O
of	O
CBF	B-DNA
beta	I-DNA
-	O
MYH11	B-RNA
transcripts	I-RNA
in	O
the	O
absence	O
of	O
apparent	O
chromosome	B-DNA
16	I-DNA
abnormalities	O
by	O
classical	O
banding	O
techniques	O
,	O
these	O
data	O
show	O
that	O
additional	O
screening	O
by	O
either	O
RT-PCR	O
or	O
FISH	O
should	O
be	O
performed	O
in	O
all	O
AML	O
M4	O
,	O
regardless	O
of	O
morphologic	O
features	O
,	O
to	O
allow	O
accurate	O
evaluation	O
of	O
the	O
prognostic	O
importance	O
of	O
this	O
fusion	B-RNA
transcript	I-RNA
.	O

HIV-1	B-protein
Tat	I-protein
potentiates	O
TNF	B-protein
-induced	O
NF-kappa	B-protein
B	I-protein
activation	O
and	O
cytotoxicity	O
by	O
altering	O
the	O
cellular	O
redox	O
state	O
.	O

This	O
study	O
demonstrates	O
that	O
human	B-protein
immunodeficiency	I-protein
virus	I-protein
type	I-protein
1	I-protein
(	I-protein
HIV-1	I-protein
)	I-protein
Tat	I-protein
protein	I-protein
amplifies	O
the	O
activity	O
of	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
(	O
TNF	B-protein
)	O
,	O
a	O
cytokine	O
that	O
stimulates	O
HIV-1	O
replication	O
through	O
activation	O
of	O
NF-kappa	B-protein
B	I-protein
.	O

In	O
HeLa	B-cell_line
cells	I-cell_line
stably	O
transfected	O
with	O
the	O
HIV-1	B-DNA
tat	I-DNA
gene	I-DNA
(	O
HeLa-tat	B-cell_line
cells	I-cell_line
)	O
,	O
expression	O
of	O
the	O
Tat	B-protein
protein	I-protein
enhanced	O
both	O
TNF	B-protein
-induced	O
activation	O
of	O
NF-kappa	B-protein
B	I-protein
and	O
TNF	B-protein
-mediated	O
cytotoxicity	O
.	O

A	O
similar	O
potentiation	O
of	O
TNF	B-protein
effects	O
was	O
observed	O
in	O
Jurkat	O
T	O
cells	O
and	O
HeLa	B-cell_line
cells	I-cell_line
treated	O
with	O
soluble	O
Tat	B-protein
protein	I-protein
.	O

TNF	B-protein
-mediated	O
activation	O
of	O
NF-kappa	B-protein
B	I-protein
and	O
cytotoxicity	O
involves	O
the	O
intracellular	O
formation	O
of	O
reactive	O
oxygen	O
intermediates	O
.	O

Therefore	O
,	O
Tat	B-protein
-mediated	O
effects	O
on	O
the	O
cellular	O
redox	O
state	O
were	O
analyzed	O
.	O

In	O
both	O
T	B-cell_type
cells	I-cell_type
and	O
HeLa	B-cell_line
cells	I-cell_line
HIV-1	B-protein
Tat	I-protein
suppressed	O
the	O
expression	O
of	O
Mn-dependent	B-protein
superoxide	I-protein
dismutase	I-protein
(	O
Mn-SOD	B-protein
)	O
,	O
a	O
mitochondrial	B-protein
enzyme	I-protein
that	O
is	O
part	O
of	O
the	O
cellular	O
defense	O
system	O
against	O
oxidative	O
stress	O
.	O

Thus	O
,	O
Mn-SOD	B-protein
RNA	O
protein	O
levels	O
and	O
activity	O
were	O
markedly	O
reduced	O
in	O
the	O
presence	O
of	O
Tat	B-protein
.	O

Decreased	O
Mn-SOD	B-protein
expression	O
was	O
associated	O
with	O
decreased	O
levels	O
of	O
glutathione	O
and	O
a	O
lower	O
ratio	O
of	O
reduced	O
:	O
oxidized	O
glutathione	O
.	O

A	O
truncated	O
Tat	B-protein
protein	I-protein
(	O
Tat1-72	B-protein
)	O
,	O
known	O
to	O
transactivate	O
the	O
HIV-1	B-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
(	O
LTR	B-DNA
)	O
,	O
no	O
longer	O
affected	O
Mn-SOD	B-protein
expression	O
,	O
the	O
cellular	O
redox	O
state	O
or	O
TNF	B-protein
-mediated	O
cytotoxicity	O
.	O

Thus	O
,	O
our	O
experiments	O
demonstrate	O
that	O
the	O
C-terminal	B-protein
region	I-protein
of	O
HIV-1	B-protein
Tat	I-protein
is	O
required	O
to	O
suppress	O
Mn-SOD	B-protein
expression	O
and	O
to	O
induce	O
pro-oxidative	O
conditions	O
reflected	O
by	O
a	O
drop	O
in	O
reduced	O
glutathione	O
(	O
GSH	B-protein
)	O
and	O
the	O
GSH	O
:	O
oxidized	O
GSH	O
(	O
GSSG	O
)	O
ratio	O
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

The	O
use	O
of	O
glucocorticoids	O
in	O
acute	O
lymphoblastic	O
leukemia	O
of	O
childhood	O
.	O

Molecular	O
,	O
cellular	O
,	O
and	O
clinical	O
considerations	O
.	O

Glucocorticoids	O
have	O
been	O
included	O
in	O
almost	O
all	O
treatment	O
regimens	O
for	O
childhood	O
acute	O
lymphoblastic	O
leukemia	O
for	O
decades	O
.	O

However	O
,	O
optimal	O
agents	O
,	O
doses	O
,	O
and/or	O
schedules	O
have	O
yet	O
to	O
be	O
defined	O
despite	O
extensive	O
clinical	O
application	O
.	O

New	O
data	O
on	O
the	O
pharmacokinetics	O
,	O
pharmacodynamics	O
,	O
and	O
molecular	O
mechanisms	O
of	O
action	O
of	O
glucocorticoids	O
have	O
suggested	O
alternative	O
approaches	O
in	O
ALL	O
.	O

These	O
suggest	O
that	O
prolonged	O
,	O
i.e.	O
28	O
day	O
,	O
glucocorticoid	O
therapy	O
may	O
be	O
unnecessary	O
as	O
exposure	O
to	O
glucocorticoid	O
induces	O
down-regulation	O
of	O
glucocorticoid	B-protein
receptors	I-protein
.	O

Dexamethasone	O
may	O
be	O
superior	O
to	O
prednisone	O
in	O
conventional	O
equi-effective	O
doses	O
.	O

Blast	O
sensitivity	O
to	O
glucocorticoids	O
correlates	O
closely	O
with	O
sensitivity	O
to	O
other	O
,	O
putatively	O
non-cross-resisting	O
agents	O
and	O
with	O
outcome	O
after	O
multi-agent	O
therapy	O
,	O
suggesting	O
overlapping	O
mechanisms	O
of	O
action	O
,	O
and	O
focusing	O
attention	O
on	O
the	O
determinants	O
of	O
the	O
threshold	O
for	O
apoptosis	O
.	O

Increasing	O
success	O
in	O
the	O
treatment	O
of	O
childhood	O
acute	O
lymphoblastic	O
leukemia	O
has	O
led	O
to	O
increasing	O
awareness	O
of	O
avascular	O
necrosis	O
of	O
bone	O
as	O
a	O
potentially	O
disabling	O
sequela	O
of	O
glucocorticoid	O
therapy	O
,	O
especially	O
in	O
adolescent	O
and	O
young	O
adult	O
patients	O
.	O

Epstein-Barr	B-protein
virus	I-protein
nuclear	I-protein
protein	I-protein
2	I-protein
transactivation	O
of	O
the	O
latent	B-DNA
membrane	I-DNA
protein	I-DNA
1	I-DNA
promoter	I-DNA
is	O
mediated	O
by	O
J	B-protein
kappa	I-protein
and	O
PU.1	B-protein
.	O

Expression	O
of	O
the	O
Epstein-Barr	B-DNA
virus	I-DNA
(	I-DNA
EBV	I-DNA
)	I-DNA
latent	I-DNA
membrane	I-DNA
protein	I-DNA
1	I-DNA
(	I-DNA
LMP-1	I-DNA
)	I-DNA
oncogene	I-DNA
is	O
regulated	O
by	O
the	O
EBV	B-protein
nuclear	I-protein
protein	I-protein
2	I-protein
(	I-protein
EBNA-2	I-protein
)	I-protein
transactivator	I-protein
.	O

EBNA-2	B-protein
is	O
known	O
to	O
interact	O
with	O
the	O
cellular	B-protein
DNA-binding	I-protein
protein	I-protein
J	B-protein
kappa	I-protein
and	O
is	O
recruited	O
to	O
promoters	B-DNA
containing	O
the	O
GTGGGAA	O
J	B-DNA
kappa	I-DNA
recognition	I-DNA
sequence	I-DNA
.	O

The	O
minimal	B-DNA
EBNA-2-responsive	I-DNA
LMP-1	I-DNA
promoter	I-DNA
includes	O
one	O
J	B-DNA
kappa-binding	I-DNA
site	I-DNA
,	O
and	O
we	O
now	O
show	O
that	O
mutation	O
of	O
that	O
site	O
,	O
such	O
that	O
J	B-protein
kappa	I-protein
can	O
not	O
bind	O
,	O
reduces	O
EBNA-2	B-protein
responsiveness	O
by	O
60	O
%	O
.	O

To	O
identify	O
other	O
factors	O
which	O
interact	O
with	O
the	O
LMP-1	B-DNA
EBNA-2	I-DNA
response	I-DNA
element	I-DNA
(	O
E2RE	B-DNA
)	O
,	O
a	O
-236/-145	B-DNA
minimal	I-DNA
E2RE	I-DNA
was	O
used	O
as	O
a	O
probe	O
in	O
an	O
electrophoretic	O
mobility	O
shift	O
assay	O
.	O

The	O
previously	O
characterized	O
factors	O
J	B-protein
kappa	I-protein
,	O
PU.1	B-protein
,	O
and	O
AML1	B-protein
bind	O
to	O
the	O
LMP-1	B-DNA
E2RE	I-DNA
,	O
along	O
with	O
six	O
other	O
unidentified	O
factors	O
(	O
LBF2	B-protein
to	O
LBF7	B-protein
)	O
.	O

Binding	O
sites	O
were	O
mapped	O
for	O
each	O
factor	O
.	O

LBF4	B-protein
is	O
B-	O
and	O
T-cell	O
specific	O
and	O
recognizes	O
the	O
PU.1	B-DNA
GGAA	I-DNA
core	I-DNA
sequence	I-DNA
as	O
shown	O
by	O
methylation	O
interference	O
.	O

LBF4	B-protein
has	O
a	O
molecular	O
mass	O
of	O
105	O
kDa	O
and	O
is	O
probably	O
unrelated	O
to	O
PU.1	B-protein
.	O

LBF2	B-protein
was	O
found	O
only	O
in	O
epithelial	B-cell_line
cell	I-cell_line
lines	I-cell_line
,	O
whereas	O
LBF3	B-protein
,	O
LBF5	B-protein
,	O
LBF6	B-protein
,	O
and	O
LBF7	B-protein
were	O
not	O
cell	O
type	O
specific	O
.	O

Mutations	O
of	O
the	O
AML1-	B-DNA
or	I-DNA
LBF4-binding	I-DNA
sites	I-DNA
had	O
no	O
effect	O
on	O
EBNA-2	B-protein
transactivation	O
,	O
whereas	O
mutation	O
of	O
the	O
PU.1-binding	B-DNA
site	I-DNA
completely	O
eliminated	O
EBNA-2	B-protein
responses	O
.	O

A	O
gst-EBNA-2	B-protein
fusion	I-protein
protein	I-protein
specifically	O
depleted	O
PU.1	B-protein
from	O
nuclear	O
extracts	O
and	O
bound	O
in	O
vitro	O
translated	O
PU.1	B-protein
,	O
providing	O
biochemical	O
evidence	O
for	O
a	O
direct	O
EBNA-2	B-protein
-PU.1	B-protein
interaction	O
.	O

Thus	O
,	O
EBNA-2	B-protein
transactivation	O
of	O
the	O
LMP-1	B-DNA
promoter	I-DNA
is	O
dependent	O
on	O
interaction	O
with	O
at	O
least	O
two	O
distinct	O
sequence-specific	O
DNA-binding	B-protein
proteins	I-protein
,	O
J	B-protein
kappa	I-protein
and	O
PU.1	B-protein
.	O

LBF3	B-protein
,	O
LBF5	B-protein
,	O
LBF6	B-protein
,	O
or	O
LBF7	B-protein
may	O
also	O
be	O
involved	O
,	O
since	O
their	O
binding	O
sites	O
also	O
contribute	O
to	O
EBNA-2	B-protein
responsiveness	O
.	O

Lymphocyte	B-protein
glucocorticoid	I-protein
receptor	I-protein
:	O
predictor	O
of	O
sertraline	O
response	O
in	O
adolescent	O
major	O
depressive	O
disorder	O
(	O
MDD	O
)	O
.	O

Major	O
depressive	O
disorder	O
(	O
MDD	O
)	O
in	O
adolescents	O
demonstrates	O
resistance	O
to	O
tricyclic	O
antidepressants	O
and	O
absence	O
of	O
hypercortisolemia	O
.	O

The	O
efficacy	O
of	O
serotonin	O
reuptake	O
inhibitors	O
(	O
SRIs	O
)	O
is	O
uncertain	O
,	O
and	O
response	O
predictors	O
are	O
unavailable	O
.	O

Abnormal	O
fast	O
feedback	O
and	O
negative	O
feedback	O
of	O
the	O
hypothalamic-pituitary-adrenal	O
axis	O
implicates	O
a	O
dampened	O
limbic-hippocampal	B-protein
glucocorticoid	I-protein
type	I-protein
II	I-protein
receptor	I-protein
(	O
GCII	B-protein
)	O
.	O

We	O
hypothesized	O
that	O
lymphocyte	B-protein
GCII	I-protein
is	O
altered	O
in	O
adolescent	O
MDD	O
and	O
could	O
serve	O
as	O
a	O
marker	O
for	O
response	O
to	O
SRIs	O
.	O

In	O
an	O
open-label	O
study	O
,	O
adolescents	O
(	O
n	O
=	O
20	O
)	O
meeting	O
DSM-III-R	O
criteria	O
for	O
MDD	O
showed	O
baseline	O
lymphocyte	B-protein
GCII	I-protein
sites	I-protein
per	O
cell	O
(	O
sites/cell	O
)	O
values	O
of	O
793	O
+/-	O
106	O
versus	O
2	O
,	O
563	O
+/-	O
499	O
(	O
+/-	O
SEM	O
)	O
for	O
matched	O
controls	O
(	O
n	O
=	O
18	O
)	O
(	O
t	O
=	O
3.5	O
;	O
df	O
=	O
36	O
;	O
p	O
<	O
.001	O
)	O
.	O

GCII	B-protein
was	O
bimodally	O
distributed	O
,	O
with	O
SRI	O
responders	O
differing	O
from	O
nonresponders	O
(	O
t	O
=	O
3.9	O
;	O
df	O
=	O
14	O
;	O
p	O
<	O
.001	O
)	O
.	O

GCII	B-protein
accurately	O
classified	O
90	O
percent	O
of	O
sertraline	O
responders	O
and	O
80	O
percent	O
of	O
nonresponders	O
.	O

Only	O
SRI	O
responders	O
showed	O
GCII	B-protein
sites/cell	O
upregulated	O
after	O
6	O
weeks	O
of	O
treatment	O
(	O
t	O
=	O
2.1	O
,	O
df	O
=	O
10	O
;	O
p	O
<	O
.05	O
)	O
.	O

The	O
role	O
of	O
NFATp	B-protein
in	O
cyclosporin	B-DNA
A-sensitive	I-DNA
tumor	I-DNA
necrosis	I-DNA
factor-alpha	I-DNA
gene	I-DNA
transcription	O
.	O

The	O
tumor	B-DNA
necrosis	I-DNA
factor-alpha	I-DNA
(	I-DNA
TNF	I-DNA
alpha	I-DNA
)	I-DNA
gene	I-DNA
is	O
an	O
immediate	O
early	O
gene	O
in	O
activated	O
T	B-cell_type
cells	I-cell_type
,	O
in	O
that	O
it	O
is	O
rapidly	O
induced	O
without	O
a	O
requirement	O
for	O
protein	O
synthesis	O
.	O

Maximal	O
induction	O
of	O
TNF	B-RNA
alpha	I-RNA
mRNA	I-RNA
can	O
be	O
induced	O
by	O
treatment	O
of	O
T	B-cell_type
cells	I-cell_type
with	O
calcium	O
ionophores	O
alone	O
,	O
via	O
a	O
calcineurin	B-protein
-dependent	O
process	O
that	O
is	O
blocked	O
by	O
cyclosporin	O
A	O
.	O

We	O
have	O
previously	O
identified	O
a	O
promoter	B-DNA
element	I-DNA
,	O
kappa	B-DNA
3	I-DNA
,	O
that	O
is	O
required	O
for	O
calcium-stimulated	O
,	O
cyclosporin	O
A-sensitive	O
induction	O
of	O
the	O
TNF	B-DNA
alpha	I-DNA
gene	I-DNA
in	O
activated	O
T	B-cell_type
cells	I-cell_type
.	O

Here	O
,	O
we	O
demonstrate	O
that	O
the	O
kappa	B-protein
3	I-protein
binding	I-protein
factor	I-protein
contains	O
NFATp	B-protein
,	O
a	O
cyclosporin-sensitive	B-protein
DNA-binding	I-protein
protein	I-protein
required	O
for	O
interleukin-2	B-DNA
gene	I-DNA
transcription	O
.	O

NFATp	B-protein
binds	O
to	O
two	O
sites	O
within	O
the	O
kappa	B-DNA
3	I-DNA
element	I-DNA
,	O
and	O
occupancy	O
of	O
both	O
sites	O
is	O
required	O
for	O
TNF	B-protein
alpha	O
gene	O
induction	O
.	O

Thus	O
,	O
although	O
the	O
kappa	B-DNA
3	I-DNA
element	I-DNA
has	O
little	O
sequence	O
similarity	O
to	O
other	O
NFATp-binding	B-DNA
sites	I-DNA
,	O
it	O
appears	O
to	O
function	O
as	O
a	O
cyclosporin-sensitive	B-DNA
promoter	I-DNA
element	I-DNA
in	O
T	B-cell_type
cells	I-cell_type
by	O
virtue	O
of	O
its	O
ability	O
to	O
bind	O
NFATp	B-protein
.	O

The	O
involvement	O
of	O
NFATp	B-protein
in	O
transcriptional	O
activation	O
of	O
both	O
the	O
interleukin-2	B-protein
and	O
TNF	B-DNA
alpha	I-DNA
genes	I-DNA
suggests	O
that	O
this	O
factor	O
plays	O
an	O
important	O
role	O
in	O
the	O
coordinate	O
induction	O
of	O
multiple	O
cytokine	B-DNA
genes	I-DNA
,	O
starting	O
at	O
the	O
earliest	O
stages	O
of	O
T	O
cell	O
activation	O
.	O

Regulation	O
and	O
specificity	O
of	O
MNDA	B-protein
expression	O
in	O
monocytes	B-cell_type
,	O
macrophages	B-cell_type
,	O
and	O
leukemia/B	B-cell_line
lymphoma	I-cell_line
cell	I-cell_line
lines	I-cell_line
.	O

The	O
expression	O
of	O
the	O
human	B-protein
myeloid	I-protein
cell	I-protein
nuclear	I-protein
differentiation	I-protein
antigen	I-protein
(	O
MNDA	B-protein
)	O
was	O
observed	O
specifically	O
in	O
cells	O
of	O
the	O
granulocyte-macrophage	O
lineage	O
in	O
our	O
earlier	O
reports	O
.	O

The	O
specificity	O
of	O
MNDA	B-protein
expression	O
for	O
cells	O
in	O
the	O
granulocyte-macrophage	O
lineage	O
was	O
reexamined	O
in	O
cell	B-cell_line
lines	I-cell_line
established	O
from	O
patients	O
with	O
Philadelphia	O
chromosome-positive	O
chronic	O
myeloid	O
leukemia	O
.	O

Cell	O
lines	O
that	O
expressed	O
MNDA	B-protein
exhibited	O
myeloid	O
cell	O
features	O
and	O
granulocyte	O
or	O
monocyte	O
differentiation	O
could	O
be	O
induced	O
in	O
vitro	O
,	O
while	O
cell	O
lines	O
exhibiting	O
properties	O
of	O
very	O
early	O
stage	O
cells	O
or	O
multipotential	B-cell_type
cells	I-cell_type
did	O
not	O
express	O
MNDA	B-protein
.	O

Cells	O
originating	O
from	O
cases	O
of	O
Burkitt	O
's	O
lymphoma	O
were	O
negative	O
.	O

By	O
contrast	O
,	O
three	O
lymphoblastoid	B-cell_line
cell	I-cell_line
lines	I-cell_line
(	O
immortalized	O
in	O
vitro	O
with	O
Epstein-Barr	O
virus	O
)	O
were	O
weakly	O
positive	O
and	O
MNDA	B-protein
was	O
up-regulated	O
by	O
interferon-alpha	B-protein
(	O
IFN-alpha	B-protein
)	O
treatment	O
.	O

As	O
we	O
reported	O
previously	O
,	O
MNDA	B-RNA
mRNA	I-RNA
level	O
in	O
adherent	O
monocytes	B-cell_type
is	O
elevated	O
by	O
IFN-alpha	B-protein
;	O
in	O
this	O
study	O
,	O
we	O
further	O
assessed	O
MNDA	B-protein
expression	O
in	O
in	O
vitro	O
monocyte-derived	O
macrophages	B-cell_type
.	O

Three	O
additional	O
agents	O
(	O
endotoxin	O
,	O
phytohemagglutinin	B-protein
,	O
and	O
phorbol	O
ester	O
)	O
and	O
other	O
conditions	O
that	O
affect	O
function	O
,	O
cytokine	B-protein
production	O
,	O
differentiation	O
,	O
and/or	O
growth	O
of	O
monocytes	B-cell_type
were	O
examined	O
for	O
their	O
ability	O
to	O
alter	O
MNDA	B-protein
expression	O
.	O

The	O
results	O
varied	O
with	O
the	O
agent	O
,	O
cell	O
type	O
,	O
and	O
stage	O
of	O
differentiation	O
.	O

Changes	O
in	O
MNDA	B-protein
expression	O
occurred	O
slowly	O
(	O
hours	O
to	O
days	O
)	O
,	O
suggesting	O
that	O
MNDA	B-protein
could	O
mediate	O
changes	O
realized	O
over	O
a	O
long	O
period	O
.	O

The	O
results	O
also	O
reveal	O
a	O
discordance	O
in	O
certain	O
MNDA	B-cell_line
positive	I-cell_line
cells	I-cell_line
between	O
steady-state	O
levels	O
or	O
changes	O
in	O
levels	O
of	O
protein	O
and	O
mRNA	B-RNA
indicating	O
that	O
the	O
regulation	O
of	O
MNDA	B-protein
expression	O
occurs	O
at	O
more	O
than	O
one	O
point	O
.	O

Changes	O
in	O
MNDA	B-protein
expression	O
are	O
consistent	O
with	O
a	O
role	O
in	O
opposing	O
macrophage	O
differentiation	O
and	O
activation	O
of	O
monocytes	B-cell_type
/macrophages	B-cell_type
.	O

DNA-binding	O
studies	O
of	O
the	O
Epstein-Barr	B-protein
virus	I-protein
nuclear	I-protein
antigen	I-protein
2	I-protein
(	O
EBNA-2	B-protein
)	O
:	O
evidence	O
for	O
complex	O
formation	O
by	O
latent	B-protein
membrane	I-protein
protein	I-protein
gene	I-protein
promoter-binding	I-protein
proteins	I-protein
in	O
EBNA-2-positive	B-cell_line
cell	I-cell_line
lines	I-cell_line
.	O

The	O
Epstein-Barr	B-protein
virus	I-protein
(	I-protein
EBV	I-protein
)	I-protein
nuclear	I-protein
antigen	I-protein
2	I-protein
(	O
EBNA-2	B-protein
)	O
protein	O
is	O
essential	O
for	O
the	O
immortalization	O
of	O
human	B-cell_type
primary	I-cell_type
B	I-cell_type
cells	I-cell_type
by	O
EBV	O
.	O

EBNA-2	B-protein
trans-activates	O
cellular	B-DNA
and	I-DNA
viral	I-DNA
genes	I-DNA
like	O
CD23	B-DNA
,	O
c-fgr	B-DNA
,	O
latent	B-protein
membrane	I-protein
protein	I-protein
1	I-protein
(	O
LMP1	B-protein
)	O
and	O
terminal	B-protein
protein	I-protein
1	I-protein
(	O
TP1	B-protein
)	O
.	O

Trans-activation	O
of	O
the	O
TP1	B-DNA
promoter	I-DNA
and	O
of	O
the	O
BamHI	B-DNA
C	I-DNA
promoter	I-DNA
has	O
already	O
been	O
investigated	O
in	O
detail	O
and	O
appears	O
to	O
be	O
mediated	O
via	O
protein-protein	O
interactions	O
and	O
not	O
by	O
direct	O
binding	O
of	O
EBNA-2	B-protein
type	I-protein
A	I-protein
(	O
of	O
EBV	O
type	O
1	O
)	O
to	O
the	O
DNA	O
.	O

EBNA-2	B-protein
is	O
able	O
to	O
trans-activate	O
the	O
expression	O
of	O
the	O
LMP	B-DNA
gene	I-DNA
in	O
several	O
cell	O
lines	O
.	O

Various	O
reports	O
have	O
delineated	O
the	O
cis-acting	B-DNA
elements	I-DNA
of	O
the	O
LMP	B-DNA
promoter	I-DNA
through	O
which	O
EBNA-2	B-protein
mediates	O
trans-activation	O
.	O

To	O
determine	O
whether	O
EBNA-2	B-protein
also	O
trans-activates	O
the	O
LMP	B-DNA
promoter	I-DNA
by	O
protein-protein	O
interactions	O
,	O
we	O
performed	O
a	O
series	O
of	O
gel	O
retardation	O
assays	O
and	O
competition	O
experiments	O
with	O
LMP	B-DNA
promoter	I-DNA
fragments	I-DNA
of	O
different	O
sizes	O
.	O

We	O
determined	O
that	O
the	O
protein-binding	B-DNA
region	I-DNA
on	O
the	O
LMP	B-DNA
promoter	I-DNA
was	O
within	O
a	O
42	B-DNA
bp	I-DNA
fragment	I-DNA
encompassing	O
nucleotides	O
-135	O
to	O
-176	O
relative	O
to	O
the	O
LMP	B-DNA
transcriptional	I-DNA
start	I-DNA
site	I-DNA
.	O

None	O
of	O
the	O
DNA	O
fragments	O
investigated	O
indicated	O
interaction	O
of	O
EBNA-2	B-protein
with	O
the	O
DNA	O
via	O
protein-protein	O
interactions	O
.	O

No	O
significant	O
differences	O
between	O
EBNA-2	B-protein
-positive	O
and	O
EBNA-2	B-protein
-negative	O
nuclear	O
extracts	O
could	O
be	O
seen	O
in	O
the	O
gel	O
retardation	O
assay	O
under	O
conditions	O
that	O
clearly	O
showed	O
binding	O
of	O
EBNA-2A	B-protein
to	O
the	O
TP1	B-DNA
promoter	I-DNA
.	O

However	O
,	O
analysis	O
of	O
sucrose	O
gradient	O
fractions	O
in	O
the	O
gel	O
retardation	O
assay	O
provided	O
evidence	O
that	O
the	O
LMP	B-protein
promoter-binding	I-protein
proteins	I-protein
form	O
a	O
complex	O
of	O
higher	O
M	O
(	O
r	O
)	O
in	O
EBNA-2-positive	B-cell_type
cell	I-cell_type
extracts	O
.	O

These	O
complexes	O
were	O
destroyed	O
by	O
detergent	O
.	O

We	O
deduce	O
from	O
these	O
results	O
that	O
EBNA-2-positive	B-cell_line
cells	I-cell_line
might	O
indeed	O
contain	O
specific	B-protein
complexes	I-protein
bound	O
to	O
the	O
LMP	B-DNA
promoter	I-DNA
which	O
are	O
,	O
however	O
,	O
too	O
labile	O
to	O
be	O
detected	O
in	O
a	O
standard	O
gel	O
retardation	O
assay	O
.	O

Simultaneous	O
activation	O
of	O
Ig	B-protein
and	O
Oct-2	B-protein
synthesis	O
and	O
reduction	O
of	O
surface	O
MHC	B-protein
class	I-protein
II	I-protein
expression	O
by	O
IL-6	B-protein
.	O

Terminal	O
differentiation	O
of	O
B	B-cell_type
cells	I-cell_type
to	O
plasma	B-cell_type
cells	I-cell_type
in	O
vivo	O
is	O
characterized	O
by	O
secretion	O
of	O
Ig	B-protein
and	O
extinction	O
of	O
MHC	B-protein
class	I-protein
II	I-protein
expression	O
on	O
the	O
cell	O
surface	O
.	O

We	O
show	O
that	O
IL-6	B-protein
signaling	O
leads	O
to	O
marked	O
increases	O
in	O
the	O
synthesis	O
and	O
secretion	O
of	O
Ig	B-protein
in	O
clonal	B-cell_line
human	I-cell_line
B	I-cell_line
cell	I-cell_line
lines	I-cell_line
and	O
newly	O
isolated	B-cell_type
polyclonal	I-cell_type
B	I-cell_type
lymphocytes	I-cell_type
in	O
vitro	O
.	O

The	O
IL-6-induced	B-cell_line
cells	I-cell_line
resemble	O
plasma	B-cell_type
cells	I-cell_type
in	O
ultrastructure	O
and	O
in	O
reduced	O
expression	O
of	O
surface	B-protein
MHC	I-protein
class	I-protein
II	I-protein
.	O

Enhanced	O
Ig	B-protein
synthesis	O
is	O
a	O
result	O
of	O
coordinated	O
transcriptional	O
activation	O
of	O
Ig	B-DNA
genes	I-DNA
without	O
promoter	O
or	O
isotype	O
specificity	O
,	O
and	O
differential	O
accumulation	O
of	O
the	O
mRNA	B-RNA
encoding	O
the	O
secreted	O
form	O
of	O
Ig	B-protein
heavy	I-protein
chain	I-protein
.	O

It	O
is	O
saturable	O
and	O
subject	O
to	O
negative	O
control	O
when	O
IL-6	B-protein
stimulation	O
is	O
prolonged	O
.	O

Coordinate	O
with	O
temporal	O
changes	O
in	O
Ig	B-protein
synthesis	O
,	O
the	O
DNA-binding	O
activity	O
and	O
the	O
synthesis	O
of	O
the	O
B	B-protein
cell-enriched	I-protein
transcription	I-protein
factor	I-protein
Oct-2	B-protein
are	O
regulated	O
.	O

Thus	O
,	O
differentiation	O
of	O
B	B-cell_type
cells	I-cell_type
with	O
IL-6	B-protein
in	O
vitro	O
recapitulates	O
the	O
hallmarks	O
of	O
terminal	O
B	O
differentiation	O
in	O
vivo	O
;	O
Oct-2	B-protein
may	O
have	O
a	O
role	O
in	O
this	O
process	O
.	O

T-cell	B-DNA
functional	I-DNA
regions	I-DNA
of	O
the	O
human	B-DNA
IL-3	I-DNA
proximal	I-DNA
promoter	I-DNA
.	O

The	O
human	B-DNA
interleukin-3	I-DNA
(	I-DNA
IL-3	I-DNA
)	I-DNA
gene	I-DNA
is	O
expressed	O
almost	O
exclusively	O
in	O
activated	O
T	B-cell_type
cells	I-cell_type
.	O

Its	O
expression	O
is	O
regulated	O
at	O
both	O
the	O
transcriptional	O
and	O
post-transcriptional	O
level	O
.	O

We	O
have	O
previously	O
shown	O
that	O
treatment	O
of	O
Jurkat	B-cell_line
T	I-cell_line
cells	I-cell_line
with	O
phytohemaglutinin	B-protein
(	O
PHA	B-protein
)	O
and	O
the	O
phorbol	O
ester	O
,	O
PMA	O
,	O
activated	O
transcription	O
initiation	O
from	O
the	O
IL-3	B-DNA
gene	I-DNA
.	O

To	O
define	O
the	O
regions	O
of	O
the	O
gene	O
required	O
for	O
transcription	O
activation	O
,	O
we	O
generated	O
a	O
series	O
of	O
reporter	O
constructs	O
containing	O
different	O
regions	O
of	O
the	O
IL-3	B-DNA
gene	I-DNA
5	I-DNA
'	I-DNA
and	I-DNA
3	I-DNA
'	I-DNA
flanking	I-DNA
sequences	I-DNA
.	O

Both	O
positive	B-DNA
and	I-DNA
negative	I-DNA
regulatory	I-DNA
elements	I-DNA
were	O
identified	O
in	O
the	O
proximal	B-DNA
5	I-DNA
'	I-DNA
flanking	I-DNA
region	I-DNA
of	O
the	O
IL-3	B-DNA
gene	I-DNA
.	O

The	O
promoter	B-DNA
region	I-DNA
between	O
-173	B-DNA
and	I-DNA
-60	I-DNA
contained	O
the	O
strongest	O
activating	B-DNA
elements	I-DNA
.	O

The	O
transcription	B-protein
factor	I-protein
AP-1	B-protein
could	O
bind	O
to	O
this	O
positive	O
activator	O
region	O
of	O
the	O
promoter	O
.	O

We	O
also	O
examined	O
the	O
function	O
of	O
the	O
IL-3	B-DNA
CK-1/CK-2	I-DNA
elements	I-DNA
that	O
are	O
present	O
in	O
many	O
cytokine	B-DNA
genes	I-DNA
and	O
found	O
that	O
they	O
acted	O
as	O
a	O
repressor	O
of	O
basal	O
level	O
expression	O
when	O
cloned	O
upstream	O
of	O
a	O
heterologous	B-DNA
promoter	I-DNA
but	O
were	O
also	O
inducible	O
by	O
PMA	O
/PHA	B-protein
.	O

Expression	O
of	O
the	O
Runt	B-DNA
domain-encoding	I-DNA
PEBP2	I-DNA
alpha	I-DNA
genes	I-DNA
in	O
T	B-cell_type
cells	I-cell_type
during	O
thymic	O
development	O
.	O

The	O
PEBP2	B-DNA
alpha	I-DNA
A	I-DNA
and	I-DNA
PEBP2	I-DNA
alpha	I-DNA
B	I-DNA
genes	I-DNA
encode	O
the	O
DNA-binding	B-protein
subunit	I-protein
of	O
a	O
murine	B-protein
transcription	I-protein
factor	I-protein
,	O
PEBP2	B-protein
,	O
which	O
is	O
implicated	O
as	O
a	O
T-cell-specific	B-protein
transcriptional	I-protein
regulator	I-protein
.	O

These	O
two	O
related	O
genes	O
share	O
the	O
evolutionarily	O
conserved	O
region	O
encoding	O
the	O
Runt	B-protein
domain	I-protein
.	O

PEBP2	B-protein
alpha	I-protein
B	I-protein
is	O
the	O
murine	B-protein
counterpart	I-protein
of	O
human	B-protein
AML1	I-protein
,	O
which	O
is	O
located	O
at	O
the	O
breakpoints	O
of	O
the	O
8	B-DNA
;	I-DNA
21	I-DNA
and	I-DNA
3	I-DNA
;	I-DNA
21	I-DNA
chromosome	I-DNA
translocations	I-DNA
associated	O
with	O
acute	O
myeloid	O
leukemia	O
.	O

Northern	O
(	O
RNA	O
)	O
blots	O
of	O
various	O
adult	O
mouse	O
tissues	O
revealed	O
that	O
the	O
levels	O
of	O
expression	O
of	O
both	O
genes	O
were	O
most	O
prominent	O
in	O
the	O
thymus	O
.	O

Furthermore	O
,	O
transcripts	O
of	O
PEBP2	B-protein
alpha	I-protein
A	I-protein
and	O
mouse	B-protein
AML1/PEBP2	I-protein
alpha	I-protein
B	I-protein
were	O
detected	O
in	O
T	B-cell_type
lymphocytes	I-cell_type
in	O
the	O
thymuses	O
from	O
day	O
16	O
embryos	O
and	O
newborns	O
,	O
as	O
well	O
as	O
4-week-old	O
adult	O
mice	O
,	O
by	O
in	O
situ	O
hybridization	O
.	O

The	O
expression	O
of	O
the	O
genes	O
persisted	O
in	O
peripheral	O
lymph	O
nodes	O
of	O
adult	O
mice	O
.	O

The	O
transcripts	O
were	O
detected	O
in	O
all	O
the	O
CD4-	B-cell_type
CD8-	I-cell_type
,	I-cell_type
CD4+	I-cell_type
CD8+	I-cell_type
,	I-cell_type
CD4+	I-cell_type
CD8-	I-cell_type
,	I-cell_type
and	I-cell_type
CD4-	I-cell_type
CD8+	I-cell_type
cell	I-cell_type
populations	I-cell_type
.	O

The	O
results	O
indicated	O
that	O
both	O
genes	O
are	O
expressed	O
in	O
T	B-cell_type
cells	I-cell_type
throughout	O
their	O
development	O
,	O
supporting	O
the	O
notion	O
that	O
PEBP2	B-protein
is	O
a	O
T-cell-specific	B-protein
transcription	I-protein
factor	I-protein
.	O

Transcripts	O
of	O
mouse	B-protein
AML1/PEBP2	I-protein
alpha	I-protein
B	I-protein
were	O
also	O
detected	O
in	O
day	O
12	O
fetal	O
hematopoietic	O
liver	O
and	O
in	O
the	O
bone	B-cell_type
marrow	I-cell_type
cells	I-cell_type
of	O
newborn	O
mice	O
.	O

The	O
implication	O
of	O
mouse	O
AML1/PEBP2	B-protein
alpha	I-protein
B	I-protein
expression	O
in	O
hematopoietic	B-cell_type
cells	I-cell_type
other	O
than	O
those	O
of	O
T-cell	B-cell_type
lineage	I-cell_type
is	O
discussed	O
in	O
relation	O
to	O
myeloid	O
leukemogenesis	O
.	O

Effects	O
of	O
glucocorticoids	O
on	O
transcription	O
factor	O
activation	O
in	O
human	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
.	O

Glucocorticoids	O
have	O
an	O
inhibitory	O
effect	O
on	O
inflammatory	O
and	O
immune	O
responses	O
,	O
and	O
this	O
may	O
be	O
through	O
the	O
modulation	O
of	O
transcription	B-protein
factor	I-protein
binding	O
to	O
DNA	O
.	O

The	O
interaction	O
of	O
the	O
transcription	B-protein
factors	I-protein
,	O
activator	B-protein
protein-1	I-protein
(	O
AP-1	B-protein
)	O
,	O
nuclear	B-protein
factor	I-protein
kappa	I-protein
B	I-protein
(	O
NF	B-protein
kappa	I-protein
B	I-protein
)	O
,	O
and	O
cAMP-responsive	B-protein
element	I-protein
binding	I-protein
protein	I-protein
(	O
CREB	B-protein
)	O
with	O
DNA	O
and	O
glucocorticoid	B-protein
receptors	I-protein
(	O
GR	B-protein
)	O
was	O
analyzed	O
in	O
human	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
by	O
gel	O
mobility	O
shift	O
assays	O
.	O

TNF-alpha	O
,	O
IL-1	O
beta	O
and	O
phorbol	O
myristate	O
acetate	O
(	O
PMA	O
)	O
treatment	O
increased	O
AP-1	B-protein
and	O
NF	O
kappa	O
B	O
DNA	O
binding	O
by	O
up	O
to	O
200	O
%	O
but	O
decreased	O
CREB	B-protein
binding	O
(	O
38	O
%	O
)	O
over	O
a	O
60-min	O
time	O
course	O
.	O

Dexamethasone	O
produced	O
a	O
rapid	O
and	O
sustained	O
increase	O
in	O
glucocorticoid	B-DNA
response	I-DNA
element	I-DNA
binding	O
and	O
a	O
concomitant	O
40-50	O
%	O
decrease	O
in	O
AP-1	O
,	O
NF	O
kappa	O
B	O
,	O
and	O
CREB	O
DNA	O
binding	O
that	O
was	O
blocked	O
by	O
combined	O
dexamethasone	O
and	O
cytokine	B-protein
or	O
PMA	O
treatment	O
.	O

These	O
latter	O
effects	O
were	O
due	O
to	O
increases	O
in	O
the	O
nuclear	O
localization	O
of	O
GR	B-protein
,	O
not	O
to	O
reduced	O
amounts	O
of	O
the	O
other	O
transcription	B-protein
factors	I-protein
.	O

This	O
suggests	O
that	O
in	O
these	O
cells	O
GR	B-protein
within	O
the	O
nucleus	O
interacts	O
with	O
cytokine-stimulated	B-protein
transcription	I-protein
factors	I-protein
by	O
the	O
process	O
of	O
cross	O
coupling	O
.	O

This	O
may	O
be	O
an	O
important	O
molecular	O
site	O
of	O
steroid	O
action	O
.	O

Differential	O
induction	O
of	O
the	O
NF-AT	B-protein
complex	I-protein
during	O
restimulation	O
and	O
the	O
induction	O
of	O
T-cell	O
anergy	O
.	O

Stimulation	O
of	O
human	B-cell_line
CD4+	I-cell_line
T-cell	I-cell_line
clones	I-cell_line
through	O
the	O
T-cell	B-protein
receptor	I-protein
(	O
TcR	B-protein
)	O
by	O
high	O
doses	O
of	O
specific	O
peptide	O
results	O
in	O
the	O
induction	O
of	O
a	O
long-lived	O
state	O
of	O
nonresponsiveness	O
that	O
has	O
been	O
called	O
anergy	O
.	O

During	O
the	O
induction	O
of	O
anergy	O
,	O
T	B-cell_type
cells	I-cell_type
are	O
phenotypically	O
similar	O
to	O
cells	O
responding	O
to	O
an	O
immunogenic	O
stimulus	O
.	O

The	O
amount	O
of	O
TcR	B-protein
at	O
the	O
cell	O
surface	O
is	O
downmodulated	O
,	O
whereas	O
the	O
CD2	B-protein
and	I-protein
CD25	I-protein
receptors	I-protein
are	O
increased	O
.	O

When	O
restimulated	O
,	O
however	O
,	O
anergic	B-cell_type
T	I-cell_type
cells	I-cell_type
fail	O
to	O
up-regulate	O
transcription	O
of	O
the	O
IL-2	B-DNA
gene	I-DNA
and	O
in	O
consequence	O
do	O
not	O
produce	O
IL-2	B-protein
.	O

In	O
this	O
study	O
,	O
we	O
have	O
compared	O
the	O
ability	O
of	O
various	O
transcription	B-protein
factors	I-protein
to	O
bind	O
to	O
their	O
appropriate	O
site	O
on	O
DNA	O
.	O

Factors	O
were	O
isolated	O
from	O
the	O
nuclei	O
of	O
T	B-cell_type
cells	I-cell_type
that	O
were	O
in	O
the	O
induction	O
phase	O
of	O
anergy	O
or	O
were	O
undergoing	O
activation	O
.	O

The	O
pattern	O
of	O
binding	O
activity	O
in	O
restimulated	O
T	B-cell_type
cells	I-cell_type
is	O
consistent	O
with	O
the	O
pattern	O
that	O
has	O
previously	O
been	O
shown	O
to	O
regulate	O
T-cell-specific	O
expression	O
of	O
the	O
IL-2	B-protein
and	O
the	O
beta	O
chain	O
of	O
the	O
TcR	B-DNA
genes	I-DNA
.	O

The	O
measured	O
binding	O
to	O
a	O
TCF-1	B-DNA
site	I-DNA
is	O
the	O
same	O
in	O
the	O
nuclei	O
of	O
resting	B-cell_type
,	I-cell_type
activated	I-cell_type
,	I-cell_type
and	I-cell_type
anergized	I-cell_type
cells	I-cell_type
.	O

The	O
inducible	B-protein
factors	I-protein
NK-kappa	B-protein
B	I-protein
,	O
beta	B-protein
E2	I-protein
,	O
CD28RC	B-protein
,	O
and	O
AP-1	B-protein
are	O
not	O
expressed	O
in	O
resting	B-cell_type
cells	I-cell_type
and	O
are	O
twofold	O
lower	O
in	O
anergized	O
as	O
compared	O
with	O
activated	O
cells	O
.	O

In	O
contrast	O
,	O
anergic	B-cell_type
T	I-cell_type
cells	I-cell_type
express	O
approximately	O
eightfold	O
lower	O
amounts	O
of	O
NF-AT	B-protein
,	O
a	O
member	O
of	O
the	O
class	O
of	O
inducible	B-protein
factors	I-protein
that	O
regulates	O
IL-2	B-DNA
gene	I-DNA
transcription	O
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

The	O
number	O
of	O
glucocorticoid	B-protein
receptors	I-protein
in	O
peripheral	B-cell_type
human	I-cell_type
lymphocytes	I-cell_type
is	O
elevated	O
by	O
a	O
zinc	O
containing	O
trace	O
element	O
preparation	O
.	O

A	O
trace	O
element	O
preparation	O
(	O
Beres	O
Drops	O
Plus	O
,	O
BDP	O
)	O
elevates	O
the	O
number	O
of	O
glucocorticoid	B-protein
receptors	I-protein
(	O
gcR	B-protein
)	O
in	O
peripheral	B-cell_type
lymphocytes	I-cell_type
isolated	O
both	O
from	O
healthy	O
blood	O
donors	O
and	O
rheumatoid	O
arthritis	O
patients	O
.	O

This	O
enhancement	O
by	O
BDP	O
was	O
found	O
either	O
for	O
constitutive	O
expression	O
of	O
gcRs	B-protein
or	O
in	O
experiments	O
when	O
the	O
lymphocytes	B-cell_type
were	O
stimulated	O
by	O
interleukin	B-protein
(	I-protein
IL	I-protein
)	I-protein
-6	I-protein
.	O

There	O
was	O
no	O
significant	O
effect	O
of	O
BDP	O
on	O
IL-1	B-protein
and	O
tumour	B-protein
necrosis	I-protein
factor	I-protein
alpha	I-protein
(	O
TNF	B-protein
alpha	I-protein
)	O
-induced	O
changes	O
of	O
gcRs	B-protein
.	O

The	O
effect	O
of	O
BDP	O
was	O
greatly	O
dependent	O
on	O
the	O
presence	O
of	O
Zn++	O
ions	O
in	O
the	O
preparation	O
,	O
since	O
the	O
augmenting	O
effect	O
was	O
abolished	O
if	O
BDP	O
did	O
not	O
contain	O
zinc	O
.	O

The	O
DNA	O
and	O
steroid	B-protein
binding	I-protein
domains	I-protein
of	O
the	O
glucocorticoid	B-protein
receptor	I-protein
are	O
not	O
altered	O
in	O
mononuclear	B-cell_type
cells	I-cell_type
of	O
treated	O
CLL	O
patients	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
whether	O
mutations	O
in	O
the	O
glucocorticoid	B-protein
receptor	I-protein
could	O
account	O
for	O
the	O
increasing	O
unresponsiveness	O
of	O
patients	O
with	O
chronic	O
lymphatic	O
leukemia	O
(	O
CLL	O
)	O
to	O
combination	O
chemotherapy	O
.	O

The	O
receptor	O
was	O
tested	O
immunocytochemically	O
,	O
in	O
steroid	O
binding	O
assays	O
,	O
and	O
by	O
a	O
mutation	O
screening	O
(	O
denaturing	O
gradient	O
gel	O
electrophoresis	O
)	O
of	O
the	O
receptor-cDNA	B-protein
.	O

The	O
receptor	O
concentration	O
,	O
as	O
measured	O
by	O
staining	O
and	O
steroid	O
binding	O
test	O
,	O
varied	O
considerably	O
but	O
showed	O
no	O
clear	O
correlation	O
to	O
clinical	O
response	O
.	O

Using	O
a	O
highly	O
sensitive	O
mutation	O
screening	O
assay	O
of	O
the	O
DNA-	B-protein
and	I-protein
the	I-protein
steroid-binding	I-protein
region	I-protein
,	O
none	O
of	O
the	O
treated	O
patients	O
revealed	O
any	O
mutation	O
,	O
suggesting	O
that	O
the	O
glucocorticoid	B-protein
receptor	I-protein
in	O
the	O
CLL	O
patients	O
tested	O
is	O
not	O
altered	O
in	O
these	O
domains	O
.	O

In	O
one	O
individual	O
who	O
had	O
not	O
been	O
treated	O
before	O
analysis	O
a	O
silent	O
mutation	O
was	O
found	O
in	O
one	O
receptor	O
allele	O
.	O

The	O
results	O
suggest	O
that	O
mechanisms	O
other	O
than	O
altered	O
ligand	O
or	O
DNA	O
binding	O
of	O
the	O
receptor	O
may	O
be	O
responsible	O
for	O
the	O
lack	O
of	O
response	O
to	O
chemotherapy	O
.	O

This	O
conclusion	O
is	O
discussed	O
in	O
relation	O
to	O
the	O
mechanism	O
of	O
corticoid	O
resistance	O
in	O
mouse	B-cell_line
and	I-cell_line
human	I-cell_line
lymphoma	I-cell_line
cells	I-cell_line
in	O
culture	O
.	O

An	O
AP1	B-DNA
binding	I-DNA
site	I-DNA
upstream	O
of	O
the	O
kappa	B-DNA
immunoglobulin	I-DNA
intron	I-DNA
enhancer	I-DNA
binds	O
inducible	B-protein
factors	I-protein
and	O
contributes	O
to	O
expression	O
.	O

Expression	O
of	O
the	O
kappa	O
immunoglobulin	O
light	O
chain	O
gene	O
requires	O
developmental-	O
and	O
tissue-specific	O
regulation	O
by	O
trans-acting	B-protein
factors	I-protein
which	O
interact	O
with	O
two	O
distinct	O
enhancer	B-DNA
elements	I-DNA
.	O

A	O
new	O
protein-DNA	O
interaction	O
has	O
been	O
identified	O
upstream	O
of	O
the	O
intron	B-DNA
enhancer	I-DNA
,	O
within	O
the	O
matrix-associated	B-DNA
region	I-DNA
of	O
the	O
J-C	B-DNA
intron	I-DNA
.	O

The	O
binding	O
activity	O
is	O
greatly	O
inducible	O
in	O
pre-B	B-cell_type
cells	I-cell_type
by	O
bacterial	O
lipopolysaccharide	O
and	O
interleukin-1	B-protein
but	O
specific	O
complexes	O
are	O
found	O
at	O
all	O
stages	O
of	O
B	O
cell	O
development	O
tested	O
.	O

The	O
footprinted	B-DNA
binding	I-DNA
site	I-DNA
is	O
homologous	O
to	O
the	O
consensus	B-DNA
AP1	I-DNA
motif	I-DNA
.	O

The	O
protein	O
components	O
of	O
this	O
complex	O
are	O
specifically	O
competed	O
by	O
an	O
AP1	B-DNA
consensus	I-DNA
motif	I-DNA
and	O
were	O
shown	O
by	O
supershift	O
to	O
include	O
c-Jun	B-protein
and	O
c-Fos	B-protein
,	O
suggesting	O
that	O
this	O
binding	B-DNA
site	I-DNA
is	O
an	O
AP1	B-DNA
motif	I-DNA
and	O
that	O
the	O
Jun	B-protein
and	I-protein
Fos	I-protein
families	I-protein
of	O
transcription	B-protein
factors	I-protein
play	O
a	O
role	O
in	O
the	O
regulation	O
of	O
the	O
kappa	B-DNA
light	I-DNA
chain	I-DNA
gene	I-DNA
.	O

Mutation	O
of	O
the	O
AP1	B-DNA
motif	I-DNA
in	O
the	O
context	O
of	O
the	O
intron	B-DNA
enhancer	I-DNA
was	O
shown	O
to	O
decrease	O
enhancer-mediated	O
activation	O
of	O
the	O
promoter	O
in	O
both	O
pre-B	B-cell_type
cells	I-cell_type
induced	O
with	O
LPS	O
and	O
constitutive	O
expression	O
in	O
mature	B-cell_type
B	I-cell_type
cells	I-cell_type
.	O

Distinct	O
DNase-I	B-DNA
hypersensitive	I-DNA
sites	I-DNA
are	O
associated	O
with	O
TAL-1	B-protein
transcription	O
in	O
erythroid	B-cell_line
and	I-cell_line
T-cell	I-cell_line
lines	I-cell_line
.	O

The	O
tal-1	B-DNA
gene	I-DNA
,	O
frequently	O
activated	O
in	O
human	O
T-cell	O
acute	O
lymphoblastic	O
leukemia	O
(	O
T-ALL	O
)	O
,	O
is	O
expressed	O
in	O
the	O
erythroid	B-cell_type
,	I-cell_type
megakaryocytic	I-cell_type
,	I-cell_type
and	I-cell_type
mast	I-cell_type
cell	I-cell_type
lineages	I-cell_type
during	O
normal	O
hematopoiesis	O
.	O

To	O
gain	O
further	O
insight	O
into	O
the	O
molecular	O
mechanisms	O
that	O
control	O
tal-1	B-DNA
expression	O
,	O
we	O
investigated	O
tal-1	B-DNA
chromatin	O
structure	O
in	O
erythroid/megakaryocytic	B-cell_line
cell	I-cell_line
lines	I-cell_line
and	O
in	O
T-cell	B-cell_line
lines	I-cell_line
either	O
with	O
or	O
without	O
tal-1	B-DNA
rearrangements	I-DNA
.	O

Tal-1	O
transcription	O
was	O
shown	O
to	O
be	O
monoallelic	O
in	O
Jurkat	B-cell_line
,	O
a	O
T-cell	O
line	O
that	O
expresses	O
tal-1	B-DNA
in	O
the	O
absence	O
of	O
apparent	O
genomic	O
alteration	O
of	O
the	O
locus	O
.	O

Methylation	O
studies	O
indicated	O
that	O
the	O
tal-15	B-DNA
'	I-DNA
GC-rich	I-DNA
region	I-DNA
behaves	O
like	O
a	O
CpG	B-DNA
island	I-DNA
,	O
hypomethylated	O
in	O
normal	B-cell_type
cells	I-cell_type
,	O
and	O
methylated	O
de	O
novo	O
on	O
transcriptionally	B-DNA
inactive	I-DNA
alleles	I-DNA
in	O
established	B-cell_line
cell	I-cell_line
lines	I-cell_line
.	O

Five	O
major	O
DNase-I	B-DNA
hypersensitive	I-DNA
sites	I-DNA
(	O
HS	B-DNA
)	O
were	O
mapped	O
in	O
the	O
tal-1	B-DNA
locus	O
.	O

HS	B-DNA
I	I-DNA
,	I-DNA
IV	I-DNA
,	I-DNA
and	I-DNA
V	I-DNA
were	O
exclusively	O
observed	O
in	O
the	O
erythroid/megakaryocytic	B-cell_line
cell	I-cell_line
lines	I-cell_line
that	O
express	O
tal-1	B-DNA
from	O
the	O
promoters	B-DNA
1a	I-DNA
and	I-DNA
1b	I-DNA
.	O

HS	B-DNA
II	I-DNA
was	O
weak	O
in	O
hematopoietic	B-cell_line
cell	I-cell_line
lines	I-cell_line
,	O
absent	O
in	O
Hela	B-cell_line
,	O
and	O
greatly	O
enhanced	O
in	O
Jurkat	B-cell_line
,	O
suggesting	O
that	O
this	O
region	O
might	O
be	O
implicated	O
in	O
the	O
cis-activation	O
of	O
tal-1	B-DNA
promoter	I-DNA
1b	I-DNA
in	O
this	O
cell	O
line	O
.	O

HS	B-DNA
III	I-DNA
was	O
weak	O
in	O
HEL	B-cell_line
and	O
Jurkat	B-cell_line
,	O
and	O
greatly	O
enhanced	O
in	O
DU528	B-cell_line
,	O
a	O
T-cell	B-cell_line
line	I-cell_line
that	O
bears	O
a	B-DNA
t	I-DNA
(	I-DNA
1	I-DNA
;	I-DNA
14	I-DNA
)	I-DNA
and	O
initiates	O
tal-1	B-DNA
transcription	O
within	O
exon	B-DNA
4	I-DNA
.	O

These	O
results	O
suggest	O
that	O
distinct	O
regulatory	B-DNA
elements	I-DNA
are	O
associated	O
with	O
the	O
use	O
of	O
the	O
different	O
tal-1	B-DNA
promoters	I-DNA
.	O

Erythropoietin	B-protein
-dependent	O
induction	O
of	O
hemoglobin	B-protein
synthesis	O
in	O
a	O
cytokine-dependent	B-cell_line
cell	I-cell_line
line	I-cell_line
M-TAT	B-cell_line
.	O

M-TAT	B-cell_line
is	O
a	O
cytokine-dependent	B-cell_line
cell	I-cell_line
line	I-cell_line
with	O
the	O
potential	O
to	O
differentiate	O
along	O
the	O
erythroid	B-cell_type
and	I-cell_type
megakaryocytic	I-cell_type
lineages	I-cell_type
.	O

We	O
cultured	O
M-TAT	B-cell_line
cells	I-cell_line
long	O
term	O
(	O
>	O
1	O
year	O
)	O
in	O
the	O
continuous	O
presence	O
of	O
erythropoietin	B-protein
(	O
EPO	B-protein
)	O
,	O
granulocyte-macrophage	B-protein
colony-stimulating	I-protein
factor	I-protein
(	O
GM-CSF	B-protein
)	O
,	O
or	O
stem	B-protein
cell	I-protein
factor	I-protein
(	O
SCF	B-protein
)	O
.	O

These	O
long	O
term	O
cultures	O
are	O
referred	O
to	O
as	O
M-TAT/EPO	B-cell_line
,	I-cell_line
M-TAT/GM-CSF	I-cell_line
,	I-cell_line
and	I-cell_line
M-TAT/SCF	I-cell_line
cells	I-cell_line
,	O
respectively	O
.	O

Hemoglobin	B-protein
concentration	O
and	O
gamma-globin	B-protein
and	O
erythroid	B-RNA
delta-aminolevulinate	I-RNA
synthase	I-RNA
mRNA	I-RNA
levels	O
were	O
significantly	O
higher	O
in	O
M-TAT/EPO	B-cell_line
cells	I-cell_line
than	O
in	O
M-TAT/GM-CSF	B-cell_line
cells	I-cell_line
.	O

When	O
the	O
supplemented	O
cytokine	B-protein
was	O
switched	O
from	O
GM-CSF	B-protein
to	O
EPO	B-protein
,	O
hemoglobin	B-protein
synthesis	O
in	O
M-TAT/GM-CSF	B-cell_line
cells	I-cell_line
increased	O
rapidly	O
(	O
within	O
5	O
h	O
)	O
,	O
and	O
the	O
level	O
of	O
GATA-1	B-RNA
mRNA	I-RNA
increased	O
.	O

In	O
contrast	O
,	O
the	O
addition	O
of	O
GM-CSF	B-protein
to	O
the	O
M-TAT/EPO	B-cell_line
cell	I-cell_line
culture	I-cell_line
decreased	O
the	O
amount	O
of	O
hemoglobin	O
,	O
even	O
in	O
the	O
presence	O
of	O
EPO	B-protein
,	O
indicating	O
that	O
the	O
EPO	B-protein
signal	O
for	O
erythroid	O
differentiation	O
is	O
suppressed	O
by	O
GM-CSF	B-protein
.	O

Thus	O
,	O
erythroid	O
development	O
of	O
M-TAT	B-cell_line
cells	I-cell_line
is	O
promoted	O
by	O
EPO	B-protein
and	O
suppressed	O
by	O
GM-CSF	B-protein
.	O

These	O
results	O
support	O
the	O
hypothesis	O
that	O
EPO	B-protein
actively	O
influences	O
the	O
programming	O
of	O
gene	O
expression	O
required	O
for	O
erythroid	B-cell_type
progenitor	I-cell_type
cell	I-cell_type
differentiation	O
.	O

The	O
role	O
of	O
cellular	B-protein
transcription	I-protein
factor	I-protein
E2F	I-protein
in	O
the	O
regulation	O
of	O
cdc2	B-RNA
mRNA	I-RNA
expression	O
and	O
cell	O
cycle	O
control	O
of	O
human	O
hematopoietic	B-cell_type
cells	I-cell_type
.	O

cdc2	B-RNA
mRNA	I-RNA
transcripts	I-RNA
were	O
detected	O
in	O
immature	B-cell_type
bone	I-cell_type
marrow	I-cell_type
cells	I-cell_type
and	O
became	O
undetectable	O
along	O
with	O
differentiation	O
.	O

Peripheral	B-cell_type
blood	I-cell_type
resting	I-cell_type
cells	I-cell_type
did	O
not	O
express	O
cdc2	B-RNA
mRNA	I-RNA
,	O
but	O
it	O
was	O
induced	O
in	O
T-lymphocytes	B-cell_type
when	O
the	O
cells	O
reentered	O
the	O
cell	O
cycle	O
in	O
response	O
to	O
specific	O
mitogens	O
.	O

In	O
contrast	O
,	O
cdc2	B-RNA
mRNA	I-RNA
could	O
not	O
be	O
induced	O
in	O
granulocytes	B-cell_type
and	O
monocytes	B-cell_type
even	O
after	O
the	O
culture	O
with	O
the	O
appropriate	O
stimulants	O
.	O

In	O
order	O
to	O
investigate	O
the	O
mechanism	O
of	O
the	O
regulation	O
of	O
cdc2	B-RNA
mRNA	I-RNA
expression	O
in	O
hematopoietic	B-cell_type
cells	I-cell_type
,	O
we	O
isolated	O
the	O
5'-flanking	B-DNA
sequence	I-DNA
of	O
the	O
cdc2	B-DNA
gene	I-DNA
and	O
found	O
the	O
putative	O
E2F	O
binding	B-DNA
site	I-DNA
at	O
the	O
position	O
of	O
nucleotides	B-DNA
-124	I-DNA
to	I-DNA
-117	I-DNA
.	O

The	O
binding	O
of	O
E2F	B-protein
at	O
this	O
region	O
was	O
detected	O
by	O
a	O
gel-retardation	O
assay	O
and	O
DNaseI	B-protein
footprinting	O
in	O
phytohemagglutinin-stimulated	B-cell_line
T-lymphocytes	I-cell_line
,	O
which	O
was	O
coincident	O
with	O
the	O
expression	O
of	O
cdc2	B-RNA
mRNA	I-RNA
.	O

E2F	B-protein
binding	O
was	O
not	O
observed	O
in	O
both	O
granulocytes	B-cell_type
and	O
monocytes	B-cell_type
.	O

Transient	O
chloramphenicol	B-protein
acetyltransferase	I-protein
assay	O
revealed	O
that	O
the	O
region	O
containing	O
E2F	B-DNA
binding	I-DNA
site	I-DNA
had	O
a	O
strong	O
promoter	O
activity	O
,	O
and	O
introduction	O
of	O
the	O
mutation	O
at	O
the	O
E2F	B-DNA
binding	I-DNA
site	I-DNA
resulted	O
in	O
a	O
significant	O
loss	O
of	O
the	O
activity	O
.	O

E2F-1	B-RNA
and	I-RNA
DP-1	I-RNA
mRNAs	I-RNA
were	O
not	O
detectable	O
in	O
granulocytes	B-cell_type
,	O
monocytes	B-cell_type
and	O
resting	B-cell_type
T-lymphocytes	I-cell_type
but	O
were	O
induced	O
after	O
the	O
mitogenic	O
stimulation	O
of	O
T-lymphocytes	B-cell_type
.	O

The	O
induction	O
of	O
E2F	B-protein
activity	O
preceded	O
the	O
appearance	O
of	O
cdc2	B-RNA
mRNA	I-RNA
,	O
which	O
is	O
consistent	O
with	O
the	O
role	O
of	O
E2F	B-protein
in	O
the	O
regulation	O
of	O
cdc2	B-cell_type
mRNA	I-cell_type
expression	I-cell_type
.	O

These	O
results	O
suggest	O
that	O
cdc2	B-RNA
mRNA	I-RNA
expression	O
is	O
related	O
to	O
the	O
cell	O
cycling	O
of	O
normal	B-cell_type
human	I-cell_type
hematopoietic	I-cell_type
cells	I-cell_type
and	O
that	O
E2F	B-protein
plays	O
some	O
roles	O
in	O
the	O
regulation	O
of	O
its	O
expression	O
.	O

Association	O
of	O
alterations	O
in	O
NF-kappa	B-protein
B	I-protein
moieties	I-protein
with	O
HIV	O
type	O
1	O
proviral	O
latency	O
in	O
certain	O
monocytic	B-cell_type
cells	I-cell_type
.	O

Human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
replication	O
is	O
controlled	O
by	O
a	O
complex	O
array	O
of	O
virally	B-protein
encoded	I-protein
and	I-protein
cellular	I-protein
proteins	I-protein
.	O

A	O
wide	O
spectrum	O
of	O
levels	O
of	O
HIV-1	O
expression	O
have	O
been	O
demonstrated	O
in	O
various	O
cells	O
,	O
both	O
in	O
cell	O
culture	O
and	O
in	O
vivo	O
.	O

Molecular	O
mechanisms	O
leading	O
to	O
restricted	O
HIV-1	O
replication	O
may	O
differ	O
between	O
certain	O
cell	O
types	O
.	O

It	O
is	O
now	O
demonstrated	O
that	O
HIV-1	O
proviral	O
latency	O
in	O
the	O
monocytic	B-cell_line
cell	I-cell_line
line	I-cell_line
U1	I-cell_line
,	O
in	O
which	O
only	O
extremely	O
low	O
levels	O
of	O
HIV-1	O
expression	O
are	O
detected	O
in	O
the	O
baseline	O
unstimulated	O
state	O
,	O
is	O
associated	O
with	O
alterations	O
in	O
nuclear	O
factor-kappa	B-protein
B	I-protein
(	I-protein
NF-kappa	I-protein
B	I-protein
)	I-protein
moieties	I-protein
demonstrated	O
in	O
these	O
cells	O
by	O
electrophoretic	O
mobility	O
shift	O
assays	O
(	O
EMSAs	O
)	O
and	O
in	O
situ	O
UV	O
cross-linking	O
studies	O
.	O

A	O
predominance	O
of	O
p50	B-protein
NF-kappa	I-protein
B	I-protein
moieties	I-protein
and	O
possibly	O
p50	B-protein
homodimers	I-protein
or	O
closely	O
related	O
species	O
,	O
rather	O
than	O
the	O
p50-p56	B-protein
heterodimer	I-protein
of	O
NF-kappa	B-protein
B	I-protein
that	O
is	O
the	O
predominant	O
NF-kappa	B-protein
B	I-protein
species	O
in	O
most	O
T	B-cell_type
lymphocytic	I-cell_type
and	I-cell_type
monocytic	I-cell_type
cells	I-cell_type
,	O
is	O
demonstrated	O
in	O
the	O
nuclei	O
of	O
U1	B-cell_line
cells	I-cell_line
.	O

This	O
pattern	O
of	O
NF-kappa	B-protein
B-related	I-protein
moieties	I-protein
differs	O
from	O
the	O
latently	B-cell_line
infected	I-cell_line
T	I-cell_line
lymphocytic	I-cell_line
cell	I-cell_line
line	I-cell_line
ACH-2	I-cell_line
,	O
and	O
from	O
the	O
U937	B-cell_line
monocytic	I-cell_line
line	I-cell_line
,	O
the	O
parental	B-cell_line
cell	I-cell_line
line	I-cell_line
of	O
the	O
U1	B-cell_line
cellular	I-cell_line
clone	I-cell_line
.	O

As	O
such	O
,	O
these	O
data	O
suggest	O
that	O
different	O
proximal	O
mechanisms	O
may	O
lead	O
to	O
restricted	O
HIV-1	O
replication	O
in	O
various	O
cell	O
types	O
.	O

[	O
Regulation	O
of	O
transcription	O
of	O
the	O
interleukin-2	B-DNA
gene	I-DNA
in	O
B-lymphocytes	B-cell_type
]	O

Since	O
most	O
B	B-cell_line
cell	I-cell_line
clones	I-cell_line
immortalized	O
with	O
EBV	O
virus	O
can	O
be	O
induced	O
to	O
produce	O
interleukin-2	B-protein
,	O
a	O
typical	O
T	B-protein
cell	I-protein
cytokine	I-protein
,	O
we	O
studied	O
the	O
role	O
of	O
different	O
elements	O
of	O
the	O
IL-2	B-DNA
promoter	I-DNA
in	O
such	O
clones	O
by	O
transfection	O
.	O

It	O
was	O
found	O
,	O
in	O
particular	O
,	O
that	O
the	O
element	O
TCEd	B-DNA
,	O
which	O
binds	O
the	O
transcription	B-protein
factor	I-protein
NF-kB	B-protein
,	O
is	O
very	O
active	O
in	O
all	O
three	O
B	B-cell_line
clones	I-cell_line
tested	O
.	O

This	O
element	O
has	O
no	O
activity	O
in	O
T	B-cell_type
cells	I-cell_type
of	O
the	O
Jurkat	B-cell_line
line	I-cell_line
.	O

The	O
NFATd	B-DNA
element	I-DNA
,	O
which	O
binds	O
the	O
transcription	B-protein
factor	I-protein
NFAT-1	B-protein
and	O
is	O
very	O
active	O
in	O
T	B-cell_type
cells	I-cell_type
,	O
is	O
only	O
weakly	O
active	O
in	O
one	O
B	B-cell_line
clone	I-cell_line
and	O
not	O
at	O
all	O
in	O
another	O
.	O

Different	O
elements	O
thus	O
contribute	O
to	O
IL-2	B-DNA
promoter	I-DNA
activity	O
in	O
different	O
cells	O
.	O

Regulation	O
of	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
and	O
p105	B-protein
in	O
monocytes	B-cell_type
and	O
macrophages	B-cell_type
persistently	O
infected	O
with	O
human	O
immunodeficiency	O
virus	O
.	O

The	O
mechanisms	O
regulating	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
persistence	O
in	O
human	O
monocytes	B-cell_type
/macrophages	B-cell_type
are	O
partially	O
understood	O
.	O

Persistent	O
HIV	O
infection	O
of	O
U937	B-cell_line
monocytic	I-cell_line
cells	I-cell_line
results	O
in	O
NF-kappa	B-protein
B	I-protein
activation	O
.	O

Whether	O
virus-induced	O
NF-kappa	B-protein
B	I-protein
activation	O
is	O
a	O
mechanism	O
that	O
favors	O
continuous	O
viral	O
replication	O
in	O
macrophages	B-cell_type
remains	O
unknown	O
.	O

To	O
further	O
delineate	O
the	O
molecular	O
mechanisms	O
involved	O
in	O
the	O
activation	O
of	O
NF-kappa	B-protein
B	I-protein
in	O
HIV-infected	O
monocytes	B-cell_type
and	O
macrophages	B-cell_type
,	O
we	O
have	O
focused	O
on	O
the	O
regulation	O
of	O
the	O
I	O
kappa	O
B	O
molecules	O
.	O

First	O
,	O
we	O
show	O
that	O
persistent	O
HIV	O
infection	O
results	O
in	O
the	O
activation	O
of	O
NF-kappa	O
B	O
not	O
only	O
in	O
monocytic	O
cells	O
but	O
also	O
in	O
macrophages	B-cell_type
.	O

In	O
HIV-infected	O
cells	O
,	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
protein	O
levels	O
are	O
decreased	O
secondary	O
to	O
enhanced	O
protein	O
degradation	O
.	O

This	O
parallels	O
the	O
increased	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
synthesis	O
secondary	O
to	O
increased	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
gene	O
transcription	O
,	O
i.e.	O
,	O
increased	O
RNA	O
and	O
transcriptional	O
activity	O
of	O
its	O
promoter-enhancer	O
.	O

Another	O
protein	O
with	O
I	O
kappa	O
B	O
function	O
,	O
p105	B-protein
,	O
is	O
also	O
modified	O
in	O
HIV-infected	O
cells	O
:	O
p105	B-protein
and	O
p50	B-protein
steady-state	O
protein	O
levels	O
are	O
increased	O
as	O
a	O
result	O
of	O
increased	O
synthesis	O
and	O
proteolytic	O
processing	O
of	O
p105	B-protein
.	O

Transcriptional	O
activity	O
of	O
p105	B-protein
is	O
also	O
increased	O
in	O
infected	B-cell_type
cells	I-cell_type
and	O
is	O
also	O
mediated	O
by	O
NF-kappa	B-protein
B	I-protein
through	O
a	O
specific	O
kappa	B-DNA
B	I-DNA
motif	I-DNA
.	O

These	O
results	O
demonstrate	O
the	O
existence	O
of	O
a	O
triple	O
autoregulatory	O
loop	O
in	O
monocytes	B-cell_type
and	O
macrophages	B-cell_type
involving	O
HIV	O
,	O
p105	B-protein
and	O
p50	B-protein
,	O
and	O
MAD3	B-protein
,	O
with	O
the	O
end	O
result	O
of	O
persistent	O
NF-kappa	O
B	O
activation	O
and	O
viral	O
persistence	O
.	O

Furthermore	O
,	O
persistent	O
HIV	O
infection	O
of	O
monocytes	B-cell_type
and	O
macrophages	B-cell_type
provides	O
a	O
useful	O
model	O
with	O
which	O
to	O
study	O
concomitant	O
modifications	O
of	O
different	O
I	B-protein
kappa	I-protein
B	I-protein
molecules	I-protein
.	O

Glucocorticoid-induced	O
apoptosis	O
of	O
human	B-cell_type
leukemic	I-cell_type
cells	I-cell_type
is	O
caused	O
by	O
the	O
repressive	O
function	O
of	O
the	O
glucocorticoid	B-protein
receptor	I-protein
.	O

Induction	O
of	O
apoptosis	O
in	O
lymphocytes	B-cell_type
,	O
which	O
may	O
account	O
for	O
the	O
therapeutic	O
effects	O
of	O
glucocorticoids	O
in	O
various	O
diseases	O
including	O
leukemia	O
,	O
depends	O
on	O
the	O
glucocorticoid	B-protein
receptor	I-protein
.	O

However	O
,	O
the	O
events	O
leading	O
from	O
the	O
activated	O
receptor	O
to	O
cell	O
lysis	O
are	O
not	O
understood	O
.	O

A	O
prevailing	O
hypothesis	O
postulates	O
induction	O
of	O
so-called	O
'	O
lysis	B-DNA
genes	I-DNA
'	O
by	O
the	O
activated	B-protein
receptor	I-protein
.	O

In	O
this	O
study	O
,	O
we	O
show	O
that	O
an	O
activation-deficient	B-protein
glucocorticoid	I-protein
receptor	I-protein
mutant	I-protein
is	O
as	O
effective	O
as	O
the	O
wild-type	B-protein
receptor	I-protein
in	O
repression	O
of	O
AP-1	B-protein
activity	O
,	O
inhibition	O
of	O
interleukin-2	B-protein
production	O
,	O
inhibition	O
of	O
c-myc	B-DNA
expression	O
and	O
induction	O
of	O
apoptosis	O
.	O

Furthermore	O
,	O
we	O
show	O
that	O
retinoic	O
acid	O
can	O
also	O
induce	O
apoptosis	O
in	O
these	O
cells	O
through	O
the	O
retinoic	B-protein
acid	I-protein
receptor	I-protein
,	O
whose	O
repressive	O
functions	O
but	O
not	O
target	O
site	O
specificity	O
,	O
are	O
similar	O
to	O
those	O
of	O
the	O
glucocorticoid	B-protein
receptor	I-protein
.	O

Therefore	O
,	O
the	O
primary	O
effect	O
of	O
the	O
receptor	O
in	O
glucocorticoid-mediated	O
apoptosis	O
correlates	O
with	O
transcriptional	O
repression	O
rather	O
than	O
activation	O
and	O
could	O
be	O
mediated	O
by	O
interference	O
with	O
other	O
transcription	B-protein
factors	I-protein
required	O
for	O
cell	O
survival	O
.	O

HIV	O
type	O
1	O
protease	B-protein
activation	O
of	O
NF-kappa	B-protein
B	I-protein
within	O
T	B-cell_type
lymphoid	I-cell_type
cells	I-cell_type
.	O

NF-kappa	B-protein
B	I-protein
is	O
a	O
nuclear	B-protein
protein	I-protein
of	O
the	O
rel	B-protein
oncogene	I-protein
family	I-protein
capable	O
of	O
enhancing	O
transcription	O
of	O
several	B-DNA
cellular	I-DNA
genes	I-DNA
,	O
including	O
IL-2	B-protein
and	O
the	O
IL-2	B-protein
receptor	I-protein
,	O
and	O
viral	B-DNA
genes	I-DNA
transcribed	O
from	O
the	O
HIV-1	B-DNA
LTR	I-DNA
.	O

It	O
has	O
been	O
reported	O
that	O
HIV-1	B-protein
protease	I-protein
may	O
cleave	O
the	O
NF-kappa	B-protein
B	I-protein
precursor	O
to	O
its	O
active	O
form	O
in	O
vitro	O
.	O

In	O
this	O
study	O
the	O
effects	O
of	O
HIV	O
protease	O
on	O
NF-kappa	B-protein
B	I-protein
precursor	O
activation	O
were	O
examined	O
in	O
Jurkat	O
T	B-cell_type
cells	I-cell_type
by	O
introducing	O
a	O
protease	B-DNA
expression	I-DNA
vector	I-DNA
into	O
the	O
cells	O
.	O

Increased	O
NF-kappa	B-protein
B	I-protein
activity	O
was	O
observed	O
and	O
this	O
increased	O
activity	O
was	O
blocked	O
by	O
a	O
specific	O
inhibitor	O
of	O
the	O
viral	B-protein
protease	I-protein
.	O

Viral	O
transcription	O
,	O
as	O
measured	O
using	O
LTR	B-DNA
-CAT	B-protein
assays	O
,	O
was	O
only	O
slightly	O
enhanced	O
in	O
the	O
HIV-protease	B-cell_type
expressing	I-cell_type
cells	I-cell_type
,	O
while	O
secretion	O
of	O
IL-2	B-protein
and	O
expression	O
of	O
the	O
IL-2	B-protein
receptor	O
were	O
not	O
affected	O
.	O

The	O
limited	O
activation	O
of	O
NF-kappa	B-protein
B	I-protein
by	O
HIV	B-protein
protease	I-protein
appears	O
unlikely	O
to	O
have	O
a	O
significant	O
effect	O
on	O
virus	O
expression	O
or	O
T	O
cell	O
function	O
.	O

Inhibition	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
replication	O
by	O
a	O
Tat-activated	B-DNA
,	I-DNA
transduced	I-DNA
interferon	I-DNA
gene	I-DNA
:	O
targeted	O
expression	O
to	O
human	B-cell_type
immunodeficiency	I-cell_type
virus	I-cell_type
type	I-cell_type
1-infected	I-cell_type
cells	I-cell_type
.	O

We	O
have	O
examined	O
the	O
feasibility	O
of	O
using	O
interferon	B-protein
(	O
IFN	B-protein
)	O
gene	O
transfer	O
as	O
a	O
novel	O
approach	O
to	O
anti-human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
therapy	O
in	O
this	O
study	O
.	O

To	O
limit	O
expression	O
of	O
a	O
transduced	O
HIV-1	B-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
(	I-DNA
LTR	I-DNA
)	I-DNA
-IFNA2	I-DNA
(	O
the	O
new	O
approved	O
nomenclature	O
for	O
IFN	B-DNA
genes	I-DNA
is	O
used	O
throughout	O
this	O
article	O
)	O
hybrid	B-DNA
gene	I-DNA
to	O
the	O
HIV-1-infected	B-cell_line
cells	I-cell_line
,	O
HIV-1	B-DNA
LTR	I-DNA
was	O
modified	O
.	O

Deletion	O
of	O
the	O
NF-kappa	B-DNA
B	I-DNA
elements	I-DNA
of	O
the	O
HIV-1	B-DNA
LTR	I-DNA
significantly	O
inhibited	O
Tat	B-protein
-mediated	O
transactivation	O
in	O
T-cell	B-cell_line
lines	I-cell_line
,	O
as	O
well	O
as	O
in	O
a	O
monocyte	B-cell_line
line	I-cell_line
,	O
U937	B-cell_line
.	O

Replacement	O
of	O
the	O
NF-kappa	B-DNA
B	I-DNA
elements	I-DNA
in	O
the	O
HIV-1	B-DNA
LTR	I-DNA
by	O
a	O
DNA	B-DNA
fragment	I-DNA
derived	O
from	O
the	O
5'-flanking	B-DNA
region	I-DNA
of	O
IFN-stimulated	B-DNA
gene	I-DNA
15	I-DNA
(	O
ISG15	B-DNA
)	O
,	O
containing	O
the	O
IFN-stimulated	B-DNA
response	I-DNA
element	I-DNA
,	O
partially	O
restored	O
Tat	B-protein
-mediated	O
activation	O
of	O
LTR	B-DNA
in	O
T	B-cell_type
cells	I-cell_type
as	O
well	O
as	O
in	O
monocytes	B-cell_type
.	O

Insertion	O
of	O
this	O
chimeric	B-DNA
promoter	I-DNA
(	O
ISG15	B-DNA
LTR	I-DNA
)	O
upstream	O
of	O
the	O
human	B-DNA
IFNA2	I-DNA
gene	I-DNA
directed	O
high	O
levels	O
of	O
IFN	B-protein
synthesis	O
in	O
Tat-expressing	B-cell_line
cells	I-cell_line
,	O
while	O
this	O
promoter	O
was	O
not	O
responsive	O
to	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
alpha	I-protein
-mediated	O
activation	O
.	O

ISG15-LTR-IFN	B-DNA
hybrid	I-DNA
gene	I-DNA
inserted	O
into	O
the	O
retrovirus	B-DNA
vector	I-DNA
was	O
transduced	O
into	O
Jurkat	B-cell_line
and	O
U937	B-cell_line
cells	I-cell_line
.	O

Selected	O
transfected	B-cell_line
clones	I-cell_line
produced	O
low	O
levels	O
of	O
IFN	B-protein
A	I-protein
(	O
IFNA	B-protein
)	O
constitutively	O
,	O
and	O
their	O
abilities	O
to	O
express	O
interleukin-2	B-protein
and	O
interleukin-2	B-protein
receptor	I-protein
upon	O
stimulation	O
with	O
phytohemagglutinin	B-protein
and	O
phorbol	O
myristate	O
acetate	O
were	O
retained	O
.	O

Enhancement	O
of	O
IFNA	B-protein
synthesis	O
observed	O
upon	O
HIV-1	O
infection	O
resulted	O
in	O
significant	O
inhibition	O
of	O
HIV-1	O
replication	O
for	O
a	O
period	O
of	O
at	O
least	O
30	O
days	O
.	O

Virus	O
isolated	O
from	O
IFNA-producing	B-cell_line
cells	I-cell_line
was	O
able	O
to	O
replicate	O
in	O
the	O
U937	B-cell_line
cells	I-cell_line
but	O
did	O
not	O
replicate	O
efficiently	O
in	O
U937	B-cell_line
cells	I-cell_line
transduced	O
with	O
the	O
IFNA	B-DNA
gene	I-DNA
.	O

These	O
results	O
suggest	O
that	O
targeting	O
IFN	B-protein
synthesis	O
to	O
HIV-1-infected	B-cell_line
cells	I-cell_line
is	O
an	O
attainable	O
goal	O
and	O
that	O
autocrine	O
IFN	B-protein
synthesis	O
results	O
in	O
a	O
long-lasting	O
and	O
permanent	O
suppression	O
of	O
HIV-1	O
replication	O
.	O

Chromosomal	O
localization	O
of	O
two	O
KOX	B-DNA
zinc	I-DNA
finger	I-DNA
genes	I-DNA
on	O
chromosome	B-DNA
bands	I-DNA
7q21-q22	B-DNA
.	O

Human	B-DNA
cDNAs	I-DNA
encoding	O
Kruppel-type	B-protein
zinc	I-protein
finger	I-protein
domains	I-protein
,	O
designated	O
KOX	B-DNA
1-32	I-DNA
,	O
have	O
been	O
cloned	O
from	O
human	B-DNA
T	I-DNA
lymphocyte	I-DNA
cell	I-DNA
line	I-DNA
libraries	I-DNA
.	O

We	O
report	O
here	O
the	O
regional	O
localizations	O
by	O
in	O
situ	O
hybridization	O
of	O
KOX	B-DNA
18	I-DNA
and	O
KOX	B-DNA
25	I-DNA
on	O
chromosome	B-DNA
bands	I-DNA
7q21q22	I-DNA
.	O

Pulse-field	O
gel	O
electrophoresis	O
(	O
PFGE	O
)	O
analysis	O
showed	O
that	O
these	O
genes	O
are	O
physically	O
located	O
within	O
a	O
DNA	B-DNA
fragment	I-DNA
of	O
250	B-DNA
kb	I-DNA
.	O

The	O
genes	O
KOX	B-DNA
4	I-DNA
and	O
KOX	B-DNA
9	I-DNA
,	O
mapped	O
on	O
chromosome	B-DNA
8q24	I-DNA
,	O
were	O
found	O
to	O
be	O
located	O
within	O
a	O
DNA	B-DNA
fragment	I-DNA
of	O
450	O
kb	O
.	O

From	O
the	O
present	O
and	O
previous	O
data	O
,	O
eighteen	O
different	O
KOX	B-DNA
genes	I-DNA
have	O
been	O
located	O
at	O
least	O
two	O
by	O
two	O
within	O
nine	O
DNA	B-DNA
fragments	I-DNA
of	O
200	O
to	O
580	O
kb	O
.	O

Influence	O
of	O
age	O
on	O
the	O
production	O
of	O
Fos	B-protein
and	O
Jun	B-protein
by	O
influenza	B-cell_type
virus-exposed	I-cell_type
T	I-cell_type
cells	I-cell_type
.	O

This	O
study	O
investigated	O
age-related	O
T	O
cell	O
responses	O
after	O
in	O
vitro	O
exposure	O
to	O
influenza	O
A	O
virus	O
.	O

Mononuclear	B-cell_type
leukocytes	I-cell_type
from	O
young	O
or	O
elderly	O
persons	O
were	O
sham-exposed	O
or	O
exposed	O
to	O
influenza	O
virus	O
for	O
1	O
,	O
24	O
,	O
and	O
72	O
h	O
.	O

Immunofluorescent	O
staining	O
and	O
flow	O
cytometric	O
analysis	O
were	O
then	O
used	O
to	O
detect	O
T	B-cell_type
cells	I-cell_type
producing	O
the	O
transcriptional	B-protein
regulating	I-protein
proteins	I-protein
Fos	B-protein
and	O
Jun	B-protein
.	O

Fewer	O
virus-exposed	O
cells	O
from	O
elderly	O
donors	O
stained	O
for	O
Fos	B-protein
and	O
Jun	B-protein
at	O
each	O
data	O
point	O
compared	O
with	O
cells	O
from	O
young	O
donors	O
.	O

Flow	O
cytometric	O
analysis	O
also	O
showed	O
that	O
at	O
72	O
h	O
of	O
virus	O
exposure	O
fewer	O
T	B-cell_type
cells	I-cell_type
from	O
the	O
elderly	O
produced	O
interferon-gamma	B-protein
(	O
IFN-gamma	B-protein
)	O
,	O
suggesting	O
a	O
link	O
between	O
the	O
magnitude	O
of	O
the	O
Fos	B-protein
and	O
Jun	B-protein
and	O
IFN-gamma	B-protein
responses	O
.	O

Thus	O
,	O
failure	O
of	O
virus-exposed	B-cell_type
T	I-cell_type
cells	I-cell_type
to	O
produce	O
Fos	B-protein
and	O
Jun	B-protein
could	O
contribute	O
to	O
the	O
increase	O
in	O
illness	O
due	O
to	O
influenza	O
virus	O
in	O
the	O
elderly	O
.	O

The	O
regulation	O
of	O
HIV	O
by	O
retinoic	O
acid	O
correlates	O
with	O
cellular	O
expression	O
of	O
the	O
retinoic	B-protein
acid	I-protein
receptors	I-protein
.	O

OBJECTIVES	O
:	O
To	O
analyze	O
the	O
effect	O
of	O
retinoic	O
acids	O
(	O
RA	O
)	O
on	O
HIV-1	O
expression	O
and	O
correlate	O
this	O
effect	O
with	O
expression	O
levels	O
of	O
RA	B-protein
receptors	I-protein
(	O
RARs	B-protein
)	O
in	O
T-lymphoid	B-cell_line
and	I-cell_line
monocytoid	I-cell_line
cell	I-cell_line
lines	I-cell_line
.	O

DESIGN	O
AND	O
METHODS	O
:	O
The	O
effect	O
of	O
all-trans	O
and	O
9-cis	O
RA	O
on	O
HIV-1	O
production	O
in	O
T-lymphoid	B-cell_line
(	O
H9	B-cell_line
,	I-cell_line
CEM	I-cell_line
)	O
and	O
monocytoid	B-cell_line
(	I-cell_line
U937	I-cell_line
,	I-cell_line
THP-1	I-cell_line
)	I-cell_line
cell	I-cell_line
lines	I-cell_line
was	O
measured	O
during	O
acute	O
and	O
chronic	O
infection	O
.	O

The	O
expression	O
levels	O
of	O
human	B-protein
RAR	I-protein
alpha	I-protein
(	O
hRAR	B-protein
alpha	I-protein
,	I-protein
receptor	I-protein
for	O
all-trans	O
RA	O
)	O
and	O
the	O
human	B-protein
retinoid-X	I-protein
receptor	I-protein
alpha	I-protein
(	O
hRXR	B-protein
alpha	I-protein
receptor	I-protein
for	O
9-cis	O
RA	O
)	O
were	O
determined	O
by	O
Northern	O
blot	O
analysis	O
.	O

RESULTS	O
:	O
Both	O
all-trans	O
and	O
9-cis	O
RA	O
inhibited	O
virus	O
replication	O
in	O
HIV-1	B-cell_line
IIIB-infected	I-cell_line
monocytoid	I-cell_line
cells	I-cell_line
,	O
in	O
the	O
presence	O
and	O
absence	O
of	O
the	O
co-stimulatory	O
agent	O
phorbol	O
myristate	O
acetate	O
(	O
PMA	O
)	O
.	O

The	O
retinoids	O
had	O
weak	O
or	O
no	O
stimulatory	O
effects	O
on	O
HIV	O
production	O
by	O
T-cell	B-cell_line
lines	I-cell_line
.	O

HIV	O
production	O
by	O
PMA-stimulated	B-cell_line
T-cell	I-cell_line
lines	I-cell_line
was	O
inhibited	O
by	O
these	O
retinoids	O
.	O

The	O
9-cis	O
RA	O
was	O
generally	O
more	O
effective	O
than	O
all-trans	O
RA	O
in	O
inhibiting	O
HIV	O
production	O
and	O
in	O
combination	O
generally	O
more	O
effective	O
than	O
the	O
single	O
agents	O
alone	O
.	O

Human	B-protein
RAR	I-protein
alpha	I-protein
was	O
expressed	O
in	O
H9	B-cell_line
,	O
U937	B-cell_line
and	O
THP-1	B-cell_line
cells	I-cell_line
,	O
but	O
almost	O
undetectable	O
in	O
CEM	B-cell_line
cells	I-cell_line
.	O

Human	B-protein
RXR	I-protein
alpha	I-protein
was	O
significantly	O
expressed	O
in	O
U937	B-cell_line
and	I-cell_line
THP-1	I-cell_line
cells	I-cell_line
,	O
weakly	O
expressed	O
in	O
H9	B-cell_line
cells	I-cell_line
and	O
not	O
detectable	O
in	O
CEM	B-cell_line
cells	I-cell_line
.	O

After	O
stimulation	O
by	O
PMA	O
,	O
RXR	B-protein
alpha	I-protein
expression	O
increased	O
in	O
H9	B-cell_line
and	O
U937	B-cell_line
cells	I-cell_line
but	O
not	O
in	O
CEM	B-cell_line
cells	I-cell_line
.	O

Human	O
RAR	O
alpha	O
expression	O
was	O
unchanged	O
in	O
H9	B-cell_line
and	O
CEM	B-cell_line
cells	I-cell_line
,	O
and	O
elevated	O
in	O
U937	B-cell_line
cells	I-cell_line
,	O
after	O
PMA	O
stimulation	O
.	O

CONCLUSION	O
:	O
The	O
effect	O
of	O
RA	O
on	O
HIV-1	O
expression	O
was	O
cell-type-dependent	O
and	O
partially	O
correlated	O
with	O
cellular	O
expression	O
of	O
RARs	B-protein
.	O

Endogenous	O
or	O
exogenously	O
administered	O
RA	O
may	O
have	O
a	O
significant	O
role	O
in	O
HIV	O
regulation	O
.	O

Functions	O
of	O
glutathione	O
and	O
glutathione	O
disulfide	O
in	O
immunology	O
and	O
immunopathology	O
.	O

Even	O
a	O
moderate	O
increase	O
in	O
the	O
cellular	O
cysteine	O
supply	O
elevates	O
the	O
intracellular	O
glutathione	O
(	O
GSH	O
)	O
and	O
glutathione	O
disulfide	O
(	O
GSSG	O
)	O
levels	O
and	O
potentiates	O
immunological	O
functions	O
of	O
lymphocytes	B-cell_type
in	O
vitro	O
.	O

At	O
low	O
GSSG	O
levels	O
,	O
T	B-cell_type
cells	I-cell_type
can	O
not	O
optimally	O
activate	O
the	O
immunologically	O
important	O
transcription	B-protein
factor	I-protein
NF	B-protein
kappa	I-protein
B	I-protein
,	O
whereas	O
high	O
GSSG	O
levels	O
inhibit	O
the	O
DNA	O
binding	O
activity	O
of	O
NF	B-protein
kappa	I-protein
B	I-protein
.	O

The	O
effects	O
of	O
GSSG	O
are	O
antagonized	O
by	O
reduced	O
thioredoxin	B-protein
(	O
TRX	B-protein
)	O
.	O

As	O
the	O
protein	B-protein
tyrosine	I-protein
kinase	I-protein
activities	O
p56lck	B-protein
and	O
p59fyn	B-protein
are	O
activated	O
in	O
intact	O
cells	O
by	O
hydrogen	O
peroxide	O
,	O
they	O
are	O
likely	O
targets	O
for	O
GSSG	O
action	O
.	O

These	O
redox-regulated	B-protein
enzymes	I-protein
trigger	O
signal	O
cascades	O
for	O
NF	B-protein
kappa	I-protein
B	I-protein
activation	O
and	O
transduce	O
signals	O
from	O
the	O
T	B-protein
cell	I-protein
antigen	I-protein
receptor	I-protein
,	O
from	O
CD4	B-protein
and	O
CD8	B-protein
molecules	I-protein
,	O
and	O
from	O
the	O
IL-2	B-protein
receptor	I-protein
beta-chain	I-protein
.	O

The	O
effector	O
phase	O
of	O
cytotoxic	B-cell_type
T	I-cell_type
cell	I-cell_type
responses	O
and	O
IL-2	B-protein
-dependent	O
functions	O
are	O
inhibited	O
even	O
by	O
a	O
partial	O
depletion	O
of	O
the	O
intracellular	O
GSH	O
pool	O
.	O

As	O
signal	O
transduction	O
is	O
facilitated	O
by	O
prooxidant	O
conditions	O
,	O
we	O
propose	O
that	O
the	O
well-known	O
immunological	O
consequences	O
of	O
GSH	O
depletion	O
ultimately	O
may	O
be	O
results	O
of	O
the	O
accompanying	O
GSSG	O
deficiency	O
.	O

As	O
HIV-infected	O
patients	O
and	O
SIV-infected	O
rhesus	O
macaques	O
have	O
,	O
on	O
the	O
average	O
,	O
significantly	O
decreased	O
plasma	O
cyst	O
(	O
e	O
)	O
ine	O
and	O
intracellular	O
GSH	O
levels	O
,	O
we	O
also	O
hypothesize	O
that	O
AIDS	O
may	O
be	O
the	O
consequence	O
of	O
a	O
GSSG	O
deficiency	O
as	O
well	O
.	O

T	B-cell_type
cells	I-cell_type
from	O
renal	O
cell	O
carcinoma	O
patients	O
exhibit	O
an	O
abnormal	O
pattern	O
of	O
kappa	O
B-specific	O
DNA-binding	O
activity	O
:	O
a	O
preliminary	O
report	O
.	O

Recent	O
data	O
suggest	O
that	O
the	O
poor	O
induction	O
of	O
a	O
T-cell	O
response	O
to	O
human	O
renal	O
cell	O
carcinoma	O
(	O
RCC	O
)	O
may	O
be	O
related	O
to	O
alterations	O
in	O
signal	O
transduction	O
pathways	O
.	O

We	O
report	O
that	O
T	B-cell_type
cells	I-cell_type
from	O
RCC	O
patients	O
have	O
two	O
alterations	O
in	O
kappa	O
B	O
motif-specific	O
DNA-binding	O
activity	O
.	O

The	O
first	O
alteration	O
involves	O
the	O
constitutive	O
expression	O
of	O
substantial	O
kappa	O
B-binding	O
activity	O
in	O
nuclear	O
extracts	O
,	O
which	O
was	O
observed	O
in	O
the	O
electrophoretic	O
mobility	O
shift	O
assay	O
.	O

The	O
magnitude	O
of	O
kappa	O
B	O
activity	O
in	O
unstimulated	B-cell_type
patient	I-cell_type
T	I-cell_type
cells	I-cell_type
was	O
similar	O
to	O
that	O
observed	O
in	O
T	B-cell_type
cells	I-cell_type
from	O
normal	O
individuals	O
that	O
had	O
been	O
activated	O
in	O
vitro	O
.	O

On	O
the	O
basis	O
of	O
Western	O
blotting	O
experiments	O
using	O
antibodies	B-protein
to	O
kappa	B-protein
B/Rel	I-protein
family	I-protein
proteins	I-protein
,	O
the	O
kappa	O
B-binding	O
activity	O
constitutively	O
expressed	O
in	O
T	B-cell_type
cells	I-cell_type
from	O
RCC	O
patients	O
is	O
composed	O
mostly	O
of	O
the	O
NF-kappa	B-protein
B1	I-protein
(	I-protein
p50	I-protein
)	I-protein
subunit	I-protein
.	O

The	O
second	O
abnormality	O
in	O
kappa	O
B-binding	O
activity	O
in	O
T	B-cell_type
cells	I-cell_type
from	O
these	O
patients	O
is	O
that	O
RelA	B-protein
,	O
a	O
member	O
of	O
the	O
Rel	B-protein
homology	I-protein
family	I-protein
which	O
is	O
part	O
of	O
the	O
normal	O
NF-kappa	B-protein
B	I-protein
complex	I-protein
,	O
was	O
not	O
induced	O
in	O
the	O
nucleus	O
following	O
activation	O
.	O

Western	O
blotting	O
analysis	O
did	O
not	O
detect	O
any	O
RelA	B-protein
in	O
nuclear	O
extracts	O
either	O
before	O
or	O
after	O
stimulation	O
of	O
T	B-cell_type
cells	I-cell_type
.	O

The	O
altered	O
kappa	O
B-binding	O
activity	O
in	O
T	B-cell_type
cells	I-cell_type
from	O
RCC	O
patients	O
may	O
impair	O
their	O
capacity	O
to	O
respond	O
normally	O
to	O
various	O
stimuli	O
.	O

Hemoglobin	B-protein
switching	O
in	O
humans	O
is	O
accompanied	O
by	O
changes	O
in	O
the	O
ratio	O
of	O
the	O
transcription	B-protein
factors	I-protein
,	O
GATA-1	B-protein
and	O
SP1	B-protein
.	O

BACKGROUND	O
:	O
Understanding	O
the	O
mechanism	O
of	O
developmental	O
regulation	O
of	O
hemoglobin	B-protein
switching	O
has	O
scientific	O
as	O
well	O
as	O
clinical	O
relevance	O
because	O
of	O
the	O
influence	O
of	O
fetal	O
hemoglobin	B-protein
(	O
HbF	B-protein
)	O
production	O
in	O
adulthood	O
on	O
the	O
clinical	O
manifestation	O
of	O
thalassemia	O
and	O
sickle	O
cell	O
anemia	O
.	O

We	O
have	O
previously	O
found	O
that	O
the	O
normal	O
developmental	O
patterns	O
of	O
globin	B-DNA
gene	I-DNA
expression	O
are	O
recapitulated	O
in	O
an	O
experimental	O
system	O
of	O
primary	B-cell_line
cultures	I-cell_line
that	O
support	O
differentiation	O
of	O
erythroid	B-cell_type
progenitors	I-cell_type
.	O

We	O
further	O
found	O
that	O
high	O
activities	O
of	O
the	O
transcriptional	B-protein
activators	I-protein
,	O
GATA-1	B-protein
and	O
SP1	B-protein
,	O
are	O
associated	O
with	O
normal	O
adult	O
erythroid	O
differentiation	O
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
In	O
the	O
present	O
work	O
,	O
we	O
have	O
studied	O
,	O
the	O
activities	O
of	O
GATA-1	B-protein
and	O
SP1	B-protein
during	O
differentiation	O
of	O
cultured	O
erythroid	B-cell_type
progenitors	I-cell_type
derived	O
from	O
cord	O
blood	O
and	O
from	O
fetal	O
livers	O
,	O
as	O
well	O
as	O
from	O
beta	O
zero-thalassemia	O
patients	O
.	O

RESULTS	O
:	O
The	O
results	O
showed	O
high	O
GATA-1	B-protein
binding	O
activity	O
and	O
very	O
low	O
SP1	B-protein
activity	O
in	O
the	O
fetal	B-cell_line
liver	I-cell_line
cultures	I-cell_line
.	O

This	O
pattern	O
was	O
in	O
contrast	O
to	O
cultures	O
derived	O
from	O
normal	O
adult	O
peripheral	O
blood	O
,	O
in	O
which	O
both	O
GATA-1	B-protein
and	O
SP1	B-protein
activities	O
were	O
high	O
.	O

Cord	O
blood	O
cultures	O
showed	O
an	O
additive	O
combination	O
of	O
``	O
adult	O
''	O
and	O
``	O
fetal	O
''	O
patterns	O
.	O

The	O
progenitors	O
derived	O
from	O
a	O
beta	O
zero-thalassemia	O
patient	O
with	O
high	O
HbF	B-protein
production	O
showed	O
``	O
fetal	O
''	O
pattern	O
.	O

On	O
the	O
other	O
hand	O
,	O
in	O
cultures	O
of	O
2	O
beta	O
zero-thalassemia	O
patients	O
without	O
high	O
HbF	B-protein
,	O
``	O
adult	O
''	O
pattern	O
was	O
observed	O
.	O

CONCLUSIONS	O
:	O
In	O
the	O
present	O
work	O
,	O
we	O
show	O
that	O
human	B-cell_type
fetal	I-cell_type
and	I-cell_type
adult	I-cell_type
erythroid	I-cell_type
progenitors	I-cell_type
are	O
distinct	O
in	O
their	O
transcription	B-protein
factors	I-protein
,	O
and	O
that	O
the	O
commitment	O
to	O
fetal	O
or	O
adult	O
program	O
occurs	O
at	O
a	O
very	O
early	O
differentiation	O
stage	O
.	O

Our	O
studies	O
also	O
demonstrate	O
that	O
under	O
anemic	O
stress	O
,	O
recruitment	O
of	O
fetal	B-cell_type
progenitors	I-cell_type
may	O
occur	O
in	O
adulthood	O
.	O

Transcription-independent	O
turnover	O
of	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
during	O
monocyte	O
adherence	O
:	O
implications	O
for	O
a	O
translational	O
component	O
regulating	O
I	B-RNA
kappa	I-RNA
B	I-RNA
alpha/MAD-3	I-RNA
mRNA	I-RNA
levels	O
.	O

We	O
identified	O
I	B-protein
kappa	I-protein
B	I-protein
alpha/MAD-3	I-protein
as	O
an	O
immediate-early	B-DNA
gene	I-DNA
in	O
human	B-cell_type
monocytes	I-cell_type
that	O
is	O
expressed	O
in	O
response	O
to	O
a	O
variety	O
of	O
signals	O
,	O
including	O
adhesion	O
,	O
lipopolysaccharide	O
,	O
and	O
phorbol	O
myristate	O
acetate	O
.	O

Within	O
5	O
min	O
of	O
monocyte	O
adhesion	O
,	O
the	O
level	O
of	O
the	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
protein	I-protein
is	O
markedly	O
diminished	O
but	O
is	O
rapidly	O
replaced	O
in	O
a	O
cycloheximide-sensitive	O
manner	O
within	O
20	O
min	O
.	O

Accompanying	O
the	O
rapid	O
turnover	O
of	O
the	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
protein	I-protein
is	O
simultaneous	O
translocation	O
of	O
NF-kappa	B-protein
B-related	I-protein
transcription	I-protein
factors	I-protein
to	O
nuclei	O
of	O
adhered	O
monocytes	O
.	O

The	O
demonstration	O
that	O
NF-kappa	B-protein
B	I-protein
can	O
regulate	O
I	B-DNA
kappa	I-DNA
B	I-DNA
alpha/MAD-3	I-DNA
gene	I-DNA
transcription	O
in	O
other	O
cell	O
types	O
suggested	O
that	O
the	O
rapid	O
increase	O
in	O
steady-state	O
I	B-RNA
kappa	I-RNA
B	I-RNA
alpha/MAD-3	I-RNA
mRNA	I-RNA
levels	O
we	O
observed	O
within	O
30	O
min	O
of	O
monocyte	O
adherence	O
would	O
result	O
from	O
NF-kappa	B-protein
B	I-protein
-dependent	O
transcriptional	O
stimulation	O
of	O
the	O
I	B-DNA
kappa	I-DNA
B	I-DNA
alpha/MAD-3	I-DNA
gene	I-DNA
.	O

Nuclear	O
run-on	O
analyses	O
indicated	O
that	O
,	O
instead	O
,	O
while	O
several	O
immediate-early	B-DNA
cytokine	I-DNA
genes	I-DNA
,	O
such	O
as	O
the	O
interleukin	B-DNA
1	I-DNA
beta	I-DNA
(	I-DNA
IL-1	I-DNA
beta	I-DNA
)	I-DNA
gene	I-DNA
,	O
were	O
transcriptionally	O
activated	O
during	O
monocyte	O
adhesion	O
,	O
the	O
rate	O
of	O
I	B-DNA
kappa	I-DNA
B	I-DNA
alpha/MAD-3	I-DNA
gene	I-DNA
transcription	O
remained	O
constant	O
.	O

The	O
adherence-dependent	O
increase	O
in	O
I	B-RNA
kappa	I-RNA
B	I-RNA
alpha/MAD-3	I-RNA
mRNA	I-RNA
levels	O
was	O
also	O
not	O
a	O
consequence	O
of	O
mRNA	B-RNA
stabilization	O
events	O
.	O

Interestingly	O
,	O
while	O
increases	O
in	O
both	O
IL-1	O
beta	O
and	O
I	O
kappa	O
B	O
alpha/MAD-3	O
mRNA	O
levels	O
were	O
detected	O
in	O
nuclei	O
of	O
adherent	B-cell_type
monocytes	I-cell_type
,	O
cytoplasmic	O
levels	O
of	O
IL-1	B-RNA
beta	I-RNA
mRNA	I-RNA
increased	O
during	O
adherence	O
whereas	O
those	O
of	O
I	B-RNA
kappa	I-RNA
B	I-RNA
alpha/MAD-3	I-RNA
mRNA	I-RNA
did	O
not	O
.	O

Taken	O
together	O
,	O
our	O
data	O
suggest	O
that	O
two	O
interactive	O
mechanisms	O
regulate	O
monocytic	B-RNA
I	I-RNA
kappa	I-RNA
B	I-RNA
alpha/MAD-3	I-RNA
mRNA	I-RNA
levels	O
.	O

We	O
propose	O
that	O
adherent	B-cell_type
monocytes	I-cell_type
regulate	O
nuclear	O
processing	O
(	O
or	O
decay	O
)	O
of	O
I	B-RNA
kappa	I-RNA
B	I-RNA
alpha/MAD-3	I-RNA
mRNA	I-RNA
,	O
thereby	O
increasing	O
mRNA	O
levels	O
without	O
stimulating	O
I	B-DNA
kappa	I-DNA
B	I-DNA
alpha/MAD-3	I-DNA
gene	I-DNA
transcription	O
.	O

Moreover	O
,	O
since	O
inhibition	O
of	O
protein	O
synthesis	O
leads	O
to	O
accumulation	O
of	O
I	B-RNA
kappa	I-RNA
B	I-RNA
alpha/MAD-3	I-RNA
mRNA	I-RNA
without	O
stimulating	O
I	B-DNA
kappa	I-DNA
B	I-DNA
alpha/MAD-3	I-DNA
gene	I-DNA
transcription	O
,	O
we	O
suggest	O
that	O
low	O
cytoplasmic	O
levels	O
of	O
I	B-RNA
kappa	I-RNA
B	I-RNA
alpha/MAD-3	I-RNA
mRNA	I-RNA
are	O
maintained	O
by	O
a	O
translation-dependent	O
degradation	O
mechanism	O
.	O

Distinct	O
roles	O
of	O
the	O
molecular	O
chaperone	B-protein
hsp90	I-protein
in	O
modulating	O
dioxin	O
receptor	O
function	O
via	O
the	O
basic	O
helix-loop-helix	B-protein
and	O
PAS	B-protein
domains	I-protein
.	O

The	O
intracellular	B-protein
dioxin	I-protein
receptor	I-protein
mediates	O
signal	O
transduction	O
by	O
dioxin	O
and	O
functions	O
as	O
a	O
ligand-activated	B-protein
transcription	I-protein
factor	I-protein
.	O

It	O
contains	O
a	O
basic	B-protein
helix-loop-helix	I-protein
(	I-protein
bHLH	I-protein
)	I-protein
motif	I-protein
contiguous	O
with	O
a	O
Per-Arnt-Sim	B-protein
(	I-protein
PAS	I-protein
)	I-protein
homology	I-protein
region	I-protein
.	O

In	O
extracts	O
from	O
nonstimulated	O
cells	O
the	O
receptor	O
is	O
recovered	O
in	O
an	O
inducible	O
cytoplasmic	O
form	O
associated	O
with	O
the	O
90-kDa	B-protein
heat	I-protein
shock	I-protein
protein	I-protein
(	O
hsp90	B-protein
)	O
,	O
a	O
molecular	B-protein
chaperone	I-protein
.	O

We	O
have	O
reconstituted	O
ligand-dependent	O
activation	O
of	O
the	O
receptor	O
to	O
a	O
DNA-binding	B-protein
form	I-protein
by	O
using	O
the	O
dioxin	B-protein
receptor	I-protein
and	O
its	O
bHLH-PAS	B-protein
partner	I-protein
factor	I-protein
Arnt	B-protein
expressed	O
by	O
in	O
vitro	O
translation	O
in	O
reticulocyte	O
lysate	O
.	O

Deletion	O
of	O
the	O
PAS	B-protein
domain	I-protein
of	O
the	O
receptor	O
resulted	O
in	O
constitutive	O
dimerization	O
with	O
Arnt	B-protein
.	O

In	O
contrast	O
,	O
this	O
receptor	O
mutant	O
showed	O
low	O
levels	O
of	O
xenobiotic	O
response	O
element-binding	O
activity	O
,	O
indicating	O
that	O
the	O
PAS	B-protein
domain	I-protein
may	O
be	O
important	O
for	O
DNA-binding	O
affinity	O
and/or	O
specificity	O
of	O
the	O
receptor	O
.	O

It	O
was	O
not	O
possible	O
to	O
reconstitute	O
dioxin	B-protein
receptor	I-protein
function	O
with	O
proteins	O
expressed	O
in	O
wheat	O
germ	O
lysate	O
.	O

In	O
line	O
with	O
these	O
observations	O
,	O
reticulocyte	O
lysate	O
but	O
not	O
wheat	O
germ	O
lysate	O
promoted	O
the	O
association	O
of	O
de	O
novo	O
synthesized	O
dioxin	B-protein
receptor	I-protein
with	O
hsp90	B-protein
.	O

At	O
least	O
two	O
distinct	O
domains	O
of	O
the	O
receptor	O
mediated	O
interaction	O
with	O
hsp90	B-protein
:	O
the	O
ligand-binding	B-protein
domain	I-protein
located	O
within	O
the	O
PAS	B-protein
region	I-protein
and	O
,	O
surprisingly	O
,	O
the	O
bHLH	B-protein
domain	I-protein
.	O

Whereas	O
ligand-binding	O
activity	O
correlated	O
with	O
association	O
with	O
hsp90	B-protein
,	O
bHLH-	O
hsp90	B-protein
interaction	O
appeared	O
to	O
be	O
important	O
for	O
DNA-binding	O
activity	O
but	O
not	O
for	O
dimerization	O
of	O
the	O
receptor	O
.	O

Several	O
distinct	O
roles	O
for	O
hsp90	B-protein
in	O
modulating	O
dioxin	B-protein
receptor	I-protein
function	O
are	O
therefore	O
likely	O
:	O
correct	O
folding	O
of	O
the	O
ligand-binding	O
domain	O
,	O
interference	O
with	O
Arnt	B-protein
heterodimerization	O
,	O
and	O
folding	O
of	O
a	O
DNA-binding	O
conformation	O
of	O
the	O
bHLH	B-protein
domain	I-protein
.	O

Thus	O
,	O
the	O
dioxin	B-protein
receptor	I-protein
system	O
provides	O
a	O
complex	O
and	O
interesting	O
model	O
of	O
the	O
regulation	O
of	O
transcription	B-protein
factors	I-protein
by	O
hsp90	B-protein
.	O

Induction	O
of	O
transcription	B-protein
factors	I-protein
in	O
human	B-cell_type
T	I-cell_type
lymphocytes	I-cell_type
by	O
aspirin-like	O
drugs	O
.	O

Aspirin-like	O
drugs	O
(	O
ALD	O
)	O
induce	O
calcium	O
mobilization	O
,	O
an	O
essential	O
component	O
of	O
T	O
cell	O
activation	O
,	O
but	O
do	O
not	O
induce	O
the	O
biosynthesis	O
of	O
IL-2	B-protein
.	O

To	O
understand	O
the	O
extent	O
to	O
which	O
ALD	O
may	O
mimic	O
mitogenic	O
stimulation	O
,	O
we	O
studied	O
cytoplasmic	O
and	O
nuclear	O
signaling	O
steps	O
in	O
ALD-treated	B-cell_line
T	I-cell_line
cells	I-cell_line
.	O

We	O
found	O
that	O
ALD	O
induce	O
a	O
transient	O
activation	O
of	O
protein	B-protein
kinase	I-protein
(	O
PKC	B-protein
)	O
but	O
have	O
no	O
effect	O
(	O
in	O
comparison	O
to	O
anti-CD3	B-protein
antibodies	I-protein
)	O
on	O
protein	O
tyrosine	O
phosphorylation	O
nor	O
on	O
PCL	O
gamma	O
1	O
tyrosine	O
phosphorylation	O
.	O

ALD-induced	O
calcium	O
mobilization	O
and	O
PKC	B-protein
activation	O
are	O
independent	O
of	O
tyrosine	B-protein
protein	I-protein
kinase	I-protein
activity	O
as	O
shown	O
by	O
the	O
lack	O
of	O
effect	O
of	O
herbimycin	O
,	O
a	O
tyrosine-protein	B-protein
kinase	I-protein
-specific	O
inhibitor	O
.	O

Although	O
we	O
detected	O
no	O
IL-2	B-RNA
mRNA	I-RNA
in	O
ALD-treated	B-cell_line
cells	I-cell_line
,	O
the	O
nuclei	O
of	O
these	O
cells	O
contain	O
proteins	O
capable	O
of	O
binding	O
to	O
three	O
regulatory	B-DNA
sequences	I-DNA
in	O
the	O
IL-2	B-DNA
promoter	I-DNA
region	I-DNA
:	O
NFAT	B-protein
,	O
NF	B-protein
kappa	I-protein
B	I-protein
,	O
and	O
AP-1	B-protein
.	O

These	O
binding	O
activities	O
are	O
expressed	O
only	O
in	O
activated	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O

The	O
expression	O
of	O
AP-1	B-protein
depended	O
on	O
calcium	O
mobilization	O
and	O
PKC	B-protein
activation	O
.	O

These	O
data	O
suggest	O
that	O
ALD	O
cause	O
transient	O
but	O
significant	O
changes	O
in	O
T	O
cell	O
transmembrane	O
signaling	O
,	O
although	O
some	O
events	O
induced	O
by	O
stimulation	O
with	O
anti-CD3	B-protein
antibodies	I-protein
are	O
not	O
induced	O
by	O
ALD	O
.	O

The	O
signal	O
is	O
transmitted	O
to	O
the	O
nucleus	O
and	O
induces	O
DNA-binding	O
activity	O
by	O
several	O
transcription	B-protein
factors	I-protein
.	O

However	O
,	O
the	O
ALD	O
stimulus	O
is	O
not	O
capable	O
of	O
causing	O
complete	O
T	O
cell	O
activation	O
.	O

Protein	B-protein
kinase	I-protein
C	I-protein
is	O
not	O
a	O
downstream	O
effector	O
of	O
p21ras	B-DNA
in	O
activated	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O

The	O
aim	O
of	O
this	O
present	O
study	O
was	O
to	O
investigate	O
the	O
role	O
of	O
protein	B-protein
kinase	I-protein
C	I-protein
(	O
PKC	B-protein
)	O
,	O
downstream	O
of	O
p21ras	B-DNA
,	O
in	O
activating	O
interleukin-2	B-DNA
(	I-DNA
IL-2	I-DNA
)	I-DNA
gene	I-DNA
expression	O
.	O

It	O
has	O
been	O
reported	O
that	O
PKC	B-protein
is	O
an	O
effector	B-protein
of	O
p21ras	B-DNA
in	O
T	B-cell_type
cells	I-cell_type
.	O

Data	O
is	O
presented	O
,	O
using	O
the	O
potent	O
and	O
selective	O
PKC	B-protein
inhibitor	O
Ro	O
31-8425	O
and	O
transient	O
expression	O
of	O
a	O
constitutively	O
active	O
ras	O
mutant	O
,	O
which	O
clearly	O
shows	O
that	O
PKC	B-protein
is	O
not	O
downstream	O
of	O
p21ras	B-DNA
in	O
the	O
induction	O
of	O
NF-AT	B-protein
and	O
AP-1	B-protein
transcriptional	O
activity	O
and	O
in	O
the	O
expression	O
of	O
IL-2	B-protein
in	O
human	B-cell_line
Jurkat	I-cell_line
T	I-cell_line
cells	I-cell_line
.	O

Reporter	O
gene	O
experiments	O
demonstrated	O
that	O
NF-kappa	B-protein
B	I-protein
transcriptional	O
activity	O
is	O
not	O
affected	O
by	O
expression	O
of	O
activated	O
p21ras	B-DNA
.	O

The	O
signaling	O
pathways	O
involving	O
PKC	B-protein
activation	O
,	O
calcium	O
mobilization	O
and	O
ras	B-protein
activation	O
combine	O
to	O
provide	O
the	O
necessary	O
components	O
for	O
production	O
of	O
IL-2	B-protein
during	O
T	O
cell	O
activation	O
.	O

The	O
C-terminus	B-protein
of	O
the	O
B	B-protein
cell	I-protein
activator	I-protein
Oct-2	B-protein
functions	O
as	O
an	O
activation	B-protein
domain	I-protein
in	O
yeast	O
.	O

Oct-1	B-protein
and	O
Oct-2	B-protein
are	O
human	O
transcriptional	B-protein
activators	I-protein
that	O
bind	O
to	O
the	O
same	O
DNA	O
element	O
but	O
activate	O
distinct	O
sets	O
of	O
genes	O
.	O

We	O
expressed	O
these	O
factors	O
in	O
S.	O
cerevisiae	O
and	O
observed	O
greater	O
than	O
5-fold	O
stimulation	O
of	O
a	O
lacZ	B-DNA
reporter	I-DNA
gene	I-DNA
only	O
with	O
Oct-2	B-protein
.	O

Transfer	O
of	O
the	O
Oct-2	B-protein
C-terminal	I-protein
domain	I-protein
onto	O
either	O
Oct-1	B-protein
(	O
Oct1.2	B-protein
)	O
or	O
a	O
nonactivating	B-protein
DNA-binding	I-protein
domain	I-protein
from	O
GAL4	B-protein
created	O
activators	O
capable	O
of	O
greater	O
than	O
15	O
and	O
10-fold	O
stimulation	O
of	O
activity	O
,	O
respectively	O
.	O

Thus	O
,	O
the	O
C-terminus	B-protein
of	O
Oct-2	B-protein
is	O
sufficient	O
to	O
confer	O
activation	O
potential	O
to	O
nonactive	O
DNA-binding	B-DNA
fragments	I-DNA
in	O
yeast	O
.	O

Glucocorticoid-induced	O
apoptosis	O
of	O
lymphoid	B-cell_type
cells	I-cell_type
.	O

The	O
induction	O
of	O
cell	O
death	O
in	O
lymphoid	B-cell_type
cells	I-cell_type
by	O
glucocorticoids	O
is	O
one	O
of	O
the	O
earliest	O
and	O
most	O
thoroughly	O
studied	O
models	O
of	O
apoptosis	O
.	O

Although	O
the	O
exact	O
mechanism	O
by	O
which	O
apoptosis	O
occurs	O
in	O
lymphocytes	B-cell_type
is	O
unknown	O
many	O
biochemical	O
and	O
molecular	O
changes	O
have	O
been	O
shown	O
to	O
occur	O
in	O
these	O
cells	O
in	O
response	O
to	O
glucocorticoids	O
.	O

The	O
role	O
of	O
chromatin	B-DNA
degradation	O
and	O
endonucleases	B-protein
in	O
the	O
apoptotic	O
process	O
has	O
been	O
closely	O
studied	O
,	O
as	O
well	O
as	O
the	O
involvement	O
of	O
several	O
oncogenes	B-DNA
in	O
glucocorticoid-induced	O
cell	O
lysis	O
.	O

In	O
addition	O
,	O
the	O
clinical	O
importance	O
of	O
glucocorticoid-induced	O
apoptosis	O
in	O
the	O
treatment	O
of	O
lymphoid	O
neoplasms	O
has	O
recently	O
received	O
increased	O
attention	O
.	O

Interleukin-2	B-protein
induces	O
tyrosine	O
phosphorylation	O
and	O
nuclear	O
translocation	O
of	O
stat3	B-protein
in	O
human	B-cell_type
T	I-cell_type
lymphocytes	I-cell_type
.	O

An	O
early	O
biochemical	O
event	O
associated	O
with	O
T	O
cell	O
activation	O
through	O
the	O
interleukin-2	B-protein
receptor	I-protein
(	O
IL-2R	B-protein
)	O
is	O
tyrosine	O
phosphorylation	O
of	O
several	O
intracellular	O
substrates	O
.	O

The	O
exact	O
mechanism	O
by	O
which	O
IL-2	B-protein
regulates	O
transcription	O
of	O
different	O
genes	O
is	O
presently	O
unknown	O
.	O

Here	O
,	O
we	O
report	O
that	O
stimulation	O
through	O
the	O
IL-2R	B-protein
induced	O
tyrosine	O
phosphorylation	O
and	O
subsequent	O
nuclear	O
translocation	O
of	O
stat3	B-protein
,	O
a	O
newly	O
identified	O
member	O
of	O
the	O
signal	B-protein
transducers	I-protein
and	I-protein
activators	I-protein
of	I-protein
transcription	I-protein
(	I-protein
STAT	I-protein
)	I-protein
family	I-protein
of	O
proteins	O
.	O

In	O
contrast	O
,	O
stat1	O
proteins	O
were	O
not	O
tyrosine	O
phosphorylated	O
after	O
IL-2	B-protein
ligation	O
,	O
whereas	O
tyrosine-phosphorylated	B-protein
stat1	I-protein
proteins	I-protein
(	O
91	B-protein
and	I-protein
84	I-protein
kDa	I-protein
proteins	I-protein
)	O
were	O
translocated	O
to	O
the	O
nucleus	O
following	O
interferon-gamma	B-protein
treatment	O
of	O
HeLa	B-cell_line
cells	I-cell_line
.	O

Apart	O
from	O
stat3	B-protein
,	O
another	O
cytoplasmic	B-protein
protein	I-protein
was	O
tyrosine	O
phosphorylated	O
and	O
subsequently	O
translocated	O
to	O
the	O
nucleus	O
in	O
response	O
to	O
IL-2	B-protein
.	O

This	O
protein	O
had	O
an	O
apparent	O
molecular	O
mass	O
of	O
84	O
kDa	O
and	O
was	O
not	O
recognized	O
by	O
stat3	B-protein
or	O
stat1	B-protein
mAb	I-protein
or	O
antisera	O
.	O

Since	O
IL-2	B-protein
induced	O
nuclear	O
translocation	O
of	O
the	O
84	B-protein
kDa	I-protein
protein	I-protein
and	O
stat3	B-protein
followed	O
identical	O
kinetics	O
,	O
p84	B-protein
is	O
a	O
candidate	O
for	O
a	O
new	O
,	O
yet	O
undefined	O
,	O
member	O
of	O
the	O
STAT	O
family	O
.	O

Taken	O
together	O
,	O
we	O
report	O
that	O
IL-2	B-protein
induces	O
tyrosine	O
phosphorylation	O
and	O
subsequent	O
nuclear	O
translocation	O
of	O
stat3	B-protein
and	O
an	O
as	O
yet	O
undefined	O
84-kDa	B-protein
protein	I-protein
in	O
antigen-specific	B-cell_line
human	I-cell_line
T	I-cell_line
cell	I-cell_line
lines	I-cell_line
.	O

Human	O
T-cell	O
leukemia	O
virus	O
type	O
I	O
Tax	B-protein
activation	O
of	O
NF-kappa	B-protein
B/Rel	I-protein
involves	O
phosphorylation	O
and	O
degradation	O
of	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
and	O
RelA	B-protein
(	O
p65	B-protein
)	O
-mediated	O
induction	O
of	O
the	O
c-rel	B-DNA
gene	I-DNA
.	O

The	O
tax	O
gene	O
product	O
of	O
human	O
T-cell	O
leukemia	O
virus	O
type	O
I	O
(	O
HTLV-I	O
)	O
is	O
a	O
potent	O
transcriptional	B-protein
activator	I-protein
that	O
both	O
stimulates	O
viral	O
gene	O
expression	O
and	O
activates	O
an	O
array	O
of	O
cellular	B-DNA
genes	I-DNA
involved	O
in	O
T-cell	B-cell_type
growth	O
.	O

Tax	O
acts	O
indirectly	O
by	O
inducing	O
or	O
modifying	O
the	O
action	O
of	O
various	O
host	O
transcription	B-protein
factors	I-protein
,	O
including	O
members	O
of	O
the	O
NF-kappa	B-protein
B/Rel	I-protein
family	I-protein
of	O
enhancer-binding	B-protein
proteins	I-protein
.	O

In	O
resting	B-cell_type
T	I-cell_type
cells	I-cell_type
,	O
many	O
of	O
these	O
NF-kappa	B-protein
B/Rel	I-protein
factors	I-protein
are	O
sequestered	O
in	O
the	O
cytoplasm	O
by	O
various	O
ankyrin-rich	B-protein
inhibitory	I-protein
proteins	I-protein
,	O
including	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
.	O

HTLV-I	B-protein
Tax	I-protein
expression	O
leads	O
to	O
the	O
constitutive	O
nuclear	O
expression	O
of	O
biologically	O
active	O
NF-kappa	B-protein
B	I-protein
and	O
c-Rel	B-protein
complexes	I-protein
;	O
however	O
,	O
the	O
biochemical	O
mechanism	O
(	O
s	O
)	O
underlying	O
this	O
response	O
remains	O
poorly	O
understood	O
.	O

In	O
this	O
study	O
,	O
we	O
demonstrate	O
that	O
Tax	B-protein
-stimulated	O
nuclear	O
expression	O
of	O
NF-kappa	B-protein
B	I-protein
in	O
both	O
HTLV-I-infected	B-cell_line
and	I-cell_line
Tax-transfected	I-cell_line
human	I-cell_line
T	I-cell_line
cells	I-cell_line
is	O
associated	O
with	O
the	O
phosphorylation	O
and	O
rapid	O
proteolytic	O
degradation	O
of	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
.	O

In	O
contrast	O
to	O
prior	O
in	O
vitro	O
studies	O
,	O
at	O
least	O
a	O
fraction	O
of	O
the	O
phosphorylated	O
form	O
of	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
remains	O
physically	O
associated	O
with	O
the	O
NF-kappa	B-protein
B	I-protein
complex	I-protein
in	O
vivo	O
but	O
is	O
subject	O
to	O
rapid	O
degradation	O
,	O
thereby	O
promoting	O
the	O
nuclear	O
translocation	O
of	O
the	O
active	O
NF-kappa	B-protein
B	I-protein
complex	I-protein
.	O

We	O
further	O
demonstrate	O
that	O
Tax	B-protein
induction	O
of	O
nuclear	O
c-Rel	B-protein
expression	O
is	O
activated	O
by	O
the	O
RelA	B-protein
(	O
p65	B-protein
)	O
subunit	O
of	O
NF-kappa	B-protein
B	I-protein
,	O
which	O
activates	O
transcription	O
of	O
the	O
c-rel	B-DNA
gene	I-DNA
through	O
an	O
intrinsic	O
kappa	B-DNA
B	I-DNA
enhancer	I-DNA
element	I-DNA
.	O

In	O
normal	O
cells	O
,	O
the	O
subsequent	O
accumulation	O
of	O
nuclear	B-protein
c-Rel	I-protein
acts	O
to	O
inhibit	O
its	O
own	O
continued	O
production	O
,	O
indicating	O
the	O
presence	O
of	O
an	O
autoregulatory	O
loop	O
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Activation	O
of	O
NF-kappa	B-protein
B	I-protein
in	O
vivo	O
is	O
regulated	O
by	O
multiple	O
phosphorylations	O
.	O

The	O
activation	O
of	O
nuclear	B-protein
factor	I-protein
kappa	I-protein
B	I-protein
(	O
NF-kappa	B-protein
B	I-protein
)	O
in	O
intact	O
cells	O
is	O
mechanistically	O
not	O
well	O
understood	O
.	O

Therefore	O
we	O
investigated	O
the	O
modifications	O
imposed	O
on	O
NF-kappa	B-protein
B/I	I-protein
kappa	I-protein
B	I-protein
components	I-protein
following	O
stimulation	O
and	O
show	O
that	O
the	O
final	O
step	O
of	O
NF-kappa	B-protein
B	I-protein
induction	O
in	O
vivo	O
involves	O
phosphorylation	O
of	O
several	O
members	O
of	O
the	O
NF-kappa	B-protein
B/I	I-protein
kappa	I-protein
B	I-protein
protein	I-protein
families	I-protein
.	O

In	O
HeLa	B-cell_line
cells	I-cell_line
as	O
well	O
as	O
in	O
B	B-cell_type
cells	I-cell_type
,	O
TNF-alpha	O
rapidly	O
induced	O
nuclear	O
translocation	O
primarily	O
of	O
p50-p65	B-protein
,	O
but	O
not	O
of	O
c-rel	B-protein
.	O

Both	O
NF-kappa	B-protein
B	I-protein
precursors	O
and	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
became	O
strongly	O
phosphorylated	O
with	O
the	O
same	O
kinetics	O
.	O

In	O
addition	O
to	O
the	O
inducible	O
phosphorylation	O
after	O
stimulation	O
,	O
B	B-cell_type
lymphocytes	I-cell_type
containing	O
constitutive	O
nuclear	O
NF-kappa	B-protein
B	I-protein
revealed	O
constitutively	O
phosphorylated	O
p65	B-protein
and	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
.	O

Phosphorylation	O
was	O
accompanied	O
by	O
induced	O
processing	O
of	O
the	O
precursors	O
p100	B-protein
and	O
p105	B-protein
and	O
by	O
degradation	O
of	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
.	O

As	O
an	O
in	O
vitro	O
model	O
we	O
show	O
that	O
phosphorylation	O
of	O
p105	B-protein
impedes	O
its	O
ability	O
to	O
interact	O
with	O
NF-kappa	B-protein
B	I-protein
,	O
as	O
has	O
been	O
shown	O
before	O
for	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
.	O

Surprisingly	O
,	O
even	O
p65	B-protein
,	O
but	O
not	O
c-rel	B-protein
,	O
was	O
phosphorylated	O
after	O
induction	O
in	O
vivo	O
,	O
suggesting	O
that	O
TNF-alpha	B-protein
selectively	O
activates	O
only	O
specific	O
NF-kappa	B-protein
B	I-protein
heteromers	O
and	O
that	O
modifications	O
regulate	O
not	O
only	O
I	B-protein
kappa	I-protein
B	I-protein
molecules	I-protein
but	O
also	O
NF-kappa	B-protein
B	I-protein
molecules	O
.	O

In	O
fact	O
,	O
cellular	O
NF-kappa	B-protein
B	I-protein
activity	O
was	O
phosphorylation-dependent	O
and	O
the	O
DNA	O
binding	O
activity	O
of	O
p65-containing	B-protein
NF-kappa	I-protein
B	I-protein
was	O
enhanced	O
by	O
phosphorylation	O
in	O
vitro	O
.	O

Furthermore	O
,	O
we	O
found	O
that	O
the	O
induction	O
by	O
hydrogen	O
peroxide	O
of	O
NF-kappa	B-protein
B	I-protein
translocation	O
to	O
the	O
nucleus	O
,	O
which	O
is	O
assumed	O
to	O
be	O
triggered	O
by	O
reactive	O
oxygen	O
intermediates	O
,	O
also	O
coincided	O
with	O
incorporation	O
of	O
phosphate	O
into	O
the	O
same	O
subunits	O
that	O
were	O
modified	O
after	O
stimulation	O
by	O
TNF-alpha	B-protein
.	O

Thus	O
,	O
phosphorylation	O
appears	O
to	O
be	O
a	O
general	O
mechanism	O
for	O
activation	O
of	O
NF-kappa	B-protein
B	I-protein
in	O
vivo	O
.	O

Treatment	O
of	O
HL60	B-cell_line
cells	I-cell_line
with	O
various	O
combinations	O
of	O
retinoids	O
and	O
1	O
alpha	O
,	O
25	O
dihydroxyvitamin	O
D3	O
results	O
in	O
differentiation	O
towards	O
neutrophils	B-cell_type
or	O
monocytes	B-cell_type
or	O
a	O
failure	O
to	O
differentiate	O
and	O
apoptosis	O
.	O

It	O
is	O
well	O
documented	O
that	O
treatment	O
of	O
serum-grown	B-cell_line
HL60	I-cell_line
cells	I-cell_line
with	O
10	O
(	O
-7	O
)	O
M	O
all-trans	O
retinoic	O
acid	O
(	O
all-trans	O
RA	O
)	O
induces	O
neutrophil	B-cell_type
differentiation	O
,	O
whereas	O
treatment	O
with	O
10	O
(	O
-7	O
)	O
M	O
1	O
alpha	O
,	O
25	O
dihydroxyvitamin	O
D3	O
(	O
D3	O
)	O
induces	O
differentiation	O
towards	O
monocytes	B-cell_type
.	O

In	O
recent	O
investigations	O
,	O
using	O
serum-free	B-cell_line
grown	I-cell_line
HL60	I-cell_line
cells	I-cell_line
,	O
we	O
observed	O
that	O
all-trans	O
RA	O
,	O
at	O
10	O
(	O
-7	O
)	O
M	O
,	O
did	O
not	O
induce	O
neutrophil	O
differentiation	O
and	O
that	O
all-trans	O
RA	O
,	O
at	O
10	O
(	O
-8	O
)	O
M	O
,	O
reduced	O
the	O
D3	O
concentration	O
required	O
for	O
monocyte	B-cell_type
differentiation	O
to	O
5	O
x	O
10	O
(	O
-9	O
)	O
M	O
.	O

In	O
this	O
study	O
,	O
co-operative	O
interactions	O
between	O
all-trans	O
and	O
9-cis	O
RA	O
and	O
D3	O
which	O
promote	O
neutrophil	O
and	O
monocyte	O
differentiation	O
of	O
HL60	B-cell_line
cells	I-cell_line
have	O
been	O
analysed	O
in	O
detail	O
.	O

Treatment	O
of	O
serum-free	B-cell_line
grown	I-cell_line
HL60	I-cell_line
cells	I-cell_line
with	O
5	O
x	O
10	O
(	O
-7	O
)	O
M	O
all-trans	O
RA	O
or	O
9-cis	O
RA	O
resulted	O
in	O
sub-optimal	O
neutrophil	O
differentiation	O
(	O
up	O
to	O
25	O
%	O
mature	O
cells	O
)	O
.	O

As	O
shown	O
for	O
all-trans	O
RA	O
,	O
9-cis	O
RA	O
cooperated	O
with	O
D3	O
to	O
promote	O
monocyte	O
differentiation	O
.	O

Culture	O
of	O
HL60	B-cell_line
cells	I-cell_line
in	O
5	O
x	O
10	O
(	O
-7	O
)	O
M	O
9-cis	O
RA	O
together	O
with	O
a	O
wide	O
range	O
of	O
concentrations	O
of	O
D3	O
resulted	O
in	O
promotion	O
of	O
neutrophil	O
differentiation	O
at	O
10	O
(	O
-15	O
)	O
-10	O
(	O
-12	O
)	O
D3	O
,	O
a	O
failure	O
to	O
differentiate	O
and	O
apoptosis	O
at	O
10	O
(	O
-11	O
)	O
-10	O
(	O
-10	O
)	O
M	O
D3	O
,	O
followed	O
by	O
co-operativity	O
between	O
9-cis	O
RA	O
and	O
5	O
x	O
10	O
(	O
-9	O
)	O
M	O
D3	O
in	O
inducing	O
monocyte	O
differentiation	O
in	O
the	O
absence	O
of	O
neutrophil	O
differentiation	O
.	O

Similar	O
results	O
were	O
obtained	O
when	O
HL60	B-cell_line
cells	I-cell_line
were	O
treated	O
with	O
5	O
x	O
10	O
(	O
-7	O
)	O
all-trans	O
RA	O
together	O
with	O
a	O
wide	O
range	O
of	O
concentrations	O
of	O
D3	O
.	O

Cross	O
titration	O
analyses	O
of	O
the	O
effects	O
of	O
9-cis	O
RA	O
and	O
D3	O
on	O
HL60	B-cell_line
cell	I-cell_line
differentiation	O
were	O
undertaken	O
to	O
determine	O
the	O
boundaries	O
of	O
the	O
concentrations	O
of	O
each	O
agent	O
,	O
alone	O
and	O
in	O
combination	O
,	O
that	O
give	O
rise	O
to	O
optimal	O
neutrophil	O
and	O
monocyte	O
differentiation	O
of	O
HL60	B-cell_line
cells	I-cell_line
.	O

The	O
observed	O
cooperativities	O
between	O
either	O
9-cis	O
RA	O
or	O
all-trans	O
RA	O
and	O
D3	O
have	O
important	O
implications	O
for	O
the	O
use	O
of	O
combinations	O
of	O
these	O
agents	O
in	O
differentiation	O
therapy	O
.	O

Isolation	O
of	O
differentially	O
expressed	O
sequence	O
tags	O
from	O
steroid-responsive	B-cell_type
cells	I-cell_type
using	O
mRNA	B-RNA
differential	O
display	O
.	O

Transcriptional	O
control	O
of	O
steroid-regulated	B-DNA
gene	I-DNA
networks	I-DNA
by	O
nuclear	B-protein
receptor	I-protein
proteins	I-protein
results	O
in	O
the	O
coordinate	O
expression	O
of	O
a	O
limited	O
number	O
of	O
target	B-DNA
genes	I-DNA
.	O

Although	O
much	O
is	O
known	O
about	O
the	O
structure	O
and	O
function	O
of	O
steroid	O
receptors	O
,	O
relatively	O
few	O
cell-specific	O
steroid-regulated	O
genes	O
have	O
been	O
isolated	O
and	O
characterized	O
.	O

In	O
this	O
paper	O
we	O
describe	O
results	O
using	O
mRNA	B-RNA
differential	O
display	O
reverse	B-protein
transcriptase	I-protein
PCR	O
(	O
DDPCR	O
)	O
to	O
identify	O
and	O
isolate	O
short	O
cDNA	O
sequence	O
tags	O
from	O
thymocyte	B-cell_type
and	O
prostate	B-cell_type
cells	I-cell_type
under	O
various	O
hormone	O
conditions	O
.	O

Using	O
this	O
technique	O
we	O
have	O
isolated	O
several	O
differentially	B-DNA
expressed	I-DNA
sequence	I-DNA
tags	I-DNA
(	O
DESTs	B-DNA
)	O
from	O
the	O
mouse	B-cell_line
thymocyte	I-cell_line
cell	I-cell_line
line	I-cell_line
WEHI	B-cell_line
7.2	I-cell_line
.	O

Two	O
of	O
these	O
DESTs	B-DNA
,	O
GIG10	B-DNA
and	O
GIG18	B-DNA
,	O
are	O
rapidly	O
induced	O
by	O
dexamethasone	O
within	O
2	O
h	O
of	O
treatment	O
.	O

GIG10	B-DNA
is	O
a	O
novel	O
sequence	O
and	O
GIG18	B-DNA
is	O
the	O
mouse	O
homologue	O
of	O
a	O
human	B-DNA
expressed	I-DNA
sequence	I-DNA
tag	I-DNA
isolated	O
from	O
activated	B-cell_type
B	I-cell_type
lymphocytes	I-cell_type
.	O

We	O
also	O
used	O
DDPCR	O
to	O
isolate	O
DESTs	B-DNA
from	O
androgen-modulated	O
rat	O
ventral	O
prostate	O
tissue	O
,	O
one	O
of	O
which	O
we	O
characterized	O
and	O
found	O
to	O
correspond	O
to	O
the	O
3	B-RNA
'	I-RNA
end	I-RNA
of	O
prostatic	B-RNA
spermine	I-RNA
binding	I-RNA
protein	I-RNA
mRNA	I-RNA
,	O
a	O
known	O
androgen-regulated	B-DNA
gene	I-DNA
.	O

Modifications	O
of	O
the	O
original	O
DDPCR	O
protocol	O
,	O
which	O
we	O
found	O
can	O
potentially	O
decrease	O
the	O
frequency	O
of	O
isolating	O
false-positive	O
DESTs	B-DNA
,	O
are	O
described	O
and	O
the	O
merits	O
of	O
DDPCR	O
,	O
relative	O
to	O
other	O
differential	O
cDNA	O
cloning	O
strategies	O
,	O
are	O
discussed	O
.	O

Activation	O
of	O
human	B-cell_type
thymocytes	I-cell_type
after	O
infection	O
by	O
EBV	O
.	O

The	O
discovery	O
of	O
EBV	O
in	O
certain	O
T	O
cell	O
malignancies	O
and	O
the	O
expression	O
of	O
the	O
EBV	B-protein
receptor	I-protein
,	O
CR2/CD21	B-protein
,	O
on	O
a	O
population	O
of	O
immature	B-cell_type
thymocytes	I-cell_type
,	O
T	B-cell_line
lymphoblastoid	I-cell_line
cell	I-cell_line
lines	I-cell_line
,	O
and	O
childhood	B-cell_type
acute	I-cell_type
T	I-cell_type
lymphoblastic	I-cell_type
leukemia	I-cell_type
cells	I-cell_type
suggested	O
that	O
EBV-receptor	O
interactions	O
on	O
T	B-cell_type
cells	I-cell_type
may	O
be	O
of	O
importance	O
.	O

We	O
have	O
shown	O
that	O
,	O
within	O
the	O
thymus	O
,	O
a	O
population	O
of	O
large	B-cell_type
,	I-cell_type
immature	I-cell_type
cells	I-cell_type
expresses	O
CD21	B-protein
.	O

EBV	O
altered	O
the	O
activation	O
responses	O
of	O
immature	B-cell_type
thymocytes	I-cell_type
in	O
vitro	O
.	O

Triggering	O
through	O
CD2	B-protein
is	O
mitogenic	O
for	O
mature	O
,	O
but	O
not	O
immature	O
,	O
T	B-cell_type
cells	I-cell_type
.	O

However	O
,	O
during	O
infection	O
by	O
EBV	O
,	O
ligation	O
of	O
CD2	B-protein
caused	O
thymocytes	B-cell_type
to	O
proliferate	O
in	O
the	O
absence	O
of	O
exogenous	B-protein
cytokines	I-protein
.	O

This	O
function	O
was	O
a	O
result	O
of	O
the	O
interaction	O
of	O
EBV	O
with	O
its	O
receptor	O
,	O
CD21	B-protein
,	O
but	O
was	O
caused	O
by	O
infection	O
rather	O
than	O
surface	O
signaling	O
,	O
because	O
neither	O
specific	B-protein
mAb	I-protein
nor	O
the	O
P3HR-1	O
strain	O
of	O
virus	O
mimicked	O
the	O
effect	O
of	O
B95-8	O
.	O

Immature	O
thymocytes	B-cell_type
were	O
infected	O
by	O
EBV	O
,	O
as	O
determined	O
by	O
the	O
internalization	O
of	O
the	O
viral	B-DNA
genome	I-DNA
and	O
its	O
transcriptional	O
activity	O
.	O

Consistent	O
with	O
the	O
activity	O
of	O
B95-8	B-protein
,	O
EBNA-2	B-RNA
transcripts	I-RNA
were	O
identified	O
within	O
infected	B-cell_line
thymocyte	I-cell_line
populations	I-cell_line
.	O

In	O
addition	O
,	O
components	O
of	O
the	O
viral	O
replicative	O
pathway	O
were	O
expressed	O
during	O
infection	O
of	O
thymocytes	B-cell_type
.	O

These	O
components	O
included	O
transcription	O
of	O
BZLF-1	B-DNA
,	O
an	O
early	B-DNA
gene	I-DNA
that	O
characterizes	O
EBV-infected	B-cell_type
B	I-cell_type
cells	I-cell_type
after	O
disruption	O
of	O
latency	O
.	O

A	O
second	O
transcript	O
was	O
identified	O
as	O
encoding	O
the	O
recently	O
characterized	O
RAZ	B-protein
,	O
which	O
also	O
is	O
associated	O
with	O
replicative	O
infection	O
.	O

The	O
consequences	O
of	O
EBV	O
infection	O
of	O
T	B-cell_type
cells	I-cell_type
at	O
an	O
early	O
stage	O
of	O
differentiation	O
may	O
lead	O
to	O
failure	O
of	O
normal	O
T	O
cell	O
repertoire	O
development	O
,	O
autoimmunity	O
,	O
or	O
malignancy	O
.	O

Effects	O
of	O
intranasal	O
glucocorticoids	O
on	O
endogenous	O
glucocorticoid	O
peripheral	O
and	O
central	O
function	O
.	O

Glucocorticoids	O
are	O
among	O
the	O
most	O
potent	O
antiinflammatory	O
agents	O
that	O
can	O
be	O
used	O
in	O
the	O
treatment	O
of	O
rhinitis	O
.	O

Their	O
mechanisms	O
of	O
action	O
are	O
multiple	O
and	O
complex	O
and	O
a	O
number	O
of	O
reports	O
describe	O
significant	O
systemic	O
effects	O
of	O
locally	O
administered	O
glucocorticoids	O
.	O

In	O
order	O
to	O
evaluate	O
the	O
short-term	O
systemic	O
effects	O
of	O
intranasally	O
administered	O
glucocorticoids	O
,	O
14	O
normal	O
healthy	O
subjects	O
were	O
treated	O
with	O
two	O
doses	O
of	O
either	O
budesonide	O
(	O
BUD	O
)	O
or	O
fluticasone	O
propionate	O
(	O
FP	O
)	O
for	O
2	O
weeks	O
.	O

Before	O
treatment	O
,	O
at	O
regular	O
intervals	O
during	O
the	O
treatment	O
,	O
1	O
week	O
and	O
finally	O
6	O
weeks	O
after	O
termination	O
of	O
treatment	O
,	O
the	O
effects	O
on	O
glucocorticoid	O
receptor	O
(	O
GR	O
)	O
and	O
methallothionein	O
(	O
MTIIa	O
)	O
mRNA	O
expression	O
levels	O
were	O
examined	O
in	O
peripheral	B-cell_type
lymphocytes	I-cell_type
using	O
a	O
solution	O
hybridization	O
assay	O
.	O

Serum	O
cortisol	O
,	O
osteocalcin	O
and	O
urinary	O
cortisol	O
levels	O
were	O
also	O
determined	O
.	O

An	O
insulin	O
tolerance	O
test	O
(	O
ITT	O
)	O
was	O
performed	O
at	O
the	O
end	O
of	O
the	O
second	O
week	O
of	O
treatment	O
and	O
at	O
the	O
end	O
of	O
the	O
6-week	O
washout	O
period	O
with	O
no	O
statistically	O
significant	O
change	O
in	O
cortisol	O
response	O
.	O

In	O
peripheral	B-cell_type
lymphocytes	I-cell_type
,	O
GR	B-RNA
mRNA	I-RNA
levels	O
were	O
significantly	O
down-regulated	O
.	O

MTIIa	B-RNA
mRNA	I-RNA
levels	O
increased	O
significantly	O
.	O

Serum	O
osteocalcin	B-protein
decreased	O
significantly	O
during	O
treatment	O
with	O
both	O
BUD	O
and	O
FP	O
.	O

Serum	O
cortisol	O
decreased	O
after	O
1	O
week	O
of	O
treatment	O
whereas	O
urinary	O
cortisol	O
was	O
not	O
affected	O
until	O
the	O
second	O
week	O
of	O
treatment	O
.	O

In	O
conclusion	O
,	O
intranasal	O
glucocorticoids	O
at	O
clinically	O
recommended	O
doses	O
have	O
not	O
only	O
significant	O
systemic	O
effects	O
on	O
adrenal	O
function	O
,	O
but	O
also	O
have	O
an	O
effect	O
on	O
specific	O
gene	O
expression	O
in	O
peripheral	B-cell_type
lymphocytes	I-cell_type
.	O

These	O
effects	O
are	O
receptor-dependent	O
,	O
reversible	O
,	O
and	O
according	O
to	O
serum	O
and	O
urinary	O
cortisol	O
levels	O
and	O
ITT	O
,	O
leave	O
the	O
hypothalamic-pituitary-adrenal	O
function	O
intact	O
.	O

Finally	O
,	O
these	O
short-term	O
systemic	O
effects	O
were	O
not	O
associated	O
with	O
any	O
of	O
the	O
noticeable	O
side-effects	O
usually	O
observed	O
during	O
long-term	O
treatment	O
with	O
glucocorticoids	O
.	O

Biphasic	O
control	O
of	O
nuclear	B-protein
factor-kappa	I-protein
B	I-protein
activation	O
by	O
the	O
T	B-protein
cell	I-protein
receptor	I-protein
complex	I-protein
:	O
role	O
of	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
alpha	I-protein
.	O

The	O
regulation	O
of	O
nuclear	B-protein
factor	I-protein
(	I-protein
NF	I-protein
)	I-protein
-kappa	I-protein
B	I-protein
activation	O
by	O
the	O
T	B-protein
cell	I-protein
receptor	I-protein
(	I-protein
TcR	I-protein
)	I-protein
/CD3	I-protein
complex	I-protein
in	O
primary	O
human	O
T	B-cell_type
cells	I-cell_type
has	O
been	O
studied	O
at	O
various	O
times	O
after	O
activation	O
.	O

Only	O
p50	B-protein
NF-kappa	I-protein
B	I-protein
protein	I-protein
bound	O
the	O
kappa	B-DNA
B	I-DNA
element	I-DNA
of	O
interleukin-2	B-DNA
receptor	I-DNA
(	I-DNA
IL-2R	I-DNA
)	I-DNA
alpha	I-DNA
chain	I-DNA
promoter	I-DNA
on	O
resting	O
T	B-cell_type
cells	I-cell_type
.	O

However	O
,	O
immediately	O
after	O
TcR/CD3	B-protein
cross-linking	O
(	O
after	O
approximately	O
1	O
h	O
;	O
immediate	O
)	O
binding	O
of	O
p50.p65	B-protein
heterodimers	I-protein
was	O
observed	O
.	O

p50.c-rel	B-protein
heterodimers	I-protein
were	O
also	O
detected	O
bound	O
to	O
this	O
sequence	O
at	O
early	O
time	O
points	O
(	O
7-16	O
h	O
;	O
early	O
)	O
,	O
and	O
both	O
remained	O
active	O
at	O
later	O
time	O
points	O
(	O
40	O
h	O
;	O
late	O
)	O
after	O
activation	O
.	O

This	O
regulation	O
takes	O
place	O
mainly	O
at	O
the	O
level	O
of	O
nuclear	O
translocation	O
of	O
p65	B-protein
and	O
c-rel	B-protein
,	O
at	O
immediate	O
and	O
early	O
time	O
points	O
.	O

Activation	O
also	O
induced	O
c-rel	O
and	O
p105/p50	O
mRNA	O
synthesis	O
,	O
but	O
not	O
p65	B-RNA
mRNA	I-RNA
whose	O
expression	O
was	O
constitutive	O
.	O

Interestingly	O
,	O
all	O
those	O
early	O
and	O
late	O
events	O
,	O
but	O
not	O
the	O
immediate	O
ones	O
,	O
were	O
inhibited	O
by	O
a	O
neutralizing	O
anti-tumor	B-protein
necrosis	I-protein
factor	I-protein
alpha	I-protein
(	I-protein
TNF-alpha	I-protein
)	I-protein
monoclonal	I-protein
antibody	I-protein
.	O

Similarly	O
,	O
cycloheximide	O
prevented	O
the	O
p65	B-protein
and	O
c-rel	B-protein
translocation	O
and	O
consequent	O
formation	O
of	O
active	O
binding	O
heterodimers	O
,	O
at	O
early	O
and	O
late	O
times	O
.	O

Cyclosporin	O
A	O
impaired	O
not	O
only	O
early	O
and	O
late	O
,	O
but	O
also	O
immediate	O
events	O
;	O
however	O
,	O
addition	O
of	O
TNF-alpha	B-protein
prevented	O
all	O
inhibition	O
.	O

These	O
results	O
indicate	O
that	O
the	O
regulation	O
of	O
NF-kappa	B-protein
B	I-protein
activation	O
during	O
T	O
cell	O
activation	O
by	O
TcR/CD3	B-protein
signals	O
is	O
biphasic	O
:	O
TcR/CD3	B-protein
triggers	O
its	O
immediate	O
translocation	O
,	O
which	O
is	O
transient	O
if	O
no	O
TNF-alpha	B-protein
is	O
present	O
.	O

TNF-alpha	B-protein
,	O
therefore	O
,	O
emerges	O
as	O
the	O
main	O
factor	O
responsible	O
for	O
a	O
second	O
phase	O
of	O
NF-kappa	B-protein
B	I-protein
regulation	O
,	O
controlling	O
both	O
translocation	O
of	O
p65	B-protein
and	O
c-rel	B-protein
,	O
and	O
new	O
mRNA	B-RNA
synthesis	O
for	O
c-rel	B-protein
and	O
p105/p50	B-protein
.	O

The	O
transcription	B-protein
factor	I-protein
Sp1	I-protein
is	O
required	O
for	O
induction	O
of	O
the	O
murine	B-DNA
GM-CSF	I-DNA
promoter	I-DNA
in	O
T	B-cell_type
cells	I-cell_type
.	O

The	O
cis-acting	B-DNA
region	I-DNA
,	O
GM-kappa	B-DNA
B/GC-box	I-DNA
(	O
positions	B-DNA
-95	I-DNA
and	O
-73	B-DNA
)	O
,	O
within	O
the	O
murine	B-DNA
GM-CSF	I-DNA
gene	I-DNA
promoter	I-DNA
is	O
required	O
for	O
maximal	O
induction	O
by	O
stimulation	O
with	O
phorbol-12-myristate	O
acetate	O
(	O
PMA	O
)	O
and	O
calcium	O
ionophore	O
(	O
A23187	O
)	O
in	O
T	B-cell_type
cells	I-cell_type
.	O

GM-kappa	B-protein
B	I-protein
defines	O
a	O
binding	O
site	O
for	O
NF-kappa	B-protein
B	I-protein
,	O
and	O
GC-box	B-DNA
defines	O
a	O
binding	O
site	O
for	O
three	O
(	O
A1	B-protein
,	O
A2	B-protein
,	O
B	B-protein
)	O
constitutive	B-protein
proteins	I-protein
.	O

We	O
report	O
here	O
that	O
three	O
copies	O
of	O
the	O
GC-box	B-DNA
can	O
functionally	O
compensate	O
for	O
the	O
GM-kappa	B-DNA
B/GC-box	I-DNA
region	I-DNA
,	O
suggesting	O
that	O
the	O
GC-motif	O
can	O
function	O
independently	O
of	O
the	O
GM-kappa	B-DNA
B	I-DNA
motif	I-DNA
.	O

The	O
major	O
GC-box	B-DNA
binding	O
activity	O
A1	B-protein
was	O
purified	O
and	O
identified	O
as	O
the	O
transcription	B-protein
factor	I-protein
Sp1	I-protein
.	O

We	O
show	O
that	O
depletion	O
of	O
Sp1	B-protein
(	O
A1	B-protein
)	O
from	O
nuclear	O
extracts	O
specifically	O
decreases	O
in	O
vitro	O
transcription	O
activity	O
on	O
GM-CSF	B-protein
templates	O
.	O

Since	O
the	O
human	B-DNA
GM-CSF	I-DNA
promoter	I-DNA
has	O
a	O
base	O
difference	O
within	O
the	O
GC-box	B-DNA
,	O
we	O
speculate	O
that	O
this	O
may	O
explain	O
why	O
the	O
human	O
promoter	O
is	O
weak	O
and	O
that	O
an	O
upstream	B-DNA
enhancer	I-DNA
is	O
required	O
for	O
the	O
induction	O
of	O
the	O
human	B-DNA
GM-CSF	I-DNA
gene	I-DNA
.	O

A	O
factor	O
that	O
regulates	O
the	O
class	B-DNA
II	I-DNA
major	I-DNA
histocompatibility	I-DNA
complex	I-DNA
gene	I-DNA
DPA	B-DNA
is	O
a	O
member	O
of	O
a	O
subfamily	O
of	O
zinc	B-protein
finger	I-protein
proteins	I-protein
that	O
includes	O
a	O
Drosophila	B-protein
developmental	I-protein
control	I-protein
protein	I-protein
.	O

A	O
novel	O
DNA	B-DNA
sequence	I-DNA
element	I-DNA
termed	O
the	O
J	B-DNA
element	I-DNA
involved	O
in	O
the	O
regulated	O
expression	O
of	O
class	B-DNA
II	I-DNA
major	I-DNA
histocompatibility	I-DNA
complex	I-DNA
genes	I-DNA
was	O
recently	O
described	O
.	O

To	O
study	O
this	O
element	O
and	O
its	O
role	O
in	O
class	B-DNA
II	I-DNA
gene	I-DNA
regulation	O
further	O
,	O
a	O
cDNA	B-DNA
library	I-DNA
was	O
screened	O
with	O
oligonucleotide	O
probes	O
containing	O
both	O
the	O
S	B-DNA
element	I-DNA
and	O
the	O
nearby	O
J	B-DNA
element	I-DNA
of	O
the	O
human	B-DNA
DPA	I-DNA
gene	I-DNA
.	O

Several	O
DNA	B-DNA
clones	I-DNA
were	O
obtained	O
by	O
this	O
procedure	O
,	O
one	O
of	O
which	O
,	O
clone	B-DNA
18	I-DNA
,	O
is	O
reported	O
and	O
characterized	O
here	O
.	O

It	O
encodes	O
a	O
protein	O
predicted	O
to	O
contain	O
688	O
amino	O
acid	O
residues	O
,	O
including	O
11	O
zinc	B-protein
finger	I-protein
motifs	I-protein
of	O
the	O
C2H2	B-protein
type	I-protein
in	O
the	O
C-terminal	B-protein
region	I-protein
,	O
that	O
are	O
Kruppel-like	O
in	O
the	O
conservation	O
of	O
the	O
H/C	B-protein
link	I-protein
sequence	I-protein
connecting	O
them	O
.	O

The	O
160	B-protein
N-terminal	I-protein
amino	I-protein
acids	I-protein
in	O
the	O
nonfinger	B-protein
region	I-protein
of	O
clone	B-protein
18	I-protein
are	O
highly	O
homologous	O
with	O
similar	O
regions	O
of	O
several	O
other	O
human	B-DNA
,	I-DNA
mouse	I-DNA
,	I-DNA
and	I-DNA
Drosophila	I-DNA
sequences	I-DNA
,	O
defining	O
a	O
subfamily	O
of	O
Kruppel-like	O
zinc	B-protein
finger	I-protein
proteins	I-protein
termed	O
TAB	B-protein
(	O
tramtrack	B-protein
[	I-protein
ttk	I-protein
]	I-protein
-associated	I-protein
box	I-protein
)	O
here	O
.	O

One	O
of	O
the	O
Drosophila	B-DNA
sequences	I-DNA
,	O
ttk	B-DNA
,	O
is	O
a	O
developmental	B-DNA
control	I-DNA
gene	I-DNA
,	O
while	O
a	O
second	O
does	O
not	O
contain	O
a	O
zinc	B-protein
finger	I-protein
region	I-protein
but	O
encodes	O
a	O
structure	O
important	O
in	O
oocyte	O
development	O
.	O

An	O
acidic	B-protein
activation	I-protein
domain	I-protein
is	O
located	O
between	O
the	O
N-terminal	B-protein
conserved	I-protein
region	I-protein
of	O
clone	B-protein
18	I-protein
and	O
its	O
zinc	B-protein
fingers	I-protein
.	O

This	O
protein	O
appears	O
to	O
require	O
both	O
the	O
S	B-DNA
and	I-DNA
J	I-DNA
elements	I-DNA
,	O
which	O
are	O
separated	O
by	O
10	O
bp	O
for	O
optimal	O
binding	O
.	O

Antisense	O
cDNA	O
to	O
clone	B-protein
18	I-protein
inhibited	O
the	O
expression	O
of	O
a	O
reporter	O
construct	O
containing	O
the	O
DPA	B-DNA
promoter	I-DNA
,	O
indicating	O
its	O
functional	O
importance	O
in	O
the	O
expression	O
of	O
this	O
class	B-DNA
II	I-DNA
gene	I-DNA
.	O

Separation	O
of	O
oxidant-initiated	O
and	O
redox-regulated	O
steps	O
in	O
the	O
NF-kappa	B-protein
B	I-protein
signal	O
transduction	O
pathway	O
.	O

Studies	O
presented	O
here	O
show	O
that	O
overall	O
NF-kappa	B-protein
B	I-protein
signal	O
transduction	O
begins	O
with	O
a	O
parallel	O
series	O
of	O
stimuli-specific	O
pathways	O
through	O
which	O
cytokines	B-protein
(	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
alpha	I-protein
)	O
,	O
oxidants	O
(	O
hydrogen	O
peroxide	O
and	O
mitomycin	O
C	O
)	O
,	O
and	O
phorbol	O
ester	O
(	O
phorbol	O
12-myristate	O
13-acetate	O
)	O
individually	O
initiate	O
signaling	O
.	O

These	O
initial	O
pathways	O
culminate	O
in	O
a	O
common	O
pathway	O
through	O
which	O
all	O
of	O
the	O
stimulating	O
agents	O
ultimately	O
signal	O
NF-kappa	B-protein
B	I-protein
activation	O
.	O

We	O
distinguish	O
the	O
stimuli-specific	O
pathways	O
by	O
showing	O
that	O
the	O
oxidative	O
stimuli	O
trigger	O
NF-kappa	B-protein
B	I-protein
activation	O
in	O
only	O
one	O
of	O
two	O
human	B-cell_line
T-cell	I-cell_line
lines	I-cell_line
(	O
Wurzburg	B-cell_line
but	O
not	O
Jurkat	B-cell_line
)	O
,	O
whereas	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
alpha	I-protein
and	O
phorbol	O
12-myristate	O
13-acetate	O
readily	O
stimulate	O
in	O
both	O
lines	O
.	O

We	O
propose	O
the	O
common	O
pathway	O
as	O
the	O
simplest	O
way	O
of	O
accounting	O
for	O
the	O
common	O
requirements	O
and	O
properties	O
of	O
the	O
signaling	O
pathway	O
.	O

We	O
include	O
a	O
redox-regulatory	O
mechanism	O
(	O
s	O
)	O
in	O
this	O
common	O
pathway	O
to	O
account	O
for	O
the	O
previously	O
demonstrated	O
redox	O
regulation	O
of	O
NF-kappa	B-protein
B	I-protein
activation	O
in	O
Jurkat	B-cell_line
cells	I-cell_line
(	O
in	O
which	O
oxidants	O
do	O
n't	O
activate	O
NF-kappa	B-protein
B	I-protein
)	O
;	O
we	O
put	O
tyrosine	O
phosphorylation	O
in	O
the	O
common	O
pathway	O
by	O
showing	O
that	O
kinase	O
activity	O
(	O
inhibitable	O
by	O
herbimycin	O
A	O
and	O
tyrphostin	O
47	O
)	O
is	O
required	O
for	O
NF-kappa	B-protein
B	I-protein
activation	O
by	O
all	O
stimuli	O
tested	O
in	O
both	O
cell	O
lines	O
.	O

Since	O
internal	O
sites	O
of	O
oxidant	O
production	O
have	O
been	O
shown	O
to	O
play	O
a	O
key	O
role	O
in	O
the	O
cytokine	B-protein
-stimulated	O
activation	O
of	O
NF-kappa	B-protein
B	I-protein
,	O
and	O
since	O
tyrosine	O
kinase	O
and	O
phosphatase	O
activities	O
are	O
known	O
to	O
be	O
altered	O
by	O
oxidants	O
,	O
these	O
findings	O
suggest	O
that	O
intracellular	O
redox	O
status	O
controls	O
NF-kappa	B-protein
B	I-protein
activation	O
by	O
regulating	O
tyrosine	O
phosphorylation	O
event	O
(	O
s	O
)	O
within	O
the	O
common	O
step	O
of	O
the	O
NF-kappa	B-protein
B	I-protein
signal	O
transduction	O
pathway	O
.	O

Deleted	O
chromosome	B-DNA
20	I-DNA
from	O
a	O
patient	O
with	O
Alagille	O
syndrome	O
isolated	O
in	O
a	O
cell	O
hybrid	O
through	O
leucine	O
transport	O
selection	O
:	O
study	O
of	O
three	O
candidate	O
genes	O
.	O

Alagille	O
syndrome	O
(	O
AGS	O
)	O
is	O
a	O
well-defined	O
genetic	O
entity	O
assigned	O
to	O
the	O
short	B-DNA
arm	I-DNA
of	O
Chromosome	B-DNA
(	I-DNA
Chr	I-DNA
)	I-DNA
20	I-DNA
by	O
a	O
series	O
of	O
observations	O
of	O
AGS	O
patients	O
associated	O
with	O
microdeletions	O
in	O
this	O
region	O
.	O

By	O
fusing	O
lymphoblastoid	B-cell_type
cells	I-cell_type
of	O
an	O
AGS	O
patient	O
that	O
exhibited	O
a	O
microdeletion	O
in	O
the	O
short	B-DNA
arm	I-DNA
of	I-DNA
Chr	I-DNA
20	I-DNA
encompassing	O
bands	O
p11.23	B-DNA
to	I-DNA
p12.3	I-DNA
with	O
rodent	B-cell_line
thermosensitive	I-cell_line
mutant	I-cell_line
cells	I-cell_line
(	O
CHOtsH1-1	B-cell_line
)	O
deficient	O
in-leucyl-tRNA	B-protein
synthetase	I-protein
,	O
we	O
isolated	O
a	O
somatic	B-cell_line
cell	I-cell_line
hybrid	I-cell_line
segregating	O
the	O
deleted	O
human	O
Chr	B-DNA
20	I-DNA
.	O

This	O
hybrid	O
clone	O
,	O
designated	O
NR2	B-cell_line
,	O
was	O
characterized	O
by	O
several	O
methods	O
,	O
including	O
PCR	O
,	O
with	O
eight	O
pairs	O
of	O
oligonucleotides	O
mapped	O
to	O
Chr	B-DNA
20	I-DNA
:	O
D20S5	B-DNA
,	O
D20S41	B-DNA
,	O
D20S42	B-DNA
,	O
D20S56	B-DNA
,	O
D20S57	B-DNA
,	O
D20S58	B-DNA
,	O
adenosine	B-DNA
deaminase	I-DNA
(	O
ADA	B-protein
)	O
,	O
and	O
Prion	B-DNA
protein	I-DNA
(	O
PRIP	B-protein
)	O
;	O
Restriction	O
Fragment	O
Length	O
Polymorphism	O
(	O
RFLP	B-DNA
)	O
analyses	O
with	O
four	O
genomic	B-DNA
anonymous	I-DNA
probes	I-DNA
(	O
D20S5	B-DNA
,	O
cD3H12	B-DNA
,	O
D20S17	B-DNA
,	O
D20S18	B-DNA
)	O
;	O
and	O
fluorescent	O
in	O
situ	O
hybridization	O
(	O
FISH	O
)	O
with	O
total	B-DNA
human	I-DNA
DNA	I-DNA
and	O
D20Z1	B-DNA
,	O
a	O
sequence	O
specific	O
to	O
the	O
human	B-DNA
Chr	I-DNA
20	I-DNA
centromere	I-DNA
,	O
as	O
probes	O
.	O

The	O
NR2	B-cell_line
hybrid	I-cell_line
allowed	O
us	O
to	O
exclude	O
three	O
candidate	B-DNA
genes	I-DNA
for	O
AGS	O
:	O
hepatic	B-DNA
nuclear	I-DNA
factor	I-DNA
3	I-DNA
beta	I-DNA
(	O
HNF3	B-DNA
beta	I-DNA
)	O
,	O
paired	B-DNA
box	I-DNA
1	I-DNA
(	O
PAX1	B-DNA
)	O
,	O
and	O
cystatin	B-DNA
C	I-DNA
(	O
CST3	B-DNA
)	O
as	O
shown	O
by	O
their	O
localization	O
outside	O
of	O
the	O
deletion	O
.	O

The	O
NR2	B-cell_line
hybrid	I-cell_line
is	O
a	O
powerful	O
tool	O
for	O
the	O
mapping	O
of	O
new	O
probes	O
of	O
this	O
region	O
,	O
as	O
well	O
as	O
for	O
obtaining	O
new	O
informative	O
probes	O
specific	O
for	O
the	O
deletion	O
by	O
subtractive	O
cloning	O
of	O
the	O
region	O
.	O

Such	O
markers	O
will	O
be	O
useful	O
for	O
linkage	O
analysis	O
and	O
screening	O
of	O
cDNA	B-DNA
libraries	I-DNA
.	O

Positive	O
and	O
negative	O
regulation	O
of	O
the	O
composite	B-DNA
octamer	I-DNA
motif	I-DNA
of	O
the	O
interleukin	B-DNA
2	I-DNA
enhancer	I-DNA
by	O
AP-1	B-protein
,	O
Oct-2	B-protein
,	O
and	O
retinoic	B-protein
acid	I-protein
receptor	I-protein
.	O

The	O
differentiating	O
agent	O
retinoic	O
acid	O
(	O
RA	O
)	O
has	O
been	O
previously	O
reported	O
to	O
interfere	O
with	O
12-O-tetradecanoyl-phorbol-13-acetate	O
(	O
TPA	O
)	O
/Ca	O
(	O
2+	O
)	O
-induced	O
signals	O
for	O
the	O
regulation	O
of	O
the	O
-96	B-DNA
to	I-DNA
-66-bp	I-DNA
octamer	I-DNA
motif	I-DNA
found	O
in	O
the	O
enhancer	O
for	O
the	O
interleukin	B-DNA
(	I-DNA
IL	I-DNA
)	I-DNA
-2	I-DNA
gene	I-DNA
,	O
which	O
encodes	O
a	O
major	O
T	B-protein
lymphocyte	I-protein
growth	I-protein
factor	I-protein
.	O

The	O
IL-2	B-DNA
octamer	I-DNA
motif	I-DNA
is	O
a	O
composite	O
cis-element	B-DNA
which	O
binds	O
Oct-1	B-protein
and	O
Oct-2	B-protein
as	O
well	O
as	O
a	O
TPA/Ca	B-protein
(	I-protein
2+	I-protein
)	I-protein
-inducible	I-protein
nuclear	I-protein
factor	I-protein
,	O
previously	O
termed	O
octamer-associated	B-protein
protein	I-protein
(	O
OAP40	B-protein
)	O
.	O

We	O
show	O
here	O
that	O
Oct-2	B-protein
,	O
despite	O
the	O
presence	O
of	O
an	O
active	O
transcriptional	O
activation	O
domain	O
,	O
requires	O
TPA/Ca	O
(	O
2+	O
)	O
-induced	O
signals	O
to	O
strongly	O
transactivate	O
the	O
IL-2	B-DNA
octamer	I-DNA
motif	I-DNA
in	O
Jurkat	O
T	O
cells	O
.	O

This	O
Oct-2	B-protein
-dependent	O
transactivation	O
is	O
inhibited	O
by	O
RA	O
.	O

The	O
presence	O
of	O
an	O
intact	B-protein
COOH-terminal	I-protein
domain	I-protein
of	O
Oct-2	B-protein
contributes	O
to	O
both	O
TPA/Ca	O
(	O
2+	O
)	O
-induced	O
transactivation	O
and	O
the	O
RA-mediated	O
repression	O
.	O

We	O
also	O
show	O
that	O
both	O
Fos	B-protein
and	O
Jun	B-protein
components	O
of	O
the	O
AP-1	B-protein
factors	O
participate	O
in	O
the	O
OAP40	B-protein
complex	I-protein
.	O

Furthermore	O
,	O
transfected	O
c-jun	B-DNA
,	I-DNA
jun-B	I-DNA
,	I-DNA
jun-D	I-DNA
,	I-DNA
c-fos	I-DNA
,	I-DNA
or	I-DNA
Fos-B	I-DNA
expression	I-DNA
vectors	I-DNA
partially	O
substitute	O
for	O
TPA	O
and	O
Ca2+	O
and	O
cooperate	O
with	O
Oct-2	B-protein
for	O
the	O
transactivation	O
of	O
the	O
combined	O
OAP/octamer	B-DNA
cis-element	I-DNA
.	O

Mutations	O
of	O
the	O
genuine	B-DNA
octamer-binding	I-DNA
site	I-DNA
abrogate	O
both	O
the	O
binding	O
of	O
Oct-1	B-protein
and	O
Oct-2	B-protein
and	O
the	O
TPA/Ca	O
(	O
2+	O
)	O
-induced	O
transactivation	O
of	O
the	O
OAP/octamer	B-DNA
motif	I-DNA
.	O

OAP	B-protein
confers	O
to	O
Oct-2	B-protein
responsivity	O
to	O
both	O
TPA/Ca2+	O
and	O
RA	O
,	O
since	O
specific	O
mutations	O
of	O
the	O
AP-1/OAP-binding	B-DNA
site	I-DNA
significantly	O
reduce	O
the	O
transactivation	O
by	O
Oct-2	B-protein
in	O
response	O
to	O
TPA	O
and	O
Ca2+	O
and	O
abolish	O
the	O
inhibition	O
by	O
RA	O
.	O

Furthermore	O
,	O
retinoic	B-protein
acid	I-protein
receptor	I-protein
(	O
RAR	B-protein
)	O
alpha	O
is	O
able	O
to	O
inhibit	O
in	O
vitro	O
the	O
formation	O
of	O
the	O
complex	O
between	O
the	O
nuclear	O
AP-1	B-protein
/OAP	B-protein
and	O
its	O
specific	O
binding	O
site	O
,	O
resulting	O
in	O
the	O
interference	O
with	O
Oct-2	B-protein
-dependent	O
cis-regulatory	O
function	O
of	O
this	O
AP-1	B-protein
element	O
.	O

Therefore	O
,	O
we	O
propose	O
that	O
the	O
TPA/calcium-activated	O
AP-1	B-protein
/OAP	B-protein
element	O
is	O
the	O
main	O
target	O
of	O
positive	O
or	O
negative	O
regulatory	O
signals	O
influencing	O
the	O
IL-2	B-DNA
octamer	I-DNA
motif	I-DNA
,	O
through	O
synergism	O
with	O
Oct-2	B-protein
and	O
antagonism	O
by	O
RAR	B-protein
.	O

Missense	O
mutation	O
in	O
exon	B-DNA
7	I-DNA
of	O
the	O
common	B-DNA
gamma	I-DNA
chain	I-DNA
gene	I-DNA
causes	O
a	O
moderate	O
form	O
of	O
X-linked	O
combined	O
immunodeficiency	O
.	O

Clinical	O
and	O
immunologic	O
features	O
of	O
a	O
recently	O
recognized	O
X-linked	O
combined	O
immunodeficiency	O
disease	O
(	O
XCID	O
)	O
suggested	O
that	O
XCID	O
and	O
X-linked	O
severe	O
combined	O
immunodeficiency	O
(	O
XSCID	O
)	O
might	O
arise	O
from	O
different	O
genetic	O
defects	O
.	O

The	O
recent	O
discovery	O
of	O
mutations	O
in	O
the	O
common	B-DNA
gamma	I-DNA
chain	I-DNA
(	I-DNA
gamma	I-DNA
c	I-DNA
)	I-DNA
gene	I-DNA
,	O
a	O
constituent	O
of	O
several	O
cytokine	B-protein
receptors	I-protein
,	O
in	O
XSCID	O
provided	O
an	O
opportunity	O
to	O
test	O
directly	O
whether	O
a	O
previously	O
unrecognized	O
mutation	O
in	O
this	O
same	O
gene	O
was	O
responsible	O
for	O
XCID	O
.	O

The	O
status	O
of	O
X	B-DNA
chromosome	I-DNA
inactivation	O
in	O
blood	O
leukocytes	O
from	O
obligate	O
carriers	O
of	O
XCID	O
was	O
determined	O
from	O
the	O
polymorphic	O
,	O
short	O
tandem	O
repeats	O
(	O
CAG	O
)	O
,	O
in	O
the	O
androgen	B-DNA
receptor	I-DNA
gene	I-DNA
,	O
which	O
also	O
contains	O
a	O
methylation-sensitive	B-DNA
HpaII	I-DNA
site	I-DNA
.	O

As	O
in	O
XSCID	O
,	O
X-chromosome	O
inactivation	O
in	O
obligate	O
carriers	O
of	O
XCID	O
was	O
nonrandom	O
in	O
T	B-cell_type
and	I-cell_type
B	I-cell_type
lymphocytes	I-cell_type
.	O

In	O
addition	O
,	O
X	B-DNA
chromosome	I-DNA
inactivation	O
in	O
PMNs	O
was	O
variable	O
.	O

Findings	O
from	O
this	O
analysis	O
prompted	O
sequencing	O
of	O
the	O
gamma	B-DNA
c	I-DNA
gene	I-DNA
in	O
this	O
pedigree	O
.	O

A	O
missense	O
mutation	O
in	O
the	O
region	O
coding	O
for	O
the	O
cytoplasmic	O
portion	O
of	O
the	O
gamma	B-DNA
c	I-DNA
gene	I-DNA
was	O
found	O
in	O
three	O
affected	O
males	O
but	O
not	O
in	O
a	O
normal	O
brother	O
.	O

Therefore	O
,	O
this	O
point	O
mutation	O
in	O
the	O
gamma	B-DNA
c	I-DNA
gene	I-DNA
leads	O
to	O
a	O
less	O
severe	O
degree	O
of	O
deficiency	O
in	O
cellular	O
and	O
humoral	O
immunity	O
than	O
that	O
seen	O
in	O
XSCID	O
.	O

Posttranscriptional	O
regulation	O
of	O
macrophage	O
tissue	B-protein
factor	I-protein
expression	O
by	O
antioxidants	O
.	O

Tissue	B-protein
factor	I-protein
(	O
TF	B-protein
)	O
expression	O
by	O
cells	O
of	O
monocyte/macrophage	B-cell_type
lineage	I-cell_type
represents	O
an	O
important	O
mechanism	O
underlying	O
the	O
initiation	O
of	O
fibrin	B-protein
deposition	O
at	O
sites	O
of	O
extravascular	O
inflammation	O
.	O

Recent	O
evidence	O
suggests	O
a	O
role	O
for	O
oxidant	O
stress	O
in	O
the	O
signalling	O
pathway	O
of	O
various	O
cell	O
types	O
by	O
virtue	O
of	O
its	O
ability	O
to	O
induce	O
DNA	O
binding	O
of	O
various	O
transcription	B-protein
factors	I-protein
,	O
including	O
nuclear	B-protein
factor	I-protein
kappa	I-protein
B	I-protein
and	O
AP-1	B-protein
.	O

The	O
effect	O
of	O
antioxidant	O
treatment	O
on	O
lipopolysaccharide	O
(	O
LPS	O
)	O
-induced	O
TF	B-protein
expression	O
was	O
examined	O
in	O
murine	B-cell_type
peritoneal	I-cell_type
macrophages	I-cell_type
and	O
human	B-cell_type
monocytes	I-cell_type
.	O

Both	O
pyrrolidine	O
dithiocarbamate	O
,	O
an	O
oxidant	O
scavenger	O
,	O
and	O
N-acetyl-cysteine	O
,	O
a	O
precursor	O
of	O
the	O
endogenous	O
antioxidant	O
glutathione	O
,	O
inhibited	O
stimulation	O
of	O
macrophage	O
procoagulant	O
activity	O
by	O
LPS	O
.	O

Northern	O
blot	O
analysis	O
showed	O
that	O
neither	O
of	O
these	O
agents	O
reduced	O
LPS-stimulated	O
TF	B-protein
mRNA	O
accumulation	O
,	O
thereby	O
suggesting	O
a	O
posttranscriptional	O
mechanism	O
for	O
the	O
effect	O
.	O

Immunofluorescence	O
studies	O
of	O
human	B-cell_type
monocytes	I-cell_type
using	O
polyclonal	O
anti-TF	B-protein
antibody	I-protein
showed	O
that	O
N-acetyl-cysteine	O
treatment	O
prevented	O
the	O
characteristic	O
plasmalemmal	O
localization	O
of	O
TF	B-protein
antigen	I-protein
that	O
occurs	O
in	O
response	O
to	O
LPS	O
.	O

Western	O
blot	O
analysis	O
showed	O
that	O
N-acetyl-cysteine	O
reduced	O
the	O
accumulation	O
of	O
the	O
47-kD	B-protein
mature	I-protein
glycoprotein	I-protein
in	O
LPS-treated	B-cell_line
cells	I-cell_line
,	O
a	O
finding	O
consistent	O
with	O
the	O
results	O
of	O
the	O
immunofluorescence	O
studies	O
.	O

Furthermore	O
,	O
these	O
conditions	O
did	O
not	O
result	O
in	O
an	O
accumulation	O
of	O
the	O
less	O
mature	O
forms	O
of	O
TF	B-protein
.	O

When	O
considered	O
together	O
,	O
these	O
data	O
suggest	O
that	O
antioxidants	O
exert	O
their	O
effects	O
by	O
impairing	O
translation	O
and/or	O
by	O
causing	O
degradation	O
of	O
newly	O
translated	B-protein
protein	I-protein
.	O

The	O
effect	O
of	O
antioxidants	O
on	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
appeared	O
to	O
be	O
species	O
specific	O
,	O
with	O
no	O
effect	O
on	O
LPS-induced	O
tumor	O
necrosis	O
factor	O
in	O
murine	O
cells	O
,	O
but	O
with	O
inhibition	O
in	O
human	B-cell_type
monocytes	I-cell_type
.	O

The	O
posttranscriptional	O
effect	O
of	O
antioxidants	O
on	O
TF	B-protein
expression	O
data	O
suggests	O
a	O
novel	O
mechanism	O
whereby	O
these	O
agents	O
might	O
modulate	O
monocyte	B-cell_type
/macrophage	B-cell_type
activation	O
.	O

Characterization	O
of	O
the	O
CD48	B-DNA
gene	I-DNA
demonstrates	O
a	O
positive	O
element	O
that	O
is	O
specific	O
to	O
Epstein-Barr	B-cell_type
virus-immortalized	I-cell_type
B-cell	I-cell_type
lines	I-cell_type
and	O
contains	O
an	O
essential	O
NF-kappa	B-DNA
B	I-DNA
site	I-DNA
.	O

Epstein-Barr	O
virus	O
(	O
EBV	O
)	O
infection	O
of	O
mature	O
,	O
resting	B-cell_type
B	I-cell_type
cells	I-cell_type
drives	O
them	O
to	O
become	O
lymphoblasts	O
expressing	O
high	O
levels	O
of	O
cell	O
surface	O
molecules	O
,	O
such	O
as	O
CD48	B-protein
,	O
characteristically	O
expressed	O
on	O
normal	B-cell_type
activated	I-cell_type
B	I-cell_type
cells	I-cell_type
.	O

Here	O
,	O
we	O
report	O
on	O
the	O
identification	O
of	O
an	O
enhancer	B-DNA
element	I-DNA
in	O
the	O
CD48	B-DNA
gene	I-DNA
which	O
reproducibly	O
confers	O
strong	O
transcriptional	O
activity	O
only	O
in	O
EBV-positive	B-cell_line
B-lymphoblastoid	I-cell_line
cell	I-cell_line
lines	I-cell_line
.	O

The	O
element	O
is	O
not	O
activated	O
upon	O
infection	O
of	O
established	O
EBV-negative	B-cell_line
B-cell	I-cell_line
lines	I-cell_line
,	O
indicating	O
that	O
EBV	O
fails	O
to	O
drive	O
these	O
cells	O
to	O
a	O
fully	O
lymphoblastoid	B-cell_type
phenotype	I-cell_type
.	O

An	O
NF-kappa	B-protein
B	I-protein
binding	O
site	O
is	O
an	O
essential	O
component	O
of	O
the	O
element	O
but	O
alone	O
is	O
not	O
sufficient	O
to	O
account	O
for	O
the	O
activity	O
or	O
the	O
specificity	O
of	O
the	O
element	O
.	O

We	O
have	O
detected	O
a	O
specific	O
nuclear	B-protein
protein	I-protein
complex	I-protein
that	O
binds	O
to	O
the	O
element	O
and	O
show	O
that	O
NF-kappa	B-protein
B1	I-protein
(	O
p50	B-protein
)	O
is	O
a	O
part	O
of	O
this	O
complex	O
.	O

The	O
EBV-encoded	B-protein
latent	I-protein
membrane	I-protein
protein	I-protein
1	I-protein
is	O
capable	O
of	O
transactivating	O
the	O
isolated	O
CD48	B-protein
NF-kappa	B-DNA
B	I-DNA
site	I-DNA
but	O
not	O
the	O
intact	B-DNA
element	I-DNA
,	O
suggesting	O
that	O
the	O
latent	B-protein
membrane	I-protein
protein	I-protein
1	I-protein
-driven	O
activation	O
of	O
NF-kappa	B-protein
B/Rel	I-protein
must	O
interact	O
with	O
other	O
regulatory	O
pathways	O
to	O
control	O
expression	O
of	O
cellular	O
genes	O
as	O
EBV	O
drives	O
resting	B-cell_type
B	I-cell_type
cells	I-cell_type
into	O
the	O
cell	O
cycle	O
.	O

Thapsigargin	O
induces	O
IL-2	B-protein
receptor	I-protein
alpha-chain	I-protein
in	O
human	B-cell_type
peripheral	I-cell_type
and	O
Jurkat	B-cell_line
T	I-cell_line
cells	I-cell_line
via	O
a	O
protein	B-protein
kinase	I-protein
C	I-protein
-independent	O
mechanism	O
.	O

Thapsigargin	O
(	O
TG	O
)	O
,	O
an	O
inhibitor	O
of	O
Ca	B-protein
(	I-protein
2+	I-protein
)	I-protein
-ATPase	I-protein
,	O
depletes	O
intracellular	O
Ca2+	O
stores	O
and	O
induces	O
a	O
sustained	O
Ca2+	O
influx	O
without	O
altering	O
phosphatidyl	O
inositol	O
levels	O
.	O

TG	O
plus	O
phorbol	O
myristate	O
acetate	O
(	O
PMA	O
)	O
but	O
not	O
TG	O
alone	O
induced	O
IL-2	B-protein
in	O
Jurkat	B-cell_line
T	I-cell_line
cells	I-cell_line
,	O
suggesting	O
that	O
TG	O
had	O
no	O
effect	O
on	O
protein	B-protein
kinase	I-protein
C	I-protein
(	O
PKC	B-protein
)	O
.	O

However	O
,	O
TG	O
induced	O
increases	O
in	O
IL-2R	B-protein
alpha	I-protein
protein	I-protein
as	O
well	O
as	O
IL-2R	B-RNA
alpha	I-RNA
mRNA	I-RNA
in	O
Jurkat	B-cell_line
T	I-cell_line
cells	I-cell_line
in	O
a	O
dose-dependent	O
manner	O
.	O

A	O
similar	O
increase	O
in	O
IL-2R	B-protein
alpha	I-protein
by	O
TG	O
was	O
also	O
observed	O
in	O
human	B-cell_type
peripheral	I-cell_type
T	I-cell_type
cells	I-cell_type
.	O

Further	O
,	O
like	O
PMA	O
,	O
TG	O
markedly	O
induced	O
NF	B-protein
kappa	I-protein
B	I-protein
in	O
Jurkat	B-cell_line
T	I-cell_line
cells	I-cell_line
.	O

However	O
,	O
TG	O
and	O
PMA	O
exhibited	O
a	O
synergistic	O
action	O
on	O
IL-2R	B-protein
alpha	I-protein
expression	O
,	O
suggesting	O
that	O
TG	O
and	O
PMA	O
induce	O
IL-2R	B-protein
alpha	I-protein
through	O
distinct	O
pathways	O
.	O

PMA	B-protein
-but	I-protein
not	I-protein
TG-induced	I-protein
IL-2R	I-protein
alpha	I-protein
is	O
inhibited	O
by	O
the	O
PKC	B-protein
inhibitor	O
H7	O
,	O
whereas	O
TG	B-protein
-but	I-protein
not	I-protein
PMA-induced	I-protein
IL-2R	I-protein
alpha	I-protein
was	O
inhibited	O
by	O
cholera	O
toxin	O
,	O
forskolin	O
and	O
1	O
,	O
9-dideoxy	O
forskolin	O
.	O

In	O
toto	O
,	O
these	O
results	O
suggest	O
that	O
TG	O
induces	O
IL-2R	B-protein
alpha	I-protein
in	O
human	B-cell_type
T	I-cell_type
cells	I-cell_type
through	O
a	O
PKC	B-protein
-independent	O
pathway	O
.	O

Physiological	O
concentration	O
of	O
estradiol	O
inhibits	O
polymorphonuclear	B-cell_type
leukocyte	I-cell_type
chemotaxis	O
via	O
a	O
receptor	O
mediated	O
system	O
.	O

Estrogen	O
exhibits	O
a	O
variety	O
of	O
actions	O
,	O
including	O
immuno-modulatory	O
effects	O
,	O
in	O
vivo	O
and	O
in	O
vitro	O
.	O

The	O
mechanism	O
by	O
which	O
estrogen	O
exerts	O
its	O
anti-inflammatory	O
effect	O
is	O
not	O
yet	O
understood	O
.	O

We	O
investigated	O
the	O
possible	O
mechanisms	O
of	O
estradiol	O
acting	O
via	O
the	O
polymorphonuclear	B-cell_type
leukocytes	I-cell_type
(	O
PMNs	B-cell_type
)	O
,	O
which	O
are	O
important	O
in	O
the	O
immune	O
response	O
.	O

The	O
agent	O
,	O
17	O
beta-estradiol	O
,	O
but	O
not	O
17	O
alpha-estradiol	O
,	O
significantly	O
reduced	O
PMNs	B-cell_type
chemotaxis	O
to	O
FMLP	O
in	O
a	O
dose-dependent	O
manner	O
(	O
control	O
vs	O
estrogen	O
10	O
(	O
-10	O
)	O
-	O
(	O
-6	O
)	O
M	O
,	O
P	O
<	O
0.05	O
)	O
.	O

Physiological	O
concentrations	O
of	O
estradiol	O
significantly	O
reduced	O
the	O
chemotaxis	O
of	O
PMNs	B-cell_type
(	O
10	O
(	O
-10	O
)	O
mol	O
)	O
.	O

Pre-incubation	O
with	O
clomiphene	O
or	O
tamoxifen	O
which	O
are	O
estrogen	O
receptor	O
antagonists	O
,	O
eliminated	O
the	O
inhibitory	O
effect	O
of	O
17	O
beta-estradiol	O
on	O
the	O
chemotaxis	O
of	O
PMNs	B-cell_type
,	O
restoring	O
it	O
to	O
the	O
control	O
level	O
.	O

These	O
observations	O
suggest	O
that	O
17	O
beta-estradiol	O
suppressed	O
the	O
chemotaxis	O
of	O
PMNs	B-cell_type
by	O
a	O
receptor-dependent	O
mechanism	O
.	O

In	O
addition	O
,	O
the	O
level	O
of	O
estradiol	O
in	O
human	B-cell_type
plasma	I-cell_type
,	O
which	O
PMNs	B-cell_type
were	O
drawn	O
,	O
showed	O
a	O
close	O
,	O
inverse	O
correlation	O
with	O
the	O
PMNs	B-cell_type
chemotaxis	O
to	O
FMLP	O
(	O
r	O
=	O
-0.821	O
p	O
<	O
0.001	O
)	O
.	O

Estrogen	O
may	O
modify	O
the	O
activity	O
of	O
neutrophils	B-cell_type
during	O
the	O
normal	O
menstrual	O
cycle	O
,	O
not	O
only	O
during	O
pregnancy	O
,	O
and	O
influence	O
inflammation	O
.	O

Identification	O
of	O
the	O
TCL1	B-DNA
gene	I-DNA
involved	O
in	O
T-cell	B-cell_type
malignancies	O
.	O

The	O
TCL1	B-DNA
locus	I-DNA
on	O
chromosome	B-DNA
14q32.1	I-DNA
is	O
frequently	O
involved	O
in	O
chromosomal	O
translocations	O
and	O
inversions	O
with	O
one	O
of	O
the	O
T-cell	B-DNA
receptor	I-DNA
loci	I-DNA
in	O
human	O
T-cell	O
leukemias	O
and	O
lymphomas	O
.	O

The	O
chromosome	B-DNA
14	I-DNA
region	I-DNA
translocated	O
or	O
rearranged	O
involves	O
approximately	O
350	O
kb	O
of	O
DNA	O
at	O
chromosome	O
band	O
14q32.1	O
.	O

Within	O
this	O
region	O
we	O
have	O
identified	O
a	O
gene	O
coding	O
for	O
a	O
1.3-kb	B-RNA
transcript	I-RNA
,	O
expressed	O
only	O
in	O
restricted	O
subsets	O
of	O
cells	O
within	O
the	O
lymphoid	B-cell_type
lineage	I-cell_type
and	O
expressed	O
at	O
high	O
levels	O
in	O
leukemic	B-cell_type
cells	I-cell_type
carrying	O
a	O
t	O
(	O
14	O
;	O
14	O
)	O
(	O
q11	O
;	O
q32	O
)	O
chromosome	O
translocation	O
or	O
a	O
inv	O
(	O
14	O
)	O
(	O
q11	O
;	O
q32	O
)	O
chromosome	O
inversion	O
.	O

The	O
cognate	B-DNA
cDNA	I-DNA
sequence	I-DNA
reveals	O
an	O
open	B-DNA
reading	I-DNA
frame	I-DNA
of	O
342	O
nt	O
encoding	O
a	O
protein	B-protein
of	I-protein
14	I-protein
kDa	I-protein
.	O

The	O
TCL1	B-DNA
gene	I-DNA
sequence	O
,	O
which	O
,	O
to	O
our	O
knowledge	O
,	O
shows	O
no	O
sequence	O
homology	O
with	O
other	O
human	B-DNA
genes	I-DNA
,	O
is	O
preferentially	O
expressed	O
early	O
in	O
T-	B-cell_type
and	I-cell_type
B-lymphocyte	I-cell_type
differentiation	O
.	O

Identification	O
of	O
a	O
region	O
which	O
directs	O
the	O
monocytic	O
activity	O
of	O
the	O
colony-stimulating	B-DNA
factor	I-DNA
1	I-DNA
(	I-DNA
macrophage	I-DNA
colony-stimulating	I-DNA
factor	I-DNA
)	I-DNA
receptor	I-DNA
promoter	I-DNA
and	O
binds	O
PEBP2/CBF	B-protein
(	O
AML1	B-protein
)	O
.	O

The	O
receptor	O
for	O
the	O
macrophage	B-protein
colony-stimulating	I-protein
factor	I-protein
(	O
or	O
colony-stimulating	B-protein
factor	I-protein
1	I-protein
[	O
CSF-1	B-protein
]	O
)	O
is	O
expressed	O
from	O
different	O
promoters	O
in	O
monocytic	B-cell_type
cells	I-cell_type
and	O
placental	B-cell_type
trophoblasts	I-cell_type
.	O

We	O
have	O
demonstrated	O
that	O
the	O
monocyte-specific	O
expression	O
of	O
the	O
CSF-1	B-protein
receptor	I-protein
is	O
regulated	O
at	O
the	O
level	O
of	O
transcription	O
by	O
a	O
tissue-specific	B-DNA
promoter	I-DNA
whose	O
activity	O
is	O
stimulated	O
by	O
the	O
monocyte/B-cell-specific	B-protein
transcription	I-protein
factor	I-protein
PU.1	B-protein
(	O
D.-E.Zhang	O
,	O
C.J.Hetherington	O
,	O
H.-M.Chen	O
,	O
and	O
D.G.Tenen	O
,	O
Mol.Cell.	O
Biol.14	O
:	O
373-381	O
,	O
1994	O
)	O
.	O

Here	O
we	O
report	O
that	O
the	O
tissue	O
specificity	O
of	O
this	O
promoter	B-DNA
is	O
also	O
mediated	O
by	O
sequences	O
in	O
a	O
region	B-DNA
II	I-DNA
(	O
bp	O
-88	O
to	O
-	O
59	O
)	O
,	O
which	O
lies	O
10	B-DNA
bp	I-DNA
upstream	I-DNA
from	O
the	O
PU.1-binding	B-DNA
site	I-DNA
.	O

When	O
analyzed	O
by	O
DNase	B-protein
footprinting	O
,	O
region	B-DNA
II	I-DNA
was	O
protected	O
preferentially	O
in	O
monocytic	B-cell_type
cells	I-cell_type
.	O

Electrophoretic	O
mobility	O
shift	O
assays	O
confirmed	O
that	O
region	B-DNA
II	I-DNA
interacts	O
specifically	O
with	O
nuclear	B-protein
proteins	I-protein
from	O
monocytic	B-cell_type
cells	I-cell_type
.	O

Two	O
gel	B-protein
shift	I-protein
complexes	I-protein
(	O
Mono	B-protein
A	I-protein
and	O
Mono	B-protein
B	I-protein
)	O
were	O
formed	O
with	O
separate	O
sequence	O
elements	O
within	O
this	O
region	O
.	O

Competition	O
and	O
supershift	O
experiments	O
indicate	O
that	O
Mono	B-protein
B	I-protein
contains	O
a	O
member	O
of	O
the	O
polyomavirus	B-protein
enhancer-binding	I-protein
protein	I-protein
2/core-binding	I-protein
factor	I-protein
(	I-protein
PEBP2/CBF	I-protein
)	I-protein
family	I-protein
,	I-protein
which	O
includes	O
the	O
AML1	O
gene	O
product	O
,	O
while	O
Mono	B-protein
A	I-protein
is	O
a	O
distinct	O
complex	O
preferentially	O
expressed	O
in	O
monocytic	B-cell_type
cells	I-cell_type
.	O

Promoter	B-DNA
constructs	I-DNA
with	O
mutations	O
in	O
these	O
sequence	O
elements	O
were	O
no	O
longer	O
expressed	O
specifically	O
in	O
monocytes	B-cell_type
.	O

Furthermore	O
,	O
multimerized	B-DNA
region	I-DNA
II	I-DNA
sequence	I-DNA
elements	I-DNA
enhanced	O
the	O
activity	O
of	O
a	O
heterologous	O
thymidine	O
kinase	O
promoter	O
in	O
monocytic	B-cell_type
cells	I-cell_type
but	O
not	O
other	O
cell	O
types	O
tested	O
.	O

These	O
results	O
indicate	O
that	O
the	O
monocyte/B-cell-specific	B-protein
transcription	I-protein
factor	I-protein
PU.1	B-protein
and	O
the	O
Mono	B-protein
A	I-protein
and	I-protein
Mono	I-protein
B	I-protein
protein	I-protein
complexes	I-protein
act	O
in	O
concert	O
to	O
regulate	O
monocyte-specific	O
transcription	O
of	O
the	O
CSF-1	B-protein
receptor	I-protein
.	O

Pyrrolidine	O
dithiocarbamate	O
,	O
a	O
potent	O
inhibitor	O
of	O
nuclear	B-protein
factor	I-protein
kappa	I-protein
B	I-protein
(	O
NF-kappa	B-protein
B	I-protein
)	O
activation	O
,	O
prevents	O
apoptosis	O
in	O
human	O
promyelocytic	B-cell_line
leukemia	I-cell_line
HL-60	I-cell_line
cells	I-cell_line
and	O
thymocytes	B-cell_type
.	O

We	O
examined	O
the	O
effect	O
of	O
pyrrolidine	O
dithiocarbamate	O
(	O
PDTC	O
)	O
,	O
which	O
potently	O
blocks	O
the	O
activation	O
of	O
nuclear	B-protein
factor	I-protein
kappa	I-protein
B	I-protein
(	O
NF-kappa	B-protein
B	I-protein
)	O
,	O
on	O
the	O
induction	O
of	O
apoptosis	O
by	O
a	O
variety	O
of	O
agents	O
.	O

Treatment	O
of	O
a	O
human	B-cell_line
promyelocytic	I-cell_line
leukemia	I-cell_line
cell	I-cell_line
line	I-cell_line
,	O
HL-60	B-cell_line
,	O
with	O
10	O
micrograms/mL	O
etoposide	O
or	O
2	O
microM	O
1-beta-D-arabinofuranosylcytosine	O
induced	O
NF-kappa	B-protein
B	I-protein
activation	O
within	O
1	O
hr	O
and	O
subsequently	O
caused	O
apoptosis	O
within	O
3-4	O
hr	O
.	O

The	O
simultaneous	O
addition	O
of	O
50-500	O
microM	O
PDTC	O
with	O
these	O
agents	O
blocked	O
NF-kappa	B-protein
B	I-protein
activation	O
and	O
completely	O
abrogated	O
both	O
morphologically	O
apoptotic	O
changes	O
and	O
internucleosomal	O
DNA	O
fragmentation	O
for	O
up	O
to	O
6	O
hr	O
.	O

However	O
,	O
PDTC	O
failed	O
to	O
inhibit	O
the	O
endonuclease	B-protein
activity	O
contained	O
in	O
the	O
whole	O
cell	O
lysates	O
.	O

The	O
inhibitory	O
effect	O
of	O
PDTC	O
was	O
also	O
observed	O
in	O
etoposide	O
-and	O
dexamethasone-induced	O
apoptosis	O
in	O
human	B-cell_type
thymocytes	I-cell_type
at	O
a	O
concentration	O
of	O
1-10	O
microM	O
.	O

Since	O
PDTC	O
has	O
both	O
antioxidant	O
and	O
metal-ion	O
chelating	O
activities	O
,	O
we	O
tested	O
the	O
effects	O
of	O
N-acetyl-L-cysteine	O
(	O
NAC	O
)	O
(	O
antioxidant	O
)	O
or	O
o-phenanthroline	O
(	O
OP	O
)	O
(	O
metal-ion	O
chelator	O
)	O
on	O
the	O
induction	O
of	O
apoptosis	O
.	O

Pretreatment	O
of	O
HL-60	O
cells	O
or	O
thymocytes	B-cell_type
with	O
100-500	O
microM	O
OP	O
for	O
2	O
hr	O
,	O
but	O
not	O
10-60	O
mM	O
NAC	O
,	O
suppressed	O
subsequent	O
occurrence	O
of	O
apoptosis	O
induced	O
by	O
etoposide	O
.	O

These	O
results	O
suggest	O
that	O
the	O
activation	O
of	O
NF-kappa	B-protein
B	I-protein
plays	O
an	O
important	O
role	O
in	O
the	O
apoptotic	O
process	O
of	O
human	B-cell_type
hematopoietic	I-cell_type
cells	I-cell_type
.	O

Overexpression	O
of	O
protein	B-protein
kinase	I-protein
C-zeta	I-protein
stimulates	O
leukemic	B-cell_type
cell	I-cell_type
differentiation	O
.	O

A	O
function	O
for	O
protein	B-protein
kinase	I-protein
C-zeta	I-protein
(	O
PKC-zeta	B-protein
)	O
,	O
a	O
member	O
of	O
the	O
phorbol	O
ester	O
nonresponsive	O
atypical	O
protein	B-protein
kinase	I-protein
C	I-protein
subfamily	I-protein
,	O
in	O
modulating	O
differentiation	O
was	O
examined	O
in	O
the	O
leukemic	B-cell_line
U937	I-cell_line
cell	I-cell_line
.	O

Transfected	O
U937	B-cell_line
cells	I-cell_line
stably	O
overexpressing	O
PKC-zeta	B-protein
displayed	O
a	O
longer	O
doubling	O
time	O
,	O
lower	O
saturation	O
density	O
at	O
confluency	O
,	O
and	O
an	O
increase	O
in	O
adherence	O
to	O
plastic	O
as	O
compared	O
to	O
control	B-cell_line
cells	I-cell_line
.	O

PKC-zeta	B-cell_line
cells	I-cell_line
expressed	O
a	O
more	O
differentiated	O
phenotype	O
as	O
assessed	O
by	O
changes	O
in	O
morphology	O
,	O
surface	O
antigen	O
expression	O
,	O
and	O
lysosomal	B-protein
enzyme	I-protein
activities	O
and	O
were	O
distinct	O
from	O
parental	B-cell_line
U937	I-cell_line
cells	I-cell_line
stimulated	O
to	O
differentiate	O
by	O
exposure	O
to	O
phorbol	O
esters	O
.	O

In	O
contrast	O
to	O
parental	O
U937	B-cell_line
cells	I-cell_line
,	O
PKC-zeta	B-cell_line
cells	I-cell_line
constitutively	O
expressed	O
mRNA	B-RNA
transcripts	I-RNA
for	O
c-jun	B-DNA
and	O
a	O
low	O
mobility	O
AP-1	B-protein
binding	O
activity	O
.	O

Thus	O
,	O
PKC-zeta	B-protein
overexpression	O
stimulates	O
a	O
type	O
of	O
phenotypic	O
differentiation	O
that	O
differs	O
significantly	O
from	O
maturation	O
occurring	O
upon	O
activation	O
of	O
other	O
PKC	B-protein
subfamilies	I-protein
induced	O
by	O
phorbol	O
ester	O
treatment	O
.	O

Increased	O
expression	O
of	O
the	O
c-jun	B-DNA
protooncogene	O
and	O
an	O
increase	O
in	O
AP-1	B-protein
binding	O
activity	O
in	O
PKC-zeta	B-cell_line
cells	I-cell_line
provides	O
a	O
potential	O
mechanism	O
for	O
explaining	O
the	O
altered	O
differentiation	O
status	O
of	O
this	O
cell	O
.	O

A	O
family	O
of	O
serine	B-protein
proteases	I-protein
expressed	O
exclusively	O
in	O
myelo-	O
monocytic	B-cell_type
cells	I-cell_type
specifically	O
processes	O
the	O
nuclear	B-protein
factor-kappa	I-protein
B	I-protein
subunit	I-protein
p65	I-protein
in	O
vitro	O
and	O
may	O
impair	O
human	O
immunodeficiency	O
virus	O
replication	O
in	O
these	O
cells	O
.	O

Two	O
groups	O
of	O
U937	B-cell_line
promonocytic	I-cell_line
cells	I-cell_line
were	O
obtained	O
by	O
limiting	O
dilution	O
cloning	O
which	O
differed	O
strikingly	O
in	O
their	O
ability	O
to	O
support	O
human	O
immunodeficiency	O
virus	O
1	O
(	O
HIV-1	O
)	O
replication	O
.	O

``	B-cell_line
Plus	I-cell_line
''	I-cell_line
clones	I-cell_line
replicated	O
the	O
virus	O
efficiently	O
,	O
whereas	O
``	B-cell_line
minus	I-cell_line
''	I-cell_line
clones	I-cell_line
did	O
not	O
.	O

We	O
examined	O
these	O
clones	O
for	O
differences	O
in	O
nuclear	B-protein
factor	I-protein
(	I-protein
NF	I-protein
)	I-protein
-kappa	I-protein
B	I-protein
activity	O
which	O
might	O
account	O
for	O
the	O
observed	O
phenomenon	O
.	O

Stimulation	O
of	O
plus	B-cell_line
clones	I-cell_line
liberated	O
the	O
classical	O
p50-p65	B-protein
complex	I-protein
from	O
cytoplasmic	O
pools	O
,	O
whereas	O
minus	B-cell_line
clones	I-cell_line
produced	O
an	O
apparently	O
novel	O
,	O
faster-migrating	B-protein
complex	I-protein
,	O
as	O
judged	O
by	O
electrophoretic	O
mobility	O
shift	O
assays	O
.	O

It	O
is	O
surprising	O
that	O
the	O
faster-migrating	B-protein
complex	I-protein
was	O
composed	O
also	O
of	O
p50	B-protein
and	O
p65	B-protein
.	O

However	O
,	O
the	O
p65	B-protein
subunit	I-protein
was	O
COOH-terminally	O
truncated	O
,	O
as	O
shown	O
by	O
immunoprecipitation	O
.	O

The	O
truncation	O
resulted	O
from	O
limited	O
proteolysis	O
of	O
p65	B-protein
during	O
cellular	O
extraction	O
which	O
released	O
particular	O
lysosomal	B-protein
serine	I-protein
proteases	I-protein
,	O
such	O
as	O
elastase	B-protein
,	O
cathepsin	B-protein
G	I-protein
,	O
and	O
proteinase	B-protein
3	I-protein
.	O

These	O
specific	O
proteases	O
are	O
coordinately	O
expressed	O
and	O
were	O
present	O
exclusively	O
in	O
the	O
minus	B-cell_line
U937	I-cell_line
clones	I-cell_line
,	O
but	O
not	O
in	O
the	O
plus	B-cell_line
clones	I-cell_line
,	O
as	O
demonstrated	O
in	O
the	O
case	O
of	O
cathepsin	B-protein
G	I-protein
.	O

In	O
addition	O
,	O
these	O
proteases	O
were	O
detected	O
in	O
certain	O
subclones	O
of	O
THP-1	B-cell_line
and	O
HL-60	B-cell_line
cells	I-cell_line
and	O
in	O
primary	O
monocytes	B-cell_type
,	O
in	O
each	O
case	O
correlating	O
with	O
the	O
truncated	O
from	O
of	O
p65	B-protein
.	O

We	O
demonstrate	O
in	O
vitro	O
cleavage	O
of	O
p65	B-protein
by	O
purified	O
elastase	B-protein
and	O
cathepsin	B-protein
G	I-protein
.	O

It	O
is	O
possible	O
that	O
particular	O
serine	B-protein
proteases	I-protein
may	O
have	O
inhibiting	O
effects	O
on	O
the	O
replication	O
of	O
HIV-1	O
in	O
myelo-monocytic	B-cell_line
cells	I-cell_line
.	O

The	O
data	O
also	O
demonstrate	O
that	O
special	O
precautions	O
must	O
be	O
taken	O
when	O
making	O
extracts	O
from	O
myelo-monocytic	B-cell_line
cells	I-cell_line
.	O

A	O
germline	B-DNA
TaqI	I-DNA
restriction	I-DNA
fragment	I-DNA
length	I-DNA
polymorphism	I-DNA
in	O
the	O
progesterone	B-DNA
receptor	I-DNA
gene	I-DNA
in	O
ovarian	O
carcinoma	O
[	O
see	O
comments	O
]	O

Clinical	O
outcome	O
in	O
ovarian	O
carcinoma	O
is	O
predicted	O
by	O
progesterone	B-protein
receptor	I-protein
status	O
,	O
indicating	O
an	O
endocrine	O
aspect	O
to	O
this	O
disease	O
.	O

Peripheral	B-DNA
leucocyte	I-DNA
genomic	I-DNA
DNAs	I-DNA
were	O
obtained	O
from	O
41	O
patients	O
with	O
primary	O
ovarian	O
carcinoma	O
and	O
83	O
controls	O
from	O
Ireland	O
,	O
as	O
well	O
as	O
from	O
26	O
primary	O
ovarian	O
carcinoma	O
patients	O
and	O
101	O
controls	O
in	O
Germany	O
.	O

Southern	O
analysis	O
using	O
a	O
human	B-DNA
progesterone	I-DNA
receptor	I-DNA
(	I-DNA
hPR	I-DNA
)	I-DNA
cDNA	I-DNA
probe	I-DNA
identified	O
a	O
germline	B-DNA
TaqI	I-DNA
restriction	I-DNA
fragment	I-DNA
length	I-DNA
polymorphism	I-DNA
(	O
RFLP	B-DNA
)	O
defined	O
by	O
two	O
alleles	O
:	O
T1	B-DNA
,	O
represented	O
by	O
a	O
2.7	B-DNA
kb	I-DNA
fragment	I-DNA
;	O
and	O
T2	B-DNA
,	O
represented	O
by	O
a	O
1.9	B-DNA
kb	I-DNA
fragment	I-DNA
and	O
characterised	O
by	O
an	O
additional	O
TaqI	B-DNA
restriction	I-DNA
site	I-DNA
with	O
respect	O
to	O
T1	B-DNA
.	O

An	O
over-representation	O
of	O
T2	B-DNA
in	O
ovarian	O
cancer	O
patients	O
compared	O
with	O
controls	O
in	O
the	O
pooled	O
Irish/German	O
population	O
(	O
P	O
<	O
0.025	O
)	O
was	O
observed	O
.	O

A	O
difference	O
(	O
P	O
<	O
0.02	O
)	O
in	O
the	O
distribution	O
of	O
the	O
RFLP	B-DNA
genotypes	O
between	O
Irish	O
and	O
German	O
control	O
populations	O
was	O
also	O
observed	O
.	O

The	O
allele	O
distributions	O
could	O
not	O
be	O
shown	O
to	O
differ	O
significantly	O
from	O
Hardy-Weinberg	O
distribution	O
in	O
any	O
subgroup	O
.	O

Using	O
hPR	B-DNA
cDNA	I-DNA
region-specific	I-DNA
probes	I-DNA
,	O
the	O
extra	O
TaqI	O
restriction	O
site	O
was	O
mapped	O
to	O
intron	B-DNA
G	I-DNA
of	O
the	O
hPR	B-DNA
gene	I-DNA
.	O

OBF-1	B-protein
,	O
a	O
novel	B-protein
B	I-protein
cell-specific	I-protein
coactivator	I-protein
that	O
stimulates	O
immunoglobulin	B-DNA
promoter	I-DNA
activity	O
through	O
association	O
with	O
octamer-binding	B-protein
proteins	I-protein
.	O

Recent	O
biochemical	O
and	O
genetic	O
studies	O
indicate	O
that	O
in	O
addition	O
to	O
the	O
octamer-binding	B-protein
proteins	I-protein
Oct-1	B-protein
and	O
Oct-2	B-protein
,	O
other	O
B	B-protein
cell	I-protein
components	I-protein
are	O
required	O
for	O
lymphoid-restricted	O
,	O
octamer	O
site-mediated	O
immunoglobulin	B-DNA
gene	I-DNA
promoter	I-DNA
activity	O
.	O

Using	O
a	O
genetic	O
screen	O
in	O
yeast	O
,	O
we	O
have	O
isolated	O
B	B-DNA
cell-derived	I-DNA
cDNAs	I-DNA
encoding	O
Oct-binding	B-protein
factor	I-protein
1	I-protein
(	O
OBF-1	B-protein
)	O
,	O
a	O
novel	O
protein	O
that	O
specifically	O
associates	O
with	O
Oct-1	B-protein
and	O
Oct-2	B-protein
.	O

Biochemical	O
studies	O
demonstrate	O
that	O
OBF-1	B-protein
has	O
no	O
intrinsic	O
DNA-binding	O
activity	O
and	O
recognizes	O
the	O
POU	B-protein
domains	I-protein
of	O
Oct-1	B-protein
and	O
Oct-2	B-protein
,	O
but	O
not	O
those	O
of	O
Oct-4	B-protein
and	O
Oct-6	B-protein
.	O

The	O
OBF-1	B-RNA
mRNA	I-RNA
is	O
expressed	O
in	O
a	O
highly	O
cell-specific	O
manner	O
,	O
being	O
most	O
abundant	O
in	O
B	B-cell_type
cells	I-cell_type
and	O
essentially	O
absent	O
in	O
most	O
of	O
the	O
other	O
cells	O
or	O
tissues	O
tested	O
.	O

Furthermore	O
,	O
expression	O
of	O
OBF-1	B-protein
in	O
HeLa	B-cell_line
cells	I-cell_line
selectively	O
stimulates	O
the	O
activity	O
of	O
a	O
natural	O
immunoglobulin	B-DNA
promoter	I-DNA
in	O
an	O
octamer	B-DNA
site	I-DNA
-dependent	O
manner	O
.	O

Thus	O
,	O
OBF-1	B-protein
has	O
all	O
the	O
properties	O
expected	O
for	O
a	O
B	B-protein
cell-specific	I-protein
transcriptional	I-protein
coactivator	I-protein
protein	I-protein
.	O

Modulation	O
of	O
transcription	B-protein
factor	I-protein
NF	I-protein
kappa	I-protein
B	I-protein
activity	O
by	O
intracellular	O
glutathione	O
levels	O
and	O
by	O
variations	O
of	O
the	O
extracellular	O
cysteine	O
supply	O
.	O

HIV-infected	O
individuals	O
and	O
SIV-infected	O
rhesus	O
macaques	O
have	O
,	O
on	O
the	O
average	O
,	O
decreased	O
plasma	O
cysteine	O
and	O
cystine	O
concentrations	O
and	O
decreased	O
intracellular	O
glutathione	O
levels	O
.	O

We	O
now	O
show	O
that	O
a	O
depletion	O
of	O
intracellular	O
glutathione	O
in	O
a	O
human	B-cell_line
T	I-cell_line
cell	I-cell_line
line	I-cell_line
(	O
Molt-4	B-cell_line
)	O
inhibits	O
the	O
activation	O
and	O
nuclear	O
translocation	O
of	O
the	O
transcription	B-protein
factor	I-protein
NF	I-protein
kappa	I-protein
B	I-protein
,	O
whereas	O
incubation	O
with	O
increasing	O
extracellular	O
concentrations	O
of	O
cysteine	O
inhibits	O
the	O
DNA-binding	O
and	O
transactivating	O
activity	O
of	O
NF	B-protein
kappa	I-protein
B	I-protein
.	O

Because	O
inhibition	O
of	O
DNA-binding	O
activity	O
is	O
associated	O
with	O
increasing	O
intracellular	O
glutathione	O
disulfide	O
levels	O
and	O
GSSG	B-protein
can	O
be	O
shown	O
to	O
inhibit	O
the	O
DNA-binding	O
activity	O
directly	O
in	O
cell-free	O
systems	O
,	O
our	O
studies	O
suggest	O
that	O
GSSG	B-protein
is	O
a	O
physiologically	O
relevant	O
inhibitor	O
in	O
intact	B-cell_type
cells	I-cell_type
also	O
.	O

NF	B-protein
kappa	I-protein
B	I-protein
controls	O
many	O
immunologically	B-DNA
important	I-DNA
genes	I-DNA
,	O
so	O
our	O
studies	O
suggest	O
that	O
the	O
immune	O
system	O
may	O
be	O
sensitive	O
not	O
only	O
against	O
a	O
cysteine	O
and	O
glutathione	O
deficiency	O
but	O
also	O
against	O
an	O
excess	O
of	O
cysteine	O
.	O

Two	O
distinct	O
signalling	O
pathways	O
are	O
involved	O
in	O
the	O
control	O
of	O
the	O
biphasic	O
junB	B-DNA
transcription	O
induced	O
by	O
interleukin-6	B-protein
in	O
the	O
B	B-cell_line
cell	I-cell_line
hybridoma	I-cell_line
7TD1	I-cell_line
.	O

We	O
have	O
measured	O
the	O
level	O
of	O
junB	B-RNA
mRNA	I-RNA
in	O
the	O
B	B-cell_line
hybridoma	I-cell_line
cell	I-cell_line
line	I-cell_line
7TD1	I-cell_line
,	O
under	O
interleukin-6	B-protein
(	O
IL-6	B-protein
)	O
stimulation	O
.	O

IL-6	B-protein
increases	O
junB	B-RNA
mRNA	I-RNA
in	O
a	O
biphasic	O
fashion	O
.	O

The	O
first	O
early-induced	O
peak	O
was	O
transient	O
and	O
likely	O
corresponds	O
to	O
the	O
well	O
documented	O
typical	O
junB	B-RNA
mRNA	I-RNA
,	O
stimulated	O
in	O
response	O
to	O
numerous	O
growth	B-protein
factors	I-protein
,	O
including	O
IL-6	B-protein
.	O

At	O
variance	O
,	O
the	O
second	O
peak	O
which	O
has	O
never	O
been	O
reported	O
previously	O
,	O
lasted	O
several	O
hours	O
.	O

As	O
a	O
consequence	O
of	O
its	O
effect	O
on	O
junB	B-RNA
mRNA	I-RNA
,	O
IL-6	B-protein
stimulated	O
,	O
in	O
a	O
biphasic	O
fashion	O
,	O
the	O
nuclear	O
accumulation	O
of	O
the	O
JunB	B-protein
protein	I-protein
.	O

In	O
this	O
study	O
,	O
we	O
demonstrated	O
that	O
IL-6	B-protein
regulation	O
occurred	O
exclusively	O
at	O
the	O
transcriptional	O
level	O
and	O
that	O
the	O
bimodal	O
increase	O
of	O
junB	B-RNA
mRNA	I-RNA
and	O
JunB	B-protein
protein	I-protein
can	O
be	O
accounted	O
for	O
by	O
a	O
biphasic	O
stimulation	O
of	O
junB	B-DNA
transcription	O
.	O

Furthermore	O
,	O
our	O
data	O
point	O
to	O
two	O
major	O
differences	O
between	O
the	O
mechanism	O
of	O
control	O
of	O
the	O
early	O
and	O
the	O
late	O
IL-6	B-protein
-induced	O
junB	B-DNA
transcription	O
waves	O
.	O

First	O
,	O
cycloheximide	O
strongly	O
potentiated	O
the	O
transcription	O
of	O
the	O
second	O
wave	O
,	O
whereas	O
it	O
failed	O
to	O
affect	O
the	O
early-induced	O
burst	O
.	O

Second	O
,	O
tyrphostin	O
,	O
a	O
tyrosine	O
kinase	O
inhibitor	O
,	O
impaired	O
the	O
expression	O
of	O
the	O
first	O
but	O
not	O
the	O
second	O
junB	B-RNA
mRNA	I-RNA
peak	O
.	O

Conversely	O
,	O
genistein	O
,	O
another	O
tyrosine	O
kinase	O
inhibitor	O
,	O
totally	O
abolished	O
the	O
expression	O
of	O
the	O
second	O
peak	O
of	O
junB	B-RNA
mRNA	I-RNA
whereas	O
it	O
did	O
not	O
affect	O
the	O
expression	O
of	O
the	O
first	O
peak	O
.	O

Altogether	O
these	O
data	O
indicate	O
that	O
,	O
in	O
7TD1	B-cell_line
cells	I-cell_line
,	O
IL-6	B-protein
controls	O
junB	B-DNA
transcription	O
in	O
a	O
biphasic	O
fashion	O
by	O
means	O
of	O
two	O
separate	O
transduction	O
pathways	O
.	O

A	O
newly	O
established	O
megakaryoblastic/erythroid	B-cell_line
cell	I-cell_line
line	I-cell_line
that	O
differentiates	O
to	O
red	B-cell_type
cells	I-cell_type
in	O
the	O
presence	O
of	O
erythropoietin	B-protein
and	O
produces	O
platelet-like	B-cell_type
particles	I-cell_type
.	O

In	O
August	O
,	O
1992	O
,	O
we	O
established	O
a	O
leukemic	B-cell_line
cell	I-cell_line
line	I-cell_line
(	O
NS-Meg	B-cell_line
)	O
from	O
a	O
patient	O
in	O
megakaryoblastic	O
transformation	O
of	O
Philadelphia	O
chromosome-positive	O
chronic	O
myeloid	O
leukemia	O
.	O

The	O
NS-Meg	B-cell_line
cells	I-cell_line
were	O
positive	O
for	O
alpha-naphthyl	B-protein
acetate	I-protein
esterase	I-protein
and	O
periodic	O
acid-Schiff	O
(	O
PAS	O
)	O
staining	O
and	O
for	O
surface	O
CD4	B-protein
,	O
CD7	B-protein
,	O
CD13	B-protein
,	O
CD34	B-protein
,	O
CD41a	B-protein
,	O
and	O
glycophorin	B-protein
A	I-protein
antigens	I-protein
.	O

Ultrastructurally	O
,	O
the	O
cells	O
had	O
alpha-granules	O
,	O
demarcation	O
membranes	O
,	O
and	O
platelet	B-protein
peroxidase	I-protein
activity	O
.	O

The	O
NS-Meg	B-cell_line
cells	I-cell_line
spontaneously	O
produced	O
platelet-like	B-cell_type
particles	I-cell_type
which	O
contained	O
alpha-granules	O
,	O
mitochondria	O
and	O
dense	O
bodies	O
,	O
strongly	O
suggesting	O
platelet	O
production	O
.	O

Erythropoietin	B-protein
(	O
Epo	B-protein
)	O
,	O
granulocyte/macrophage	B-protein
colony	I-protein
stimulating	I-protein
factor	I-protein
(	O
GM-CSF	B-protein
)	O
,	O
and	O
interleukin	B-protein
3	I-protein
(	O
IL-3	B-protein
)	O
promoted	O
the	O
growth	O
of	O
NS-Meg	B-cell_line
cells	I-cell_line
.	O

Phorbol-12-myristate-13-acetate	O
increased	O
the	O
expression	O
of	O
both	O
CD41a	B-protein
and	O
CD61	O
antigens	O
.	O

Ten-day	O
exposure	O
to	O
Epo	B-protein
induced	O
mature	B-cell_type
erythroblasts	I-cell_type
and	O
red	B-cell_type
cells	I-cell_type
.	O

These	O
benzidine-positive	B-cell_line
cells	I-cell_line
were	O
positive	O
for	O
hemoglobin	B-protein
F	O
staining	O
.	O

Untreated	O
NS-Meg	B-cell_line
cells	I-cell_line
expressed	O
mRNA	B-RNA
for	O
the	O
Epo	B-protein
receptor	I-protein
(	O
EpoR	B-protein
)	O
,	O
for	O
GATA-1	B-protein
,	O
and	O
for	O
alpha	B-DNA
1	I-DNA
,	I-DNA
alpha	I-DNA
2	I-DNA
and	I-DNA
gamma	I-DNA
globin	I-DNA
genes	I-DNA
.	O

These	O
results	O
indicate	O
that	O
NS-Meg	B-cell_line
cells	I-cell_line
undergo	O
terminal	O
differentiation	O
of	O
both	O
megakaryocytic	B-cell_type
and	I-cell_type
erythroid	I-cell_type
lineages	I-cell_type
.	O

This	O
cell	B-cell_line
line	I-cell_line
should	O
be	O
a	O
very	O
useful	O
tool	O
for	O
the	O
investigation	O
of	O
both	O
megakaryocytic	O
and	O
erythroid	O
maturation	O
.	O

Differential	O
regulation	O
of	O
proto-oncogenes	B-DNA
c-jun	B-DNA
and	O
c-fos	B-DNA
in	O
T	B-cell_type
lymphocytes	I-cell_type
activated	O
through	O
CD28	B-protein
.	O

The	O
T	B-protein
cell	I-protein
surface	I-protein
molecule	I-protein
CD28	B-protein
binds	O
to	O
ligands	O
on	O
accessory	B-cell_type
cells	I-cell_type
and	O
APCs	B-cell_type
,	O
playing	O
an	O
important	O
costimulatory	O
role	O
in	O
the	O
response	O
of	O
T	B-cell_type
cells	I-cell_type
to	O
Ags	B-protein
.	O

Our	O
knowledge	O
of	O
the	O
intracellular	O
signaling	O
pathways	O
coupled	O
to	O
this	O
receptor	O
is	O
incomplete	O
.	O

In	O
addition	O
to	O
activation	O
of	O
phospholipase	B-protein
C	I-protein
gamma	I-protein
1	I-protein
,	O
ligation	O
of	O
this	O
receptor	O
also	O
seems	O
to	O
activate	O
a	O
calcium-independent	O
,	O
CD28	B-protein
-specific	O
pathway	O
.	O

In	O
this	O
paper	O
,	O
we	O
report	O
that	O
cross-linking	O
of	O
CD28	B-protein
(	O
but	O
not	O
CD2	B-protein
,	O
CD5	B-protein
,	O
LFA-1	B-protein
,	O
or	O
CD7	B-protein
)	O
leads	O
to	O
an	O
elevation	O
of	O
c-jun	B-RNA
mRNA	I-RNA
,	O
with	O
only	O
minimal	O
activation	O
of	O
c-fos	B-DNA
expression	O
.	O

CD28	B-protein
-dependent	O
induction	O
of	O
c-jun	B-DNA
expression	O
requires	O
protein	B-protein
tyrosine	I-protein
kinase	I-protein
activity	O
,	O
but	O
does	O
not	O
depend	O
on	O
activation	O
of	O
a	O
phorbol	B-protein
ester-responsive	I-protein
protein	I-protein
kinase	I-protein
C	I-protein
or	O
elevation	O
of	O
cytosolic	O
calcium	O
.	O

Furthermore	O
,	O
CD28	B-protein
-dependent	O
elevation	O
of	O
c-jun	B-RNA
mRNA	I-RNA
does	O
not	O
appear	O
to	O
be	O
mediated	O
at	O
the	O
level	O
of	O
mRNA	O
stability	O
.	O

A	O
mechanism	O
is	O
suggested	O
whereby	O
expression	O
of	O
c-jun	B-DNA
and	O
junB	B-DNA
,	O
in	O
the	O
absence	O
of	O
members	O
of	O
the	O
fos	B-DNA
family	I-DNA
,	O
can	O
prevent	O
inappropriate	O
activation	O
of	O
T	B-cell_type
cells	I-cell_type
caused	O
by	O
ligation	O
of	O
CD28	B-protein
in	O
the	O
absence	O
of	O
a	O
specific	O
antigenic	O
stimulus	O
.	O

Enhanced	O
responsiveness	O
to	O
nuclear	B-protein
factor	I-protein
kappa	I-protein
B	I-protein
contributes	O
to	O
the	O
unique	O
phenotype	O
of	O
simian	O
immunodeficiency	O
virus	O
variant	O
SIVsmmPBj14	O
.	O

Infection	O
with	O
a	O
variant	O
of	O
simian	O
immunodeficiency	O
virus	O
,	O
SIVsmmPBj14	O
,	O
leads	O
to	O
severe	O
acute	O
disease	O
in	O
macaques	O
.	O

This	O
study	O
was	O
designed	O
to	O
investigate	O
the	O
functional	O
significance	O
of	O
previously	O
described	O
mutations	O
in	O
the	O
viral	B-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
(	O
LTR	B-DNA
)	O
and	O
to	O
elucidate	O
their	O
contribution	O
to	O
the	O
unique	O
phenotype	O
of	O
SIVsmmPBj14	O
.	O

LTR	B-DNA
-directed	O
transcription	O
was	O
measured	O
by	O
using	O
luciferase	B-DNA
reporter	I-DNA
constructs	I-DNA
that	O
were	O
transiently	O
transfected	O
into	O
cultured	B-cell_line
cells	I-cell_line
.	O

In	O
a	O
wide	O
range	O
of	O
cell	O
types	O
,	O
the	O
basal	O
transcriptional	O
activity	O
of	O
the	O
LTR	B-DNA
from	O
SIVsmmPBj14	O
was	O
found	O
to	O
be	O
2-	O
to	O
4.5-fold	O
higher	O
than	O
that	O
of	O
an	O
LTR	B-DNA
from	O
a	O
non-acutely	O
pathogenic	O
strain	O
.	O

These	O
LTRs	B-DNA
differ	O
by	O
five	O
point	O
mutations	O
and	O
a	O
22-bp	B-DNA
duplication	I-DNA
in	O
SIVsmmPBj14	O
,	O
which	O
includes	O
a	O
nuclear	B-DNA
factor	I-DNA
kappa	I-DNA
B	I-DNA
(	I-DNA
NF	I-DNA
kappa	I-DNA
B	I-DNA
)	I-DNA
site	I-DNA
.	O

Transcriptional	O
differences	O
between	O
these	O
LTRs	B-DNA
were	O
further	O
enhanced	O
by	O
two-	O
to	O
threefold	O
upon	O
treatment	O
of	O
cells	O
with	O
phorbol	O
ester	O
or	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
alpha	I-protein
or	O
by	O
cotransfection	O
with	O
plasmids	B-DNA
expressing	O
NF	B-protein
kappa	I-protein
B	I-protein
subunits	O
.	O

Mutagenesis	O
studies	O
,	O
and	O
the	O
use	O
of	O
a	O
reporter	O
construct	O
containing	O
an	O
enhancerless	O
promoter	O
,	O
indicate	O
that	O
these	O
transcriptional	O
effects	O
are	O
due	O
principally	O
to	O
the	O
22-bp	B-DNA
sequence	I-DNA
duplication	I-DNA
and	O
the	O
NF	B-DNA
kappa	I-DNA
B	I-DNA
site	I-DNA
contained	O
within	O
it	O
.	O

Finally	O
,	O
infectious	O
virus	O
stocks	O
that	O
were	O
isogenic	O
except	O
for	O
the	O
LTR	B-DNA
were	O
generated	O
.	O

The	O
LTR	B-DNA
from	O
SIVsmmPBj14	O
was	O
found	O
to	O
confer	O
an	O
increase	O
in	O
the	O
kinetics	O
of	O
virus	O
replication	O
in	O
cultured	B-cell_line
cells	I-cell_line
.	O

Inclusion	O
of	O
this	O
LTR	B-DNA
in	O
recombinant	O
SIVs	O
also	O
resulted	O
in	O
a	O
two-	O
to	O
threefold	O
rise	O
in	O
the	O
extent	O
of	O
cellular	O
proliferation	O
that	O
was	O
induced	O
in	O
quiescent	B-cell_line
simian	I-cell_line
peripheral	I-cell_line
blood	I-cell_line
mononuclear	I-cell_line
cells	I-cell_line
.	O

These	O
studies	O
are	O
consistent	O
with	O
the	O
hypothesis	O
that	O
LTR	B-DNA
mutations	O
assist	O
SIVsmmPBj14	O
in	O
responding	O
efficiently	O
to	O
cellular	O
stimulation	O
and	O
allow	O
it	O
to	O
replicate	O
to	O
high	O
titers	O
during	O
the	O
acute	O
phase	O
of	O
viral	O
infection	O
.	O

Constitutive	O
nuclear	B-protein
NF-kappa	I-protein
B	I-protein
in	O
cells	O
of	O
the	O
monocyte	O
lineage	O
.	O

In	O
monocytes	B-cell_type
,	O
the	O
nuclear	B-protein
factor	I-protein
NF-kappa	I-protein
B	I-protein
has	O
been	O
invoked	O
as	O
an	O
important	O
transcription	B-protein
factor	I-protein
in	O
the	O
expression	O
of	O
cytokine	B-DNA
genes	I-DNA
,	O
of	O
cell-surface	B-protein
receptors	I-protein
and	O
in	O
the	O
expression	O
of	O
human	O
immunodeficiency	O
virus	O
.	O

In	O
such	O
cells	O
,	O
DNA	O
binding	O
activity	O
of	O
NF-kappa	B-protein
B	I-protein
can	O
be	O
detected	O
without	O
intentional	O
stimulation	O
.	O

In	O
our	O
studies	O
,	O
cells	O
of	O
the	O
human	B-cell_line
monocytic	I-cell_line
line	I-cell_line
Mono	B-cell_line
Mac	I-cell_line
6	I-cell_line
,	O
cultured	O
in	O
medium	O
containing	O
fetal-calf	O
serum	O
and	O
low	O
levels	O
of	O
lipopolysaccharide	O
(	O
LPS	O
)	O
,	O
also	O
exhibit	O
such	O
'constitutive	O
'	O
NF-kappa	B-protein
B	I-protein
,	O
as	O
demonstrated	O
by	O
mobility-shift	O
analysis	O
of	O
nuclear	O
extracts	O
.	O

This	O
nuclear	B-protein
NF-kappa	I-protein
B	I-protein
was	O
still	O
present	O
when	O
contaminant	O
LPS	O
was	O
removed	O
by	O
ultrafiltration	O
and	O
when	O
serum	O
was	O
omitted	O
.	O

Protein-DNA	O
complexes	O
of	O
constitutive	O
NF-kappa	B-protein
B	I-protein
are	O
similar	O
in	O
mobility	O
to	O
the	O
LPS-induced	B-protein
NF-kappa	I-protein
B	I-protein
and	O
both	O
are	O
recognized	O
by	O
an	O
antibody	O
specific	O
to	O
the	O
p50	B-protein
subunit	I-protein
of	O
NF-kappa	B-protein
B	I-protein
.	O

By	O
contrast	O
,	O
treatment	O
of	O
cells	O
with	O
pyrrolidine	O
dithiocarbamate	O
(	O
PDTC	O
)	O
will	O
only	O
block	O
LPS-induced	B-protein
NF-kappa	I-protein
B	I-protein
,	O
but	O
not	O
the	O
constitutive	B-protein
binding	I-protein
protein	I-protein
.	O

Using	O
LPS-free	O
and	O
serum-free	O
conditions	O
,	O
constitutive	O
NF-kappa	B-protein
B	I-protein
can	O
be	O
detected	O
in	O
different	O
cell	B-cell_line
lines	I-cell_line
of	O
the	O
monocytic	B-cell_type
lineage	I-cell_type
(	O
HL60	B-cell_line
,	O
U937	B-cell_line
,	O
THP-1	B-cell_line
,	O
Mono	B-cell_line
Mac	I-cell_line
1	I-cell_line
and	O
Mono	B-cell_line
Mac	I-cell_line
6	I-cell_line
)	O
,	O
but	O
not	O
in	O
Molt	B-cell_line
4	I-cell_line
T	I-cell_line
cells	I-cell_line
or	O
K562	B-cell_line
stem	I-cell_line
cells	I-cell_line
.	O

When	O
ordered	O
according	O
to	O
stage	O
of	O
maturation	O
,	O
the	O
amount	O
of	O
constitutive	O
NF-kappa	B-protein
B	I-protein
was	O
not	O
increased	O
in	O
more	O
mature	B-cell_line
cell	I-cell_line
lines	I-cell_line
.	O

Furthermore	O
,	O
when	O
inducing	O
differentiation	O
in	O
Mono	B-cell_line
Mac	I-cell_line
6	I-cell_line
cells	I-cell_line
,	O
with	O
vitamin	O
D3	O
,	O
no	O
change	O
in	O
constitutive	O
or	O
inducible	O
NF-kappa	B-protein
B	I-protein
can	O
be	O
detected	O
.	O

Analysis	O
of	O
primary	O
cells	O
revealed	O
substantial	O
constitutive	O
NF-kappa	B-protein
B	I-protein
-binding	O
activity	O
in	O
blood	B-cell_type
monocytes	I-cell_type
,	O
pleural	B-cell_type
macrophages	I-cell_type
and	O
alveolar	B-cell_type
macrophages	I-cell_type
.	O

The	O
constitutive	O
NF-kappa	B-protein
B	I-protein
appears	O
to	O
be	O
functionally	O
active	O
,	O
since	O
a	O
low	O
level	O
of	O
tumour	B-RNA
necrosis	I-RNA
factor	I-RNA
(	I-RNA
TNF	I-RNA
)	I-RNA
transcript	I-RNA
is	O
detectable	O
in	O
monocytes	B-cell_type
,	O
and	O
this	O
level	O
can	O
be	O
increased	O
by	O
blocking	O
transcript	O
degradation	O
using	O
cycloheximide	O
.	O

The	O
level	O
of	O
constitutive	O
NF-kappa	B-protein
B	I-protein
in	O
these	O
cells	O
is	O
variable	O
and	O
is	O
frequently	O
found	O
to	O
be	O
lower	O
in	O
the	O
more	O
mature	B-cell_type
macrophages	I-cell_type
.	O

Constitutive	O
NF-kappa	B-protein
B	I-protein
was	O
not	O
maintained	O
by	O
autocrine	O
action	O
of	O
cytokines	B-protein
TNF	B-protein
,	O
interleukin	B-protein
6	I-protein
,	O
interleukin	B-protein
10	O
,	O
granulocyte-macrophage	B-protein
colony-stimulating	I-protein
factor	I-protein
or	O
macrophage	B-protein
colony-stimulating	I-protein
factor	I-protein
,	O
since	O
neutralizing	O
antibodies	O
did	O
not	O
reduce	O
constitutive	O
DNA-binding	O
activity	O
.	O

Furthermore	O
,	O
blockade	O
of	O
prostaglandin	O
or	O
leukotriene	O
biosynthesis	O
did	O
not	O
affect	O
constitutive	O
NF-kappa	B-protein
B	I-protein
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
400	O
WORDS	O
)	O

Steel	B-protein
factor	I-protein
affects	O
SCL	B-protein
expression	O
during	O
normal	O
erythroid	O
differentiation	O
.	O

Steel	B-protein
factor	I-protein
is	O
one	O
of	O
the	O
growth	B-protein
factors	I-protein
that	O
controls	O
the	O
proliferation	O
and	O
differentiation	O
of	O
hematopoietic	B-cell_type
cells	I-cell_type
and	O
SCL	B-protein
,	O
also	O
known	O
as	O
Tcl-5	B-protein
or	O
Tal-1	B-protein
,	O
is	O
a	O
transcription	B-protein
factor	I-protein
involved	O
in	O
erythropoiesis	O
.	O

In	O
this	O
report	O
,	O
we	O
studied	O
the	O
role	O
of	O
SCL	O
in	O
the	O
proliferation	O
of	O
human	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
burst-forming	I-cell_type
unit-erythroid	I-cell_type
(	O
BFU-E	B-cell_type
)	O
and	O
the	O
effects	O
of	O
Steel	B-protein
factor	I-protein
on	O
SCL	B-protein
expression	O
in	O
proliferating	B-cell_type
erythroid	I-cell_type
cells	I-cell_type
.	O

BFU-E-derived	B-cell_line
colonies	I-cell_line
increase	O
progressively	O
in	O
size	O
,	O
as	O
determined	O
by	O
cell	O
number	O
,	O
from	O
day	O
7	O
to	O
day	O
14	O
of	O
culture	O
,	O
with	O
the	O
greatest	O
increase	O
in	O
colony	O
size	O
(	O
10-fold	O
expansion	O
)	O
occurring	O
between	O
day	O
7	O
and	O
day	O
10	O
.	O

SCL	B-protein
protein	I-protein
levels	O
in	O
BFU-E-derived	B-cell_line
cells	I-cell_line
were	O
highest	O
in	O
day	O
7	O
cells	O
and	O
decreased	O
progressively	O
from	O
day	O
7	O
to	O
day	O
14	O
of	O
culture	O
,	O
suggesting	O
an	O
association	O
of	O
SCL	B-protein
with	O
erythroid	O
proliferation	O
.	O

In	O
contrast	O
,	O
SCL	B-RNA
mRNA	I-RNA
levels	O
did	O
not	O
decrease	O
significantly	O
between	O
day	O
7	O
and	O
day	O
14	O
cells	O
,	O
suggesting	O
that	O
posttranscriptional	O
mechanisms	O
are	O
largely	O
responsible	O
for	O
the	O
decrease	O
in	O
SCL	B-protein
protein	I-protein
observed	O
.	O

The	O
role	O
of	O
SCL	B-protein
in	O
Steel	B-protein
factor	I-protein
-induced	O
erythroid	O
proliferation	O
was	O
then	O
examined	O
.	O

In	O
BFU-E-derived	B-cell_line
colonies	I-cell_line
cultured	O
with	O
Steel	B-protein
factor	I-protein
,	O
colony	O
size	O
was	O
significantly	O
increased	O
compared	O
to	O
control	O
.	O

In	O
day	O
7	O
and	O
day	O
10	O
erythroid	B-cell_type
precursors	I-cell_type
cultured	O
with	O
Steel	B-protein
factor	I-protein
,	O
SCL	B-protein
protein	I-protein
was	O
increased	O
significantly	O
compared	O
to	O
control	O
.	O

The	O
increase	O
in	O
SCL	B-protein
protein	O
levels	O
in	O
early	O
erythroid	B-cell_type
precursors	I-cell_type
stimulated	O
with	O
Steel	B-protein
factor	I-protein
suggests	O
one	O
mechanism	O
through	O
which	O
Steel	B-protein
factor	I-protein
may	O
enhance	O
normal	O
erythroid	O
proliferation	O
.	O

SCL	B-RNA
mRNA	I-RNA
levels	O
assessed	O
by	O
Northern	O
blot	O
in	O
day	O
7	O
cells	O
did	O
not	O
increase	O
significantly	O
in	O
response	O
to	O
Steel	B-protein
factor	I-protein
stimulation	O
,	O
suggesting	O
that	O
posttranscriptional	O
mechanisms	O
may	O
also	O
be	O
important	O
in	O
the	O
increase	O
in	O
SCL	B-protein
protein	I-protein
observed	O
in	O
response	O
to	O
Steel	B-protein
.	O

C/EBP	B-protein
beta	I-protein
regulation	O
of	O
the	O
tumor	B-DNA
necrosis	I-DNA
factor	I-DNA
alpha	I-DNA
gene	I-DNA
.	O

Activated	B-cell_type
macrophages	I-cell_type
contribute	O
to	O
chronic	O
inflammation	O
by	O
the	O
secretion	O
of	O
cytokines	B-protein
and	O
proteinases	B-protein
.	O

Tumor	B-protein
necrosis	I-protein
factor	I-protein
alpha	I-protein
(	O
TNF	B-protein
alpha	I-protein
)	O
is	O
particularly	O
important	O
in	O
this	O
process	O
because	O
of	O
its	O
ability	O
to	O
regulate	O
other	O
inflammatory	O
mediators	O
in	O
an	O
autocrine	O
and	O
paracrine	O
fashion	O
.	O

The	O
mechanism	O
(	O
s	O
)	O
responsible	O
for	O
the	O
cell	O
type-specific	O
regulation	O
of	O
TNF	B-protein
alpha	I-protein
is	O
not	O
known	O
.	O

We	O
present	O
data	O
to	O
show	O
that	O
the	O
expression	O
of	O
TNF	B-protein
alpha	I-protein
is	O
regulated	O
by	O
the	O
transcription	B-protein
factor	I-protein
C/EBP	B-protein
beta	I-protein
(	O
NF-IL6	B-protein
)	O
.	O

C/EBP	B-protein
beta	I-protein
activated	O
the	O
TNF	B-DNA
alpha	I-DNA
gene	I-DNA
promoter	I-DNA
in	O
cotransfection	O
assays	O
and	O
bound	O
to	O
it	O
at	O
a	O
site	O
which	O
failed	O
to	O
bind	O
the	O
closely	O
related	O
protein	O
C/EBP	B-protein
alpha	I-protein
.	O

Finally	O
,	O
a	O
dominant-negative	O
version	O
of	O
C/EBP	B-protein
beta	I-protein
blocked	O
TNF	B-DNA
alpha	I-DNA
promoter	I-DNA
activation	O
in	O
myeloid	B-cell_type
cells	I-cell_type
.	O

Our	O
results	O
implicate	O
C/EBP	B-protein
beta	I-protein
as	O
an	O
important	O
regulator	O
of	O
TNF	B-protein
alpha	I-protein
by	O
myelomonocytic	B-cell_type
cells	I-cell_type
.	O

Calcium/calmodulin-dependent	B-protein
protein	I-protein
kinase	I-protein
II	I-protein
downregulates	O
both	O
calcineurin	O
and	O
protein	O
kinase	O
C-mediated	O
pathways	O
for	O
cytokine	B-DNA
gene	I-DNA
transcription	O
in	O
human	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O

Engagement	O
of	O
the	O
T	B-protein
cell	I-protein
receptor	I-protein
for	O
antigen	O
activates	O
phospholipase	B-protein
C	I-protein
resulting	O
in	O
an	O
increase	O
in	O
intracellular	O
free	O
calcium	O
concentration	O
(	O
[	O
Ca2+	O
]	O
i	O
)	O
and	O
activation	O
of	O
protein	B-protein
kinase	I-protein
C	I-protein
(	O
PKC	B-protein
)	O
.	O

Increased	O
[	O
Ca2+	O
]	O
i	O
activates	O
Ca2+/calmodulin-dependent	B-protein
kinases	I-protein
including	O
the	O
multifunctional	O
Ca2+/calmodulin-dependent	B-protein
protein	I-protein
kinase	I-protein
II	I-protein
(	O
CaM-K	B-protein
II	I-protein
)	O
,	O
as	O
well	O
as	O
calcineurin	B-protein
,	O
a	O
type	B-protein
2B	I-protein
protein	I-protein
phosphatase	I-protein
.	O

Recent	O
studies	O
have	O
identified	O
calcineurin	B-protein
as	O
a	O
key	O
enzyme	O
for	O
interleukin	O
(	O
IL	O
)	O
-2	O
and	O
IL-4	O
promoter	O
activation	O
.	O

However	O
,	O
the	O
role	O
of	O
CaM-K	B-protein
II	I-protein
remains	O
unknown	O
.	O

We	O
have	O
used	O
mutants	O
of	O
these	O
kinases	B-protein
and	O
phosphatases	B-protein
(	O
gamma	B-protein
B*CaM-K	I-protein
and	O
delta	B-protein
CaM-AI	I-protein
,	O
respectively	O
)	O
to	O
explore	O
their	O
relative	O
role	O
in	O
cytokine	B-DNA
gene	I-DNA
transcription	O
and	O
their	O
interactions	O
with	O
PKC	B-protein
-dependent	O
signaling	O
systems	O
.	O

gamma	B-protein
B*CaM-K	I-protein
and	O
delta	B-protein
CaM-AI	I-protein
,	O
known	O
to	O
exhibit	O
constitutive	O
Ca	O
(	O
2+	O
)	O
-independent	O
activity	O
,	O
were	O
cotransfected	O
(	O
alone	O
or	O
in	O
combination	O
)	O
in	O
Jurkat	B-cell_line
T	I-cell_line
cells	I-cell_line
with	O
a	O
plasmid	O
containing	O
the	O
intact	O
IL-2	B-DNA
promoter	I-DNA
driving	O
the	O
expression	O
of	O
the	O
chloramphenicol	B-DNA
acetyltransferase	I-DNA
reporter	I-DNA
gene	I-DNA
.	O

Cotransfection	O
of	O
gamma	B-protein
B*CaM-K	I-protein
with	O
the	O
IL-2	B-DNA
promoter	I-DNA
construct	I-DNA
downregulated	O
its	O
transcription	O
in	O
response	O
to	O
stimulation	O
with	O
ionomycin	O
and	O
phorbol	O
myristate	O
acetate	O
(	O
PMA	O
)	O
.	O

The	O
inhibitory	O
effect	O
of	O
CaM-K	B-protein
II	I-protein
on	O
IL-2	B-DNA
promoter	I-DNA
was	O
associated	O
with	O
decreased	O
transcription	O
of	O
its	O
AP-1	O
and	O
NF-AT	O
transactivating	O
pathways	O
.	O

Under	O
the	O
same	O
conditions	O
,	O
delta	B-protein
CaM-AI	I-protein
superinduced	O
IL-2	B-DNA
promoter	I-DNA
activity	O
(	O
approximately	O
twofold	O
increase	O
)	O
.	O

When	O
both	O
mutants	O
were	O
used	O
in	O
combination	O
,	O
gamma	B-protein
B*CaM-K	I-protein
inhibited	O
the	O
induction	O
of	O
the	O
IL-2	B-DNA
promoter	I-DNA
by	O
delta	B-protein
CaM-AI	I-protein
.	O

Similar	O
results	O
were	O
obtained	O
when	O
a	O
construct	O
containing	O
the	O
IL-4	B-DNA
promoter	I-DNA
also	O
was	O
used	O
.	O

gamma	B-protein
B*CaM-K	I-protein
also	O
downregulated	O
the	O
activation	O
of	O
AP-1	B-protein
in	O
response	O
to	O
transfection	O
with	O
a	O
constitutively	O
active	O
mutant	O
of	O
PKC	B-protein
or	O
stimulation	O
with	O
PMA	O
.	O

These	O
results	O
suggest	O
that	O
CaM-K	B-protein
II	I-protein
may	O
exert	O
negative	O
influences	O
on	O
cytokine	B-DNA
gene	I-DNA
transcription	O
in	O
human	B-cell_type
T	I-cell_type
cells	I-cell_type
,	O
and	O
provide	O
preliminary	O
evidence	O
for	O
negative	O
cross-talk	O
with	O
the	O
calcineurin-	O
and	O
PKC-	O
dependent	O
signaling	O
systems	O
.	O

Induction	O
of	O
ICAM-1	B-protein
and	O
LFA-3	B-protein
by	O
Tax1	B-protein
of	O
human	O
T-cell	O
leukemia	O
virus	O
type	O
1	O
and	O
mechanism	O
of	O
down-regulation	O
of	O
ICAM-1	B-protein
or	O
LFA-1	B-protein
in	O
adult-T-cell-leukemia	B-cell_line
cell	I-cell_line
lines	I-cell_line
.	O

The	O
present	O
study	O
was	O
undertaken	O
to	O
determine	O
the	O
role	O
of	O
HTLV-I	B-protein
TaxI	I-protein
in	O
the	O
up-regulation	O
of	O
ICAM-I	B-protein
and	O
LFA-3	B-protein
in	O
human	B-cell_type
T	I-cell_type
cells	I-cell_type
transformed	O
with	O
HTLV-I	O
and	O
the	O
mechanism	O
of	O
down-regulation	O
of	O
ICAM-I	B-protein
and	O
LFA-I	B-protein
in	O
ATL-derived	B-cell_line
cell	I-cell_line
lines	I-cell_line
.	O

Induction	O
of	O
TaxI	B-protein
in	O
a	O
human	B-cell_line
T-cell	I-cell_line
line	I-cell_line
Jurkat	I-cell_line
carrying	O
the	O
TaxI	B-DNA
gene	I-DNA
under	O
the	O
metallothionein	B-DNA
promoter	I-DNA
led	O
to	O
increases	O
in	O
mRNA	B-RNA
and	O
surface	O
expression	O
of	O
ICAM-I	B-protein
.	O

The	O
response	O
of	O
LFA-3	B-protein
to	O
TaxI	B-protein
induction	O
was	O
,	O
on	O
the	O
other	O
hand	O
,	O
relatively	O
slow	O
and	O
weak	O
,	O
and	O
might	O
be	O
indirect	O
.	O

Transactivation	O
of	O
the	O
ICAM-I	B-DNA
promoter	I-DNA
by	O
TaxI	B-protein
was	O
further	O
shown	O
by	O
co-transfection	O
of	O
a	O
CAT	B-DNA
reporter	I-DNA
construct	I-DNA
with	O
the	O
ICAM-I	B-DNA
promoter	I-DNA
and	O
a	O
plasmid	B-DNA
expressing	O
TaxI	B-protein
.	O

The	O
mechanism	O
of	O
down-regulation	O
of	O
ICAM-I	B-protein
or	O
LFA-I	B-protein
in	O
4	B-cell_line
ATL	I-cell_line
cell	I-cell_line
lines	I-cell_line
was	O
next	O
examined	O
.	O

ICAM-I	B-RNA
mRNA	I-RNA
was	O
quite	O
low	O
in	O
MT-I	B-cell_line
,	O
but	O
no	O
genomic	O
changes	O
were	O
found	O
.	O

The	O
CAT	B-DNA
reporter	I-DNA
with	O
the	O
ICAM-I	B-DNA
promoter	I-DNA
was	O
inactive	O
in	O
MT-I	B-cell_line
.	O

Finally	O
,	O
combined	O
treatment	O
of	O
MT-I	B-cell_line
with	O
5-azacytidine	O
and	O
IFN-gamma	B-protein
induced	O
re-expression	O
of	O
ICAM-I	B-protein
.	O

Collectively	O
,	O
(	O
a	O
)	O
transcriptional	B-protein
factor	I-protein
(	O
s	O
)	O
necessary	O
for	O
expression	O
of	O
ICAM-I	B-DNA
gene	I-DNA
may	O
be	O
repressed	O
in	O
MT-I	B-cell_line
through	O
DNA	O
methylation	O
.	O

Three	O
other	O
ATL	B-cell_line
cell	I-cell_line
lines	I-cell_line
(	O
TL-OmI	B-cell_line
,	O
H582	B-cell_line
,	O
HuT102	B-cell_line
)	O
were	O
found	O
to	O
have	O
little	O
mRNA	B-RNA
for	O
the	O
LFA-I	B-protein
beta	I-protein
chain	I-protein
(	O
CD18	B-protein
)	O
.	O

H582	B-cell_line
and	O
HuT102	B-cell_line
were	O
also	O
negative	O
for	O
the	O
LFA-I	B-RNA
alpha	I-RNA
chain	I-RNA
(	I-RNA
CDIIa	I-RNA
)	I-RNA
mRNA	I-RNA
.	O

No	O
genomic	O
changes	O
were	O
found	O
,	O
and	O
a	O
CAT	B-DNA
reporter	I-DNA
gene	I-DNA
with	O
the	O
CD18	B-DNA
promoter	I-DNA
was	O
inactive	O
in	O
the	O
3	O
of	O
them	O
,	O
again	O
suggesting	O
lack	O
of	O
(	O
a	O
)	O
transcriptional	B-protein
factor	I-protein
(	O
s	O
)	O
necessary	O
for	O
CD18	B-protein
expression	O
.	O

Infection	O
with	O
Theileria	O
annulata	O
induces	O
expression	O
of	O
matrix	B-protein
metalloproteinase	I-protein
9	I-protein
and	O
transcription	B-protein
factor	I-protein
AP-1	B-protein
in	O
bovine	B-cell_type
leucocytes	I-cell_type
.	O

Theileria	O
annulata	O
infects	O
bovine	B-cell_type
leucocytes	I-cell_type
and	O
results	O
in	O
their	O
reversible	O
transformation	O
such	O
that	O
they	O
become	O
immortalised	O
and	O
metastatic	O
.	O

The	O
present	O
study	O
describes	O
parasite-induced	O
changes	O
in	O
host	B-DNA
cell	I-DNA
gene	I-DNA
expression	O
which	O
have	O
a	O
direct	O
bearing	O
on	O
this	O
transformation	O
process	O
.	O

T.	B-cell_type
annulata-infected	I-cell_type
leucocytes	I-cell_type
produce	O
a	O
number	O
of	O
novel	O
metalloproteinase	B-protein
activities	O
.	O

One	O
of	O
these	O
,	O
previously	O
called	O
B1	B-protein
,	O
is	O
a	O
97-kDa	B-protein
protein	I-protein
which	O
is	O
secreted	O
in	O
large	O
amounts	O
and	O
has	O
been	O
purified	O
from	O
protein-free	O
,	O
conditioned	O
medium	O
.	O

An	O
antiserum	O
to	O
this	O
enzyme	O
was	O
used	O
to	O
isolate	O
a	O
cDNA	B-DNA
clone	I-DNA
.	O

The	O
predicted	O
protein	O
sequence	O
of	O
B1	B-protein
is	O
81	O
%	O
identical	O
to	O
human	O
matrix	B-protein
metalloproteinase	I-protein
9	I-protein
(	O
MMP9	B-protein
)	O
,	O
demonstrating	O
that	O
it	O
is	O
the	O
bovine	O
homologue	O
of	O
this	O
enzyme	O
.	O

RNAase	B-protein
protection	O
assays	O
demonstrated	O
that	O
the	O
MMP9	B-protein
activity	O
,	O
unique	O
to	O
infected	B-cell_type
cells	I-cell_type
,	O
is	O
due	O
to	O
increased	O
MMP9	B-protein
mRNA	O
levels	O
.	O

We	O
also	O
assayed	O
the	O
levels	O
of	O
transcription	B-protein
factor	I-protein
AP-1	B-protein
and	O
demonstrated	O
that	O
it	O
was	O
constitutively	O
present	O
in	O
increased	O
amounts	O
in	O
Theileria-infected	B-cell_type
cells	I-cell_type
.	O

In	O
addition	O
we	O
assayed	O
the	O
level	O
of	O
mRNA	B-RNA
encoding	O
c-Fos	B-protein
,	O
a	O
common	O
component	O
of	O
AP-1	B-protein
and	O
observed	O
that	O
it	O
was	O
indeed	O
up-regulated	O
in	O
infected	B-cell_type
cells	I-cell_type
.	O

Since	O
AP-1	B-protein
is	O
implicated	O
in	O
the	O
control	O
of	O
the	O
cell	O
cycle	O
,	O
and	O
MMP9	B-protein
can	O
confer	O
metastatic	O
properties	O
,	O
these	O
results	O
are	O
of	O
considerable	O
significance	O
with	O
respect	O
to	O
the	O
transformed	O
phenotype	O
induced	O
by	O
Theileria	O
infection	O
.	O

B-cell	B-cell_type
proliferation	O
and	O
induction	O
of	O
early	O
G1-regulating	B-protein
proteins	I-protein
by	O
Epstein-Barr	O
virus	O
mutants	O
conditional	O
for	O
EBNA2	B-protein
.	O

Infection	O
of	O
primary	B-cell_type
B-lymphocytes	I-cell_type
by	O
Epstein-Barr	O
virus	O
(	O
EBV	O
)	O
leads	O
to	O
growth	O
transformation	O
of	O
these	O
B-cells	B-cell_type
in	O
vitro	O
.	O

EBV	O
nuclear	O
antigen	O
2	O
(	O
EBNA2	B-protein
)	O
,	O
one	O
of	O
the	O
first	O
genes	O
expressed	O
after	O
EBV	O
infection	O
of	O
B-cells	B-cell_type
,	O
is	O
a	O
transcriptional	O
activator	O
of	O
viral	B-DNA
and	I-DNA
cellular	I-DNA
genes	I-DNA
and	O
is	O
essential	O
for	O
the	O
transforming	O
potential	O
of	O
the	O
virus	O
.	O

We	O
generated	O
conditional	O
EBV	O
mutants	O
by	O
expressing	O
EBNA2	B-protein
as	O
chimeric	B-protein
fusion	I-protein
protein	I-protein
with	O
the	O
hormone	O
binding	O
domain	O
of	O
the	O
estrogen	B-protein
receptor	I-protein
on	O
the	O
genetic	O
background	O
of	O
the	O
virus	O
.	O

Growth	O
transformation	O
of	O
primary	B-cell_type
normal	I-cell_type
B-cells	I-cell_type
by	O
mutant	O
virus	O
resulted	O
in	O
estrogen-dependent	B-cell_line
lymphoblastoid	I-cell_line
cell	I-cell_line
lines	I-cell_line
expressing	O
the	O
chimeric	O
EBNA2	B-protein
protein	I-protein
.	O

In	O
the	O
absence	O
of	O
estrogen	O
about	O
half	O
of	O
the	O
cells	O
enter	O
a	O
quiescent	O
non-proliferative	O
state	O
whereas	O
the	O
others	O
die	O
by	O
apoptosis	O
.	O

EBNA2	B-protein
is	O
thus	O
required	O
not	O
only	O
for	O
initiation	O
but	O
also	O
for	O
maintenance	O
of	O
transformation	O
.	O

Growth	O
arrest	O
occurred	O
at	O
G1	O
and	O
G2	O
stages	O
of	O
the	O
cell	O
cycle	O
,	O
indicating	O
that	O
functional	O
EBNA2	B-protein
is	O
required	O
at	O
different	O
restriction	O
points	O
of	O
the	O
cell	O
cycle	O
.	O

Growth	O
arrest	O
is	O
reversible	O
for	O
G1/G0	B-cell_type
cells	I-cell_type
as	O
indicated	O
by	O
the	O
sequential	O
accumulation	O
and	O
modification	O
of	O
cell	B-protein
cycle	I-protein
regulating	I-protein
proteins	I-protein
.	O

EBV	O
induces	O
the	O
same	O
cell	O
cycle	O
regulating	O
proteins	O
as	O
polyclonal	O
stimuli	O
in	O
primary	O
B-cells	B-cell_type
.	O

These	O
data	O
suggest	O
that	O
EBV	O
is	O
using	O
a	O
common	O
pathway	O
for	O
B-cell	O
activation	O
bypassing	O
the	O
requirement	O
for	O
antigen	O
,	O
T-cell	O
signals	O
and	O
growth	B-protein
factors	I-protein
.	O

IL-1	B-protein
receptor	I-protein
and	O
TCR	B-protein
signals	O
synergize	O
to	O
activate	O
NF-kappa	B-protein
B	I-protein
-mediated	O
gene	O
transcription	O
.	O

Previous	O
studies	O
have	O
demonstrated	O
that	O
IL-1	B-protein
receptor	I-protein
(	O
IL-1R	B-protein
)	O
-	O
and	O
TCR	B-protein
-initiated	O
signals	O
can	O
interact	O
synergistically	O
to	O
increase	O
the	O
rate	O
of	O
transcription	O
of	O
several	O
lymphokine	B-DNA
and	I-DNA
lymphokine	I-DNA
receptor	I-DNA
genes	I-DNA
during	O
the	O
competence	O
phase	O
of	O
the	O
activation	O
program	O
in	O
T	B-cell_type
helper	I-cell_type
lymphocytes	I-cell_type
.	O

In	O
this	O
report	O
we	O
describe	O
how	O
signals	O
initiated	O
through	O
the	O
type	B-protein
I	I-protein
IL-1R	I-protein
interact	O
with	O
signals	O
from	O
the	O
antigen	O
receptor	O
to	O
synergistically	O
augment	O
the	O
transactivating	O
properties	O
of	O
NF-kappa	B-protein
B	I-protein
.	O

The	O
synergistic	O
antigen	B-protein
receptor	I-protein
initiated	O
signals	O
are	O
mediated	O
through	O
protein	B-protein
kinase	I-protein
C	I-protein
because	O
they	O
can	O
be	O
mimicked	O
by	O
the	O
phorbol	O
ester	O
,	O
12-O-tetradecanoylphorbol-13-acetate	O
,	O
but	O
not	O
with	O
calcium	O
ionophores	O
;	O
and	O
are	O
staurosporine	O
sensitive	O
but	O
cyclosporine	O
resistant	O
.	O

Gel	O
shift	O
analyses	O
demonstrate	O
that	O
NF-kappa	B-protein
B	I-protein
nuclear	O
translocation	O
is	O
stimulated	O
primarily	O
by	O
IL-1	B-protein
rather	O
than	O
by	O
antigen	B-protein
receptor	I-protein
signals	O
.	O

Western	O
blot	O
and	O
phosphorylation	O
analyses	O
demonstrate	O
that	O
the	O
synergistic	O
effect	O
on	O
NF-kappa	B-protein
B	I-protein
functional	O
activity	O
is	O
independent	O
of	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
(	O
MAD3	B-protein
)	O
-	O
NF-kappa	B-protein
B	I-protein
dissociation	O
in	O
the	O
cytosol	O
and	O
is	O
not	O
associated	O
with	O
I	B-protein
kappa	I-protein
B	I-protein
nuclear	O
translocation	O
.	O

The	O
IL-1	B-protein
-induced	O
NF-kappa	B-protein
B	I-protein
DNA	O
nuclear	O
localization	O
is	O
transient	O
and	O
can	O
be	O
prolonged	O
either	O
by	O
an	O
antigen	O
receptor-initiated	O
signal	O
or	O
by	O
inhibiting	O
protein	O
synthesis	O
.	O

These	O
results	O
suggest	O
that	O
IL-1	B-protein
induces	O
both	O
NF-kappa	B-protein
B	I-protein
nuclear	O
translocation	O
and	O
the	O
synthesis	O
of	O
a	O
protein	O
(	O
s	O
)	O
responsible	O
for	O
terminating	O
NF-kappa	B-protein
B	I-protein
-DNA	O
interaction	O
in	O
the	O
nucleus	O
.	O

Antigen	O
receptor	O
signals	O
prolong	O
NF-kappa	B-protein
B	I-protein
-DNA	O
interaction	O
,	O
probably	O
by	O
functionally	O
antagonizing	O
the	O
IL-1	B-protein
-induced	O
synthesis	O
of	O
a	O
protein	O
(	O
s	O
)	O
responsible	O
for	O
the	O
transient	O
NF-kappa	B-protein
B	I-protein
-DNA	O
interaction	O
and	O
consequently	O
synergistically	O
enhance	O
IL-1	B-protein
-induced	O
NF-kappa	B-protein
B	I-protein
-dependent	O
gene	O
transcription	O
.	O

Identification	O
of	O
the	O
promoter	B-DNA
region	I-DNA
of	O
chicken	O
anemia	O
virus	O
(	O
CAV	O
)	O
containing	O
a	O
novel	O
enhancer-like	B-DNA
element	I-DNA
.	O

The	O
single	O
promoter	B-DNA
region	I-DNA
in	O
the	O
cloned	O
genome	O
[	O
Noteborn	O
et	O
al.	O
,	O
J.	O
Virol.	O
65	O
(	O
1991	O
)	O
3131-3139	O
]	O
of	O
chicken	O
anemia	O
virus	O
(	O
CAV	O
)	O
in	O
chicken	B-cell_type
T-cells	I-cell_type
was	O
analysed	O
via	O
CAT	B-protein
assays	O
.	O

A	O
unique	O
region	O
containing	O
four	O
or	O
five	O
near-perfect	O
direct	O
repeats	O
(	O
DR	O
)	O
of	O
21	O
bp	O
with	O
one	O
12-bp	B-DNA
insert	I-DNA
was	O
proven	O
to	O
be	O
the	O
main	O
transcription-activation	B-DNA
element	I-DNA
,	O
with	O
enhancer-like	O
characteristics	O
.	O

PCR	O
studies	O
revealed	O
that	O
CAV	O
isolates	O
from	O
across	O
the	O
world	O
all	O
contained	O
this	O
promoter	B-DNA
sequence	I-DNA
.	O

Electrophoretic	O
mobility-shift	O
assays	O
(	O
EMSA	O
)	O
showed	O
that	O
individual	B-DNA
DR	I-DNA
units	I-DNA
,	O
as	O
well	O
as	O
the	O
12-bp	B-DNA
insert	I-DNA
,	O
can	O
bind	O
to	O
nuclear	B-protein
factors	I-protein
of	O
chicken	B-cell_type
T-cells	I-cell_type
.	O

Competition	O
assays	O
revealed	O
that	O
the	O
DR	B-DNA
units	I-DNA
bound	O
to	O
factors	O
other	O
than	O
the	O
12-bp	B-DNA
insert	I-DNA
.	O

A	O
synthetic	O
oligodeoxyribonucleotide	O
containing	O
an	O
SP1-box	B-DNA
(	O
5'-GGGCGG	O
)	O
could	O
compete	O
with	O
factors	O
binding	O
to	O
the	O
12-bp	B-DNA
insert	I-DNA
.	O

Purified	O
human	B-protein
SP1	I-protein
was	O
shown	O
to	O
have	O
very	O
strong	O
affinity	O
for	O
the	O
12-bp	B-DNA
insert	I-DNA
.	O

Functional	O
Myc-Max	B-protein
heterodimer	I-protein
is	O
required	O
for	O
activation-induced	O
apoptosis	O
in	O
T	B-cell_line
cell	I-cell_line
hybridomas	I-cell_line
.	O

T	B-cell_line
cell	I-cell_line
hybridomas	I-cell_line
respond	O
to	O
activation	O
signals	O
by	O
undergoing	O
apoptotic	O
cell	O
death	O
,	O
and	O
this	O
is	O
likely	O
to	O
represent	O
comparable	O
events	O
related	O
to	O
tolerance	O
induction	O
in	O
immature	B-cell_type
and	I-cell_type
mature	I-cell_type
T	I-cell_type
cells	I-cell_type
in	O
vivo	O
.	O

Previous	O
studies	O
using	O
antisense	O
oligonucleotides	O
implicated	O
the	O
c-Myc	B-protein
protein	I-protein
in	O
the	O
phenomenon	O
of	O
activation-induced	O
apoptosis	O
.	O

This	O
role	O
for	O
c-Myc	B-protein
in	O
apoptosis	O
is	O
now	O
confirmed	O
in	O
studies	O
using	O
a	O
dominant	O
negative	O
form	O
of	O
its	O
heterodimeric	O
binding	O
partner	O
,	O
Max	B-protein
,	O
which	O
we	O
show	O
here	O
inhibits	O
activation-induced	O
apoptosis	O
.	O

Further	O
,	O
coexpression	O
of	O
a	O
reciprocally	B-protein
mutant	I-protein
Myc	I-protein
protein	I-protein
capable	O
of	O
forming	O
functional	O
heterodimers	B-protein
with	O
the	O
mutant	O
Max	B-protein
can	O
compensate	O
for	O
the	O
dominant	O
negative	O
activity	O
and	O
restore	O
activation-induced	O
apoptosis	O
.	O

These	O
results	O
imply	O
that	O
Myc	B-protein
promotes	O
activation-induced	O
apoptosis	O
by	O
obligatory	O
heterodimerization	O
with	O
Max	B-protein
,	O
and	O
therefore	O
,	O
by	O
regulating	O
gene	O
transcription	O
.	O

Epstein-Barr	B-protein
virus	I-protein
SM	I-protein
protein	I-protein
.	O

The	O
protein	O
products	O
of	O
the	O
Epstein-Barr	O
virus	O
(	O
EBV	O
)	O
BMLF1	O
open	O
reading	O
frame	O
have	O
been	O
characterized	O
in	O
the	O
early	O
productive	O
cycle	O
in	O
B95-8	B-cell_line
and	O
Akata	B-cell_line
cells	I-cell_line
.	O

The	O
SM	B-protein
protein	I-protein
derived	O
from	O
the	O
spliced	O
RNA	O
joining	O
BSLF2	B-protein
to	O
BMLF1	B-protein
is	O
much	O
the	O
most	O
abundant	O
protein	O
.	O

SM	B-protein
is	O
a	O
phosphoprotein	B-protein
in	O
EBV	O
-infected	B-cell_type
cells	I-cell_type
and	O
can	O
be	O
phosphorylated	O
in	O
vitro	O
with	O
casein	B-protein
kinase	I-protein
II	I-protein
(	O
CKII	B-protein
)	O
.	O

Computer	O
analysis	O
of	O
the	O
SM	B-protein
protein	I-protein
sequence	O
showed	O
a	O
C	B-protein
terminal	I-protein
section	I-protein
of	O
SM	B-protein
to	O
be	O
related	O
to	O
genome	B-protein
positional	I-protein
homologues	I-protein
of	O
four	O
other	O
herpesviruses	O
and	O
revealed	O
consensus	B-protein
CKII	I-protein
sites	I-protein
near	O
the	O
N	B-protein
termini	I-protein
of	O
the	O
EBV	B-protein
SM	I-protein
protein	I-protein
,	O
the	O
herpes	B-protein
simplex	I-protein
virus	I-protein
(	I-protein
HSV	I-protein
)	I-protein
ICP27	I-protein
protein	I-protein
and	O
the	O
herpesvirus	B-protein
saimiri	I-protein
(	I-protein
HVS	I-protein
)	I-protein
open	I-protein
reading	I-protein
frame	I-protein
57	I-protein
protein	I-protein
.	O

Site-directed	O
mutagenesis	O
of	O
the	O
consensus	B-DNA
CKII	I-DNA
site	I-DNA
in	O
EBV	O
SM	O
greatly	O
reduced	O
the	O
in	O
vitro	O
phosphorylation	O
of	O
SM	B-protein
by	O
CKII	B-protein
.	O

The	O
mechanism	O
of	O
transactivation	O
by	O
BMLF1	B-protein
proteins	I-protein
has	O
been	O
controversial	O
but	O
SM	B-protein
was	O
shown	O
to	O
transactivate	O
gene	O
expression	O
from	O
a	O
CAT	B-DNA
reporter	I-DNA
construct	I-DNA
by	O
increasing	O
the	O
amount	O
of	O
cytoplasmic	B-RNA
CAT	I-RNA
mRNA	I-RNA
.	O

Mutagenesis	O
of	O
the	O
CKII	B-protein
site	O
in	O
SM	B-protein
made	O
no	O
difference	O
to	O
the	O
transactivation	O
in	O
this	O
transient	O
transfection	O
assay	O
.	O

Inducible	O
binding	O
to	O
the	O
c-fos	O
serum	O
response	O
element	O
during	O
T	O
cell	O
activation	O
is	O
regulated	O
by	O
a	O
phosphotyrosine-containing	B-protein
protein	I-protein
.	O

The	O
proto-oncogene	B-DNA
c-fos	I-DNA
is	O
an	O
immediate-early	B-DNA
gene	I-DNA
,	O
and	O
one	O
of	O
the	O
first	O
genes	O
transcribed	O
after	O
stimulation	O
of	O
most	O
cells	O
with	O
a	O
variety	O
of	O
ligands	O
.	O

Fos	O
expression	O
may	O
be	O
a	O
pivotal	O
event	O
in	O
converting	O
ligand-receptor	O
interactions	O
at	O
the	O
membrane	O
into	O
functional	O
modulation	O
of	O
cell	O
phenotype	O
.	O

The	O
serum	B-DNA
response	I-DNA
element	I-DNA
(	O
SRE	B-DNA
)	O
in	O
the	O
c-fos	B-DNA
regulatory	I-DNA
region	I-DNA
participates	O
in	O
induction	O
of	O
transcription	O
by	O
various	O
growth	B-protein
factors	I-protein
and	O
by	O
phorbol	O
esters	O
and	O
subsequent	O
squelching	O
of	O
transcription	O
.	O

We	O
show	O
that	O
an	O
inducible	O
protein	B-protein
complex	I-protein
(	O
Band	B-protein
A	I-protein
)	O
binds	O
to	O
SRE	B-DNA
DNA	I-DNA
within	O
10	O
min	O
after	O
mitogenic	O
stimulation	O
of	O
human	B-cell_line
PBL-T	I-cell_line
,	O
and	O
becomes	O
nondetectable	O
by	O
60	O
min	O
.	O

Band	B-protein
A	I-protein
contains	O
the	O
serum	B-protein
response	I-protein
factor	I-protein
plus	O
additional	O
factor	O
(	O
s	O
)	O
.	O

A	O
protein	O
that	O
is	O
phosphorylated	O
on	O
a	O
tyrosine	O
residue	O
in	O
resting	B-cell_line
PBL-T	I-cell_line
suppresses	O
binding	O
of	O
a	O
component	O
of	O
Band	B-protein
A	I-protein
to	O
the	O
SRE	B-DNA
motif	I-DNA
.	O

Upon	O
stimulation	O
of	O
the	O
cells	O
,	O
this	O
protein	O
no	O
longer	O
prevents	O
binding	O
of	O
DNA	O
by	O
Band	B-protein
A	I-protein
,	O
and	O
suppression	O
of	O
binding	O
is	O
restored	O
within	O
30	O
min	O
.	O

The	O
phosphorylated	O
tyrosine	O
residue	O
itself	O
is	O
important	O
for	O
the	O
protein-protein	O
interaction	O
.	O

In	O
vivo	O
modification	O
of	O
major	B-DNA
histocompatibility	I-DNA
complex	I-DNA
class	I-DNA
II	I-DNA
DRA	I-DNA
promoter	I-DNA
occupancy	O
mediated	O
by	O
the	O
AIR-1	B-protein
trans-activator	I-protein
.	O

RJ	B-cell_line
2.2.5	I-cell_line
is	O
a	O
human	B-cell_line
B	I-cell_line
cell	I-cell_line
mutant	I-cell_line
derived	O
from	O
the	O
Burkitt	B-cell_line
lymphoma	I-cell_line
Raji	I-cell_line
cell	I-cell_line
which	O
is	O
defective	O
in	O
the	O
AIR-1	O
locus	O
function	O
.	O

This	O
locus	O
encodes	O
a	O
transcriptional	O
trans-activator	O
required	O
for	O
the	O
constitutive	O
expression	O
of	O
major	B-DNA
histocompatibility	I-DNA
complex	I-DNA
(	I-DNA
MHC	I-DNA
)	I-DNA
class	I-DNA
II	I-DNA
genes	I-DNA
.	O

Here	O
we	O
show	O
,	O
by	O
in	O
vivo	O
DNase	B-protein
I	I-protein
footprinting	O
,	O
that	O
the	O
AIR-1	B-DNA
locus	I-DNA
defect	I-DNA
correlates	O
with	O
changes	O
in	O
the	O
DRA	B-DNA
promoter	I-DNA
occupancy	O
.	O

Interestingly	O
,	O
reexpression	O
of	O
human	B-DNA
MHC	I-DNA
class	I-DNA
II	I-DNA
genes	I-DNA
in	O
RJ	B-cell_line
2.2.5	I-cell_line
x	I-cell_line
mouse	I-cell_line
spleen	I-cell_line
cell	I-cell_line
hybrids	I-cell_line
is	O
associated	O
with	O
partial	O
reversion	O
of	O
DRA	B-DNA
promoter	I-DNA
occupancy	O
to	O
the	O
Raji	O
pattern	O
.	O

DRA	B-DNA
promoter	I-DNA
occupancy	O
in	O
other	O
class	B-cell_line
II-negative	I-cell_line
B	I-cell_line
cell	I-cell_line
lines	I-cell_line
,	O
derived	O
from	O
patients	O
with	O
bare	O
lymphocyte	O
syndrome	O
,	O
is	O
drastically	O
different	O
from	O
the	O
one	O
observed	O
in	O
RJ	B-cell_line
2.2.5	I-cell_line
and	O
Raji	B-cell_line
cells	I-cell_line
.	O

Moreover	O
,	O
the	O
use	O
of	O
the	O
DNase	B-protein
I	I-protein
as	O
an	O
in	O
vivo	O
footprinting	O
agent	O
reveals	O
that	O
the	O
patients	B-cell_line
'	I-cell_line
cell	I-cell_line
lines	I-cell_line
do	O
not	O
display	O
a	O
completely	O
``	O
bare	B-DNA
promoter	I-DNA
``	O
as	O
previously	O
reported	O
using	O
dimethyl	O
sulfate	O
as	O
the	O
footprinting	O
agent	O
.	O

Thus	O
,	O
the	O
use	O
of	O
DNase	B-protein
I	I-protein
allowed	O
us	O
,	O
for	O
the	O
first	O
time	O
,	O
to	O
correlate	O
the	O
AIR-1	B-DNA
locus	I-DNA
defect	I-DNA
with	O
class	B-DNA
II	I-DNA
promoter	I-DNA
occupancy	O
alterations	O
and	O
distinguish	O
these	O
alterations	O
from	O
the	O
ones	O
observed	O
in	O
phenotypically	O
similar	O
but	O
genetically	O
distinct	O
MHC	B-cell_line
class	I-cell_line
II-negative	I-cell_line
cells	I-cell_line
.	O

Regulation	O
of	O
cell-type-specific	O
interleukin-2	B-protein
receptor	I-protein
alpha-chain	I-protein
gene	O
expression	O
:	O
potential	O
role	O
of	O
physical	O
interactions	O
between	O
Elf-1	B-protein
,	O
HMG-I	B-protein
(	I-protein
Y	I-protein
)	I-protein
,	O
and	O
NF-kappa	B-protein
B	I-protein
family	I-protein
proteins	I-protein
.	O

The	O
interleukin	B-DNA
2	I-DNA
receptor	I-DNA
alpha-chain	I-DNA
(	I-DNA
IL-2R	I-DNA
alpha	I-DNA
)	I-DNA
gene	I-DNA
is	O
rapidly	O
and	O
potently	O
induced	O
in	O
T	B-cell_type
cells	I-cell_type
in	O
response	O
to	O
mitogenic	O
stimuli	O
.	O

Previously	O
,	O
an	O
inducible	B-DNA
enhancer	I-DNA
between	O
nucleotides	B-DNA
-299	I-DNA
and	I-DNA
-228	I-DNA
that	O
contains	O
NF-kappa	B-DNA
B	I-DNA
and	I-DNA
CArG	I-DNA
motifs	I-DNA
was	O
identified	O
.	O

We	O
now	O
report	O
the	O
characterization	O
of	O
a	O
second	O
essential	B-DNA
positive	I-DNA
regulatory	I-DNA
element	I-DNA
located	O
between	O
nucleotides	B-DNA
-137	I-DNA
and	I-DNA
-64	I-DNA
that	O
binds	O
Elf-1	B-protein
and	O
HMG-I	B-protein
(	I-protein
Y	I-protein
)	I-protein
.	O

This	O
element	O
had	O
maximal	O
activity	O
in	O
lymphoid	B-cell_type
cells	I-cell_type
,	O
paralleling	O
the	O
cell	O
type	O
specificity	O
of	O
Elf-1	B-protein
expression	O
.	O

Transcription	O
from	O
the	O
IL-2R	B-DNA
alpha	I-DNA
promoter	I-DNA
was	O
inhibited	O
when	O
either	O
the	O
Elf-1	B-DNA
or	I-DNA
the	I-DNA
HMG-I	I-DNA
(	I-DNA
Y	I-DNA
)	I-DNA
binding	I-DNA
site	I-DNA
was	O
mutated	O
.	O

Coexpression	O
of	O
both	O
proteins	O
activated	O
transcription	O
of	O
the	O
-137	B-DNA
to	I-DNA
-64	I-DNA
element	I-DNA
in	O
COS-7	B-cell_line
cells	I-cell_line
.	O

Elf-1	B-protein
physically	O
associated	O
with	O
HMG-I	B-protein
and	O
with	O
NF-kappa	B-protein
B	I-protein
p50	B-protein
and	O
c-Rel	B-protein
in	O
vitro	O
,	O
suggesting	O
that	O
protein-protein	O
interactions	O
might	O
functionally	O
coordinate	O
the	O
actions	O
of	O
the	O
upstream	B-DNA
and	I-DNA
downstream	I-DNA
positive	I-DNA
regulatory	I-DNA
elements	I-DNA
.	O

This	O
is	O
the	O
first	O
report	O
of	O
a	O
physical	O
interaction	O
between	O
an	O
Ets	O
family	O
member	O
and	O
NF-kappa	B-protein
B	I-protein
family	I-protein
proteins	I-protein
.	O

These	O
findings	O
provide	O
significant	O
new	O
insights	O
into	O
the	O
protein-protein	O
and	O
protein-DNA	O
interactions	O
that	O
regulate	O
cell-type-specific	O
and	O
inducible	O
IL-2R	B-protein
alpha	I-protein
gene	O
expression	O
and	O
also	O
have	O
implications	O
for	O
other	O
genes	O
regulated	O
by	O
Elf-1	B-protein
and	O
NF-kappa	B-protein
B	I-protein
family	I-protein
proteins	I-protein
.	O

Isolation	O
of	O
cDNA	B-DNA
clones	I-DNA
for	O
42	O
different	O
Kruppel-related	B-protein
zinc	I-protein
finger	I-protein
proteins	I-protein
expressed	O
in	O
the	O
human	B-cell_line
monoblast	I-cell_line
cell	I-cell_line
line	I-cell_line
U-937	I-cell_line
.	O

To	O
study	O
the	O
complexity	O
and	O
structural	O
characteristics	O
of	O
zinc	B-protein
finger	I-protein
proteins	I-protein
expressed	O
during	O
human	O
hematopoiesis	O
and	O
to	O
isolate	O
novel	O
regulators	O
of	O
blood	O
cell	O
development	O
,	O
a	O
degenerate	O
oligonucleotide	O
probe	O
specific	O
for	O
a	O
consensus	B-protein
zinc	I-protein
finger	I-protein
peptide	I-protein
domain	I-protein
was	O
used	O
to	O
isolate	O
63	O
cDNA	B-DNA
clones	I-DNA
for	O
Kruppel-related	B-DNA
zinc	I-DNA
finger	I-DNA
genes	I-DNA
from	O
the	O
human	B-cell_line
monoblast	I-cell_line
cell	I-cell_line
line	I-cell_line
U-937	I-cell_line
.	O

By	O
extensive	O
nucleotide	O
sequence	O
and	O
Northern	O
blot	O
analysis	O
,	O
these	O
cDNA	B-DNA
clones	I-DNA
were	O
found	O
to	O
originate	O
from	O
approximately	O
42	O
different	O
genes	O
(	O
HZF	B-DNA
1-42	I-DNA
)	O
of	O
which	O
only	O
8	O
have	O
previously	O
been	O
described	O
.	O

Northern	O
blot	O
analysis	O
showed	O
that	O
a	O
majority	O
of	O
these	O
genes	O
were	O
expressed	O
at	O
comparable	O
levels	O
in	O
U-937	B-cell_line
and	O
HeLa	B-cell_line
cells	I-cell_line
.	O

The	O
large	O
number	O
of	O
individual	O
genes	O
represented	O
among	O
the	O
63	O
clones	O
and	O
their	O
apparent	O
non-cell-type-specific	O
expression	O
suggest	O
that	O
the	O
majority	O
of	O
the	O
Kruppel-related	B-DNA
zinc	I-DNA
finger	I-DNA
genes	I-DNA
are	O
likely	O
to	O
be	O
expressed	O
in	O
most	O
human	O
tissues	O
.	O

In	O
contrast	O
,	O
some	O
of	O
the	O
genes	O
displayed	O
a	O
restricted	O
expression	O
pattern	O
,	O
indicating	O
that	O
they	O
represent	O
potential	O
regulators	O
of	O
monocyte	O
differentiation	O
or	O
proliferation	O
.	O

Detailed	O
structural	O
analysis	O
of	O
the	O
first	O
12	O
cDNAs	B-DNA
(	O
HZF	B-DNA
1-10	I-DNA
)	O
and	O
a	O
partial	O
characterization	O
of	O
HZF	B-DNA
11-42	I-DNA
revealed	O
that	O
a	O
common	O
feature	O
of	O
human	B-protein
Kruppel-related	I-protein
zinc	I-protein
finger	I-protein
proteins	I-protein
is	O
the	O
presence	O
of	O
tandem	O
arrays	O
of	O
zinc	B-protein
fingers	I-protein
ranging	O
in	O
number	O
from	O
3	O
to	O
over	O
20	O
that	O
are	O
preferentially	O
located	O
in	O
the	O
carboxy-terminal	B-protein
regions	I-protein
of	O
the	O
proteins	O
.	O

In	O
addition	O
,	O
several	O
novel	O
KRAB-containing	B-DNA
zinc	I-DNA
finger	I-DNA
genes	I-DNA
and	O
a	O
novel	O
conserved	B-DNA
sequence	I-DNA
element	I-DNA
were	O
identified	O
.	O

CAG	O
repeat	O
length	O
variation	O
in	O
sperm	B-cell_type
from	O
a	O
patient	O
with	O
Kennedy	O
's	O
disease	O
.	O

Using	O
a	O
modified	O
sperm	B-cell_type
typing	O
protocol	O
,	O
the	O
mutation	O
frequency	O
of	O
the	O
CAG	B-DNA
repeat	I-DNA
region	I-DNA
at	O
the	O
androgen	B-DNA
receptor	I-DNA
locus	I-DNA
has	O
been	O
measured	O
using	O
a	O
rare	O
semen	O
sample	O
from	O
an	O
individual	O
with	O
spinal	O
and	O
bulbar	O
muscular	O
atrophy	O
(	O
SBMA	O
)	O
.	O

Among	O
258	O
X	B-cell_type
chromosome-containing	I-cell_type
sperm	I-cell_type
,	O
19	O
%	O
had	O
a	O
repeat	O
number	O
equal	O
to	O
the	O
donor	B-DNA
's	I-DNA
somatic	I-DNA
DNA	I-DNA
(	O
47	O
repeats	O
)	O
,	O
66	O
%	O
were	O
expansions	O
and	O
15	O
%	O
were	O
contractions	O
.	O

The	O
average	O
expansion	O
was	O
2.7	O
repeats	O
.	O

More	O
than	O
half	O
of	O
the	O
expansions	O
involved	O
one	O
or	O
two	O
repeats	O
;	O
the	O
largest	O
was	O
11	O
repeats	O
.	O

68	O
%	O
of	O
the	O
contractions	O
were	O
also	O
one	O
or	O
two	O
repeats	O
but	O
six	O
(	O
16	O
%	O
)	O
were	O
very	O
large	O
(	O
12-25	O
repeats	O
)	O
.	O

One	O
contraction	O
generated	O
an	O
allele	O
in	O
an	O
intermediate	O
size	O
range	O
(	O
33-39	O
repeats	O
)	O
.	O

Such	O
alleles	O
have	O
not	O
been	O
observed	O
among	O
more	O
than	O
900	O
normal	O
and	O
SBMA	B-DNA
X-chromosomes	I-DNA
that	O
have	O
been	O
examined	O
.	O

Comparison	O
of	O
the	O
SBMA	O
sperm	B-cell_type
typing	O
results	O
with	O
mutation	O
frequency	O
data	O
on	O
normal	O
alleles	O
supports	O
the	O
hypothesis	O
that	O
trinucleotide	B-DNA
repeat	I-DNA
expansions	O
may	O
have	O
a	O
different	O
molecular	O
origin	O
than	O
contractions	O
.	O

Aspirin-like	O
drugs	O
can	O
protect	O
human	B-cell_type
T	I-cell_type
lymphocytes	I-cell_type
against	O
benzoquinone	O
cytotoxicity	O
:	O
evidence	O
for	O
a	O
NAD	B-protein
(	I-protein
P	I-protein
)	I-protein
H	I-protein
:	I-protein
quinone	I-protein
reductase	I-protein
-dependent	O
mechanism	O
.	O

Benzene	O
toxicity	O
towards	O
lymphocytes	B-cell_type
is	O
thought	O
to	O
be	O
mediated	O
by	O
metabolites	O
of	O
benzene	O
including	O
benzoquinone	O
(	O
BQ	O
)	O
.	O

NAD	B-protein
(	I-protein
P	I-protein
)	I-protein
H	I-protein
:	I-protein
quinone	I-protein
reductase	I-protein
(	O
QR	B-protein
)	O
is	O
known	O
to	O
protect	O
against	O
BQ	O
toxicity	O
.	O

The	O
expression	O
of	O
the	O
QR	B-DNA
gene	I-DNA
is	O
regulated	O
by	O
the	O
transcription	B-protein
factor	I-protein
AP-1	B-protein
.	O

We	O
had	O
previously	O
found	O
that	O
aspirin-like	O
drugs	O
(	O
ALD	O
)	O
induce	O
AP-1	B-protein
in	O
human	B-cell_type
T	I-cell_type
lymphocytes	I-cell_type
.	O

It	O
was	O
therefore	O
hypothesized	O
that	O
ALD	O
would	O
protect	O
lymphocytes	B-cell_type
against	O
BQ	O
toxicity	O
by	O
inducing	O
QR	B-protein
.	O

Molt-4	B-cell_line
cells	I-cell_line
(	O
M4	B-cell_line
)	O
,	O
a	O
human	B-cell_line
T	I-cell_line
lymphocyte	I-cell_line
cell	I-cell_line
line	I-cell_line
,	O
were	O
incubated	O
with	O
different	O
concentrations	O
of	O
two	O
ALD	O
,	O
flurbiprofen	O
and	O
sodium	O
diclofenac	O
,	O
and	O
then	O
exposed	O
to	O
BQ	O
.	O

Toxicity	O
was	O
measured	O
by	O
viability	O
(	O
trypan	O
blue	O
exclusion	O
)	O
.	O

Both	O
drugs	O
protected	O
the	O
cells	O
against	O
BQ	O
cytotoxicity	O
in	O
a	O
dose-dependent	O
manner	O
,	O
e.g.	O
,	O
sodium	O
diclofenac	O
at	O
15	O
microM	O
reduced	O
the	O
fraction	O
of	O
BQ-treated	O
dead	O
cells	O
by	O
70	O
%	O
.	O

ALDs	O
induced	O
QR	B-protein
activity	O
in	O
the	O
M4	O
cells	O
in	O
the	O
same	O
range	O
of	O
concentrations	O
that	O
protected	O
the	O
cells	O
against	O
BQ	O
toxicity	O
.	O

The	O
protective	O
effect	O
of	O
ALD	O
was	O
significantly	O
reduced	O
by	O
dicoumarol	O
,	O
a	O
QR	B-protein
-specific	O
inhibitor	O
.	O

Since	O
human	B-cell_type
T	I-cell_type
cells	I-cell_type
and	O
T	B-cell_type
cell	I-cell_type
lines	I-cell_type
do	O
not	O
metabolize	O
arachidonic	O
acid	O
,	O
our	O
data	O
suggest	O
that	O
ALD	O
can	O
protect	O
human	B-cell_type
T	I-cell_type
lymphocytes	I-cell_type
against	O
a	O
metabolite	O
of	O
benzene	O
by	O
induction	O
of	O
QR	B-protein
activity	O
.	O

Correlation	O
of	O
differentiation-inducing	O
activity	O
of	O
retinoids	O
on	O
human	B-cell_line
leukemia	I-cell_line
cell	I-cell_line
lines	I-cell_line
HL-60	B-cell_line
and	O
NB4	B-cell_line
.	O

Retinoids	O
,	O
including	O
all-trans-retinoic	O
acid	O
,	O
its	O
isomers	O
,	O
and	O
fifty	O
synthetic	O
retinoids	O
(	O
retinobenzoic	O
acids	O
)	O
,	O
were	O
tested	O
for	O
differentiation-inducing	O
activity	O
on	O
human	B-cell_line
leukemia	I-cell_line
cell	I-cell_line
lines	I-cell_line
HL-60	B-cell_line
and	O
NB4	B-cell_line
.	O

A	O
good	O
linear	O
correlation	O
,	O
with	O
an	O
r	O
value	O
of	O
0.91	O
,	O
between	O
the	O
ED50	O
values	O
for	O
the	O
differentiation-inducing	O
activity	O
towards	O
HL-60	B-cell_line
cells	I-cell_line
and	O
that	O
towards	O
NB4	B-cell_line
cells	I-cell_line
was	O
found	O
.	O

Platelet-activating	B-protein
factor	I-protein
(	O
PAF	B-protein
)	O
positively	O
auto-regulates	O
the	O
expression	O
of	O
human	B-protein
PAF	I-protein
receptor	I-protein
transcript	I-protein
1	I-protein
(	O
leukocyte-type	O
)	O
through	O
NF-kappa	B-protein
B	I-protein
.	O

The	O
human	B-DNA
platelet-activating	I-DNA
factor	I-DNA
receptor	I-DNA
(	I-DNA
PAFR	I-DNA
)	I-DNA
gene	I-DNA
is	O
transcribed	O
by	O
two	O
distinct	O
promoters	B-DNA
(	O
promoter	B-DNA
1	I-DNA
and	O
promoter	B-DNA
2	I-DNA
)	O
to	O
generate	O
two	O
transcripts	O
(	O
designated	O
as	O
PAFR	B-RNA
transcript	I-RNA
1	I-RNA
and	O
PAFR	B-RNA
transcript	I-RNA
2	I-RNA
)	O
,	O
though	O
their	O
open	O
reading	O
frames	O
are	O
identical	O
.	O

By	O
primer	O
extension	O
analysis	O
to	O
discriminate	O
two	O
transcripts	O
,	O
we	O
found	O
that	O
the	O
levels	O
of	O
PAFR	B-RNA
transcript	I-RNA
1	I-RNA
(	O
leukocyte-type	O
)	O
,	O
but	O
not	O
PAFR	B-RNA
transcript	I-RNA
2	I-RNA
(	O
tissue-type	O
)	O
,	O
are	O
upregulated	O
by	O
PAF	B-protein
as	O
well	O
as	O
by	O
12-O-tetradecanoylphorbol-13-acetate	O
(	O
TPA	O
)	O
in	O
the	O
human	B-cell_line
stomach	I-cell_line
cancer	I-cell_line
cell	I-cell_line
line	I-cell_line
(	O
JR-St	B-cell_line
cells	I-cell_line
)	O
which	O
expresses	O
both	O
functional	O
PAFR	B-RNA
transcript	I-RNA
1	I-RNA
and	O
PAFR	B-RNA
transcript	I-RNA
2	I-RNA
endogenously	O
.	O

Functional	O
analysis	O
of	O
the	O
promoter	B-DNA
1	I-DNA
with	O
a	O
transient	O
expression	O
assay	O
using	O
chloramphenicol	B-DNA
acetyltransferase	I-DNA
(	I-DNA
CAT	I-DNA
)	I-DNA
gene	I-DNA
as	O
a	O
reporter	O
showed	O
that	O
both	O
PAF	B-protein
and	O
TPA	O
activated	O
the	O
promoter	B-DNA
1	I-DNA
but	O
not	O
the	O
deleted	O
promoter	O
lacking	O
the	O
three	O
consensus	B-DNA
binding	I-DNA
sites	I-DNA
for	O
NF-kappa	B-protein
B	I-protein
located	O
from	O
-571	O
bp	O
to	O
-459	O
bp	O
.	O

These	O
findings	O
suggest	O
a	O
molecular	O
mechanism	O
of	O
positive	O
regulation	O
of	O
PAFR	B-protein
gene	O
expression	O
by	O
PAF	B-protein
through	O
NF-kappa	B-protein
B	I-protein
,	O
possibly	O
by	O
a	O
phosphorylation	O
reaction	O
involving	O
protein	B-protein
kinase	I-protein
C	I-protein
by	O
PAF	B-protein
.	O

One	O
gene	O
,	O
two	O
transcripts	B-RNA
:	O
isolation	O
of	O
an	O
alternative	O
transcript	O
encoding	O
for	O
the	O
autoantigen	B-protein
La/SS-B	I-protein
from	O
a	O
cDNA	B-DNA
library	I-DNA
of	O
a	O
patient	O
with	O
primary	O
Sjogrens	O
'	O
syndrome	O
.	O

A	O
cDNA	B-DNA
library	I-DNA
was	O
prepared	O
from	O
peripheral	O
blood	O
lymphocytes	B-cell_type
of	O
an	O
autoimmune	O
patient	O
with	O
primary	O
Sjogrens	O
'	O
syndrome	O
.	O

The	O
cDNA	B-DNA
library	I-DNA
was	O
screened	O
with	O
the	O
patients	O
own	O
autoimmune	O
serum	O
being	O
monospecific	O
for	O
the	O
nuclear	B-protein
autoantigen	I-protein
La/SS-B	I-protein
.	O

Thereby	O
an	O
alternative	O
type	O
of	O
La	B-RNA
mRNA	I-RNA
was	O
identified	O
that	O
differed	O
from	O
the	O
known	O
La	B-RNA
mRNA	I-RNA
due	O
to	O
an	O
exchange	O
of	O
the	O
exon	B-DNA
1	I-DNA
.	O

Sequencing	O
of	O
the	O
genomic	O
region	O
between	O
the	O
exons	B-DNA
1	I-DNA
and	I-DNA
2	I-DNA
showed	O
that	O
the	O
alternative	B-DNA
5'-end	I-DNA
is	O
a	O
part	O
of	O
the	O
intron	B-DNA
.	O

In	O
addition	O
,	O
the	O
presence	O
of	O
an	O
alternative	B-DNA
promoter	I-DNA
site	I-DNA
,	O
which	O
exists	O
within	O
the	O
intron	B-DNA
downstream	O
of	O
the	O
exon	B-DNA
1	I-DNA
,	O
became	O
evident	O
.	O

In	O
consequence	O
,	O
the	O
alternative	B-RNA
La	I-RNA
mRNA	I-RNA
is	O
the	O
result	O
of	O
a	O
promoter	O
switching	O
combined	O
with	O
an	O
alternative	O
splicing	O
mechanism	O
.	O

In	O
the	O
intron	O
,	O
further	O
transcription	B-protein
factor	I-protein
binding	O
sites	O
,	O
including	O
a	O
NF-kappa	B-DNA
B	I-DNA
element	I-DNA
,	O
were	O
identified	O
leading	O
to	O
the	O
suggestion	O
that	O
the	O
expression	O
of	O
the	O
gene	O
encoding	O
for	O
the	O
nuclear	B-protein
autoantigen	I-protein
La/SS-B	I-protein
alters	O
in	O
dependence	O
on	O
disease	O
conditions	O
.	O

Cross-linking	O
CD40	B-protein
on	O
B	B-cell_type
cells	I-cell_type
rapidly	O
activates	O
nuclear	B-protein
factor-kappa	I-protein
B	I-protein
.	O

The	O
B	B-protein
cell-associated	I-protein
surface	I-protein
molecule	I-protein
CD40	I-protein
functions	O
to	O
regulate	O
B	O
cell	O
responses	O
.	O

Cross-linking	O
CD40	B-protein
on	O
B	B-cell_type
cells	I-cell_type
can	O
lead	O
to	O
homotypic	O
cell	O
adhesion	O
,	O
IL-6	B-protein
production	O
,	O
and	O
,	O
in	O
combination	O
with	O
cytokines	B-protein
,	O
to	O
Ig	O
isotype	O
switching	O
.	O

Tyrosine	O
kinase	O
activity	O
is	O
increased	O
shortly	O
after	O
engagement	O
of	O
this	O
receptor	O
.	O

Little	O
is	O
known	O
about	O
how	O
the	O
very	O
early	O
events	O
induced	O
by	O
CD40	B-protein
cross-linking	O
link	O
to	O
cellular	O
responses	O
.	O

In	O
this	O
study	O
,	O
we	O
demonstrate	O
that	O
nuclear	B-protein
factor	I-protein
(	I-protein
NF	I-protein
)	I-protein
-kappa	I-protein
B	I-protein
and	O
NF-kappa	B-protein
B-like	I-protein
transcription	I-protein
factors	I-protein
are	O
activated	O
after	O
cross-linking	O
CD40	B-protein
on	O
resting	O
human	B-cell_type
tonsillar	I-cell_type
B	I-cell_type
cells	I-cell_type
and	O
on	O
B	B-cell_line
cell	I-cell_line
lines	I-cell_line
.	O

The	O
activation	O
is	O
rapid	O
and	O
is	O
mediated	O
through	O
a	O
tyrosine	O
kinase-dependent	O
pathway	O
.	O

The	O
complexes	O
detected	O
in	O
electrophoretic	O
mobility	O
shift	O
assays	O
contain	O
p50	B-protein
,	O
p65	B-protein
(	O
RelA	B-protein
)	O
,	O
c-Rel	B-protein
,	O
and	O
most	O
likely	O
other	O
components	O
.	O

By	O
using	O
transient	O
transfection	O
assays	O
,	O
we	O
found	O
that	O
cross-linking	O
CD40	B-protein
supports	O
NF-kappa	B-protein
B	I-protein
-dependent	O
gene	O
expression	O
.	O

Our	O
results	O
define	O
the	O
NF-kappa	B-protein
B	I-protein
system	O
as	O
an	O
intermediate	O
event	O
in	O
CD40	B-protein
signaling	O
and	O
suggest	O
that	O
the	O
CD40	B-protein
pathway	O
can	O
influence	O
the	O
expression	O
of	O
B	B-DNA
cell-associated	I-DNA
genes	I-DNA
with	O
NF-kappa	B-DNA
B	I-DNA
consensus	I-DNA
sites	I-DNA
.	O

Protease	O
inhibitors	O
block	O
lipopolysaccharide	O
induction	O
of	O
tissue	O
factor	O
gene	O
expression	O
in	O
human	B-cell_type
monocytic	I-cell_type
cells	I-cell_type
by	O
preventing	O
activation	O
of	O
c-Rel/p65	B-protein
heterodimers	I-protein
.	O

Tissue	B-protein
factor	I-protein
(	O
TF	B-protein
)	O
is	O
expressed	O
rapidly	O
by	O
human	B-cell_type
monocytes	I-cell_type
exposed	O
to	O
bacterial	B-protein
endotoxin	I-protein
(	O
lipopolysaccharide	O
,	O
or	O
LPS	O
)	O
.	O

Transcriptional	O
regulation	O
is	O
mediated	O
by	O
binding	O
of	O
c-Rel/p65	B-protein
heterodimers	I-protein
to	O
a	O
kappa	B-DNA
B-like	I-DNA
site	I-DNA
in	O
the	O
TF	B-DNA
promoter	I-DNA
.	O

Nuclear	O
translocation	O
of	O
cytosolic	B-protein
c-Rel/p65	I-protein
heterodimers	I-protein
and	O
other	O
members	O
of	O
the	O
NF-kappa	B-protein
B/Rel	I-protein
family	I-protein
requires	O
dissociation	O
and	O
proteolytic	O
degradation	O
of	O
the	O
inhibitor	B-protein
protein	I-protein
,	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
.	O

The	O
protease	O
inhibitors	O
N	O
alpha-tosylphenylalanyl	O
chloromethyl	O
ketone	O
(	O
TPCK	O
)	O
and	O
N	O
alpha-tosyl-L-lysine	O
chloromethyl	O
ketone	O
(	O
TLCK	O
)	O
block	O
activation	O
of	O
NF-kappa	B-protein
B/Rel	I-protein
proteins	I-protein
by	O
preventing	O
degradation	O
of	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
.	O

To	O
determine	O
if	O
TPCK	O
and	O
TLCK	O
inhibited	O
LPS	O
induction	O
of	O
TF	B-protein
expression	O
,	O
freshly	O
isolated	O
human	B-cell_type
monocytes	I-cell_type
and	O
monocytic	B-cell_line
THP-1	I-cell_line
cells	I-cell_line
were	O
pretreated	O
with	O
these	O
inhibitors	O
for	O
30	O
min	O
before	O
LPS	O
stimulation	O
.	O

Both	O
TPCK	O
and	O
TLCK	O
inhibited	O
LPS	O
induction	O
of	O
TF	B-protein
protein	I-protein
,	O
TF	B-RNA
mRNA	I-RNA
and	O
TF	B-protein
promoter	O
activity	O
in	O
a	O
dose-dependent	O
manner	O
.	O

These	O
inhibitors	O
specifically	O
prevented	O
degradation	O
of	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
and	O
nuclear	O
translocation	O
of	O
c-Rel/p65	B-protein
heterodimers	I-protein
.	O

In	O
contrast	O
,	O
TPCK	O
and	O
TLCK	O
did	O
not	O
block	O
induction	O
of	O
an	O
immediate-early	B-DNA
gene	I-DNA
encoding	O
the	O
transcription	B-protein
factor	I-protein
,	O
Egr-1	B-protein
.	O

Taken	O
together	O
,	O
these	O
data	O
indicated	O
that	O
inhibiting	O
nuclear	O
translocation	O
of	O
c-Rel/p65	B-protein
heterodimers	I-protein
prevented	O
LPS	O
induction	O
of	O
TF	B-protein
gene	O
transcription	O
in	O
monocytic	B-cell_type
cells	I-cell_type
.	O

1	B-protein
,	I-protein
25-Dihydroxyvitamin	I-protein
D3	I-protein
receptors	I-protein
in	O
peripheral	B-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
from	O
patients	O
with	O
primary	O
and	O
secondary	O
hyperparathyroidism	O
.	O

A	O
decreased	O
number	O
of	O
calcitriol	B-protein
(	I-protein
1	I-protein
,	I-protein
25	I-protein
(	I-protein
OH	I-protein
)	I-protein
2D3	I-protein
)	I-protein
receptors	I-protein
has	O
been	O
observed	O
in	O
parathyroid	O
glands	O
of	O
uremic	O
animals	O
.	O

In	O
humans	O
,	O
studies	O
carried	O
out	O
in	O
surgically	O
removed	O
parathyroid	O
glands	O
have	O
shown	O
that	O
calcitriol	O
binding	O
is	O
higher	O
in	O
primary	O
than	O
in	O
secondary	O
hyperparathyroidism	O
.	O

Since	O
specific	O
receptors	O
for	O
calcitriol	O
have	O
been	O
described	O
in	O
peripheral	B-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
(	O
PBMC	B-cell_type
)	O
,	O
we	O
have	O
investigated	O
the	O
specific	O
uptake	O
of	O
3H-labelled	O
1	O
,	O
25	O
(	O
OH	O
)	O
2D3	O
in	O
PBMC	B-cell_type
of	O
12	O
women	O
with	O
primary	O
hyperparathyroidism	O
(	O
PHP	O
)	O
,	O
8	O
women	O
with	O
hyperparathyroidism	O
secondary	O
to	O
chronic	O
renal	O
failure	O
(	O
SH	O
)	O
,	O
9	O
women	O
with	O
renal	O
transplant	O
(	O
RT	O
)	O
,	O
and	O
23	O
healthy	O
women	O
.	O

The	O
median	O
dissociation	O
constant	O
(	O
Kd	O
)	O
was	O
similar	O
in	O
all	O
three	O
groups	O
of	O
patients	O
and	O
in	O
healthy	O
women	O
(	O
mean	O
+/-	O
S.D.	O
(	O
range	O
)	O
:	O
PHP	O
,	O
1.2	O
+/-	O
1.0	O
(	O
0.2-4	O
)	O
x	O
10	O
(	O
-10	O
)	O
M	O
;	O
SH	O
,	O
0.6	O
+/-	O
0.4	O
(	O
0.2-1.2	O
)	O
x	O
10	O
(	O
-10	O
)	O
M	O
;	O
RT	O
,	O
1.1	O
+/-	O
0.5	O
(	O
0.4-1.9	O
)	O
x	O
10	O
(	O
-10	O
)	O
M	O
;	O
controls	O
,	O
1.0	O
+/-	O
0.6	O
(	O
0.3-2.6	O
)	O
x	O
10	O
(	O
-10	O
)	O
M	O
)	O
.	O
However	O
,	O
the	O
maximal	O
binding	O
capacity	O
(	O
Nmax	O
)	O
was	O
significantly	O
enhanced	O
in	O
PHP	O
(	O
3.9	O
+/-	O
1.9	O
(	O
1.3-7.6	O
)	O
fmol/10	O
(	O
7	O
)	O
cells	O
vs.	O
2.3	O
+/-	O
0.9	O
(	O
1.1-4.4	O
)	O
fmol/10	O
(	O
7	O
)	O
cells	O
in	O
controls	O
;	O
P	O
=	O
0.0006	O
)	O
and	O
decreased	O
in	O
SH	O
(	O
0.8	O
+/-	O
0.5	O
(	O
0.2-1.6	O
)	O
fmol/10	O
(	O
7	O
)	O
cells	O
vs.	O
2.3	O
+/-	O
0.9	O
(	O
1.1-4.4	O
)	O
fmol/10	O
(	O
7	O
)	O
cells	O
in	O
controls	O
;	O
P	O
=	O
0.0001	O
)	O
,	O
whereas	O
no	O
changes	O
were	O
seen	O
in	O
RT	O
(	O
2.3	O
+/-	O
0.7	O
(	O
1.2-3.3	O
)	O
fmol/10	O
(	O
7	O
)	O
cells	O
vs.	O
2.3	O
+/-	O
0.9	O
(	O
1.1-4.4	O
)	O
fmol/10	O
(	O
7	O
)	O
cells	O
in	O
controls	O
)	O
.	O

In	O
three	O
patients	O
with	O
PHP	O
who	O
were	O
subjected	O
to	O
parathyroidectomy	O
,	O
the	O
calcitriol	O
number	O
came	O
down	O
to	O
normal	O
.	O

Changes	O
of	O
calcitriol	B-protein
receptors	I-protein
in	O
primary	O
and	O
secondary	O
hyperparathyroidism	O
could	O
magnify	O
the	O
consequences	O
of	O
disturbances	O
in	O
serum	O
concentration	O
of	O
calcitriol	O
itself	O
and	O
might	O
play	O
an	O
important	O
role	O
in	O
the	O
development	O
of	O
secondary	O
hyperparathyroidism	O
in	O
uremia	O
.	O

The	O
severe	O
phenotype	O
of	O
females	O
with	O
tiny	B-DNA
ring	I-DNA
X	I-DNA
chromosomes	I-DNA
is	O
associated	O
with	O
inability	O
of	O
these	O
chromosomes	B-DNA
to	O
undergo	O
X	O
inactivation	O
.	O

Mental	O
retardation	O
and	O
a	O
constellation	O
of	O
congenital	O
malformations	O
not	O
usually	O
associated	O
with	O
Turner	O
syndrome	O
are	O
seen	O
in	O
some	O
females	O
with	O
a	O
mosaic	O
45	O
,	O
X/46	O
,	O
X	O
,	O
r	O
(	O
X	O
)	O
karyotype	O
.	O

Studies	O
of	O
these	O
females	O
show	O
that	O
the	O
XIST	B-DNA
locus	I-DNA
on	O
their	O
tiny	B-DNA
ring	I-DNA
X	I-DNA
chromosomes	I-DNA
is	O
either	O
not	O
present	O
or	O
not	O
expressed	O
.	O

As	O
XIST	B-DNA
transcription	O
is	O
well	O
correlated	O
with	O
inactivation	O
of	O
the	O
X	B-DNA
chromosome	I-DNA
in	O
female	B-cell_type
somatic	I-cell_type
cells	I-cell_type
and	O
spermatogonia	B-cell_type
,	O
nonexpression	O
of	O
the	O
locus	O
even	O
when	O
it	O
is	O
present	O
suggests	O
that	O
these	O
chromosomes	B-DNA
are	O
transcriptionally	O
active	O
.	O

We	O
examined	O
the	O
transcriptional	O
activity	O
of	O
ring	O
X	B-DNA
chromosomes	I-DNA
lacking	O
XIST	B-DNA
expression	O
(	O
XISTE-	O
)	O
,	O
from	O
three	O
females	O
with	O
severe	O
phenotypes	O
.	O

The	O
two	O
tiny	O
ring	O
X	B-DNA
chromosomes	I-DNA
studied	O
with	O
an	O
antibody	B-protein
specific	O
for	O
the	O
acetylated	O
isoforms	O
of	O
histone	B-protein
H4	I-protein
marking	O
transcribed	B-DNA
chromatin	I-DNA
domains	I-DNA
were	O
labeled	O
at	O
a	O
level	O
consistent	O
with	O
their	O
being	O
active	O
.	O

We	O
also	O
examined	O
tow	O
of	O
the	O
XISTE-	B-DNA
ring	I-DNA
chromosomes	I-DNA
to	O
determine	O
whether	O
genes	B-DNA
that	O
are	O
normally	O
silent	O
on	O
an	O
inactive	B-DNA
X	I-DNA
are	O
expressed	O
from	O
these	O
chromosomes	B-DNA
.	O

Analyses	O
of	O
hybrid	B-cell_line
cells	I-cell_line
show	O
that	O
TIMP	B-DNA
,	O
ZXDA	B-DNA
,	O
and	O
ZXDB	B-DNA
loci	I-DNA
on	O
the	O
proximal	B-DNA
short	I-DNA
arm	I-DNA
,	O
and	O
AR	B-DNA
and	O
PHKA1	B-DNA
loci	I-DNA
on	O
the	O
long	O
arm	O
,	O
are	O
well	O
expressed	O
from	O
the	O
tiny	B-DNA
ring	I-DNA
X	I-DNA
chromosome	I-DNA
lacking	O
XIST	B-DNA
DNA	I-DNA
.	O

Studies	O
of	O
the	O
ring	B-DNA
chromosome	I-DNA
that	O
has	O
XIST	B-DNA
DNA	I-DNA
but	O
does	O
not	O
transcribe	O
it	O
show	O
that	O
its	O
AR	O
allele	O
is	O
transcribed	O
along	O
with	O
the	O
one	O
on	O
the	O
normal	O
X	O
allele	O
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Inhibition	O
of	O
activation	O
of	O
transcription	B-protein
factor	I-protein
AP-1	I-protein
by	O
CD28	B-protein
signalling	O
in	O
human	B-cell_type
T-cells	I-cell_type
.	O

Co-stimulation	O
of	O
T-lymphocytes	B-cell_type
by	O
T-cell	B-protein
receptor	I-protein
(	O
TcR	B-protein
)	O
occupancy	O
and	O
activation	O
of	O
the	O
CD28	B-protein
surface	I-protein
molecule	I-protein
results	O
in	O
enhanced	O
proliferation	O
and	O
interleukin	B-protein
2	I-protein
(	O
IL-2	B-protein
)	O
production	O
.	O

The	O
increase	O
in	O
IL-2	B-protein
gene	O
expression	O
triggered	O
by	O
CD28	B-protein
involves	O
a	O
kappa	B-DNA
B-like	I-DNA
sequence	I-DNA
in	O
the	O
5'-regulatory	B-DNA
region	I-DNA
of	O
the	O
IL-2	B-DNA
promoter	I-DNA
,	O
called	O
CD28-responsive	B-DNA
element	I-DNA
.	O

Stimulation	O
of	O
T-cells	B-cell_type
by	O
agonistic	O
anti-CD28	B-protein
antibodies	I-protein
in	O
conjunction	O
with	O
phorbol	O
12-myristate	O
13-acetate	O
(	O
PMA	O
)	O
-	O
or	O
TcR	B-protein
-derived	O
signals	O
induces	O
the	O
enhanced	O
activation	O
of	O
the	O
transcription	B-protein
factor	I-protein
NF-kappa	B-protein
B	I-protein
.	O

Here	O
we	O
report	O
that	O
CD28	B-protein
engagement	O
,	O
however	O
,	O
exerts	O
opposite	O
effects	O
on	O
the	O
transcription	B-protein
factor	I-protein
AP-1	I-protein
.	O

Whereas	O
anti-CD28	B-protein
together	O
with	O
PMA	O
increased	O
the	O
DNA	O
binding	O
and	O
trans-activation	O
activity	O
of	O
NF-kappa	B-protein
B	I-protein
,	O
PMA-induced	O
activation	O
of	O
AP-1	B-protein
was	O
significantly	O
suppressed	O
.	O

The	O
inhibitory	O
effect	O
exerted	O
by	O
anti-CD28	B-protein
was	O
observed	O
at	O
the	O
level	O
of	O
DNA	O
binding	O
as	O
well	O
as	O
in	O
functional	O
reporter-gene	O
assays	O
.	O

These	O
results	O
suggest	O
that	O
the	O
two	O
transcription	B-protein
factors	I-protein
are	O
independently	O
regulated	O
and	O
may	O
perform	O
different	O
functions	O
during	O
T-cell	O
activation	O
.	O

HIV-1	B-protein
Nef	I-protein
leads	O
to	O
inhibition	O
or	O
activation	O
of	O
T	B-cell_type
cells	I-cell_type
depending	O
on	O
its	O
intracellular	O
localization	O
.	O

Nef	B-protein
of	O
primate	O
lentiviruses	O
is	O
required	O
for	O
viremia	O
and	O
progression	O
to	O
AIDS	O
in	O
monkeys	O
.	O

Negative	O
,	O
positive	O
,	O
and	O
no	O
effects	O
of	O
Nef	B-protein
have	O
also	O
been	O
reported	O
on	O
viral	O
replication	O
in	O
cells	O
.	O

To	O
reconcile	O
these	O
observations	O
,	O
we	O
expressed	O
a	O
hybrid	B-protein
CD8-Nef	I-protein
protein	I-protein
in	O
Jurkat	B-cell_line
cells	I-cell_line
.	O

Two	O
opposite	O
phenotypes	O
were	O
found	O
,	O
which	O
depended	O
on	O
the	O
intracellular	O
localization	O
of	O
Nef	B-protein
.	O

Expressed	O
in	O
the	O
cytoplasm	O
or	O
on	O
the	O
cell	O
surface	O
,	O
the	O
chimera	B-protein
inhibited	O
or	O
activated	O
early	O
signaling	O
events	O
from	O
the	O
T	B-protein
cell	I-protein
antigen	I-protein
receptor	I-protein
.	O

Activated	O
Jurkat	B-cell_line
cells	I-cell_line
died	O
by	O
apoptosis	O
,	O
and	O
only	O
cells	O
with	O
mutated	O
nef	B-DNA
genes	I-DNA
expressing	O
truncated	O
Nefs	B-protein
survived	O
,	O
which	O
rendered	O
Nef	B-protein
nonfunctional	O
.	O

These	O
mutations	O
paralleled	O
those	O
in	O
other	O
viral	O
strains	O
passaged	O
in	O
vitro	O
.	O

Not	O
only	O
do	O
these	O
positional	O
effects	O
of	O
Nef	B-protein
reconcile	O
diverse	O
phenotypes	O
of	O
Nef	B-protein
and	O
suggest	O
a	O
role	O
for	O
its	O
N-terminal	O
myristylation	O
,	O
but	O
they	O
also	O
explain	O
effects	O
of	O
Nef	B-protein
in	O
HIV	O
infection	O
and	O
progression	O
to	O
AIDS	O
.	O

An	O
intricate	O
arrangement	O
of	O
binding	O
sites	O
for	O
the	O
Ets	B-protein
family	I-protein
of	O
transcription	B-protein
factors	I-protein
regulates	O
activity	O
of	O
the	O
alpha	B-DNA
4	I-DNA
integrin	I-DNA
gene	I-DNA
promoter	I-DNA
.	O

alpha	B-protein
4	I-protein
integrins	I-protein
mediate	O
cell-cell	O
and	O
cell-extracellular	O
matrix	O
interactions	O
that	O
are	O
critical	O
for	O
maturation	O
and	O
function	O
of	O
the	O
immune	O
system	O
as	O
well	O
as	O
differentiation	O
of	O
skeletal	O
muscle	O
.	O

Here	O
we	O
examine	O
molecular	O
mechanisms	O
controlling	O
the	O
pattern	O
of	O
alpha	B-protein
4	I-protein
expression	O
.	O

The	O
activity	O
of	O
constructs	O
containing	O
5	B-DNA
'	I-DNA
deletion	I-DNA
mutants	I-DNA
of	O
the	O
alpha	B-DNA
4	I-DNA
gene	I-DNA
promoter	I-DNA
was	O
compared	O
in	O
transfection	O
assays	O
into	O
cell	B-cell_line
lines	I-cell_line
that	O
express	O
alpha	B-protein
4	I-protein
and	O
cell	B-cell_line
lines	I-cell_line
that	O
do	O
not	O
.	O

The	O
sequence	O
between	O
position	O
-42	B-DNA
and	I-DNA
-76	I-DNA
base	I-DNA
pairs	I-DNA
(	O
bp	O
)	O
was	O
required	O
for	O
efficient	O
transcription	O
in	O
cells	O
that	O
express	O
alpha	B-protein
4	I-protein
,	O
but	O
it	O
showed	O
no	O
activity	O
in	O
HeLa	B-cell_line
cells	I-cell_line
,	O
which	O
do	O
not	O
express	O
alpha	B-protein
4	I-protein
.	O

Three	O
binding	B-DNA
sites	I-DNA
for	O
the	O
Ets	B-protein
family	I-protein
of	O
transcription	B-protein
factors	I-protein
are	O
found	O
in	O
this	O
region	O
:	O
two	O
adjacent	O
sites	O
at	O
positions	O
-50	B-DNA
and	I-DNA
-54	I-DNA
bp	I-DNA
and	O
a	O
more	O
5	B-DNA
'	I-DNA
site	I-DNA
at	O
position	O
-67	B-DNA
bp	I-DNA
.	O

Using	O
a	O
series	O
of	O
constructs	O
containing	O
deletions	O
and	O
mutations	O
in	O
this	O
region	O
,	O
we	O
found	O
that	O
the	O
3'-most	B-DNA
site	I-DNA
alone	O
was	O
sufficient	O
for	O
binding	O
GA-binding	B-protein
protein	I-protein
alpha	I-protein
(	O
GABP	B-protein
alpha	I-protein
)	I-protein
/GABP	I-protein
beta	I-protein
and	O
for	O
a	O
low	O
level	O
of	O
transcriptional	O
activation	O
.	O

When	O
all	O
three	O
sites	O
were	O
present	O
,	O
a	O
second	O
complex	O
``	O
a	O
''	O
was	O
detected	O
,	O
which	O
contains	O
an	O
unknown	O
member	O
of	O
the	O
Ets	B-protein
family	I-protein
.	O

Formation	O
of	O
complex	O
a	O
was	O
cell-type	O
specific	O
and	O
correlated	O
with	O
a	O
high	O
level	O
of	O
transcription	O
.	O

Deletion	O
of	O
the	O
5'-most	B-DNA
Ets	I-DNA
site	I-DNA
had	O
no	O
effect	O
on	O
binding	O
to	O
GABP	B-protein
alpha/GABP	I-protein
beta	I-protein
,	O
but	O
it	O
eliminated	O
a	O
.	O

Concomitant	O
with	O
this	O
loss	O
of	O
a	O
,	O
a	O
new	B-protein
Ets-1-containing	I-protein
complex	I-protein
``	O
c	B-protein
``	O
appeared	O
.	O

Complex	O
c	O
substituted	O
efficiently	O
for	O
complex	O
a	O
in	O
transcriptional	O
activation	O
.	O

We	O
conclude	O
that	O
although	O
neither	O
of	O
the	O
two	O
5'-most	B-DNA
Ets	I-DNA
sites	I-DNA
alone	O
binds	O
nuclear	B-protein
protein	I-protein
,	O
they	O
appear	O
to	O
act	O
as	O
modulators	O
which	O
control	O
the	O
pattern	O
of	O
Ets	B-protein
proteins	I-protein
that	O
bind	O
the	O
alpha	B-DNA
4	I-DNA
gene	I-DNA
promoter	I-DNA
.	O

This	O
arrangement	O
of	O
Ets	B-DNA
sites	I-DNA
,	O
coupled	O
with	O
the	O
tissue-	O
and	O
developmental-specific	O
expression	O
of	O
Ets	B-protein
members	I-protein
,	O
likely	O
play	O
a	O
key	O
role	O
in	O
defining	O
the	O
pattern	O
of	O
alpha	B-protein
4	I-protein
integrin	I-protein
.	O

Mechanism	O
of	O
antiandrogen	O
action	O
:	O
conformational	O
changes	O
of	O
the	O
receptor	O
.	O

Androgen	B-RNA
receptor	I-RNA
mRNA	I-RNA
was	O
translated	O
in	O
vitro	O
,	O
and	O
androgen-	B-protein
and	I-protein
antiandrogen-bound	I-protein
receptor	I-protein
complexes	I-protein
were	O
studied	O
using	O
limited	O
proteolytic	O
digestion	O
by	O
trypsin	B-protein
.	O

Partial	O
proteolysis	O
of	O
androgen-bound	B-protein
receptor	I-protein
protein	I-protein
resulted	O
in	O
a	O
29-kDa	B-protein
proteolysis-resisting	I-protein
fragment	I-protein
,	O
whereas	O
antiandrogen	O
binding	O
stabilised	O
a	O
35-kDa	B-protein
fragment	I-protein
.	O

Both	O
fragments	O
contain	O
the	O
entire	O
ligand	B-protein
binding	I-protein
domain	I-protein
,	O
and	O
the	O
35-kDa	B-protein
fragment	I-protein
extended	O
into	O
the	O
hinge	B-protein
region	I-protein
of	O
the	O
receptor	O
.	O

Several	O
antiandrogens	O
show	O
agonistic	O
properties	O
for	O
a	O
mutated	B-protein
androgen	I-protein
receptor	I-protein
(	O
LNCaP	B-cell_line
cell	I-cell_line
variant	I-cell_line
)	O
;	O
trypsin	B-protein
digestion	O
of	O
antiandrogen-bound	B-protein
mutated	I-protein
receptor	I-protein
also	O
resulted	O
in	O
a	O
29-kDa	B-protein
fragment	I-protein
.	O

Our	O
results	O
point	O
to	O
an	O
important	O
difference	O
between	O
antiandrogens	O
and	O
antagonists	O
of	O
other	O
steroid	B-protein
hormone	I-protein
receptors	I-protein
.	O

Antiandrogens	O
result	O
in	O
protection	O
of	O
both	O
the	O
hinge	B-protein
region	I-protein
and	O
C-terminus	B-protein
of	O
the	O
androgen	B-protein
receptor	I-protein
agonist	O
proteolytic	O
attack	O
,	O
whereas	O
other	O
studies	O
showed	O
that	O
antiestrogens	O
and	O
antiprogestagens	O
expose	O
the	O
C-terminal	B-protein
end	I-protein
of	O
the	O
ligand	B-protein
binding	I-protein
domain	I-protein
of	O
their	O
respective	O
receptors	O
to	O
protease	B-protein
.	O

Differences	O
in	O
conformation	O
of	O
the	O
hinge	B-protein
region	I-protein
distinguish	O
androgen-bound	B-protein
from	O
antiandrogen-bound	B-protein
receptor	I-protein
complexes	I-protein
,	O
which	O
represents	O
an	O
important	O
feature	O
of	O
antiandrogen	O
action	O
.	O

Activation	O
of	O
nuclear	B-protein
factor	I-protein
kappa	I-protein
B	I-protein
in	O
human	B-cell_line
neuroblastoma	I-cell_line
cell	I-cell_line
lines	I-cell_line
.	O

The	O
nuclear	B-protein
factor	I-protein
kappa	I-protein
B	I-protein
(	O
NF-kappa	B-protein
B	I-protein
)	O
is	O
a	O
eukaryotic	O
transcription	B-protein
factor	I-protein
.	O

In	O
B	B-cell_type
cells	I-cell_type
and	O
macrophages	B-cell_type
it	O
is	O
constitutively	O
present	O
in	O
cell	O
nuclei	O
,	O
whereas	O
in	O
many	O
other	O
cell	O
types	O
,	O
NF-kappa	B-protein
B	I-protein
translocates	O
from	O
cytosol	O
to	O
nucleus	O
as	O
a	O
result	O
of	O
transduction	O
by	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
alpha	I-protein
(	O
TNF	B-protein
alpha	I-protein
)	O
,	O
phorbol	O
ester	O
,	O
and	O
other	O
polyclonal	O
signals	O
.	O

Using	O
neuroblastoma	B-cell_line
cell	I-cell_line
lines	I-cell_line
as	O
models	O
,	O
we	O
have	O
shown	O
that	O
in	O
neural	B-cell_type
cells	I-cell_type
NF-kappa	B-protein
B	I-protein
was	O
present	O
in	O
the	O
cytosol	O
and	O
translocated	O
into	O
nuclei	O
as	O
a	O
result	O
of	O
TNF	B-protein
alpha	I-protein
treatment	O
.	O

The	O
TNF	B-protein
alpha	I-protein
-activated	O
NF-kappa	B-protein
B	I-protein
was	O
transcriptionally	O
functional	O
.	O

NF-kappa	B-protein
B	I-protein
activation	O
by	O
TNF	B-protein
alpha	I-protein
was	O
not	O
correlated	O
with	O
cell	O
differentiation	O
or	O
proliferation	O
.	O

However	O
,	O
reagents	O
such	O
as	O
nerve	B-protein
growth	I-protein
factor	I-protein
(	O
NGF	B-protein
)	O
and	O
the	O
phorbol	O
ester	O
phorbol	O
12-myristate	O
13-acetate	O
(	O
PMA	O
)	O
,	O
which	O
induce	O
phenotypical	O
differentiation	O
of	O
the	O
SH-SY5Y	B-cell_line
neuroblastoma	I-cell_line
cell	I-cell_line
line	I-cell_line
,	O
activated	O
NF-kappa	B-protein
B	I-protein
,	O
but	O
only	O
in	O
that	O
particular	O
cell	B-cell_line
line	I-cell_line
.	O

In	O
a	O
NGF-responsive	B-cell_line
rat	I-cell_line
pheochromocytoma	I-cell_line
cell	I-cell_line
line	I-cell_line
,	O
PC12	B-cell_line
,	O
PMA	O
activated	O
NF-kappa	B-protein
B	I-protein
,	O
whereas	O
NGF	B-protein
did	O
not	O
.	O

In	O
other	O
neuroblastoma	B-cell_line
cell	I-cell_line
lines	I-cell_line
,	O
such	O
as	O
SK-N-Be	B-cell_line
(	I-cell_line
2	I-cell_line
)	I-cell_line
,	O
the	O
lack	O
of	O
PMA	O
induction	O
of	O
differentiation	O
was	O
correlated	O
with	O
the	O
lack	O
of	O
NF-kappa	B-protein
B	I-protein
activation	O
.	O

We	O
found	O
,	O
moreover	O
,	O
that	O
in	O
SK-N-Be	B-cell_line
(	I-cell_line
2	I-cell_line
)	I-cell_line
cells	I-cell_line
protein	B-protein
kinase	I-protein
C	I-protein
(	O
PKC	B-protein
)	O
enzymatic	O
activity	O
was	O
much	O
lower	O
compared	O
with	O
that	O
in	O
a	O
control	B-cell_line
cell	I-cell_line
line	I-cell_line
and	O
that	O
the	O
low	O
PKC	B-protein
enzymatic	O
activity	O
was	O
due	O
to	O
low	O
PKC	B-protein
protein	O
expression	O
.	O

NF-kappa	B-protein
B	I-protein
was	O
not	O
activated	O
by	O
retinoic	O
acid	O
,	O
which	O
induced	O
morphological	O
differentiation	O
of	O
all	O
the	O
neuroblastoma	B-cell_line
cell	I-cell_line
lines	I-cell_line
used	O
in	O
the	O
present	O
study	O
.	O

Thus	O
,	O
NF-kappa	B-protein
B	I-protein
activation	O
was	O
not	O
required	O
for	O
neuroblastoma	B-cell_type
cell	O
differentiation	O
.	O

Furthermore	O
,	O
the	O
results	O
obtained	O
with	O
TNF	B-protein
alpha	I-protein
proved	O
that	O
NF-kappa	B-protein
B	I-protein
activation	O
was	O
not	O
sufficient	O
for	O
induction	O
of	O
neuroblastoma	B-cell_type
differentiation	O
.	O

ERP	B-protein
,	O
a	O
new	O
member	O
of	O
the	O
ets	B-protein
transcription	I-protein
factor/oncoprotein	I-protein
family	I-protein
:	O
cloning	O
,	O
characterization	O
,	O
and	O
differential	O
expression	O
during	O
B-lymphocyte	O
development	O
.	O

The	O
ets	B-DNA
gene	I-DNA
family	I-DNA
encodes	O
a	O
group	O
of	O
proteins	O
which	O
function	O
as	O
transcription	B-protein
factors	I-protein
under	O
physiological	O
conditions	O
and	O
,	O
if	O
aberrantly	O
expressed	O
,	O
can	O
cause	O
cellular	O
transformation	O
.	O

We	O
have	O
recently	O
identified	O
two	O
regulatory	O
elements	O
in	O
the	O
murine	B-DNA
immunoglobulin	I-DNA
heavy-chain	I-DNA
(	I-DNA
IgH	I-DNA
)	I-DNA
enhancer	I-DNA
,	O
pi	B-DNA
and	O
microB	B-DNA
,	O
which	O
exhibit	O
striking	O
similarity	O
to	O
binding	B-DNA
sites	I-DNA
for	O
ets-related	B-DNA
proteins	I-DNA
.	O

To	O
identify	O
ets-related	B-protein
transcriptional	I-protein
regulators	I-protein
expressed	O
in	O
pre-B	B-cell_type
lymphocytes	I-cell_type
that	O
may	O
interact	O
with	O
either	O
the	O
pi	B-DNA
or	O
the	O
microB	B-DNA
site	I-DNA
,	O
we	O
have	O
used	O
a	O
PCR	O
approach	O
with	O
degenerate	O
oligonucleotides	O
encoding	O
conserved	O
sequences	O
in	O
all	O
members	O
of	O
the	O
ets	B-DNA
family	I-DNA
.	O

We	O
have	O
cloned	O
the	O
gene	O
for	O
a	O
new	O
ets-related	B-protein
transcription	I-protein
factor	I-protein
,	O
ERP	B-protein
(	O
ets-related	B-protein
protein	I-protein
)	O
,	O
from	O
the	O
murine	B-cell_line
pre-B	I-cell_line
cell	I-cell_line
line	I-cell_line
BASC	B-cell_line
6C2	I-cell_line
and	O
from	O
mouse	O
lung	O
tissue	O
.	O

The	O
ERP	B-protein
protein	O
contains	O
a	O
region	O
of	O
high	O
homology	O
with	O
the	O
ETS	O
DNA-binding	O
domain	O
common	O
to	O
all	O
members	O
of	O
the	O
ets	B-protein
transcription	I-protein
factor/oncoprotein	I-protein
family	I-protein
.	O

Three	O
additional	O
smaller	O
regions	O
show	O
homology	O
to	O
the	O
ELK-1	O
and	O
SAP-1	B-protein
genes	O
,	O
a	O
subgroup	O
of	O
the	O
ets	B-DNA
gene	I-DNA
family	I-DNA
that	O
interacts	O
with	O
the	O
serum	B-protein
response	I-protein
factor	I-protein
.	O

Full-length	O
ERP	B-protein
expresses	O
only	O
negligible	O
DNA-binding	O
activity	O
by	O
itself	O
.	O

Removal	O
of	O
the	O
carboxy	B-protein
terminus	I-protein
enables	O
ERP	B-protein
to	O
interact	O
with	O
a	O
variety	O
of	O
ets-binding	B-DNA
sites	I-DNA
including	O
the	O
E74	B-DNA
site	I-DNA
,	O
the	O
IgH	B-DNA
enhancer	I-DNA
pi	I-DNA
site	I-DNA
,	O
and	O
the	O
lck	B-DNA
promoter	I-DNA
ets	I-DNA
site	I-DNA
,	O
suggesting	O
a	O
carboxy-terminal	B-protein
negative	I-protein
regulatory	I-protein
domain	I-protein
.	O

At	O
least	O
three	O
ERP-related	B-protein
transcripts	I-protein
are	O
expressed	O
in	O
a	O
variety	O
of	O
tissues	O
.	O

However	O
,	O
within	O
the	O
B-cell	B-cell_type
lineage	I-cell_type
,	O
ERP	B-protein
is	O
highly	O
expressed	O
primarily	O
at	O
early	O
stages	O
of	O
B-lymphocyte	B-cell_type
development	O
,	O
and	O
expression	O
declines	O
drastically	O
upon	O
B-cell	O
maturation	O
,	O
correlating	O
with	O
the	O
enhancer	O
activity	O
of	O
the	O
IgH	B-DNA
pi	I-DNA
site	I-DNA
.	O

These	O
data	O
suggest	O
that	O
ERP	B-protein
might	O
play	O
a	O
role	O
in	O
B-cell	B-cell_type
development	O
and	O
in	O
IgH	B-DNA
gene	I-DNA
regulation	O
.	O

Gene	O
for	O
a	O
tissue-specific	B-protein
transcriptional	I-protein
activator	I-protein
(	O
EBF	B-protein
or	O
Olf-1	B-protein
)	O
,	O
expressed	O
in	O
early	B-cell_type
B	I-cell_type
lymphocytes	I-cell_type
,	O
adipocytes	B-cell_type
,	O
and	O
olfactory	B-cell_type
neurons	I-cell_type
,	O
is	O
located	O
on	O
human	B-DNA
chromosome	I-DNA
5	I-DNA
,	O
band	B-DNA
q34	I-DNA
,	O
and	O
proximal	B-DNA
mouse	I-DNA
chromosome	I-DNA
11	I-DNA
.	O

Murine	B-cell_type
B	I-cell_type
lymphocytes	I-cell_type
,	O
adipocytes	B-cell_type
,	O
and	O
olfactory	B-cell_type
neurons	I-cell_type
contain	O
a	O
DNA-binding	B-protein
protein	I-protein
that	O
participates	O
in	O
the	O
regulation	O
of	O
genes	B-DNA
encoding	O
tissue-specific	O
components	O
of	O
signal	O
transduction	O
.	O

Purification	O
and	O
cloning	O
of	O
this	O
protein	O
,	O
termed	O
early	O
B-cell	B-protein
factor	I-protein
(	O
EBF	B-protein
)	O
,	O
from	O
murine	B-cell_type
B	I-cell_type
lymphocytes	I-cell_type
and	O
independent	O
cloning	O
of	O
a	O
protein	O
,	O
termed	O
Olf-1	B-protein
,	O
from	O
olfactory	B-cell_type
neuronal	I-cell_type
cells	I-cell_type
revealed	O
virtual	O
complete	O
amino	O
acid	O
sequence	O
identity	O
between	O
these	O
proteins	O
.	O

As	O
a	O
first	O
step	O
towards	O
identifying	O
a	O
human	O
genetic	O
disorder	O
or	O
mouse	O
mutation	O
for	O
which	O
EBF	B-protein
could	O
be	O
a	O
candidate	O
gene	O
,	O
we	O
have	O
chromosomally	O
mapped	O
the	O
corresponding	O
locus	O
in	O
both	O
species	O
.	O

By	O
Southern	O
hybridization	O
analyses	O
of	O
somatic	O
cell	O
hybrid	O
panels	O
with	O
murine	B-DNA
cDNA	I-DNA
probe	I-DNA
,	O
fluorescence	O
chromosomal	O
in	O
situ	O
hybridization	O
(	O
FISH	O
)	O
of	O
human	B-DNA
genomic	I-DNA
clones	I-DNA
,	O
and	O
analysis	O
of	O
recombinant	B-cell_line
inbred	I-cell_line
mouse	I-cell_line
strains	I-cell_line
,	O
we	O
have	O
found	O
single	O
sites	O
for	O
EBF	B-DNA
homologous	I-DNA
sequences	I-DNA
on	O
human	O
Chromosome	O
(	O
Chr	O
)	O
5	O
,	O
band	B-DNA
q34	I-DNA
,	O
and	O
on	O
proximal	B-DNA
mouse	I-DNA
Chr	I-DNA
11	I-DNA
,	O
in	O
an	O
evolutionarily	B-DNA
conserved	I-DNA
region	I-DNA
.	O

Calcineurin	B-protein
activates	O
transcription	O
from	O
the	O
GM-CSF	B-DNA
promoter	I-DNA
in	O
synergy	O
with	O
either	O
protein	B-protein
kinase	I-protein
C	I-protein
or	O
NF-kappa	B-protein
B	I-protein
/AP-1	B-protein
in	O
T	B-cell_type
cells	I-cell_type
.	O

Two	O
cis-acting	B-DNA
elements	I-DNA
GM-kappa	B-DNA
B/GC-box	I-DNA
and	O
CLE0	B-DNA
,	O
of	O
the	O
granulocyte-macrophage	B-DNA
colony-stimulating	I-DNA
factor	I-DNA
(	I-DNA
GM-CSF	I-DNA
)	I-DNA
gene	I-DNA
are	O
required	O
for	O
maximal	O
induction	O
in	O
Jurkat	B-cell_line
T	I-cell_line
cells	I-cell_line
by	O
costimulation	O
with	O
phorbol-12-myristate	O
acetate	O
(	O
PMA	O
)	O
and	O
Ca2+	O
ionophore	O
(	O
A23187	O
)	O
.	O

The	O
GM-kappa	B-DNA
B	I-DNA
sequence	I-DNA
is	O
recognized	O
by	O
NF-kappa	B-protein
B	I-protein
,	O
which	O
is	O
mainly	O
induced	O
by	O
PMA	O
.	O

The	O
CLE0	B-DNA
sequence	I-DNA
interacts	O
with	O
factors	O
,	O
related	O
to	O
a	O
PMA-induced	B-protein
AP-1	I-protein
and	O
a	O
PMA/A23187-induced	B-protein
NF-AT	I-protein
.	O

We	O
examined	O
whether	O
signal	O
transducing	O
components	O
in	O
T	B-cell_type
cells	I-cell_type
can	O
activate	O
transcription	O
of	O
the	O
GM-CSF	B-DNA
gene	I-DNA
.	O

Cotransfection	O
of	O
NF-kappa	B-DNA
B	I-DNA
(	I-DNA
p50/p65	I-DNA
)	I-DNA
-	I-DNA
or	I-DNA
AP-1	I-DNA
(	I-DNA
c-Jun/c-Fos	I-DNA
)	I-DNA
-	I-DNA
expression	I-DNA
vectors	I-DNA
into	O
Jurkat	B-cell_line
cells	I-cell_line
with	O
a	O
luciferase	B-DNA
reporter	I-DNA
containing	O
the	O
GM-CSF	B-DNA
promoter	I-DNA
did	O
not	O
stimulate	O
transcription	O
from	O
the	O
GM-CSF	B-DNA
promoter	I-DNA
.	O

In	O
contrast	O
,	O
cotransfection	O
with	O
a	O
combination	O
of	O
NF-kappa	B-protein
B	I-protein
and	O
AP-1	B-protein
significantly	O
augmented	O
transcription	O
from	O
the	O
GM-CSF	B-DNA
promoter	I-DNA
containing	O
the	O
GM-kappa	B-DNA
B/GC-box	I-DNA
and	O
the	O
CLE0	B-DNA
(	O
AP-1/NF-AT	B-protein
)	O
.	O

Expression	O
of	O
a	O
constitutively	O
active	O
calcineurin	B-protein
(	O
CN	B-protein
)	O
,	O
a	O
Ca2+/calmodulin-dependent	B-protein
protein	I-protein
phosphatase	I-protein
,	O
potentiated	O
by	O
two	O
fold	O
the	O
transcriptional	O
activation	O
by	O
NF-kappa	B-protein
B	I-protein
/AP-1	B-protein
.	O

Both	O
constitutively	O
active	O
forms	O
of	O
CN	B-protein
and	O
protein	B-protein
kinase	I-protein
C	I-protein
(	O
PKC	B-protein
)	O
synergistically	O
activated	O
transcription	O
from	O
the	O
GM-CSF	B-DNA
promoter	I-DNA
.	O

These	O
results	O
suggest	O
that	O
cooperation	O
among	O
NF-kappa	B-DNA
B-	I-DNA
,	I-DNA
AP-1-	I-DNA
and	I-DNA
NF-AT-binding	I-DNA
sequences	I-DNA
is	O
required	O
for	O
induction	O
of	O
the	O
GM-CSF	B-DNA
gene	I-DNA
through	O
PKC-	O
and	O
Ca2+-	O
signaling	O
pathways	O
downstream	O
of	O
T	O
cell	O
activation	O
.	O

Nonpituitary	B-DNA
human	I-DNA
prolactin	I-DNA
gene	I-DNA
transcription	O
is	O
independent	O
of	O
Pit-1	B-protein
and	O
differentially	O
controlled	O
in	O
lymphocytes	B-cell_type
and	O
in	O
endometrial	O
stroma	O
.	O

Expression	O
of	O
the	O
human	B-DNA
PRL	I-DNA
(	I-DNA
hPRL	I-DNA
)	I-DNA
gene	I-DNA
in	O
extrapituitary	O
sites	O
such	O
as	O
the	O
uterus	O
(	O
decidualized	O
endometrial	O
stroma	O
and	O
myometrium	O
)	O
and	O
cells	O
of	O
the	O
hematopoietic	B-cell_type
lineage	I-cell_type
is	O
directed	O
by	O
an	O
alternative	B-DNA
promoter	I-DNA
which	O
is	O
located	O
approximately	O
6	B-DNA
kilobases	I-DNA
(	I-DNA
kb	I-DNA
)	I-DNA
upstream	I-DNA
of	O
the	O
pituitary-specific	B-DNA
start	I-DNA
site	I-DNA
.	O

In	O
order	O
to	O
delineate	O
the	O
tissue-specific	O
mechanisms	O
governing	O
the	O
control	O
of	O
nonpituitary	O
PRL	B-DNA
gene	I-DNA
expression	O
,	O
we	O
have	O
cloned	O
and	O
sequenced	O
3	B-DNA
kb	I-DNA
5'-flanking	I-DNA
DNA	I-DNA
of	O
the	O
upstream	O
decidual/lymphoid	B-DNA
(	I-DNA
dPRL	I-DNA
)	I-DNA
promoter	I-DNA
.	O

Based	O
on	O
sequence	O
homology	O
we	O
identified	O
two	O
binding	B-DNA
motifs	I-DNA
for	O
Pit-1	B-protein
and	O
seven	O
half-sites	B-DNA
for	O
glucocorticoid	B-protein
receptor/progesterone	I-protein
receptor	I-protein
(	O
PR	B-protein
)	O
binding	O
.	O

We	O
focused	O
our	O
studies	O
on	O
the	O
role	O
of	O
Pit-1	B-protein
and	O
of	O
PR	B-protein
as	O
potential	O
transcriptional	B-protein
regulators	I-protein
,	O
since	O
the	O
POU	B-protein
domain	I-protein
protein	I-protein
Pit-1	B-protein
is	O
essential	O
in	O
the	O
control	O
of	O
pituitary	O
PRL	B-protein
expression	O
,	O
and	O
progesterone	O
induces	O
decidual	O
transformation	O
of	O
the	O
endometrial	O
stroma	O
,	O
a	O
differentiation	O
process	O
during	O
which	O
the	O
decidual	O
PRL	B-DNA
gene	I-DNA
is	O
activated	O
.	O

We	O
demonstrate	O
in	O
a	O
variety	O
of	O
cell	O
types	O
,	O
including	O
lymphocytes	B-cell_type
and	O
endometrial	O
stroma	O
,	O
that	O
Pit-1	B-protein
is	O
not	O
involved	O
in	O
the	O
regulation	O
of	O
dPRL	B-DNA
promoter/reporter	I-DNA
gene	I-DNA
constructs	I-DNA
carrying	O
3	B-DNA
kb	I-DNA
5'-flanking	I-DNA
DNA	I-DNA
.	O

Our	O
experiments	O
also	O
show	O
that	O
activated	O
PR	B-protein
does	O
not	O
confer	O
direct	O
transcriptional	O
control	O
on	O
the	O
dPRL	B-DNA
promoter	I-DNA
.	O

When	O
we	O
compared	O
the	O
activity	O
of	O
the	O
transfected	O
dPRL	B-DNA
promoter	I-DNA
in	O
PRL-secreting	B-cell_type
and	I-cell_type
nonsecreting	I-cell_type
lymphoid	I-cell_type
cells	I-cell_type
,	O
we	O
found	O
that	O
the	O
3	B-DNA
kb	I-DNA
5'-flanking	I-DNA
region	I-DNA
of	O
the	O
dPRL	B-DNA
promoter	I-DNA
did	O
not	O
contain	O
elements	O
restricting	O
expression	O
to	O
only	O
those	O
lymphocytes	B-cell_type
that	O
produce	O
PRL	O
but	O
allowed	O
expression	O
of	O
fusion	O
reporter	O
genes	O
irrespective	O
of	O
the	O
status	O
of	O
the	O
endogenous	O
PRL	B-DNA
gene	I-DNA
.	O

This	O
was	O
in	O
sharp	O
contrast	O
to	O
endometrial	O
cells	O
where	O
3	O
kb	O
5'-flanking	O
DNA	O
conferred	O
strong	O
transcriptional	O
activation	O
on	O
the	O
dPRL	B-DNA
promoter	I-DNA
in	O
decidualized	O
endometrial	B-cell_type
stromal	I-cell_type
cells	I-cell_type
actively	O
secreting	O
PRL	B-protein
,	O
but	O
did	O
not	O
allow	O
transcription	O
in	O
undifferentiated	O
non-PRL-secreting	B-cell_type
endometrial	I-cell_type
stromal	I-cell_type
cells	I-cell_type
.	O

Activation	O
of	O
the	O
dPRL	B-DNA
promoter	I-DNA
construct	O
in	O
these	O
undifferentiated	O
cells	O
could	O
however	O
be	O
induced	O
by	O
the	O
addition	O
of	O
cAMP	O
,	O
in	O
the	O
absence	O
of	O
progesterone	O
,	O
suggesting	O
that	O
a	O
signal	O
transduced	O
through	O
the	O
cAMP	O
signaling	O
pathway	O
is	O
a	O
primary	O
inducer	O
of	O
decidual	O
PRL	B-DNA
gene	I-DNA
expression	O
.	O

Signals	O
and	O
nuclear	B-protein
factors	I-protein
that	O
regulate	O
the	O
expression	O
of	O
interleukin-4	B-DNA
and	I-DNA
interleukin-5	I-DNA
genes	I-DNA
in	O
helper	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O

Mouse	B-cell_line
thymoma	I-cell_line
line	I-cell_line
EL-4	I-cell_line
cells	I-cell_line
produce	O
cytokines	B-protein
such	O
as	O
interleukin	B-protein
(	I-protein
IL	I-protein
)	I-protein
-2	I-protein
,	O
IL-3	B-protein
,	O
IL-4	B-protein
,	O
IL-10	B-protein
,	O
and	O
granulocyte-macrophage	B-protein
colony-stimulating	I-protein
factor	I-protein
in	O
response	O
to	O
phorbol	O
12-myristate	O
13-acetate	O
(	O
PMA	O
)	O
.	O

EL-4	B-cell_line
cells	I-cell_line
also	O
produce	O
low	O
levels	O
of	O
IL-5	B-protein
when	O
stimulated	O
by	O
PMA	O
alone	O
;	O
however	O
,	O
cAMP	O
greatly	O
augments	O
PMA-dependent	O
IL-5	B-protein
production	O
.	O

A	O
transient	O
transfection	O
assay	O
revealed	O
that	O
two	O
signals	O
,	O
PMA	O
and	O
cAMP	O
,	O
are	O
required	O
for	O
optimal	O
activation	O
of	O
the	O
IL-5	B-DNA
promoter	I-DNA
.	O

In	O
contrast	O
,	O
cAMP	O
almost	O
completely	O
inhibited	O
the	O
PMA-dependent	O
activation	O
of	O
the	O
endogenous	B-DNA
IL-2	I-DNA
gene	I-DNA
,	O
as	O
well	O
as	O
the	O
transfected	O
IL-2	B-DNA
promoter	I-DNA
.	O

These	O
results	O
indicate	O
that	O
the	O
IL-5	B-DNA
gene	I-DNA
is	O
positively	O
regulated	O
by	O
cAMP	O
in	O
a	O
manner	O
opposite	O
to	O
that	O
for	O
the	O
IL-2	B-DNA
gene	I-DNA
.	O

One	O
of	O
the	O
nuclear	B-protein
factors	I-protein
(	O
NFs	B-protein
)	O
that	O
regulates	O
the	O
response	O
of	O
the	O
IL-5	B-DNA
promoter	I-DNA
to	O
cAMP	O
and	O
PMA	O
has	O
properties	O
similar	O
to	O
NF	B-protein
for	O
activated	B-cell_type
t	I-cell_type
cell	I-cell_type
.	O

The	O
P	B-DNA
sequence	I-DNA
of	O
the	O
IL-4	B-DNA
gene	I-DNA
,	O
defined	O
as	O
a	O
responsive	B-DNA
element	I-DNA
for	O
PMA	O
and	O
calcium	O
ionophore	O
(	O
A23187	O
)	O
,	O
shares	O
sequence	O
similarity	O
with	O
the	O
NF	B-DNA
kappa	I-DNA
B	I-DNA
and	I-DNA
the	I-DNA
NF-activated	I-DNA
T	I-DNA
cell	I-DNA
binding	I-DNA
sites	I-DNA
.	O

We	O
attempted	O
to	O
determine	O
whether	O
NF	B-protein
(	I-protein
P	I-protein
)	I-protein
,	O
a	O
nuclear	O
factor	O
specific	O
for	O
the	O
P	B-DNA
sequence	I-DNA
,	O
is	O
related	O
to	O
NF-kappa	B-protein
B	I-protein
and	O
nuclear	B-protein
factor	I-protein
for	I-protein
activated	I-protein
T	I-protein
cell	I-protein
(	O
NF-AT	B-protein
)	O
.	O

In	O
electromobility	O
shift	O
assays	O
both	O
NF-kappa	B-protein
B	I-protein
(	O
P65	B-protein
or	O
P65/P50	B-protein
heterodimer	I-protein
)	O
and	O
NF-AT	B-protein
bound	O
to	O
the	O
P	B-DNA
sequence	I-DNA
.	O

However	O
,	O
sequence	O
specificity	O
of	O
NF-AT	B-protein
was	O
more	O
similar	O
to	O
that	O
of	O
NF	B-protein
(	I-protein
P	I-protein
)	I-protein
,	O
and	O
only	O
a	O
small	O
amount	O
of	O
P65	B-protein
was	O
detected	O
in	O
NF	B-protein
(	I-protein
P	I-protein
)	I-protein
.	O

These	O
results	O
indicate	O
that	O
a	O
component	O
or	O
components	O
of	O
NF-AT	B-protein
have	O
the	O
potential	O
to	O
reconstitute	O
NF	B-protein
(	I-protein
P	I-protein
)	I-protein
,	O
whereas	O
NF-kappa	B-protein
B	I-protein
alone	O
does	O
not	O
account	O
for	O
NF	B-protein
(	I-protein
P	I-protein
)	I-protein
in	O
Jurkat	O
crude	O
extract	O
.	O

Taken	O
together	O
,	O
these	O
results	O
suggest	O
that	O
NF-AT-like	B-protein
factors	I-protein
are	O
involved	O
in	O
the	O
regulation	O
of	O
IL-4	B-DNA
and	I-DNA
IL-5	I-DNA
genes	I-DNA
.	O

Solution	O
structure	O
of	O
a	O
POU-specific	B-protein
homeodomain	I-protein
:	O
3D-NMR	O
studies	O
of	O
human	O
B-cell	B-protein
transcription	I-protein
factor	I-protein
Oct-2	B-protein
.	O

The	O
POU	B-protein
DNA-binding	I-protein
motif	I-protein
defines	O
a	O
conserved	O
family	O
of	O
eukaryotic	B-protein
transcription	I-protein
factors	I-protein
involved	O
in	O
regulation	O
of	O
gene	O
expression	O
.	O

This	O
bipartite	B-protein
motif	I-protein
consists	O
of	O
an	O
N-terminal	B-protein
POU-specific	I-protein
domain	I-protein
(	O
POUs	B-protein
)	O
,	O
a	O
flexible	B-protein
linker	I-protein
,	O
and	O
a	O
C-terminal	B-protein
POU-specific	I-protein
homeodomain	I-protein
(	O
POUHD	B-protein
)	O
.	O

Here	O
we	O
describe	O
the	O
solution	O
structure	O
of	O
a	O
POU-specific	B-protein
homeodomain	I-protein
.	O

An	O
NMR	O
model	O
is	O
obtained	O
from	O
Oct-2	B-protein
,	O
a	O
human	B-protein
B-cell	I-protein
specific	I-protein
transcription	I-protein
factor	I-protein
which	O
participates	O
in	O
the	O
regulation	O
of	O
immunoglobulin	B-DNA
genes	I-DNA
.	O

A	O
fragment	O
of	O
Oct-2	B-protein
containing	O
POUHD	B-protein
and	O
an	O
adjoining	O
linker	O
was	O
expressed	O
in	O
Escherichia	O
coli	O
and	O
characterized	O
by	O
three-dimensional	O
nuclear	O
magnetic	O
resonance	O
(	O
3D-NMR	O
)	O
spectroscopy	O
.	O

Complete	O
1H	O
and	O
15N	O
resonance	O
assignment	O
of	O
the	O
POUHD	B-protein
moiety	I-protein
is	O
presented	O
.	O

The	O
POUHD	B-protein
solution	O
structure	O
,	O
as	O
calculated	O
by	O
distance	O
geometry	O
and	O
simulated	O
annealing	O
(	O
DG/SA	O
)	O
,	O
is	O
similar	O
to	O
that	O
of	O
canonical	B-protein
homeodomains	I-protein
.	O

A	O
salient	O
difference	O
between	O
solution	O
and	O
crystal	O
structures	O
is	O
observed	O
in	O
the	O
C-terminal	B-protein
segment	I-protein
of	O
alpha-helix	B-protein
3	I-protein
(	O
the	O
HTH	B-protein
recognition	I-protein
helix	I-protein
)	O
,	O
which	O
is	O
not	O
well	O
ordered	O
in	O
solution	O
.	O

Because	O
this	O
segment	O
presumably	O
folds	O
upon	O
specific	O
DNA	O
binding	O
,	O
its	O
flexibility	O
in	O
solution	O
may	O
reduce	O
the	O
intrinsic	O
DNA	O
affinity	O
of	O
POUHD	B-protein
in	O
the	O
absence	O
of	O
POUs	B-protein
.	O

NF-kappa	O
B-dependent	O
and	O
-independent	O
pathways	O
of	O
HIV	O
activation	O
in	O
a	O
chronically	B-cell_line
infected	I-cell_line
T	I-cell_line
cell	I-cell_line
line	I-cell_line
.	O

J	B-cell_line
delta	I-cell_line
K	I-cell_line
cells	I-cell_line
were	O
isolated	O
as	O
a	O
chronically	B-cell_line
infected	I-cell_line
survivor	I-cell_line
cell	I-cell_line
line	I-cell_line
,	O
following	O
infection	O
of	O
Jurkat	B-cell_line
CD4+	I-cell_line
T	I-cell_line
cells	I-cell_line
with	O
dl-NF	O
,	O
a	O
mutated	O
strain	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
containing	O
a	O
deletion	O
of	O
the	O
long	B-DNA
terminal	I-DNA
repeat	I-DNA
(	O
LTR	B-DNA
)	O
NF-kappa	B-protein
B	I-protein
sites	O
.	O

J	B-cell_line
delta	I-cell_line
K	I-cell_line
cells	I-cell_line
exhibited	O
very	O
low	O
levels	O
of	O
constitutive	O
HIV	O
production	O
.	O

HIV-1	O
expression	O
was	O
activated	O
from	O
J	B-cell_line
delta	I-cell_line
K	I-cell_line
cells	I-cell_line
by	O
treatment	O
with	O
phorbol	O
myristate	O
acetate	O
(	O
PMA	O
)	O
,	O
sodium	O
butyrate	O
(	O
NaB	O
)	O
,	O
or	O
hexamethylene	O
bisacetamide	O
(	O
HMBA	O
)	O
,	O
but	O
not	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
alpha	I-protein
(	O
TNF-alpha	B-protein
)	O
,	O
confirming	O
the	O
role	O
of	O
NF-kappa	B-protein
B	I-protein
in	O
mediating	O
TNF-alpha	B-protein
induction	O
of	O
HIV	O
transcription	O
.	O

The	O
strong	O
induction	O
of	O
HIV	O
expression	O
by	O
NaB	O
or	O
HMBA	O
in	O
J	B-cell_line
delta	I-cell_line
K	I-cell_line
cells	I-cell_line
clearly	O
demonstrates	O
the	O
existence	O
of	O
NF-kappa	B-protein
B	I-protein
-independent	O
mechanisms	O
of	O
HIV	O
activation	O
in	O
chronically	B-cell_type
infected	I-cell_type
cells	I-cell_type
.	O

J	B-cell_line
delta	I-cell_line
K	I-cell_line
cells	I-cell_line
may	O
provide	O
a	O
useful	O
model	O
for	O
characterizing	O
NF-kappa	B-protein
B	I-protein
-independent	O
transcriptional	O
activation	O
of	O
the	O
HIV	B-DNA
LTR	I-DNA
.	O

JNK	B-protein
is	O
involved	O
in	O
signal	O
integration	O
during	O
costimulation	O
of	O
T	B-cell_type
lymphocytes	I-cell_type
.	O

T	B-cell_type
lymphocyte	I-cell_type
activation	O
and	O
interleukin-2	B-protein
(	O
IL-2	B-protein
)	O
production	O
require	O
at	O
least	O
two	O
signals	O
,	O
generated	O
by	O
phorbol	O
ester	O
(	O
TPA	O
)	O
and	O
Ca2+	O
ionophore	O
or	O
costimulation	O
of	O
the	O
T	B-protein
cell	I-protein
receptor	I-protein
(	O
TCR	B-protein
)	O
and	O
the	O
CD28	B-protein
auxiliary	I-protein
receptor	I-protein
.	O

We	O
investigated	O
how	O
these	O
stimuli	O
affect	O
mitogen	B-protein
activated	I-protein
protein	I-protein
(	I-protein
MAP	I-protein
)	I-protein
kinases	I-protein
.	O

Full	O
activation	O
of	O
the	O
MAP	B-protein
kinases	I-protein
that	O
phosphorylate	O
the	O
Jun	B-protein
activation	I-protein
domain	I-protein
,	O
JNK1	B-protein
and	O
JNK2	B-protein
,	O
required	O
costimulation	O
of	O
T	B-cell_type
cells	I-cell_type
with	O
either	O
TPA	O
and	O
Ca2+	O
ionophore	O
or	O
antibodies	O
to	O
TCR	B-protein
and	O
CD28	B-protein
.	O

Alone	O
,	O
each	O
stimulus	O
resulted	O
in	O
little	O
or	O
no	O
activation	O
.	O

Similar	O
to	O
its	O
effect	O
on	O
IL-2	B-protein
induction	O
,	O
cyclosporin	O
A	O
(	O
CsA	O
)	O
inhibited	O
the	O
synergistic	O
activation	O
of	O
JNK	B-protein
,	O
and	O
a	O
competitive	O
inhibitor	O
of	O
Jun	B-protein
phosphorylation	O
by	O
JNK	B-protein
inhibited	O
IL-2	B-DNA
promoter	I-DNA
activation	O
.	O

By	O
contrast	O
,	O
the	O
MAP	B-protein
kinases	I-protein
ERK1	B-protein
and	O
ERK2	B-protein
were	O
fully	O
activated	O
by	O
TPA	O
or	O
TCR	B-protein
stimulation	O
and	O
were	O
not	O
affected	O
by	O
Ca2+	O
,	O
CD28	O
,	O
or	O
CsA	O
.	O

Hence	O
,	O
integration	O
of	O
signals	O
that	O
lead	O
to	O
T	O
cell	O
activation	O
occurs	O
at	O
the	O
level	O
of	O
JNK	B-protein
activation	O
.	O

Inhibition	O
of	O
rat	B-cell_type
splenocyte	I-cell_type
proliferation	O
with	O
methylprednisolone	O
:	O
in	O
vivo	O
effect	O
of	O
liposomal	O
formulation	O
.	O

The	O
effect	O
of	O
a	O
liposomal	O
formulation	O
of	O
methylprednisolone	O
(	O
MPL	O
)	O
on	O
the	O
inhibition	O
of	O
lymphocyte	O
proliferation	O
in	O
spleen	B-cell_type
cells	I-cell_type
was	O
investigated	O
following	O
IV	O
dosing	O
in	O
rats	O
.	O

Liposomes	O
do	O
not	O
alter	O
the	O
suppressive	O
action	O
of	O
MPL	O
when	O
placed	O
in	O
lymphocyte	B-cell_line
culture	I-cell_line
.	O

Rat	B-cell_type
splenocytes	I-cell_type
were	O
found	O
to	O
have	O
greater	O
sensitivity	O
to	O
MPL	O
(	O
EC50	O
=	O
7.9	O
nM	O
)	O
than	O
do	O
human	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
lymphocytes	I-cell_type
(	O
EC50	O
=	O
28	O
nM	O
)	O
.	O

In	O
vivo	O
studies	O
in	O
rats	O
utilized	O
2	O
mg/kg	O
IV	O
bolus	O
doses	O
of	O
liposomal	O
MPL	O
compared	O
to	O
drug	O
in	O
solution	O
.	O

Animals	O
were	O
sacrificed	O
at	O
various	O
times	O
post-dosing	O
until	O
120	O
h	O
,	O
spleen	O
was	O
excised	O
and	O
,	O
after	O
incubation	O
of	O
lymphocytes	B-cell_type
with	O
PHA	B-protein
,	O
splenocyte	O
blastogenic	O
responses	O
were	O
assessed	O
by	O
measuring	O
cellular	O
incorporation	O
of	O
3H-thymidine	O
.	O

The	O
suppressive	O
effect	O
of	O
liposomal	O
MPL	O
in	O
comparison	O
with	O
free	O
drug	O
was	O
significantly	O
prolonged	O
(	O
>	O
120	O
h	O
vs	O
<	O
18	O
h	O
)	O
.	O

Inhibition	O
effects	O
versus	O
time	O
were	O
described	O
by	O
a	O
pharmacodynamic	O
model	O
using	O
MPL	O
concentrations	O
in	O
plasma	B-cell_type
as	O
an	O
input	O
function	O
.	O

A	O
nonlinear	O
relationship	O
was	O
found	O
between	O
suppression	O
of	O
splenocyte	B-cell_type
proliferation	O
and	O
the	O
concentration	O
of	O
bound	O
glucocorticoid	B-protein
receptors	I-protein
in	O
spleen	O
.	O

Only	O
partial	O
receptor	O
occupancy	O
accompanied	O
complete	O
lymphocyte	O
suppression	O
.	O

The	O
suppression	O
of	O
endogenous	O
corticosterone	O
in	O
plasma	B-cell_type
for	O
both	O
treatments	O
was	O
similar	O
with	O
values	O
from	O
L-MPL	O
rats	O
returning	O
to	O
baseline	O
after	O
24	O
h	O
.	O

These	O
results	O
demonstrate	O
enhanced	O
efficacy	O
of	O
local	O
immunosuppression	O
by	O
targeting	O
spleen	O
with	O
liposomal	O
MPL	O
.	O

Function	O
of	O
NF-kappa	B-DNA
B/Rel	I-DNA
binding	I-DNA
sites	I-DNA
in	O
the	O
major	B-DNA
histocompatibility	I-DNA
complex	I-DNA
class	I-DNA
II	I-DNA
invariant	I-DNA
chain	I-DNA
promoter	I-DNA
is	O
dependent	O
on	O
cell-specific	O
binding	O
of	O
different	O
NF-kappa	B-protein
B/Rel	I-protein
subunits	I-protein
.	O

The	O
promoter	B-DNA
of	O
the	O
human	O
major	O
histocompatibility	B-DNA
complex	I-DNA
class	I-DNA
II-associated	I-DNA
invariant-chain	I-DNA
gene	I-DNA
(	O
Ii	B-DNA
)	O
contains	O
two	O
NF-kappa	B-DNA
B/Rel	I-DNA
binding	I-DNA
sites	I-DNA
located	O
at	O
-109	B-DNA
to	I-DNA
-118	I-DNA
(	O
Ii	B-DNA
kappa	I-DNA
B-1	I-DNA
)	O
and	O
-163	B-DNA
to	I-DNA
-172	I-DNA
(	O
Ii	B-DNA
kappa	I-DNA
B-2	I-DNA
)	O
from	O
the	O
transcription	O
start	O
site	O
.	O

We	O
report	O
here	O
that	O
the	O
differential	O
function	O
of	O
each	O
of	O
these	O
NF-kappa	B-DNA
B/Rel	I-DNA
sites	I-DNA
in	O
several	O
distinct	O
cell	O
types	O
depends	O
on	O
cell-specific	O
binding	O
of	O
NF-kappa	B-protein
B/Rel	I-protein
transcription	I-protein
factors	I-protein
.	O

Ii	B-DNA
kappa	I-DNA
B-1	I-DNA
is	O
a	O
positive	B-DNA
regulatory	I-DNA
element	I-DNA
in	O
B-cell	B-cell_line
lines	I-cell_line
and	O
in	O
the	O
Ii-expressing	B-cell_line
T-cell	I-cell_line
line	I-cell_line
,	O
H9	B-cell_line
,	O
but	O
acts	O
as	O
a	O
negative	B-DNA
regulatory	I-DNA
element	I-DNA
in	O
myelomonocytic	B-cell_line
and	I-cell_line
glia	I-cell_line
cell	I-cell_line
lines	I-cell_line
.	O

In	O
vivo	O
protein-DNA	O
contacts	O
are	O
detectable	O
at	O
Ii	B-DNA
kappa	I-DNA
B-1	I-DNA
in	O
cell	B-cell_line
lines	I-cell_line
in	O
which	O
this	O
site	O
is	O
functional	O
as	O
either	O
a	O
positive	B-DNA
or	I-DNA
negative	I-DNA
regulator	I-DNA
.	O

Electrophoretic	O
mobility	O
supershift	O
assays	O
determine	O
that	O
members	O
of	O
the	O
NF-kappa	B-protein
B/Rel	I-protein
family	I-protein
of	O
transcription	B-protein
factors	I-protein
can	O
bind	O
to	O
this	O
site	O
in	O
vitro	O
and	O
that	O
DNA-binding	B-protein
complexes	I-protein
that	O
contain	O
p50	B-protein
,	O
p52	B-protein
,	O
p65	B-protein
,	O
and	O
cRel	B-protein
correlate	O
with	O
positive	O
regulation	O
whereas	O
the	O
presence	O
of	O
p50	B-protein
correlates	O
with	O
negative	O
regulation	O
.	O

Ii	B-DNA
kappa	I-DNA
B-2	I-DNA
is	O
a	O
site	O
of	O
positive	O
regulation	O
in	O
B-cell	B-cell_line
lines	I-cell_line
and	O
a	O
site	O
of	O
negative	O
regulation	O
in	O
H9	B-cell_line
T	I-cell_line
cells	I-cell_line
,	O
myelomonocytic	B-cell_line
,	I-cell_line
and	I-cell_line
glial	I-cell_line
cell	I-cell_line
lines	I-cell_line
.	O

In	O
vivo	O
occupancy	O
of	O
this	O
site	O
is	O
observed	O
only	O
in	O
the	O
H9	B-cell_line
T-cell	I-cell_line
line	I-cell_line
.	O

Again	O
,	O
in	O
vitro	O
supershift	O
studies	O
indicate	O
that	O
the	O
presence	O
of	O
p50	B-protein
,	O
p52	B-protein
,	O
p65	B-protein
,	O
and	O
cRel	B-protein
correlates	O
with	O
positive	O
function	O
whereas	O
the	O
presence	O
of	O
only	O
p50	B-protein
and	O
p52	B-protein
correlates	O
with	O
negative	O
function	O
.	O

This	O
differential	O
binding	O
of	O
specific	O
NF-kappa	B-protein
B/Rel	I-protein
subunits	I-protein
is	O
likely	O
to	O
mediate	O
the	O
disparate	O
functions	O
of	O
these	O
two	O
NF-kappa	B-DNA
B/Rel	I-DNA
binding	I-DNA
sites	I-DNA
.	O

Epstein-Barr	O
virus	O
(	O
EBV	O
)	O
replicative	O
gene	O
expression	O
in	O
tumour	B-cell_type
cells	I-cell_type
of	O
AIDS-related	O
non-Hodgkin	O
's	O
lymphoma	O
in	O
relation	O
to	O
CD4	B-protein
cell	O
number	O
and	O
antibody	O
titres	O
to	O
EBV	O
.	O

OBJECTIVE	O
:	O
To	O
determine	O
whether	O
activation	O
of	O
Epstein-Barr	O
virus	O
(	O
EBV	O
)	O
replication	O
in	O
tumour	B-cell_type
cells	I-cell_type
of	O
AIDS-related	O
non-Hodgkin	O
's	O
lymphoma	O
(	O
ARNHL	O
)	O
is	O
correlated	O
with	O
CD4+	B-protein
cell	O
counts	O
and	O
influences	O
antibody	O
response	O
to	O
EBV	O
[	O
anti-Z	B-protein
Epstein-Barr	I-protein
replicative	I-protein
activator	I-protein
(	O
ZEBRA	B-protein
)	O
,	O
anti-early	B-protein
antigen	I-protein
(	O
EA	B-protein
)	O
,	O
anti-viral	B-protein
capsid	I-protein
antigen	I-protein
(	O
VCA	B-protein
)	O
]	O
.	O

DESIGN	O
:	O
Retrospective	O
study	O
based	O
on	O
immunohistochemistry	O
and	O
in	O
situ	O
hybridization	O
to	O
detect	O
EBV	O
replicative	O
gene	O
products	O
in	O
tissue	O
samples	O
from	O
patients	O
affected	O
by	O
ARNHL	O
and	O
correlation	O
with	O
CD4+	B-protein
cell	O
counts	O
and	O
results	O
of	O
EBV	O
serology	O
(	O
including	O
anti-	O
ZEBRA	B-protein
activity	O
)	O
in	O
sera	O
from	O
the	O
same	O
patients	O
.	O

METHODS	O
:	O
Seventeen	O
out	O
of	O
22	O
cases	O
of	O
ARNHL	O
were	O
selected	O
for	O
the	O
presence	O
of	O
EBV	O
[	O
Epstein-Barr	O
early	O
region	O
(	O
EBER	O
)	O
RNA-positive	O
]	O
.	O

Immunohistochemistry	O
was	O
performed	O
with	O
anti-ZEBRA	B-protein
,	O
anti-EA-restricted	B-protein
,	I-protein
anti-VCA	I-protein
antibodies	I-protein
and	O
in	O
situ	O
hybridization	O
with	O
BHLF1/NotI	O
oligoprobes	O
on	O
tumour	O
samples	O
.	O

Results	O
were	O
statistically	O
correlated	O
with	O
those	O
of	O
CD4+	B-protein
cell	O
counts	O
(	O
17	O
out	O
of	O
17	O
)	O
and	O
with	O
anti-EBV	O
antibody	O
titres	O
(	O
13	O
out	O
of	O
17	O
)	O
assessed	O
using	O
standard	O
immunofluorescence	O
method	O
and	O
enzyme-linked	O
immunosorbent	O
assay	O
procedure	O
using	O
recombinant	B-protein
ZEBRA	I-protein
protein	I-protein
and	O
synthetic	O
peptides	O
as	O
antigens	B-protein
.	O

RESULTS	O
:	O
BZLF1	B-protein
(	O
ZEBRA	B-protein
)	O
or	O
early	B-protein
gene	I-protein
products	I-protein
(	O
EA-R	B-protein
and	O
EA-D/BHLF1/NotI	B-protein
)	O
were	O
detected	O
in	O
a	O
small	O
proportion	O
(	O
<	O
0.01-5	O
%	O
)	O
of	O
tumour	B-cell_type
cells	I-cell_type
in	O
eight	O
of	O
these	O
17	O
cases	O
by	O
immunohistochemistry	O
and	O
in	O
situ	O
hybridization	O
.	O

Demonstration	O
of	O
replicative	O
gene	O
expression	O
did	O
not	O
correlate	O
with	O
either	O
low	O
CD4+	B-protein
cell	O
counts	O
(	O
P	O
>	O
0.05	O
)	O
or	O
anti-EBV	O
antibody	O
titres	O
(	O
P	O
>	O
0.05	O
)	O
.	O

Anti-	O
ZEBRA	B-protein
activity	O
was	O
not	O
significantly	O
increased	O
in	O
patients	O
affected	O
with	O
ARNHL	O
,	O
the	O
cells	O
of	O
which	O
expressed	O
replicative	O
gene	O
products	O
(	O
P	O
>	O
0.05	O
)	O
.	O

CONCLUSION	O
:	O
The	O
degree	O
of	O
immunodeficiency	O
does	O
not	O
clearly	O
enhance	O
replicative	O
gene	O
expression	O
in	O
tumour	B-cell_type
cells	I-cell_type
of	O
ARNHL	O
.	O

EBV	O
serology	O
,	O
including	O
anti-	O
ZEBRA	B-protein
activity	O
,	O
is	O
not	O
a	O
reliable	O
tool	O
for	O
predicting	O
the	O
occurrence	O
of	O
such	O
proliferations	O
.	O

Effects	O
of	O
prostaglandin	B-protein
E2	I-protein
on	O
Th0-type	B-cell_line
human	I-cell_line
T	I-cell_line
cell	I-cell_line
clones	I-cell_line
:	O
modulation	O
of	O
functions	O
of	O
nuclear	B-protein
proteins	I-protein
involved	O
in	O
cytokine	B-protein
production	O
.	O

The	O
effects	O
of	O
prostaglandin	B-protein
E2	I-protein
(	O
PGE2	B-protein
)	O
on	O
cytokine	B-protein
production	O
and	O
proliferation	O
of	O
the	O
CD4+	B-cell_line
human	I-cell_line
helper	I-cell_line
T	I-cell_line
cell	I-cell_line
clone	I-cell_line
SP-B21	I-cell_line
were	O
investigated	O
.	O

In	O
cells	O
stimulated	O
with	O
anti-CD3	B-protein
mAb	I-protein
,	O
PGE2	B-protein
inhibited	O
cell	O
proliferation	O
and	O
the	O
production	O
of	O
all	O
the	O
cytokines	B-protein
examined	O
.	O

Addition	O
of	O
rIL-2	B-protein
fully	O
restored	O
the	O
proliferative	O
response	O
and	O
partially	O
restored	O
the	O
production	O
of	O
IL-4	B-protein
and	O
IL-5	B-protein
,	O
but	O
not	O
that	O
of	O
other	O
cytokines	B-protein
.	O

In	O
contrast	O
,	O
in	O
cells	O
stimulated	O
with	O
phorbol	O
myristate	O
acetate	O
(	O
PMA	O
)	O
/A23187	O
,	O
PGE2	B-protein
enhanced	O
the	O
production	O
of	O
IL-4	B-protein
and	O
IL-5	B-protein
,	O
and	O
only	O
partially	O
inhibited	O
the	O
production	O
of	O
other	O
cytokines	B-protein
.	O

Therefore	O
,	O
the	O
effects	O
of	O
PGE2	B-protein
vary	O
depending	O
on	O
the	O
mode	O
of	O
T	O
cell	O
activation	O
,	O
and	O
the	O
IL-4	B-protein
and	O
IL-5	B-protein
are	O
regulated	O
differently	O
from	O
other	O
cytokines	B-protein
.	O

In	O
a	O
mobility	O
shift	O
assay	O
,	O
only	O
the	O
NF-kappa	B-protein
B	I-protein
(	I-protein
p50/p50	I-protein
)	I-protein
homodimer	I-protein
was	O
observed	O
in	O
a	O
complex	O
formed	O
with	O
the	O
kappa	B-DNA
B	I-DNA
sequence	I-DNA
in	O
unstimulated	O
SP-B21	O
cells	O
.	O

When	O
cells	O
were	O
stimulated	O
with	O
anti-CD3	B-protein
mAb	I-protein
or	O
PMA/A23187	O
,	O
a	O
complex	O
formation	O
of	O
NF-kappa	B-protein
B	I-protein
(	O
p50	B-protein
/p65	B-protein
)	O
heterodimer	O
with	O
the	O
kappa	B-DNA
B	I-DNA
sequence	I-DNA
was	O
induced	O
.	O

Interestingly	O
,	O
PGE2	B-protein
or	O
di-butyryl	O
(	O
Bt2	O
)	O
cAMP	O
abolished	O
the	O
binding	O
of	O
NF-kappa	B-protein
B	I-protein
(	I-protein
p50/p65	I-protein
)	I-protein
heterodimer	I-protein
to	O
the	O
kappa	B-DNA
B	I-DNA
sequence	I-DNA
in	O
cells	O
stimulated	O
with	O
anti-CD3	B-protein
mAb	I-protein
but	O
not	O
with	O
PMA/A23187	O
.	O

Our	O
results	O
suggest	O
that	O
the	O
target	O
of	O
PGE2	B-protein
action	O
is	O
a	O
component	O
in	O
the	O
signal	O
transduction	O
pathway	O
leading	O
to	O
the	O
activation	O
of	O
protein	B-protein
kinase	I-protein
C	I-protein
.	O

However	O
,	O
the	O
inhibition	O
of	O
the	O
T	O
cell	O
activation	O
signals	O
by	O
PGE2	B-protein
is	O
selective	O
.	O

PGE2	B-protein
enhanced	O
the	O
complex	O
formation	O
with	O
NF-AT	B-DNA
,	I-DNA
AP-1	I-DNA
and	I-DNA
CLE0	I-DNA
sequences	I-DNA
when	O
the	O
cells	O
were	O
activated	O
by	O
either	O
anti-CD3	B-protein
mAb	I-protein
or	O
PMA/A23187	O
stimulation	O
.	O

It	O
seems	O
therefore	O
that	O
PGE2	B-protein
,	O
by	O
elevating	O
cAMP	O
levels	O
,	O
interferes	O
with	O
the	O
activation	O
pathway	O
for	O
NF-kappa	B-protein
B	I-protein
but	O
not	O
for	O
NF-AT	B-protein
,	O
AP-1	B-protein
or	O
CLE0	B-protein
binding	I-protein
protein	I-protein
.	O

Characterization	O
of	O
NF	B-protein
(	I-protein
P	I-protein
)	I-protein
,	O
the	O
nuclear	B-protein
factor	I-protein
that	O
interacts	O
with	O
the	O
regulatory	O
P	B-DNA
sequence	I-DNA
(	O
5'-CGAAAATTTCC-3	O
'	O
)	O
of	O
the	O
human	B-DNA
interleukin-4	I-DNA
gene	I-DNA
:	O
relationship	O
to	O
NF-kappa	B-protein
B	I-protein
and	O
NF-AT	B-protein
.	O

The	O
P	B-DNA
sequence	I-DNA
of	O
the	O
human	B-DNA
interleukin-4	I-DNA
(	I-DNA
IL-4	I-DNA
)	I-DNA
gene	I-DNA
,	O
which	O
was	O
defined	O
as	O
a	O
responsive	B-DNA
element	I-DNA
for	O
phorbol	O
12-myristate	O
13-acetate	O
and	O
calcium	O
ionophore	O
(	O
A23187	O
)	O
in	O
Jurkat	B-cell_line
T	I-cell_line
cells	I-cell_line
,	O
shares	O
sequence	O
similarity	O
with	O
the	O
NF-kappa	B-DNA
B	I-DNA
and	I-DNA
the	I-DNA
NF-AT	I-DNA
binding	I-DNA
sites	I-DNA
.	O

We	O
examined	O
whether	O
NF	B-protein
(	I-protein
P	I-protein
)	I-protein
,	O
a	O
nuclear	B-protein
factor	I-protein
specific	O
for	O
the	O
P	B-DNA
sequence	I-DNA
,	O
is	O
related	O
to	O
NF-kappa	B-protein
B	I-protein
and	O
NF-AT	B-protein
.	O

NF-kappa	B-protein
B	I-protein
(	O
P65	B-protein
or	O
P65/P50	B-protein
heterodimer	I-protein
)	O
bound	O
to	O
the	O
P	B-DNA
sequence	I-DNA
in	O
electrophoretic	O
mobility	O
shift	O
assays	O
(	O
EMSA	O
)	O
and	O
activated	O
transcription	O
through	O
the	O
P	B-DNA
sequence	I-DNA
when	O
expression	B-DNA
plasmids	I-DNA
were	O
cotransfected	O
with	O
P	B-DNA
sequence-driven	I-DNA
reporter	I-DNA
plasmids	I-DNA
in	O
Jurkat	B-cell_line
T	I-cell_line
cells	I-cell_line
.	O

In	O
EMSAs	O
,	O
NF	B-protein
(	I-protein
P	I-protein
)	I-protein
binding	O
was	O
inhibited	O
by	O
the	O
unlabeled	B-DNA
NF-AT	I-DNA
binding	I-DNA
site	I-DNA
but	O
not	O
by	O
the	O
unlabeled	B-DNA
AP1	I-DNA
binding	I-DNA
site	I-DNA
and	O
purified	B-protein
NF-AT	I-protein
contained	O
an	O
activity	O
that	O
bound	O
to	O
the	O
P	B-DNA
sequence	I-DNA
.	O

Both	O
mobility	O
shift	O
and	O
sequence	O
specificity	O
of	O
NF-AT	B-protein
were	O
similar	O
to	O
those	O
of	O
NF	B-protein
(	I-protein
P	I-protein
)	I-protein
and	O
only	O
a	O
small	O
amount	O
of	O
P65	B-protein
was	O
detected	O
in	O
NF	B-protein
(	I-protein
P	I-protein
)	I-protein
in	O
crude	O
nuclear	O
extracts	O
.	O

These	O
results	O
indicate	O
that	O
the	O
component	O
(	O
s	O
)	O
of	O
NF-AT	B-protein
has	O
the	O
potential	O
to	O
reconstitute	O
NF	B-protein
(	I-protein
P	I-protein
)	I-protein
whereas	O
NF-kappa	B-protein
B	I-protein
alone	O
can	O
not	O
account	O
for	O
NF	B-protein
(	I-protein
P	I-protein
)	I-protein
in	O
crude	O
extracts	O
.	O

Unlike	O
NF-AT	B-protein
,	O
NF	B-protein
(	I-protein
P	I-protein
)	I-protein
does	O
not	O
contain	O
AP1	B-protein
as	O
its	O
DNA	B-protein
binding	I-protein
component	I-protein
.	O

Activation	O
of	O
early	B-DNA
growth	I-DNA
response	I-DNA
1	I-DNA
gene	I-DNA
transcription	O
and	O
pp90rsk	B-protein
during	O
induction	O
of	O
monocytic	O
differentiation	O
.	O

The	O
present	O
work	O
has	O
studied	O
mechanisms	O
responsible	O
for	O
induction	O
of	O
early	B-DNA
growth	I-DNA
response	I-DNA
1	I-DNA
(	I-DNA
EGR-1	I-DNA
)	I-DNA
gene	I-DNA
expression	O
during	O
monocytic	O
differentiation	O
of	O
U-937	B-cell_line
myeloid	I-cell_line
leukemia	I-cell_line
cells	I-cell_line
.	O

Differentiation	O
of	O
U-937	B-cell_line
cells	I-cell_line
with	O
12-O-tetradecanoylphorbol-13-acetate	O
(	O
TPA	O
)	O
,	O
an	O
activator	O
of	O
the	O
serine/threonine	B-protein
protein	I-protein
kinase	I-protein
C	I-protein
,	O
was	O
associated	O
with	O
transcriptional	O
activation	O
of	O
EGR-1	B-DNA
promoter-reporter	I-DNA
constructs	I-DNA
.	O

The	O
EGR-1	B-DNA
promoter	I-DNA
contains	O
six	O
CC	O
(	O
A/T	O
)	O
6GG	O
(	O
CArG	O
)	O
motifs	O
.	O

The	O
two	O
5'-most	B-DNA
distal	I-DNA
CArG	I-DNA
sequences	I-DNA
conferred	O
TPA	O
inducibility	O
.	O

In	O
contrast	O
,	O
there	O
was	O
little	O
effect	O
of	O
TPA	O
on	O
EGR-1	B-DNA
transcription	O
in	O
a	O
TPA-resistant	B-cell_line
U-937	I-cell_line
cell	I-cell_line
variant	I-cell_line
,	O
designated	O
TUR	B-cell_line
.	O

Treatment	O
of	O
both	O
U-937	B-cell_line
and	O
TUR	B-cell_line
cells	I-cell_line
with	O
okadaic	O
acid	O
,	O
an	O
inhibitor	O
of	O
serine/threonine	B-protein
protein	I-protein
phosphatases	I-protein
1	I-protein
and	I-protein
2A	I-protein
,	O
was	O
associated	O
with	O
induction	O
of	O
monocytic	O
differentiation	O
and	O
EGR-1	B-DNA
transcription	O
through	O
the	O
5'-most	B-DNA
CArG	I-DNA
element	I-DNA
.	O

Since	O
these	O
findings	O
supported	O
the	O
involvement	O
of	O
serine/threonine	O
protein	O
phosphorylation	O
in	O
the	O
regulation	O
of	O
EGR-1	B-DNA
expression	O
,	O
we	O
studied	O
activation	O
of	O
the	O
40S	B-protein
ribosomal	I-protein
protein	I-protein
S6	I-protein
serine/threonine	I-protein
kinases	I-protein
,	O
pp70S6K	B-protein
and	O
pp90rsk	B-protein
.	O

Although	O
both	O
kinases	O
participate	O
in	O
regulating	O
cell	O
growth	O
,	O
there	O
was	O
no	O
detectable	O
activation	O
of	O
pp70S6K	B-protein
during	O
TPA-	O
or	O
okadaic	O
acid-induced	O
monocytic	O
differentiation	O
.	O

Moreover	O
,	O
rapamycin	O
,	O
an	O
inhibitor	O
of	O
pp70S6K	B-protein
activation	O
,	O
had	O
no	O
effect	O
on	O
induction	O
of	O
EGR-1	B-DNA
expression	O
.	O

In	O
contrast	O
,	O
analysis	O
of	O
pp90rsk	B-protein
activity	O
by	O
phosphorylation	O
of	O
a	O
peptide	O
derived	O
from	O
S6	B-protein
protein	I-protein
demonstrated	O
stimulation	O
of	O
this	O
kinase	B-protein
in	O
TPA-treated	B-cell_line
U-937	I-cell_line
,	I-cell_line
and	I-cell_line
not	I-cell_line
TUR	I-cell_line
,	I-cell_line
cells	I-cell_line
.	O

Okadaic	O
acid	O
treatment	O
of	O
both	O
cell	O
types	O
was	O
associated	O
with	O
activation	O
of	O
pp90rsk	B-protein
.	O

Antioxidants	O
inhibit	O
monocyte	B-cell_type
adhesion	O
by	O
suppressing	O
nuclear	B-protein
factor-kappa	I-protein
B	I-protein
mobilization	O
and	O
induction	O
of	O
vascular	B-protein
cell	I-protein
adhesion	I-protein
molecule-1	I-protein
in	O
endothelial	B-cell_type
cells	I-cell_type
stimulated	O
to	O
generate	O
radicals	O
.	O

Cell	O
adhesion	O
to	O
endothelial	B-cell_type
cells	I-cell_type
stimulated	B-protein
by	I-protein
tumor	I-protein
necrosis	I-protein
factor-alpha	I-protein
(	O
TNF	B-protein
)	O
is	O
due	O
to	O
induction	O
of	O
surface	B-protein
receptors	I-protein
,	O
such	O
as	O
vascular	B-protein
cell	I-protein
adhesion	I-protein
molecule-1	I-protein
(	O
VCAM-1	B-protein
)	O
.	O

The	O
antioxidant	O
pyrrolidine	O
dithiocarbamate	O
(	O
PDTC	O
)	O
specifically	O
inhibits	O
activation	O
of	O
nuclear	B-protein
factor-kappa	I-protein
B	I-protein
(	O
NF-kappa	B-protein
B	I-protein
)	O
.	O

Since	O
kappa	B-DNA
B	I-DNA
motifs	I-DNA
are	O
present	O
in	O
VCAM-1	B-DNA
and	I-DNA
intercellular	I-DNA
adhesion	I-DNA
molecule-1	I-DNA
(	I-DNA
ICAM-1	I-DNA
)	I-DNA
promoters	I-DNA
,	O
we	O
used	O
PDTC	O
to	O
study	O
the	O
regulatory	O
mechanisms	O
of	O
VCAM-1	B-protein
and	O
ICAM-1	B-protein
induction	O
and	O
subsequent	O
monocyte	B-cell_type
adhesion	O
in	O
TNF-treated	B-cell_line
human	I-cell_line
umbilical	I-cell_line
vein	I-cell_line
endothelial	I-cell_line
cells	I-cell_line
(	O
HUVECs	B-cell_line
)	O
.	O

PDTC	O
or	O
N-acetylcysteine	O
dose	O
dependently	O
reduced	O
TNF-induced	B-protein
VCAM-1	I-protein
but	O
not	O
ICAM-1	B-protein
surface	I-protein
protein	I-protein
(	O
also	O
in	O
human	B-cell_type
umbilical	I-cell_type
arterial	I-cell_type
endothelial	I-cell_type
cells	I-cell_type
)	O
and	O
mRNA	O
expression	O
(	O
by	O
70	O
%	O
at	O
100	O
mumol/L	O
PDTC	O
)	O
in	O
HUVECs	B-cell_line
as	O
assessed	O
by	O
flow	O
cytometry	O
and	O
polymerase	O
chain	O
reaction	O
.	O

Gel-shift	O
analysis	O
in	O
HUVECs	B-cell_line
demonstrated	O
that	O
PDTC	O
prevented	O
NF-kappa	B-protein
B	I-protein
mobilization	O
by	O
TNF	B-protein
,	O
suggesting	O
that	O
only	O
VCAM-1	B-protein
induction	O
was	O
controlled	O
by	O
NF-kappa	B-protein
B	I-protein
.	O

Since	O
HUVECs	B-cell_line
released	O
superoxide	O
anions	O
in	O
response	O
to	O
TNF	O
,	O
and	O
H2O2	O
induces	O
VCAM-1	B-protein
,	O
PDTC	O
may	O
act	O
as	O
a	O
radical	O
scavenger	O
.	O

Although	O
ICAM-1	B-protein
induction	O
was	O
unaffected	O
,	O
inhibitors	O
of	O
NADPH	B-protein
oxidase	I-protein
(	O
apocynin	O
)	O
or	O
cytochrome	B-protein
P-450	I-protein
(	O
SKF525a	O
)	O
suppressed	O
VCAM-1	B-protein
induction	O
by	O
TNF	O
,	O
revealing	O
that	O
several	O
radical-generating	O
systems	O
are	O
involved	O
in	O
its	O
regulation	O
.	O

PDTC	O
,	O
apocynin	O
,	O
or	O
SKF525a	O
decreased	O
adhesion	O
of	O
monocytic	B-cell_line
U937	I-cell_line
cells	I-cell_line
to	O
TNF-treated	B-cell_line
HUVECs	I-cell_line
(	O
by	O
75	O
%	O
at	O
100	O
mumol/L	O
PDTC	O
)	O
.	O

Inhibition	O
by	O
anti-VCAM-1	B-protein
monoclonal	I-protein
antibody	I-protein
1G11	B-protein
indicated	O
that	O
U937	B-cell_line
adhesion	O
was	O
VCAM-1	B-protein
dependent	O
and	O
suppression	O
by	O
antioxidants	O
was	O
due	O
to	O
reduced	O
VCAM-1	B-protein
induction	O
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Displacement	O
of	O
an	O
E-box-binding	B-protein
repressor	I-protein
by	O
basic	B-protein
helix-loop-helix	I-protein
proteins	I-protein
:	O
implications	O
for	O
B-cell	O
specificity	O
of	O
the	O
immunoglobulin	B-DNA
heavy-chain	I-DNA
enhancer	I-DNA
.	O

The	O
activity	O
of	O
the	O
immunoglobulin	B-DNA
heavy-chain	I-DNA
(	I-DNA
IgH	I-DNA
)	I-DNA
enhancer	I-DNA
is	O
restricted	O
to	O
B	B-cell_type
cells	I-cell_type
,	O
although	O
it	O
binds	O
both	O
B-cell-restricted	B-protein
and	I-protein
ubiquitous	I-protein
transcription	I-protein
factors	I-protein
.	O

Activation	O
of	O
the	O
enhancer	B-DNA
in	O
non-B	B-cell_type
cells	I-cell_type
upon	O
overexpression	O
of	O
the	O
basic	B-protein
helix-loop-helix	I-protein
(	I-protein
bHLH	I-protein
)	I-protein
protein	I-protein
E2A	B-protein
appears	O
to	O
be	O
mediated	O
not	O
only	O
by	O
the	O
binding	O
of	O
E2A	B-protein
to	O
its	O
cognate	O
E	B-DNA
box	I-DNA
but	O
also	O
by	O
the	O
resulting	O
displacement	O
of	O
a	O
repressor	B-protein
from	O
that	O
same	O
site	O
.	O

We	O
have	O
identified	O
a	O
``	B-protein
two-handed	I-protein
''	I-protein
zinc	I-protein
finger	I-protein
protein	I-protein
,	O
denoted	O
ZEB	B-protein
,	O
the	O
DNA-binding	O
specificity	O
of	O
which	O
mimics	O
that	O
of	O
the	O
cellular	B-protein
repressor	I-protein
.	O

By	O
employing	O
a	O
derivative	O
E	B-DNA
box	I-DNA
that	O
binds	O
ZEB	B-protein
but	O
not	O
E2A	B-protein
,	O
we	O
have	O
shown	O
that	O
the	O
repressor	B-protein
is	O
active	O
in	O
B	B-cell_type
cells	I-cell_type
and	O
the	O
IgH	B-DNA
enhancer	I-DNA
is	O
silenced	O
in	O
the	O
absence	O
of	O
binding	O
competition	O
by	O
bHLH	B-protein
proteins	I-protein
.	O

Hence	O
,	O
we	O
propose	O
that	O
a	O
necessary	O
prerequisite	O
of	O
enhancer	B-DNA
activity	O
is	O
the	O
B-cell-specific	O
displacement	O
of	O
a	O
ZEB-like	B-protein
repressor	I-protein
by	O
bHLH	B-protein
proteins	I-protein
.	O

Inhibition	O
of	O
NF-kappa	B-protein
B	I-protein
by	O
sodium	O
salicylate	O
and	O
aspirin	O
[	O
see	O
comments	O
]	O

The	O
transcription	B-protein
factor	I-protein
nuclear	B-protein
factor-kappa	I-protein
B	I-protein
(	O
NF-kappa	B-protein
B	I-protein
)	O
is	O
critical	O
for	O
the	O
inducible	O
expression	O
of	O
multiple	O
cellular	B-DNA
and	I-DNA
viral	I-DNA
genes	I-DNA
involved	O
in	O
inflammation	O
and	O
infection	O
including	O
interleukin-1	B-protein
(	O
IL-1	B-protein
)	O
,	O
IL-6	B-protein
,	O
and	O
adhesion	B-protein
molecules	I-protein
.	O

The	O
anti-inflammatory	O
drugs	O
sodium	O
salicylate	O
and	O
aspirin	O
inhibited	O
the	O
activation	O
of	O
NF-kappa	B-protein
B	I-protein
,	O
which	O
further	O
explains	O
the	O
mechanism	O
of	O
action	O
of	O
these	O
drugs	O
.	O

This	O
inhibition	O
prevented	O
the	O
degradation	O
of	O
the	O
NF-kappa	B-protein
B	I-protein
inhibitor	I-protein
,	O
I	B-protein
kappa	I-protein
B	I-protein
,	O
and	O
therefore	O
NF-kappa	B-protein
B	I-protein
was	O
retained	O
in	O
the	O
cytosol	O
.	O

Sodium	O
salicylate	O
and	O
aspirin	O
also	O
inhibited	O
NF-kappa	B-protein
B	I-protein
-dependent	O
transcription	O
from	O
the	O
Ig	B-DNA
kappa	I-DNA
enhancer	I-DNA
and	O
the	O
human	B-DNA
immunodeficiency	I-DNA
virus	I-DNA
(	I-DNA
HIV	I-DNA
)	I-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
(	O
LTR	B-DNA
)	O
in	O
transfected	B-cell_line
T	I-cell_line
cells	I-cell_line
.	O

Effects	O
of	O
the	O
antisense	O
myb	O
expression	O
on	O
hemin-	O
and	O
erythropoietin-	O
induced	O
erythroid	O
differentiation	O
of	O
K562	B-cell_line
cells	I-cell_line
.	O

In	O
order	O
to	O
elucidate	O
the	O
role	O
of	O
c-myb	B-DNA
gene	I-DNA
in	O
erythroid	O
differentiation	O
of	O
K562	B-cell_line
cell	I-cell_line
induced	O
by	O
hemin	B-protein
(	O
Hm	B-protein
)	O
and	O
erythropoietin	B-protein
(	O
Epo	B-protein
)	O
,	O
we	O
constructed	O
recombinant	B-DNA
plasmid	I-DNA
that	O
could	O
produce	O
antisense	B-RNA
myb	I-RNA
RNA	I-RNA
after	O
induction	O
with	O
dexamethasone	O
.	O

During	O
treatment	O
with	O
Hm	B-protein
,	O
K562	B-cell_line
cells	I-cell_line
constitutively	O
expressed	O
c-myb	B-RNA
mRNA	I-RNA
,	O
and	O
50	O
%	O
of	O
them	O
began	O
to	O
synthesize	O
hemoglobin	B-protein
(	O
Hb	B-protein
)	O
.	O

Expression	O
of	O
antisense	B-RNA
myb	I-RNA
RNA	I-RNA
reduced	O
the	O
amount	O
of	O
c-myb	B-RNA
mRNA	I-RNA
,	O
and	O
the	O
percentage	O
of	O
Hb-synthesizing	B-cell_line
cells	I-cell_line
was	O
decreased	O
to	O
20	O
%	O
.	O

In	O
the	O
presence	O
of	O
Epo	B-protein
,	O
c-myb	B-RNA
mRNA	I-RNA
declined	O
and	O
20	O
%	O
of	O
K562	B-cell_line
cells	I-cell_line
synthesized	O
Hb	B-protein
regardless	O
of	O
antisense	B-RNA
myb	I-RNA
RNA	I-RNA
expression	O
.	O

It	O
is	O
suggested	O
that	O
constitutive	O
expression	O
of	O
c-myb	B-RNA
mRNA	I-RNA
is	O
necessary	O
for	O
Hm	B-protein
-induced	O
differentiation	O
,	O
and	O
that	O
a	O
decrease	O
in	O
the	O
amount	O
of	O
c-myb	B-RNA
mRNA	I-RNA
induced	O
by	O
antisense	B-RNA
myb	I-RNA
RNA	I-RNA
expression	O
suppresses	O
Hm	B-protein
-induced	O
differentiation	O
.	O

The	O
amount	O
of	O
c-myb	B-RNA
mRNA	I-RNA
in	O
K562	B-cell_line
cells	I-cell_line
was	O
reduced	O
during	O
the	O
differentiation	O
induced	O
by	O
Epo	B-protein
.	O

Expression	O
of	O
GATA-1	B-RNA
mRNA	I-RNA
was	O
almost	O
constant	O
during	O
Hm	B-protein
-induced	O
differentiation	O
,	O
but	O
increased	O
during	O
Epo	B-protein
treatment	O
.	O

It	O
is	O
supposed	O
that	O
the	O
mechanism	O
of	O
Hm	B-protein
-induced	O
differentiation	O
is	O
distinguished	O
from	O
that	O
of	O
Epo	B-protein
-induced	O
differentiation	O
in	O
K562	B-cell_line
cells	I-cell_line
.	O

Prenatal	O
immune	O
challenge	O
alters	O
the	O
hypothalamic-pituitary-adrenocortical	O
axis	O
in	O
adult	O
rats	O
.	O

We	O
investigated	O
whether	O
non-abortive	O
maternal	O
infections	O
would	O
compromise	O
fetal	O
brain	O
development	O
and	O
alter	O
hypothalamic-pituitary-adrenocortical	O
(	O
HPA	O
)	O
axis	O
functioning	O
when	O
adult	O
.	O

To	O
study	O
putative	O
teratogenic	O
effects	O
of	O
a	O
T	O
cell-mediated	O
immune	O
response	O
versus	O
an	O
endotoxic	O
challenge	O
,	O
10-d-pregnant	O
rats	O
received	O
a	O
single	O
intraperitoneal	O
injection	O
of	O
5	O
x	O
10	O
(	O
8	O
)	O
human	B-cell_type
red	I-cell_type
blood	I-cell_type
cells	I-cell_type
(	O
HRBC	B-cell_type
)	O
or	O
gram-negative	O
bacterial	O
endotoxin	O
(	O
Escherichia	O
coli	O
LPS	O
:	O
30	O
micrograms/kg	O
)	O
.	O

The	O
adult	O
male	O
progeny	O
(	O
3	O
mo	O
old	O
)	O
of	O
both	O
experimental	O
groups	O
showed	O
increased	O
basal	O
plasma	O
corticosterone	O
levels	O
.	O

In	O
addition	O
,	O
after	O
novelty	O
stress	O
the	O
HRBC	B-cell_type
group	O
,	O
but	O
not	O
the	O
LPS	B-cell_line
group	I-cell_line
,	O
showed	O
increased	O
ACTH	O
and	O
corticosterone	O
levels	O
.	O

Both	O
groups	O
showed	O
substantial	O
decreases	O
in	O
mineralocorticoid	O
(	O
MR	O
)	O
and	O
glucocorticoid	O
receptor	O
(	O
GR	O
)	O
levels	O
in	O
the	O
hippocampus	O
,	O
a	O
limbic	O
brain	O
structure	O
critical	O
for	O
HPA	O
axis	O
regulation	O
,	O
whereas	O
GR	B-protein
concentrations	O
in	O
the	O
hypothalamus	O
were	O
unchanged	O
and	O
in	O
anterior	O
pituitary	O
were	O
slightly	O
increased	O
.	O

HRBC	B-cell_type
and	O
LPS	O
indeed	O
stimulated	O
the	O
maternal	O
immune	O
system	O
as	O
revealed	O
by	O
specific	O
anti-HRBC	B-protein
antibody	I-protein
production	O
and	O
enhanced	O
IL-1	O
beta	O
mRNA	O
expression	O
in	O
splenocytes	B-cell_type
,	O
respectively	O
.	O

This	O
study	O
demonstrates	O
that	O
a	O
T	O
cell-mediated	O
immune	O
response	O
as	O
well	O
as	O
an	O
endotoxic	O
challenge	O
during	O
pregnancy	O
can	O
induce	O
anomalies	O
in	O
HPA	O
axis	O
function	O
in	O
adulthood	O
.	O

Clinically	O
,	O
it	O
may	O
be	O
postulated	O
that	O
disturbed	O
fetal	O
brain	O
development	O
due	O
to	O
prenatal	O
immune	O
challenge	O
increases	O
the	O
vulnerability	O
to	O
develop	O
mental	O
illness	O
involving	O
inadequate	O
responses	O
to	O
stress	O
.	O

A	O
low	O
NM23.H1	B-DNA
gene	I-DNA
expression	O
identifying	O
high	O
malignancy	O
human	O
melanomas	O
.	O

The	O
NM23	B-DNA
gene	I-DNA
has	O
been	O
proposed	O
as	O
a	O
metastasis-suppressor	B-DNA
gene	I-DNA
,	O
and	O
its	O
use	O
has	O
been	O
suggested	O
as	O
prognostic	O
factor	O
.	O

NM23	B-protein
was	O
identified	O
in	O
a	O
system	O
of	O
murine	B-cell_line
melanoma	I-cell_line
cell	I-cell_line
lines	I-cell_line
,	O
in	O
which	O
an	O
inverse	O
relationship	O
was	O
found	O
between	O
NM23	B-protein
expression	O
and	O
metastatic	O
ability	O
.	O

In	O
a	O
human	O
malignant	O
melanoma	O
study	O
NM23	B-protein
expression	O
was	O
found	O
to	O
be	O
significantly	O
lower	O
in	O
metastases	O
that	O
developed	O
less	O
than	O
24	O
months	O
after	O
diagnosis	O
of	O
the	O
primary	O
tumours	O
.	O

The	O
present	O
paper	O
studies	O
the	O
expression	O
of	O
the	O
NM23.H1	B-DNA
gene	I-DNA
in	O
cell	B-cell_line
lines	I-cell_line
which	O
derive	O
from	O
primary	O
or	O
metastatic	O
human	O
malignant	O
melanomas	O
in	O
relation	O
to	O
staging	O
,	O
infiltration	O
degree	O
,	O
lymphocytic	O
infiltration	O
,	O
cell	O
morphology	O
,	O
cell	O
pigmentation	O
,	O
karyotype	O
,	O
and	O
disease-free	O
survival	O
.	O

The	O
level	O
of	O
mRNA	O
expression	O
of	O
the	O
NM23	B-DNA
gene	I-DNA
is	O
significantly	O
lower	O
in	O
cell	B-cell_line
lines	I-cell_line
that	O
derive	O
from	O
more	O
infiltrating	O
primary	O
melanomas	O
than	O
in	O
cell	B-cell_line
lines	I-cell_line
obtained	O
from	O
less	O
infiltrating	O
tumours	O
.	O

Moreover	O
,	O
cell	B-cell_line
lines	I-cell_line
derived	O
from	O
tumours	O
of	O
patients	O
with	O
a	O
disease-free	O
survival	O
of	O
more	O
than	O
24	O
months	O
(	O
24-58	O
months	O
)	O
express	O
the	O
NM23	B-DNA
gene	I-DNA
at	O
higher	O
levels	O
than	O
cell	B-cell_line
lines	I-cell_line
obtained	O
from	O
melanomas	O
of	O
patients	O
with	O
a	O
disease-free	O
survival	O
of	O
less	O
than	O
24	O
months	O
(	O
6-15	O
months	O
)	O
.	O

Activation	O
of	O
a	O
novel	O
serine/threonine	B-protein
kinase	I-protein
that	O
phosphorylates	O
c-Fos	B-protein
upon	O
stimulation	O
of	O
T	B-cell_type
and	I-cell_type
B	I-cell_type
lymphocytes	I-cell_type
via	O
antigen	O
and	O
cytokine	B-protein
receptors	I-protein
.	O

Ligation	O
of	O
Ag	B-protein
receptors	I-protein
in	O
T	B-cell_type
and	I-cell_type
B	I-cell_type
lymphocytes	I-cell_type
initiates	O
signal	O
transduction	O
cascades	O
which	O
alter	O
the	O
expression	O
of	O
genes	O
that	O
regulate	O
cellular	O
proliferation	O
and	O
differentiation	O
.	O

The	O
transmission	O
of	O
signals	O
from	O
the	O
membrane	O
to	O
the	O
nucleus	O
is	O
mediated	O
principally	O
through	O
the	O
action	O
of	O
protein	B-protein
tyrosine	I-protein
and	I-protein
serine/threonine	I-protein
kinases	I-protein
.	O

We	O
have	O
identified	O
and	O
characterized	O
a	O
novel	O
serine/threonine	B-protein
kinase	I-protein
that	O
phosphorylated	O
the	O
proto-oncogene	B-protein
product	I-protein
,	O
c-Fos	B-protein
,	O
and	O
is	O
termed	O
Fos	B-protein
kinase	I-protein
.	O

Fos	B-protein
kinase	I-protein
was	O
rapidly	O
activated	O
after	O
ligation	O
of	O
the	O
CD3	B-protein
and	I-protein
CD2	I-protein
receptors	I-protein
in	O
Jurkat	B-cell_line
and	O
normal	B-cell_type
human	I-cell_type
T	I-cell_type
lymphocytes	I-cell_type
and	O
in	O
response	O
to	O
IL-6	B-protein
and	O
anti-IgM	B-protein
in	O
the	O
human	B-cell_line
B	I-cell_line
cell	I-cell_line
lines	I-cell_line
AF10	B-cell_line
and	O
Ramos	B-cell_line
,	O
respectively	O
.	O

The	O
phorbol	O
ester	O
,	O
PMA	O
,	O
was	O
also	O
a	O
potent	O
inducer	O
of	O
Fos	B-protein
kinase	I-protein
activity	O
in	O
all	O
of	O
the	O
above	O
populations	O
,	O
suggesting	O
that	O
PKC	B-protein
plays	O
a	O
role	O
in	O
the	O
regulation	O
of	O
this	O
enzyme	B-protein
.	O

Fos	B-protein
kinase	I-protein
phosphorylates	O
c-Fos	B-protein
at	O
a	O
site	O
near	O
the	O
C-terminus	B-protein
,	O
as	O
well	O
as	O
a	O
peptide	O
derived	O
from	O
this	O
region	O
(	O
residues	B-protein
359-370	I-protein
,	O
RKGSSSNEPSSD	B-protein
)	O
,	O
and	O
Fos	O
peptide	O
competitively	O
inhibited	O
c-Fos	B-protein
phosphorylation	O
.	O

Fos	B-protein
kinase	I-protein
was	O
shown	O
to	O
be	O
distinct	O
from	O
other	O
identified	O
serine/threonine	B-protein
kinases	I-protein
,	O
including	O
protein	B-protein
kinase	I-protein
A	I-protein
,	O
protein	B-protein
kinase	I-protein
C	I-protein
,	O
casein	B-protein
kinase	I-protein
II	I-protein
,	O
MAP	B-protein
kinases	I-protein
,	O
p70S6K	B-protein
and	O
p90RSK	B-protein
.	O

Fos	B-protein
kinase	I-protein
was	O
purified	O
by	O
anion	O
exchange	O
chromatography	O
and	O
exhibited	O
an	O
apparent	O
M	O
(	O
r	O
)	O
=	O
65	O
,	O
000	O
and	O
isoelectric	O
point	O
=	O
6.1	O
.	O

Fos	B-protein
kinase	I-protein
may	O
play	O
a	O
role	O
in	O
transcriptional	O
regulation	O
through	O
its	O
capacity	O
to	O
phosphorylate	O
c-Fos	B-protein
at	O
a	O
site	O
required	O
for	O
expression	O
of	O
the	O
transcriptional	O
transrepressive	O
activity	O
of	O
this	O
molecule	O
.	O

Moreover	O
,	O
its	O
rapid	O
activation	O
suggests	O
it	O
may	O
have	O
a	O
wider	O
role	O
within	O
signal	O
transduction	O
cascades	O
in	O
lymphocytes	B-cell_type
.	O

Antigenic	O
specificities	O
of	O
human	B-cell_line
CD4+	I-cell_line
T-cell	I-cell_line
clones	I-cell_line
recovered	O
from	O
recurrent	O
genital	O
herpes	O
simplex	O
virus	O
type	O
2	O
lesions	O
.	O

Lesions	O
resulting	O
from	O
recurrent	O
genital	O
herpes	O
simplex	O
virus	O
(	O
HSV	O
)	O
infection	O
are	O
characterized	O
by	O
infiltration	O
of	O
CD4+	B-cell_type
lymphocytes	I-cell_type
.	O

We	O
have	O
investigated	O
the	O
antigenic	O
specificity	O
of	O
47	O
HSV-specific	B-cell_line
CD4+	I-cell_line
T-cell	I-cell_line
clones	I-cell_line
recovered	O
from	O
the	O
HSV-2	O
buttock	O
and	O
thigh	O
lesions	O
of	O
five	O
patients	O
.	O

Clones	O
with	O
proliferative	O
responses	O
to	O
recombinant	B-protein
truncated	I-protein
glycoprotein	I-protein
B	I-protein
(	O
gB	B-protein
)	O
or	O
gD	B-protein
of	O
HSV-2	O
or	O
purified	O
natural	O
gC	O
of	O
HSV-2	O
comprised	O
a	O
minority	O
of	O
the	O
total	O
number	O
of	O
HSV-specific	B-cell_line
clones	I-cell_line
isolated	O
from	O
lesions	O
.	O

The	O
gC2-	B-cell_line
and	I-cell_line
gD2-specific	I-cell_line
CD4+	I-cell_line
clones	I-cell_line
had	O
cytotoxic	O
activity	O
.	O

The	O
approximate	O
locations	O
of	O
the	O
HSV-2	O
genes	O
encoding	O
HSV-2	O
type-specific	O
CD4+	B-protein
antigens	I-protein
have	O
been	O
determined	O
by	O
using	O
HSV-1	O
x	O
HSV-2	O
intertypic	O
recombinant	O
virus	O
and	O
include	O
the	O
approximate	O
map	O
regions	O
0.30	O
to	O
0.46	O
,	O
0.59	O
to	O
0.67	O
,	O
0.67	O
to	O
0.73	O
,	O
and	O
0.82	O
to	O
1.0	O
units	O
.	O

The	O
antigenic	O
specificity	O
of	O
an	O
HLA	B-cell_line
DQ2-restricted	I-cell_line
,	I-cell_line
HSV-2	I-cell_line
type-specific	I-cell_line
T-cell	I-cell_line
clone	I-cell_line
was	O
mapped	O
to	O
amino	B-protein
acids	I-protein
425	I-protein
to	I-protein
444	I-protein
of	O
VP16	B-protein
of	O
HSV-2	O
by	O
sequential	O
use	O
of	O
an	O
intertypic	O
recombinant	O
virus	O
containing	O
VP16	B-protein
of	O
HSV-2	O
in	O
an	O
HSV-1	O
background	O
,	O
recombinant	B-protein
VP16	I-protein
fusion	I-protein
proteins	I-protein
,	O
and	O
synthetic	O
peptides	O
.	O

Each	O
of	O
the	O
remaining	O
four	O
patients	O
also	O
yielded	O
at	O
least	O
one	O
type-specific	B-cell_line
T-cell	I-cell_line
clone	I-cell_line
reactive	O
with	O
an	O
HSV-2	O
epitope	O
mapping	O
to	O
approximately	O
0.67	O
to	O
0.73	O
map	O
units	O
.	O

The	O
antigenic	O
specificities	O
of	O
lesion-derived	B-cell_line
CD4+	I-cell_line
T-cell	I-cell_line
clones	I-cell_line
are	O
quite	O
diverse	O
and	O
include	O
at	O
least	O
10	O
epitopes	O
.	O

Human	B-cell_line
T-cell	I-cell_line
clones	I-cell_line
reactive	O
with	O
gC	B-protein
and	O
VP16	B-protein
are	O
reported	O
here	O
for	O
the	O
first	O
time	O
.	O

Marked	O
basophilia	O
in	O
acute	O
promyelocytic	O
leukaemia	O
treated	O
with	O
all-trans	O
retinoic	O
acid	O
:	O
molecular	O
analysis	O
of	O
the	O
cell	O
origin	O
of	O
the	O
basophils	B-cell_type
.	O

We	O
report	O
a	O
patient	O
with	O
acute	O
promyelocytic	O
leukaemia	O
who	O
developed	O
marked	O
basophilia	O
during	O
all-trans	O
retinoic	O
acid	O
treatment	O
.	O

We	O
studied	O
genomic	B-DNA
DNA	I-DNA
and	O
RNA	O
extracted	O
from	O
the	O
patient	O
's	O
peripheral	B-cell_type
leucocytes	I-cell_type
in	O
order	O
to	O
determine	O
the	O
origin	O
of	O
the	O
basophils	B-cell_type
.	O

The	O
RAR	B-protein
alpha	I-protein
rearranged	O
band	O
in	O
the	O
Southern	O
blot	O
analysis	O
and	O
a	O
chimaeric	B-protein
product	I-protein
of	O
PML-RAR	B-protein
alpha	I-protein
by	O
polymerase	O
chain	O
reaction	O
were	O
strongly	O
visible	O
before	O
ATRA	O
treatment	O
,	O
but	O
at	O
the	O
time	O
of	O
maximal	O
basophilia	O
both	O
of	O
them	O
were	O
markedly	O
diminished	O
.	O

These	O
findings	O
suggest	O
that	O
the	O
basophils	B-cell_type
which	O
appeared	O
during	O
the	O
ATRA	O
treatment	O
are	O
reactive	O
in	O
nature	O
rather	O
than	O
a	O
leukaemic	B-cell_line
clone	I-cell_line
.	O

Activation	O
of	O
the	O
interleukin	B-DNA
6	I-DNA
gene	I-DNA
by	O
Mycobacterium	O
tuberculosis	O
or	O
lipopolysaccharide	O
is	O
mediated	O
by	O
nuclear	B-protein
factors	I-protein
NF-IL6	I-protein
and	O
NF-kappa	B-protein
B	I-protein
[	O
published	O
erratum	O
appears	O
in	O
Proc	O
Natl	O
Acad	O
Sci	O
U	O
S	O
A	O
1995	O
Apr	O
11	O
;	O
92	O
(	O
8	O
)	O
:	O
3632	O
]	O

The	O
host	O
response	O
to	O
Mycobacterium	O
tuberculosis	O
includes	O
granuloma	O
formation	O
at	O
sites	O
of	O
infection	O
and	O
systemic	O
symptoms	O
.	O

Cytokines	B-protein
have	O
been	O
identified	O
by	O
immunohistochemistry	O
in	O
granulomas	O
in	O
animal	O
models	O
of	O
bacillus	O
Calmette-Guerin	O
(	O
BCG	O
)	O
infection	O
and	O
are	O
released	O
by	O
mononuclear	B-cell_type
phagocytes	I-cell_type
upon	O
stimulation	O
by	O
mycobacterial	O
proteins	O
.	O

In	O
this	O
regard	O
,	O
the	O
cytokine	B-protein
interleukin	B-protein
6	I-protein
(	O
IL-6	B-protein
)	O
may	O
play	O
a	O
role	O
in	O
the	O
clinical	O
manifestations	O
and	O
pathological	O
events	O
of	O
tuberculosis	O
infection	O
.	O

We	O
have	O
demonstrated	O
that	O
lipoarabinomannan	B-protein
(	O
LAM	B-protein
)	O
from	O
the	O
mycobacterial	O
cell	O
wall	O
,	O
which	O
was	O
virtually	O
devoid	O
of	O
lipopolysaccharide	O
(	O
LPS	O
)	O
,	O
stimulated	O
mononuclear	B-cell_type
phagocytes	I-cell_type
to	O
release	O
IL-6	B-protein
in	O
a	O
dose-response	O
manner	O
.	O

LAM	B-protein
and	O
LPS	O
were	O
potent	O
inducers	O
of	O
IL-6	B-DNA
gene	I-DNA
expression	O
in	O
peripheral	B-cell_type
blood	I-cell_type
monocytes	I-cell_type
.	O

Both	O
LAM	B-protein
-and	O
LPS-inducible	B-DNA
IL-6	I-DNA
promoter	I-DNA
activity	O
was	O
localized	O
to	O
a	O
DNA	B-DNA
fragment	I-DNA
,	O
positions	O
-158	B-DNA
to	I-DNA
-49	I-DNA
,	O
by	O
deletion	O
analysis	O
and	O
chloramphenicol	B-protein
acetyltransferase	I-protein
assay	O
.	O

Two	O
nuclear	B-protein
factor	I-protein
NF-IL6	I-protein
(	O
positions	O
-153	B-DNA
to	I-DNA
-145	I-DNA
and	O
-83	O
to	O
-75	O
)	O
and	O
one	O
nuclear	B-DNA
factor	I-DNA
NF-kappa	I-DNA
B	I-DNA
(	I-DNA
positions	I-DNA
-72	I-DNA
to	I-DNA
-63	I-DNA
)	I-DNA
motifs	I-DNA
are	O
present	O
within	O
this	O
fragment	O
.	O

Site-directed	O
mutagenesis	O
of	O
one	O
or	O
more	O
of	O
these	O
motifs	O
within	O
the	O
IL-6	B-protein
promoter	O
demonstrated	O
that	O
each	O
has	O
positive	O
regulatory	O
activity	O
and	O
that	O
they	O
could	O
act	O
in	O
a	O
function-	O
and	O
orientation-independent	O
manner	O
.	O

Deletion	O
of	O
all	O
three	O
elements	O
abolished	O
inducibility	O
of	O
IL-6	B-DNA
promoter	I-DNA
activity	O
by	O
both	O
LAM	B-protein
and	O
LPS	O
.	O

We	O
conclude	O
that	O
the	O
NF-IL6	B-DNA
and	I-DNA
NF-kappa	I-DNA
B	I-DNA
sites	I-DNA
mediate	O
IL-6	B-protein
induction	O
in	O
response	O
to	O
both	O
LPS	O
and	O
LAM	B-protein
,	O
acting	O
as	O
bacterial	B-DNA
or	I-DNA
mycobacterial	I-DNA
response	I-DNA
elements	I-DNA
.	O

Regulation	O
of	O
CD14	B-protein
expression	O
during	O
monocytic	O
differentiation	O
induced	O
with	O
1	O
alpha	O
,	O
25-dihydroxyvitamin	O
D3	O
.	O

CD14	B-protein
,	O
a	O
monocyte/macrophage	B-protein
receptor	I-protein
for	O
the	O
complex	O
of	O
LPS	O
and	O
LPS	B-protein
binding	I-protein
protein	I-protein
,	O
is	O
a	O
differentiation	O
marker	O
for	O
the	O
monocyte/macrophage	B-cell_type
lineage	I-cell_type
.	O

We	O
have	O
analyzed	O
the	O
regulation	O
of	O
CD14	B-protein
expression	O
during	O
1	O
alpha	O
,	O
25-dihydroxyvitamin	O
D3	O
(	O
VitD3	O
)	O
-induced	O
monocytic	O
differentiation	O
.	O

Using	O
FACS	O
,	O
Northern	O
blotting	O
,	O
and	O
nuclear	O
run-on	O
analyses	O
,	O
we	O
demonstrate	O
that	O
the	O
up-regulation	O
of	O
CD14	B-protein
expression	O
during	O
monocytic	O
cell	O
maturation	O
is	O
regulated	O
mainly	O
at	O
the	O
level	O
of	O
gene	O
transcription	O
,	O
and	O
that	O
new	O
protein	O
synthesis	O
is	O
required	O
for	O
CD14	B-protein
induction	O
.	O

We	O
have	O
recently	O
cloned	O
the	O
CD14	B-DNA
5	I-DNA
'	I-DNA
upstream	I-DNA
sequence	I-DNA
and	O
demonstrated	O
its	O
tissue-specific	B-DNA
promoter	I-DNA
activity	O
.	O

Using	O
stable	O
transfection	O
of	O
the	O
monocytoid	B-cell_line
U937	I-cell_line
cell	I-cell_line
line	I-cell_line
with	O
a	O
series	O
of	O
deletion	O
mutants	O
of	O
the	O
CD14	B-DNA
5	I-DNA
'	I-DNA
upstream	I-DNA
sequence	I-DNA
coupled	O
to	O
a	O
reporter	O
gene	O
construct	O
,	O
we	O
show	O
that	O
bp	B-DNA
-128	I-DNA
to	I-DNA
-70	I-DNA
is	O
the	O
critical	O
region	O
for	O
the	O
induction	O
of	O
CD14	B-protein
expression	O
.	O

This	O
region	O
contains	O
two	O
binding	B-DNA
sites	I-DNA
for	O
the	O
Sp1	B-protein
transcription	I-protein
factor	I-protein
.	O

A	O
3-bp	O
mutation	O
at	O
the	O
distal	O
Sp1-binding	B-DNA
site	I-DNA
not	O
only	O
eliminates	O
Sp1	B-protein
interaction	O
,	O
but	O
also	O
abolishes	O
most	O
of	O
the	O
VitD3	O
induction	O
of	O
CD14	B-protein
expression	O
.	O

Electrophoretic	O
mobility	O
shift	O
analysis	O
does	O
not	O
detect	O
a	O
direct	O
interaction	O
of	O
the	O
CD14	B-protein
distal	O
Sp1-binding	B-DNA
site	I-DNA
with	O
the	O
vitamin	B-protein
D3	I-protein
receptor	I-protein
and	O
its	O
partner	O
,	O
the	O
retinoid	B-protein
X	I-protein
receptor	I-protein
.	O

These	O
data	O
demonstrate	O
that	O
VitD3	O
induces	O
CD14	B-protein
indirectly	O
through	O
some	O
intermediary	B-protein
factor	I-protein
,	O
and	O
suggest	O
a	O
critical	O
role	O
for	O
Sp1	B-protein
in	O
this	O
process	O
.	O

DNA-binding	O
and	O
transcriptional	O
regulatory	O
properties	O
of	O
hepatic	B-protein
leukemia	I-protein
factor	I-protein
(	O
HLF	B-protein
)	O
and	O
the	O
t	O
(	O
17	O
;	O
19	O
)	O
acute	B-protein
lymphoblastic	I-protein
leukemia	I-protein
chimera	I-protein
E2A-HLF	I-protein
.	O

The	O
t	B-DNA
(	I-DNA
17	I-DNA
;	I-DNA
19	I-DNA
)	I-DNA
translocation	O
in	O
acute	O
lymphoblastic	O
leukemias	O
results	O
in	O
creation	O
of	O
E2A-hepatic	B-protein
leukemia	I-protein
factor	I-protein
(	O
HLF	B-protein
)	O
chimeric	B-protein
proteins	I-protein
that	O
contain	O
the	O
DNA-binding	B-protein
and	I-protein
protein	I-protein
dimerization	I-protein
domains	I-protein
of	O
the	O
basic	B-protein
leucine	I-protein
zipper	I-protein
(	I-protein
bZIP	I-protein
)	I-protein
protein	I-protein
HLF	B-protein
fused	O
to	O
a	O
portion	O
of	O
E2A	B-protein
proteins	I-protein
with	O
transcriptional	O
activation	O
properties	O
.	O

An	O
in	O
vitro	O
binding	O
site	O
selection	O
procedure	O
was	O
used	O
to	O
determine	O
DNA	O
sequences	O
preferentially	O
bound	O
by	O
wild-type	B-protein
HLF	I-protein
and	O
chimeric	B-protein
E2A-HLF	I-protein
proteins	O
isolated	O
from	O
various	O
t	B-cell_line
(	I-cell_line
17	I-cell_line
;	I-cell_line
19	I-cell_line
)	I-cell_line
-bearing	I-cell_line
leukemias	I-cell_line
.	O

All	O
were	O
found	O
to	O
selectively	O
bind	O
the	O
consensus	B-DNA
sequence	I-DNA
5'-GTTACGTAAT-3	O
'	O
with	O
high	O
affinity	O
.	O

Wild-type	O
and	O
chimeric	B-protein
HLF	I-protein
proteins	I-protein
also	O
bound	O
closely	O
related	O
sites	O
identified	O
previously	O
for	O
bZIP	B-protein
proteins	I-protein
of	O
both	O
the	O
proline	B-protein
-and	O
acidic	O
amino	O
acid-rich	O
(	O
PAR	B-protein
)	O
and	O
C/EBP	B-protein
subfamilies	I-protein
;	O
however	O
,	O
E2A-HLF	B-protein
proteins	O
were	O
significantly	O
less	O
tolerant	O
of	O
certain	O
deviations	O
from	O
the	O
HLF	B-DNA
consensus	I-DNA
binding	I-DNA
site	I-DNA
.	O

These	O
differences	O
were	O
directly	O
attributable	O
to	O
loss	O
of	O
an	O
HLF	B-DNA
ancillary	I-DNA
DNA-binding	I-DNA
domain	I-DNA
in	O
all	O
E2A-HLF	B-protein
chimeras	I-protein
and	O
were	O
further	O
exacerbated	O
by	O
a	O
zipper	O
mutation	O
in	O
one	O
isolate	O
.	O

Both	O
wild-type	B-protein
and	O
chimeric	B-protein
HLF	I-protein
proteins	I-protein
displayed	O
transcriptional	B-protein
activator	I-protein
properties	O
in	O
lymphoid	B-cell_type
and	I-cell_type
nonlymphoid	I-cell_type
cells	I-cell_type
on	O
reporter	B-DNA
genes	I-DNA
containing	O
HLF	B-DNA
or	I-DNA
C/EBP	I-DNA
consensus	I-DNA
binding	I-DNA
sites	I-DNA
.	O

But	O
on	O
reporter	B-DNA
genes	I-DNA
with	O
nonoptimal	B-DNA
binding	I-DNA
sites	I-DNA
,	O
their	O
transcriptional	O
properties	O
diverged	O
and	O
E2A-HLF	B-protein
competitively	O
inhibited	O
activation	O
by	O
wild-type	B-protein
PAR	I-protein
proteins	I-protein
.	O

These	O
findings	O
establish	O
a	O
spectrum	O
of	O
binding	O
site-specific	O
transcriptional	O
properties	O
for	O
E2A-HLF	B-protein
which	O
may	O
preferentially	O
activate	O
expression	O
of	O
select	O
subordinate	O
genes	O
as	O
a	O
homodimer	O
and	O
potentially	O
antagonize	O
expression	O
of	O
others	O
through	O
heteromeric	O
interactions	O
.	O

ZAP-70	B-protein
tyrosine	I-protein
kinase	I-protein
,	O
CD45	B-protein
,	O
and	O
T	B-protein
cell	I-protein
receptor	I-protein
involvement	O
in	O
UV-	O
and	O
H2O2-induced	O
T	O
cell	O
signal	O
transduction	O
.	O

Several	O
mammalian	O
responses	O
to	O
UV	O
irradiation	O
,	O
including	O
the	O
activation	O
of	O
NF-kappa	B-protein
B	I-protein
,	O
are	O
believed	O
to	O
involve	O
tyrosine	O
phosphorylation	O
.	O

UV	O
irradiation	O
and	O
H2O2	O
treatment	O
of	O
T	B-cell_type
lymphocytes	I-cell_type
induce	O
protein	O
tyrosine	O
phosphorylation	O
and	O
Ca2+	O
signals	O
similar	O
to	O
those	O
observed	O
following	O
biological	O
stimulation	O
.	O

We	O
have	O
examined	O
the	O
role	O
of	O
cell	O
surface	O
molecules	O
in	O
these	O
responses	O
.	O

Normal	O
T	B-cell_type
lymphocytes	I-cell_type
whose	O
surface	O
expression	O
of	O
CD3	B-protein
was	O
depleted	O
showed	O
impaired	O
UV-induced	O
tyrosine	O
phosphorylation	O
and	O
Ca2+	O
signals	O
.	O

Similarly	O
,	O
Jurkat	B-cell_line
T	I-cell_line
cell	I-cell_line
lines	I-cell_line
deficient	O
in	O
CD3	O
or	O
CD45	O
expression	O
also	O
gave	O
impaired	O
UV	O
responses	O
.	O

However	O
,	O
all	O
these	O
cell	O
types	O
still	O
gave	O
strong	O
Ca2+	O
and	O
tyrosine	O
phosphorylation	O
responses	O
to	O
H2O2	O
.	O

The	O
T	O
cell	O
tyrosine	O
kinase	B-protein
ZAP-70	I-protein
was	O
found	O
to	O
be	O
highly	O
responsive	O
to	O
UV	O
and	O
H2O2	O
treatment	O
.	O

ZAP-70	B-protein
responsiveness	O
to	O
UV	O
required	O
expression	O
of	O
both	O
CD3	B-protein
and	O
CD45	B-protein
,	O
whereas	O
only	O
CD3	B-protein
was	O
required	O
for	O
the	O
response	O
to	O
H2O2	O
.	O

UV-induced	O
activation	O
of	O
NF-kappa	B-protein
B	I-protein
was	O
blocked	O
by	O
CD3	B-protein
depletion	O
,	O
indicating	O
the	O
importance	O
of	O
such	O
cell	B-protein
surface	I-protein
molecules	I-protein
in	O
biological	O
responses	O
to	O
UV	O
.	O

In	O
nonlymphoid	B-cell_type
cells	I-cell_type
,	O
the	O
epidermal	B-protein
growth	I-protein
factor	I-protein
receptor	I-protein
displayed	O
increased	O
tyrosine	O
phosphorylation	O
within	O
seconds	O
of	O
UV	O
irradiation	O
.	O

These	O
results	O
suggest	O
that	O
UV-induced	O
signal	O
transduction	O
is	O
mediated	O
via	O
cell	B-protein
surface	I-protein
receptors	I-protein
that	O
normally	O
respond	O
to	O
biological	O
stimulation	O
,	O
whereas	O
H2O2	O
is	O
able	O
to	O
partially	O
bypass	O
this	O
requirement	O
.	O

Inhibition	O
of	O
the	O
differentiation	O
of	O
human	B-cell_line
myeloid	I-cell_line
cell	I-cell_line
lines	I-cell_line
by	O
redox	O
changes	O
induced	O
through	O
glutathione	O
depletion	O
.	O

We	O
have	O
investigated	O
the	O
effect	O
of	O
redox	O
changes	O
in	O
vivo	O
on	O
the	O
differentiation	O
of	O
two	O
human	B-cell_line
myeloid	I-cell_line
cell	I-cell_line
lines	I-cell_line
,	O
HL-60	B-cell_line
and	O
KG-1	B-cell_line
.	O

The	O
glutathione-depleting	O
agent	O
diethyl	O
maleate	O
(	O
DEM	O
)	O
prevented	O
the	O
development	O
of	O
differentiated	O
features	O
in	O
response	O
to	O
phorbol	O
esters	O
,	O
including	O
adherence	O
of	O
the	O
cells	O
to	O
plastic	O
surfaces	O
and	O
repression	O
of	O
the	O
myeloperoxidase	B-DNA
and	I-DNA
CD34	I-DNA
genes	I-DNA
.	O

Moreover	O
,	O
DEM	O
abolished	O
phorbol	O
12-myristate	O
13-acetate-induced	O
activation	O
of	O
the	O
transcription	B-protein
factors	I-protein
AP-1	B-protein
and	O
Egr-1	B-protein
,	O
suggesting	O
that	O
inhibition	O
of	O
differentiation	O
may	O
be	O
due	O
,	O
at	O
least	O
in	O
part	O
,	O
to	O
redox	O
modifications	O
of	O
these	O
proteins	B-protein
.	O

Lipopolysaccharide	O
induction	O
of	O
tissue	B-DNA
factor	I-DNA
gene	I-DNA
expression	O
in	O
monocytic	B-cell_type
cells	I-cell_type
is	O
mediated	O
by	O
binding	O
of	O
c-Rel/p65	B-protein
heterodimers	I-protein
to	O
a	O
kappa	B-DNA
B-like	I-DNA
site	I-DNA
.	O

Exposure	O
of	O
monocytic	B-cell_type
cells	I-cell_type
to	O
bacterial	O
lipopolysaccharide	O
(	O
LPS	O
)	O
activates	O
the	O
NF-kappa	B-protein
B/Rel	I-protein
family	I-protein
of	O
proteins	O
and	O
leads	O
to	O
the	O
rapid	O
induction	O
of	O
inflammatory	B-protein
gene	I-protein
products	I-protein
,	O
including	O
tissue	B-protein
factor	I-protein
(	O
TF	B-protein
)	O
.	O

TF	B-protein
is	O
the	O
primary	O
cellular	O
initiator	O
of	O
the	O
coagulation	B-protein
protease	I-protein
cascades	O
.	O

Here	O
we	O
report	O
the	O
characterization	O
of	O
a	O
nuclear	B-protein
complex	I-protein
from	O
human	O
monocytic	B-cell_type
cells	I-cell_type
that	O
bound	O
to	O
a	O
kappa	B-DNA
B-like	I-DNA
site	I-DNA
,	O
5'-CGGAGTTTCC-3	B-DNA
'	I-DNA
,	O
in	O
the	O
5'-flanking	B-DNA
region	I-DNA
of	O
the	O
human	B-DNA
TF	I-DNA
gene	I-DNA
.	O

This	O
nuclear	B-protein
complex	I-protein
was	O
activated	O
by	O
LPS	O
with	O
kinetics	O
that	O
preceded	O
induction	O
of	O
the	O
TF	B-DNA
gene	I-DNA
.	O

In	O
vitro	O
binding	O
studies	O
demonstrated	O
that	O
the	O
TF	B-DNA
site	I-DNA
bound	O
translated	O
c-Rel	B-protein
and	I-protein
p65	I-protein
homodimers	I-protein
but	O
not	O
p50/p65	B-protein
heterodimers	I-protein
or	O
p50	B-protein
homodimers	I-protein
.	O

Base-pair	O
substitutions	O
in	O
the	O
TF	B-DNA
site	I-DNA
indicated	O
that	O
the	O
presence	O
of	O
a	O
cytosine	O
at	O
position	B-protein
1	I-protein
precluded	O
binding	O
of	O
NF-kappa	B-protein
B	I-protein
.	O

In	O
fact	O
,	O
under	O
low-ionic-strength	O
conditions	O
,	O
the	O
TF	B-protein
complex	I-protein
did	O
not	O
migrate	O
with	O
translated	O
p50/p65	B-protein
dimers	I-protein
but	O
instead	O
comigrated	O
with	O
c-Rel/p65	B-protein
dimers	I-protein
.	O

Antibodies	O
against	O
the	O
NF-kappa	B-protein
B	I-protein
and	O
Rel	O
proteins	O
and	O
UV	O
cross-linking	O
studies	O
revealed	O
the	O
presence	O
of	O
c-Rel	B-protein
and	O
p65	O
and	O
the	O
absence	O
of	O
p50	B-protein
in	O
the	O
TF	B-protein
complex	I-protein
and	O
further	O
showed	O
that	O
c-Rel/p65	B-protein
heterodimers	I-protein
selectively	O
bound	O
to	O
the	O
TF	B-DNA
kappa	I-DNA
B-like	I-DNA
site	I-DNA
.	O

Functional	O
studies	O
indicated	O
that	O
the	O
TF	B-DNA
site	I-DNA
conferred	O
LPS	O
inducibility	O
on	O
a	O
heterologous	B-DNA
promoter	I-DNA
and	O
was	O
transactivated	O
by	O
c-Rel	B-protein
or	O
p65	O
.	O

Taken	O
together	O
,	O
our	O
results	O
demonstrated	O
that	O
binding	O
of	O
c-Rel/p65	B-protein
heterodimers	I-protein
to	O
a	O
novel	O
kappa	B-DNA
B-like	I-DNA
site	I-DNA
mediated	O
LPS	O
induction	O
of	O
TF	B-protein
gene	O
expression	O
in	O
monocytic	B-cell_type
cells	I-cell_type
.	O

Inhibition	O
of	O
T	O
cell	O
activation	O
by	O
the	O
extracellular	B-protein
matrix	I-protein
protein	I-protein
tenascin	B-protein
.	O

Tenascin	B-protein
(	O
TN	B-protein
)	O
is	O
an	O
extracellular	B-protein
matrix	I-protein
protein	I-protein
that	O
is	O
expressed	O
widely	O
in	O
the	O
fetus	O
and	O
sparingly	O
in	O
the	O
adult	O
,	O
but	O
reappears	O
at	O
high	O
levels	O
in	O
certain	O
areas	O
of	O
tissue	O
insult	O
such	O
as	O
tumor	O
matrices	O
and	O
sites	O
of	O
wound	O
healing	O
.	O

We	O
show	O
here	O
that	O
soluble	O
TN	B-protein
inhibits	O
proliferation	O
of	O
human	B-cell_type
T	I-cell_type
cells	I-cell_type
in	O
response	O
to	O
alpha	B-protein
CD3	I-protein
Ab	I-protein
co-immobilized	O
with	O
the	O
extracellular	B-protein
matrix	I-protein
protein	I-protein
fibronectin	B-protein
(	O
FN	B-protein
)	O
.	O

TN	B-protein
also	O
inhibits	O
proliferation	O
driven	O
by	O
alpha	B-protein
CD3/IL-2	I-protein
or	O
by	O
phorbol	B-protein
ester/IL-2	I-protein
,	I-protein
and	O
it	O
prevents	O
high	O
level	O
induction	O
of	O
IL-2R	B-protein
.	O

The	O
presence	O
of	O
TN	B-protein
in	O
culture	O
medium	O
does	O
not	O
detectably	O
alter	O
the	O
pattern	O
of	O
tyrosine	O
phosphorylation	O
resulting	O
from	O
T	O
cell	O
triggering	O
with	O
alpha	B-protein
CD3	I-protein
,	O
but	O
at	O
later	O
time	O
points	O
prevents	O
the	O
appearance	O
of	O
functional	O
NF-AT1	B-protein
transcription	I-protein
factor	I-protein
complexes	I-protein
in	O
T	O
cell	O
nuclear	O
extracts	O
.	O

These	O
findings	O
are	O
consistent	O
with	O
the	O
postulated	O
role	O
for	O
TN	B-protein
as	O
a	O
natural	O
antagonist	O
to	O
FN	B-protein
action	O
,	O
and	O
suggest	O
that	O
T	O
cell	O
responses	O
occurring	O
at	O
tissue	O
sites	O
in	O
which	O
TN	B-protein
is	O
expressed	O
could	O
be	O
influenced	O
by	O
its	O
presence	O
.	O

Human	O
immunodeficiency	O
virus	O
type	O
1	O
Nef	O
protein	O
down-regulates	O
transcription	B-protein
factors	I-protein
NF-kappa	B-protein
B	I-protein
and	O
AP-1	B-protein
in	O
human	B-cell_type
T	I-cell_type
cells	I-cell_type
in	O
vitro	O
after	O
T-cell	O
receptor	O
stimulation	O
.	O

Human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
negative	B-protein
factor	I-protein
(	O
Nef	B-protein
)	O
has	O
been	O
shown	O
to	O
down-regulate	O
the	O
transcription	B-protein
factors	I-protein
NF-kappa	B-protein
B	I-protein
and	O
AP-1	B-protein
in	O
vitro	O
.	O

To	O
define	O
the	O
mechanism	O
of	O
action	O
of	O
the	O
Nef	B-protein
protein	O
,	O
the	O
signal	O
transduction	O
pathways	O
which	O
may	O
be	O
affected	O
in	O
T	B-cell_type
cells	I-cell_type
by	O
constitutive	O
expression	O
of	O
the	O
nef	O
gene	O
were	O
examined	O
.	O

Stimulation	O
of	O
T	B-cell_type
cells	I-cell_type
with	O
tumor	O
necrosis	O
factor	O
,	O
interleukin-1	O
,	O
or	O
lipopolysaccharide	O
resulted	O
in	O
the	O
recruitment	O
of	O
transcriptional	O
factors	O
to	O
a	O
similar	O
level	O
whether	O
or	O
not	O
the	O
cells	O
expressed	O
the	O
nef	O
gene	O
.	O

On	O
the	O
other	O
hand	O
,	O
stimulation	O
of	O
T	B-cell_type
cells	I-cell_type
by	O
mitogens	O
or	O
antibodies	O
to	O
the	O
T-cell	O
receptor	O
(	O
TCR	O
)	O
-	O
CD3	B-protein
complex	O
resulted	O
in	O
the	O
down-regulation	O
of	O
transcriptional	O
factors	O
NF-kappa	B-protein
B	I-protein
and	O
AP-1	B-protein
in	O
cells	O
expressing	O
the	O
nef	O
gene	O
compared	O
with	O
cells	O
not	O
expressing	O
the	O
nef	O
gene	O
.	O

Because	O
the	O
Nef	B-protein
protein	O
does	O
not	O
affect	O
the	O
surface	O
expression	O
of	O
the	O
CD3	B-protein
-TCR	O
complex	O
,	O
we	O
conclude	O
that	O
the	O
Nef	B-protein
protein	O
down-regulates	O
the	O
transcriptional	O
factors	O
NF-kappa	B-protein
B	I-protein
and	O
AP-1	B-protein
in	O
T	B-cell_type
cells	I-cell_type
in	O
vitro	O
through	O
an	O
effect	O
on	O
the	O
TCR-dependent	O
signal	O
transduction	O
pathway	O
.	O

Effects	O
of	O
alpha-lipoic	O
acid	O
and	O
dihydrolipoic	O
acid	O
on	O
expression	O
of	O
proto-oncogene	B-DNA
c-fos	I-DNA
.	O

The	O
transcription	B-protein
factor	I-protein
AP-1	B-protein
is	O
an	O
important	O
human	O
mediator	O
of	O
the	O
cellular	O
response	O
to	O
serum	O
,	O
growth	B-protein
factors	I-protein
,	O
and	O
phorbol	O
esters	O
such	O
as	O
12-O-tetradecanoyl-phorbol-13	O
acetate	O
(	O
TPA	O
)	O
.	O

The	O
AP-1	B-protein
complex	O
consists	O
of	O
distinct	O
protein	B-protein
heterodimers	I-protein
encoded	O
by	O
the	O
proto-oncogene	B-DNA
c-fos	I-DNA
and	O
c-jun	B-RNA
mRNA	I-RNA
whose	O
gene	O
expression	O
can	O
be	O
induced	O
by	O
TPA	O
,	O
cyclic	O
AMP	O
and	O
growth	B-protein
factors	I-protein
.	O

Recent	O
findings	O
suggest	O
an	O
involvement	O
of	O
reactive	O
oxygen	O
species	O
in	O
the	O
pathway	O
of	O
TPA	O
and	O
protein	B-protein
kinase	I-protein
C	I-protein
leading	O
to	O
expression	O
of	O
c-fos	B-RNA
and	I-RNA
c-jun	I-RNA
mRNA	I-RNA
.	O

To	O
investigate	O
the	O
role	O
of	O
reactive	O
oxygen	O
species	O
we	O
studied	O
the	O
effects	O
of	O
alpha-lipoic	O
acid	O
and	O
dihydrolipoic	O
acid	O
(	O
natural	O
thiol	O
antioxidants	O
)	O
on	O
the	O
expression	O
of	O
c-fos	B-RNA
mRNA	I-RNA
in	O
human	B-cell_line
Jurkat	I-cell_line
T	I-cell_line
cells	I-cell_line
.	O

When	O
cells	O
were	O
preincubated	O
with	O
dihydrolipoic	O
acid	O
(	O
0.2	O
mM	O
)	O
the	O
expression	O
of	O
c-fos	B-RNA
mRNA	I-RNA
was	O
suppressed	O
at	O
30	O
min	O
after	O
stimulation	O
of	O
TPA	O
(	O
0.5	O
microM	O
)	O
whereas	O
in	O
the	O
case	O
of	O
preincubation	O
of	O
alpha-lipoic	O
acid	O
(	O
0.2	O
microM	O
)	O
,	O
the	O
expression	O
was	O
enhanced	O
at	O
30	O
min	O
.	O

These	O
studies	O
support	O
the	O
idea	O
that	O
superoxide	O
anion	O
radical	O
plays	O
a	O
role	O
in	O
the	O
expression	O
of	O
c-fos	B-RNA
mRNA	I-RNA
.	O

Appraisal	O
of	O
potential	O
therapeutic	O
index	O
of	O
antioxidants	O
on	O
the	O
basis	O
of	O
their	O
in	O
vitro	O
effects	O
on	O
HIV	O
replication	O
in	O
monocytes	B-cell_type
and	O
interleukin	B-protein
2	I-protein
-induced	O
lymphocyte	O
proliferation	O
.	O

Antioxidant	O
molecules	O
have	O
been	O
suggested	O
to	O
be	O
of	O
therapeutic	O
value	O
in	O
the	O
treatment	O
of	O
HIV-infected	O
patients	O
.	O

To	O
evaluate	O
this	O
possibility	O
,	O
we	O
examined	O
in	O
vitro	O
the	O
effects	O
of	O
two	O
types	O
of	O
antioxidant	O
molecules	O
in	O
terms	O
of	O
inhibition	O
of	O
HIV	O
replication	O
in	O
monocytes	B-cell_type
,	O
one	O
of	O
the	O
main	O
reservoirs	O
of	O
HIV	O
,	O
and	O
also	O
in	O
terms	O
of	O
modulation	O
of	O
the	O
immune	O
competence	O
as	O
measured	O
by	O
PBMC	B-cell_type
proliferation	O
.	O

We	O
tested	O
the	O
effects	O
of	O
BHA	O
,	O
a	O
phenolic	O
,	O
lipid-soluble	O
,	O
chain-breaking	O
antioxidant	O
,	O
and	O
NAC	O
,	O
a	O
known	O
glutathione	O
precursor	O
with	O
some	O
direct	O
free-radical	O
scavenging	O
properties	O
as	O
well	O
,	O
on	O
the	O
regulation	O
of	O
HIV-1	O
expression	O
in	O
latently	O
infected	O
U1	B-cell_line
cells	I-cell_line
and	O
in	O
productively	O
and	O
chronically	O
infected	O
U937	B-cell_line
cells	I-cell_line
.	O

Both	O
antioxidants	O
inhibited	O
TNF	B-protein
-or	O
PMA-induced	O
NF-kappa	B-protein
B	I-protein
activity	O
in	O
U1	B-cell_line
cells	I-cell_line
,	O
as	O
well	O
as	O
the	O
sustained	O
NF-kappa	B-protein
B	I-protein
activity	O
permanently	O
induced	O
by	O
the	O
virus	O
itself	O
in	O
chronically	O
HIV-infected	O
U937	B-cell_line
cells	I-cell_line
.	O

This	O
resulted	O
in	O
only	O
a	O
partial	O
inhibition	O
of	O
TNF	B-protein
-or	O
PMA-	O
induced	O
HIV	O
replication	O
in	O
U1	B-cell_line
cells	I-cell_line
,	O
and	O
no	O
detectable	O
effect	O
on	O
HIV	O
replication	O
in	O
chronically	B-cell_line
infected	I-cell_line
U937	I-cell_line
cells	I-cell_line
.	O

This	O
may	O
be	O
the	O
first	O
limitation	O
to	O
potential	O
antiviral	O
effects	O
of	O
antioxidant	O
therapies	O
.	O

Another	O
limitation	O
is	O
that	O
antioxidant	O
concentrations	O
high	O
enough	O
to	O
block	O
NK-kappa	B-protein
B	I-protein
activation	O
were	O
shown	O
to	O
have	O
a	O
suppressive	O
effect	O
on	O
immune	O
functions	O
in	O
vitro	O
,	O
because	O
NAC	O
and	O
BHA	O
blocked	O
IL-2-induced	B-cell_type
PBMC	I-cell_type
proliferation	O
.	O

These	O
data	O
warrant	O
prudence	O
in	O
the	O
design	O
of	O
antioxidant-based	O
therapies	O
aimed	O
at	O
suppressing	O
HIV	O
replication	O
.	O

Isolation	O
and	O
characterization	O
of	O
gelatinase	O
granules	O
from	O
human	B-cell_type
neutrophils	I-cell_type
.	O

We	O
recently	O
confirmed	O
the	O
existence	O
of	O
gelatinase	O
granules	O
as	O
a	O
subpopulation	O
of	O
peroxidase-negative	O
granules	O
by	O
double-labeling	O
immunogold	O
electron	O
microscopy	O
on	O
intact	O
cells	O
and	O
by	O
subcellular	O
fractionation	O
.	O

Further	O
characterization	O
of	O
gelatinase	O
granules	O
has	O
been	O
hampered	O
by	O
poor	O
separation	O
of	O
specific	O
and	O
gelatinase	O
granules	O
on	O
both	O
two-layer	O
Percoll	O
gradients	O
and	O
sucrose	O
gradients	O
.	O

We	O
have	O
developed	O
a	O
three-layer	O
Percoll	O
density	O
gradient	O
that	O
allows	O
separation	O
of	O
the	O
different	O
granules	O
and	O
vesicles	O
from	O
human	B-cell_type
neutrophils	I-cell_type
;	O
in	O
particular	O
,	O
it	O
allows	O
separation	O
of	O
specific	O
and	O
gelatinase	O
granules	O
.	O

This	O
allows	O
us	O
to	O
characterize	O
these	O
two	O
granule	O
populations	O
with	O
regard	O
to	O
their	O
content	O
of	O
membrane	B-protein
proteins	I-protein
,	O
which	O
become	O
incorporated	O
into	O
the	O
plasma	O
membrane	O
during	O
exocytosis	O
.	O

We	O
found	O
that	O
gelatinase	O
granules	O
,	O
defined	O
as	O
peroxidase-negative	O
granules	O
containing	O
gelatinase	B-protein
but	O
lacking	O
lactoferrin	B-protein
,	O
contain	O
50	O
%	O
of	O
total	O
cell	O
gelatinase	B-protein
,	O
with	O
the	O
remaining	O
residing	O
in	O
specific	O
granules	O
.	O

Furthermore	O
,	O
we	O
found	O
that	O
20	O
%	O
to	O
25	O
%	O
of	O
both	O
the	O
adhesion	B-protein
protein	I-protein
Mac-1	I-protein
and	O
the	O
NADPH-oxidase	B-protein
component	I-protein
cytochrome	I-protein
b558	B-protein
is	O
localized	O
in	O
gelatinase	B-protein
granules	O
.	O

Although	O
no	O
qualitative	O
difference	O
was	O
observed	O
between	O
specific	O
granules	O
and	O
gelatinase	B-protein
granules	O
with	O
respect	O
to	O
cytochrome	B-protein
b558	I-protein
and	O
Mac-1	B-protein
,	O
stimulation	O
of	O
the	O
neutrophil	B-cell_type
with	O
FMLP	B-protein
resulted	O
in	O
a	O
selective	O
mobilization	O
of	O
the	O
least	O
dense	O
peroxidase-negative	O
granules	O
,	O
ie	O
,	O
gelatinase	B-protein
granules	O
,	O
which	O
,	O
in	O
concert	O
with	O
secretory	O
vesicles	O
,	O
furnish	O
the	O
plasma	O
membrane	O
with	O
Mac-1	B-protein
and	O
cytochrome	B-protein
b558	I-protein
.	O

This	O
shows	O
that	O
gelatinase	B-protein
granules	O
are	O
functionally	O
important	O
relative	O
to	O
specific	O
granules	O
in	O
mediating	O
early	O
inflammatory	O
responses	O
.	O

Regulation	O
of	O
interleukin-2	B-protein
receptor	I-protein
alpha	I-protein
chain	I-protein
expression	O
and	O
nuclear	B-protein
factor.kappa	I-protein
B	I-protein
activation	O
by	O
protein	B-protein
kinase	I-protein
C	I-protein
in	O
T	B-cell_type
lymphocytes	I-cell_type
.	O

Autocrine	O
role	O
of	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
alpha	I-protein
.	O

The	O
regulation	O
of	O
interleukin-2	B-protein
receptor	I-protein
alpha	I-protein
chain	I-protein
(	O
IL-2R	B-protein
alpha	I-protein
)	O
expression	O
and	O
nuclear	B-protein
factor	I-protein
(	O
NF	O
)	O
activation	O
by	O
protein	B-protein
kinase	I-protein
C	I-protein
(	O
PKC	B-protein
)	O
in	O
resting	B-cell_type
T	I-cell_type
cells	I-cell_type
,	O
has	O
been	O
studied	O
.	O

Treatment	O
of	O
human	O
resting	B-cell_type
T	I-cell_type
cells	I-cell_type
with	O
phorbol	O
esters	O
strongly	O
induced	O
the	O
expression	O
of	O
IL-2R	B-protein
alpha	I-protein
and	O
the	O
activation	O
of	O
NF.kappa	B-protein
B	I-protein
.	O

This	O
activation	O
was	O
due	O
to	O
the	O
translocation	O
of	O
p65	B-protein
and	O
c-Rel	B-protein
NF.kappa	B-protein
B	I-protein
proteins	O
from	O
cytoplasmic	O
stores	O
to	O
the	O
nucleus	O
,	O
where	O
they	O
bound	O
the	O
kappa	B-DNA
B	I-DNA
sequence	I-DNA
of	O
the	O
IL-2R	B-DNA
alpha	I-DNA
promoter	I-DNA
either	O
as	O
p50.p65	B-protein
or	O
as	O
p50.c-Rel	B-protein
heterodimers	O
.	O

Interestingly	O
,	O
all	O
of	O
those	O
events	O
were	O
largely	O
indirect	O
and	O
mediated	O
by	O
endogenously	O
secreted	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
alpha	I-protein
(	O
TNF	B-protein
alpha	I-protein
)	O
,	O
as	O
they	O
were	O
strongly	O
inhibited	O
by	O
a	O
neutralizing	B-protein
anti-TNF	I-protein
alpha	I-protein
monoclonal	I-protein
antibody	I-protein
.	O

Furthermore	O
,	O
cyclosporin	O
A	O
,	O
which	O
blocked	O
TNF	B-protein
alpha	I-protein
production	O
induced	O
by	O
PKC	B-protein
,	O
strongly	O
inhibited	O
IL-2R	B-protein
alpha	I-protein
and	O
NF.kappa	B-protein
B	I-protein
activation	O
.	O

The	O
addition	O
of	O
either	O
TNF	B-protein
alpha	I-protein
or	O
IL-2	B-protein
partially	O
recovered	O
cyclosporin	O
A-induced	O
IL-2R	B-protein
alpha	I-protein
inhibition	O
,	O
but	O
only	O
TNF	B-protein
alpha	I-protein
completely	O
recovered	O
NF.kappa	B-protein
B	I-protein
activation	O
.	O

Those	O
results	O
indicate	O
that	O
,	O
in	O
resting	B-cell_type
T	I-cell_type
cells	I-cell_type
,	O
PKC	B-protein
activation	O
has	O
only	O
a	O
triggering	O
role	O
,	O
whereas	O
the	O
endogenously	O
secreted	O
TNF	B-protein
alpha	I-protein
plays	O
an	O
essential	O
role	O
in	O
the	O
quantitative	O
control	O
of	O
the	O
expression	O
of	O
IL-2R	B-protein
alpha	I-protein
chain	O
or	O
NF.kappa	B-protein
B	I-protein
activation	O
.	O

Superantigens	B-protein
activate	O
HIV-1	O
gene	O
expression	O
in	O
monocytic	B-cell_type
cells	I-cell_type
.	O

Binding	O
of	O
superantigens	O
to	O
MHC	B-protein
class	I-protein
II	I-protein
molecules	I-protein
results	O
in	O
transduction	O
of	O
biochemical	O
signals	O
leading	O
to	O
cellular	O
activation	O
and	O
gene	O
expression	O
.	O

We	O
demonstrate	O
that	O
the	O
staphylococcal	B-protein
superantigens	I-protein
toxic	B-protein
shock	I-protein
syndrome	I-protein
toxin-1	I-protein
(	O
TSST-1	B-protein
)	O
and	O
staphylococcal	B-protein
enterotoxin	I-protein
A	I-protein
(	O
SEA	B-protein
)	O
activate	O
HIV-1-LTR	B-DNA
-driven	O
transcription	O
of	O
chloramphenicol	B-protein
acetyl	I-protein
transferase	I-protein
in	O
the	O
human	B-cell_line
monocytic	I-cell_line
cell	I-cell_line
line	I-cell_line
THP-1	B-cell_line
.	O

Induction	O
of	O
HIV-1-	O
LTR	B-DNA
-driven	O
transcription	O
in	O
THP-1	B-cell_line
cells	I-cell_line
by	O
superantigens	B-protein
was	O
associated	O
with	O
the	O
induction	O
of	O
nuclear	B-protein
factor-kappa	I-protein
B	I-protein
DNA-binding	O
activity	O
.	O

Superantigens	B-protein
also	O
increased	O
viral	O
protein	O
secretion	O
from	O
the	O
granulocyte-macrophage	B-cell_line
colony-stimulating	I-cell_line
factor-pretreated	I-cell_line
chronically	I-cell_line
infected	I-cell_line
human	I-cell_line
monocytic	I-cell_line
cell	I-cell_line
line	I-cell_line
U1	I-cell_line
.	O

Induction	O
of	O
HIV-1	O
gene	O
expression	O
in	O
monocytic	B-cell_type
cells	I-cell_type
by	O
superantigens	B-protein
occurred	O
via	O
tumor	O
necrosis	O
factor-alpha-dependent	O
and	O
-independent	O
mechanisms	O
.	O

Our	O
results	O
suggest	O
that	O
superantigens	B-protein
and	O
other	O
MHC	B-protein
class	I-protein
II	I-protein
ligands	I-protein
may	O
activate	O
HIV-1	O
gene	O
expression	O
in	O
monocytes/macrophages	B-cell_type
.	O

Mitogen	O
activation	O
of	O
human	B-cell_type
peripheral	I-cell_type
T	I-cell_type
lymphocytes	I-cell_type
induces	O
the	O
formation	O
of	O
new	O
cyclic	B-protein
AMP	I-protein
response	I-protein
element-binding	I-protein
protein	I-protein
nuclear	I-protein
complexes	I-protein
.	O

A	O
large	O
body	O
of	O
evidence	O
indicates	O
that	O
experimental	O
agents	O
which	O
raise	O
cellular	O
cAMP	O
levels	O
inhibit	O
T	O
cell	O
growth	O
and	O
division	O
.	O

By	O
contrast	O
,	O
many	O
studies	O
have	O
reported	O
that	O
mitogen	B-protein
activation	O
of	O
T	B-cell_type
cells	I-cell_type
increases	O
cAMP	O
levels	O
,	O
implying	O
a	O
positive	O
physiological	O
role	O
for	O
cAMP	O
in	O
the	O
activation	O
process	O
.	O

In	O
the	O
present	O
study	O
we	O
demonstrate	O
that	O
mitogen	B-protein
activation	O
of	O
human	B-cell_type
peripheral	I-cell_type
T	I-cell_type
lymphocytes	I-cell_type
induces	O
nuclear	O
factors	O
that	O
form	O
complexes	O
with	O
cyclic	B-protein
AMP	I-protein
response	I-protein
element-binding	I-protein
protein	I-protein
(	O
CREB	B-protein
)	O
.	O

Four	O
complexes	O
are	O
identified	O
by	O
the	O
electrophoretic	O
mobility	O
shift	O
assay	O
,	O
two	O
of	O
which	O
are	O
induced	O
by	O
mitogen	B-protein
activation	O
.	O

All	O
four	O
complexes	O
contain	O
CREB	B-protein
and	O
are	O
bound	O
to	O
the	O
cAMP	B-DNA
response	I-DNA
element	I-DNA
(	I-DNA
CRE	I-DNA
)	I-DNA
core	I-DNA
sequence	I-DNA
(	O
TGACGTCA	O
)	O
,	O
as	O
indicated	O
by	O
antibody	O
and	O
oligonucleotide	O
competition	O
experiments	O
.	O

Binding	O
of	O
the	O
four	O
complexes	O
to	O
CRE	B-DNA
is	O
prevented	O
by	O
dephosphorylation	O
of	O
nuclear	O
extracts	O
and	O
is	O
restored	O
by	O
rephosphorylation	O
with	O
cAMP-dependent	B-protein
protein	I-protein
kinase	I-protein
or	O
endogenous	B-protein
kinases	I-protein
.	O

Similar	O
complexes	O
are	O
detected	O
in	O
nuclear	O
extracts	O
of	O
Jurkat	B-cell_line
cells	I-cell_line
.	O

Mitogen	O
induction	O
of	O
the	O
electrophoretic	B-protein
mobility	I-protein
shift	I-protein
assay	I-protein
complexes	I-protein
is	O
not	O
accounted	O
for	O
by	O
protein	O
phosphorylation	O
or	O
by	O
induction	O
of	O
CREB	B-protein
.	O

Rather	O
,	O
the	O
data	O
indicate	O
that	O
mitogen	O
increases	O
the	O
levels	O
of	O
a	O
nuclear	O
factor	O
(	O
s	O
)	O
that	O
dimerizes	O
with	O
CREB	B-protein
.	O

Induction	O
of	O
new	O
CREB	B-protein
complexes	I-protein
implies	O
a	O
physiological	O
role	O
for	O
cAMP	O
in	O
mitogen	B-protein
activation	O
of	O
T	B-cell_type
lymphocytes	I-cell_type
.	O

Alpha-tocopherol	O
inhibits	O
agonist-induced	O
monocytic	O
cell	O
adhesion	O
to	O
cultured	B-cell_line
human	I-cell_line
endothelial	I-cell_line
cells	I-cell_line
.	O

Antioxidants	O
have	O
been	O
proposed	O
to	O
be	O
anti-atherosclerotic	O
agents	O
;	O
however	O
,	O
the	O
mechanisms	O
underlying	O
their	O
beneficial	O
effects	O
are	O
poorly	O
understood	O
.	O

We	O
have	O
examined	O
the	O
effect	O
of	O
alpha-tocopherol	O
(	O
alpha-tcp	O
)	O
on	O
one	O
cellular	O
event	O
in	O
atherosclerotic	O
plaque	O
development	O
,	O
monocyte	O
adhesion	O
to	O
stimulated	B-cell_type
endothelial	I-cell_type
cells	I-cell_type
(	O
ECs	B-cell_type
)	O
.	O

Human	O
umbilical	O
vein	O
ECs	B-cell_type
were	O
pretreated	O
with	O
alpha-tcp	O
before	O
stimulation	O
with	O
known	O
agonists	O
of	O
monocyte	O
adhesion	O
:	O
IL-1	B-protein
(	O
10	O
ng/ml	O
)	O
,	O
LPS	O
(	O
10	O
ng/ml	O
)	O
,	O
thrombin	B-protein
(	O
30	O
U/ml	O
)	O
,	O
or	O
PMA	O
(	O
10	O
nM	O
)	O
.	O

Agonist-induced	O
monocytic	O
cell	O
adhesion	O
,	O
but	O
not	O
basal	O
adhesion	O
,	O
was	O
inhibited	O
in	O
a	O
time-	O
and	O
concentration-dependent	O
manner	O
by	O
alpha-tcp	O
.	O

The	O
IC50	O
of	O
alpha-tcp	O
on	O
an	O
IL-1	B-protein
-induced	O
response	O
was	O
45	O
microM	O
.	O

The	O
inhibition	O
correlated	O
with	O
a	O
decrease	O
in	O
steady	O
state	O
levels	O
of	O
E-selectin	B-RNA
mRNA	I-RNA
and	O
cell	O
surface	O
expression	O
of	O
E-selectin	B-protein
which	O
is	O
consistent	O
with	O
the	O
ability	O
of	O
a	O
monoclonal	B-protein
antibody	I-protein
to	O
E-selectin	B-protein
to	O
inhibit	O
monocytic	O
cell	O
adhesion	O
in	O
this	O
system	O
.	O

Probucol	O
(	O
50	O
microM	O
)	O
and	O
N-acetylcysteine	O
(	O
20	O
mM	O
)	O
also	O
inhibited	O
agonist-induced	O
monocytic	O
cell	O
adhesion	O
;	O
whereas	O
,	O
several	O
other	O
antioxidants	O
had	O
no	O
significant	O
effect	O
.	O

Protein	B-protein
kinase	I-protein
C	I-protein
(	O
PKC	B-protein
)	O
does	O
not	O
appear	O
to	O
play	O
a	O
role	O
in	O
the	O
alpha-tcp	O
effect	O
since	O
no	O
suppression	O
of	O
phosphorylation	O
of	O
PKC	B-protein
substrates	O
was	O
observed	O
.	O

Activation	O
of	O
the	O
transcription	B-protein
factor	I-protein
NF-kappa	B-protein
B	I-protein
is	O
reported	O
to	O
be	O
necessary	O
but	O
not	O
sufficient	O
for	O
E-selectin	B-protein
expression	O
in	O
EC	B-cell_line
.	O

Electrophoretic	O
mobility	O
shift	O
assays	O
failed	O
to	O
show	O
an	O
alpha-tcp-induced	O
decrease	O
in	O
activation	O
of	O
this	O
transcription	B-protein
factor	I-protein
after	O
cytokine	B-protein
stimulation	O
.	O

It	O
has	O
been	O
hypothesized	O
that	O
alpha-tcp	O
acts	O
as	O
an	O
anti-atherosclerotic	O
molecule	O
by	O
inhibiting	O
generation	O
of	O
oxidized	O
LDL	O
--	O
a	O
putative	O
triggering	O
molecule	O
in	O
the	O
atherosclerotic	O
process	O
.	O

Our	O
results	O
point	O
to	O
a	O
novel	O
alternative	O
mechanism	O
of	O
action	O
of	O
alpha-tcp	O
.	O

Central	B-cell_type
nervous	I-cell_type
system-derived	I-cell_type
cells	I-cell_type
express	O
a	O
kappa	O
B-binding	O
activity	O
that	O
enhances	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
transcription	O
in	O
vitro	O
and	O
facilitates	O
TAR	B-DNA
-independent	O
transactivation	O
by	O
Tat	B-protein
.	O

The	O
Tat	B-protein
protein	I-protein
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
is	O
a	O
potent	O
activator	O
of	O
long	B-DNA
terminal	I-DNA
repeat	I-DNA
-directed	O
transcription	O
.	O

While	O
in	O
most	O
cell	O
types	O
,	O
activation	O
requires	O
interaction	O
of	O
Tat	O
with	O
the	O
unusual	O
transcription	B-DNA
element	I-DNA
TAR	B-DNA
,	O
astrocytic	B-cell_type
glial	I-cell_type
cells	I-cell_type
support	O
TAR	B-DNA
-independent	O
transactivation	O
of	O
HIV-1	O
transcription	O
by	O
Tat	O
.	O

This	O
alternative	O
pathway	O
of	O
Tat	B-protein
activation	O
is	O
mediated	O
by	O
the	O
viral	B-DNA
enhancer	I-DNA
,	O
a	O
kappa	O
B	O
domain	O
capable	O
of	O
binding	O
the	O
prototypical	O
form	O
of	O
the	O
transcription	B-protein
factor	I-protein
nuclear	O
factor	O
kappa	O
B	O
(	O
NF-kappa	B-protein
B	I-protein
)	O
present	O
in	O
many	O
cell	O
types	O
,	O
including	O
T	B-cell_type
lymphocytes	I-cell_type
.	O

Tat	B-protein
transactivation	O
mediated	O
by	O
the	O
kappa	B-DNA
B	I-DNA
domain	I-DNA
is	O
sufficient	O
to	O
allow	O
replication	O
of	O
TAR	B-DNA
-deleted	O
mutant	O
HIV-1	O
in	O
astrocytes	B-cell_type
.	O

The	O
present	O
study	O
demonstrates	O
the	O
existence	O
of	O
kappa	B-protein
B-specific	I-protein
binding	I-protein
factors	I-protein
present	O
in	O
human	B-cell_type
glial	I-cell_type
astrocytes	I-cell_type
that	O
differ	O
from	O
prototypical	O
NF-kappa	B-protein
B	I-protein
.	O

The	O
novel	O
astrocyte-derived	O
kappa	O
B-binding	O
activity	O
is	O
retained	O
on	O
an	O
HIV-1	O
Tat	B-protein
affinity	O
column	O
,	O
while	O
prototypical	O
NF-kappa	B-protein
B	I-protein
from	O
Jurkat	B-cell_line
T	I-cell_line
cells	I-cell_line
is	O
not	O
.	O

In	O
vitro	O
transcription	O
studies	O
demonstrate	O
that	O
astrocyte-derived	B-protein
kappa	I-protein
B-binding	I-protein
factors	I-protein
activate	O
transcription	O
of	O
the	O
HIV-1	B-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
and	O
that	O
this	O
activation	O
is	O
dependent	O
on	O
the	O
kappa	B-DNA
B	I-DNA
domain	I-DNA
.	O

Moreover	O
,	O
TAR	B-DNA
-independent	O
transactivation	O
of	O
HIV-1	O
transcription	O
is	O
reproduced	O
in	O
vitro	O
in	O
an	O
astrocyte	O
factor-dependent	O
manner	O
which	O
correlates	O
with	O
kappa	O
B-binding	O
activity	O
.	O

The	O
importance	O
of	O
the	O
central	B-protein
nervous	I-protein
system-enriched	I-protein
kappa	I-protein
B	I-protein
transcription	B-protein
factor	I-protein
in	O
the	O
regulation	O
of	O
HIV-1	O
expression	O
is	O
discussed	O
.	O

Human	B-protein
interleukin-13	I-protein
activates	O
the	O
interleukin-4-dependent	B-protein
transcription	I-protein
factor	I-protein
NF-IL4	B-protein
sharing	O
a	O
DNA	B-protein
binding	I-protein
motif	I-protein
with	O
an	O
interferon-gamma-induced	B-protein
nuclear	I-protein
binding	I-protein
factor	I-protein
.	O

The	O
effects	O
of	O
interleukin-13	B-protein
(	O
IL-13	B-protein
)	O
and	O
interleukin-4	B-protein
(	O
IL-4	B-protein
)	O
on	O
cellular	O
functions	O
were	O
shown	O
to	O
be	O
quite	O
similar	O
.	O

We	O
provide	O
evidence	O
that	O
in	O
monocytes	O
as	O
well	O
as	O
in	O
T	B-cell_type
lymphocytes	I-cell_type
both	O
IL-4	B-protein
and	O
IL-13	B-protein
activate	O
the	O
same	O
recently	O
identified	O
transcription	B-protein
factor	I-protein
NF-IL4	B-protein
which	O
binds	O
to	O
the	O
specific	B-DNA
responsive	I-DNA
element	I-DNA
IL-4RE	I-DNA
.	O

In	O
addition	O
,	O
we	O
show	O
that	O
a	O
nuclear	B-protein
factor	I-protein
activated	O
by	O
interferon-gamma	O
also	O
interacts	O
with	O
the	O
IL-4RE	B-DNA
.	O

It	O
differs	O
from	O
NF-IL4	B-protein
in	O
the	O
electrophoretic	O
mobility	O
of	O
the	O
complex	O
with	O
DNA	O
,	O
in	O
its	O
DNA-binding	O
specificity	O
and	O
in	O
the	O
proteins	O
interacting	O
with	O
the	O
DNA	B-DNA
sequence	I-DNA
.	O

Sensitivity	O
against	O
various	O
enzyme	O
inhibitors	O
suggests	O
that	O
components	O
of	O
the	O
signal	O
transduction	O
pathway	O
are	O
shared	O
by	O
all	O
three	O
cytokines	B-protein
.	O

Encephalomyocarditis	O
virus	O
internal	O
ribosomal	O
entry	O
site	O
RNA-protein	O
interactions	O
.	O

Translational	O
initiation	O
of	O
encephalomyocarditis	B-RNA
virus	I-RNA
(	I-RNA
EMCV	I-RNA
)	I-RNA
mRNA	I-RNA
occurs	O
by	O
ribosomal	O
entry	O
into	O
the	O
5	B-DNA
'	I-DNA
nontranslated	I-DNA
region	I-DNA
of	O
the	O
EMCV	B-RNA
mRNA	I-RNA
,	O
rather	O
than	O
by	O
ribosomal	O
scanning	O
.	O

Internal	O
ribosomal	O
binding	O
requires	O
a	O
cis-acting	B-DNA
element	I-DNA
termed	O
the	O
internal	B-DNA
ribosomal	I-DNA
entry	I-DNA
site	I-DNA
(	O
IRES	B-DNA
)	O
.	O

IRES	B-DNA
elements	I-DNA
have	O
been	O
proposed	O
to	O
be	O
involved	O
in	O
the	O
translation	O
of	O
picornavirus	B-RNA
mRNAs	I-RNA
and	O
some	O
cellular	B-RNA
mRNAs	I-RNA
.	O

Internal	O
ribosome	O
binding	O
likely	O
requires	O
the	O
interaction	O
of	O
trans-acting	B-protein
factors	I-protein
that	O
recognize	O
both	O
the	O
mRNA	B-RNA
and	O
the	O
ribosomal	B-protein
complex	I-protein
.	O

Five	O
cellular	B-protein
proteins	I-protein
(	O
p52	B-protein
,	O
p57	B-protein
,	O
p70	B-protein
,	O
p72	B-protein
,	O
and	O
p100	B-protein
)	O
cross-link	O
the	O
EMCV	O
IRES	B-DNA
or	O
fragments	O
of	O
the	O
IRES	B-DNA
.	O

For	O
one	O
of	O
these	O
proteins	O
,	O
p57	B-protein
,	O
binding	O
to	O
the	O
IRES	B-DNA
correlates	O
with	O
translation	O
.	O

Recently	O
,	O
p57	B-protein
was	O
identified	O
to	O
be	O
very	O
similar	O
,	O
if	O
not	O
identical	O
,	O
to	O
polypyrimidine	B-protein
tract-binding	I-protein
protein	I-protein
.	O

On	O
the	O
basis	O
of	O
cross-linking	O
results	O
with	O
21	O
different	O
EMCV	B-DNA
IRES	I-DNA
fragments	I-DNA
and	O
cytoplasmic	O
HeLa	O
extract	O
or	O
rabbit	O
reticulocyte	O
lysate	O
as	O
the	O
source	O
of	O
polypeptides	O
,	O
consensus	B-DNA
binding	I-DNA
sites	I-DNA
for	O
p52	B-protein
,	O
p57	B-protein
,	O
p70	B-protein
,	O
and	O
p100	B-protein
are	O
proposed	O
.	O

It	O
is	O
suggested	O
that	O
each	O
of	O
these	O
proteins	O
recognizes	O
primarily	O
a	O
structural	O
feature	O
of	O
the	O
RNA	O
rather	O
than	O
a	O
specific	O
sequence	O
.	O

A	O
novel	O
heterodimerization	B-protein
partner	I-protein
for	O
thyroid	B-protein
hormone	I-protein
receptor	I-protein
.	O

Peroxisome	B-protein
proliferator-activated	I-protein
receptor	I-protein
.	O

Retinoid-like	B-protein
receptors	I-protein
play	O
a	O
central	O
role	O
in	O
hormonal	O
responses	O
by	O
forming	O
heterodimers	B-protein
with	O
other	O
nuclear	B-protein
hormone	I-protein
receptors	I-protein
.	O

In	O
this	O
study	O
we	O
have	O
identified	O
the	O
peroxisome	B-protein
proliferator-activated	I-protein
receptor	I-protein
(	O
PPAR	B-protein
)	O
as	O
a	O
new	O
thyroid	B-protein
hormone	I-protein
receptor	I-protein
(	I-protein
THR	I-protein
)	I-protein
auxiliary	I-protein
nuclear	I-protein
protein	I-protein
,	O
heterodimerizing	O
with	O
THR	B-protein
in	O
solution	O
.	O

Although	O
these	O
heterodimers	B-protein
do	O
not	O
recognize	O
a	O
classical	O
thyroid	B-DNA
hormone	I-DNA
response	I-DNA
element	I-DNA
(	O
TRE	B-DNA
)	O
characterized	O
by	O
direct	O
repeat	O
separated	O
by	O
four	O
nucleotides	O
(	O
DR+4	B-DNA
)	O
,	O
PPAR	B-protein
behaves	O
as	O
a	O
dominant	O
negative	O
regulator	O
of	O
thyroid	O
hormone	O
(	O
TH	O
)	O
action	O
.	O

However	O
,	O
a	O
TH-dependent	O
positive	O
effect	O
is	O
elicited	O
by	O
selective	O
interaction	O
of	O
the	O
THR	B-protein
beta-PPAR	I-protein
but	O
not	O
the	O
THR	B-protein
alpha-PPAR	I-protein
heterodimer	I-protein
with	O
a	O
novel	O
TRE	B-DNA
(	O
DR+2	B-DNA
)	O
.	O

The	O
critical	O
region	O
of	O
THR	B-protein
beta	O
was	O
mapped	O
to	O
3	O
amino	O
acids	O
in	O
the	O
distal	B-protein
box	I-protein
of	O
the	O
DNA	B-protein
binding	I-protein
domain	I-protein
.	O

Hence	O
,	O
PPAR	B-protein
can	O
positively	O
or	O
negatively	O
influence	O
TH	O
action	O
depending	O
on	O
TRE	B-DNA
structure	O
and	O
THR	B-protein
isotype	I-protein
.	O

Comparison	O
of	O
retinoic	O
acid	O
and	O
phorbol	O
myristate	O
acetate	O
as	O
inducers	O
of	O
monocytic	O
differentiation	O
.	O

Several	O
human	B-cell_line
myeloid	I-cell_line
leukemia	I-cell_line
cell	I-cell_line
lines	I-cell_line
growing	O
in	O
vitro	O
can	O
be	O
induced	O
to	O
differentiate	O
to	O
more	O
mature	O
monocyte/macrophage-like	B-cell_type
cells	I-cell_type
by	O
treatment	O
with	O
protein	B-protein
kinase	I-protein
C	I-protein
-activating	O
phorbol	O
esters	O
,	O
such	O
as	O
PMA	O
.	O

In	O
addition	O
to	O
PMA	O
,	O
cells	O
of	O
the	O
THP-1	B-cell_line
myeloid	I-cell_line
leukemia	I-cell_line
cell	I-cell_line
line	I-cell_line
acquire	O
macrophage-like	O
characteristics	O
after	O
treatment	O
with	O
all-trans	O
retinoic	O
acid	O
(	O
RA	O
)	O
.	O

To	O
analyze	O
the	O
signal	O
transduction	O
mechanisms	O
induced	O
by	O
RA	O
,	O
we	O
first	O
compared	O
the	O
effects	O
of	O
PMA	O
and	O
RA	O
on	O
the	O
expression	O
of	O
genes	O
which	O
are	O
known	O
to	O
be	O
regulated	O
during	O
monocytic	O
differentiation	O
.	O

Both	O
RA	O
and	O
PMA	O
effectively	O
down-regulated	O
c-myc	B-DNA
expression	O
,	O
while	O
c-myb	B-DNA
expression	O
decreased	O
only	O
after	O
PMA	O
treatment	O
.	O

Expression	O
of	O
the	O
beta	B-DNA
2-integrin	I-DNA
genes	I-DNA
,	O
CD11a	B-DNA
and	O
CD11b	B-DNA
,	O
was	O
clearly	O
increased	O
after	O
both	O
of	O
these	O
treatments	O
.	O

Their	O
effects	O
on	O
the	O
src-family	B-DNA
tyrosine	I-DNA
kinase	I-DNA
genes	I-DNA
were	O
different	O
:	O
hck	B-DNA
expression	O
was	O
similarly	O
induced	O
by	O
these	O
agents	O
but	O
lyn	O
expression	O
was	O
stronger	O
and	O
more	O
rapid	O
after	O
RA	O
treatment	O
.	O

RA	O
also	O
enhanced	O
lyn	B-RNA
mRNA	I-RNA
production	O
rapidly	O
in	O
HL-60	B-cell_line
,	O
indicating	O
that	O
the	O
activation	O
of	O
lyn	B-DNA
gene	I-DNA
expression	O
is	O
common	O
in	O
monocytic	O
and	O
granulocytic	O
maturation	O
of	O
myeloid	B-cell_type
leukemia	I-cell_type
cells	I-cell_type
.	O

To	O
examine	O
whether	O
the	O
AP-1	B-DNA
enhancer	I-DNA
activity	O
is	O
involved	O
in	O
RA-induced	O
monocytic	O
differentiation	O
,	O
THP-1	B-cell_line
cells	I-cell_line
were	O
transiently	O
transfected	O
with	O
a	O
chloramphenicol	B-DNA
acetyl	I-DNA
transferase	I-DNA
(	I-DNA
CAT	I-DNA
)	I-DNA
-reporter	I-DNA
gene	I-DNA
containing	O
5	O
copies	O
of	O
the	O
AP-1	B-DNA
binding	I-DNA
sites	I-DNA
.	O

In	O
contrast	O
to	O
PMA	O
,	O
RA	O
did	O
not	O
induce	O
any	O
CAT	B-protein
activity	O
in	O
these	O
cells	O
,	O
thus	O
suggesting	O
that	O
the	O
RA-induced	O
changes	O
in	O
the	O
expression	O
of	O
those	O
genes	O
described	O
above	O
were	O
not	O
dependent	O
on	O
the	O
AP-1	B-DNA
enhancer	I-DNA
activity	O
.	O

An	O
active	O
v-abl	B-protein
protein	I-protein
tyrosine	I-protein
kinase	I-protein
blocks	O
immunoglobulin	B-DNA
light-chain	I-DNA
gene	I-DNA
rearrangement	O
.	O

Lymphoid	B-cell_type
cells	I-cell_type
transformed	O
by	O
Abelson	O
murine	O
leukemia	O
virus	O
have	O
provided	O
one	O
of	O
the	O
classic	O
models	O
for	O
study	O
of	O
early	O
B-cell	O
development	O
and	O
immunoglobulin	B-protein
rearrangement	O
.	O

Most	O
of	O
these	O
cells	O
have	O
rearranged	O
their	O
heavy-chain	B-DNA
locus	I-DNA
but	O
not	O
their	O
light	B-DNA
chain	I-DNA
genes	I-DNA
,	O
suggesting	O
that	O
an	O
active	O
v-abl	B-protein
protein	I-protein
interferes	O
with	O
this	O
differentiation	O
step	O
.	O

To	O
test	O
this	O
hypothesis	O
,	O
light-chain	B-DNA
gene	I-DNA
structure	I-DNA
was	O
examined	O
in	O
pre-B	B-cell_line
cells	I-cell_line
transformed	O
by	O
temperature-sensitive	O
mutants	O
of	O
the	O
Abelson	O
virus	O
and	O
in	O
derivatives	O
that	O
survive	O
at	O
the	O
nonpermissive	O
temperature	O
because	O
they	O
express	O
a	O
human	B-DNA
BCL-2	I-DNA
gene	I-DNA
.	O

Our	O
studies	O
reveal	O
that	O
inactivation	O
of	O
the	O
v-abl	B-protein
protein	I-protein
tyrosine	I-protein
kinase	I-protein
triggers	O
high-frequency	O
rearrangement	O
of	O
kappa	B-DNA
and	I-DNA
lambda	I-DNA
light-chain	I-DNA
genes	I-DNA
.	O

These	O
events	O
are	O
accompanied	O
by	O
marked	O
increases	O
in	O
the	O
expression	O
of	O
RAG-1	B-RNA
and	I-RNA
RAG-2	I-RNA
RNAs	I-RNA
.	O

These	O
increases	O
occur	O
in	O
the	O
absence	O
of	O
protein	O
synthesis	O
but	O
are	O
dependent	O
on	O
inactivation	O
of	O
the	O
v-abl	B-protein
protein	I-protein
tyrosine	I-protein
kinase	I-protein
.	O

As	O
documented	O
in	O
the	O
accompanying	O
paper	O
(	O
Klug	O
et	O
al.	O
,	O
this	O
issue	O
)	O
,	O
an	O
active	O
v-abl	B-protein
protein	I-protein
also	O
suppresses	O
the	O
activity	O
of	O
NF-kappa	B-protein
B/rel	I-protein
and	O
expression	O
controlled	O
by	O
the	O
kappa	B-DNA
intron	I-DNA
enhancer	I-DNA
.	O

Together	O
these	O
data	O
demonstrate	O
that	O
the	O
v-abl	B-protein
protein	I-protein
specifically	O
interferes	O
with	O
light-chain	B-DNA
gene	I-DNA
rearrangement	O
by	O
suppressing	O
at	O
least	O
two	O
pathways	O
essential	O
for	O
this	O
stage	O
of	O
B-cell	B-cell_type
differentiation	O
and	O
suggest	O
that	O
tyrosine	O
phosphorylation	O
is	O
important	O
in	O
regulating	O
RAG	B-DNA
gene	I-DNA
expression	O
.	O

Calcium	O
signalling	O
in	O
T	B-cell_type
cells	I-cell_type
stimulated	O
by	O
a	O
cyclophilin	B-protein
B-binding	I-protein
protein	I-protein
.	O

The	O
immunosuppressant	O
drug	O
cyclosporin	O
A	O
blocks	O
a	O
calcium-dependent	O
signal	O
from	O
the	O
T-cell	B-protein
receptor	I-protein
(	O
TCR	B-protein
)	O
that	O
normally	O
leads	O
to	O
T-cell	O
activation	O
.	O

When	O
bound	O
to	O
cyclophilin	B-protein
,	O
cyclosporin	O
A	O
binds	O
and	O
inactivates	O
the	O
key	O
signalling	O
intermediate	O
calcineurin	B-protein
.	O

To	O
identify	O
potential	O
cellular	O
homologues	O
of	O
cyclosporin	O
A	O
that	O
might	O
regulate	O
calcium	O
signalling	O
,	O
we	O
have	O
cloned	O
human	O
genes	O
encoding	O
cyclophilin	B-protein
B-binding-proteins	I-protein
using	O
the	O
yeast	O
two-hybrid	O
system	O
.	O

One	O
gene	O
product	O
,	O
when	O
overexpressed	O
in	O
Jurkat	B-cell_line
T	I-cell_line
cells	I-cell_line
,	O
specifically	O
induced	O
transcription	O
from	O
the	O
interleukin-2	B-DNA
enhancer	I-DNA
,	O
by	O
activating	O
the	O
T-cell-specific	B-protein
transcription	I-protein
factors	I-protein
NF-AT	B-protein
and	O
NF-IL2A	B-protein
.	O

This	O
protein	O
,	O
termed	O
calcium-signal	B-protein
modulating	I-protein
cyclophilin	I-protein
ligand	I-protein
(	O
CAML	B-protein
)	O
,	O
acts	O
downstream	O
of	O
the	O
TCR	B-protein
and	O
upstream	O
of	O
calcineurin	B-protein
by	O
causing	O
an	O
influx	O
of	O
calcium	O
.	O

CAML	B-protein
appears	O
to	O
be	O
a	O
new	O
participant	O
in	O
the	O
calcium-signal	O
transduction	O
pathway	O
,	O
implicating	O
cyclophilin	B-protein
B	I-protein
in	O
calcium	O
signalling	O
,	O
even	O
in	O
the	O
absence	O
of	O
cyclosporin	O
.	O

Expression	O
and	O
genomic	O
configuration	O
of	O
GM-CSF	B-protein
,	O
IL-3	B-protein
,	O
M-CSF	B-protein
receptor	I-protein
(	O
C-FMS	B-protein
)	O
,	O
early	B-DNA
growth	I-DNA
response	I-DNA
gene-1	I-DNA
(	O
EGR-1	B-DNA
)	O
and	O
M-CSF	B-DNA
genes	I-DNA
in	O
primary	O
myelodysplastic	O
syndromes	O
.	O

Peripheral	O
blood	O
mononuclear	O
cells	O
from	O
seventeen	O
patients	O
with	O
primary	O
myelodysplastic	O
syndromes	O
(	O
MDS	O
)	O
in	O
advanced	O
stage	O
were	O
enriched	O
for	O
blasts	B-cell_type
and	O
tested	O
for	O
(	O
1	O
)	O
karyotype	O
,	O
(	O
2	O
)	O
genomic	O
configuration	O
and	O
(	O
3	O
)	O
expression	O
of	O
IL-3	B-DNA
,	I-DNA
GM-CSF	I-DNA
,	I-DNA
FMS	I-DNA
and	I-DNA
EGR-1	I-DNA
genes	I-DNA
which	O
are	O
all	O
located	O
on	O
the	O
long	B-DNA
arm	I-DNA
of	I-DNA
chromosome	I-DNA
5	I-DNA
.	O

The	O
expression	O
of	O
the	O
M-CSF	B-DNA
gene	I-DNA
,	O
that	O
has	O
been	O
recently	O
reassigned	O
to	O
the	O
short	B-DNA
arm	I-DNA
of	I-DNA
chromosome	I-DNA
1	I-DNA
(	O
lp	B-DNA
)	O
,	O
was	O
also	O
investigated	O
.	O

Aims	O
of	O
the	O
study	O
were	O
to	O
(	O
1	O
)	O
assess	O
the	O
potential	O
role	O
of	O
the	O
expression	O
of	O
these	O
genes	O
in	O
the	O
maintenance	O
and	O
expansion	O
of	O
the	O
neoplastic	B-cell_line
clones	I-cell_line
and	O
(	O
2	O
)	O
search	O
for	O
constitutional	O
losses	O
or	O
rearrangements	O
of	O
one	O
allele	B-DNA
followed	O
by	O
a	O
deletion	O
of	O
the	O
second	O
allele	B-DNA
of	O
the	O
same	O
genes	O
in	O
the	O
leukemic	B-cell_type
cells	I-cell_type
.	O

The	O
latter	O
issue	O
was	O
investigated	O
by	O
comparing	O
,	O
in	O
8	O
cases	O
,	O
constitutive	B-DNA
DNA	I-DNA
from	O
skin	B-cell_type
fibroblasts	I-cell_type
with	O
leukemic	B-DNA
DNA	I-DNA
.	O

Eleven	O
of	O
the	O
17	O
patients	O
had	O
abnormal	O
karyotypes	O
.	O

The	O
M-CSF	B-DNA
gene	I-DNA
was	O
expressed	O
in	O
6	O
cases	O
and	O
the	O
FMS	B-DNA
and	O
the	O
EGR-1	B-DNA
genes	I-DNA
were	O
expressed	O
in	O
2	O
of	O
the	O
latter	O
cases	O
.	O

An	O
autocrine	O
mechanism	O
of	O
growth	O
could	O
be	O
hypothesized	O
only	O
for	O
the	O
2	O
patients	O
whose	O
cells	O
expressed	O
both	O
the	O
M-CSF	B-DNA
and	I-DNA
FMS	I-DNA
genes	I-DNA
.	O

No	O
germline	O
changes	O
or	O
rearrangements	O
were	O
observed	O
in	O
any	O
of	O
the	O
genes	O
studied	O
.	O

Thus	O
,	O
deregulation	O
of	O
genes	O
encoding	O
for	O
certain	O
hemopoietic	B-protein
growth	I-protein
factors	I-protein
or	O
receptors	O
does	O
not	O
seem	O
to	O
represent	O
a	O
major	O
mechanism	O
of	O
MDS	O
progression	O
.	O

A	O
novel	O
human	B-DNA
homeobox	I-DNA
gene	I-DNA
distantly	O
related	O
to	O
proboscipedia	B-DNA
is	O
expressed	O
in	O
lymphoid	O
and	O
pancreatic	O
tissues	O
.	O

A	O
novel	O
human	B-DNA
homeobox	I-DNA
gene	I-DNA
,	O
HB9	B-DNA
,	O
was	O
isolated	O
from	O
a	O
cDNA	B-DNA
library	I-DNA
prepared	O
from	O
in	O
vitro	B-cell_type
stimulated	I-cell_type
human	I-cell_type
tonsil	I-cell_type
B	I-cell_type
lymphocytes	I-cell_type
and	O
from	O
a	O
human	B-DNA
genomic	I-DNA
library	I-DNA
.	O

The	O
HB9	B-DNA
gene	I-DNA
is	O
composed	O
of	O
3	O
exons	B-DNA
spread	O
over	O
6	O
kilobases	O
of	O
DNA	O
.	O

An	O
open	B-DNA
reading	I-DNA
frame	I-DNA
of	O
1206	O
nucleotides	O
is	O
in	O
frame	O
with	O
a	O
diverged	B-DNA
homeodomain	I-DNA
.	O

The	O
predicted	O
HB9	B-protein
protein	I-protein
has	O
a	O
molecular	O
mass	O
of	O
41	O
kilodaltons	O
and	O
is	O
enriched	O
for	O
alanine	O
,	O
glycine	O
,	O
and	O
leucine	O
.	O

The	O
HB9	B-DNA
homeodomain	I-DNA
is	O
most	O
similar	O
to	O
that	O
of	O
the	O
Drosophila	B-DNA
melanogaster	I-DNA
homeobox	I-DNA
gene	I-DNA
proboscipedia	B-DNA
.	O

Northern	O
blot	O
analysis	O
of	O
poly	B-RNA
(	I-RNA
A	I-RNA
)	I-RNA
RNA	I-RNA
purified	O
from	O
the	O
human	B-cell_line
B	I-cell_line
cell	I-cell_line
line	I-cell_line
RPMI	I-cell_line
8226	I-cell_line
and	O
from	O
activated	B-cell_type
T	I-cell_type
cells	I-cell_type
revealed	O
a	O
major	B-RNA
mRNA	I-RNA
transcript	I-RNA
of	O
2.2	O
kilobases	O
.	O

Similar	O
analysis	O
of	O
poly	B-RNA
(	I-RNA
A	I-RNA
)	I-RNA
RNA	I-RNA
from	O
a	O
variety	O
of	O
adult	O
tissues	O
demonstrated	O
HB9	B-DNA
transcripts	O
in	O
pancreas	O
,	O
small	O
intestine	O
,	O
and	O
colon	O
.	O

Reverse	O
transcriptase-polymerase	O
chain	O
reaction	O
was	O
used	O
to	O
examine	O
HB9	B-RNA
RNA	I-RNA
transcripts	I-RNA
in	O
hematopoietic	B-cell_line
cell	I-cell_line
lines	I-cell_line
.	O

HB9	B-RNA
RNA	I-RNA
transcripts	I-RNA
were	O
most	O
prevalent	O
in	O
several	O
human	B-cell_line
B	I-cell_line
cell	I-cell_line
lines	I-cell_line
and	O
K562	B-cell_line
cells	I-cell_line
.	O

In	O
addition	O
,	O
transcripts	O
were	O
detected	O
in	O
RNA	O
prepared	O
from	O
tonsil	B-cell_type
B	I-cell_type
cells	I-cell_type
and	O
in	O
situ	O
hybridization	O
studies	O
localized	O
them	O
in	O
the	O
germinal	O
center	O
region	O
of	O
adult	O
tonsil	O
.	O

These	O
findings	O
suggest	O
the	O
involvement	O
of	O
HB9	B-DNA
in	O
regulating	O
gene	O
transcription	O
in	O
lymphoid	O
and	O
pancreatic	O
tissues	O
.	O

Human	B-protein
immunodeficiency	I-protein
virus	I-protein
type	I-protein
1	I-protein
Tat	I-protein
upregulates	O
interleukin-2	B-protein
secretion	O
in	O
activated	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O

Dysregulation	O
of	O
cytokines	B-protein
secreted	O
by	O
T	B-cell_type
cells	I-cell_type
may	O
play	O
an	O
important	O
role	O
in	O
the	O
pathogenesis	O
of	O
AIDS	O
.	O

To	O
investigate	O
the	O
effects	O
of	O
human	B-protein
immunodeficiency	I-protein
virus	I-protein
type	I-protein
1	I-protein
(	I-protein
HIV-1	I-protein
)	I-protein
Tat	I-protein
on	O
interleukin-2	B-protein
(	O
IL-2	B-protein
)	O
expression	O
,	O
we	O
used	O
IL-2	B-DNA
promoter-chloramphenicol	I-DNA
acetyltransferase	I-DNA
constructs	I-DNA
and	O
IL-2-secreting	B-cell_line
Jurkat	I-cell_line
T	I-cell_line
cells	I-cell_line
as	O
a	O
model	O
system	O
.	O

Transient	O
expression	O
of	O
HIV-1	B-protein
Tat	I-protein
induced	O
a	O
five-	O
to	O
eightfold	O
increase	O
in	O
IL-2	B-DNA
promoter	I-DNA
activity	O
in	O
Jurkat	B-cell_line
T	I-cell_line
cells	I-cell_line
stimulated	O
with	O
phytohemagglutinin	B-protein
and	O
phorbol	O
myristate	O
acetate	O
.	O

IL-2	B-protein
secretion	O
was	O
increased	O
more	O
than	O
twofold	O
in	O
both	O
Jurkat	B-cell_line
T	I-cell_line
cells	I-cell_line
and	O
primary	B-cell_line
T	I-cell_line
cells	I-cell_line
stimulated	O
by	O
extracellular	B-protein
HIV-1	I-protein
Tat	I-protein
protein	I-protein
.	O

Analysis	O
of	O
mRNA	B-RNA
suggested	O
that	O
Tat	O
exerts	O
its	O
effect	O
on	O
IL-2	B-protein
primarily	O
at	O
the	O
transcriptional	O
level	O
.	O

The	O
NF-kappa	B-DNA
B	I-DNA
site	I-DNA
at	O
positions	O
-206	B-DNA
to	I-DNA
-195	I-DNA
of	O
the	O
IL-2	B-DNA
promoter	I-DNA
was	O
required	O
but	O
not	O
sufficient	O
for	O
the	O
Tat	B-protein
effect	O
.	O

The	O
Tat	B-protein
-mediated	O
increase	O
in	O
IL-2	B-DNA
promoter	I-DNA
activity	O
could	O
selectively	O
be	O
blocked	O
by	O
antisense	O
tat	O
or-unlike	O
the	O
analogous	O
effect	O
of	O
human	B-protein
T-cell	I-protein
lymphotropic	I-protein
virus	I-protein
type	I-protein
1	I-protein
Tax	I-protein
-by	O
cyclosporin	O
A	O
.	O

The	O
observed	O
increase	O
in	O
IL-2	B-protein
levels	O
might	O
facilitate	O
virus	O
spread	O
from	O
or	O
to	O
T	B-cell_type
cells	I-cell_type
.	O

Furthermore	O
,	O
it	O
might	O
contribute	O
to	O
the	O
hypergammaglobulinemia	O
or	O
,	O
together	O
with	O
other	O
cytokines	B-protein
found	O
to	O
be	O
dysregulated	O
,	O
the	O
T-helper	O
cell	O
dysfunctions	O
observed	O
in	O
AIDS	O
patients	O
.	O

Activation	O
of	O
nuclear	B-protein
factor	I-protein
kappa	I-protein
B	I-protein
in	O
human	B-cell_type
lymphoblastoid	I-cell_type
cells	I-cell_type
by	O
low-dose	O
ionizing	O
radiation	O
.	O

Nuclear	B-protein
factor	I-protein
kappa	I-protein
B	I-protein
(	O
NF-kappa	B-protein
B	I-protein
)	O
is	O
a	O
pleiotropic	B-protein
transcription	I-protein
factor	I-protein
which	O
is	O
involved	O
in	O
the	O
transcriptional	O
regulation	O
of	O
several	O
specific	O
genes	O
.	O

Recent	O
reports	O
demonstrated	O
that	O
ionizing	O
radiation	O
in	O
the	O
dose	O
range	O
of	O
2-50	O
Gy	O
results	O
in	O
expression	O
of	O
NF-kappa	B-protein
B	I-protein
in	O
human	B-cell_line
KG-1	I-cell_line
myeloid	I-cell_line
leukemia	I-cell_line
cells	I-cell_line
and	O
human	B-cell_type
B-lymphocyte	I-cell_type
precursor	I-cell_type
cells	I-cell_type
;	O
the	O
precise	O
mechanism	O
involved	O
and	O
the	O
significance	O
are	O
not	O
yet	O
known	O
.	O

The	O
present	O
report	O
demonstrates	O
that	O
even	O
lower	O
doses	O
of	O
ionizing	O
radiation	O
,	O
0.25-2.0	O
Gy	O
,	O
are	O
capable	O
of	O
inducing	O
expression	O
of	O
NF-kappa	B-protein
B	I-protein
in	O
EBV-transformed	B-cell_line
244B	I-cell_line
human	I-cell_line
lymphoblastoid	I-cell_line
cells	I-cell_line
.	O

These	O
results	O
are	O
in	O
a	O
dose	O
range	O
where	O
the	O
viability	O
of	O
the	O
cells	O
remains	O
very	O
high	O
.	O

After	O
exposure	O
to	O
137Cs	O
gamma	O
rays	O
at	O
a	O
dose	O
rate	O
of	O
1.17	O
Gy/min	O
,	O
a	O
maximum	O
in	O
expression	O
of	O
NF-kappa	B-protein
B	I-protein
was	O
seen	O
at	O
8	O
h	O
after	O
a	O
0.5-Gy	O
exposure	O
.	O

Time-course	O
studies	O
revealed	O
a	O
biphasic	O
time-dependent	O
expression	O
after	O
0.5-	O
,	O
1-	O
and	O
2-Gy	O
exposures	O
.	O

However	O
,	O
for	O
each	O
time	O
examined	O
,	O
the	O
expression	O
of	O
NF-kappa	B-protein
B	I-protein
was	O
maximum	O
after	O
the	O
0.5-Gy	O
exposure	O
.	O

The	O
expression	O
of	O
the	O
p50	B-protein
and	I-protein
p65	I-protein
NF-kappa	I-protein
B	I-protein
subunits	I-protein
was	O
also	O
shown	O
to	O
be	O
regulated	O
differentially	O
after	O
exposures	O
to	O
1.0	O
and	O
2.0	O
Gy	O
.	O

Alternative	O
splicing	O
of	O
RNA	B-RNA
transcripts	I-RNA
encoded	O
by	O
the	O
murine	B-DNA
p105	I-DNA
NF-kappa	I-DNA
B	I-DNA
gene	I-DNA
generates	O
I	B-protein
kappa	I-protein
B	I-protein
gamma	I-protein
isoforms	I-protein
with	O
different	O
inhibitory	O
activities	O
.	O

The	O
gene	O
encoding	O
the	O
105-kDa	B-protein
protein	I-protein
(	I-protein
p105	I-protein
)	I-protein
precursor	I-protein
of	O
the	O
p50	B-protein
subunit	O
of	O
transcription	O
factor	O
NF-kappa	B-protein
B	I-protein
also	O
encodes	O
a	O
p70	B-protein
I	I-protein
kappa	I-protein
B	I-protein
protein	I-protein
,	O
I	B-protein
kappa	I-protein
B	I-protein
gamma	I-protein
,	O
which	O
is	O
identical	O
to	O
the	O
C-terminal	B-protein
607	I-protein
amino	I-protein
acids	I-protein
of	O
p105	B-protein
.	O

Here	O
we	O
show	O
that	O
alternative	O
RNA	O
splicing	O
generates	O
I	B-protein
kappa	I-protein
B	I-protein
gamma	I-protein
isoforms	I-protein
with	O
properties	O
different	O
from	O
those	O
of	O
p70	B-protein
.	O

One	O
63-kDa	B-protein
isoform	I-protein
,	O
termed	O
I	B-protein
kappa	I-protein
B	I-protein
gamma-1	I-protein
,	O
which	O
lacks	O
59	O
amino	O
acids	O
C-terminal	O
to	O
ankyrin	B-protein
repeat	I-protein
7	I-protein
,	O
has	O
a	O
novel	O
35-amino	B-protein
acid	I-protein
C	I-protein
terminus	I-protein
encoded	O
by	O
an	O
alternative	B-DNA
reading	I-DNA
frame	I-DNA
of	O
the	O
p105	B-DNA
gene	I-DNA
.	O

A	O
55-kDa	B-protein
isoform	I-protein
,	O
I	B-protein
kappa	I-protein
B	I-protein
gamma-2	I-protein
,	O
lacks	O
the	O
190	B-protein
C-terminal	I-protein
amino	I-protein
acids	I-protein
of	O
p70	B-protein
I	B-protein
kappa	I-protein
B	I-protein
gamma	I-protein
.	O

In	O
contrast	O
to	O
p70	B-protein
I	B-protein
kappa	I-protein
B	I-protein
gamma	I-protein
,	O
which	O
is	O
a	O
cytoplasmic	B-protein
protein	I-protein
,	O
I	B-protein
kappa	I-protein
B	I-protein
gamma-1	I-protein
is	O
found	O
in	O
both	O
the	O
cytoplasm	O
and	O
nucleus	O
,	O
whereas	O
I	B-protein
kappa	I-protein
B	I-protein
gamma-2	I-protein
is	O
predominantly	O
nuclear	O
.	O

The	O
I	B-protein
kappa	I-protein
B	I-protein
gamma	I-protein
isoforms	I-protein
also	O
display	O
differences	O
in	O
specificity	O
and	O
affinity	O
for	O
Rel/NF-kappa	B-protein
B	I-protein
proteins	I-protein
.	O

While	O
p70	B-protein
I	B-protein
kappa	I-protein
B	I-protein
gamma	I-protein
inhibits	O
p50-	O
,	O
p65-	O
,	O
and	O
c-Rel-mediated	O
transactivation	O
and/or	O
DNA	O
binding	O
,	O
both	O
I	B-protein
kappa	I-protein
B	I-protein
gamma-1	I-protein
and	O
I	B-protein
kappa	I-protein
B	I-protein
gamma-2	I-protein
are	O
specific	O
for	O
p50	B-protein
and	O
have	O
different	O
affinities	O
for	O
this	O
subunit	O
.	O

The	O
absence	O
in	O
I	B-protein
kappa	I-protein
B	I-protein
gamma-1	I-protein
and	O
I	B-protein
kappa	I-protein
B	I-protein
gamma-2	I-protein
of	O
a	O
protein	B-DNA
kinase	I-DNA
A	I-DNA
site	I-DNA
whose	O
phosphorylation	O
modulates	O
p70	B-protein
I	B-protein
kappa	I-protein
B	I-protein
gamma	I-protein
inhibitory	O
activity	O
suggests	O
that	O
alternative	O
RNA	O
splicing	O
may	O
be	O
used	O
to	O
generate	O
I	B-protein
kappa	I-protein
B	I-protein
gamma	I-protein
isoforms	I-protein
that	O
respond	O
differently	O
to	O
intracellular	O
signals	O
.	O

Structure	O
and	O
expression	O
of	O
the	O
human	B-DNA
GATA3	I-DNA
gene	I-DNA
.	O

GATA3	B-protein
,	O
a	O
member	O
of	O
the	O
GATA	B-protein
family	I-protein
that	O
is	O
abundantly	O
expressed	O
in	O
the	O
T-lymphocyte	B-cell_type
lineage	I-cell_type
,	O
is	O
thought	O
to	O
participate	O
in	O
T-cell	B-protein
receptor	I-protein
gene	O
activation	O
through	O
binding	O
to	O
enhancers	B-DNA
.	O

To	O
understand	O
GATA3	B-DNA
gene	I-DNA
regulation	O
,	O
we	O
cloned	O
the	O
human	B-DNA
gene	I-DNA
and	O
the	O
5	B-DNA
'	I-DNA
end	I-DNA
of	O
the	O
mouse	B-DNA
GATA3	I-DNA
gene	I-DNA
.	O

We	O
show	O
that	O
the	O
human	B-DNA
GATA3	I-DNA
gene	I-DNA
contains	O
six	O
exons	B-DNA
distributed	O
over	O
17	O
kb	O
of	O
DNA	O
.	O

The	O
two	O
human	B-protein
GATA3	I-protein
zinc	I-protein
fingers	I-protein
are	O
encoded	O
by	O
two	O
separate	O
exons	B-DNA
highly	O
conserved	O
with	O
those	O
of	O
GATA1	B-protein
,	O
but	O
no	O
other	O
structural	O
homologies	O
between	O
these	O
two	O
genes	O
can	O
be	O
found	O
.	O

The	O
human	B-DNA
and	I-DNA
mouse	I-DNA
GATA3	I-DNA
transcription	I-DNA
units	I-DNA
start	O
at	O
a	O
major	B-DNA
initiation	I-DNA
site	I-DNA
.	O

The	O
promoter	O
sequence	O
analysis	O
of	O
these	O
two	O
genes	O
revealed	O
that	O
they	O
are	O
embedded	O
within	O
a	O
CpG	B-DNA
island	I-DNA
and	O
share	O
structural	O
features	O
often	O
found	O
in	O
the	O
promoters	B-DNA
of	O
housekeeping	B-DNA
genes	I-DNA
.	O

Finally	O
,	O
we	O
show	O
that	O
a	O
DNA	B-DNA
fragment	I-DNA
containing	O
the	O
human	B-DNA
GATA3	I-DNA
transcription	I-DNA
unit	I-DNA
,	O
3	B-DNA
kb	I-DNA
upstream	I-DNA
from	O
the	O
initiation	B-DNA
site	I-DNA
and	O
4	B-DNA
kb	I-DNA
downstream	I-DNA
from	O
the	O
polyadenylation	B-DNA
site	I-DNA
,	O
displays	O
T-cell	O
specificity	O
.	O

Characterization	O
of	O
the	O
human	B-DNA
gene	I-DNA
encoding	O
LBR	B-protein
,	O
an	O
integral	B-protein
protein	I-protein
of	O
the	O
nuclear	O
envelope	O
inner	O
membrane	O
.	O

We	O
have	O
characterized	O
the	O
human	B-DNA
gene	I-DNA
encoding	O
LBR	B-protein
,	O
an	O
integral	B-protein
protein	I-protein
of	O
the	O
nuclear	O
envelope	O
inner	O
membrane	O
.	O

Restriction	O
mapping	O
shows	O
that	O
the	O
transcription	B-DNA
unit	I-DNA
spans	O
approximately	O
35	O
kilobases	O
.	O

A	O
transcription	O
start	O
site	O
is	O
located	O
approximately	O
4	O
kilobases	O
5	O
'	O
to	O
the	O
translation	B-DNA
initiation	I-DNA
codon	I-DNA
,	O
and	O
an	O
RNA	O
splice	O
of	O
3863	O
bases	O
occurs	O
in	O
the	O
5'-untranslated	B-DNA
region	I-DNA
to	O
generate	O
mature	B-RNA
HeLa	I-RNA
cell	I-RNA
mRNA	I-RNA
.	O

5	O
'	O
to	O
the	O
identified	O
transcription	B-DNA
start	I-DNA
site	I-DNA
are	O
two	O
CCAAT	B-DNA
sequences	I-DNA
and	O
potential	B-DNA
recognition	I-DNA
sites	I-DNA
for	O
several	O
transcription	B-protein
factors	I-protein
including	O
Sp1	B-protein
,	O
AP-1	B-protein
,	O
AP-2	B-protein
,	O
and	O
NF-kB	B-protein
.	O

There	O
are	O
13	O
protein	O
coding	O
exons	B-DNA
in	O
the	O
LBR	B-DNA
gene	I-DNA
.	O

LBR	B-protein
's	O
nucleoplasmic	B-protein
domain	I-protein
is	O
encoded	O
by	O
exons	B-DNA
1-4	I-DNA
,	O
and	O
its	O
hydrophobic	B-protein
domain	I-protein
,	O
with	O
eight	O
putative	O
transmembrane	B-protein
segments	I-protein
,	O
is	O
encoded	O
by	O
exons	B-DNA
5-13	I-DNA
.	O

The	O
hydrophobic	B-protein
domain	I-protein
is	O
homologous	O
to	O
three	O
yeast	O
polypeptides	O
,	O
suggesting	O
that	O
this	O
higher	B-DNA
eukaryotic	I-DNA
gene	I-DNA
could	O
have	O
evolved	O
from	O
recombination	O
between	O
a	O
gene	O
that	O
encoded	O
a	O
soluble	B-protein
nuclear	I-protein
protein	I-protein
and	O
a	O
membrane	B-DNA
protein	I-DNA
gene	I-DNA
similar	O
to	O
those	O
in	O
yeast	O
.	O

These	O
results	O
are	O
the	O
first	O
to	O
demonstrate	O
the	O
structural	O
organization	O
of	O
a	O
vertebrate	B-DNA
gene	I-DNA
encoding	O
an	O
integral	B-protein
membrane	I-protein
protein	I-protein
of	O
the	O
nuclear	O
envelope	O
that	O
may	O
be	O
a	O
member	O
of	O
a	O
family	O
of	O
polypeptides	O
conserved	O
in	O
evolution	O
.	O

Retinoic	O
acid-induced	O
expression	O
of	O
CD38	B-protein
antigen	I-protein
in	O
myeloid	B-cell_type
cells	I-cell_type
is	O
mediated	O
through	O
retinoic	B-protein
acid	I-protein
receptor-alpha	I-protein
.	O

CD38	B-protein
is	O
a	O
leukocyte	B-protein
differentiation	I-protein
antigen	I-protein
that	O
has	O
been	O
thought	O
to	O
be	O
a	O
phenotypic	O
marker	O
of	O
different	O
subpopulations	O
of	O
T-	B-cell_type
and	I-cell_type
B-	I-cell_type
lymphocytes	I-cell_type
.	O

In	O
myeloid	B-cell_type
cells	I-cell_type
,	O
CD38	B-protein
is	O
expressed	O
during	O
early	O
stages	O
of	O
differentiation	O
.	O

Virtually	O
no	O
information	O
is	O
available	O
on	O
regulation	O
and	O
functions	O
of	O
CD38	B-protein
.	O

Recently	O
we	O
reported	O
that	O
all-trans-retinoic	O
acid	O
(	O
ATRA	O
)	O
is	O
a	O
potent	O
and	O
highly	O
specific	O
inducer	O
of	O
CD38	B-protein
expression	O
in	O
human	B-cell_type
promyelocytic	I-cell_type
leukemia	I-cell_type
cells	I-cell_type
.	O

Here	O
we	O
report	O
that	O
ATRA-induced	O
expression	O
of	O
CD38	B-protein
antigen	I-protein
in	O
myeloid	B-cell_type
cells	I-cell_type
is	O
mediated	O
through	O
retinoic	B-protein
acid-alpha	I-protein
receptor	I-protein
(	O
RAR	B-protein
alpha	I-protein
)	O
.	O

ATRA	O
failed	O
to	O
induce	O
CD38	B-protein
expression	O
in	O
a	O
mutant	B-cell_line
subclone	I-cell_line
of	O
the	O
HL-60	B-cell_line
myeloid	I-cell_line
leukemia	I-cell_line
cell	I-cell_line
line	I-cell_line
(	O
designated	O
HL-60R	B-cell_line
)	O
that	O
is	O
relatively	O
resistant	O
to	O
ATRA-induced	O
granulocytic	O
differentiation	O
.	O

Retroviral	O
vector-mediated	O
transduction	O
of	O
RA	B-protein
receptor	I-protein
(	O
RAR	B-protein
alpha	I-protein
)	O
into	O
this	O
HL-60R	B-cell_line
subclone	I-cell_line
completely	O
restored	O
the	O
sensitivity	O
of	O
these	O
cells	O
to	O
ATRA	O
in	O
terms	O
of	O
their	O
ability	O
to	O
express	O
CD38	B-protein
.	O

In	O
contrast	O
,	O
CD38	B-protein
expression	O
was	O
not	O
inducible	O
by	O
ATRA	O
in	O
HL-60R	B-cell_line
cells	I-cell_line
,	O
transfected	O
with	O
a	O
functional	O
RAR	B-protein
beta	I-protein
,	O
RAR	B-protein
gamma	I-protein
,	O
or	O
RXR	B-protein
alpha	I-protein
receptor	I-protein
.	O

Induction	O
of	O
CD38	B-protein
in	O
acute	B-cell_type
promyelocytic	I-cell_type
and	I-cell_type
acute	I-cell_type
myeloblastic	I-cell_type
leukemia	I-cell_type
cells	I-cell_type
was	O
independent	O
of	O
ATRA-induced	O
cytodifferentiation	O
.	O

Following	O
culture	O
with	O
ATRA	O
,	O
increased	O
CD38	B-protein
protein	O
levels	O
were	O
also	O
observed	O
in	O
normal	B-cell_type
CD34+	I-cell_type
bone	I-cell_type
marrow	I-cell_type
cells	I-cell_type
,	O
but	O
not	O
on	O
normal	B-cell_type
circulating	I-cell_type
granulocytes	I-cell_type
.	O

From	O
these	O
results	O
,	O
we	O
conclude	O
that	O
CD38	B-protein
is	O
ATRA	O
inducible	O
in	O
myeloid	B-cell_type
leukemia	I-cell_type
cells	I-cell_type
and	O
normal	B-cell_type
CD34+	I-cell_type
bone	I-cell_type
marrow	I-cell_type
cells	I-cell_type
.	O

This	O
effect	O
is	O
independent	O
of	O
differentiation	O
and	O
is	O
mediated	O
by	O
RAR	B-protein
alpha	I-protein
in	O
HL-60	B-cell_type
cells	I-cell_type
,	O
suggesting	O
a	O
similar	O
role	O
for	O
RAR	B-protein
alpha	I-protein
in	O
CD38	B-protein
expression	O
in	O
other	O
hematopoietic	B-cell_type
cells	I-cell_type
.	O

Some	O
antioxidants	O
inhibit	O
,	O
in	O
a	O
co-ordinate	O
fashion	O
,	O
the	O
production	O
of	O
tumor	B-protein
necrosis	I-protein
factor-alpha	I-protein
,	O
IL-beta	B-protein
,	O
and	O
IL-6	B-protein
by	O
human	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
.	O

Some	O
antioxidants	O
,	O
including	O
butylated	O
hydroxyanisole	O
(	O
BHA	O
)	O
,	O
tetrahydropapaveroline	O
(	O
THP	O
)	O
,	O
nordihydroguiauretic	O
acid	O
,	O
and	O
10	O
,	O
11-dihydroxyaporphine	O
(	O
DHA	O
)	O
,	O
were	O
found	O
to	O
be	O
potent	O
inhibitors	O
of	O
the	O
production	O
of	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
(	I-protein
TNF	I-protein
)	I-protein
-alpha	I-protein
,	O
IL-1	B-protein
beta	I-protein
,	O
and	O
IL-6	B-protein
by	O
human	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
(	O
PBMC	B-cell_type
)	O
stimulated	O
by	O
lipopolysaccharide	O
(	O
LPS	O
)	O
(	O
IC50s	O
in	O
the	O
low	O
micromolar	O
range	O
)	O
.	O

Inhibition	O
of	O
cytokine	B-protein
production	O
was	O
gene	O
selective	O
and	O
not	O
due	O
to	O
general	O
effects	O
on	O
protein	O
synthesis	O
.	O

Inhibition	O
of	O
cytokine	B-protein
production	O
by	O
PBMC	B-cell_type
was	O
observed	O
also	O
when	O
other	O
inducers	O
were	O
used	O
(	O
staphylococci	O
,	O
silica	O
,	O
zymosan	O
)	O
.	O

Much	O
higher	O
concentrations	O
of	O
other	O
antioxidants	O
--	O
including	O
ascorbic	O
acid	O
,	O
trolox	O
,	O
alpha-tocopherol	O
,	O
butylated	O
hydroxytoluene	O
,	O
and	O
the	O
5-lipoxygenase	O
inhibitor	O
zileuton	O
--	O
did	O
not	O
affect	O
the	O
production	O
of	O
these	O
cytokines	B-protein
.	O

The	O
active	O
compounds	O
did	O
not	O
inhibit	O
IL-1	B-protein
-induced	O
production	O
of	O
IL-6	B-protein
in	O
fibroblasts	B-cell_type
,	O
showing	O
the	O
cell	O
selectivity	O
of	O
the	O
effect	O
.	O

Antioxidant-mediated	O
inhibition	O
of	O
cytokine	B-protein
production	O
was	O
correlated	O
with	O
low	O
levels	O
of	O
the	O
corresponding	O
messenger	B-RNA
RNAs	I-RNA
.	O

Nuclear	O
run-on	O
experiments	O
showed	O
that	O
THP	O
inhibited	O
transcription	O
of	O
the	O
IL-1	B-DNA
beta	I-DNA
gene	I-DNA
.	O

THP	O
decreased	O
the	O
concentration	O
of	O
the	O
transcription	B-protein
factors	I-protein
NF-kappa	B-protein
B	I-protein
and	O
AP-1	B-protein
detected	O
in	O
nuclear	O
extracts	O
of	O
PBMC	B-cell_type
cultured	O
in	O
the	O
presence	O
or	O
absence	O
of	O
LPS	O
.	O

THP	O
and	O
DHA	O
markedly	O
decreased	O
the	O
levels	O
of	O
TNF-alpha	B-protein
and	O
IL-1	B-protein
beta	I-protein
in	O
the	O
circulation	O
of	O
mice	O
following	O
LPS	O
injection	O
.	O

Thus	O
antioxidants	O
vary	O
widely	O
in	O
potency	O
as	O
inhibitors	O
of	O
the	O
activation	O
of	O
transcription	B-protein
factors	I-protein
and	O
of	O
the	O
transcription	O
of	O
genes	B-DNA
for	O
pro-inflammatory	B-protein
cytokines	I-protein
.	O

Coordinate	O
inhibition	O
of	O
the	O
transcription	O
of	O
genes	O
for	O
inflammatory	O
cytokines	B-protein
could	O
provide	O
a	O
strategy	O
for	O
therapy	O
of	O
diseases	O
with	O
inflammatory	O
pathogenesis	O
and	O
for	O
septic	O
shock	O
.	O

An	O
interleukin-4-induced	B-protein
transcription	I-protein
factor	I-protein
:	O
IL-4	B-protein
Stat	I-protein
.	O

Interleukin-4	B-protein
(	O
IL-4	B-protein
)	O
is	O
an	O
immunomodulatory	O
cytokine	O
secreted	O
by	O
activated	O
T	B-cell_type
lymphocytes	I-cell_type
,	O
basophils	B-cell_type
,	O
and	O
mast	B-cell_type
cells	I-cell_type
.	O

It	O
plays	O
an	O
important	O
role	O
in	O
modulating	O
the	O
balance	O
of	O
T	B-cell_type
helper	I-cell_type
(	I-cell_type
Th	I-cell_type
)	I-cell_type
cell	I-cell_type
subsets	I-cell_type
,	O
favoring	O
expansion	O
of	O
the	O
Th2	B-cell_type
lineage	I-cell_type
relative	O
to	O
Th1	B-cell_type
.	O

Imbalance	O
of	O
these	O
T	B-cell_type
lymphocyte	I-cell_type
subsets	I-cell_type
has	O
been	O
implicated	O
in	O
immunological	O
diseases	O
including	O
allergy	O
,	O
inflammation	O
,	O
and	O
autoimmune	O
disease	O
.	O

IL-4	B-protein
may	O
mediate	O
its	O
biological	O
effects	O
,	O
at	O
least	O
in	O
part	O
,	O
by	O
activating	O
a	O
tyrosine-phosphorylated	B-protein
DNA	I-protein
binding	I-protein
protein	I-protein
.	O

This	O
protein	O
has	O
now	O
been	O
purified	O
and	O
its	O
encoding	O
gene	O
cloned	O
.	O

Examination	O
of	O
the	O
primary	O
amino	O
acid	O
sequence	O
of	O
this	O
protein	O
indicates	O
that	O
it	O
is	O
a	O
member	O
of	O
the	O
signal	B-protein
transducers	I-protein
and	I-protein
activators	I-protein
of	I-protein
transcription	I-protein
(	I-protein
Stat	I-protein
)	I-protein
family	I-protein
of	O
DNA	B-protein
binding	I-protein
proteins	I-protein
,	O
hereby	O
designated	O
IL-4	B-protein
Stat	I-protein
.	O

Study	O
of	O
the	O
inhibitory	O
activities	O
of	O
phosphotyrosine-containing	O
peptides	O
derived	O
from	O
the	O
intracellular	B-protein
domain	I-protein
of	I-protein
the	I-protein
IL-4	I-protein
receptor	I-protein
provided	O
evidence	O
for	O
direct	O
coupling	O
of	O
receptor	B-protein
and	O
transcription	B-protein
factor	I-protein
during	O
the	O
IL-4	B-protein
Stat	I-protein
activation	O
cycle	O
.	O

Such	O
observations	O
indicate	O
that	O
IL-4	B-protein
Stat	I-protein
has	O
the	O
same	O
functional	B-protein
domain	I-protein
for	O
both	O
receptor	O
coupling	O
and	O
dimerization	O
.	O

Evaluation	O
of	O
the	O
respiratory	O
epithelium	O
of	O
normals	O
and	O
individuals	O
with	O
cystic	O
fibrosis	O
for	O
the	O
presence	O
of	O
adenovirus	B-DNA
E1a	I-DNA
sequences	I-DNA
relevant	O
to	O
the	O
use	O
of	O
E1a-	O
adenovirus	O
vectors	O
for	O
gene	O
therapy	O
for	O
the	O
respiratory	O
manifestations	O
of	O
cystic	O
fibrosis	O
.	O

Lung	O
disease	O
associated	O
with	O
disorders	O
such	O
as	O
cystic	O
fibrosis	O
(	O
CF	O
)	O
may	O
be	O
amenable	O
to	O
somatic	O
gene	O
therapy	O
in	O
which	O
there	O
is	O
delivery	O
of	O
the	O
normal	B-DNA
gene	I-DNA
directly	O
to	O
the	O
respiratory	O
epithelium	O
using	O
E1a-	O
adenovirus	O
(	O
Ad	O
)	O
type	O
2-	O
or	O
5-based	O
vectors	O
.	O

For	O
safety	O
reasons	O
,	O
the	O
Ad	O
vectors	O
are	O
rendered	O
replication	O
deficient	O
by	O
deletion	O
of	O
the	O
E1a	B-DNA
region	I-DNA
.	O

Because	O
there	O
is	O
the	O
theoretical	O
possibility	O
of	O
an	O
E1a-	O
replication-deficient	O
vector	O
replicating	O
as	O
a	O
result	O
of	O
recombination	O
or	O
complementation	O
with	O
Ad	B-DNA
2/5	I-DNA
E1a	I-DNA
sequences	I-DNA
present	O
in	O
the	O
target	O
cell	O
,	O
this	O
study	O
is	O
directed	O
toward	O
evaluating	O
respiratory	O
epithelium	O
of	O
normals	O
and	O
individuals	O
with	O
CF	O
for	O
the	O
presence	O
of	O
E1a	O
sequences	O
.	O

Using	O
Ad	B-DNA
2/5	I-DNA
E1a-specific	I-DNA
primers	I-DNA
and	O
the	O
polymerase	O
chain	O
reaction	O
to	O
evaluate	O
DNA	O
recovered	O
from	O
freshly	O
isolated	O
nasal	O
and	O
bronchial	O
epithelium	O
recovered	O
by	O
brushing	O
,	O
E1a	B-DNA
sequences	I-DNA
were	O
detected	O
in	O
respiratory	O
epithelium	O
of	O
19	O
of	O
91	O
normals	O
(	O
21	O
%	O
)	O
.	O

In	O
the	O
E1a-positive	O
samples	O
,	O
the	O
average	O
of	O
E1a	O
copy	O
number	O
was	O
55	O
+/-	O
18/10	O
(	O
3	O
)	O
recovered	O
cells	O
.	O

In	O
CF	O
individuals	O
,	O
7	O
of	O
52	O
(	O
13	O
%	O
)	O
had	O
detectable	O
E1a	B-DNA
sequences	I-DNA
in	O
the	O
respiratory	O
epithelium	O
,	O
with	O
E1a	O
copy	O
number	O
in	O
the	O
positive	O
samples	O
of	O
80	O
+/-	O
21/10	O
(	O
3	O
)	O
recovered	O
cells	O
.	O

These	O
results	O
demonstrate	O
that	O
there	O
are	O
detectable	O
Ad	B-DNA
2/5	I-DNA
E1a	I-DNA
sequences	I-DNA
in	O
the	O
respiratory	O
epithelium	O
of	O
a	O
small	O
percentage	O
of	O
normals	O
and	O
individuals	O
with	O
CF	O
.	O

Because	O
of	O
the	O
theoretical	O
potential	O
of	O
such	O
sequences	O
supporting	O
replication	O
of	O
E1a-	O
Ad	O
vectors	O
,	O
human	O
gene	O
therapy	O
protocols	O
for	O
CF	O
utilizing	O
such	O
vectors	O
should	O
consider	O
evaluating	O
study	O
individuals	O
for	O
the	O
presence	O
of	O
Ad	B-DNA
2/5	I-DNA
E1a	I-DNA
sequences	I-DNA
in	O
the	O
respiratory	O
epithelium	O
.	O

Leiomyosarcoma	O
of	O
the	O
vulva	O
:	O
report	O
of	O
a	O
case	O
.	O

A	O
52-year-old	O
female	O
presented	O
with	O
a	O
progressively	O
enlarging	O
vulvar	O
mass	O
.	O

Pathological	O
evaluation	O
revealed	O
a	O
high-grade	O
vulvar	O
leiomyosarcoma	O
.	O

Immunohistochemical	O
and	O
ultrastructural	O
studies	O
were	O
performed	O
to	O
support	O
the	O
diagnosis	O
.	O

In	O
an	O
effort	O
to	O
better	O
understand	O
the	O
biology	O
of	O
this	O
tumor	O
additional	O
immunohistochemical	O
studies	O
for	O
the	O
protein	B-protein
product	I-protein
of	O
p53	B-DNA
tumor	I-DNA
suppressor	I-DNA
gene	I-DNA
and	O
estrogen	B-protein
receptor	I-protein
expression	O
by	O
tumor	B-cell_type
cells	I-cell_type
,	O
as	O
well	O
as	O
the	O
type	O
of	O
immune	B-cell_type
cells	I-cell_type
infiltrating	O
the	O
tumor	O
were	O
performed	O
.	O

Tumor	B-cell_type
cells	I-cell_type
showed	O
an	O
overexpression	O
of	O
p53	B-protein
protein	I-protein
and	O
were	O
estrogen	B-protein
receptor	I-protein
-positive	O
.	O

Macrophages	B-cell_type
and	O
T	B-cell_type
and	I-cell_type
B	I-cell_type
lymphocytes	I-cell_type
infiltrated	O
the	O
tumor	O
in	O
moderate	O
numbers	O
with	O
occasional	O
lymphoid	O
aggregate	O
formation	O
.	O

This	O
study	O
is	O
the	O
first	O
attempt	O
to	O
better	O
understand	O
the	O
biology	O
of	O
these	O
tumors	O
.	O

Stimulation	O
of	O
HIV	O
replication	O
in	O
mononuclear	B-cell_type
phagocytes	I-cell_type
by	O
leukemia	B-protein
inhibitory	I-protein
factor	I-protein
.	O

This	O
study	O
examined	O
the	O
effects	O
of	O
leukemia	B-protein
inhibitory	I-protein
factor	I-protein
(	O
LIF	B-protein
)	O
on	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
replication	O
in	O
mononuclear	B-cell_type
phagocytes	I-cell_type
(	O
MNP	B-cell_type
)	O
.	O

LIF	B-protein
induced	O
a	O
dose-dependent	O
increase	O
in	O
p24	B-protein
antigen	I-protein
production	O
in	O
the	O
chronically	B-cell_line
infected	I-cell_line
promonocytic	I-cell_line
cell	I-cell_line
line	I-cell_line
U1	I-cell_line
.	O

The	O
magnitude	O
and	O
time	O
kinetics	O
of	O
the	O
LIF	B-protein
effects	O
were	O
similar	O
to	O
interleukin	B-protein
1	I-protein
(	O
IL-1	B-protein
)	O
,	O
IL-6	B-protein
,	O
and	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
(	O
TNF	B-protein
)	O
,	O
other	O
cytokines	O
known	O
to	O
induce	O
HIV	O
replication	O
in	O
this	O
cell	O
line	O
.	O

To	O
characterize	O
mechanisms	O
responsible	O
for	O
these	O
LIF	B-protein
effects	O
,	O
levels	O
of	O
HIV	B-RNA
mRNA	I-RNA
,	O
activation	O
of	O
the	O
DNA	B-protein
binding	I-protein
protein	I-protein
nuclear	I-protein
factor	I-protein
(	B-protein
NF	I-protein
)	I-protein
-kB	I-protein
,	O
signal	O
transduction	O
pathways	O
,	O
and	O
potential	O
interactions	O
with	O
other	O
cytokines	B-protein
were	O
analyzed	O
.	O

LIF	B-protein
increased	O
steady-state	O
levels	O
of	O
HIV	B-RNA
mRNA	I-RNA
at	O
2.0	O
,	O
4.3	O
,	O
and	O
9.2	O
kB	O
.	O

This	O
was	O
detectable	O
by	O
24	O
h	O
and	O
persisted	O
until	O
72	O
h	O
.	O

The	O
DNA	B-protein
binding	I-protein
protein	I-protein
NF-kB	I-protein
is	O
a	O
central	O
mediator	O
in	O
cytokine	B-protein
activation	O
of	O
HIV	O
transcription	O
.	O

NF-kB	B-protein
levels	O
were	O
higher	O
in	O
unstimulated	B-cell_line
U1	I-cell_line
cells	I-cell_line
as	O
compared	O
to	O
the	O
parent	B-cell_line
cell	I-cell_line
line	I-cell_line
U937	B-cell_line
.	O

In	O
both	O
cell	O
lines	O
LIF	B-protein
increased	O
NF-kB	B-protein
activity	O
.	O

Induction	O
of	O
NF-kB	B-protein
and	O
HIV	O
replication	O
by	O
cytokines	B-protein
are	O
at	O
least	O
in	O
part	O
dependent	O
on	O
reactive	O
oxygen	O
intermediates	O
.	O

The	O
oxygen	O
radical	O
scavenger	O
N-acetyl-L-cysteine	O
,	O
but	O
not	O
an	O
inhibitor	O
of	O
nitric	B-protein
oxide	I-protein
synthase	I-protein
,	O
inhibited	O
LIF	B-protein
-induced	O
HIV	O
replication	O
.	O

LIF	B-protein
induces	O
the	O
production	O
of	O
other	O
cytokines	B-protein
in	O
monocytes	O
but	O
its	O
effects	O
on	O
HIV	O
replication	O
were	O
not	O
inhibited	O
by	O
antibodies	B-protein
to	O
IL-1	B-protein
,	O
TNF	B-protein
,	O
or	O
IL-6	B-protein
.	O

These	O
results	O
identify	O
LIF	B-protein
as	O
a	O
stimulus	O
of	O
HIV	O
replication	O
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Mechanisms	O
involved	O
in	O
the	O
inhibition	O
of	O
growth	O
of	O
a	O
human	B-cell_line
B	I-cell_line
lymphoma	I-cell_line
cell	I-cell_line
line	I-cell_line
,	O
B104	B-cell_line
,	O
by	O
anti-MHC	B-protein
class	I-protein
II	I-protein
antibodies	I-protein
.	O

The	O
mechanisms	O
involved	O
in	O
the	O
inhibition	O
of	O
growth	O
of	O
a	O
human	B-cell_line
B	I-cell_line
lymphoma	I-cell_line
cell	I-cell_line
line	I-cell_line
,	O
B104	B-cell_line
,	O
by	O
anti-MHC	B-protein
class	I-protein
II	I-protein
antibodies	I-protein
(	O
Ab	B-protein
)	O
were	O
compared	O
with	O
those	O
in	O
anti-IgM	B-protein
Ab	I-protein
-induced	O
B104	O
growth	O
inhibition	O
.	O

Two	O
anti-MHC	B-protein
class	I-protein
II	I-protein
Ab	I-protein
,	O
L227	B-protein
and	O
2.06	B-protein
,	O
inhibited	O
the	O
growth	O
of	O
B104	B-cell_line
cells	I-cell_line
,	O
although	O
2.06	B-protein
,	O
but	O
not	O
L227	B-protein
,	O
needed	O
to	O
be	O
further	O
cross-linked	O
with	O
a	O
goat	B-protein
anti-mouse	I-protein
IgG	I-protein
Ab	I-protein
(	O
GAM	B-protein
)	O
to	O
show	O
the	O
effect	O
.	O

L227	B-protein
induced	O
an	O
increase	O
in	O
intracellular	O
free	O
Ca2+	O
concentration	O
(	O
[	O
Ca2+	O
]	O
i	O
)	O
from	O
the	O
intracellular	O
pool	O
and	O
little	O
or	O
no	O
protein	O
tyrosine	O
phosphorylation	O
,	O
phosphatidyl	O
inositol	O
turnover	O
,	O
or	O
expression	O
of	O
Egr-1	B-RNA
mRNA	I-RNA
,	O
whereas	O
2.06	B-protein
plus	O
GAM	B-protein
induced	O
an	O
increase	O
in	O
[	O
Ca2+	O
]	O
i	O
from	O
both	O
the	O
intracellular	O
and	O
,	O
in	O
particular	O
,	O
the	O
extracellular	O
pools	O
.	O

The	O
inhibition	O
of	O
B104	B-cell_line
cell	I-cell_line
growth	O
induced	O
by	O
anti-MHC	B-protein
class	I-protein
II	I-protein
Ab	I-protein
was	O
Ca	O
(	O
2+	O
)	O
-independent	O
and	O
not	O
inhibited	O
by	O
actinomycin	O
D	O
or	O
cyclosporin	O
A	O
,	O
and	O
cell	O
cycle	O
arrest	O
at	O
the	O
G2/M	O
interphase	O
was	O
not	O
observed	O
.	O

These	O
features	O
are	O
very	O
different	O
from	O
those	O
observed	O
in	O
B104	B-cell_line
cell	I-cell_line
death	O
induced	O
by	O
anti-IgM	B-protein
Ab	I-protein
.	O

Neither	O
DNA	O
fragmentation	O
nor	O
the	O
morphology	O
of	O
apoptosis	O
was	O
observed	O
.	O

These	O
findings	O
demonstrate	O
that	O
cross-linking	O
of	O
MHC	B-protein
class	I-protein
II	I-protein
molecules	I-protein
transduced	O
the	O
negative	O
signals	O
through	O
intracellular	O
mechanisms	O
different	O
from	O
those	O
present	O
in	O
the	O
cross-linking	O
of	O
surface	O
IgM	B-protein
.	O

Functional	O
block	O
for	O
1	O
alpha	O
,	O
25-dihydroxyvitamin	O
D3-mediated	O
gene	O
regulation	O
in	O
human	B-cell_type
B	I-cell_type
lymphocytes	I-cell_type
.	O

Elements	O
necessary	O
for	O
the	O
steroid	O
hormone	O
1	O
alpha	O
,	O
25-dihydroxyvitamin	O
D3	O
(	O
1	O
alpha	O
,	O
25-	O
(	O
OH	O
)	O
2D3	O
)	O
to	O
induce	O
a	O
biological	O
response	O
include	O
the	O
presence	O
of	O
specific	O
intracellular	B-protein
receptors	I-protein
(	O
vitamin	B-protein
D3	I-protein
receptors	I-protein
(	O
VDR	B-protein
)	O
)	O
and	O
modulation	O
of	O
gene	O
expression	O
via	O
hormone-activated	O
receptor	O
binding	O
to	O
regulatory	B-protein
regions	I-protein
of	O
target	B-DNA
genes	I-DNA
.	O

These	O
parameters	O
were	O
examined	O
in	O
normal	O
and	O
Epstein-Barr	B-cell_line
virus-immortalized	I-cell_line
human	I-cell_line
B	I-cell_line
cells	I-cell_line
and	O
compared	O
with	O
1	B-cell_line
alpha	I-cell_line
,	I-cell_line
25-	I-cell_line
(	I-cell_line
OH	I-cell_line
)	I-cell_line
2D3-responsive	I-cell_line
cells	I-cell_line
of	O
the	O
T	B-cell_type
and	I-cell_type
monocytic	I-cell_type
lineages	I-cell_type
.	O

Although	O
resting	O
tonsillar	O
B	O
cells	O
did	O
not	O
express	O
VDR	B-RNA
mRNA	I-RNA
,	O
activation	O
of	O
these	O
cells	O
with	O
interleukin-4	B-protein
induced	O
VDR	B-protein
in	O
the	O
absence	O
of	O
exogenously	O
supplemented	O
1	O
alpha	O
,	O
25-	O
(	O
OH	O
)	O
2D3	O
.	O

As	O
indicators	O
of	O
hormone-mediated	O
gene	O
regulation	O
we	O
analyzed	O
modulation	O
of	O
CD23	B-protein
,	O
a	O
common	B-protein
B	I-protein
cell/monocyte	I-protein
surface	I-protein
antigen	I-protein
,	O
and	O
24-hydroxylase	B-protein
.	O

1	O
alpha	O
,	O
25-	O
(	O
OH	O
)	O
2D3	O
inhibited	O
CD23	B-protein
expression	O
in	O
U937	B-cell_line
cells	I-cell_line
,	O
yet	O
failed	O
to	O
modulate	O
CD23	B-protein
expression	O
in	O
B	B-cell_type
cells	I-cell_type
.	O

Furthermore	O
,	O
1	O
alpha	O
,	O
25-	O
(	O
OH	O
)	O
2D3	O
induced	O
24-hydroxylase	B-protein
mRNA	O
expression	O
and	O
metabolic	O
activity	O
in	O
both	O
U937	B-cell_line
cells	I-cell_line
and	O
lectin-activated	B-cell_type
T	I-cell_type
cells	I-cell_type
,	O
yet	O
failed	O
to	O
induce	O
24-hydroxylase	B-RNA
mRNA	I-RNA
or	O
its	O
metabolic	O
activity	O
in	O
B	B-cell_type
cells	I-cell_type
.	O

These	O
findings	O
suggest	O
that	O
although	O
human	B-cell_type
B	I-cell_type
lymphocytes	I-cell_type
can	O
express	O
VDR	B-RNA
mRNA	I-RNA
and	O
protein	B-protein
,	O
they	O
exhibit	O
a	O
functional	O
block	O
for	O
vitamin	O
D-dependent	O
gene	O
regulation	O
.	O

Positive	O
and	O
negative	O
regulation	O
of	O
IL-2	B-protein
gene	O
expression	O
:	O
role	O
of	O
multiple	O
regulatory	O
sites	O
.	O

Interleukin	O
2	O
(	O
IL-2	B-protein
)	O
is	O
an	O
important	O
lymphokine	B-protein
required	O
in	O
the	O
process	O
of	O
T	O
cell	O
activation	O
,	O
proliferation	O
,	O
clonal	O
expansion	O
and	O
differentiation	O
.	O

The	O
IL-2	B-DNA
gene	I-DNA
displays	O
both	O
T	O
cell	O
specific	O
and	O
inducible	O
expression	O
:	O
it	O
is	O
only	O
expressed	O
in	O
CD4+	B-cell_type
T	I-cell_type
cells	I-cell_type
after	O
antigenic	O
or	O
mitogenic	O
stimulation	O
.	O

Several	O
cis-acting	B-DNA
regulatory	I-DNA
sites	I-DNA
are	O
required	O
for	O
induction	O
of	O
the	O
IL-2	B-DNA
gene	I-DNA
after	O
stimulation	O
.	O

In	O
this	O
study	O
,	O
we	O
have	O
analysed	O
the	O
function	O
of	O
these	O
cis-acting	B-DNA
regulatory	I-DNA
sites	I-DNA
in	O
the	O
context	O
of	O
the	O
native	O
IL-2	B-DNA
enhancer	I-DNA
and	O
promoter	B-DNA
sequence	I-DNA
.	O

The	O
results	O
of	O
this	O
study	O
suggest	O
that	O
the	O
NFAT	B-protein
(	O
-276	B-DNA
to	I-DNA
-261	I-DNA
)	O
,	O
the	O
distal	B-DNA
octamer	I-DNA
(	O
-256	B-DNA
to	I-DNA
-248	I-DNA
)	O
and	O
the	O
proximal	B-DNA
octamer	I-DNA
(	O
-75	B-DNA
to	I-DNA
-66	I-DNA
)	O
sites	O
not	O
only	O
act	O
as	O
enhancers	O
of	O
IL-2	B-DNA
gene	I-DNA
transcription	O
in	O
the	O
presence	O
of	O
cellular	O
stimulation	O
,	O
but	O
also	O
have	O
a	O
silencing	O
effect	O
on	O
IL-2	B-DNA
gene	I-DNA
expression	O
in	O
resting	O
cells	O
.	O

Two	O
other	O
sites	O
display	O
disparate	O
effects	O
on	O
IL-2	B-DNA
gene	I-DNA
expression	O
in	O
different	O
T	B-cell_line
leukemia	I-cell_line
cell	I-cell_line
lines	I-cell_line
:	O
the	O
distal	B-DNA
purine	I-DNA
box	I-DNA
(	O
-291	B-DNA
to	I-DNA
-277	I-DNA
)	O
and	O
the	O
proximal	B-DNA
purine	I-DNA
box	I-DNA
sites	I-DNA
(	O
-145	B-DNA
to	I-DNA
-128	I-DNA
)	O
.	O

Finally	O
,	O
the	O
AP-1	B-DNA
(	I-DNA
-186	I-DNA
to	I-DNA
-176	I-DNA
)	I-DNA
and	I-DNA
the	I-DNA
kappa	I-DNA
B	I-DNA
sites	I-DNA
(	O
-206	B-DNA
to	I-DNA
-195	I-DNA
)	O
respond	O
to	O
different	O
cellular	O
activation	O
in	O
EL4	B-cell_line
cells	I-cell_line
.	O

The	O
AP-1	B-DNA
site	I-DNA
mediated	O
the	O
response	O
to	O
PMA	O
stimulation	O
while	O
the	O
kappa	B-DNA
B	I-DNA
site	I-DNA
responded	O
to	O
IL-1	B-protein
stimulation	O
.	O

These	O
data	O
suggest	O
that	O
the	O
regulation	O
of	O
IL-2	B-DNA
gene	I-DNA
expression	O
is	O
a	O
complex	O
process	O
and	O
multiple	O
cis-acting	B-DNA
regulatory	I-DNA
sites	I-DNA
interact	O
to	O
exert	O
different	O
effects	O
in	O
T	B-cell_type
cells	I-cell_type
representative	O
of	O
alternative	O
stages	O
of	O
differentiation	O
.	O

Sp1	B-protein
is	O
a	O
critical	O
factor	O
for	O
the	O
monocytic	O
specific	O
expression	O
of	O
human	B-protein
CD14	I-protein
.	O

CD14	B-protein
is	O
a	O
membrane	B-protein
glycoprotein	I-protein
expressed	O
specifically	O
on	O
monocytes	B-cell_type
and	O
macrophages	B-cell_type
,	O
and	O
its	O
expression	O
is	O
markedly	O
increased	O
during	O
the	O
process	O
of	O
monocyte	B-cell_type
differentiation	O
.	O

In	O
order	O
to	O
study	O
CD14	B-DNA
gene	I-DNA
regulation	O
,	O
the	O
human	B-DNA
CD14	I-DNA
gene	I-DNA
was	O
cloned	O
from	O
a	O
partial	O
EcoRI	B-DNA
digested	I-DNA
chromosome	I-DNA
5	I-DNA
library	I-DNA
.	O

A	O
5.5-kilobase	B-DNA
genomic	I-DNA
clone	I-DNA
contained	O
the	O
full-length	O
CD14	B-DNA
coding	I-DNA
sequence	I-DNA
and	O
4.2	B-DNA
kilobases	I-DNA
of	I-DNA
5'-upstream	I-DNA
sequence	I-DNA
.	O

One	O
major	B-DNA
and	I-DNA
one	I-DNA
minor	I-DNA
transcription	I-DNA
start	I-DNA
site	I-DNA
were	O
identified	O
101	B-DNA
and	I-DNA
130	I-DNA
base	I-DNA
pairs	I-DNA
(	I-DNA
bp	I-DNA
)	I-DNA
upstream	I-DNA
,	O
respectively	O
,	O
from	O
the	O
protein	B-DNA
translation	I-DNA
start	I-DNA
ATG	I-DNA
.	O

A	O
DNA	B-DNA
fragment	I-DNA
containing	O
128	B-DNA
bp	I-DNA
of	I-DNA
upstream	I-DNA
sequence	I-DNA
had	O
strong	O
,	O
monocyte-specific	O
promoter	O
activity	O
in	O
the	O
CD14	B-cell_line
positive	I-cell_line
monocytic	I-cell_line
cell	I-cell_line
line	I-cell_line
Mono	B-cell_line
Mac	I-cell_line
6	I-cell_line
as	O
compared	O
to	O
the	O
nonmonocytic	B-cell_line
cell	I-cell_line
lines	I-cell_line
HeLa	B-cell_line
and	O
REX	B-cell_line
.	O

Four	O
regions	O
in	O
this	O
DNA	B-DNA
fragment	I-DNA
interact	O
with	O
nuclear	B-protein
proteins	I-protein
isolated	O
from	O
monocytic	B-cell_type
cells	I-cell_type
.	O

The	O
Sp1	B-protein
transcription	B-protein
factor	I-protein
bound	O
to	O
three	O
different	O
regions	O
in	O
the	O
CD14	B-DNA
promoter	I-DNA
.	O

Mutation	O
of	O
the	O
major	B-DNA
Sp1	I-DNA
binding	I-DNA
site	I-DNA
(	O
-110	B-DNA
bp	I-DNA
)	O
decreased	O
tissue-specific	O
promoter	O
activity	O
,	O
and	O
these	O
results	O
,	O
together	O
with	O
transactivation	O
experiments	O
,	O
demonstrate	O
that	O
Sp1	B-protein
plays	O
a	O
critical	O
role	O
in	O
the	O
tissue-specific	O
expression	O
of	O
CD14	B-protein
in	O
monocytic	B-cell_type
cells	I-cell_type
.	O

CD14	B-protein
Sp1	B-protein
site	O
oligonucleotides	O
bound	O
preferentially	O
to	O
a	O
105-kDa	B-protein
Sp1	I-protein
species	I-protein
,	O
which	O
is	O
present	O
in	O
higher	O
relative	O
levels	O
in	O
monocytic	B-cell_type
than	O
non-monocytic	B-cell_type
cells	I-cell_type
,	O
suggesting	O
that	O
modification	O
of	O
Sp1	B-protein
,	O
such	O
as	O
phosphorylation	O
,	O
may	O
explain	O
how	O
the	O
Sp1	B-protein
site	O
mediates	O
monocytic	O
specific	O
promoter	O
activity	O
.	O

The	O
interleukin-8	B-DNA
AP-1	I-DNA
and	I-DNA
kappa	I-DNA
B-like	I-DNA
sites	I-DNA
are	O
genetic	O
end	O
targets	O
of	O
FK506-sensitive	O
pathway	O
accompanied	O
by	O
calcium	O
mobilization	O
.	O

FK506	O
,	O
an	O
immunosuppressant	O
,	O
inhibits	O
the	O
production	O
of	O
several	O
cytokines	B-protein
in	O
T	B-cell_type
lymphocytes	I-cell_type
.	O

We	O
observed	O
that	O
FK506	O
suppressed	O
the	O
transcription	O
of	O
a	O
chemotactic	B-protein
cytokine	I-protein
,	O
interleukin-8	B-protein
(	O
IL-8	B-protein
)	O
in	O
a	O
human	B-cell_line
T	I-cell_line
cell	I-cell_line
line	I-cell_line
,	O
Jurkat	B-cell_line
cells	I-cell_line
,	O
activated	O
by	O
phorbol	O
12-myristate	O
13-acetate	O
(	O
PMA	O
)	O
and	O
calcium	O
(	O
Ca2+	O
)	O
ionophore	O
(	O
ionomycin	O
)	O
.	O

By	O
deleted	O
and	O
mutated	O
analysis	O
of	O
the	O
IL-8	B-DNA
promoters	I-DNA
,	O
the	O
AP-1	B-DNA
and	I-DNA
kappa	I-DNA
B-like	I-DNA
sites	I-DNA
were	O
identified	O
as	O
the	O
responsive	O
elements	O
for	O
PMA	O
and	O
ionomycin	O
.	O

FK506	O
suppressed	O
the	O
transcriptions	O
through	O
the	O
AP-1	B-DNA
or	O
kappa	B-DNA
B-like	I-DNA
sites	I-DNA
induced	O
by	O
PMA	O
plus	O
Ca	O
(	O
2+	O
)	O
-mobilizing	O
agents	O
,	O
but	O
not	O
those	O
induced	O
by	O
Ca	O
(	O
2+	O
)	O
-independent	O
stimuli	O
.	O

In	O
gel	O
retardation	O
analysis	O
,	O
FK506	O
had	O
little	O
effect	O
on	O
the	O
binding	O
to	O
the	O
AP-1	B-DNA
site	I-DNA
of	O
PMA/ionomycin-induced	O
nuclear	O
factors	O
,	O
which	O
were	O
recognized	O
with	O
anti-JunD	B-protein
or	O
c-Fos	B-protein
antibody	I-protein
.	O

In	O
contrast	O
,	O
FK506	O
or	O
EGTA	O
(	O
Ca2+	O
chelator	O
)	O
similarly	O
affected	O
the	O
formation	O
of	O
kappa	B-protein
B-like	I-protein
site	I-protein
binding	I-protein
complexes	I-protein
,	O
which	O
were	O
not	O
recognized	O
by	O
any	O
antibodies	B-protein
against	O
the	O
human	B-protein
Rel	I-protein
family	I-protein
proteins	I-protein
(	O
c-Rel	B-protein
,	O
p65	B-protein
,	O
p50	B-protein
,	O
and	O
p49	B-protein
)	O
.	O

Furthermore	O
,	O
we	O
confirmed	O
the	O
previous	O
report	O
that	O
FK506	O
suppressed	O
the	O
PMA/ionomycin-induced	O
activation	O
through	O
authentic	O
kappa	B-DNA
B	I-DNA
site	I-DNA
of	O
immunoglobulin	B-DNA
(	I-DNA
Ig	I-DNA
)	I-DNA
gene	I-DNA
,	O
to	O
which	O
NF-kappa	B-protein
B	I-protein
binding	O
was	O
also	O
decreased	O
by	O
FK506	O
,	O
indicating	O
that	O
both	O
IL-8	B-DNA
kappa	I-DNA
B-like	I-DNA
site	I-DNA
and	O
Ig	O
kappa	B-DNA
B	I-DNA
site	I-DNA
are	O
FK506-sensitive	O
in	O
spite	O
of	O
the	O
difference	O
of	O
binding	B-protein
factors	I-protein
.	O

Our	O
results	O
indicate	O
that	O
not	O
only	O
the	O
reported	O
IL-2	B-DNA
NF-AT	I-DNA
and	I-DNA
NFIL-2A	I-DNA
sites	I-DNA
and	O
Ig	O
kappa	B-DNA
B	I-DNA
site	I-DNA
,	O
but	O
also	O
the	O
IL-8	B-protein
AP-1	B-DNA
and	O
kappa	B-DNA
B-like	I-DNA
sites	I-DNA
are	O
terminals	O
of	O
FK506-sensitive	O
pathway	O
involving	O
Ca2+	O
mobilization	O
.	O

Androgen	B-protein
binding	I-protein
sites	I-protein
in	O
peripheral	B-cell_type
human	I-cell_type
mononuclear	I-cell_type
leukocytes	I-cell_type
of	O
healthy	O
males	O
and	O
females	O
.	O

Androgen	B-protein
binding	I-protein
sites	I-protein
have	O
been	O
identified	O
in	O
circulating	B-cell_type
human	I-cell_type
mononuclear	I-cell_type
leukocytes	I-cell_type
of	O
healthy	O
donors	O
of	O
both	O
sexes	O
.	O

Cells	O
were	O
separated	O
from	O
blood	O
samples	O
on	O
a	O
Ficoll	O
gradient	O
and	O
incubated	O
with	O
different	O
concentrations	O
of	O
[	O
3H	O
]	O
testosterone	O
in	O
the	O
presence	O
or	O
absence	O
of	O
a	O
400-fold	O
excess	O
of	O
unlabelled	O
testosterone	O
.	O

Binding	O
data	O
were	O
derived	O
from	O
Scatchard	O
analysis	O
.	O

The	O
binding	B-protein
sites	I-protein
fulfil	O
the	O
required	O
criteria	O
for	O
specific	O
steroid	B-protein
binding	I-protein
sites	I-protein
however	O
differ	O
somewhat	O
from	O
the	O
classic	O
androgen	B-protein
receptors	I-protein
from	O
genital	B-cell_type
skin	I-cell_type
fibroblast	I-cell_type
:	O
in	O
fertile	O
adult	O
males	O
(	O
n	O
=	O
20	O
)	O
the	O
binding	B-protein
sites	I-protein
showed	O
(	O
1	O
)	O
a	O
high	O
affinity	O
for	O
testosterone	O
(	O
1.32	O
+/-	O
0.49	O
nM	O
;	O
mean	O
+/-	O
SD	O
)	O
,	O
(	O
2	O
)	O
a	O
saturable	O
capacity	O
(	O
184	O
+/-	O
52	O
binding	B-protein
sites	I-protein
per	O
cell	O
;	O
mean	O
+/-	O
SD	O
)	O
,	O
and	O
(	O
3	O
)	O
a	O
characteristic	O
competitive	O
binding	O
profile	O
for	O
other	O
steroid	O
hormones	O
(	O
relative	O
binding	O
affinities	O
:	O
testosterone	O
=	O
dihydrotestosterone	O
>	O
17	O
beta-estradiol	O
>	O
progesterone	O
,	O
whereas	O
aldosterone	O
,	O
17-hydroxy-progesterone	O
and	O
cortisol	O
did	O
not	O
compete	O
appreciably	O
)	O
.	O

Furthermore	O
the	O
number	O
of	O
binding	B-protein
sites	I-protein
determined	O
using	O
[	O
3H	O
]	O
dihydrotestosterone	O
,	O
[	O
3H	O
]	O
RU-1881	O
,	O
or	O
[	O
3H	O
]	O
testosterone	O
were	O
comparable	O
.	O

This	O
raises	O
the	O
possibility	O
that	O
androgen	B-protein
receptors	I-protein
in	O
peripheral	B-cell_type
mononuclear	I-cell_type
leukocytes	I-cell_type
differ	O
from	O
those	O
in	O
genital	B-cell_type
skin	I-cell_type
fibroblasts	I-cell_type
.	O

There	O
was	O
no	O
apparent	O
correlation	O
between	O
serum	O
testosterone	O
concentrations	O
and	O
androgen	B-protein
binding	I-protein
sites	I-protein
.	O

In	O
fertile	O
women	O
remarkable	O
changes	O
in	O
androgen	B-protein
binding	I-protein
sites	I-protein
were	O
seen	O
in	O
the	O
course	O
of	O
the	O
menstrual	O
cycle	O
,	O
with	O
a	O
significant	O
increase	O
in	O
the	O
immediate	O
preovulatory	O
period	O
.	O

The	O
presence	O
of	O
androgen	B-protein
receptors	I-protein
in	O
peripheral	B-cell_type
mononuclear	I-cell_type
leukocytes	I-cell_type
provides	O
for	O
the	O
first	O
time	O
the	O
experimental	O
basis	O
for	O
an	O
hypothesis	O
of	O
direct	O
,	O
receptor-mediated	O
effects	O
of	O
androgens	O
on	O
mature	B-cell_type
immunocompetent	I-cell_type
cells	I-cell_type
.	O

The	O
immunological	O
implications	O
of	O
these	O
results	O
are	O
discussed	O
.	O

Induction	O
of	O
IL-8	B-protein
expression	O
in	O
T	B-cell_type
cells	I-cell_type
uses	O
the	O
CD28	B-protein
costimulatory	O
pathway	O
.	O

IL-8	B-protein
,	O
a	O
potent	O
chemotactic	B-protein
factor	I-protein
for	O
neutrophil	B-cell_type
granulocytes	I-cell_type
and	O
lymphocytes	B-cell_type
,	O
is	O
a	O
proinflammatory	O
cytokine	O
secreted	O
by	O
a	O
variety	O
of	O
cell	O
types	O
,	O
including	O
T	B-cell_type
cells	I-cell_type
.	O

Stimulation	O
of	O
the	O
CD28	B-protein
cell	I-protein
surface	I-protein
molecule	I-protein
delivers	O
costimulatory	O
signals	O
essential	O
for	O
lymphokine	B-protein
production	O
in	O
activated	B-cell_type
T	I-cell_type
cells	I-cell_type
via	O
a	O
conserved	B-DNA
sequence	I-DNA
element	I-DNA
found	O
in	O
the	O
promoter	B-DNA
of	O
several	O
lymphokine	B-DNA
genes	I-DNA
.	O

Anti-CD28-stimulated	B-cell_line
T	I-cell_line
cells	I-cell_line
produced	O
significant	O
amounts	O
of	O
IL-8	B-protein
;	O
additionally	O
,	O
costimulation	O
with	O
anti-CD3	B-protein
and	O
anti-CD28	B-protein
Abs	I-protein
resulted	O
in	O
a	O
synergistic	O
induction	O
of	O
IL-8	B-protein
secretion	O
.	O

Sequence	O
homology	O
,	O
single	O
nucleotide	O
mutations	O
,	O
and	O
anti-CD28	B-protein
Ab	I-protein
stimulation	O
studies	O
established	O
that	O
the	O
NF-kappa	B-DNA
B-like	I-DNA
sequence	I-DNA
in	O
the	O
promoter	B-DNA
of	O
the	O
IL-8	B-DNA
gene	I-DNA
functioned	O
as	O
a	O
CD28	B-DNA
response	I-DNA
element	I-DNA
.	O

Furthermore	O
,	O
cyclosporin	O
A	O
,	O
but	O
not	O
rapamycin	O
,	O
blocked	O
the	O
synergistic	O
induction	O
of	O
IL-8	B-protein
expression	O
achieved	O
with	O
anti-CD3	B-protein
and	O
anti-	O
CD28	B-protein
costimulation	O
.	O

The	O
involvement	O
of	O
a	O
CD28	B-DNA
response	I-DNA
element	I-DNA
in	O
the	O
induction	O
of	O
IL-8	B-protein
expression	O
in	O
activated	B-cell_type
T	I-cell_type
cells	I-cell_type
may	O
provide	O
new	O
insights	O
into	O
the	O
pathogenesis	O
and	O
persistence	O
of	O
immune	O
disorders	O
characterized	O
by	O
increased	O
levels	O
of	O
IL-8	B-protein
,	O
such	O
as	O
psoriasis	O
and	O
rheumatoid	O
arthritis	O
.	O

MHC	B-protein
class	I-protein
II	I-protein
signaling	O
in	O
B-cell	B-cell_type
activation	O
[	O
see	O
comments	O
]	O

The	O
cognate	O
interaction	O
between	O
T	B-cell_type
cells	I-cell_type
and	O
antigen-presenting	B-cell_type
cells	I-cell_type
(	O
APCs	B-cell_type
)	O
,	O
mediated	O
by	O
major	B-protein
histocompatibility	I-protein
complex	I-protein
(	I-protein
MHC	I-protein
)	I-protein
class	I-protein
II	I-protein
molecules	I-protein
,	O
results	O
in	O
the	O
delivery	O
of	O
activation	O
signals	O
to	O
the	O
APC	B-cell_type
.	O

These	O
signals	O
contribute	O
to	O
the	O
expression	O
of	O
co-stimulatory	O
activity	O
by	O
APCs	B-cell_type
and	O
have	O
important	O
consequences	O
for	O
cell	O
effector	O
function	O
.	O

MHC	B-protein
class	I-protein
II	I-protein
molecules	O
also	O
serve	O
as	O
receptors	O
for	O
B-cell	B-cell_type
stimulation	O
by	O
microbial	B-protein
superantigens	I-protein
.	O

In	O
this	O
review	O
,	O
Paul	O
Scholl	O
and	O
Raif	O
Geha	O
discuss	O
recent	O
advances	O
in	O
our	O
understanding	O
of	O
mechanisms	O
of	O
MHC	B-protein
class	I-protein
II	I-protein
signaling	O
and	O
analyse	O
their	O
role	O
in	O
human	O
B-cell	B-cell_type
activation	O
.	O

Effects	O
of	O
glucocorticoids	O
in	O
rheumatoid	O
arthritis	O
.	O

Diminished	O
glucocorticoid	B-protein
receptors	I-protein
do	O
not	O
result	O
in	O
glucocorticoid	O
resistance	O
.	O

OBJECTIVE	O
.	O

Lymphocytes	O
of	O
patients	O
with	O
rheumatoid	O
arthritis	O
(	O
RA	O
)	O
have	O
diminished	O
receptor	O
density	O
;	O
thus	O
,	O
patients	O
with	O
RA	O
should	O
show	O
partial	O
resistance	O
to	O
glucocorticoids	O
.	O

We	O
investigated	O
the	O
glucocorticoid	O
sensitivity	O
of	O
lymphocytes	B-cell_type
in	O
RA	O
patients	O
compared	O
with	O
healthy	O
subjects	O
.	O

METHODS	O
.	O

We	O
determined	O
the	O
effects	O
of	O
glucocorticoids	O
on	O
lymphocyte	B-cell_type
proliferation	O
and	O
cytokine	B-protein
release	O
.	O

RESULTS	O
.	O

Proliferation	O
and	O
cytokine	B-protein
release	O
were	O
inhibited	O
in	O
RA	O
patients	O
to	O
the	O
same	O
extent	O
as	O
in	O
healthy	O
controls	O
.	O

CONCLUSION	O
.	O

Diminished	O
receptor	O
density	O
in	O
RA	O
patients	O
does	O
not	O
result	O
in	O
glucocorticoid	O
resistance	O
.	O

Arrested	O
development	O
:	O
understanding	O
v-abl	B-DNA
.	O

The	O
protein	B-protein
tyrosine	I-protein
kinase	I-protein
activity	O
of	O
the	O
v-abl	B-DNA
oncogene	I-DNA
has	O
been	O
demonstrated	O
to	O
subvert	O
the	O
normal	O
second	O
messenger	O
systems	O
used	O
by	O
lymphoid	B-cell_type
cells	I-cell_type
for	O
growth	O
and	O
differentiation	O
.	O

Transformation	O
of	O
bone	O
marrow	O
with	O
the	O
Abelson	O
murine	O
leukemia	O
virus	O
results	O
in	O
the	O
appearance	O
of	O
B	B-cell_type
cell	I-cell_type
lineage	I-cell_type
cells	I-cell_type
arrested	O
at	O
the	O
pre-B	O
cell	O
stage	O
.	O

Recent	O
reports	O
have	O
characterized	O
these	O
cells	O
expressing	O
high	O
v-abl	B-DNA
kinase	O
activity	O
as	O
deficient	O
in	O
detectable	O
NF-kappaB	B-protein
DNA	O
binding	O
activity	O
and	O
low	O
level	O
RAG	B-DNA
gene	I-DNA
expression	O
.	O

These	O
observations	O
suggest	O
that	O
v-abl	B-DNA
may	O
be	O
inhibiting	O
the	O
differentiation	O
of	O
B	B-cell_type
cells	I-cell_type
by	O
blocking	O
these	O
two	O
crucial	O
elements	O
in	O
the	O
maturation	O
pathway	O
.	O

Corticosteroid	B-protein
receptors	I-protein
in	O
lymphocytes	B-cell_type
:	O
a	O
possible	O
marker	O
of	O
brain	O
involution	O
?	O

A	O
similarity	O
has	O
recently	O
been	O
found	O
between	O
the	O
regulation	O
of	O
corticosteroid	B-protein
receptors	I-protein
in	O
brain	O
and	O
in	O
lymphoid	O
tissue	O
.	O

We	O
have	O
studied	O
the	O
regulation	O
of	O
corticosteroid	B-protein
receptors	I-protein
in	O
human	B-cell_type
mononuclear	I-cell_type
leukocytes	I-cell_type
as	O
a	O
possible	O
marker	O
of	O
brain	O
involution	O
.	O

Type	B-protein
I	I-protein
corticosteroid	I-protein
receptors	I-protein
are	O
down	O
regulated	O
by	O
excess	O
of	O
mineralocorticoids	O
(	O
primary	O
and	O
secondary	O
hyperaldosteronism	O
,	O
pseudohyperaldosteronism	O
)	O
and	O
of	O
glucocorticoids	O
(	O
Cushing	O
's	O
syndrome	O
)	O
.	O
Type	B-protein
II	I-protein
corticosteroid	I-protein
receptors	I-protein
are	O
not	O
reduced	O
by	O
excess	O
of	O
endogenous	O
corticosteroids	O
(	O
Cushing	O
's	O
syndrome	O
)	O
.	O

In	O
normal	O
adults	O
there	O
is	O
a	O
direct	O
significant	O
correlation	O
between	O
plasma	O
cortisol	O
and	O
Type	B-protein
I	I-protein
and	O
between	O
plasma	O
cortisol	O
and	O
Type	B-protein
II	I-protein
receptors	I-protein
in	O
mononuclear	B-cell_type
leukocytes	I-cell_type
,	O
while	O
in	O
Cushing	O
's	O
syndrome	O
the	O
correlation	O
is	O
inverse	O
between	O
plasma	O
cortisol	O
at	O
8	O
a.m.	O
and	O
Type	B-protein
II	I-protein
receptors	I-protein
.	O

In	O
an	O
aged	O
population	O
the	O
mean	O
numbers	O
of	O
Type	B-protein
I	I-protein
and	O
of	O
Type	B-protein
II	I-protein
receptors	I-protein
are	O
lower	O
and	O
plasma	O
cortisol	O
is	O
higher	O
than	O
in	O
adult	O
controls	O
,	O
but	O
the	O
increase	O
of	O
plasma	O
cortisol	O
is	O
not	O
followed	O
by	O
a	O
clinical	O
picture	O
of	O
hypercorticism	O
.	O

Corticosteroid	B-protein
Type	I-protein
I	I-protein
and	I-protein
Type	I-protein
II	I-protein
receptors	I-protein
are	O
inversely	O
correlated	O
with	O
age	O
.	O

After	O
dexamethasone	O
suppression	O
(	O
1	O
mg	O
at	O
11	O
p.m.	O
)	O
Type	B-protein
I	I-protein
receptors	I-protein
always	O
decrease	O
in	O
controls	O
while	O
the	O
response	O
of	O
Type	B-protein
II	I-protein
is	O
not	O
homogeneous	O
.	O

In	O
an	O
aged	O
group	O
of	O
patients	O
,	O
both	O
receptors	O
are	O
reduced	O
by	O
dexamethasone	O
.	O

We	O
conclude	O
that	O
the	O
decrease	O
with	O
age	O
of	O
corticosteroid	B-protein
receptors	I-protein
is	O
possibly	O
related	O
to	O
a	O
physiological	O
involution	O
of	O
corticosteroid	B-protein
receptors	I-protein
and	O
that	O
this	O
reduction	O
does	O
increase	O
plasma	O
cortisol	O
concentration	O
,	O
without	O
affecting	O
the	O
glucocorticoid	O
effector	O
mechanism	O
.	O

All-trans	O
retinoic	O
acid	O
and	O
1	O
alpha	O
,	O
25-dihydroxyvitamin	O
D3	O
co-operate	O
to	O
promote	O
differentiation	O
of	O
the	O
human	B-cell_line
promyeloid	I-cell_line
leukemia	I-cell_line
cell	I-cell_line
line	I-cell_line
HL60	B-cell_line
to	O
monocytes	B-cell_type
.	O

A	O
basis	O
for	O
differentiation	O
therapy	O
of	O
leukemias	O
is	O
provided	O
by	O
knowledge	O
of	O
agents	O
which	O
induce	O
specific	O
lineage	O
maturation	O
.	O

All-trans	O
retinoic	O
acid	O
(	O
RA	O
)	O
induces	O
differentiation	O
of	O
HL60	B-cell_line
cells	I-cell_line
to	O
neutrophils	B-cell_type
and	O
is	O
used	O
to	O
treat	O
acute	O
promyelocytic	O
leukemia	O
.	O

We	O
observed	O
that	O
RA	O
did	O
not	O
induced	O
neutrophil	O
differentiation	O
in	O
serum-free	B-cell_line
grown	I-cell_line
HL60	I-cell_line
cells	I-cell_line
whereas	O
50	O
nM	O
1	O
alpha	O
,	O
25-dihydroxyvitamin	O
D3	O
(	O
D3	O
)	O
induced	O
maximal	O
monocyte	O
differentiation	O
.	O

Increasing	O
RA	O
concentrations	O
reduced	O
the	O
D3	O
concentration	O
required	O
for	O
monocyte	O
differentiation	O
.	O

Cells	O
treated	O
with	O
5	O
nM	O
D3	O
showed	O
little	O
response	O
,	O
but	O
differentiated	O
maximally	O
with	O
5	O
nM	O
D3	O
and	O
10	O
nM	O
RA	O
.	O

The	O
D3	O
analogs	O
MC903	O
,	O
EB1089	O
and	O
KH1060	O
were	O
more	O
potent	O
inducers	O
of	O
monocyte	O
differentiation	O
.	O

The	O
extent	O
to	O
which	O
analog	O
activity	O
was	O
increased	O
after	O
cotreatment	O
with	O
RA	O
was	O
inversely	O
related	O
to	O
potency	O
.	O

Twenty-four	O
hour	O
treatment	O
with	O
10	O
nM	O
RA	B-cell_line
primed	I-cell_line
cells	I-cell_line
for	O
response	O
to	O
5	O
nM	O
D3	O
;	O
the	O
reverse	O
sequence	O
being	O
ineffective	O
.	O

Priming	O
with	O
10	O
nM	O
RA	O
,	O
or	O
subsequent	O
treatment	O
with	O
D3	O
(	O
5	O
nM	O
)	O
,	O
did	O
not	O
alter	O
expression	O
of	O
mRNAs	B-RNA
encoding	O
receptors	B-protein
for	O
D3	O
(	O
VDR	B-protein
)	O
,	O
RA	O
(	O
RAR	B-protein
alpha	I-protein
)	O
or	O
9-CIS	O
RA	O
(	O
RXR	B-protein
alpha	I-protein
,	I-protein
beta	I-protein
,	I-protein
gamma	I-protein
)	O
.	O

That	O
RA	O
promotes	O
both	O
neutrophil	O
and	O
monocyte	O
differentiation	O
has	O
implications	O
for	O
the	O
use	O
of	O
RA	O
and	O
D3	O
in	O
treatment	O
of	O
leukemias	O
and	O
provides	O
insight	O
into	O
mechanisms	O
whereby	O
RAR	O
,	O
VDR	B-protein
and	O
RXR	B-protein
facilitate	O
monocyte	O
differentiation	O
.	O

[	O
An	O
overexpression	O
of	O
retinoic	B-protein
acid	I-protein
receptor	I-protein
alpha	I-protein
blocks	O
myeloid	B-cell_type
cell	I-cell_type
differentiation	O
at	O
the	O
promyelocyte	O
stage	O
]	O

Retinoic	O
acid	O
(	O
RA	O
)	O
,	O
a	O
vitamin	O
A	O
derivative	O
,	O
exerts	O
a	O
wide	O
range	O
of	O
biological	O
effects	O
related	O
to	O
cell	O
proliferation	O
and	O
differentiation	O
.	O

The	O
pleiotropic	O
effects	O
of	O
RA	O
are	O
thought	O
to	O
be	O
mediated	O
through	O
specific	O
nuclear	O
RA	B-protein
receptors	I-protein
(	O
RARs	B-protein
)	O
.	O

RARs	B-protein
are	O
members	O
of	O
the	O
steroid/thyroid	B-protein
hormone	I-protein
receptor	I-protein
superfamily	I-protein
and	O
exhibit	O
a	O
molecular	O
structure	O
that	O
possess	O
discrete	O
DNA-binding	O
and	O
RA	B-protein
(	I-protein
ligand	I-protein
)	I-protein
-binding	I-protein
domains	I-protein
.	O

In	O
hematopoietic	O
system	O
,	O
RA	O
and	O
RARs	B-protein
,	O
predominantly	O
RAR	B-protein
alpha	I-protein
may	O
play	O
key	O
roles	O
for	O
the	O
proliferation	O
and	O
differentiation	O
of	O
hematopoietic	B-cell_type
progenitors	I-cell_type
.	O

However	O
,	O
it	O
is	O
currently	O
unknown	O
how	O
RA	O
and	O
RARs	B-protein
are	O
involved	O
in	O
regulating	O
normal	O
hematopoietic	O
differentiation	O
.	O

To	O
make	O
clear	O
the	O
roles	O
of	O
RA	O
and	O
RAR	B-protein
alpha	I-protein
in	O
the	O
normal	O
hematopoiesis	O
,	O
I	O
have	O
introduced	O
the	O
construct	O
of	O
human	B-protein
RAR	I-protein
alpha	I-protein
(	O
hRAR	B-protein
alpha	I-protein
)	O
into	O
murine	B-cell_type
bone	I-cell_type
marrow	I-cell_type
cells	I-cell_type
with	O
retroviral	O
vector	O
,	O
and	O
selected	O
infected	O
cells	O
with	O
drug	B-DNA
resistant	I-DNA
marker	I-DNA
(	O
Neo	B-DNA
(	I-DNA
r	I-DNA
)	I-DNA
)	O
cultured	O
on	O
the	O
stroma	B-cell_line
cell	I-cell_line
line	I-cell_line
(	O
PA6-neo	B-cell_line
)	O
,	O
and	O
analyzed	O
the	O
behavior	O
of	O
infected	B-cell_type
cells	I-cell_type
.	O

All	O
of	O
procedure	O
were	O
done	O
in	O
vitro	O
.	O

Most	O
cells	O
infected	O
with	O
hRAR	B-protein
alpha	I-protein
exhibited	O
promyelocytic	B-cell_type
morphology	I-cell_type
and	O
were	O
thought	O
to	O
be	O
blocked	O
at	O
the	O
promyelocytic	O
stage	O
in	O
their	O
myeloid	O
differentiation	O
.	O

Furthermore	O
,	O
these	O
immature	B-cell_type
cells	I-cell_type
differentiated	O
terminally	O
into	O
mature	O
granulocytes	O
by	O
adding	O
with	O
RA	O
(	O
10	O
(	O
-6	O
)	O
M	O
)	O
.	O

RAR	B-protein
alpha	I-protein
infected	B-cell_type
cells	I-cell_type
were	O
also	O
able	O
to	O
differentiate	O
into	O
mature	B-cell_type
macrophages	I-cell_type
in	O
the	O
both	O
of	O
long	O
term	O
culture	O
and	O
IL3	B-cell_line
colony	I-cell_line
.	O

These	O
observations	O
suggest	O
that	O
an	O
overexpression	O
of	O
RAR	B-protein
alpha	I-protein
alone	O
is	O
effective	O
to	O
suppress	O
myeloid	B-cell_type
cell	I-cell_type
differentiation	O
and	O
RAR	B-protein
alpha	I-protein
plays	O
a	O
crucial	O
role	O
in	O
the	O
terminal	O
differentiation	O
of	O
myeloid	O
precursors	O
.	O

The	O
system	O
described	O
here	O
may	O
serve	O
as	O
a	O
model	O
for	O
studying	O
the	O
the	O
essential	B-DNA
genes	I-DNA
for	O
differentiation	O
of	O
normal	B-cell_type
bone	I-cell_type
marrow	I-cell_type
cells	I-cell_type
.	O

Hypoxic	O
induction	O
of	O
interleukin-8	B-DNA
gene	I-DNA
expression	O
in	O
human	B-cell_type
endothelial	I-cell_type
cells	I-cell_type
.	O

Because	O
leukocyte-mediated	O
tissue	O
damage	O
is	O
an	O
important	O
component	O
of	O
the	O
pathologic	O
picture	O
in	O
ischemia/reperfusion	O
,	O
we	O
have	O
sought	O
mechanisms	O
by	O
which	O
PMNs	B-cell_type
are	O
directed	O
into	O
hypoxic	O
tissue	O
.	O

Incubation	O
of	O
human	B-cell_type
endothelial	I-cell_type
cells	I-cell_type
(	O
ECs	B-cell_type
)	O
in	O
hypoxia	O
,	O
PO2	O
approximately	O
14-18	O
Torr	O
,	O
led	O
to	O
time-dependent	O
release	O
of	O
IL-8	B-protein
antigen	O
into	O
the	O
conditioned	O
medium	O
;	O
this	O
was	O
accompanied	O
by	O
increased	O
chemotactic	O
activity	O
for	O
PMNs	B-cell_type
,	O
blocked	O
by	O
antibody	O
to	O
IL-8	B-protein
.	O

Production	O
of	O
IL-8	B-protein
by	O
hypoxic	O
ECs	B-cell_type
occurred	O
concomitantly	O
with	O
both	O
increased	O
levels	O
of	O
IL-8	B-RNA
mRNA	I-RNA
,	O
based	O
on	O
polymerase	O
chain	O
reaction	O
analysis	O
,	O
and	O
increased	O
IL-8	B-protein
transcription	O
,	O
based	O
on	O
nuclear	O
run-on	O
assays	O
.	O

Northern	O
analysis	O
of	O
mRNA	O
from	O
hypoxic	O
ECs	B-cell_type
also	O
demonstrated	O
increased	O
levels	O
of	O
mRNA	B-RNA
for	O
macrophage	B-protein
chemotactic	I-protein
protein-1	I-protein
,	O
another	O
member	O
of	O
the	O
chemokine	B-protein
superfamily	I-protein
of	O
proinflammatory	B-protein
cytokines	I-protein
.	O

IL-8	B-DNA
gene	I-DNA
induction	O
was	O
associated	O
with	O
the	O
presence	O
of	O
increased	O
binding	O
activity	O
in	O
nuclear	O
extracts	O
from	O
hypoxic	B-cell_type
ECs	I-cell_type
for	O
the	O
NF-kB	O
site	O
.	O

Studies	O
with	O
human	O
umbilical	O
vein	O
segments	O
exposed	O
to	O
hypoxia	O
also	O
demonstrated	O
increased	O
elaboration	O
of	O
IL-8	B-protein
antigen	I-protein
compared	O
with	O
normoxic	O
controls	O
.	O

In	O
mice	O
exposed	O
to	O
hypoxia	O
(	O
PO2	O
approximately	O
30-40	O
Torr	O
)	O
,	O
there	O
was	O
increased	O
pulmonary	O
leukostasis	O
,	O
as	O
evidenced	O
by	O
increased	O
myeloperoxidase	B-protein
activity	O
in	O
tissue	O
homogenates	O
.	O

In	O
parallel	O
,	O
increased	O
levels	O
of	O
transcripts	O
for	O
IP-10	B-protein
,	O
a	O
murine	O
homologue	O
in	O
the	O
chemokine	B-protein
family	I-protein
related	O
to	O
IL-8	B-protein
,	O
were	O
observed	O
in	O
hypoxic	O
lung	O
tissue	O
.	O

Taken	O
together	O
,	O
these	O
data	O
suggest	O
that	O
hypoxia	O
constitutes	O
a	O
stimulus	O
for	O
leukocyte	O
chemotaxis	O
and	O
tissue	O
leukostasis	O
.	O

Thrombin	B-protein
and	O
thrombin	B-protein
receptor	I-protein
agonist	O
peptide	O
induce	O
early	O
events	O
of	O
T	O
cell	O
activation	O
and	O
synergize	O
with	O
TCR	B-protein
cross-linking	O
for	O
CD69	B-protein
expression	O
and	O
interleukin	O
2	O
production	O
.	O

Thrombin	B-protein
stimulation	O
of	O
the	O
T	B-cell_line
leukemic	I-cell_line
cell	I-cell_line
line	I-cell_line
Jurkat	I-cell_line
induced	O
a	O
transient	O
increase	O
in	O
[	O
Ca2+	O
]	O
i	O
.	O

Proteolytic	O
activity	O
of	O
the	O
enzyme	B-protein
was	O
required	O
for	O
this	O
effect	O
since	O
diisopropyl	B-protein
fluorophosphate-thrombin	I-protein
failed	O
to	O
increase	O
[	O
Ca2+	O
]	O
i	O
.	O

Furthermore	O
,	O
hirudin	O
and	O
anti-thrombin	B-protein
III	I-protein
inhibited	O
the	O
thrombin-induced	O
[	O
Ca2+	O
]	O
i	O
rise	O
in	O
Jurkat	B-cell_line
T	I-cell_line
cells	I-cell_line
.	O

A	O
synthetic	O
thrombin	B-protein
receptor	I-protein
agonist	O
peptide	O
(	O
TRP	O
)	O
of	O
7	O
residues	O
(	O
SFLLRNP	O
)	O
was	O
found	O
to	O
be	O
as	O
effective	O
as	O
thrombin	B-protein
for	O
[	O
Ca2+	O
]	O
i	O
mobilization	O
,	O
and	O
both	O
agonists	O
induced	O
Ca2+	O
release	O
exclusively	O
from	O
internal	O
stores	O
.	O

Thrombin	B-protein
stimulated	O
tyrosine	O
phosphorylation	O
of	O
several	O
proteins	O
of	O
molecular	B-protein
mass	I-protein
40	I-protein
,	I-protein
42	I-protein
,	I-protein
70	I-protein
,	I-protein
120	I-protein
,	I-protein
and	I-protein
130	I-protein
kDa	I-protein
.	O

There	O
was	O
a	O
good	O
correlation	O
between	O
thrombin	B-protein
-induced	O
tyrosine	O
phosphorylation	O
of	O
the	O
latter	O
three	O
proteins	O
and	O
Ca2+	O
mobilization	O
.	O

Thrombin	B-protein
and	O
TRP	O
also	O
caused	O
translocation	O
of	O
protein	B-protein
kinase	I-protein
C	I-protein
from	O
the	O
cytosol	O
to	O
the	O
plasma	O
membrane	O
.	O

As	O
a	O
likely	O
consequence	O
of	O
these	O
events	O
,	O
thrombin	B-protein
activated	O
the	O
nuclear	B-protein
factor	I-protein
NF-kB	I-protein
.	O

Several	O
cell	O
lines	O
of	O
hematopoietic	O
origin	O
including	O
the	O
leukemic	B-cell_line
T	I-cell_line
cell	I-cell_line
line	I-cell_line
HPB.ALL	I-cell_line
and	O
the	O
erythroleukemic	B-cell_line
cell	I-cell_line
line	I-cell_line
K562	I-cell_line
were	O
responsive	O
to	O
thrombin	B-protein
,	O
whereas	O
others	O
such	O
as	O
THP1	B-cell_line
,	O
a	O
myelomonocytic	B-cell_line
cell	I-cell_line
line	I-cell_line
,	O
and	O
BL2	B-cell_line
,	I-cell_line
a	O
Burkitt	B-cell_line
lymphoma	I-cell_line
were	O
refractory	O
to	O
thrombin	B-protein
or	O
TRP	O
stimulation	O
.	O

The	O
magnitude	O
of	O
the	O
thrombin	B-protein
response	O
in	O
the	O
different	O
cell	O
types	O
paralleled	O
the	O
expression	O
of	O
the	O
thrombin	B-RNA
receptor	I-RNA
mRNA	I-RNA
.	O

We	O
found	O
that	O
activation	O
of	O
Jurkat	B-cell_line
T	I-cell_line
cells	I-cell_line
by	O
a	O
combination	O
of	O
phytohemagglutinin	B-protein
and	O
phorbol	O
12-myristate	O
13-acetate	O
led	O
to	O
a	O
dramatic	O
inhibition	O
of	O
thrombin	B-RNA
receptor	I-RNA
mRNA	I-RNA
expression	O
and	O
to	O
a	O
concomitant	O
loss	O
of	O
the	O
thrombin	B-protein
response	O
.	O

Finally	O
,	O
we	O
demonstrate	O
that	O
thrombin	B-protein
and	O
TRP	O
enhanced	O
CD69	B-protein
expression	O
and	O
interleukin	B-protein
2	I-protein
production	O
induced	O
by	O
T	B-protein
cell	I-protein
receptor	I-protein
cross-linking	O
in	O
both	O
Jurkat	B-cell_line
T	I-cell_line
cells	I-cell_line
and	O
peripheral	O
blood	O
lymphocytes	B-cell_type
.	O

These	O
findings	O
highlight	O
the	O
role	O
of	O
thrombin	B-protein
as	O
a	O
potential	O
regulator	O
of	O
T	B-cell_type
lymphocyte	I-cell_type
activation	O
.	O

Stress	O
response	O
of	O
senescent	B-cell_type
T	I-cell_type
lymphocytes	I-cell_type
:	O
reduced	O
hsp70	B-protein
is	O
independent	O
of	O
the	O
proliferative	O
block	O
.	O

Senescent	B-cell_line
human	I-cell_line
T	I-cell_line
lymphocyte	I-cell_line
cultures	I-cell_line
are	O
unable	O
to	O
undergo	O
proliferation	O
,	O
but	O
show	O
no	O
difference	O
from	O
early	B-cell_line
passage	I-cell_line
cells	I-cell_line
in	O
cytotoxic	O
function	O
or	O
surface	O
antigenic	O
profile	O
.	O

A	O
second	O
feature	O
of	O
senescent	B-cell_line
T	I-cell_line
cells	I-cell_line
is	O
the	O
dramatic	O
reduction	O
in	O
hsp70	B-protein
production	O
in	O
response	O
to	O
heat	O
shock	O
.	O

This	O
decline	O
is	O
associated	O
with	O
a	O
decrease	O
in	O
binding	O
of	O
nuclear	O
extracts	O
to	O
the	O
consensus	B-DNA
heat	I-DNA
shock	I-DNA
element	I-DNA
.	O

Interestingly	O
,	O
the	O
progressive	O
decline	O
in	O
the	O
heat	O
shock	O
response	O
of	O
cultured	B-cell_line
T	I-cell_line
cells	I-cell_line
correlates	O
with	O
the	O
percent	O
proliferative	O
life	O
span	O
completed	O
rather	O
than	O
with	O
the	O
actual	O
proliferative	O
activity	O
at	O
the	O
time	O
of	O
heat	O
shock	O
.	O

This	O
suggests	O
that	O
for	O
senescent	B-cell_type
T	I-cell_type
cells	I-cell_type
the	O
reduced	O
ability	O
to	O
respond	O
to	O
heat	O
shock	O
by	O
producing	O
hsp70	B-protein
,	O
although	O
possibly	O
lying	O
at	O
the	O
level	O
of	O
transcriptional	O
control	O
,	O
may	O
nevertheless	O
be	O
unrelated	O
to	O
the	O
reduced	O
DNA	O
synthesis	O
or	O
the	O
diminished	O
proliferative	O
activity	O
also	O
manifested	O
by	O
these	O
cells	O
.	O

Involvement	O
of	O
phospholipase	B-protein
D	I-protein
in	O
the	O
activation	O
of	O
transcription	B-protein
factor	I-protein
AP-1	I-protein
in	O
human	B-cell_line
T	I-cell_line
lymphoid	I-cell_line
Jurkat	I-cell_line
cells	I-cell_line
.	O

The	O
induction	O
of	O
the	O
AP-1	B-protein
transcription	B-protein
factor	I-protein
has	O
been	O
ascribed	O
to	O
the	O
early	O
events	O
leading	O
to	O
T	O
lymphocyte	O
activation	O
.	O

We	O
have	O
examined	O
the	O
possibility	O
that	O
stimulation	O
of	O
phospholipase	B-protein
D	I-protein
(	O
PLD	B-protein
)	O
may	O
regulate	O
activation	O
of	O
transcription	B-protein
factor	I-protein
AP-1	I-protein
in	O
human	O
T	O
cells	O
by	O
transfecting	O
human	O
T	B-cell_line
lymphocyte	I-cell_line
Jurkat	I-cell_line
cells	I-cell_line
with	O
a	O
plasmid	O
containing	O
an	O
AP-1	B-DNA
enhancer	I-DNA
element	I-DNA
and	O
a	O
chloramphenicol	B-DNA
acetyltransferase	I-DNA
reporter	I-DNA
gene	I-DNA
.	O

We	O
have	O
detected	O
activatable	O
PLD	B-protein
in	O
Jurkat	B-cell_line
cells	I-cell_line
,	O
and	O
we	O
have	O
found	O
that	O
addition	O
of	O
phosphatidic	O
acid	O
(	O
PA	O
)	O
,	O
the	O
physiologic	O
product	O
of	O
PLD	B-protein
action	O
on	O
phospholipids	O
,	O
is	O
rapidly	O
incorporated	O
into	O
Jurkat	B-cell_line
cells	I-cell_line
and	O
leads	O
to	O
activation	O
of	O
transcription	B-protein
factor	I-protein
AP-1	I-protein
.	O

Treatment	O
of	O
Jurkat	B-cell_line
cells	I-cell_line
with	O
anti-CD3	B-protein
mAb	I-protein
activated	O
both	O
PLD	B-protein
and	O
transcription	B-protein
factor	I-protein
AP-1	I-protein
.	O

Wortmannin	O
,	O
an	O
inhibitor	O
of	O
receptor-coupled	O
PLD	B-protein
activation	O
,	O
blocked	O
the	O
anti-CD3	B-protein
-induced	O
increases	O
in	O
both	O
PLD	B-protein
activity	O
and	O
AP-1	B-DNA
enhancer	I-DNA
activity	O
.	O

We	O
found	O
a	O
good	O
correlation	O
in	O
the	O
transfected	B-cell_line
cells	I-cell_line
between	O
PLD	B-protein
activation	O
and	O
induction	O
of	O
AP-1	B-DNA
enhancer	I-DNA
activity	O
under	O
different	O
experimental	O
conditions	O
.	O

Furthermore	O
,	O
ethanol	O
,	O
an	O
inhibitor	O
of	O
the	O
PLD	B-protein
pathway	O
,	O
blocked	O
the	O
anti-CD3-stimulated	O
AP-1	B-DNA
enhancer	I-DNA
activity	O
.	O

However	O
,	O
this	O
anti-CD3	B-protein
-mediated	O
response	O
was	O
not	O
inhibited	O
by	O
neomycin	O
,	O
an	O
inhibitor	O
of	O
phosphoinositide	O
hydrolysis	O
.	O

The	O
increases	O
in	O
AP-1	B-DNA
enhancer	I-DNA
activity	O
induced	O
by	O
PA	O
or	O
anti-CD3	B-protein
mAb	I-protein
were	O
efficiently	O
abrogated	O
by	O
the	O
presence	O
of	O
propranolol	O
,	O
an	O
inhibitor	O
of	O
PA	O
phosphohydrolase	B-protein
and	O
protein	B-protein
kinase	I-protein
C	I-protein
(	O
PKC	B-protein
)	O
.	O

Furthermore	O
,	O
the	O
PA	O
-and	O
the	O
anti-CD3	B-protein
-induced	O
increases	O
in	O
AP-1	B-DNA
enhancer	I-DNA
activity	O
were	O
blocked	O
by	O
the	O
presence	O
of	O
PKC	B-protein
inhibitors	O
or	O
by	O
PKC	B-protein
down-regulation	O
.	O

These	O
data	O
indicate	O
that	O
PLD	B-protein
stimulation	O
can	O
activate	O
the	O
transcription	B-protein
factor	I-protein
AP-1	I-protein
in	O
T	B-cell_type
lymphocytes	I-cell_type
,	O
and	O
suggest	O
that	O
the	O
induction	O
of	O
AP-1	B-DNA
enhancer	I-DNA
factor	O
activity	O
by	O
PA	O
is	O
mediated	O
via	O
PKC	B-protein
stimulation	O
,	O
either	O
through	O
a	O
direct	O
activating	O
effect	O
of	O
PA	O
or	O
through	O
PA-derived	O
diacylglycerol	O
formation	O
.	O

These	O
data	O
also	O
provide	O
evidence	O
for	O
a	O
role	O
of	O
PLD	B-protein
-derived	O
lipids	O
in	O
the	O
induction	O
of	O
AP-1	B-DNA
enhancer	I-DNA
activity	O
resulting	O
from	O
stimulation	O
of	O
the	O
TCR/CD3	B-protein
complex	I-protein
,	O
suggesting	O
that	O
increased	O
PLD	B-protein
activity	O
can	O
play	O
an	O
important	O
role	O
in	O
T	B-cell_type
lymphocyte	I-cell_type
activation	O
.	O

Upregulation	O
of	O
bcl-2	B-DNA
by	O
the	O
Epstein-Barr	B-protein
virus	I-protein
latent	I-protein
membrane	I-protein
protein	I-protein
LMP1	B-protein
:	O
a	O
B-cell-specific	O
response	O
that	O
is	O
delayed	O
relative	O
to	O
NF-kappa	B-protein
B	I-protein
activation	O
and	O
to	O
induction	O
of	O
cell	B-protein
surface	I-protein
markers	I-protein
.	O

An	O
ability	O
of	O
the	O
Epstein-Barr	B-protein
virus	I-protein
latent	I-protein
membrane	I-protein
protein	I-protein
LMP1	B-protein
to	O
enhance	O
the	O
survival	O
of	O
infected	B-cell_type
B	I-cell_type
cells	I-cell_type
through	O
upregulation	O
of	O
the	O
bcl-2	B-DNA
oncogene	I-DNA
was	O
first	O
suggested	O
by	O
experiments	O
involving	O
gene	O
transfection	O
and	O
the	O
selection	O
of	O
stable	O
LMP1+	B-cell_line
clones	I-cell_line
(	O
S.Henderson	O
,	O
M.	O
Rowe	O
,	O
C.Gregory	O
,	O
F.Wang	O
,	O
E.Kieff	O
,	O
and	O
A.Rickinson	O
,	O
Cell	O
65	O
:	O
1107-1115	O
,	O
1991	O
)	O
.	O

However	O
,	O
it	O
was	O
not	O
possible	O
to	O
ascertain	O
whether	O
Bcl-2	B-protein
upregulation	O
was	O
a	O
specific	O
consequence	O
of	O
LMP1	B-protein
expression	O
or	O
an	O
artifact	O
of	O
the	O
selection	O
procedure	O
whereby	O
rare	O
Bcl-2+	B-cell_line
cells	I-cell_line
already	O
present	O
in	O
the	O
starting	O
population	O
might	O
best	O
be	O
able	O
to	O
tolerate	O
the	O
potentially	O
toxic	O
effects	O
of	O
LMP1	B-protein
.	O

We	O
therefore	O
reexamined	O
this	O
issue	O
by	O
using	O
two	O
different	O
experimental	O
approaches	O
that	O
allowed	O
LMP1	B-protein
-induced	O
effects	O
to	O
be	O
monitored	O
immediately	O
following	O
expression	O
of	O
the	O
viral	O
protein	O
and	O
in	O
the	O
absence	O
of	O
selective	O
pressures	O
;	O
activation	O
of	O
the	O
NF-kappa	B-protein
B	I-protein
transcription	B-protein
factor	I-protein
and	O
upregulation	O
of	O
the	O
cell	B-protein
adhesion	I-protein
molecule	I-protein
ICAM-1	B-protein
were	O
used	O
as	O
early	O
indices	O
of	O
LMP1	B-protein
function	O
.	O

In	O
the	O
first	O
approach	O
,	O
stable	O
clones	O
of	O
two	O
B-cell	B-cell_line
lines	I-cell_line
carrying	O
an	O
LMP1	B-protein
gene	O
under	O
the	O
control	O
of	O
an	O
inducible	O
metallothionein	B-DNA
promoter	I-DNA
were	O
induced	O
to	O
express	O
LMP1	B-protein
in	O
all	O
cells	O
.	O

Activation	O
of	O
NK-kappa	B-protein
B	I-protein
and	O
upregulation	O
of	O
ICAM-1	B-protein
occurred	O
within	O
24	O
h	O
and	O
were	O
followed	O
at	O
48	O
to	O
72	O
h	O
by	O
upregulation	O
of	O
Bcl-2	B-protein
.	O

In	O
the	O
second	O
approach	O
,	O
we	O
tested	O
the	O
generality	O
of	O
this	O
phenomenon	O
by	O
transiently	O
expressing	O
LMP1	B-protein
from	O
a	O
strong	O
constitutively	O
active	O
promoter	O
in	O
a	O
range	O
of	O
different	O
cell	O
types	O
.	O

All	O
six	O
B-cell	B-cell_line
lines	I-cell_line
tested	O
showed	O
NF-kappa	B-protein
B	I-protein
activation	O
in	O
response	O
to	O
LMP1	B-protein
expression	O
,	O
and	O
this	O
was	O
followed	O
in	O
five	O
of	O
six	O
lines	O
by	O
expression	O
of	O
ICAM-1	B-protein
and	O
Bcl-2	B-protein
.	O

In	O
the	O
same	O
experiments	O
,	O
all	O
three	O
non-	O
B-cell	B-cell_line
lines	I-cell_line
showed	O
NF-kappa	B-protein
B	I-protein
activation	O
and	O
ICAM-1	B-protein
upregulation	O
but	O
never	O
any	O
effect	O
upon	O
Bcl-2	B-protein
.	O

We	O
therefore	O
conclude	O
that	O
Bcl-2	B-protein
upregulation	O
is	O
part	O
of	O
the	O
panoply	O
of	O
cellular	O
changes	O
induced	O
by	O
LMP1	B-protein
but	O
that	O
the	O
effect	O
is	O
cell	O
type	O
specific	O
.	O

Our	O
data	O
also	O
suggest	O
that	O
whilst	O
NF-kappa	B-protein
B	I-protein
may	O
be	O
an	O
essential	O
component	O
of	O
LMP1	B-protein
signal	O
transduction	O
,	O
other	O
cell-specific	B-protein
factors	I-protein
may	O
be	O
required	O
to	O
effect	O
some	O
functions	O
of	O
the	O
viral	B-protein
protein	I-protein
.	O

Long-term	O
inositol	O
phosphate	O
release	O
,	O
but	O
not	O
tyrosine	B-protein
kinase	I-protein
activity	O
,	O
correlates	O
with	O
IL-2	B-protein
secretion	O
and	O
NF-AT	B-protein
induction	O
in	O
anti-CD3-activated	B-cell_line
peripheral	I-cell_line
human	I-cell_line
T	I-cell_line
lymphocytes	I-cell_line
.	O

The	O
cascade	O
of	O
events	O
within	O
the	O
first	O
few	O
minutes	O
of	O
T	B-cell_type
cell	I-cell_type
stimulation	O
has	O
been	O
well	O
characterized	O
.	O

Although	O
many	O
second	O
messengers	O
have	O
been	O
shown	O
to	O
be	O
necessary	O
and	O
sufficient	O
for	O
T	B-cell_type
cell	I-cell_type
activation	O
in	O
a	O
number	O
of	O
model	O
systems	O
,	O
the	O
rate-limiting	O
step	O
in	O
peripheral	B-cell_type
T	I-cell_type
cells	I-cell_type
has	O
not	O
been	O
demonstrated	O
.	O

To	O
model	O
effective	O
versus	O
ineffective	O
CD3	B-protein
-mediated	O
stimulation	O
in	O
peripheral	B-cell_type
T	I-cell_type
cells	I-cell_type
,	O
we	O
used	O
two	O
anti-CD3	B-protein
mAbs	I-protein
that	O
differ	O
in	O
their	O
ability	O
to	O
stimulate	O
purified	B-cell_type
T	I-cell_type
cells	I-cell_type
:	O
OKT3	B-protein
,	O
which	O
causes	O
early	O
second	O
messenger	O
generation	O
but	O
is	O
unable	O
to	O
activate	O
T	B-cell_type
cells	I-cell_type
without	O
a	O
second	O
signal	O
,	O
and	O
64.1	B-protein
,	O
which	O
stimulates	O
T	B-cell_type
cell	I-cell_type
proliferation	O
on	O
its	O
own	O
.	O

We	O
found	O
that	O
tyrosine	B-protein
kinase	I-protein
activity	O
was	O
similar	O
for	O
both	O
mAbs	B-protein
over	O
a	O
period	O
of	O
hours	O
.	O

However	O
,	O
the	O
inositol	O
phosphate	O
response	O
was	O
stronger	O
for	O
64.1	B-protein
than	O
for	O
OKT3	B-protein
.	O

To	O
tie	O
these	O
events	O
to	O
gene	O
activation	O
,	O
we	O
measured	O
NF-kappa	B-protein
B	I-protein
and	O
NF-AT	B-protein
activity	O
in	O
the	O
nucleus	O
after	O
anti-CD3	B-protein
stimulation	O
.	O

Both	O
stimuli	O
induced	O
the	O
appearance	O
of	O
the	O
NF-kappa	B-protein
B	I-protein
components	I-protein
(	O
c-Rel	B-protein
,	O
p65	B-protein
(	O
RelA	B-protein
)	O
,	O
and	O
p50	B-protein
(	O
NF-kappa	B-protein
B1	I-protein
)	O
)	O
and	O
NF-kappa	B-protein
B	I-protein
DNA	O
binding	O
activity	O
in	O
the	O
nucleus	O
.	O

However	O
,	O
only	O
64.1	B-protein
induced	O
NF-AT	B-protein
in	O
the	O
nucleus	O
,	O
correlating	O
with	O
its	O
ability	O
to	O
activate	O
T	B-cell_type
cells	I-cell_type
.	O

Thus	O
,	O
NF-AT	B-protein
induction	O
and	O
IL-2	B-protein
secretion	O
were	O
correlated	O
with	O
the	O
levels	O
of	O
inositol	O
phosphate	O
release	O
but	O
not	O
with	O
gross	O
levels	O
of	O
tyrosine	B-protein
kinase	I-protein
activity	O
induced	O
late	O
following	O
the	O
response	O
.	O

On	O
the	O
other	O
hand	O
,	O
NF-kappa	B-protein
B	I-protein
induction	O
and	O
IL-2	B-protein
receptor	O
expression	O
occurred	O
even	O
with	O
the	O
smaller	O
second	O
messenger	O
response	O
generated	O
by	O
OKT3	B-protein
.	O

HLA-DR-	O
,	O
CD33+	O
,	O
CD56+	O
,	O
CD16-	O
myeloid/natural	O
killer	O
cell	O
acute	O
leukemia	O
:	O
a	O
previously	O
unrecognized	O
form	O
of	O
acute	O
leukemia	O
potentially	O
misdiagnosed	O
as	O
French-American-British	O
acute	O
myeloid	O
leukemia-M3	O
[	O
see	O
comments	O
]	O

We	O
have	O
identified	O
and	O
characterized	O
a	O
previously	O
unrecognized	O
form	O
of	O
acute	O
leukemia	O
that	O
shares	O
features	O
of	O
both	O
myeloid	B-cell_type
and	I-cell_type
natural	I-cell_type
killer	I-cell_type
(	I-cell_type
NK	I-cell_type
)	I-cell_type
cells	I-cell_type
.	O

From	O
a	O
consecutive	O
series	O
of	O
350	O
cases	O
of	O
adult	O
de	O
novo	O
acute	O
myeloid	O
leukemia	O
(	O
AML	O
)	O
,	O
we	O
identified	O
20	O
cases	O
(	O
6	O
%	O
)	O
with	O
a	O
unique	O
immunophenotype	O
:	O
CD33+	O
,	O
CD56+	O
,	O
CD11a+	O
,	O
CD13lo	O
,	O
CD15lo	O
,	O
CD34+/-	O
,	O
HLA-DR	B-protein
-	O
,	O
CD16	B-protein
-	O
.	O

Multicolor	O
flow	O
cytometric	O
assays	O
confirmed	O
the	O
coexpression	O
of	O
myeloid	B-protein
(	I-protein
CD33	I-protein
,	I-protein
CD13	I-protein
,	I-protein
CD15	I-protein
)	I-protein
and	I-protein
NK	I-protein
cell-associated	I-protein
(	I-protein
CD56	I-protein
)	I-protein
antigens	I-protein
in	O
each	O
case	O
,	O
whereas	O
reverse	O
transcription	O
polymerase	O
chain	O
reaction	O
(	O
RT-PCR	O
)	O
assays	O
confirmed	O
the	O
identity	O
of	O
CD56	B-protein
(	O
neural	B-protein
cell	I-protein
adhesion	I-protein
molecule	I-protein
)	O
in	O
leukemic	B-cell_type
blasts	I-cell_type
.	O

Although	O
two	O
cases	O
expressed	O
CD4	B-protein
,	O
no	O
case	O
expressed	O
CD2	B-protein
,	O
CD3	B-protein
,	O
or	O
CD8	B-protein
and	O
no	O
case	O
showed	O
clonal	O
rearrangement	O
of	O
genes	O
encoding	O
the	O
T-cell	B-protein
receptor	I-protein
(	O
TCR	B-protein
beta	I-protein
,	I-protein
gamma	I-protein
,	I-protein
delta	I-protein
)	O
.	O

Leukemic	O
blasts	O
in	O
the	O
majority	O
of	O
cases	O
shared	O
unique	O
morphologic	O
features	O
(	O
deeply	O
invaginated	O
nuclear	O
membranes	O
,	O
scant	O
cytoplasm	O
with	O
fine	O
azurophilic	O
granularity	O
,	O
and	O
finely	O
granular	O
Sudan	O
black	O
B	O
and	O
myeloperoxidase	B-protein
cytochemical	O
reactivity	O
)	O
that	O
were	O
remarkably	O
similar	O
to	O
those	O
of	O
acute	O
promyelocytic	O
leukemia	O
(	O
APL	O
)	O
;	O
particularly	O
the	O
microgranular	B-protein
variant	I-protein
(	O
FAB	B-protein
AML-M3v	I-protein
)	O
.	O

However	O
,	O
all	O
20	O
cases	O
lacked	O
the	O
t	O
(	O
15	O
;	O
17	O
)	O
and	O
17	O
cases	O
tested	O
lacked	O
the	O
promyelocytic/retinoic	B-RNA
acid	I-RNA
receptor	I-RNA
alpha	I-RNA
(	I-RNA
RAR	I-RNA
alpha	I-RNA
)	I-RNA
fusion	I-RNA
transcript	I-RNA
in	O
RT-PCR	O
assays	O
;	O
12	O
cases	O
had	O
46	O
,	O
XX	O
or	O
46	O
,	O
XY	O
karyotypes	O
,	O
whereas	O
2	O
cases	O
had	O
abnormalities	O
of	O
chromosome	B-DNA
17q	I-DNA
:	O
1	O
with	O
del	B-DNA
(	I-DNA
17	I-DNA
)	I-DNA
(	I-DNA
q25	I-DNA
)	I-DNA
and	O
the	O
other	O
with	O
t	B-DNA
(	I-DNA
11	I-DNA
;	I-DNA
17	I-DNA
)	I-DNA
(	I-DNA
q23	I-DNA
;	I-DNA
q21	I-DNA
)	I-DNA
and	O
the	O
promyelocytic	B-RNA
leukemia	I-RNA
zinc	I-RNA
finger/RAR	I-RNA
alpha	I-RNA
fusion	I-RNA
transcript	I-RNA
.	O

All	O
cases	O
tested	O
(	O
6/20	O
)	O
,	O
including	O
the	O
case	O
with	O
t	B-DNA
(	I-DNA
11	I-DNA
;	I-DNA
17	I-DNA
)	I-DNA
,	O
failed	O
to	O
differentiate	O
in	O
vitro	O
in	O
response	O
to	O
all-trans	O
retinoic	O
acid	O
(	O
ATRA	O
)	O
,	O
suggesting	O
that	O
these	O
cases	O
may	O
account	O
for	O
some	O
APLs	O
that	O
have	O
not	O
shown	O
a	O
clinical	O
response	O
to	O
ATRA	O
.	O

Four	O
of	O
6	O
cases	O
tested	O
showed	O
functional	O
NK	O
cell-mediated	O
cytotoxicity	O
,	O
suggesting	O
a	O
relationship	O
between	O
these	O
unique	O
CD33+	O
,	O
CD56+	O
,	O
CD16	B-protein
-acute	O
leukemias	O
and	O
normal	B-cell_type
CD56+	I-cell_type
,	I-cell_type
CD16-	I-cell_type
NK	I-cell_type
precursor	I-cell_type
cells	I-cell_type
.	O

Using	O
a	O
combination	O
of	O
panning	O
and	O
multiparameter	O
flow	O
cytometric	O
sorting	O
,	O
we	O
identified	O
a	O
normal	B-cell_type
CD56+	I-cell_type
,	I-cell_type
CD33+	I-cell_type
,	I-cell_type
CD16-	I-cell_type
counterpart	I-cell_type
cell	I-cell_type
at	O
a	O
frequency	O
of	O
1	O
%	O
to	O
2	O
%	O
in	O
the	O
peripheral	O
blood	O
of	O
healthy	O
individuals	O
.	O

Our	O
studies	O
suggest	O
that	O
this	O
form	O
of	O
acute	O
leukemia	O
may	O
arise	O
from	O
transformation	O
of	O
a	O
precursor	O
cell	O
common	O
to	O
both	O
the	O
myeloid	B-cell_type
and	I-cell_type
NK	I-cell_type
cell	I-cell_type
lineages	I-cell_type
;	O
thus	O
we	O
propose	O
the	O
designation	O
myeloid/NK	O
acute	O
leukemia	O
.	O

Recognition	O
of	O
this	O
new	O
leukemic	O
entity	O
will	O
be	O
important	O
in	O
distinguishing	O
these	O
ATRA-nonresponsive	O
cases	O
from	O
ATRA-responsive	O
true	O
APL	O
.	O

IL-4	B-protein
down-regulates	O
IL-2	B-protein
-	O
,	O
IL-3	B-protein
-	O
,	O
and	O
GM-CSF	B-protein
-induced	O
cytokine	O
gene	O
expression	O
in	O
peripheral	O
blood	O
monocytes	O
.	O

IL-4	B-protein
,	O
a	O
product	O
of	O
the	O
T-helper	B-cell_type
0	I-cell_type
(	I-cell_type
Th0	I-cell_type
)	I-cell_type
and	I-cell_type
2	I-cell_type
(	I-cell_type
Th2	I-cell_type
)	I-cell_type
subset	I-cell_type
,	O
was	O
originally	O
described	O
as	O
a	O
B-cell	B-protein
stimulatory	I-protein
factor	I-protein
and	O
has	O
subsequently	O
been	O
found	O
to	O
suppress	O
IL-1	O
alpha	O
,	O
IL-1	O
beta	O
,	O
IL-6	O
,	O
IL-8	O
,	O
and	O
TNF-alpha	O
gene	O
expression	O
in	O
monocytes	B-cell_type
stimulated	O
with	O
LPS	O
,	O
and	O
to	O
upregulate	O
IL-1	B-DNA
receptor	I-DNA
antagonist	I-DNA
(	I-DNA
IL1-RA	I-DNA
)	I-DNA
gene	I-DNA
expression	O
.	O

In	O
this	O
study	O
we	O
investigated	O
the	O
effect	O
of	O
IL-4	B-protein
on	O
the	O
expression	O
of	O
cytokine	B-DNA
genes	I-DNA
in	O
monocytes	B-cell_type
evoked	O
by	O
other	O
T-helper	B-protein
cell	I-protein
cytokines	I-protein
:	O
IL-2	B-protein
,	O
IL-3	B-protein
,	O
and	O
GM-CSF	B-protein
.	O

IL-4	B-protein
down-regulated	O
mRNA	O
accumulation	O
of	O
the	O
proinflammatory	B-protein
cytokines	I-protein
IL-1	B-protein
beta	I-protein
,	O
IL-8	B-protein
,	O
and	O
TNF-alpha	B-protein
in	O
monocytes	B-cell_type
stimulated	O
with	O
IL-2	B-protein
,	O
IL-3	B-protein
,	O
and	O
GM-CSF	B-protein
.	O

IL-4	B-protein
also	O
suppressed	O
the	O
IL-2	B-protein
-induced	O
IL-6	B-protein
mRNA	O
expression	O
.	O

Temporal	O
analysis	O
of	O
the	O
IL-4	B-protein
down-regulatory	O
effect	O
on	O
the	O
IL-2-	O
,	O
IL-3-	O
,	O
or	O
GM-CSF-induced	O
proinflammatory	O
cytokine	O
gene	O
expression	O
in	O
monocytes	B-cell_type
provided	O
evidence	O
that	O
IL-4	B-protein
acts	O
predominantly	O
on	O
the	O
post-transcriptional	O
level	O
.	O

This	O
was	O
supported	O
by	O
the	O
observation	O
that	O
the	O
down-regulatory	O
capacity	O
of	O
IL-4	B-protein
appeared	O
to	O
be	O
dependent	O
on	O
de	O
novo	O
protein	O
synthesis	O
.	O

IL-4	B-protein
did	O
not	O
exert	O
significant	O
influence	O
on	O
the	O
induction	O
of	O
expression	O
of	O
IL-1-RA	B-protein
or	O
various	O
CSFs	B-protein
by	O
IL-2	B-protein
,	O
IL-3	B-protein
,	O
and	O
GM-CSF	B-protein
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Induction	O
of	O
proto-oncogene	B-DNA
and	O
cytokine	B-protein
expression	O
in	O
human	O
peripheral	O
blood	O
monocytes	B-cell_type
and	O
the	O
monocytic	B-cell_line
cell	I-cell_line
line	I-cell_line
THP-1	B-cell_line
after	O
stimulation	O
with	O
mycoplasma-derived	O
material	O
MDHM	O
.	O

Mycoplasma	O
fermentans-derived	O
high-molecular-weight	O
material	O
(	O
MDHM	O
)	O
was	O
originally	O
described	O
to	O
induce	O
differentiation	O
of	O
murine	B-cell_type
thymocytes	I-cell_type
to	O
cytolytic	B-cell_type
effector	I-cell_type
T-cells	I-cell_type
by	O
stimulating	O
IL-6	B-protein
release	O
from	O
adherent	B-cell_type
cells	I-cell_type
.	O

This	O
study	O
shows	O
that	O
human	O
peripheral	O
blood	O
monocytes	B-cell_type
(	O
PBMo	B-cell_type
)	O
also	O
respond	O
to	O
MDHM	O
with	O
increases	O
in	O
IL-1	B-protein
beta	I-protein
,	O
IL-6	B-protein
and	O
TNF	B-protein
alpha	I-protein
expression	O
,	O
both	O
at	O
the	O
mRNA	O
and	O
protein	O
level	O
.	O

The	O
induced	O
expression	O
of	O
IL-1	B-RNA
beta	I-RNA
and	I-RNA
TNF	I-RNA
alpha	I-RNA
mRNA	I-RNA
in	O
the	O
monocytic	O
THP-1	B-cell_line
cell	I-cell_line
line	I-cell_line
increased	O
as	O
quickly	O
as	O
in	O
primary	B-cell_type
cells	I-cell_type
.	O

In	O
contrast	O
to	O
PBMo	B-cell_type
,	O
THP-1	B-cell_line
and	O
14	O
other	O
monocytic/myeloid	B-cell_line
leukemia-derived	I-cell_line
cell	I-cell_line
lines	I-cell_line
did	O
not	O
secrete	O
measurable	O
amounts	O
of	O
the	O
cytokines	B-protein
upon	O
treatment	O
with	O
MDHM	O
.	O

IL-1	B-DNA
beta	I-DNA
and	I-DNA
IL-6	I-DNA
genes	I-DNA
contain	O
AP-1	B-DNA
binding	I-DNA
sites	I-DNA
as	O
regulatory	B-DNA
elements	I-DNA
,	O
the	O
AP-1	B-protein
protein	O
being	O
composed	O
of	O
c-jun	B-protein
and	I-protein
c-fos	I-protein
gene	I-protein
products	I-protein
.	O

In	O
THP-1	B-cell_line
cells	I-cell_line
c-jun	B-RNA
mRNA	I-RNA
expression	O
increased	O
after	O
incubation	O
with	O
MDHM	O
while	O
positive	O
c-fos	B-DNA
expression	O
remained	O
unaffected	O
.	O

Although	O
these	O
data	O
suggest	O
AP-1	B-protein
regulated	O
cytokine	B-protein
mRNA	O
expression	O
,	O
results	O
from	O
PBMo	B-cell_type
are	O
not	O
in	O
accordance	O
with	O
this	O
notion	O
.	O

In	O
the	O
primary	B-cell_type
cells	I-cell_type
MDHM-induced	O
elevation	O
of	O
cytokine	B-RNA
mRNA	I-RNA
levels	O
was	O
preceded	O
by	O
a	O
downregulation	O
of	O
c-fos	B-DNA
expression	O
while	O
positive	O
c-jun	B-DNA
expression	O
was	O
not	O
modulated	O
.	O

c-myc	B-RNA
mRNA	I-RNA
expression	O
,	O
constitutively	O
high	O
in	O
THP-1	B-cell_line
cells	I-cell_line
,	O
was	O
induced	O
in	O
MDHM-stimulated	O
PBMo	B-cell_type
.	O

In	O
conclusion	O
,	O
MDHM-stimulated	O
induction	O
of	O
cytokine	B-RNA
mRNA	I-RNA
expression	O
was	O
accompanied	O
by	O
different	O
proto-oncogene	B-DNA
responses	O
in	O
PBMo	B-cell_type
and	O
THP-1	B-cell_line
cells	I-cell_line
.	O

These	O
differences	O
may	O
represent	O
different	O
regulatory	O
pathways	O
of	O
the	O
two	O
cell	O
systems	O
.	O

Alternatively	O
,	O
these	O
data	O
support	O
the	O
notion	O
that	O
neither	O
AP-1	B-protein
nor	O
the	O
c-myc	B-protein
protein	I-protein
are	O
involved	O
in	O
the	O
MDHM-induced	O
increase	O
in	O
IL-1	O
beta	O
,	O
IL-6	O
or	O
TNF	O
alpha	O
mRNA	O
levels	O
.	O

Furthermore	O
,	O
the	O
present	O
results	O
demonstrate	O
clearly	O
that	O
mycoplasma	B-protein
products	I-protein
can	O
have	O
a	O
profound	O
impact	O
on	O
the	O
activation	O
status	O
of	O
eukaryotic	B-cell_type
cells	I-cell_type
.	O

Novel	B-protein
membrane	I-protein
receptors	I-protein
for	O
aldosterone	O
in	O
human	B-cell_type
lymphocytes	I-cell_type
:	O
a	O
50	B-protein
kDa	I-protein
protein	I-protein
on	O
SDS-PAGE	O
.	O

Fast	O
in	O
vitro	O
effects	O
of	O
aldosterone	O
on	O
the	O
Na+/H	B-protein
(	I-protein
+	I-protein
)	I-protein
-exchanger	I-protein
,	O
inositoltrisphosphate	O
generation	O
and	O
corresponding	O
specific	O
binding	O
to	O
plasma	O
membranes	O
at	O
Kd-values	O
of	O
approximately	O
0.1	O
nM	O
have	O
been	O
found	O
in	O
human	B-cell_type
mononuclear	I-cell_type
leukocytes	I-cell_type
and	O
vascular	B-cell_type
smooth	I-cell_type
muscle	I-cell_type
cells	I-cell_type
.	O

The	O
novel	O
aldosterone	O
membrane	O
receptor	O
was	O
analyzed	O
on	O
SDS-PAGE	O
after	O
labeling	O
of	O
microsomal	O
membranes	O
from	O
human	B-cell_type
mononuclear	I-cell_type
leukocytes	I-cell_type
with	O
a	O
[	O
125I	O
]	O
-aldosterone-derivative	O
by	O
use	O
of	O
BASED	O
as	O
a	O
photoactivatable	O
crosslinker	O
.	O

Binding	O
of	O
1	O
nM	O
[	O
125I	O
]	O
-aldosterone	O
was	O
found	O
at	O
a	O
molecular	O
weight	O
of	O
approximately	O
50	O
kDa	O
which	O
was	O
absent	O
with	O
1	O
microM	O
cold	O
aldosterone	O
,	O
but	O
not	O
cortisol	O
in	O
the	O
binding	O
media	O
.	O

This	O
aldosterone-selectivity	O
is	O
typical	O
and	O
discriminatory	O
for	O
the	O
new	O
aldosterone	B-protein
membrane	I-protein
receptor	I-protein
.	O

Solubilization	O
of	O
the	O
receptor	B-protein
protein	I-protein
from	O
membranes	O
by	O
high	O
salt	O
concentrations	O
(	O
1	O
M	O
NaCl	O
,	O
1	O
mM	O
EDTA	O
)	O
was	O
not	O
achieved	O
.	O

It	O
,	O
thus	O
,	O
appears	O
as	O
an	O
integral	B-protein
membrane	I-protein
protein	I-protein
.	O

Dithiothreitol	O
,	O
a	O
sulfhydryl	O
agent	O
,	O
does	O
not	O
reduce	O
specific	O
aldosterone	O
binding	O
indicating	O
the	O
absence	O
of	O
SH-groups	B-protein
in	O
the	O
binding	B-protein
domain	I-protein
or	O
sensitive	O
structures	O
of	O
the	O
receptors	O
.	O

The	O
results	O
are	O
the	O
first	O
to	O
characterize	O
the	O
novel	B-protein
membrane	I-protein
receptor	I-protein
for	O
aldosterone	O
with	O
regard	O
to	O
molecular	O
weight	O
and	O
basic	O
properties	O
.	O

These	O
findings	O
and	O
other	O
related	O
results	O
are	O
reviewed	O
here	O
.	O

A	O
transcriptional	B-DNA
regulatory	I-DNA
element	I-DNA
is	O
associated	O
with	O
a	O
nuclease-hypersensitive	B-DNA
site	I-DNA
in	O
the	O
pol	B-DNA
gene	I-DNA
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
.	O

Analysis	O
of	O
the	O
chromatin	O
organization	O
of	O
the	O
integrated	O
human	B-DNA
immunodeficiency	I-DNA
virus	I-DNA
type	I-DNA
1	I-DNA
(	I-DNA
HIV-1	I-DNA
)	I-DNA
genome	I-DNA
has	O
previously	O
revealed	O
a	O
major	B-DNA
constitutive	I-DNA
DNase	I-DNA
I-hypersensitive	I-DNA
site	I-DNA
associated	O
with	O
the	O
pol	B-DNA
gene	I-DNA
(	O
E.	O
Verdin	O
,	O
J.	O
Virol.	O
65	O
:	O
6790-6799	O
,	O
1991	O
)	O
.	O

In	O
the	O
present	O
report	O
,	O
high-resolution	O
mapping	O
of	O
this	O
site	O
with	O
DNase	B-protein
I	I-protein
and	O
micrococcal	B-protein
nuclease	I-protein
identified	O
a	O
nucleosome-free	B-DNA
region	I-DNA
centered	O
around	O
nucleotides	B-DNA
(	I-DNA
nt	I-DNA
)	I-DNA
4490	I-DNA
to	I-DNA
4766	I-DNA
.	O

A	O
500-bp	B-DNA
fragment	I-DNA
encompassing	O
this	O
hypersensitive	B-DNA
site	I-DNA
(	O
nt	B-DNA
4481	I-DNA
to	I-DNA
4982	I-DNA
)	O
exhibited	O
transcription-enhancing	O
activity	O
(	O
two-	O
to	O
threefold	O
)	O
when	O
it	O
was	O
cloned	O
in	O
its	O
natural	O
position	O
with	O
respect	O
to	O
the	O
HIV-1	B-DNA
promoter	I-DNA
after	O
transient	O
transfection	O
in	O
U937	B-cell_line
and	O
CEM	B-cell_line
cells	I-cell_line
.	O

Using	O
in	O
vitro	O
footprinting	O
and	O
gel	O
shift	O
assays	O
,	O
we	O
have	O
identified	O
four	O
distinct	O
binding	B-DNA
sites	I-DNA
for	O
nuclear	B-protein
proteins	I-protein
within	O
this	O
positive	B-DNA
regulatory	I-DNA
element	I-DNA
.	O

Site	B-DNA
B	I-DNA
(	O
nt	B-DNA
4519	I-DNA
to	I-DNA
4545	I-DNA
)	O
specifically	O
bound	O
four	O
distinct	O
nuclear	B-protein
protein	I-protein
complexes	I-protein
:	O
a	O
ubiquitous	B-protein
factor	I-protein
,	O
a	O
T-cell-specific	B-protein
factor	I-protein
,	O
a	O
B-cell-specific	B-protein
factor	I-protein
,	O
and	O
the	O
monocyte/macrophage-	B-protein
and	I-protein
B-cell-specific	I-protein
transcription	I-protein
factor	I-protein
PU.1/Spi-1	B-protein
.	O

In	O
most	O
HIV-1	O
isolates	O
in	O
which	O
this	O
PU	B-DNA
box	I-DNA
was	O
not	O
conserved	O
,	O
it	O
was	O
replaced	O
by	O
a	O
binding	B-DNA
site	I-DNA
for	O
the	O
related	O
factor	O
Ets1	B-protein
.	O

Factors	O
binding	O
to	O
site	B-DNA
C	I-DNA
(	O
nt	B-DNA
4681	I-DNA
to	I-DNA
4701	I-DNA
)	O
had	O
a	O
DNA-binding	O
specificity	O
similar	O
to	O
that	O
of	O
factors	O
binding	O
to	O
site	B-DNA
B	I-DNA
,	O
except	O
for	O
PU.1/Spi-1	B-protein
.	O

A	O
GC	B-DNA
box	I-DNA
containing	O
a	O
binding	B-DNA
site	I-DNA
for	O
Sp1	B-protein
was	O
identified	O
(	O
nt	B-DNA
4623	I-DNA
to	I-DNA
4631	I-DNA
)	O
.	O

Site	B-DNA
D	I-DNA
(	O
nt	B-DNA
4816	I-DNA
to	I-DNA
4851	I-DNA
)	O
specifically	O
bound	O
a	O
ubiquitously	B-protein
expressed	I-protein
factor	I-protein
.	O

These	O
results	O
identify	O
a	O
transcriptional	B-DNA
regulatory	I-DNA
element	I-DNA
associated	O
with	O
a	O
nuclease-hypersensitive	B-DNA
site	I-DNA
in	O
the	O
pol	B-DNA
gene	I-DNA
of	O
HIV-1	O
and	O
suggest	O
that	O
its	O
activity	O
may	O
be	O
controlled	O
by	O
a	O
complex	O
interplay	O
of	O
cis-	O
regulatory	B-DNA
elements	I-DNA
.	O

Expression	O
of	O
v-src	B-DNA
in	O
T	B-cell_type
cells	I-cell_type
correlates	O
with	O
nuclear	O
expression	O
of	O
NF-kappa	B-protein
B	I-protein
.	O

NF-kappa	B-protein
B	I-protein
is	O
a	O
rapidly	O
inducible	O
transcriptional	B-DNA
activator	I-DNA
that	O
responds	O
to	O
a	O
variety	O
of	O
signals	O
and	O
influences	O
the	O
expression	O
of	O
many	O
genes	O
involved	O
in	O
the	O
immune	O
response	O
.	O

Protein	O
tyrosine	B-protein
kinases	I-protein
transmit	O
signals	O
from	O
cytokine	B-protein
and	I-protein
immune	I-protein
receptors	I-protein
.	O

Very	O
little	O
information	O
exists	O
linking	O
these	O
two	O
important	O
classes	O
of	O
signaling	B-protein
molecules	I-protein
.	O

We	O
now	O
demonstrate	O
that	O
v-src	B-DNA
expression	O
correlates	O
with	O
nuclear	O
expression	O
of	O
a	O
kappa	B-protein
B	I-protein
binding	I-protein
complex	I-protein
similar	O
to	O
that	O
induced	O
by	O
phorbol	O
ester	O
and	O
ionomycin	O
,	O
as	O
detected	O
by	O
electrophoretic	O
mobility	O
shift	O
assay	O
using	O
a	O
variety	O
of	O
kappa	B-DNA
B	I-DNA
sites	I-DNA
.	O

This	O
complex	O
was	O
blocked	O
by	O
the	O
tyrosine	B-protein
kinase	I-protein
inhibitor	O
,	O
herbimycin	O
A	O
.	O

The	O
v-src-induced	B-protein
complex	I-protein
comprised	O
the	O
p50	B-protein
and	O
p65	B-protein
components	O
of	O
NF-kappa	B-protein
B	I-protein
,	O
as	O
determined	O
by	O
supershift	O
and	O
immunoblot	O
analysis	O
.	O

As	O
a	O
functional	O
correlate	O
of	O
this	O
finding	O
,	O
transient	O
co-transfection	O
of	O
HIV-1	B-DNA
LTR	I-DNA
reporter	I-DNA
constructs	I-DNA
in	O
a	O
different	O
T	B-cell_line
cell	I-cell_line
line	I-cell_line
demonstrated	O
that	O
v-src	B-DNA
activated	O
this	O
promoter	B-protein
in	O
a	O
kappa	O
B-dependent	O
manner	O
.	O

We	O
found	O
that	O
transactivation	O
of	O
the	O
HIV-1	B-DNA
LTR	I-DNA
by	O
v-src	B-DNA
was	O
more	O
sensitive	O
to	O
mutations	O
of	O
the	O
proximal	O
,	O
rather	O
than	O
the	O
distal	O
,	O
kappa	B-DNA
B	I-DNA
element	I-DNA
.	O

The	O
implications	O
for	O
T	B-protein
cell	I-protein
receptor	I-protein
signaling	O
and	O
HIV-1	B-DNA
gene	I-DNA
expression	O
are	O
considered	O
.	O

trans-activation	O
of	O
the	O
HIV	B-DNA
promoter	I-DNA
by	O
a	O
cDNA	O
and	O
its	O
genomic	O
clones	O
of	O
human	O
herpesvirus-6	O
.	O

Human	O
herpesvirus	O
6	O
(	O
HHV-6	O
)	O
is	O
a	O
lymphotropic	O
herpesvirus	O
,	O
and	O
in	O
vitro	O
,	O
it	O
can	O
productively	O
infect	O
human	O
CD4+	B-cell_line
T	I-cell_line
cells	I-cell_line
as	O
HIV-1	O
.	O

Co-infection	O
of	O
T	B-cell_type
cells	I-cell_type
by	O
HIV-1	O
and	O
HHV-6	O
can	O
lead	O
to	O
both	O
activation	O
of	O
the	O
HIV-1	B-DNA
promoter	I-DNA
and	O
acceleration	O
of	O
the	O
cytopathic	O
effects	O
.	O

An	O
HHV-6	B-DNA
(	I-DNA
GS	I-DNA
)	I-DNA
cDNA	I-DNA
clone	I-DNA
,	O
pCD41	B-DNA
,	O
encoding	O
for	O
a	O
41-kDa	B-protein
nuclear	I-protein
protein	I-protein
was	O
identified	O
and	O
characterized	O
previously	O
(	O
Chang	O
and	O
Balachandran	O
,	O
J.	O
Virol.	O
65	O
,	O
2884-2894	O
and	O
7085	O
,	O
1991	O
)	O
.	O

Sequence	O
analyses	O
show	O
that	O
this	O
protein	O
has	O
significant	O
homology	O
with	O
the	O
human	B-DNA
cytomegalovirus	I-DNA
UL44	I-DNA
gene	I-DNA
coding	O
for	O
the	O
ICP36	B-protein
family	I-protein
of	O
early-late-class	B-protein
phosphoprotein	I-protein
.	O

Using	O
this	O
cDNA	B-DNA
as	O
the	O
probe	O
,	O
a	O
3.8-kb	B-DNA
EcoRI	I-DNA
genomic	I-DNA
fragment	I-DNA
encoding	O
the	O
HHV-6	B-protein
(	I-protein
GS	I-protein
)	I-protein
P41	I-protein
was	O
cloned	O
and	O
designated	O
as	O
pGD41	B-DNA
.	O

When	O
cotransfected	O
with	O
the	O
HIV	B-DNA
LTR	I-DNA
CAT	I-DNA
into	O
CV-1	B-cell_line
cells	I-cell_line
,	O
both	O
the	O
pCD41	B-DNA
and	O
pGD41	B-DNA
clones	O
trans-activated	O
the	O
HIV	B-DNA
LTR	I-DNA
.	O

Sequence	O
analyses	O
of	O
pCD41	B-DNA
indicate	O
that	O
there	O
are	O
two	O
potential	O
open	B-DNA
reading	I-DNA
frames	I-DNA
(	O
ORFs	B-DNA
)	O
,	O
A	B-DNA
and	O
B	B-DNA
,	O
which	O
are	O
homologous	O
to	O
the	O
ORFs	B-DNA
found	O
in	O
the	O
genomic	O
clone	O
pGD41	B-DNA
.	O

Deletion	O
constructs	O
of	O
the	O
pCD41	B-DNA
clone	I-DNA
demonstrated	O
that	O
ORF-A	B-protein
was	O
critical	O
for	O
the	O
HIV	B-DNA
LTR	I-DNA
activation	O
.	O

Deletion	O
analyses	O
of	O
the	O
pCD41	B-DNA
ORF-A	B-protein
and	O
the	O
use	O
of	O
promoter	B-DNA
constructs	I-DNA
further	O
mapped	O
an	O
internal	O
functional	O
promoter	O
within	O
the	O
pCD41	B-DNA
sequence	O
that	O
can	O
direct	O
the	O
synthesis	O
of	O
the	O
trans-activating	B-protein
protein	I-protein
.	O

By	O
using	O
HIV	B-DNA
LTR	I-DNA
deletion	I-DNA
mutants	I-DNA
,	O
the	O
NF-kappa	B-protein
B	I-protein
binding	B-DNA
sites	I-DNA
were	O
found	O
to	O
be	O
critical	O
for	O
response	O
to	O
the	O
pCD41	B-DNA
trans-activation	O
.	O

CD14	B-protein
-mediated	O
translocation	O
of	O
nuclear	B-protein
factor-kappa	I-protein
B	I-protein
induced	O
by	O
lipopolysaccharide	O
does	O
not	O
require	O
tyrosine	B-protein
kinase	I-protein
activity	O
.	O

During	O
the	O
course	O
of	O
serious	O
bacterial	O
infections	O
,	O
lipopolysaccharide	O
(	O
LPS	O
)	O
is	O
believed	O
to	O
interact	O
with	O
macrophage	B-protein
receptors	I-protein
,	O
resulting	O
in	O
the	O
generation	O
of	O
inflammatory	O
mediators	O
and	O
systemic	O
symptoms	O
including	O
hemodynamic	O
instability	O
and	O
shock	O
.	O

CD14	B-protein
,	O
a	O
glycosylphosphatidylinositol-linked	B-protein
antigen	I-protein
,	O
functions	O
as	O
an	O
LPS	B-protein
signaling	I-protein
receptor	I-protein
.	O

A	O
critical	O
issue	O
concerns	O
the	O
mechanism	O
by	O
which	O
CD14	B-protein
,	O
which	O
has	O
no	O
transmembrane	B-protein
domain	I-protein
,	O
transduces	O
its	O
signal	O
following	O
LPS	O
binding	O
.	O

Recently	O
,	O
investigators	O
have	O
hypothesized	O
that	O
CD14	B-protein
-mediated	O
signaling	O
is	O
effected	O
through	O
a	O
receptor-associated	O
tyrosine	B-protein
kinase	I-protein
(	O
TK	O
)	O
,	O
suggesting	O
a	O
multicomponent	O
receptor	O
model	O
of	O
LPS	O
signaling	O
.	O

Wild-type	O
Chinese	B-cell_line
hamster	I-cell_line
ovary	I-cell_line
(	I-cell_line
CHO	I-cell_line
)	I-cell_line
-K1	I-cell_line
cells	I-cell_line
can	O
be	O
activated	O
by	O
endotoxin	O
to	O
release	O
arachidonate	O
following	O
transfection	O
with	O
human	O
CD14	B-protein
(	O
CHO/CD14	B-protein
)	O
.	O

Nuclear	O
translocation	O
of	O
cytosolic	O
NF-kappa	O
B	O
is	O
correlated	O
with	O
a	O
number	O
of	O
LPS-inducible	O
responses	O
.	O

We	O
sought	O
to	O
determine	O
if	O
this	O
pathway	O
were	O
present	O
in	O
CHO/CD14	B-cell_line
cells	I-cell_line
and	O
to	O
elucidate	O
the	O
relationship	O
of	O
NF-kappa	B-protein
B	I-protein
activation	O
to	O
the	O
CD14	B-protein
receptor	O
system	O
.	O

LPS-stimulated	O
translocation	O
of	O
NF-kappa	B-protein
B	I-protein
in	O
CHO/CD14	B-cell_line
cells	I-cell_line
resembled	O
the	O
same	O
response	O
in	O
the	O
murine	B-cell_line
macrophage-like	I-cell_line
cell	I-cell_line
line	I-cell_line
RAW	B-cell_line
264.7	I-cell_line
.	O

Protein	O
synthesis	O
inhibitors	O
and	O
corticosteroids	O
,	O
which	O
suppress	O
arachidonate	O
release	O
and	O
the	O
synthesis	O
of	O
proinflammatory	B-protein
cytokines	I-protein
,	O
had	O
no	O
effect	O
on	O
translocation	O
of	O
NF-kappa	B-protein
B	I-protein
in	O
CHO/	O
CD14	B-protein
or	O
RAW	B-cell_line
264.7	I-cell_line
cells	I-cell_line
,	O
demonstrating	O
that	O
NF-kappa	B-protein
B	I-protein
translocation	O
is	O
an	O
early	O
event	O
.	O

Although	O
TK	O
activity	O
was	O
consistently	O
observed	O
by	O
immunoblotting	O
extracts	O
from	O
activated	O
RAW	B-cell_line
264.7	I-cell_line
cells	I-cell_line
,	O
LPS-induced	O
phosphotyrosine	O
residues	O
were	O
not	O
observed	O
from	O
similarly	O
treated	O
CHO/CD14	B-cell_line
cells	I-cell_line
.	O

Furthermore	O
,	O
the	O
TK	O
inhibitors	O
herbimycin	O
A	O
and	O
genistein	O
failed	O
to	O
inhibit	O
translocation	O
of	O
NF-kappa	B-protein
B	I-protein
in	O
CHO/CD14	B-cell_line
or	O
RAW	B-cell_line
264.7	I-cell_line
cells	I-cell_line
,	O
although	O
both	O
of	O
these	O
agents	O
inhibited	O
LPS-induced	O
TK	O
activity	O
in	O
RAW	B-cell_line
264.7	I-cell_line
cells	I-cell_line
.	O

These	O
results	O
imply	O
that	O
TK	O
activity	O
is	O
not	O
obligatory	O
for	O
CD14	B-protein
-mediated	O
signal	O
transduction	O
to	O
occur	O
in	O
response	O
to	O
LPS	O
.	O

Signals	O
transduced	O
through	O
the	O
CD4	B-protein
molecule	I-protein
on	O
T	B-cell_type
lymphocytes	I-cell_type
activate	O
NF-kappa	B-protein
B	I-protein
.	O

We	O
have	O
demonstrated	O
that	O
native	B-protein
envelope	I-protein
glycoproteins	I-protein
of	O
HIV-1	O
,	O
gp160	O
can	O
induce	O
activation	O
of	O
the	O
transcription	B-protein
factor	I-protein
,	O
NF-kappa	B-protein
B	I-protein
.	O

The	O
stimulatory	O
effects	O
of	O
gp160	O
are	O
mediated	O
through	O
the	O
CD4	B-protein
molecule	I-protein
,	O
since	O
pretreatment	O
with	O
soluble	O
CD4	B-protein
abrogates	O
its	O
activity	O
.	O

The	O
gp160-induced	B-protein
NF-kappa	I-protein
B	I-protein
complex	I-protein
consists	O
of	O
p65	B-protein
,	O
p50	B-protein
and	O
c-rel	B-protein
proteins	I-protein
.	O

The	O
stimulatory	O
effect	O
of	O
gp160	O
on	O
NF-kappa	B-protein
B	I-protein
activation	O
is	O
protein	O
synthesis	O
independent	O
,	O
is	O
dependent	O
upon	O
protein	O
tyrosine	O
phosphorylation	O
,	O
and	O
abrogated	O
by	O
inhibitors	O
of	O
protein	B-protein
kinase	I-protein
C	I-protein
.	O

The	O
gp160-mediated	O
activation	O
of	O
NF-kappa	B-protein
B	I-protein
in	O
CD4	B-cell_type
positive	I-cell_type
T	I-cell_type
cells	I-cell_type
may	O
be	O
involved	O
in	O
biological	O
effects	O
,	O
e.g.	O
,	O
enhanced	O
HIV	O
replication	O
,	O
hypergammaglobulinemia	O
,	O
increased	O
cytokine	B-protein
secretion	O
,	O
hypercellularity	O
in	O
bone	O
marrow	O
and	O
apoptosis	O
.	O

No	O
evidence	O
for	O
the	O
expression	O
of	O
the	O
progesterone	B-protein
receptor	I-protein
on	O
peripheral	B-cell_type
blood	I-cell_type
lymphocytes	I-cell_type
during	O
pregnancy	O
[	O
see	O
comments	O
]	O

The	O
expression	O
of	O
the	O
progesterone	B-protein
receptor	I-protein
in	O
human	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
lymphocytes	I-cell_type
was	O
analysed	O
,	O
using	O
an	O
enzyme	O
linked	O
immunosorbent	O
assay	O
(	O
Abbott	O
PgR-EIA	O
monoclonal	O
)	O
,	O
in	O
order	O
to	O
evaluate	O
its	O
prognostic	O
character	O
in	O
the	O
context	O
of	O
spontaneous	O
abortion	O
.	O

Cytosols	O
were	O
prepared	O
from	O
lymphocytes	O
of	O
24	O
healthy	O
pregnant	O
women	O
(	O
11	O
first	O
,	O
10	O
second	O
and	O
three	O
third	O
trimester	O
)	O
,	O
seven	O
healthy	O
non-pregnant	O
women	O
,	O
nine	O
women	O
with	O
recurrent	O
spontaneous	O
abortion	O
,	O
and	O
six	O
healthy	O
men	O
.	O

In	O
addition	O
,	O
a	O
human	B-cell_line
breast	I-cell_line
carcinoma	I-cell_line
cell	I-cell_line
line	I-cell_line
(	O
ZR-75-1	B-cell_line
)	O
,	O
which	O
expresses	O
the	O
progesterone	B-protein
receptor	I-protein
,	O
was	O
analysed	O
throughout	O
.	O

The	O
ZR-75-1	B-cell_line
cell	I-cell_line
line	I-cell_line
showed	O
an	O
expression	O
of	O
642	O
fmol/mg	O
whereas	O
lymphocytes	O
of	O
pregnant	O
women	O
showed	O
an	O
expression	O
<	O
or	O
=	O
4	O
fmol/mg	O
.	O

Lymphocytes	B-cell_type
of	O
non-pregnant	O
women	O
,	O
women	O
with	O
threatened	O
pre-term	O
delivery	O
,	O
and	O
men	O
showed	O
equivalent	O
levels	O
:	O
3	O
+/-	O
1	O
,	O
3	O
+/-	O
2	O
and	O
5	O
+/-	O
4	O
fmol/mg	O
respectively	O
.	O

These	O
results	O
show	O
that	O
there	O
is	O
no	O
evidence	O
of	O
specific	O
expression	O
of	O
the	O
progesterone	B-protein
receptor	I-protein
in	O
pregnancy	O
and	O
exclude	O
any	O
prognostic	O
character	O
in	O
spontaneous	O
abortion	O
.	O

A	O
role	O
for	O
the	O
progesterone	B-protein
receptor	I-protein
in	O
the	O
mechanism	O
of	O
the	O
known	O
effect	O
of	O
progesterone	O
on	O
peripheral	B-cell_type
blood	I-cell_type
lymphocytes	I-cell_type
is	O
also	O
excluded	O
.	O

Tolerance	O
to	O
lipopolysaccharide	O
involves	O
mobilization	O
of	O
nuclear	B-protein
factor	I-protein
kappa	I-protein
B	I-protein
with	O
predominance	O
of	O
p50	B-protein
homodimers	O
.	O

Stimulation	O
of	O
the	O
human	B-cell_line
monocytic	I-cell_line
cell	I-cell_line
line	I-cell_line
Mono	B-cell_line
Mac	I-cell_line
6	I-cell_line
with	O
lipopolysaccharide	O
(	O
LPS	O
)	O
leads	O
to	O
rapid	O
and	O
transient	O
expression	O
of	O
cytokines	B-protein
like	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
(	O
TNF	B-protein
)	O
.	O

When	O
such	O
cells	O
are	O
precultured	O
for	O
2	O
days	O
with	O
a	O
low	O
dose	O
of	O
LPS	O
(	O
20	O
ng/ml	O
)	O
followed	O
by	O
stimulation	O
with	O
a	O
high	O
dose	O
of	O
LPS	O
(	O
1	O
microgram/ml	O
)	O
,	O
expression	O
of	O
the	O
TNF	B-DNA
gene	I-DNA
is	O
minimal	O
,	O
i.e.	O
the	O
cells	O
are	O
tolerant	O
.	O

In	O
nuclear	O
run-on	O
analysis	O
,	O
such	O
tolerant	B-cell_type
cells	I-cell_type
show	O
only	O
a	O
low	O
degree	O
of	O
transcription	O
,	O
indicating	O
that	O
tolerance	O
operates	O
at	O
or	O
upstream	O
of	O
the	O
transcription	O
level	O
.	O

The	O
CD14	B-protein
LPS	O
receptor	O
is	O
,	O
however	O
,	O
up-regulated	O
(	O
not	O
down-regulated	O
)	O
in	O
tolerant	B-cell_line
cells	I-cell_line
,	O
and	O
LPS	O
can	O
,	O
in	O
fact	O
,	O
still	O
lead	O
to	O
activation	O
of	O
tolerant	B-cell_line
cells	I-cell_line
as	O
evidenced	O
by	O
mobilization	O
of	O
the	O
transcription	B-protein
factor	I-protein
nuclear	B-protein
factor	I-protein
kappa	I-protein
B	I-protein
(	O
NF-kappa	B-protein
B	I-protein
)	O
.	O

Resolution	O
of	O
the	O
NF-kappa	B-protein
B	I-protein
complex	I-protein
in	O
gel	O
shift	O
analysis	O
shows	O
that	O
the	O
binding	B-protein
protein	I-protein
,	O
mobilized	O
in	O
naive	B-cell_line
Mono	I-cell_line
Mac	I-cell_line
6	I-cell_line
cells	I-cell_line
,	O
consists	O
mainly	O
of	O
p50-p65	B-protein
heterodimers	I-protein
,	O
while	O
in	O
tolerant	B-cell_line
cells	I-cell_line
,	O
the	O
p50	B-protein
homodimer	I-protein
is	O
predominant	O
.	O

This	O
increase	O
in	O
p50	B-protein
homodimers	I-protein
coincides	O
with	O
an	O
increase	O
in	O
p105	B-RNA
mRNA	I-RNA
,	O
suggestive	O
of	O
a	O
transcriptional	O
up-regulation	O
of	O
p50	B-protein
.	O

Reporter	O
gene	O
analysis	O
reveals	O
that	O
the	O
NF-kappa	B-protein
B	I-protein
complex	I-protein
mobilized	O
in	O
tolerant	B-cell_line
cells	I-cell_line
is	O
functionally	O
inactive	O
in	O
that	O
NF-kappa	B-DNA
B-dependent	I-DNA
luciferase	I-DNA
constructs	I-DNA
containing	O
the	O
human	B-DNA
immunodeficiency	I-DNA
virus	I-DNA
long	I-DNA
terminal	I-DNA
repeat	I-DNA
or	O
the	O
TNF	B-DNA
5'-region	I-DNA
show	O
only	O
minimal	O
transactivation	O
after	O
LPS	O
stimulation	O
.	O

Similar	O
to	O
Mono	B-cell_line
Mac	I-cell_line
6	I-cell_line
cells	I-cell_line
,	O
primary	B-cell_type
blood	I-cell_type
monocytes	I-cell_type
,	O
when	O
precultured	O
with	O
a	O
low	O
dose	O
of	O
LPS	O
,	O
also	O
become	O
tolerant	O
and	O
produce	O
little	O
TNF	B-protein
after	O
LPS	O
stimulation	O
.	O

The	O
tolerant	B-cell_type
blood	I-cell_type
monocytes	I-cell_type
also	O
up-regulate	O
CD14	B-protein
,	O
and	O
they	O
mobilize	O
NF-kappa	B-protein
B	I-protein
with	O
a	O
predominance	O
of	O
p50	B-protein
homodimers	I-protein
.	O

Taken	O
together	O
,	O
these	O
results	O
demonstrate	O
that	O
tolerance	O
to	O
LPS	O
is	O
determined	O
by	O
post-receptor	O
mechanisms	O
that	O
involve	O
an	O
altered	O
composition	O
of	O
the	O
NF-kappa	B-protein
B	I-protein
complex	I-protein
.	O

Analysis	O
of	O
Oct2-isoform	B-protein
expression	O
in	O
lipopolysaccharide-stimulated	B-cell_line
B	I-cell_line
lymphocytes	I-cell_line
.	O

Oct2-isoform	B-protein
expression	O
in	O
splenic	B-cell_type
B	I-cell_type
cells	I-cell_type
stimulated	O
with	O
lipopolysaccharide	O
or	O
lipopolysaccharide	O
plus	O
phorbol-di-butyrate	O
was	O
analysed	O
by	O
cDNA	O
cloning	O
.	O

The	O
frequency	O
of	O
Oct2-positive	B-cell_line
clones	I-cell_line
was	O
1/15	O
,	O
000	O
in	O
both	O
libraries	O
.	O

Two	O
new	O
isoforms	O
were	O
found	O
that	O
generate	O
novel	O
amino-	B-protein
or	I-protein
carboxy-terminal	I-protein
sequences	I-protein
.	O

An	O
isoform	O
lacking	O
exon	B-DNA
11	I-DNA
destroyed	O
the	O
carboxy-terminal	B-protein
leucin-zipper	I-protein
region	I-protein
and	O
introduced	O
a	O
frame	O
shift	O
creating	O
a	O
novel	O
,	O
proline-rich	B-protein
carboxy	I-protein
terminus	I-protein
.	O

A	O
new	O
exon	B-DNA
containing	O
a	O
highly	O
basic	O
region	O
(	O
4c	O
)	O
was	O
characterized	O
,	O
between	B-DNA
exons	I-DNA
4	I-DNA
and	I-DNA
5	I-DNA
.	O

This	O
exon	O
was	O
inserted	O
between	B-DNA
glutamine-rich	I-DNA
regions	I-DNA
2	I-DNA
and	I-DNA
3	I-DNA
,	O
carboxy	B-protein
terminal	I-protein
of	O
a	O
tentative	O
leucine-zipper	B-protein
structure	I-protein
.	O

In	O
addition	O
,	O
a	O
new	O
combination	O
isoform	O
containing	O
Oct2a	B-protein
's	I-protein
amino	I-protein
terminal	I-protein
insert	I-protein
(	O
exon	B-DNA
7a	I-DNA
)	O
and	O
Oct2b	B-protein
's	I-protein
carboxy	I-protein
terminal	I-protein
insert	I-protein
(	O
exon	B-DNA
13	I-DNA
)	O
was	O
found	O
that	O
created	O
a	O
novel	O
large	O
isoform	O
,	O
Oct2ab	B-protein
.	O

More	O
frequent	O
use	O
of	O
the	O
classical	O
Oct2a	B-protein
and	O
Oct2b	B-protein
isoforms	O
was	O
observed	O
in	O
the	O
lipopolysaccharide-stimulated	B-cell_line
B	I-cell_line
cells	I-cell_line
,	O
while	O
a	O
preference	O
for	O
the	O
Oct2ab	B-protein
and	O
Oct2ba	B-protein
isoforms	O
was	O
observed	O
in	O
lipopolysaccharide	B-cell_line
plus	I-cell_line
phorbol-di-butyrate-treated	I-cell_line
cells	I-cell_line
.	O

Positive	O
regulators	O
of	O
the	O
lineage-specific	O
transcription	B-protein
factor	I-protein
GATA-1	B-protein
in	O
differentiating	B-cell_type
erythroid	I-cell_type
cells	I-cell_type
.	O

The	O
zinc	B-protein
finger	I-protein
transcription	I-protein
factor	I-protein
GATA-1	B-protein
is	O
a	O
major	O
regulator	O
of	O
gene	O
expression	O
in	O
erythroid	B-cell_type
,	I-cell_type
megakaryocyte	I-cell_type
,	I-cell_type
and	I-cell_type
mast	I-cell_type
cell	I-cell_type
lineages	I-cell_type
.	O

GATA-1	B-protein
binds	O
to	O
WGATAR	B-DNA
consensus	I-DNA
motifs	I-DNA
in	O
the	O
regulatory	B-DNA
regions	I-DNA
of	O
virtually	O
all	O
erythroid	B-DNA
cell-specific	I-DNA
genes	I-DNA
.	O

Analyses	O
with	O
cultured	B-cell_line
cells	I-cell_line
and	O
cell-free	O
systems	O
have	O
provided	O
strong	O
evidence	O
that	O
GATA-1	B-protein
is	O
involved	O
in	O
control	O
of	O
globin	B-DNA
gene	I-DNA
expression	O
during	O
erythroid	O
differentiation	O
.	O

Targeted	O
mutagenesis	O
of	O
the	O
GATA-1	B-DNA
gene	I-DNA
in	O
embryonic	B-cell_type
stem	I-cell_type
cells	I-cell_type
has	O
demonstrated	O
its	O
requirement	O
in	O
normal	O
erythroid	O
development	O
.	O

Efficient	O
rescue	O
of	O
the	O
defect	O
requires	O
an	O
intact	O
GATA	B-DNA
element	I-DNA
in	O
the	O
distal	B-DNA
promoter	I-DNA
,	O
suggesting	O
autoregulatory	O
control	O
of	O
GATA-1	B-protein
transcription	O
.	O

To	O
examine	O
whether	O
GATA-1	B-protein
expression	O
involves	O
additional	O
regulatory	B-protein
factors	I-protein
or	O
is	O
maintained	O
entirely	O
by	O
an	O
autoregulatory	O
loop	O
,	O
we	O
have	O
used	O
a	O
transient	O
heterokaryon	O
system	O
to	O
test	O
the	O
ability	O
of	O
erythroid	B-protein
factors	I-protein
to	O
activate	O
the	O
GATA-1	B-DNA
gene	I-DNA
in	O
nonerythroid	O
nuclei	O
.	O

We	O
show	O
here	O
that	O
proerythroblasts	B-cell_type
and	O
mature	B-cell_type
erythroid	I-cell_type
cells	I-cell_type
contain	O
a	O
diffusible	O
activity	O
(	O
TAG	O
)	O
capable	O
of	O
transcriptional	O
activation	O
of	O
GATA-1	B-protein
and	O
that	O
this	O
activity	O
decreases	O
during	O
the	O
terminal	O
differentiation	O
of	O
erythroid	B-cell_type
cells	I-cell_type
.	O

Nuclei	O
from	O
GATA-1	B-cell_line
-mutant	I-cell_line
embryonic	I-cell_line
stem	I-cell_line
cells	I-cell_line
can	O
still	O
be	O
reprogrammed	O
to	O
express	O
their	O
globin	B-DNA
genes	I-DNA
in	O
erythroid	B-cell_type
heterokaryons	I-cell_type
,	O
indicating	O
that	O
de	O
novo	O
induction	O
of	O
GATA-1	B-protein
is	O
not	O
required	O
for	O
globin	B-DNA
gene	I-DNA
activation	O
following	O
cell	O
fusion	O
.	O

Role	O
of	O
HIV-1	B-protein
Nef	I-protein
expression	O
in	O
activation	O
pathways	O
in	O
CD4	B-protein
+	O
T	O
cells	O
.	O

The	O
role	O
of	O
the	O
human	B-protein
immunodeficiency	I-protein
virus	I-protein
(	I-protein
HIV-1	I-protein
)	I-protein
Nef	I-protein
protein	I-protein
in	O
T	O
cell	O
activation	O
pathways	O
was	O
investigated	O
using	O
a	O
Jurkat	B-cell_line
CD4+	I-cell_line
cell	I-cell_line
line	I-cell_line
stably	O
transfected	O
with	O
a	O
Nef	O
expression	O
vector	O
.	O

Secretion	O
of	O
IL-2	B-protein
and	O
TNF-alpha	B-protein
,	O
surface	O
expression	O
of	O
IL-2R	B-protein
,	O
and	O
DNA-binding	O
activity	O
of	O
NF-kappa	B-protein
B	I-protein
and	O
AP-1	B-protein
(	I-protein
Fos/Jun	I-protein
)	I-protein
complex	I-protein
in	O
response	O
to	O
phorbol	O
myristate	O
acetate	O
,	O
TNF-alpha	B-protein
,	O
or	O
immobilized	O
antibodies	O
to	O
CD3	B-protein
were	O
monitored	O
.	O

These	O
parameters	O
were	O
not	O
modified	O
by	O
Nef	B-protein
expression	O
in	O
Jurkat	B-cell_line
cells	I-cell_line
,	O
whereas	O
stimulation	O
with	O
the	O
same	O
stimuli	O
resulted	O
in	O
partial	O
inhibition	O
of	O
LTR	B-DNA
activation	O
in	O
Nef+	B-cell_line
Jurkat	I-cell_line
cells	I-cell_line
.	O

This	O
inhibition	O
was	O
not	O
mediated	O
through	O
Nef	B-protein
phosphorylation	O
on	O
Thr-15	O
or	O
GTP-binding	O
activity	O
because	O
mutations	O
in	O
critical	O
sites	O
did	O
not	O
alter	O
this	O
inhibition	O
.	O

Analysis	O
of	O
truncated	O
LTRs	B-DNA
confirmed	O
that	O
inhibition	O
of	O
LTR	B-DNA
activation	O
was	O
not	O
mediated	O
through	O
NF-kappa	B-protein
B	I-protein
-binding	O
activity	O
but	O
through	O
the	O
region	O
containing	O
the	O
negative	B-DNA
responding	I-DNA
elements	I-DNA
(	O
NREs	B-DNA
)	O
.	O

These	O
results	O
suggest	O
that	O
Nef	B-protein
downmodulates	O
LTR	B-DNA
activation	O
without	O
significantly	O
inhibiting	O
the	O
capacity	O
of	O
T	B-cell_type
cells	I-cell_type
to	O
respond	O
to	O
immunological	O
activations	O
.	O

Tat-binding	B-protein
protein	I-protein
7	I-protein
is	O
a	O
subunit	O
of	O
the	O
26S	B-protein
protease	I-protein
.	O

Subunit	B-protein
6	I-protein
(	O
S6	B-protein
)	O
,	O
an	O
integral	O
component	O
of	O
the	O
26S	B-protein
protease	I-protein
from	O
human	B-cell_type
erythrocytes	I-cell_type
,	O
has	O
been	O
studied	O
by	O
SDS-PAGE	O
,	O
peptide	O
mapping	O
and	O
sequence	O
analysis	O
.	O

S6	B-protein
was	O
cleaved	O
with	O
CNBr	B-protein
and	O
three	O
internal	O
peptides	O
were	O
sequenced	O
.	O

A	O
comparison	O
with	O
known	O
proteins	O
in	O
Genbank	O
revealed	O
that	O
all	O
three	O
S6	B-protein
peptides	O
match	O
the	O
predicted	O
sequence	O
of	O
TBP7	B-protein
,	O
Tat-binding	B-protein
protein	I-protein
7	I-protein
.	O

Based	O
on	O
peptide	O
matches	O
covering	O
more	O
than	O
10	O
%	O
of	O
the	O
TBP7	B-protein
sequence	O
,	O
and	O
the	O
fact	O
that	O
the	O
migration	O
of	O
S6	B-protein
on	O
SDS-PAGE	O
is	O
consistent	O
with	O
the	O
estimated	O
molecular	O
mass	O
for	O
TBP7	B-protein
,	O
we	O
conclude	O
that	O
subunit	B-protein
6	I-protein
of	O
the	O
26S	B-protein
protease	I-protein
is	O
TBP7	B-protein
.	O

Hypoxia	O
causes	O
the	O
activation	O
of	O
nuclear	B-protein
factor	I-protein
kappa	I-protein
B	I-protein
through	O
the	O
phosphorylation	O
of	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
on	O
tyrosine	O
residues	O
.	O

The	O
response	O
of	O
mammalian	B-cell_type
cells	I-cell_type
to	O
stress	O
is	O
controlled	O
by	O
transcriptional	B-protein
regulatory	I-protein
proteins	I-protein
such	O
as	O
nuclear	B-protein
factor	I-protein
kappa	I-protein
B	I-protein
(	O
NF-kappa	B-protein
B	I-protein
)	O
to	O
induce	O
a	O
wide	O
variety	O
of	O
early	B-DNA
response	I-DNA
genes	I-DNA
.	O

In	O
this	O
report	O
,	O
we	O
show	O
that	O
exposure	O
of	O
cells	O
to	O
hypoxia	O
(	O
0.02	O
%	O
O2	O
)	O
results	O
in	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
degradation	O
,	O
increased	O
NF-kappa	B-protein
B	I-protein
DNA	O
binding	O
activity	O
,	O
and	O
transactivation	O
of	O
a	O
reporter	B-DNA
gene	I-DNA
construct	I-DNA
containing	O
two	O
NF-kappa	B-DNA
B	I-DNA
DNA	I-DNA
binding	I-DNA
sites	I-DNA
.	O

Pretreatment	O
of	O
cells	O
with	O
protein	O
tyrosine	B-protein
kinase	I-protein
inhibitors	O
and	O
the	O
dominant	B-DNA
negative	I-DNA
allele	I-DNA
of	O
c-Raf-1	B-DNA
(	O
Raf	B-protein
301	I-protein
)	O
inhibited	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
degradation	O
,	O
NF-kappa	B-protein
B	I-protein
binding	O
,	O
and	O
transactivation	O
of	O
kappa	B-DNA
B	I-DNA
reporter	I-DNA
constructs	I-DNA
by	O
hypoxia	O
.	O

To	O
demonstrate	O
a	O
direct	O
link	O
between	O
changes	O
in	O
the	O
phosphorylation	O
pattern	O
of	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
with	O
NF-kappa	B-protein
B	I-protein
activation	O
,	O
we	O
immunoprecipitated	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
after	O
varying	O
times	O
of	O
hypoxic	O
exposure	O
and	O
found	O
that	O
its	O
tyrosine	O
phosphorylation	O
status	O
increased	O
during	O
hypoxic	O
exposure	O
.	O

Inhibition	O
of	O
the	O
transfer	O
of	O
tyrosine	O
phosphoryl	O
groups	O
onto	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
prevented	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
degradation	O
and	O
NF-kappa	B-protein
B	I-protein
binding	O
.	O

In	O
comparison	O
to	O
other	O
activators	O
of	O
NF-kappa	B-protein
B	I-protein
such	O
as	O
phorbol	O
myristate	O
acetate	O
or	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
,	O
we	O
did	O
not	O
detect	O
changes	O
in	O
the	O
tyrosine	O
phosphorylation	O
status	O
of	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
following	O
treatment	O
with	O
either	O
of	O
these	O
agents	O
.	O

These	O
results	O
suggest	O
that	O
tyrosine	O
phosphorylation	O
of	O
I	B-protein
kappa	I-protein
B	I-protein
alpha	I-protein
during	O
hypoxia	O
is	O
an	O
important	O
proximal	O
step	O
which	O
precedes	O
its	O
dissociation	O
and	O
degradation	O
from	O
NF-kappa	B-protein
B	I-protein
.	O

Overproduction	O
of	O
NFKB2	B-protein
(	O
lyt-10	B-protein
)	O
and	O
c-Rel	B-protein
:	O
a	O
mechanism	O
for	O
HTLV-I	B-protein
Tax	I-protein
-mediated	O
trans-activation	O
via	O
the	O
NF-kappa	B-protein
B	I-protein
signalling	O
pathway	O
.	O

Molecular	O
,	O
biochemical	O
and	O
epidemiological	O
evidence	O
implicate	O
HTLV-I	O
as	O
an	O
etiologic	O
agent	O
of	O
adult	O
T	O
cell	O
leukemia	O
(	O
ATL	O
)	O
.	O

The	O
Tax	B-protein
protein	I-protein
of	O
HTLV-I	O
,	O
a	O
positive	B-protein
transcriptional	I-protein
activator	I-protein
of	O
HTLV-I	O
gene	O
expression	O
,	O
is	O
a	O
viral	O
oncogene	O
that	O
also	O
increases	O
transcription	O
of	O
cellular	B-DNA
genes	I-DNA
including	O
GM-CSF	B-protein
,	O
IL-2R	B-protein
alpha	I-protein
and	O
IL-2	B-protein
.	O

One	O
of	O
the	O
cellular	O
targets	O
of	O
the	O
trans-activating	O
effects	O
of	O
Tax	O
is	O
the	O
NF-kappa	B-protein
B/Rel	I-protein
family	I-protein
of	O
transcription	B-protein
factors	I-protein
,	O
pleiotropic	B-protein
regulators	I-protein
of	O
immunoregulatory	O
,	O
cytokine	O
and	O
viral	O
gene	O
expression	O
.	O

In	O
this	O
report	O
,	O
we	O
demonstrate	O
that	O
NFKB2	B-protein
(	O
lyt-10	B-protein
)	O
and	O
c-Rel	B-protein
are	O
overexpressed	O
in	O
HTLV-I	O
infected	O
and	O
Tax-expressing	B-cell_type
cells	I-cell_type
and	O
,	O
together	O
,	O
account	O
for	O
the	O
majority	O
of	O
the	O
constitutive	O
NF-kappa	B-protein
B	I-protein
binding	O
activity	O
in	O
these	O
cells	O
before	O
and	O
after	O
PMA	O
stimulation	O
.	O

Most	O
importantly	O
,	O
we	O
show	O
a	O
Tax	B-protein
-dependent	O
correlation	O
between	O
expression	O
of	O
NFKB2	B-protein
(	O
p100	B-protein
)	O
and	O
processing	O
to	O
the	O
DNA	O
binding	O
NFKB2	B-protein
(	O
p52	B-protein
)	O
form	O
,	O
induction	O
of	O
c-Rel	B-protein
,	O
and	O
trans-activation	O
of	O
NF-kappa	B-protein
B	I-protein
-mediated	O
gene	O
expression	O
.	O

Furthermore	O
,	O
the	O
NFKB2	B-protein
precursor	O
is	O
physically	O
associated	O
with	O
c-Rel	B-protein
and	O
with	O
Tax	B-protein
in	O
HTLV-I	B-cell_type
infected	I-cell_type
cells	I-cell_type
.	O

We	O
propose	O
that	O
NFKB2	B-protein
synthesis	O
and	O
processing	O
allows	O
continuous	O
nuclear	O
expression	O
of	O
an	O
otherwise	O
cytoplasmic	B-protein
protein	I-protein
and	O
,	O
in	O
conjunction	O
with	O
overexpression	O
of	O
c-Rel	B-protein
,	O
NFKB2	B-protein
alters	O
the	O
NF-kappa	B-protein
B	I-protein
signalling	O
pathway	O
and	O
contributes	O
to	O
leukemic	O
transformation	O
of	O
T	B-cell_type
cells	I-cell_type
by	O
HTLV-I	O
.	O

Retinoic	O
acid	O
downmodulates	O
erythroid	O
differentiation	O
and	O
GATA1	B-protein
expression	O
in	O
purified	B-cell_line
adult-progenitor	I-cell_line
culture	I-cell_line
.	O

All-trans	O
retinoic	O
acid	O
(	O
RA	O
)	O
is	O
an	O
important	O
morphogen	O
in	O
vertebrate	O
development	O
,	O
a	O
normal	O
constituent	O
in	O
human	O
adult	O
blood	O
and	O
is	O
also	O
involved	O
in	O
the	O
control	O
of	O
cell	O
growth	O
and	O
differentiation	O
in	O
acute	O
promyelocytic	O
leukemia	O
.	O

We	O
have	O
examined	O
the	O
effects	O
of	O
RA	O
on	O
normal	O
hematopoiesis	O
by	O
using	O
early	O
hematopoietic	B-cell_type
progenitor	I-cell_type
cells	I-cell_type
(	O
HPC	B-cell_type
)	O
stringently	O
purified	O
from	O
adult	O
peripheral	O
blood	O
.	O

In	O
clonogenetic	B-cell_line
fetal	I-cell_line
calf	I-cell_line
serum-supplemented	I-cell_line
(	I-cell_line
FCS+	I-cell_line
)	I-cell_line
or	I-cell_line
-nonsupplemented	I-cell_line
(	I-cell_line
FCS-	I-cell_line
)	I-cell_line
culture	I-cell_line
treated	O
with	O
saturating	O
levels	O
of	O
interleukin-3	B-protein
(	O
IL-3	B-protein
)	O
granulocyte-macrophage	B-protein
colony-stimulating	I-protein
factor	I-protein
(	O
GM-CSF	B-protein
)	O
and	O
erythropoietin	B-protein
(	O
Ep	B-protein
)	O
(	O
combined	O
with	O
c-kit	B-protein
ligand	O
in	O
FCS	O
(	O
-	O
)	O
-culture	O
conditions	O
)	O
,	O
RA	O
induces	O
a	O
dramatic	O
dose-dependent	O
shift	O
from	O
erythroid	O
to	O
granulomonocytic	O
colony	O
formation	O
,	O
the	O
latter	O
colonies	O
being	O
essentially	O
represented	O
by	O
granulocytic	B-cell_line
clones	I-cell_line
.	O

This	O
shift	O
is	O
apparently	O
not	O
caused	O
by	O
a	O
recruitment	O
phenomenon	O
,	O
because	O
in	O
FCS+	B-cell_line
culture	I-cell_line
,	O
the	O
total	O
number	O
of	O
colonies	O
is	O
not	O
significantly	O
modified	O
by	O
RA	O
addition	O
.	O

In	O
FCS-	B-cell_line
liquid-suspension	I-cell_line
culture	I-cell_line
supplemented	O
with	O
saturating	O
Ep	B-protein
level	O
and	O
low-dose	B-protein
IL-3/GM-CSF	I-protein
,	O
adult	O
HPC	B-cell_type
undergo	O
unilineage	O
erythropoietic	O
differentiation	O
:	O
Here	O
again	O
,	O
treatment	O
with	O
high-dose	O
RA	O
induces	O
a	O
shift	O
from	O
the	O
erythroid	O
to	O
granulocytic	O
differentiation	O
pathway	O
.	O

Studies	O
on	O
RA	O
time-response	O
or	O
pulse	O
treatment	O
in	O
semisolid	O
or	O
liquid	O
culture	O
show	O
that	O
early	O
RA	O
addition	O
is	O
most	O
effective	O
,	O
thus	O
indicating	O
that	O
early	O
but	O
not	O
late	O
HPC	B-cell_type
are	O
sensitive	O
to	O
its	O
action	O
.	O

We	O
then	O
analyzed	O
the	O
expression	O
of	O
the	O
master	B-DNA
GATA1	I-DNA
gene	I-DNA
,	O
which	O
encodes	O
a	O
finger	B-protein
transcription	I-protein
factor	I-protein
required	O
for	O
normal	O
erythroid	O
development	O
;	O
addition	O
of	O
RA	O
to	O
HPC	B-cell_type
stimulated	O
into	O
unilineage	O
erythropoietic	O
differentiation	O
in	O
liquid	O
culture	O
caused	O
a	O
virtually	O
complete	O
inhibition	O
of	O
GATA1	B-RNA
mRNA	I-RNA
induction	O
.	O

These	O
results	O
indicate	O
that	O
RA	O
directly	O
inhibits	O
the	O
erythroid	O
differentiation	O
program	O
at	O
the	O
level	O
of	O
early	O
adult	O
HPC	B-cell_type
,	O
and	O
may	O
lead	O
to	O
a	O
shift	O
from	O
the	O
erythroid	O
to	O
granulocytic	O
differentiation	O
pathway	O
.	O

This	O
phenomenon	O
is	O
correlated	O
with	O
inhibition	O
of	O
GATA1	B-protein
induction	O
in	O
the	O
early	O
stages	O
of	O
erythropoietic	O
differentiation	O
.	O

Induction	O
of	O
phosphatidylinositol	O
turnover	O
and	O
EGR-1	B-RNA
mRNA	I-RNA
expression	O
by	O
crosslinking	O
of	O
surface	O
IgM	B-protein
and	O
IgD	B-protein
in	O
the	O
human	B-cell_line
B	I-cell_line
cell	I-cell_line
line	I-cell_line
B104	I-cell_line
.	O

We	O
have	O
previously	O
shown	O
that	O
a	O
human	B-cell_line
B	I-cell_line
lymphoma	I-cell_line
cell	I-cell_line
line	I-cell_line
,	I-cell_line
B104	I-cell_line
,	O
expressed	O
surface	B-protein
IgM	I-protein
(	O
sIgM	B-protein
)	O
and	O
surface	B-protein
IgD	I-protein
(	O
sIgD	B-protein
)	O
,	O
and	O
that	O
crosslinking	O
of	O
sIgM	B-protein
and	O
sIgD	B-protein
by	O
anti-IgM	B-protein
antibody	I-protein
(	I-protein
Ab	I-protein
)	I-protein
and	O
anti-IgD	B-protein
Ab	I-protein
,	O
respectively	O
,	O
induced	O
Ca2+	O
influx	O
to	O
almost	O
the	O
same	O
degree	O
,	O
whereas	O
only	O
sIgM	B-protein
-crosslinking	O
caused	O
B104	B-cell_line
cell	I-cell_line
death	O
.	O

Here	O
,	O
we	O
investigated	O
the	O
accumulation	O
of	O
cyclic	O
AMP	O
(	O
cAMP	O
)	O
,	O
the	O
hydrolysis	O
of	O
inositol	O
phosphates	O
,	O
protein	B-protein
kinase	I-protein
C	I-protein
(	O
PKC	B-protein
)	O
activity	O
and	O
the	O
induction	O
of	O
Egr-1	O
and	O
c-fos	O
mRNA	O
expression	O
by	O
sIgM-	O
and	O
sIgD-crosslinking	O
to	O
examine	O
differences	O
in	O
the	O
signals	O
mediated	O
through	O
sIgM	B-protein
and	O
sIgD	B-protein
in	O
B104	B-cell_line
cells	I-cell_line
.	O

Both	O
sIgM-	O
and	O
sIgD-crosslinking	O
with	O
antibodies	O
induced	O
elevation	O
of	O
cAMP	O
levels	O
,	O
phosphatidylinositol	O
turnover	O
,	O
PKC	B-protein
activation	O
and	O
expression	O
of	O
Egr-1	B-RNA
and	I-RNA
c-fos	I-RNA
mRNA	I-RNA
,	O
although	O
sIgM	B-protein
-crosslinking	O
was	O
more	O
effective	O
than	O
sIgD	B-protein
-crosslinking	O
,	O
presumably	O
due	O
to	O
the	O
higher	O
expression	O
of	O
sIgM	B-protein
than	O
of	O
sIgD	B-protein
.	O

Egr-1	B-RNA
mRNA	I-RNA
expression	O
induced	O
by	O
sIgM-	O
and	O
sIgD-crosslinking	O
was	O
inhibited	O
by	O
H7	B-protein
,	O
erbstatin	O
and	O
genistein	O
,	O
but	O
not	O
by	O
HA1004	O
.	O

Erbstatin	O
and	O
genistein	O
inhibited	O
the	O
sIg-crosslinking-induced	O
Egr-1	B-RNA
mRNA	I-RNA
expression	O
in	O
a	O
dose-dependent	O
manner	O
parallel	O
to	O
that	O
observed	O
in	O
the	O
inhibition	O
of	O
sIg-crosslinking-induced	O
protein	O
tyrosine	O
phosphorylation	O
.	O

Phorbol	O
myristate	O
acetate	O
induced	O
Egr-1	B-RNA
mRNA	I-RNA
expression	O
but	O
forskolin	O
and	O
dibutyryl	O
cyclic	O
AMP	O
did	O
not	O
.	O

These	O
findings	O
suggest	O
that	O
the	O
Egr-1	B-RNA
mRNA	I-RNA
activating	O
signals	O
through	O
sIgM	B-protein
and	O
sIgD	B-protein
are	O
protein	O
tyrosine	O
kinase-	O
and	O
PKC-dependent	O
,	O
but	O
protein	B-protein
kinase	I-protein
A	I-protein
-independent	O
.	O

Cyclosporin	O
A	O
(	O
CsA	O
)	O
and	O
FK506	O
rescued	O
B104	B-cell_line
cells	I-cell_line
from	O
death	O
induced	O
by	O
anti-IgM	B-protein
Ab	I-protein
,	O
but	O
did	O
not	O
affect	O
the	O
expression	O
of	O
Egr-1	B-protein
and	O
c-fos	B-RNA
mRNA	I-RNA
,	O
showing	O
that	O
CsA	O
and	O
FK506	O
affect	O
signal	O
transducers	O
differently	O
from	O
or	O
downstream	O
to	O
these	O
molecules	O
.	O

The	O
difference	O
in	O
signals	O
transduced	O
through	O
sIgM	B-protein
and	O
sIgD	B-protein
in	O
B104	B-cell_line
cells	I-cell_line
is	O
discussed	O
.	O

Direct	O
exposure	O
to	O
2	O
,	O
3	O
,	O
7	O
,	O
8-tetrachlorodibenzo-p-dioxin	O
(	O
TCDD	O
)	O
increases	O
infectivity	O
of	O
human	B-cell_type
erythrocytes	I-cell_type
to	O
a	O
malarial	O
parasite	O
.	O

Direct	O
exposure	O
to	O
10	O
nM	O
2	O
,	O
3	O
,	O
7	O
,	O
8-TCDD	O
caused	O
a	O
75	O
%	O
increase	O
and	O
a	O
2-fold	O
increase	O
in	O
the	O
infectivity	O
of	O
isolated	O
human	B-cell_type
erythrocytes	I-cell_type
to	O
P.	O
falciparum	O
after	O
48	O
hours	O
when	O
the	O
parasites	O
were	O
in	O
an	O
unsynchronized	O
or	O
synchronized	O
state	O
of	O
growth	O
,	O
respectively	O
.	O

Treatment	O
of	O
human	B-cell_type
erythrocytes	I-cell_type
with	O
10	O
microM	O
sodium	O
orthovanadate	O
(	O
NaOV	O
)	O
,	O
an	O
inhibitor	O
of	O
plasma	B-protein
membrane	I-protein
Ca-ATPase	I-protein
and	O
phosphotyrosine	B-protein
phosphatase	I-protein
,	O
decreased	O
parasitemia	O
by	O
30	O
%	O
.	O

Co-treatment	O
of	O
RBCs	B-cell_type
with	O
TCDD	O
and	O
NaOV	O
completely	O
blocked	O
the	O
TCDD-induced	O
increase	O
in	O
parasitemia	O
.	O

Because	O
erythrocytes	B-cell_type
are	O
anucleated	O
,	O
these	O
results	O
are	O
discussed	O
as	O
evidence	O
for	O
biochemical	O
changes	O
by	O
TCDD	O
without	O
requiring	O
the	O
activation	O
of	O
gene	B-protein
products	I-protein
.	O

Evidence	O
for	O
a	O
trans-acting	B-protein
activator	I-protein
function	O
regulating	O
the	O
expression	O
of	O
the	O
human	B-protein
CD5	I-protein
antigen	I-protein
.	O

Interspecies	O
somatic	B-cell_line
cell	I-cell_line
hybrids	I-cell_line
were	O
generated	O
by	O
fusing	O
the	O
mouse	B-cell_line
T-lymphoma	I-cell_line
cell	I-cell_line
line	I-cell_line
,	O
BW5147	B-cell_line
,	O
with	O
normal	B-cell_type
human	I-cell_type
T	I-cell_type
lymphocytes	I-cell_type
at	O
different	O
stages	O
of	O
differentiation	O
.	O

Thymocytes	B-cell_type
,	O
activated	B-cell_type
peripheral	I-cell_type
T	I-cell_type
lymphocytes	I-cell_type
,	O
or	O
an	O
activated	B-cell_line
T-cell	I-cell_line
clone	I-cell_line
were	O
used	O
as	O
human	O
partners	O
,	O
respectively	O
,	O
in	O
three	O
independent	O
fusions	O
.	O

Irrespective	O
of	O
the	O
human	O
cell	O
partner	O
used	O
for	O
fusion	O
,	O
a	O
certain	O
number	O
of	O
hybrids	B-cell_line
lost	O
CD5	B-protein
surface	O
expression	O
over	O
a	O
period	O
of	O
time	O
in	O
culture	O
.	O

Analysis	O
at	O
the	O
phenotype	O
and	O
genetic	O
level	O
showed	O
that	O
lack	O
of	O
CD5	B-protein
expression	O
was	O
due	O
neither	O
to	O
segregation	O
of	O
human	B-DNA
autosome	I-DNA
11	I-DNA
,	O
on	O
which	O
the	O
CD5	B-DNA
gene	I-DNA
has	O
been	O
mapped	O
,	O
nor	O
to	O
deletion	O
of	O
the	O
CD5	B-DNA
structural	I-DNA
gene	I-DNA
.	O

Furthermore	O
,	O
loss	O
of	O
CD5	B-protein
surface	O
expression	O
correlated	O
with	O
the	O
absence	O
of	O
specific	O
mRNA	B-RNA
.	O

Since	O
these	O
hybrids	O
preferentially	O
segregate	O
human	O
chromosomes	O
,	O
these	O
results	O
indicate	O
the	O
existence	O
of	O
a	O
non-syntenic	B-DNA
trans-active	I-DNA
locus	I-DNA
,	O
or	O
loci	O
,	O
positively	O
controlling	O
the	O
expression	O
of	O
the	O
human	B-DNA
CD5	I-DNA
gene	I-DNA
.	O

Induction	O
of	O
the	O
CD11b	B-DNA
gene	I-DNA
during	O
activation	O
of	O
the	O
monocytic	B-cell_line
cell	I-cell_line
line	I-cell_line
U937	I-cell_line
requires	O
a	O
novel	O
nuclear	B-protein
factor	I-protein
MS-2	B-protein
[	O
published	O
erratum	O
appears	O
in	O
J	O
Immunol	O
1999	O
Jul	O
15	O
;	O
163	O
(	O
2	O
)	O
:	O
1091	O
]	O

The	O
differentiation	O
of	O
myeloid	B-cell_type
precursors	I-cell_type
into	O
mature	O
myelomonocytic	B-cell_type
cells	I-cell_type
is	O
characterized	O
by	O
the	O
induction	O
of	O
the	O
gene	O
encoding	O
the	O
beta2	B-protein
integrin	I-protein
CD11b	B-protein
.	O

The	O
transcription	B-protein
factors	I-protein
Sp1	B-protein
and	O
PU.1	B-protein
prime	I-protein
the	O
CD11b	B-DNA
promoter	I-DNA
,	O
but	O
the	O
nature	O
of	O
the	O
factors	O
responsible	O
for	O
its	O
inducible	O
expression	O
are	O
unknown	O
.	O

In	O
addition	O
to	O
the	O
CD11b	B-DNA
gene	I-DNA
,	O
the	O
homologous	O
genes	O
encoding	O
CD11a	B-protein
and	O
CD11c	B-protein
also	O
exhibit	O
inducible	O
expression	O
during	O
myeloid	O
differentiation	O
.	O

Therefore	O
,	O
we	O
compared	O
the	O
nucleotide	B-DNA
sequences	I-DNA
of	O
the	O
CD11a	B-DNA
,	I-DNA
CD11b	I-DNA
,	I-DNA
and	I-DNA
CD11c	I-DNA
gene	I-DNA
promoters	I-DNA
to	O
identify	O
common	O
elements	O
that	O
might	O
contribute	O
to	O
inducible	O
expression	O
.	O

This	O
analysis	O
identified	O
one	O
such	O
element	O
repeated	O
four	O
times	O
within	O
the	O
CD11b	B-DNA
promoter	I-DNA
.	O

Mutation	O
of	O
these	O
elements	O
indicated	O
that	O
two	O
,	O
MS-2beta	B-protein
and	O
MS-2gamma	B-protein
,	O
are	O
critical	O
to	O
the	O
induction	O
of	O
the	O
CD11b	B-DNA
gene	I-DNA
during	O
differentiation	O
of	O
the	O
pro-monocytic	B-cell_line
cell	I-cell_line
line	I-cell_line
U937	I-cell_line
.	O

Electrophoretic	O
mobility	O
shift	O
assays	O
indicate	O
that	O
MS-2beta	B-protein
and	O
MS-2gamma	B-protein
interact	O
with	O
nuclear	B-protein
factors	I-protein
that	O
are	O
induced	O
during	O
U937	B-cell_line
differentiation	O
.	O

These	O
factors	O
are	O
detected	O
at	O
the	O
time	O
the	O
CD11b	B-DNA
promoter	I-DNA
is	O
activated	O
.	O

The	O
molecular	O
mass	O
of	O
these	O
factors	O
is	O
approximately	O
28	O
kDa	O
,	O
and	O
their	O
DNA	O
binding	O
characteristics	O
are	O
indistinguishable	O
from	O
those	O
of	O
the	O
novel	O
nuclear	B-protein
factor	I-protein
MS-2	B-protein
.	O

Taken	O
together	O
,	O
our	O
data	O
indicate	O
that	O
MS-2	B-protein
mediates	O
induction	O
of	O
the	O
CD11b	B-DNA
gene	I-DNA
as	O
cells	O
of	O
the	O
monocytic	O
lineage	O
mature	O
.	O

The	O
presence	O
of	O
multiple	O
potential	O
binding	O
sites	O
for	O
MS-2	B-protein
in	O
the	O
promoter	O
regions	O
of	O
a	O
wide	O
range	O
of	O
genes	O
expressed	O
in	O
mature	B-cell_type
myeloid	I-cell_type
cells	I-cell_type
suggests	O
this	O
factor	O
plays	O
a	O
general	O
role	O
in	O
myeloid	O
differentiation	O
.	O

Acetylsalicylic	O
acid	O
and	O
sodium	O
salicylate	O
inhibit	O
LPS-induced	O
NF-kappa	B-protein
B/c-Rel	I-protein
nuclear	O
translocation	O
,	O
and	O
synthesis	O
of	O
tissue	B-protein
factor	I-protein
(	O
TF	B-protein
)	O
and	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
alfa	I-protein
(	O
TNF-alpha	B-protein
)	O
in	O
human	B-cell_type
monocytes	I-cell_type
.	O

We	O
have	O
investigated	O
the	O
effects	O
of	O
acetylsalicylic	O
acid	O
and	O
sodium	O
salicylate	O
on	O
the	O
LPS-induced	O
synthesis	O
of	O
the	O
pro-coagulant	O
protein	O
tissue	O
factor	O
(	O
TF	O
)	O
and	O
the	O
pro-inflammatory	O
protein	O
tumor	O
necrosis	O
factor-alpha	O
(	O
TNF-alpha	B-protein
)	O
,	O
as	O
well	O
as	O
the	O
prostaglandin	B-protein
PGE2	I-protein
in	O
human	B-cell_type
monocytes	I-cell_type
.	O

Both	O
drugs	O
dose-dependently	O
inhibited	O
LPS-induced	B-protein
TF	I-protein
and	O
TNF-alpha	B-protein
synthesis	O
at	O
the	O
mRNA	B-RNA
and	O
the	O
protein	O
level	O
,	O
and	O
reduced	O
PGE2	B-protein
production	O
.	O

As	O
evidenced	O
by	O
electro	O
mobility	O
shift	O
assay	O
(	O
EMSA	O
)	O
and	O
the	O
use	O
of	O
a	O
NF-kappa	B-DNA
B	I-DNA
prototypic	I-DNA
probe	I-DNA
,	O
these	O
drugs	O
probably	O
exert	O
their	O
inhibitory	O
effects	O
by	O
interference	O
with	O
the	O
nuclear	O
translocation	O
of	O
NF-kappa	B-protein
B/c-Rel	I-protein
proteins	I-protein
.	O

These	O
data	O
may	O
expand	O
the	O
understanding	O
of	O
the	O
anti-thrombotic	O
and	O
anti-inflammatory	O
effects	O
of	O
these	O
drugs	O
when	O
activation	O
of	O
monocytes	B-cell_type
occurs	O
.	O

Interferon	O
augments	O
PML	B-protein
and	O
PML/RAR	B-protein
alpha	I-protein
expression	O
in	O
normal	O
myeloid	B-cell_type
and	O
acute	B-cell_type
promyelocytic	I-cell_type
cells	I-cell_type
and	O
cooperates	O
with	O
all-trans	O
retinoic	O
acid	O
to	O
induce	O
maturation	O
of	O
a	O
retinoid-resistant	B-cell_line
promyelocytic	I-cell_line
cell	I-cell_line
line	I-cell_line
.	O

The	O
PML	B-DNA
gene	I-DNA
is	O
fused	O
to	O
the	O
retinoic	B-DNA
acid	I-DNA
receptor	I-DNA
alpha	I-DNA
gene	I-DNA
(	O
RAR	B-DNA
alpha	I-DNA
)	O
in	O
the	O
acute	O
promyelocytic	O
leukemia	O
(	O
APL	O
)	O
15	O
;	O
17	O
translocation	O
.	O

PML	B-protein
is	O
expressed	O
in	O
diverse	O
tissues	O
and	O
cell	O
lines	O
and	O
localized	O
in	O
the	O
nucleus	O
with	O
a	O
typical	O
speckled	O
pattern	O
.	O

In	O
the	O
bone	O
marrow	O
,	O
it	O
is	O
preferentially	O
expressed	O
in	O
myeloid	B-cell_type
cells	I-cell_type
.	O

PML	B-protein
appears	O
to	O
be	O
transcriptionally	O
regulated	O
by	O
class	B-protein
I	I-protein
and	I-protein
II	I-protein
interferons	I-protein
,	O
which	O
raises	O
the	O
possibility	O
that	O
interferons	O
modulate	O
the	O
function	O
and	O
growth	O
and	O
differentiation	O
potential	O
of	O
normal	O
myeloid	B-cell_type
cells	I-cell_type
and	O
precursors	O
by	O
activating	O
PML	B-protein
-dependent	O
pathways	O
.	O

Similarly	O
,	O
interferons	O
could	O
act	O
on	O
APL	B-cell_type
cells	I-cell_type
,	O
alone	O
or	O
in	O
combination	O
with	O
all-trans	O
retinoic	O
acid	O
(	O
RA	O
)	O
,	O
especially	O
if	O
the	O
PML/RAR	B-RNA
alpha	I-RNA
fusion	I-RNA
transcript	I-RNA
that	O
results	O
from	O
the	O
t	B-DNA
(	I-DNA
15	I-DNA
;	I-DNA
17	I-DNA
)	I-DNA
is	O
induced	O
by	O
interferon	B-protein
.	O

We	O
report	O
here	O
that	O
PML	B-protein
is	O
expressed	O
at	O
low	O
levels	O
or	O
not	O
expressed	O
in	O
normal	O
circulating	O
human	B-cell_type
monocytes	I-cell_type
,	O
lymphocytes	B-cell_type
,	O
and	O
polymorphonucleate	B-cell_type
cells	I-cell_type
,	O
but	O
is	O
markedly	O
induced	O
by	O
interferon	B-protein
;	O
that	O
PML	B-protein
and	O
PML/RAR	B-protein
alpha	I-protein
expression	O
is	O
augmented	O
by	O
interferon	B-protein
in	O
the	O
NB4	B-cell_line
APL	I-cell_line
cell	I-cell_line
line	I-cell_line
,	O
which	O
carries	O
the	O
t	B-DNA
(	I-DNA
15	I-DNA
;	I-DNA
17	I-DNA
)	I-DNA
,	O
and	O
in	O
APL	B-cell_type
blasts	I-cell_type
from	O
patients	O
;	O
that	O
interferon	B-protein
inhibits	O
growth	O
and	O
survival	O
of	O
NB4	O
APL	B-cell_type
cells	I-cell_type
in	O
cooperation	O
with	O
RA	O
;	O
that	O
interferons	O
alone	O
have	O
minimal	O
maturation	O
effect	O
on	O
NB4	B-cell_line
cells	I-cell_line
;	O
and	O
,	O
finally	O
,	O
that	O
interferon	B-protein
gamma	I-protein
,	I-protein
but	I-protein
not	I-protein
alpha	I-protein
or	I-protein
beta	I-protein
,	O
induces	O
maturation	O
and	O
growth	O
suppression	O
of	O
NB4	B-cell_line
cells	I-cell_line
with	O
de	O
novo	O
retinoid	O
resistance	O
,	O
and	O
partially	O
restores	O
RA	O
response	O
.	O

Effects	O
of	O
Ara-C	O
on	O
neutral	B-protein
sphingomyelinase	I-protein
and	O
mitogen-	B-protein
and	I-protein
stress-	I-protein
activated	I-protein
protein	I-protein
kinases	I-protein
in	O
T-lymphocyte	B-cell_line
cell	I-cell_line
lines	I-cell_line
.	O

Neutral	B-protein
sphingomyelinase	I-protein
(	O
SMase	B-protein
)	O
can	O
be	O
activated	O
by	O
extracellular	O
signals	O
to	O
produce	O
ceramide	O
,	O
which	O
may	O
affect	O
mitogen-activated	B-protein
protein	I-protein
kinase	I-protein
(	O
MAPK	B-protein
)	O
activities	O
.	O

Neutral	O
SMase	B-protein
activity	O
was	O
assessed	O
in	O
membranes	O
from	O
Jurkat	B-cell_line
,	O
a	O
human	B-cell_line
T-cell	I-cell_line
line	I-cell_line
,	O
and	O
EL4	B-cell_line
,	O
a	O
murine	B-cell_line
T-cell	I-cell_line
line	I-cell_line
.	O

Ara-C	O
activated	O
SMase	B-protein
with	O
10	O
minutes	O
in	O
both	O
Jurkat	O
and	O
EL4	B-cell_line
cells	I-cell_line
,	O
while	O
phorbol	O
ester	O
(	O
PMA	O
)	O
had	O
no	O
effect	O
.	O

PMA	O
,	O
but	O
not	O
Ara-C	O
or	O
ceramides	O
,	O
activated	O
ERK	B-protein
MAPKS	I-protein
,	O
in	O
Jurkat	B-cell_line
and	O
EL4	B-cell_line
.	O

PMA	O
acted	O
synergistically	O
with	O
ionomycin	O
to	O
activate	O
JNK	B-protein
MAPKs	I-protein
in	O
Jurkat	B-cell_line
and	O
EL4	B-cell_line
within	O
10	O
minutes	O
.	O

Ara-C	O
activated	O
JNKs	B-protein
only	O
after	O
prolonged	O
incubation	O
(	O
90-120	O
minutes	O
)	O
.	O

Thus	O
,	O
ceramide	O
is	O
not	O
a	O
positive	O
signal	O
for	O
ERK	B-protein
activation	O
in	O
T-cell	B-cell_line
lines	I-cell_line
.	O

The	O
effects	O
of	O
Ara-C	O
on	O
JNK	B-protein
activity	O
may	O
be	O
mediated	O
through	O
secondary	O
response	O
pathways	O
.	O

Comparative	O
analysis	O
identifies	O
conserved	O
tumor	B-DNA
necrosis	I-DNA
factor	I-DNA
receptor-associated	I-DNA
factor	I-DNA
3	I-DNA
binding	I-DNA
sites	I-DNA
in	O
the	O
human	B-DNA
and	I-DNA
simian	I-DNA
Epstein-Barr	I-DNA
virus	I-DNA
oncogene	I-DNA
LMP1	I-DNA
.	O

Nonhuman	O
primates	O
are	O
naturally	O
infected	O
with	O
a	O
B-lymphotropic	O
herpesvirus	O
closely	O
related	O
to	O
Epstein-Barr	O
virus	O
(	O
EBV	O
)	O
.	O

These	O
simian	O
EBV	O
share	O
considerable	O
genetic	O
,	O
biologic	O
,	O
and	O
epidemiologic	O
features	O
with	O
human	O
EBV	O
,	O
including	O
virus-induced	O
tumorigenesis	O
.	O

However	O
,	O
latent	O
,	O
transformation-associated	O
viral	O
genes	O
demonstrate	O
marked	O
sequence	O
divergence	O
among	O
species	O
despite	O
the	O
conserved	O
functions	O
.	O

We	O
have	O
cloned	O
the	O
latent	B-protein
membrane	I-protein
protein	I-protein
1	I-protein
(	I-protein
LMP1	I-protein
)	I-protein
homologs	I-protein
from	O
the	O
simian	O
EBV	O
naturally	O
infecting	O
baboons	O
(	O
cercopithicine	O
herpesvirus	O
12	O
,	O
herpesvirus	O
papio	O
)	O
and	O
rhesus	O
monkeys	O
(	O
cercopithicine	O
herpesvirus	O
15	O
)	O
for	O
a	O
comparative	O
study	O
with	O
the	O
human	O
EBV	O
oncogene	O
.	O

The	O
transmembrane	O
domains	O
are	O
well	O
conserved	O
,	O
but	O
there	O
is	O
striking	O
sequence	O
divergence	O
of	O
the	O
carboxy-terminal	B-protein
cytoplasmic	I-protein
domain	I-protein
essential	O
for	O
B-cell	B-cell_type
immortalization	O
and	O
interaction	O
with	O
the	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
receptor	I-protein
signaling	O
pathway	O
.	O

Nevertheless	O
,	O
the	O
simian	B-protein
EBV	I-protein
LMP1s	I-protein
retain	O
most	O
functions	O
in	O
common	O
with	O
EBV	O
LMP1	B-protein
,	O
including	O
the	O
ability	O
to	O
induce	O
NF-	B-protein
(	I-protein
kappa	I-protein
)	I-protein
B	I-protein
activity	O
in	O
human	B-cell_type
cells	I-cell_type
,	O
to	O
bind	O
the	O
tumor	B-protein
necrosis	I-protein
factor-associated	I-protein
factor	I-protein
3	I-protein
(	O
TRAF3	B-protein
)	O
in	O
vitro	O
,	O
and	O
to	O
induce	O
expression	O
of	O
tumor	B-DNA
necrosis	I-DNA
factor-responsive	I-DNA
genes	I-DNA
,	O
such	O
as	O
ICAM1	B-DNA
,	O
in	O
human	B-cell_type
B	I-cell_type
lymphocytes	I-cell_type
.	O

Multiple	O
TRAF3	B-DNA
binding	I-DNA
sites	I-DNA
containing	O
a	O
PXQXT/S	B-DNA
core	I-DNA
sequence	I-DNA
can	O
be	O
identified	O
in	O
the	O
simian	B-protein
EBV	I-protein
LMP1s	I-protein
by	O
an	O
in	O
vitro	O
binding	O
assay	O
.	O

A	O
PXQXT/S-containing	B-DNA
sequence	I-DNA
is	O
also	O
present	O
in	O
the	O
cytoplasmic	B-protein
domain	I-protein
of	O
the	O
Hodgkin	O
's	O
disease	O
marker	O
,	O
CD30	B-protein
,	O
and	O
binds	O
TRAF3	B-protein
in	O
vitro	O
.	O

The	O
last	B-protein
13	I-protein
amino	I-protein
acids	I-protein
containing	O
a	O
PXQXT/S	B-DNA
sequence	I-DNA
are	O
highly	O
conserved	O
in	O
human	O
and	O
simian	O
EBV	O
LMP1	B-protein
but	O
do	O
not	O
bind	O
TRAF3	B-protein
,	O
suggesting	O
a	O
distinct	O
role	O
for	O
this	O
conserved	O
region	O
of	O
LMP1	B-protein
.	O

The	O
conserved	O
TRAF3	B-DNA
binding	I-DNA
sites	I-DNA
in	O
LMP1	B-protein
and	O
the	O
CD30	B-protein
Hodgkin	I-protein
's	I-protein
disease	I-protein
marker	I-protein
provides	O
further	O
evidence	O
that	O
a	O
TRAF3	B-protein
-mediated	O
signal	O
transduction	O
pathway	O
may	O
be	O
important	O
in	O
malignant	O
transformation	O
.	O

Chromosome	B-DNA
1	I-DNA
aneusomy	O
with	O
1p36	B-DNA
under-representation	O
is	O
related	O
to	O
histologic	O
grade	O
,	O
DNA	O
aneuploidy	O
,	O
high	O
c-erb	B-protein
B-2	I-protein
and	O
loss	O
of	O
bcl-2	B-DNA
expression	O
in	O
ductal	O
breast	O
carcinoma	O
.	O

Chromosome	B-DNA
1	I-DNA
abnormalities	O
with	O
loss	O
of	O
1p36	B-DNA
have	O
been	O
investigated	O
in	O
95	O
breast-cancer	O
samples	O
by	O
means	O
of	O
a	O
dual-target	O
fluorescence	O
in-situ	O
hybridization	O
(	O
FISH	O
)	O
technique	O
using	O
the	O
pUC	B-DNA
1.77	I-DNA
and	O
p1-79	B-DNA
probes	I-DNA
,	O
specific	O
for	O
the	O
1q12	B-DNA
and	I-DNA
1p36	I-DNA
regions	I-DNA
,	O
respectively	O
.	O

Abnormalities	O
for	O
one	O
or	O
both	O
probes	O
were	O
detected	O
in	O
83/95	O
samples	O
.	O

Relative	O
1p36	B-DNA
under-representation	O
was	O
found	O
in	O
79/95	O
.	O

The	O
clinical	O
relevance	O
of	O
these	O
alterations	O
was	O
studied	O
by	O
comparing	O
the	O
FISH	O
results	O
with	O
several	O
parameters	O
currently	O
used	O
in	O
breast-cancer	O
pathology	O
.	O

Distinct	O
patterns	O
of	O
chromosome	B-DNA
1	I-DNA
abnormalities	O
were	O
found	O
among	O
the	O
histologic	O
types	O
of	O
breast	O
carcinoma	O
.	O

Lobular	O
or	O
mucinous	O
samples	O
showed	O
few	O
or	O
no	O
alterations	O
,	O
whereas	O
most	O
ductal	O
samples	O
had	O
high	O
chromosome	B-DNA
1	I-DNA
polysomy	O
with	O
under-representation	O
of	O
1p36	B-DNA
.	O

In	O
ductal	O
carcinomas	O
,	O
chromosome	B-DNA
1	I-DNA
alterations	O
increased	O
with	O
histologic	O
grade	O
,	O
DNA	O
aneuploidy	O
,	O
loss	O
of	O
bcl-2	O
and	O
high	O
c-erb	B-protein
B-2	I-protein
expression	O
.	O

These	O
associations	O
were	O
found	O
to	O
be	O
statistically	O
significant	O
.	O

No	O
correlation	O
between	O
chromosome	B-DNA
1	I-DNA
alterations	O
and	O
nuclear	O
grade	O
,	O
age	O
,	O
size	O
,	O
lymph-node	O
involvement	O
,	O
hormonal	O
receptor	O
presence	O
,	O
proliferation	O
activity	O
or	O
p53	B-protein
protein	O
expression	O
was	O
detected	O
.	O

These	O
results	O
indicate	O
the	O
utility	O
of	O
this	O
FISH	O
technique	O
for	O
a	O
better	O
definition	O
of	O
the	O
biological	O
characteristics	O
of	O
ductal	O
carcinomas	O
.	O

G	O
(	O
Anh	O
)	O
MTetra	O
,	O
a	O
natural	O
bacterial	O
cell	O
wall	O
breakdown	O
product	O
,	O
induces	O
interleukin-1	B-protein
beta	I-protein
and	O
interleukin-6	B-protein
expression	O
in	O
human	B-cell_type
monocytes	I-cell_type
.	O

A	O
study	O
of	O
the	O
molecular	O
mechanisms	O
involved	O
in	O
inflammatory	B-protein
cytokine	I-protein
expression	O
[	O
published	O
erratum	O
appears	O
in	O
J	O
Biol	O
Chem	O
1994	O
Jun	O
17	O
;	O
269	O
(	O
24	O
)	O
:	O
16983	O
]	O

It	O
is	O
believed	O
that	O
induction	O
of	O
cytokine	B-protein
expression	O
by	O
bacterial	O
cell	O
wall	O
components	O
plays	O
a	O
role	O
in	O
the	O
development	O
and	O
course	O
of	O
sepsis	O
.	O

However	O
,	O
most	O
attention	O
has	O
been	O
focused	O
on	O
lipopolysaccharide	O
(	O
LPS	O
)	O
.	O

We	O
studied	O
the	O
ability	O
of	O
N-acetylglucosaminyl-1	O
,	O
6-anhydro-N-acetylmuramyl-L-alanyl-D-	O
isoglutamyl-m-diaminopimelyl-D-alanine	O
(	O
G	O
(	O
Anh	O
)	O
MTetra	O
)	O
,	O
a	O
naturally	O
occurring	O
breakdown	O
product	O
of	O
peptidoglycan	O
that	O
is	O
produced	O
by	O
soluble	O
lytic	B-protein
transglycosylase	I-protein
of	O
Escherichia	O
coli	O
,	O
to	O
induce	O
cytokine	B-protein
expression	O
in	O
human	B-cell_type
monocytes	I-cell_type
.	O

G	O
(	O
Anh	O
)	O
MTetra	O
was	O
found	O
to	O
strongly	O
induce	O
interleukin	B-protein
(	I-protein
IL	I-protein
)	I-protein
-1	I-protein
beta	I-protein
and	O
IL-6	B-RNA
mRNA	I-RNA
expression	O
after	O
2	O
h	O
and	O
IL-1	B-protein
beta	I-protein
and	O
IL-6	B-protein
protein	I-protein
secretion	O
after	O
48	O
h	O
of	O
activation	O
.	O

The	O
increase	O
in	O
mRNA	O
accumulation	O
was	O
at	O
least	O
partly	O
due	O
to	O
an	O
increase	O
in	O
the	O
transcription	O
rates	O
of	O
the	O
respective	O
genes	B-DNA
and	O
was	O
accompanied	O
by	O
a	O
strong	O
induction	O
of	O
nuclear	O
factor-kappa	O
B	O
and	O
activator	O
protein-1	O
transcription	O
factor	O
expression	O
.	O

Experiments	O
using	O
inhibitors	O
of	O
protein	B-protein
kinase	I-protein
C	I-protein
,	O
protein	B-protein
kinase	I-protein
A	I-protein
,	O
and	O
tyrosine	O
kinase-dependent	O
pathways	O
revealed	O
that	O
G	O
(	O
Anh	O
)	O
MTetra-induced	O
IL-1	B-protein
beta	I-protein
and	O
IL-6	B-RNA
mRNA	I-RNA
expression	O
involves	O
activation	O
of	O
an	O
H7-inhibitable	O
pathway	O
.	O

By	O
using	O
the	O
protein	O
synthesis	O
inhibitor	O
cycloheximide	O
,	O
it	O
was	O
shown	O
that	O
G	O
(	O
Anh	O
)	O
MTetra-induced	O
IL-6	B-RNA
mRNA	I-RNA
expression	O
depends	O
on	O
the	O
synthesis	O
of	O
new	O
protein	O
,	O
whereas	O
G	O
(	O
Anh	O
)	O
MTetra-induced	O
IL-1	B-protein
beta	I-protein
mRNA	O
accumulation	O
does	O
not	O
.	O

When	O
responses	O
to	O
G	O
(	O
Anh	O
)	O
MTetra	O
were	O
compared	O
with	O
those	O
to	O
LPS	O
and	O
muramyldipeptide	O
(	O
MDP	O
)	O
,	O
it	O
was	O
found	O
that	O
the	O
optimal	O
response	O
to	O
G	O
(	O
Anh	O
)	O
MTetra	O
induction	O
was	O
similar	O
to	O
that	O
of	O
LPS	O
but	O
significantly	O
higher	O
than	O
the	O
response	O
to	O
MDP	O
.	O

Furthermore	O
,	O
maximal	O
G	O
(	O
Anh	O
)	O
MTetra-induced	O
IL-1	B-protein
beta	I-protein
and	O
IL-6	B-RNA
mRNA	I-RNA
expression	O
could	O
be	O
enhanced	O
by	O
co-stimulation	O
with	O
LPS	O
or	O
MDP	O
,	O
suggesting	O
that	O
different	O
receptors	O
and/or	O
transduction	O
pathways	O
were	O
involved	O
.	O

These	O
results	O
indicate	O
that	O
G	O
(	O
Anh	O
)	O
MTetra	O
induces	O
IL-1	B-protein
beta	I-protein
and	O
IL-6	B-protein
expression	O
in	O
human	B-cell_type
monocytes	I-cell_type
suggesting	O
a	O
possible	O
role	O
for	O
G	O
(	O
Anh	O
)	O
MTetra	O
in	O
the	O
release	O
of	O
cytokines	B-protein
during	O
sepsis	O
.	O

Increased	O
proliferation	O
,	O
cytotoxicity	O
,	O
and	O
gene	O
expression	O
after	O
stimulation	O
of	O
human	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
T	I-cell_type
lymphocytes	I-cell_type
through	O
a	O
surface	O
ganglioside	O
(	O
GD3	O
)	O
[	O
published	O
erratum	O
appears	O
in	O
J	O
Immunol	O
1994	O
Jul	O
15	O
;	O
153	O
(	O
2	O
)	O
:	O
910	O
]	O

Previous	O
studies	O
have	O
suggested	O
that	O
gangliosides	O
have	O
an	O
important	O
role	O
in	O
cell	O
signaling	O
and	O
recognition	O
.	O

However	O
,	O
their	O
specific	O
function	O
in	O
these	O
processes	O
has	O
not	O
been	O
clearly	O
defined	O
.	O

A	O
mAb	B-protein
,	O
R24	B-protein
,	O
that	O
reacts	O
specifically	O
with	O
a	O
cell	O
surface	O
ganglioside	O
(	O
GD3	O
)	O
has	O
been	O
demonstrated	O
to	O
stimulate	O
proliferation	O
of	O
T	B-cell_type
cells	I-cell_type
derived	O
from	O
human	O
peripheral	O
blood	O
.	O

In	O
this	O
study	O
,	O
we	O
have	O
investigated	O
the	O
mechanisms	O
by	O
which	O
the	O
R24	B-protein
mAb	I-protein
affects	O
T	O
cell	O
functions	O
.	O

We	O
have	O
observed	O
that	O
the	O
R24	B-protein
mAb	I-protein
stimulates	O
GD3+	O
T	O
cell	O
proliferation	O
,	O
cytotoxicity	O
,	O
and	O
surface	O
marker	O
expression	O
of	O
IL-2R	B-protein
alpha-chain	I-protein
,	O
IL-2R	B-protein
beta-chain	I-protein
,	O
HLA-DR	B-protein
,	O
CD11a	B-protein
,	O
and	O
CD11c	B-protein
.	O

Additionally	O
,	O
IFN-gamma	B-protein
activity	O
but	O
not	O
IL-1	O
,	O
IL-2	O
,	O
or	O
IL-4	O
activity	O
was	O
present	O
in	O
culture	O
supernatants	O
72	O
h	O
after	O
R24	B-protein
stimulation	O
.	O

In	O
some	O
donors	O
,	O
increased	O
IL-6	B-protein
and	O
TNF-alpha	B-protein
activity	O
also	O
was	O
detected	O
after	O
R24	B-protein
treatment	O
.	O

Furthermore	O
,	O
R24	B-protein
treatment	O
resulted	O
in	O
translocation	O
of	O
c-rel	B-protein
,	O
but	O
little	O
or	O
no	O
NF	B-protein
kappa	I-protein
B	I-protein
p50	I-protein
or	O
p65	B-protein
,	O
from	O
the	O
cytoplasm	O
to	O
the	O
nucleus	O
and	O
an	O
increase	O
of	O
NF	B-protein
kappa	I-protein
B	I-protein
binding	I-protein
complexes	I-protein
containing	O
c-rel	B-protein
and	O
p50	B-protein
.	O

This	O
treatment	O
also	O
caused	O
increased	O
tyrosine	O
phosphorylation	O
of	O
specific	O
protein	O
substrates	O
.	O

R24	B-protein
-stimulated	O
increases	O
in	O
proliferation	O
,	O
cytotoxicity	O
,	O
and	O
cell	O
surface	O
protein	O
expression	O
could	O
be	O
blocked	O
by	O
cyclosporin	O
and	O
staurosporin	O
,	O
indicating	O
that	O
cyclophilin/calcineurin	B-protein
and	O
protein	B-protein
kinase	I-protein
C	I-protein
may	O
be	O
involved	O
in	O
the	O
R24	B-protein
signaling	O
pathway	O
.	O

Additionally	O
,	O
herbimycin	O
A	O
,	O
a	O
tyrosine	B-protein
kinase	I-protein
inhibitor	O
,	O
blocked	O
the	O
R24	B-protein
-stimulated	O
increase	O
in	O
proliferation	O
but	O
not	O
cytotoxicity	O
at	O
concentrations	O
consistent	O
with	O
specificity	O
for	O
tyrosine	B-protein
kinases	I-protein
.	O

These	O
results	O
suggest	O
that	O
multiple	O
biochemical	O
pathways	O
are	O
involved	O
in	O
the	O
activation	O
of	O
human	B-cell_type
T	I-cell_type
cells	I-cell_type
by	O
R24	B-protein
.	O

Genes	O
encoding	O
general	B-protein
initiation	I-protein
factors	I-protein
for	O
RNA	B-protein
polymerase	I-protein
II	I-protein
transcription	O
are	O
dispersed	O
in	O
the	O
human	B-DNA
genome	I-DNA
.	O

General	B-protein
transcription	I-protein
factors	I-protein
are	O
required	O
for	O
accurate	O
initiation	O
of	O
transcription	O
by	O
RNA	B-protein
polymerase	I-protein
II	I-protein
.	O

Human	B-DNA
cDNAs	I-DNA
encoding	O
subunits	O
of	O
these	O
factors	O
have	O
been	O
cloned	O
and	O
sequenced	O
.	O

Using	O
fluorescence	O
in	O
situ	O
hybridization	O
(	O
FISH	O
)	O
,	O
we	O
show	O
here	O
that	O
the	O
genes	B-DNA
encoding	O
the	O
TATA-box	B-protein
binding	I-protein
protein	I-protein
(	O
TBP	B-protein
)	O
,	O
TFIIB	B-protein
,	O
TFIIE	B-protein
alpha	I-protein
,	O
TFIIE	B-protein
beta	I-protein
,	O
RAP30	B-protein
,	O
RAP74	B-protein
and	O
the	O
62	B-protein
kDa	I-protein
subunit	I-protein
,	O
of	O
TFIIH	B-protein
are	O
located	O
at	O
the	O
human	B-DNA
chromosomal	I-DNA
bands	I-DNA
6q26-27	I-DNA
,	I-DNA
1p21-22	I-DNA
,	I-DNA
3q21-24	I-DNA
,	I-DNA
8p12	I-DNA
,	I-DNA
13q14	I-DNA
,	I-DNA
19p13.3	I-DNA
and	I-DNA
11p14-15.1	I-DNA
,	O
respectively	O
.	O

This	O
dispersed	O
localization	O
of	O
a	O
group	O
of	O
functionally	O
related	O
gene	O
provides	O
insights	O
into	O
the	O
molecular	O
mechanism	O
of	O
human	B-DNA
genome	I-DNA
evolution	O
and	O
their	O
possible	O
involvement	O
in	O
human	O
diseases	O
.	O

BCL-6	B-protein
and	O
the	O
molecular	O
pathogenesis	O
of	O
B-cell	O
lymphoma	O
.	O

The	O
results	O
presented	O
identify	O
the	O
first	O
genetic	O
lesion	O
associated	O
with	O
DLCL	O
,	O
the	O
most	O
clinically	O
relevant	O
form	O
of	O
NHL	O
.	O

Although	O
no	O
proof	O
yet	O
exists	O
of	O
a	O
role	O
for	O
these	O
lesions	O
in	O
DLCL	O
pathogenesis	O
,	O
the	O
feature	O
of	O
the	O
BCL-6	B-protein
gene	I-protein
product	I-protein
,	O
its	O
specific	O
pattern	O
of	O
expression	O
in	O
B	B-cell_type
cells	I-cell_type
,	O
and	O
the	O
clustering	O
of	O
lesions	O
disrupting	O
its	O
regulatory	O
domain	O
strongly	O
suggest	O
that	O
deregulation	O
of	O
BCL-6	B-protein
expression	O
may	O
contribute	O
to	O
DLCL	O
development	O
.	O

A	O
more	O
precise	O
definition	O
of	O
the	O
role	O
of	O
BCL-6	B-protein
in	O
normal	O
and	O
neoplastic	O
B-cell	O
development	O
is	O
the	O
goal	O
of	O
ongoing	O
study	O
of	O
transgenic	O
mice	O
engineered	O
either	O
to	O
express	O
BCL-6	B-protein
under	O
heterologous	B-DNA
promoters	I-DNA
or	O
lacking	O
BCL-6	B-protein
function	O
due	O
to	O
targeted	O
deletions	O
.	O

In	O
addition	O
to	O
contributing	O
to	O
the	O
understanding	O
of	O
DLCL	O
pathogenesis	O
,	O
the	O
identification	O
of	O
BCL-6	B-protein
lesions	O
may	O
have	O
relevant	O
clinical	O
implications	O
.	O

DLCL	O
represent	O
a	O
heterogeneous	O
group	O
of	O
neoplasms	O
which	O
are	O
treated	O
homogeneously	O
despite	O
the	O
fact	O
that	O
only	O
50	O
%	O
of	O
patients	O
experience	O
long-term	O
disease-free	O
survival	O
(	O
Schneider	O
et	O
al.	O
1990	O
)	O
.	O

The	O
fact	O
that	O
BCL-6	B-protein
rearrangements	O
identify	O
biologically	O
and	O
clinically	O
distinct	O
subsets	O
of	O
DLCL	O
suggests	O
that	O
these	O
lesions	O
may	O
be	O
useful	O
as	O
markers	O
in	O
selection	O
of	O
differential	O
therapeutic	O
strategies	O
based	O
on	O
different	O
risk	O
groups	O
.	O

Furthermore	O
,	O
the	O
BCL-6	B-protein
rearrangements	O
can	O
be	O
used	O
to	O
identify	O
and	O
monitor	O
the	O
malignant	B-cell_type
clone	I-cell_type
with	O
sensitive	O
PCR-based	O
techniques	O
.	O

Since	O
clinical	O
remission	O
has	O
been	O
observed	O
in	O
a	O
significant	O
fraction	O
of	O
DLCL	O
cases	O
,	O
these	O
markers	O
may	O
serve	O
as	O
critical	O
tools	O
for	O
sensitive	O
monitoring	O
of	O
minimal	O
residual	O
disease	O
and	O
early	O
diagnosis	O
of	O
relapse	O
(	O
Gribben	O
et	O
al.	O
1993	O
)	O
.	O

Pancreatic	O
development	O
and	O
maturation	O
of	O
the	O
islet	B-cell_type
B	I-cell_type
cell	I-cell_type
.	O

Studies	O
of	O
pluripotent	B-cell_line
islet	I-cell_line
cultures	I-cell_line
.	O

Pancreas	O
organogenesis	O
is	O
a	O
highly	O
regulated	O
process	O
,	O
in	O
which	O
two	O
anlage	O
evaginate	O
from	O
the	O
primitive	O
gut	O
.	O

They	O
later	O
fuse	O
,	O
and	O
,	O
under	O
the	O
influence	O
of	O
the	O
surrounding	O
mesenchyme	O
,	O
the	O
mature	O
organ	O
develops	O
,	O
being	O
mainly	O
composed	O
of	O
ductal	O
,	O
exocrine	O
and	O
endocrine	O
compartments	O
.	O

Early	O
buds	O
are	O
characterized	O
by	O
a	O
branching	O
morphogenesis	O
of	O
the	O
ductal	O
epithelium	O
from	O
which	O
endocrine	B-cell_type
and	I-cell_type
exocrine	I-cell_type
precursor	I-cell_type
cells	I-cell_type
bud	O
to	O
eventually	O
form	O
the	O
two	O
other	O
compartments	O
.	O

The	O
three	O
compartments	O
are	O
thought	O
to	O
be	O
of	O
common	O
endodermal	O
origin	O
;	O
in	O
contrast	O
to	O
earlier	O
hypotheses	O
,	O
which	O
suggested	O
that	O
the	O
endocrine	O
compartment	O
was	O
of	O
neuroectodermal	O
origin	O
.	O

It	O
is	O
thus	O
generally	O
believed	O
that	O
the	O
pancreatic	O
endocrine-lineage	O
possesses	O
the	O
ability	O
to	O
mature	O
along	O
a	O
differentiation	O
pathway	O
that	O
shares	O
many	O
characteristics	O
with	O
those	O
of	O
neuronal	O
differentiation	O
.	O

During	O
recent	O
years	O
,	O
studies	O
of	O
insulin-gene	B-DNA
regulation	O
and	O
,	O
in	O
particular	O
,	O
the	O
tissue-specific	O
transcriptional	O
control	O
of	O
insulin-gene	B-DNA
activity	O
have	O
provided	O
information	O
on	O
pancreas	O
development	O
in	O
general	O
.	O

The	O
present	O
review	O
summarizes	O
these	O
findings	O
,	O
with	O
a	O
special	O
focus	O
on	O
our	O
own	O
studies	O
on	O
pluripotent	B-cell_line
endocrine	I-cell_line
cultures	I-cell_line
of	O
rat	O
pancreas	O
.	O

Octamer	O
independent	O
activation	O
of	O
transcription	O
from	O
the	O
kappa	B-DNA
immunoglobulin	I-DNA
germline	I-DNA
promoter	I-DNA
.	O

Previous	O
analyses	O
of	O
immunoglobulin	B-DNA
V	I-DNA
region	I-DNA
promoters	I-DNA
has	O
led	O
to	O
the	O
discovery	O
of	O
a	O
common	O
octamer	B-DNA
motif	I-DNA
which	O
is	O
functionally	O
important	O
in	O
the	O
tissue-specific	O
and	O
developmentally	O
regulated	O
transcriptional	O
activation	O
of	O
immunoglobulin	B-DNA
genes	I-DNA
.	O

The	O
germline	B-DNA
promoters	I-DNA
(	O
Ko	B-DNA
)	O
located	O
upstream	O
of	O
the	O
J	B-DNA
region	I-DNA
gene	I-DNA
segments	I-DNA
of	O
the	O
kappa	B-DNA
locus	I-DNA
also	O
contain	O
an	O
octamer	B-DNA
motif	I-DNA
(	O
containing	O
a	O
single	O
base	B-DNA
pair	I-DNA
mutation	I-DNA
and	O
referred	O
to	O
as	O
the	O
variant	O
octamer	O
)	O
which	O
has	O
been	O
shown	O
previously	O
to	O
bind	O
Oct-1	B-protein
and	O
Oct-2	B-protein
transcription	B-protein
factors	I-protein
in	O
vitro	O
.	O

To	O
further	O
elucidate	O
the	O
role	O
of	O
this	O
variant	O
octamer	B-DNA
motif	I-DNA
in	O
the	O
regulation	O
of	O
germline	B-DNA
transcription	O
from	O
the	O
unrearranged	O
kappa	B-DNA
locus	I-DNA
,	O
we	O
have	O
quantitated	O
the	O
relative	O
binding	O
affinity	O
of	O
Oct-1	B-protein
and	O
Oct-2	B-protein
for	O
the	O
variant	O
octamer	B-DNA
motif	I-DNA
and	O
determined	O
the	O
functional	O
role	O
of	O
this	O
octamer	B-DNA
motif	I-DNA
in	O
transcriptional	O
activation	O
.	O

We	O
find	O
that	O
,	O
although	O
the	O
variant	O
octamer	B-DNA
motif	I-DNA
binds	O
Oct-1	B-protein
and	O
Oct-2	B-protein
in	O
vitro	O
with	O
5-fold	O
lower	O
affinity	O
than	O
the	O
consensus	B-DNA
octamer	I-DNA
motif	I-DNA
,	O
mutation	O
of	O
the	O
variant	O
octamer	B-DNA
motif	I-DNA
to	O
either	O
a	O
consensus	B-DNA
octamer	I-DNA
or	O
non-octamer	B-DNA
motif	I-DNA
has	O
no	O
effect	O
on	O
transcriptional	O
activation	O
from	O
the	O
germline	B-DNA
promoter	I-DNA
.	O

We	O
also	O
find	O
significant	O
differences	O
in	O
activation	O
of	O
germline	B-DNA
and	O
V	B-DNA
region	I-DNA
promoters	I-DNA
by	O
kappa	B-DNA
enhancers	I-DNA
.	O

Our	O
results	O
suggest	O
that	O
the	O
germline	B-DNA
promoters	I-DNA
and	O
V	B-DNA
region	I-DNA
promoters	I-DNA
differ	O
in	O
their	O
dependence	O
on	O
octamer	B-DNA
for	O
activation	O
and	O
respond	O
differently	O
to	O
enhancer	O
activation	O
.	O

These	O
findings	O
have	O
important	O
implications	O
in	O
regulation	O
of	O
germline	B-DNA
transcription	O
as	O
well	O
as	O
concomitant	O
activation	O
of	O
the	O
V-J	O
recombination	O
of	O
the	O
kappa	B-DNA
light	I-DNA
chain	I-DNA
locus	I-DNA
.	O

Generation	O
of	O
CD1+RelB+	B-cell_type
dendritic	I-cell_type
cells	I-cell_type
and	O
tartrate-resistant	B-cell_type
acid	I-cell_type
phosphatase-positive	I-cell_type
osteoclast-like	I-cell_type
multinucleated	I-cell_type
giant	I-cell_type
cells	I-cell_type
from	O
human	B-cell_type
monocytes	I-cell_type
.	O

We	O
previously	O
showed	O
that	O
granulocyte-macrophage	B-protein
colony-stimulating	I-protein
factor	I-protein
(	O
GM-CSF	B-protein
)	O
and	O
macrophage	B-protein
colony-stimulating	I-protein
factor	I-protein
(	O
M-CSF	B-protein
)	O
stimulate	O
the	O
differentiation	O
of	O
human	B-cell_type
monocytes	I-cell_type
into	O
two	O
phenotypically	O
distinct	O
types	O
of	O
macrophages	B-cell_type
.	O

However	O
,	O
in	O
vivo	O
,	O
not	O
only	O
CSF	B-protein
but	O
also	O
many	O
other	O
cytokines	B-protein
are	O
produced	O
under	O
various	O
conditions	O
.	O

Those	O
cytokines	B-protein
may	O
modulate	O
the	O
differentiation	O
of	O
monocytes	B-cell_type
by	O
CSFs	B-protein
.	O

In	O
the	O
present	O
study	O
,	O
we	O
showed	O
that	O
CD14+	B-cell_type
adherent	I-cell_type
human	I-cell_type
monocytes	I-cell_type
can	O
differentiate	O
into	O
CD1+relB+	B-cell_type
dendritic	I-cell_type
cells	I-cell_type
(	O
DC	B-cell_type
)	O
by	O
the	O
combination	O
of	O
GM-CSF	B-protein
plus	O
interleukin-4	B-protein
(	O
IL-4	B-protein
)	O
and	O
that	O
they	O
differentiate	O
into	O
tartrate-resistant	B-cell_type
acid	I-cell_type
phosphatase	I-cell_type
(	I-cell_type
TRAP	I-cell_type
)	I-cell_type
-positive	I-cell_type
osteoclast-like	I-cell_type
multinucleated	I-cell_type
giant	I-cell_type
cells	I-cell_type
(	O
MGC	B-cell_type
)	O
by	O
the	O
combination	O
of	O
M-CSF	B-protein
plus	O
IL-4	B-protein
.	O

However	O
,	O
the	O
monocyte-derived	B-cell_line
DC	I-cell_line
were	O
not	O
terminally	B-cell_line
differentiated	I-cell_line
cells	I-cell_line
;	O
they	O
could	O
still	O
convert	O
to	O
macrophages	B-cell_type
in	O
response	O
to	O
M-CSF	B-protein
.	O

Tumor	B-protein
necrosis	I-protein
factor-alpha	I-protein
(	O
TNF-alpha	B-protein
)	O
stimulated	O
the	O
terminal	O
differentiation	O
of	O
the	O
DC	B-cell_type
by	O
downregulating	O
the	O
expression	O
of	O
the	O
M-CSF	B-protein
receptor	I-protein
,	O
cfms	B-RNA
mRNA	I-RNA
,	O
and	O
aborting	O
the	O
potential	O
to	O
convert	O
to	O
macrophages	B-cell_type
.	O

In	O
contrast	O
to	O
IL-4	B-protein
,	O
interferon-gamma	B-protein
(	O
IFN-gamma	B-protein
)	O
had	O
no	O
demonstrable	O
effect	O
on	O
the	O
differentiation	O
of	O
monocytes	B-cell_type
.	O

Rather	O
,	O
IFN-gamma	B-protein
antagonized	O
the	O
effect	O
of	O
IL-4	B-protein
and	O
suppressed	O
the	O
DC	B-cell_type
and	O
MGC	B-cell_type
formation	O
induced	O
by	O
GM-CSF	B-protein
+	O
IL-4	B-protein
and	O
M-CSF	B-protein
+	O
IL-4	B-protein
,	O
respectively	O
.	O

Taken	O
together	O
,	O
these	O
results	O
provide	O
a	O
new	O
aspect	O
to	O
our	O
knowledge	O
of	O
monocyte	O
differentiation	O
and	O
provide	O
evidence	O
that	O
human	B-cell_type
monocytes	I-cell_type
are	O
flexible	O
in	O
their	O
differentiation	O
potential	O
and	O
are	O
precursors	O
not	O
only	O
of	O
macrophages	B-cell_type
but	O
also	O
of	O
CD1+relB+DC	B-cell_type
and	O
TRAP-positive	B-cell_type
MGC	I-cell_type
.	O

Such	O
a	O
diverse	O
pathway	O
of	O
monocyte	O
differentiation	O
may	O
constitute	O
one	O
of	O
the	O
basic	O
mechanisms	O
of	O
immune	O
regulation	O
.	O

The	O
NF-kappa	B-protein
B	I-protein
inhibitor	O
,	O
tepoxalin	O
,	O
suppresses	O
surface	O
expression	O
of	O
the	O
cell	B-protein
adhesion	I-protein
molecules	I-protein
CD62E	B-protein
,	O
CD11b/CD18	B-protein
and	O
CD106	B-protein
.	O

Tepoxalin	O
,	O
a	O
dual	O
enzyme	O
inhibitor	O
of	O
cyclooxygenase	B-protein
and	O
5-lipoxygenase	B-protein
has	O
been	O
shown	O
to	O
inhibit	O
T-cell	O
activation	O
.	O

Its	O
immunosuppressive	O
property	O
is	O
distinct	O
from	O
cyclosporin	O
because	O
only	O
tepoxalin	O
,	O
but	O
not	O
cyclosporin	O
,	O
suppresses	O
NF-kappa	B-protein
B	I-protein
activation	O
.	O

Here	O
we	O
report	O
that	O
tepoxalin	O
selectively	O
inhibits	O
intercellular	B-protein
adhesion	I-protein
molecule-1	I-protein
(	B-protein
ICAM-1	I-protein
,	I-protein
CD54	I-protein
)	I-protein
/MAC-1	I-protein
(	O
CD11b/CD18	B-protein
)	O
dependent	O
adhesion	O
of	O
polymorphonuclear	B-cell_type
cells	I-cell_type
to	O
IL-1	B-protein
activated	O
human	B-cell_type
umbilical	I-cell_type
vein	I-cell_type
endothelial	I-cell_type
cells	I-cell_type
.	O

The	O
mechanism	O
of	O
inhibition	O
is	O
related	O
to	O
the	O
surface	O
expression	O
of	O
several	O
cell	O
adhesion	B-protein
molecules	I-protein
.	O

Flow	O
cytometry	O
analyses	O
on	O
cultured	O
cells	O
that	O
were	O
treated	O
with	O
tepoxalin	O
or	O
antisense	O
oligonucleotides	O
to	O
the	O
P65/p50	B-protein
subunit	I-protein
of	O
NF-kappa	B-protein
B	I-protein
,	O
and	O
then	O
stimulated	O
with	O
PMA	O
,	O
revealed	O
a	O
reduced	O
expression	O
of	O
CD11b/CD18	B-protein
on	O
monocytic	B-cell_line
HL60	I-cell_line
cells	I-cell_line
,	O
and	O
endothelial	B-protein
adhesion	I-protein
molecule-1	I-protein
(	O
CD62E	B-protein
)	O
and	O
vascular	B-protein
adhesion	I-protein
molecule-1	I-protein
(	O
CD106	B-protein
)	O
on	O
human	B-cell_type
umbilical	I-cell_type
vein	I-cell_type
endothelial	I-cell_type
cells	I-cell_type
.	O

Expression	O
of	O
other	O
adhesion	B-protein
molecules	I-protein
such	O
as	O
lymphocyte	B-protein
function	I-protein
associated-antigen-1	I-protein
(	O
CD11a/CD18	B-protein
)	O
and	O
CD54	B-protein
were	O
unaffected	O
.	O

Tepoxalin	O
also	O
inhibited	O
the	O
secretion	O
of	O
a	O
NF-kappa	B-protein
B	I-protein
regulated	I-protein
chemokine	I-protein
,	O
IL-8	B-protein
,	O
a	O
known	O
inducer	O
of	O
CD11b/CD18	B-protein
expression	O
.	O

Thus	O
the	O
suppression	O
of	O
CD11b/CD18	B-protein
expression	O
by	O
tepoxalin	O
may	O
involve	O
IL-8	B-protein
.	O

Our	O
results	O
suggest	O
that	O
by	O
inhibiting	O
NF-kappa	B-protein
B	I-protein
activation	O
,	O
surface	O
expression	O
of	O
several	O
adhesion	B-protein
molecules	I-protein
can	O
be	O
modulated	O
and	O
that	O
tepoxalin	O
may	O
be	O
useful	O
in	O
treating	O
selected	O
adhesion	O
mediated	O
events	O
such	O
as	O
leukocyte	O
migration	O
or	O
atherosclerotic	O
plaque	O
formation	O
.	O

Characterization	O
of	O
a	O
CD43/leukosialin	B-protein
-mediated	O
pathway	O
for	O
inducing	O
apoptosis	O
in	O
human	B-cell_type
T-lymphoblastoid	I-cell_type
cells	I-cell_type
.	O

The	O
monoclonal	B-protein
antibody	I-protein
(	O
mAb	B-protein
)	O
J393	B-protein
induces	O
apoptosis	O
in	O
Jurkat	B-cell_line
T-cells	I-cell_line
.	O

NH2	B-protein
-terminal	O
amino	O
acid	O
sequence	O
analysis	O
identified	O
the	O
140-kDa	B-protein
surface	I-protein
antigen	I-protein
for	O
mAb	B-protein
J393	I-protein
as	O
CD43/leukosialin	B-protein
,	O
the	O
major	O
sialoglycoprotein	B-protein
of	O
leukocytes	B-cell_type
.	O

While	O
Jurkat	B-cell_line
cells	I-cell_line
co-expressed	O
two	O
discrete	O
cell-surface	B-protein
isoforms	I-protein
of	O
CD43	B-protein
,	O
recognized	O
by	O
mAb	B-protein
J393	I-protein
and	O
mAb	B-protein
G10-2	I-protein
,	O
respectively	O
,	O
only	O
J393/CD43	B-protein
signaled	O
apoptosis	O
.	O

J393/CD43	B-protein
was	O
found	O
to	O
be	O
hyposialylated	O
,	O
bearing	O
predominantly	O
O-linked	O
monosaccharide	O
glycans	O
,	O
whereas	O
G10-2/CD43	B-protein
bore	O
complex	O
sialylated	O
tetra-	O
and	O
hexasaccharide	O
chains	O
.	O

Treatment	O
with	O
soluble	O
,	O
bivalent	O
mAb	B-protein
J393	I-protein
killed	O
25-50	O
%	O
of	O
the	O
cell	B-cell_line
population	I-cell_line
,	O
while	O
concomitant	O
engagement	O
of	O
either	O
the	O
CD3.TcR	B-protein
complex	I-protein
or	O
the	O
integrins	B-protein
CD18	B-protein
and	O
CD29	B-protein
significantly	O
potentiated	O
this	O
effect	O
.	O

Treatment	O
of	O
Jurkat	B-cell_line
cells	I-cell_line
with	O
mAb	B-protein
J393	I-protein
induced	O
tyrosine	O
phosphorylation	O
of	O
specific	O
protein	B-protein
substrates	I-protein
that	O
underwent	O
hyperphosphorylation	O
upon	O
antigen	B-protein
receptor	I-protein
costimulation	O
.	O

Tyrosine	B-protein
kinase	I-protein
inhibition	O
by	O
herbimycin	O
A	O
diminished	O
J393/CD43	B-protein
-mediated	O
apoptosis	O
,	O
whereas	O
inhibition	O
of	O
phosphotyrosine	B-protein
phosphatase	I-protein
activity	O
by	O
bis	O
(	O
maltolato	O
)	O
oxovanadium-IV	O
enhanced	O
cell	O
death	O
.	O

Signal	O
transduction	O
through	O
tyrosine	O
kinase	O
activation	O
may	O
lead	O
to	O
altered	O
gene	O
expression	O
,	O
as	O
J393/	O
CD43	B-protein
ligation	O
prompted	O
decreases	O
in	O
the	O
nuclear	O
localization	O
of	O
the	O
transcriptional	B-protein
regulatory	I-protein
protein	I-protein
NF-kappaB	B-protein
and	O
proteins	O
binding	O
the	O
interferon-inducible	B-DNA
regulatory	I-DNA
element	I-DNA
.	O

Since	O
peripheral	B-cell_type
blood	I-cell_type
T-lymphocytes	I-cell_type
express	O
cryptic	B-protein
epitopes	I-protein
for	O
mAb	B-protein
J393	I-protein
,	O
these	O
findings	O
demonstrate	O
the	O
existence	O
of	O
a	O
tightly	O
regulated	O
CD43	B-protein
-mediated	O
pathway	O
for	O
inducing	O
apoptosis	O
in	O
human	B-cell_type
T-cell	I-cell_type
lineages	I-cell_type
.	O

Sterol	O
dependent	O
LDL-receptor	B-DNA
gene	I-DNA
transcription	O
in	O
lymphocytes	B-cell_type
from	O
normal	O
and	O
CML	O
patients	O
.	O

Sterol	B-DNA
regulatory	I-DNA
element	I-DNA
(	O
SRE	B-DNA
)	O
has	O
been	O
recognized	O
to	O
regulate	O
various	O
key	O
genes	B-DNA
coding	O
for	O
especially	O
low	B-protein
density	I-protein
lipoprotein	I-protein
(	I-protein
LDL	I-protein
)	I-protein
-receptor	I-protein
,	O
3-hydroxy-3-methylglutaryl	B-protein
coenzyme	I-protein
A	I-protein
(	I-protein
HMG-CoA	I-protein
)	I-protein
reductase	I-protein
and	O
HMG-CoA	B-protein
synthase	I-protein
known	O
to	O
play	O
a	O
crucial	O
role	O
in	O
the	O
cholesterol	O
feedback	O
mechanism	O
.	O

The	O
deranged	O
cholesterol	O
feedback	O
mechanism	O
has	O
been	O
widely	O
recognised	O
in	O
initiation	O
as	O
well	O
as	O
progression	O
of	O
various	O
types	O
of	O
cancers	O
including	O
chronic	O
myeloid	O
leukaemia	O
(	O
CML	O
)	O
.	O

Consequently	O
,	O
the	O
present	O
study	O
was	O
addressed	O
to	O
understand	O
this	O
phenomenon	O
and	O
revealed	O
the	O
existence	O
of	O
a	O
unique	B-protein
47	I-protein
kDa	I-protein
protein	I-protein
factor	I-protein
having	O
affinity	O
for	O
this	O
SRE	B-DNA
sequence	I-DNA
in	O
lymphocytes	B-cell_type
from	O
normal	O
subjects	O
as	O
well	O
as	O
its	O
absence	O
in	O
lymphocytes	B-cell_type
from	O
untreated	O
CML	O
patients	O
.	O

However	O
,	O
this	O
factor	O
appeared	O
when	O
the	O
CML	O
patients	O
achieved	O
complete	O
haematological	O
remission	O
(	O
CHR	O
)	O
through	O
alpha-interferon	B-protein
therapy	O
.	O

Further	O
,	O
an	O
inverse	O
relationship	O
was	O
also	O
observed	O
between	O
sterol	O
modulated	O
LDL-receptor	B-DNA
gene	I-DNA
transcription	O
and	O
the	O
binding	O
affinity	O
of	O
this	O
47	B-protein
kDa	I-protein
factor	I-protein
to	O
the	O
SRE	B-DNA
sequence	I-DNA
.	O

Based	O
upon	O
these	O
results	O
we	O
propose	O
that	O
alpha-interferon	B-protein
through	O
its	O
receptor	O
initiates	O
phosphatidic	O
acid	O
dependent	O
signalling	O
which	O
in	O
turn	O
regulates	O
the	O
affinity	O
of	O
47	B-protein
kDa	I-protein
sterol	I-protein
regulatory	I-protein
element	I-protein
binding	I-protein
factor	I-protein
as	O
well	O
as	O
LDL-receptor	B-DNA
gene	I-DNA
transcription	O
in	O
lymphocytes	B-cell_type
from	O
CML	O
patients	O
.	O

Multiple	O
prolactin-responsive	B-DNA
elements	I-DNA
mediate	O
G1	O
and	O
S	O
phase	O
expression	O
of	O
the	O
interferon	B-DNA
regulatory	I-DNA
factor-1	I-DNA
gene	I-DNA
.	O

The	O
interferon	B-DNA
regulatory	I-DNA
factor-1	I-DNA
(	I-DNA
IRF-1	I-DNA
)	I-DNA
gene	I-DNA
is	O
both	O
an	O
immediate-early	B-DNA
G1	I-DNA
phase	I-DNA
gene	I-DNA
and	O
an	O
S	B-DNA
phase	I-DNA
gene	I-DNA
inducible	O
by	O
PRL	B-protein
in	O
rat	B-cell_line
Nb2	I-cell_line
T	I-cell_line
lymphocytes	I-cell_line
.	O

To	O
understand	O
the	O
mechanism	O
by	O
which	O
PRL	B-protein
regulates	O
the	O
biphasic	O
expression	O
of	O
IRF-1	B-protein
,	O
we	O
cloned	O
the	O
rat	B-DNA
IRF-1	I-DNA
gene	I-DNA
and	O
functionally	O
characterized	O
the	O
IRF-1	B-DNA
promoter	I-DNA
.	O

Upon	O
transfection	O
into	O
Nb2	B-cell_line
T	I-cell_line
cells	I-cell_line
,	O
1.7	O
kilobases	O
(	O
kb	O
)	O
of	O
IRF-1	B-DNA
5'-flanking	I-DNA
DNA	I-DNA
linked	O
to	O
a	O
chloramphenicol	B-DNA
acetyl	I-DNA
transferase	I-DNA
(	I-DNA
CAT	I-DNA
)	I-DNA
reporter	I-DNA
gene	I-DNA
mediated	O
a	O
30-fold	O
induction	O
of	O
CAT	B-protein
enzyme	I-protein
activity	O
in	O
response	O
to	O
24	O
h	O
of	O
PRL	B-protein
stimulation	O
.	O

Deletion	O
mutants	O
containing	O
1.3	B-DNA
,	I-DNA
0.6	I-DNA
,	I-DNA
and	I-DNA
0.2	I-DNA
kb	I-DNA
5'-flanking	I-DNA
DNA	I-DNA
were	O
incrementally	O
less	O
transcriptionally	O
active	O
,	O
although	O
0.2	O
kb	O
still	O
mediated	O
a	O
12-fold	O
induction	O
by	O
PRL	B-protein
.	O

The	O
sequence	O
between	O
-1.7	O
and	O
-0.2	O
kb	O
linked	O
to	O
a	O
heterologous	B-DNA
thymidine	I-DNA
kinase	I-DNA
promoter	I-DNA
failed	O
to	O
respond	O
to	O
PRL	B-protein
stimulation	O
,	O
suggesting	O
that	O
the	O
activity	O
of	O
upstream	B-DNA
PRL	I-DNA
response	I-DNA
elements	I-DNA
may	O
require	O
an	O
interaction	O
with	O
promoter-proximal	B-DNA
elements	I-DNA
.	O

By	O
assaying	O
CAT	B-protein
enzyme	I-protein
activity	O
across	O
a	O
24-h	O
PRL	B-protein
induction	O
time	O
course	O
,	O
we	O
were	O
able	O
to	O
assign	O
G1	O
vs.	O
S	O
phase	O
PRL	B-protein
responses	O
of	O
the	O
IRF-1	B-DNA
gene	I-DNA
to	O
different	O
regions	O
of	O
the	O
IRF-1	B-protein
5'-flanking	B-DNA
and	O
promoter	B-DNA
DNA	I-DNA
.	O

The	O
0.2-kb	O
IRF-CAT	B-DNA
construct	I-DNA
was	O
induced	O
by	O
PRL	B-protein
stimulation	O
during	O
the	O
G1	O
phase	O
of	O
the	O
cell	O
cycle	O
.	O

In	O
contrast	O
,	O
the	O
1.7-kb	O
IRF-	O
CAT	B-protein
construct	O
was	O
inducible	O
by	O
PRL	B-protein
during	O
both	O
G1	O
and	O
S	O
phase	O
of	O
the	O
cell	O
cycle	O
.	O

Hence	O
,	O
the	O
PRL	B-protein
-induced	O
biphasic	O
expression	O
of	O
the	O
IRF-1	B-DNA
gene	I-DNA
appears	O
to	O
be	O
controlled	O
by	O
separate	O
PRL-responsive	B-DNA
elements	I-DNA
:	O
elements	O
in	O
the	O
first	O
0.2	O
kb	O
of	O
the	O
IRF-1	B-DNA
promoter	I-DNA
region	I-DNA
act	O
during	O
early	O
activation	O
,	O
and	O
elements	O
between	O
0.2	O
and	O
1.7	O
kb	O
act	O
in	O
concert	O
with	O
the	O
proximal	O
0.2-kb	O
region	O
during	O
S	O
phase	O
progression	O
.	O

Regulation	O
of	O
the	O
BZLF1	B-DNA
promoter	I-DNA
of	O
Epstein-Barr	O
virus	O
by	O
second	O
messengers	O
in	O
anti-immunoglobulin-treated	B-cell_line
B	I-cell_line
cells	I-cell_line
.	O

Initiation	O
of	O
the	O
Epstein-Barr	O
virus	O
(	O
EBV	O
)	O
lytic	O
cycle	O
is	O
dependent	O
on	O
the	O
transcription	O
of	O
the	O
BZLF1	B-DNA
gene	I-DNA
.	O

The	O
BZLF1	B-DNA
gene	I-DNA
promoter	I-DNA
(	O
Zp	B-DNA
)	O
was	O
activated	O
by	O
crosslinking	O
of	O
cell	B-protein
surface	I-protein
immunoglobulin	I-protein
(	O
Ig	B-protein
)	O
with	O
anti-Ig	B-protein
antibody	I-protein
in	O
B	B-cell_type
cells	I-cell_type
,	O
even	O
in	O
the	O
absence	O
of	O
other	O
viral	O
genes	O
.	O

We	O
identified	O
several	O
anti-Ig	O
response	O
elements	O
within	O
Zp	B-DNA
,	O
which	O
were	O
originally	O
defined	O
as	O
12-O-tetradecanoylphorbol-13-acetate	B-DNA
(	I-DNA
TPA	I-DNA
)	I-DNA
response	I-DNA
elements	I-DNA
(	O
ZI	O
repeats	O
and	O
ZII	B-DNA
,	O
an	O
AP-1-like	B-DNA
domain	I-DNA
)	O
.	O

Since	O
anti-Ig	O
crosslinking	O
leads	O
to	O
activation	O
of	O
protein	B-protein
kinase	I-protein
C	I-protein
(	O
PKC	B-protein
)	O
and	O
an	O
increase	O
in	O
intracellular	O
calcium	O
level	O
,	O
Zp	B-DNA
was	O
tested	O
for	O
the	O
response	O
to	O
these	O
cellular	B-protein
factors	I-protein
.	O

Treatment	O
with	O
calcium	O
ionophore	O
A23187	O
increased	O
Zp	B-DNA
activity	O
.	O

When	O
the	O
calcium	O
ionophore	O
was	O
used	O
in	O
conjunction	O
with	O
TPA	O
,	O
a	O
PKC	B-protein
activator	O
,	O
the	O
Zp	B-DNA
induction	O
was	O
synergistically	O
enhanced	O
.	O

1-	O
(	O
5-Isoquinolinyl	O
sulfonyl	O
)	O
-2-methylpiperazine	O
,	O
an	O
inhibitor	O
of	O
PKC	B-protein
,	O
inhibited	O
the	O
anti-Ig	B-protein
inducibility	O
of	O
Zp	B-DNA
.	O

Calmodulin	O
antagonists	O
,	O
compound	O
R24571	O
and	O
trifluoperazine	O
,	O
blocked	O
the	O
Zp	B-DNA
activation	O
with	O
anti-Ig	B-protein
.	O

These	O
findings	O
suggest	O
that	O
Zp	B-DNA
responds	O
directly	O
to	O
changes	O
in	O
the	O
activity	O
of	O
both	O
PKC	B-protein
and	O
calcium/calmodulin-dependent	B-protein
protein	I-protein
kinase	I-protein
.	O

Requirement	O
of	O
tyrosine	B-protein
kinase	I-protein
activation	O
for	O
the	O
anti-Ig	B-protein
-mediated	O
Zp	B-DNA
activation	O
was	O
also	O
demonstrated	O
through	O
the	O
use	O
of	O
the	O
tyrosine	O
kinase	O
inhibitor	O
herbimycin	O
.	O

These	O
cellular	B-protein
gene	I-protein
regulatory	I-protein
molecules	I-protein
induced	O
with	O
anti-Ig	O
may	O
cooperatively	O
play	O
an	O
important	O
part	O
in	O
achieving	O
efficient	O
EBV	O
activation	O
as	O
seen	O
with	O
anti-Ig	B-protein
treatment	O
in	O
B	B-cell_type
cells	I-cell_type
.	O

The	O
SCL	B-protein
protein	I-protein
displays	O
cell-specific	O
heterogeneity	O
in	O
size	O
.	O

SCL	B-protein
protein	I-protein
production	O
was	O
examined	O
in	O
a	O
variety	O
of	O
hemopoietic	B-cell_line
cell	I-cell_line
lines	I-cell_line
by	O
immunoblotting	O
using	O
specific	O
polyclonal	O
antisera	O
.	O

SCL	B-protein
protein	I-protein
was	O
detected	O
in	O
erythroid	B-cell_line
,	I-cell_line
megakaryocyte	I-cell_line
,	I-cell_line
mast	I-cell_line
and	I-cell_line
early	I-cell_line
myeloid	I-cell_line
cell	I-cell_line
lines	I-cell_line
,	O
as	O
well	O
as	O
in	O
several	O
lymphoid	B-cell_line
leukemia	I-cell_line
cell	I-cell_line
lines	I-cell_line
which	O
are	O
known	O
to	O
harbor	O
SCL	B-DNA
gene	I-DNA
rearrangements	I-DNA
.	O

In	O
most	O
cell	O
lines	O
,	O
proteins	O
of	O
molecular	O
weight	O
49	O
and	O
44	O
kDa	O
were	O
found	O
,	O
however	O
two	O
myeloid	O
cell	O
lines	O
expressed	O
only	O
lower	O
molecular	B-protein
weight	I-protein
species	I-protein
of	I-protein
24	I-protein
and	I-protein
22	I-protein
kDa	I-protein
.	O

This	O
size	O
discrepancy	O
appeared	O
to	O
be	O
due	O
to	O
cell-specific	O
translational	O
regulation	O
,	O
since	O
overexpression	O
of	O
a	O
retrovirally	O
transfected	O
SCL	B-DNA
gene	I-DNA
yielded	O
the	O
higher	O
molecular	O
weight	O
forms	O
in	O
most	O
cell	B-cell_line
lines	I-cell_line
(	O
GP+E-86	B-cell_line
,	O
AT2.5	B-cell_line
,	O
M1	B-cell_line
)	O
but	O
only	O
the	O
22	B-protein
kDa	I-protein
form	I-protein
in	O
the	O
myeloid	B-cell_line
cell	I-cell_line
line	I-cell_line
,	O
WEHI-3B/D+	B-cell_line
.	O

Overexpression	O
of	O
full-length	O
SCL	B-protein
protein	I-protein
in	O
the	O
lymphoid	B-cell_line
cell	I-cell_line
lines	I-cell_line
,	O
SupT1	O
and	O
Raji	O
,	O
did	O
not	O
alter	O
cell	O
phenotype	O
and	O
there	O
was	O
no	O
evidence	O
for	O
autoregulation	O
of	O
SCL	B-protein
transcription	O
.	O

The	O
restricted	O
pattern	O
of	O
SCL	B-protein
protein	I-protein
synthesis	O
is	O
consistent	O
with	O
the	O
restricted	O
expression	O
of	O
SCL	B-RNA
mRNA	I-RNA
documented	O
previously	O
.	O

In	O
addition	O
,	O
the	O
present	O
results	O
indicate	O
that	O
SCL	B-protein
protein	I-protein
size	O
was	O
determined	O
by	O
regulation	O
of	O
translation	O
in	O
a	O
cell-specific	O
manner	O
.	O

Description	O
and	O
functional	O
implications	O
of	O
a	O
novel	O
mutation	O
in	O
the	O
sex-determining	B-DNA
gene	I-DNA
SRY	B-DNA
.	O

The	O
sex-determining	O
gene	O
SRY	B-DNA
was	O
screened	O
for	O
molecular	O
alteration	O
in	O
an	O
XY	O
sex-reversed	O
female	O
by	O
single-strand	O
conformation	O
polymorphism	O
(	O
SSCP	O
)	O
technique	O
.	O

An	O
A-to-G	O
transition	O
was	O
detected	O
which	O
leads	O
to	O
an	O
exchange	O
of	O
a	O
tyrosine	O
by	O
a	O
cysteine	O
in	O
the	O
SRY	B-protein
protein	I-protein
.	O

The	O
affected	O
tyrosine	O
residue	O
located	O
at	O
the	O
C	B-protein
terminus	I-protein
of	O
the	O
DNA	B-protein
binding	I-protein
protein	I-protein
is	O
evolutionarily	O
strongly	O
conserved	O
among	O
the	O
members	O
of	O
the	O
HMG	B-protein
box	I-protein
containing	I-protein
proteins	I-protein
.	O

Using	O
gel	O
shift	O
assay	O
and	O
peptide	O
synthesis	O
such	O
a	O
mutation	O
is	O
shown	O
to	O
abolish	O
the	O
SRY	B-DNA
protein	O
DNA	O
binding	O
ability	O
.	O

The	O
involvement	O
of	O
this	O
particular	O
amino	O
acid	O
in	O
the	O
binding	O
specificity	O
is	O
also	O
discussed	O
.	O

Induction	O
of	O
tyrosine	O
phosphorylation	O
and	O
T-cell	B-cell_type
activation	O
by	O
vanadate	O
peroxide	O
,	O
an	O
inhibitor	O
of	O
protein	B-protein
tyrosine	I-protein
phosphatases	I-protein
.	O

Rapid	O
tyrosine	O
phosphorylation	O
of	O
key	O
cellular	O
proteins	O
is	O
a	O
crucial	O
event	O
in	O
the	O
transduction	O
of	O
activation	O
signals	O
to	O
T-lymphocytes	B-cell_type
.	O

The	O
regulatory	O
role	O
of	O
protein	B-protein
tyrosine	I-protein
phosphatases	I-protein
(	O
PTPases	B-protein
)	O
in	O
this	O
process	O
was	O
explored	O
by	O
studying	O
the	O
effects	O
of	O
a	O
powerful	O
PTPase	B-protein
inhibitor	O
,	O
vanadate	O
peroxide	O
(	O
pervanadate	O
)	O
,	O
on	O
the	O
activation	O
cascade	O
of	O
Jurkat	B-cell_line
human	I-cell_line
leukaemic	I-cell_line
T-cells	I-cell_line
.	O

Pervanadate	O
induced	O
activation	O
of	O
the	O
tyrosine	B-protein
kinases	I-protein
lck	B-protein
and	O
fyn	B-protein
(	O
4-	O
and	O
3-fold	O
respectively	O
)	O
and	O
a	O
dramatic	O
increase	O
in	O
tyrosine	O
phosphorylation	O
of	O
cellular	B-protein
proteins	I-protein
,	O
notably	O
phospholipase	B-protein
C	I-protein
gamma	I-protein
1	I-protein
.	O

After	O
this	O
event	O
,	O
we	O
observed	O
a	O
rise	O
in	O
intracellular	O
Ca2+	O
concentration	O
,	O
corresponding	O
to	O
an	O
influx	O
.	O

This	O
effect	O
required	O
surface	O
expression	O
of	O
the	O
CD45	B-protein
PTPase	I-protein
and	O
was	O
not	O
observed	O
in	O
CD45-deficient	B-cell_line
variants	I-cell_line
of	O
Jurkat	B-cell_line
cells	I-cell_line
.	O

In	O
the	O
CD45-negative	B-cell_line
variant	I-cell_line
,	O
the	O
effect	O
of	O
pervanadate	O
on	O
tyrosine	O
phosphorylation	O
was	O
globally	O
decreased	O
and	O
some	O
phosphorylated	O
substrates	O
were	O
specifically	O
missing	O
.	O

Pervanadate	O
also	O
stimulated	O
transcription	O
of	O
the	O
c-fos	B-DNA
gene	I-DNA
and	O
accumulation	O
of	O
its	O
mRNA	B-RNA
as	O
well	O
as	O
several	O
other	O
hallmarks	O
of	O
T-lymphocyte	B-cell_type
activation	O
such	O
as	O
surface	O
expression	O
of	O
the	O
CD69	O
antigen	O
and	O
the	O
interleukin	O
2	O
receptor	O
alpha-chain	O
(	O
CD25	O
)	O
.	O

Pervanadate	O
synergized	O
with	O
signals	O
delivered	O
by	O
T-cell	B-cell_type
antigen	B-protein
receptor	I-protein
engagement	O
or	O
by	O
a	O
phorbol	O
ester	O
to	O
induce	O
interleukin	O
2	O
production	O
.	O

Pervanadate	B-protein
activated	I-protein
NF-kappa	I-protein
B	I-protein
,	O
as	O
shown	O
by	O
an	O
increase	O
in	O
DNA-binding	O
activity	O
of	O
this	O
transcription	B-protein
factor	I-protein
.	O

We	O
thus	O
conclude	O
that	O
PTPases	B-protein
play	O
a	O
crucial	O
role	O
in	O
the	O
negative	O
regulation	O
of	O
signal	O
transduction	O
culminating	O
in	O
T-lymphocyte	B-cell_type
activation	O
.	O

Moreover	O
,	O
induction	O
of	O
tyrosine	O
phosphorylation	O
appears	O
sufficient	O
per	O
se	O
to	O
initiate	O
a	O
complete	O
activation	O
programme	O
.	O

Activation	O
of	O
nuclear	B-protein
factor-kappaB	I-protein
via	O
T	B-protein
cell	I-protein
receptor	I-protein
requires	O
a	O
Raf	B-protein
kinase	I-protein
and	O
Ca2+	O
influx	O
.	O

Functional	O
synergy	O
between	O
Raf	B-protein
and	O
calcineurin	B-protein
.	O

Signals	O
transduced	O
via	O
the	O
TCR	B-protein
activate	O
the	O
transcription	B-protein
factor	I-protein
nuclear	B-protein
factor-kappaB	I-protein
(	O
NF-kappaB	B-protein
)	O
,	O
which	O
,	O
in	O
turn	O
,	O
is	O
critical	O
to	O
the	O
transcriptional	O
induction	O
of	O
many	O
genes	O
important	O
for	O
the	O
proliferation	O
and	O
expression	O
of	O
a	O
differentiated	O
phenotype	O
.	O

Treatment	O
of	O
T	B-cell_type
cells	I-cell_type
with	O
the	O
protein	B-protein
kinase	I-protein
C	I-protein
activator	O
PMA	O
in	O
combination	O
with	O
Ca2+	O
ionophores	O
mimics	O
this	O
process	O
,	O
and	O
the	O
two	O
agents	O
are	O
often	O
substituted	O
for	O
TCR	B-protein
stimulation	O
,	O
bypassing	O
the	O
TCR	B-protein
.	O

Here	O
we	O
identify	O
intracellular	O
signaling	O
components	O
involved	O
in	O
activation	O
of	O
NF-kappaB	B-protein
following	O
TCR	B-protein
stimulation	O
.	O

TCR	B-protein
signaling	O
was	O
triggered	O
by	O
treating	O
Jurkat	B-cell_line
T	I-cell_line
cells	I-cell_line
with	O
PHA	B-protein
or	O
anti-CD3	B-protein
Abs	I-protein
,	O
and	O
NF-kappaB	B-protein
activation	O
was	O
monitored	O
by	O
electrophoretic	O
mobility	O
shift	O
assays	O
and/or	O
by	O
kappaB	B-protein
-dependent	O
reporter	O
assays	O
.	O

Contrary	O
to	O
the	O
idea	O
that	O
protein	B-protein
kinase	I-protein
C	I-protein
is	O
involved	O
in	O
TCR	B-protein
-mediated	O
activation	O
of	O
NF-kappaB	B-protein
,	O
high	O
doses	O
of	O
staurosporine	O
did	O
not	O
interfere	O
with	O
activation	O
of	O
NF-kappaB	B-protein
by	O
PHA	B-protein
,	O
while	O
the	O
same	O
dose	O
of	O
staurosporine	O
completely	O
blocked	O
activation	O
by	O
PMA	O
.	O

PHA	B-protein
-induced	O
kappaB-dependent	O
reporter	O
activity	O
was	O
,	O
however	O
,	O
effectively	O
blocked	O
by	O
a	O
dominant	O
negative	O
form	O
of	O
Raf-1	B-protein
,	O
suggesting	O
a	O
critical	O
role	O
for	O
a	O
Raf	B-protein
kinase	I-protein
.	O

The	O
TCR	B-protein
-mediated	O
activation	O
of	O
NF-kappaB	B-protein
was	O
also	O
dependent	O
on	O
a	O
Ca2+	O
influx	O
,	O
because	O
the	O
Ca2+	O
channel	O
blocker	O
,	O
SK	O
&	O
F	O
96365	O
,	O
as	O
well	O
as	O
other	O
agents	O
that	O
prevented	O
the	O
Ca2+	O
influx	O
,	O
inhibited	O
NF-kappaB	B-protein
activation	O
.	O

Cotransfection	O
of	O
a	O
constitutively	O
active	O
form	O
of	O
calcineurin	B-protein
largely	O
substituted	O
for	O
the	O
Ca2+	O
requirement	O
and	O
reversed	O
the	O
blockade	O
by	O
SK	O
&	O
F	O
96365	O
.	O

Consistent	O
with	O
these	O
observations	O
,	O
coexpression	O
of	O
constitutively	O
active	O
forms	O
of	O
Raf-1	B-protein
and	O
calcineurin	B-protein
synergistically	O
induced	O
kappaB	B-protein
-dependent	O
reporter	O
activity	O
,	O
suggesting	O
a	O
physiologically	O
relevant	O
functional	O
interaction	O
between	O
the	O
kinase	B-protein
and	O
the	O
phosphatase	B-protein
.	O

Synergistic	O
interactions	O
between	O
overlapping	B-DNA
binding	I-DNA
sites	I-DNA
for	O
the	O
serum	B-protein
response	I-protein
factor	I-protein
and	O
ELK-1	B-protein
proteins	I-protein
mediate	O
both	O
basal	O
enhancement	O
and	O
phorbol	O
ester	O
responsiveness	O
of	O
primate	B-DNA
cytomegalovirus	I-DNA
major	I-DNA
immediate-early	I-DNA
promoters	I-DNA
in	O
monocyte	O
and	O
T-lymphocyte	B-cell_type
cell	O
types	O
.	O

Cytomegalovirus	O
(	O
CMV	O
)	O
infection	O
is	O
nonpermissive	O
or	O
persistent	O
in	O
many	O
lymphoid	B-cell_type
and	I-cell_type
myeloid	I-cell_type
cell	I-cell_type
types	I-cell_type
but	O
can	O
be	O
activated	O
in	O
differentiated	B-cell_type
macrophages	I-cell_type
.	O

We	O
have	O
shown	O
elsewhere	O
that	O
both	O
the	O
major	B-DNA
immediate-early	I-DNA
gene	I-DNA
(	O
MIE	B-DNA
)	O
and	O
lytic	O
cycle	O
infectious	O
progeny	O
virus	O
expression	O
can	O
be	O
induced	O
in	O
otherwise	O
nonpermissive	O
monocyte-like	B-cell_line
U-937	I-cell_line
cell	I-cell_line
cultures	I-cell_line
infected	O
with	O
either	O
human	O
CMV	O
(	O
HCMV	O
)	O
or	O
simian	O
CMV	O
(	O
SCMV	O
)	O
by	O
treatment	O
with	O
the	O
phorbol	O
ester	O
12-O-tetradecanoylphorbol-13-acetate	O
(	O
TPA	O
)	O
.	O

Two	O
multicopy	B-DNA
basal	I-DNA
enhancer	I-DNA
motifs	I-DNA
within	O
the	O
SCMV	O
MIE	B-DNA
enhancer	I-DNA
,	O
namely	O
,	O
11	O
copies	O
of	O
the	O
16-bp	O
cyclic	B-DNA
AMP	I-DNA
response	I-DNA
element	I-DNA
(	O
CRE	B-DNA
)	O
and	O
3	O
copies	O
of	O
novel	O
17-bp	O
serum	B-DNA
response	I-DNA
factor	I-DNA
(	I-DNA
SRF	I-DNA
)	I-DNA
binding	I-DNA
sites	I-DNA
referred	O
to	O
as	O
the	O
SNE	B-DNA
(	O
SRF/NFkappaB-like	B-DNA
element	I-DNA
)	O
,	O
as	O
well	O
as	O
four	O
classical	O
NFkappaB	B-DNA
sites	I-DNA
within	O
the	O
HCMV	O
version	O
,	O
contribute	O
to	O
TPA	O
responsiveness	O
in	O
transient	O
assays	O
in	O
monocyte	B-cell_type
and	I-cell_type
T-cell	I-cell_type
types	I-cell_type
.	O

The	O
SCMV	B-DNA
SNE	I-DNA
sites	I-DNA
contain	O
potential	O
overlapping	O
core	O
recognition	O
binding	O
motifs	O
for	O
SRF	B-protein
,	O
Rel/NFkappaB	B-protein
,	O
ETS	B-protein
,	O
and	O
YY1	B-protein
class	I-protein
transcription	I-protein
factors	I-protein
but	O
fail	O
to	O
respond	O
to	O
either	O
serum	B-protein
or	I-protein
tumor	I-protein
necrosis	I-protein
factor	I-protein
alpha	I-protein
.	O

Therefore	O
,	O
to	O
evaluate	O
the	O
mechanism	O
of	O
TPA	O
responsiveness	O
of	O
the	O
SNE	B-DNA
motifs	I-DNA
and	O
of	O
a	O
related	O
16-bp	O
SEE	B-DNA
(	O
SRF/ETS	B-DNA
element	I-DNA
)	O
motif	O
found	O
in	O
the	O
HCMV	B-DNA
and	I-DNA
chimpanzee	I-DNA
CMV	I-DNA
MIE	I-DNA
enhancers	I-DNA
,	O
we	O
have	O
examined	O
the	O
functional	O
responses	O
and	O
protein	O
binding	O
properties	O
of	O
multimerized	B-DNA
wild-type	I-DNA
and	I-DNA
mutant	I-DNA
elements	I-DNA
added	O
upstream	O
to	O
the	O
SCMV	B-DNA
MIE	I-DNA
or	O
simian	B-DNA
virus	I-DNA
40	I-DNA
minimal	I-DNA
promoter	I-DNA
regions	I-DNA
in	O
the	O
U-937	B-cell_line
,	O
K-562	B-cell_line
,	O
HL-60	B-cell_line
,	O
THP-1	B-cell_line
,	O
and	O
Jurkat	B-cell_line
cell	I-cell_line
lines	I-cell_line
.	O

Unlike	O
classical	O
NFkappaB	B-DNA
sites	I-DNA
,	O
neither	O
the	O
SNE	B-DNA
nor	O
the	O
SEE	B-DNA
motif	I-DNA
responded	O
to	O
phosphatase	O
inhibition	O
by	O
okadaic	O
acid	O
.	O

However	O
,	O
the	O
TPA	O
responsiveness	O
of	O
both	O
CMV	B-DNA
elements	I-DNA
proved	O
to	O
involve	O
synergistic	O
interactions	O
between	O
the	O
core	O
SRF	B-DNA
binding	I-DNA
site	I-DNA
(	O
CCATATATGG	O
)	O
and	O
the	O
adjacent	O
inverted	O
ETS	B-DNA
binding	I-DNA
motifs	I-DNA
(	O
TTCC	O
)	O
,	O
which	O
correlated	O
directly	O
with	O
formation	O
of	O
a	O
bound	O
tripartite	B-protein
complex	I-protein
containing	O
both	O
the	O
cellular	O
SRF	B-protein
and	O
ELK-1	B-protein
proteins	I-protein
.	O

This	O
protein	B-protein
complex	I-protein
was	O
more	O
abundant	O
in	O
U-937	O
,	O
K-562	O
,	O
and	O
HeLa	O
cell	O
extracts	O
than	O
in	O
Raji	B-cell_line
,	O
HF	B-cell_line
,	O
BALB/c	B-cell_line
3T3	I-cell_line
,	O
or	O
HL-60	B-cell_line
cells	I-cell_line
,	O
but	O
the	O
binding	O
activity	O
was	O
altered	O
only	O
twofold	O
after	O
TPA	O
treatment	O
.	O

A	O
40-fold	O
stimulation	O
of	O
chloramphenicol	B-protein
acetyltransferase	I-protein
activity	O
mediated	O
by	O
four	O
tandem	B-DNA
repeats	I-DNA
of	O
the	O
SNE	B-DNA
could	O
be	O
induced	O
within	O
2	O
h	O
(	O
and	O
up	O
to	O
250-fold	O
within	O
6	O
h	O
)	O
after	O
addition	O
of	O
TPA	O
in	O
DNA-transfected	B-cell_line
U-937	I-cell_line
cells	I-cell_line
,	O
indicating	O
that	O
the	O
stimulation	O
appeared	O
likely	O
to	O
be	O
a	O
true	O
protein	B-protein
kinase	I-protein
C	I-protein
-mediated	O
signal	O
transduction	O
event	O
rather	O
than	O
a	O
differentiation	O
response	O
.	O

Slight	O
differences	O
in	O
the	O
sequence	O
of	O
the	O
core	B-DNA
SRF	I-DNA
binding	I-DNA
site	I-DNA
compared	O
with	O
that	O
of	O
the	O
classical	O
c-Fos	B-DNA
promoter	I-DNA
serum	I-DNA
response	I-DNA
element	I-DNA
,	O
together	O
with	O
differences	O
in	O
the	O
spacing	O
between	O
the	O
SRF	B-DNA
and	I-DNA
ETS	I-DNA
motifs	I-DNA
,	O
appear	O
to	O
account	O
for	O
the	O
inability	O
of	O
the	O
SCMV	B-DNA
SNEs	I-DNA
to	O
respond	O
to	O
serum	O
induction	O
.	O

T-cell	B-cell_type
-directed	O
TAL-1	B-protein
expression	O
induces	O
T-cell	O
malignancies	O
in	O
transgenic	O
mice	O
.	O

The	O
TAL-1	B-DNA
gene	I-DNA
specifies	O
for	O
a	O
basic	O
domain-helix-loop-helix	B-protein
protein	I-protein
,	O
which	O
is	O
involved	O
in	O
the	O
control	O
of	O
normal	O
hematopoiesis	O
.	O

In	O
human	O
pathology	O
,	O
the	O
TAL-1	B-protein
gene	I-protein
product	I-protein
is	O
expressed	O
in	O
a	O
high	O
percentage	O
of	O
T-cell	B-cell_type
acute	O
lymphoblastic	O
leukemias	O
in	O
the	O
pediatric	O
age	O
range	O
;	O
however	O
,	O
it	O
has	O
not	O
been	O
established	O
whether	O
the	O
expression	O
has	O
a	O
causal	O
role	O
in	O
oncogenesis	O
.	O

In	O
this	O
report	O
,	O
we	O
describe	O
the	O
phenotype	O
of	O
mouse	B-cell_line
transgenic	I-cell_line
lines	I-cell_line
obtained	O
by	O
inducing	O
tal-1	B-protein
protein	I-protein
expression	O
in	O
lymphoid	O
tissues	O
using	O
the	O
LCK	B-DNA
promoter	I-DNA
.	O

The	O
survival	O
rate	O
of	O
tal-1	B-DNA
transgenic	O
animals	O
was	O
much	O
lower	O
as	O
compared	O
with	O
control	O
mice	O
.	O

Histopathological	O
analysis	O
revealed	O
lymphomas	O
of	O
T-cell	O
type	O
,	O
often	O
comprising	O
a	O
minor	O
B-cell	O
component	O
.	O

Some	O
mice	O
showed	O
marked	O
splenic	O
lymphocyte	O
depletion	O
.	O

Primary	B-cell_line
lymphocyte	I-cell_line
cultures	I-cell_line
showed	O
partial	O
independence	O
from	O
exogenous	O
growth	O
stimuli	O
and	O
increased	O
resistance	O
to	O
low-serum	O
apoptosis	O
.	O

To	O
further	O
unravel	O
the	O
tal-1	B-DNA
oncogenic	O
potential	O
,	O
a	O
strain	O
of	O
tal-1	B-DNA
transgenic	O
mice	O
was	O
crossbred	O
with	O
p53-/-	O
mice	O
;	O
the	O
survival	O
rate	O
in	O
these	O
animals	O
was	O
reduced	O
by	O
more	O
than	O
one-half	O
when	O
compared	O
with	O
that	O
of	O
tal-1	B-DNA
mice	O
,	O
and	O
histopathological	O
analysis	O
revealed	O
exclusively	O
T-cell	B-cell_type
lymphomas	O
.	O

These	O
data	O
indicate	O
that	O
TAL-1	B-protein
,	O
expressed	O
in	O
T	B-cell_type
cells	I-cell_type
,	O
is	O
per	O
se	O
a	O
potent	O
oncogene	O
,	O
which	O
may	O
exert	O
a	O
key	O
leukemogenetic	O
role	O
in	O
the	O
majority	O
of	O
T-cell	B-cell_type
acute	O
lymphoblastic	O
leukemias	O
.	O

Tissue	O
and	O
cell-type	O
specific	O
expression	O
of	O
the	O
tuberous	B-DNA
sclerosis	I-DNA
gene	I-DNA
,	O
TSC2	B-DNA
,	O
in	O
human	O
tissues	O
.	O

TSC2	B-DNA
is	O
a	O
gene	O
on	O
chromosome	B-DNA
16p13.3	I-DNA
associated	O
with	O
the	O
autosomal	O
dominant	O
neurocutaneous	O
disorder	O
,	O
tuberous	O
sclerosis	O
complex	O
(	O
TSC	O
)	O
.	O

By	O
using	O
a	O
partial	O
nucleotide	O
sequence	O
from	O
the	O
cloned	O
TSC2	B-DNA
and	O
polymerase	O
chain	O
reaction	O
methodology	O
,	O
we	O
constructed	O
a	O
digoxigenin-labeled	B-DNA
complementary	I-DNA
DNA	I-DNA
probe	I-DNA
to	O
examine	O
TSC2	B-DNA
gene	O
expression	O
in	O
autopsy-	O
or	O
biopsy-derived	O
human	O
tissues	O
by	O
in	O
situ	O
hybridization	O
.	O

TSC2	B-RNA
messenger	I-RNA
RNA	I-RNA
was	O
widely	O
expressed	O
in	O
various	O
cell	O
types	O
throughout	O
the	O
body	O
,	O
including	O
epithelia	O
,	O
lymphocytes	B-cell_type
,	O
and	O
cells	O
with	O
endocrine	O
functions	O
,	O
e.g.	O
,	O
adrenal	O
cortex	O
and	O
anterior	O
pituitary	O
.	O

It	O
was	O
prominently	O
and	O
selectively	O
(	O
within	O
the	O
central	O
nervous	O
system	O
)	O
expressed	O
in	O
pyramidal	B-cell_type
cells	I-cell_type
of	O
the	O
cerebral	O
cortex	O
and	O
other	O
motor	B-cell_type
neurons	I-cell_type
,	O
e.g.	O
,	O
in	O
spinal	O
cord	O
and	O
brainstem	O
nuclei	O
.	O

Visceral	O
TSC2	B-DNA
expression	O
was	O
comparable	O
in	O
autopsy	O
tissues	O
from	O
patients	O
with	O
and	O
without	O
TSC	O
;	O
TSC2	B-DNA
messenger	O
RNA	O
expression	O
was	O
most	O
prominent	O
in	O
cells	O
with	O
a	O
rapid	O
mitotic	O
rate	O
and	O
turnover	O
,	O
e.g.	O
,	O
epithelia	O
and	O
lymphocytes	B-cell_type
,	O
with	O
central	O
nervous	O
system	O
pyramidal	B-cell_type
cells	I-cell_type
and	O
other	O
neurons	O
being	O
an	O
obvious	O
exception	O
,	O
and/or	O
in	O
cells	O
with	O
important	O
secretory/transport	O
functions	O
.	O

This	O
widespread	O
expression	O
of	O
the	O
TSC2	B-DNA
gene	I-DNA
supports	O
the	O
view	O
that	O
it	O
encodes	O
a	O
protein	O
vital	O
to	O
cell	O
growth	O
and	O
metabolism	O
or	O
one	O
that	O
functions	O
as	O
a	O
tumor/growth	O
suppressor	O
.	O

Apoptosis	O
signaling	O
pathways	O
in	O
normal	O
T	B-cell_type
cells	I-cell_type
:	O
differential	O
activity	O
of	O
Bcl-2	B-protein
and	O
IL-1beta-converting	B-protein
enzyme	I-protein
family	I-protein
protease	O
inhibitors	O
on	O
glucocorticoid-	O
and	O
Fas-mediated	O
cytotoxicity	O
.	O

Fas	B-protein
-mediated	O
apoptosis	O
plays	O
an	O
important	O
role	O
in	O
regulating	O
the	O
immune	O
response	O
in	O
peripheral	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O

Restimulation	O
of	O
T	B-cell_type
cell	I-cell_type
blasts	I-cell_type
up-regulates	O
Fas	B-protein
and	O
Fas	B-protein
ligand	O
expression	O
,	O
with	O
subsequent	O
interaction	O
leading	O
to	O
cell	O
death	O
.	O

Overexpression	O
of	O
Bcl-2	B-protein
in	O
tumor	B-cell_type
cells	I-cell_type
blocks	O
apoptosis	O
induced	O
by	O
many	O
stimuli	O
,	O
but	O
inhibition	O
of	O
Fas	B-protein
-mediated	O
killing	O
has	O
not	O
been	O
consistently	O
observed	O
.	O

To	O
examine	O
the	O
behavior	O
of	O
Bcl-2	B-protein
in	O
normal	B-cell_type
cells	I-cell_type
,	O
T	B-cell_type
cell	I-cell_type
blasts	I-cell_type
were	O
transiently	O
transfected	O
with	O
Bcl-2	B-protein
and	O
related	O
gene	B-protein
products	I-protein
to	O
determine	O
the	O
effect	O
on	O
apoptotic	O
signaling	O
.	O

Transient	O
overexpression	O
of	O
Bcl-2	B-protein
in	O
mouse	O
and	O
human	O
T	B-cell_type
cell	I-cell_type
blasts	I-cell_type
did	O
not	O
block	O
Fas	B-protein
-mediated	O
apoptosis	O
,	O
whereas	O
etoposide-	O
and	O
glucocorticoid-induced	O
cytotoxicity	O
was	O
potently	O
inhibited	O
.	O

Expression	O
of	O
Bcl-xL	B-protein
and	O
adenovirus	B-protein
E1B	I-protein
19K	I-protein
did	O
not	O
interfere	O
with	O
anti-	O
Fas	B-protein
killing	O
.	O

In	O
contrast	O
,	O
interleukin-1beta-converting	O
enzyme	O
family	O
protease	O
inhibitors	O
Ac-DEVD-CHO	O
and	O
CrmA	O
blocked	O
Fas	B-protein
-mediated	O
apoptosis	O
.	O

These	O
results	O
suggest	O
that	O
peripheral	B-cell_type
T	I-cell_type
cells	I-cell_type
use	O
distinct	O
apoptosis	O
signaling	O
pathways	O
with	O
differential	O
sensitivity	O
to	O
Bcl-2	B-protein
and	O
interleukin-1beta-converting	O
enzyme	O
family	O
protease	O
inhibitors	O
.	O

Since	O
T	B-cell_type
cells	I-cell_type
normally	O
express	O
Bcl-2	B-protein
and	O
Bcl-xL	B-protein
following	O
activation	O
,	O
their	O
inability	O
to	O
block	O
Fas	B-protein
-mediated	O
apoptosis	O
may	O
allow	O
for	O
the	O
elimination	O
of	O
self-reactive	B-cell_type
cells	I-cell_type
and	O
the	O
appropriate	O
regulation	O
of	O
immune	O
responses	O
.	O

Increased	O
interleukin	B-protein
2	I-protein
transcription	O
in	O
murine	B-cell_type
lymphocytes	I-cell_type
by	O
ciprofloxacin	O
.	O

The	O
fluoroquinolone	O
antibiotic	O
,	O
ciprofloxacin	O
(	O
cipro	O
)	O
,	O
induces	O
hyperproduction	O
of	O
interleukin	B-protein
2	I-protein
(	O
IL-2	B-protein
)	O
and	O
interferon-gamma	B-protein
(	O
IFN-gamma	B-protein
)	O
in	O
stimulated	O
human	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
lymphocytes	I-cell_type
.	O

In	O
this	O
investigation	O
an	O
enhanced	O
and	O
prolonged	O
IL-2	B-protein
and	O
IL-2	B-RNA
mRNA	I-RNA
response	O
was	O
also	O
detected	O
in	O
both	O
stimulated	O
(	O
T	B-protein
cell	I-protein
mitogens	I-protein
or	O
alloantigens	B-protein
)	O
murine	B-cell_type
splenocytes	I-cell_type
and	O
in	O
the	O
stimulated	O
murine	B-cell_line
T	I-cell_line
cell	I-cell_line
line	I-cell_line
EL-4	I-cell_line
in	O
the	O
presence	O
of	O
ciprofloxacin	O
(	O
5-80	O
micrograms/ml	O
)	O
as	O
compared	O
to	O
control	O
cells	O
without	O
antibiotics	O
.	O

However	O
,	O
in	O
contrast	O
to	O
human	B-cell_type
lymphocytes	I-cell_type
,	O
IFN-gamma	B-protein
production	O
was	O
inhibited	O
and	O
IFN-gamma	B-RNA
mRNA	I-RNA
levels	O
were	O
unaffected	O
at	O
24	O
h	O
and	O
only	O
slightly	O
upregulated	O
at	O
48	O
and	O
72	O
h	O
of	O
culture	O
in	O
murine	B-cell_type
splenocytes	I-cell_type
incubated	O
with	O
cipro	O
(	O
20	O
micrograms/ml	O
)	O
.	O

EL-4	B-cell_type
cells	I-cell_type
were	O
transfected	O
with	O
a	O
plasmid	O
containing	O
the	O
IL-2	B-DNA
promoter	I-DNA
and	O
enhancer	B-DNA
region	I-DNA
linked	O
to	O
the	O
chloramphenicol	B-DNA
acetyltransferase	I-DNA
(	I-DNA
CAT	I-DNA
)	I-DNA
reporter	I-DNA
gene	I-DNA
.	O

Analysis	O
of	O
CAT	B-protein
activity	O
revealed	O
that	O
cipro	O
enhanced	O
IL-2	O
gene	O
induction	O
.	O

In	O
addition	O
,	O
EL-4	B-cell_type
cells	I-cell_type
incubated	O
with	O
ciprofloxacin	O
showed	O
an	O
early	O
peak	O
and	O
more	O
activated	O
nuclear	O
factor	O
of	O
activated	B-cell_type
T	I-cell_type
cells	I-cell_type
(	O
NFAT-1	B-protein
)	O
as	O
compared	O
to	O
control	O
cells	O
without	O
antibiotics	O
.	O

Cipro	O
did	O
not	O
affect	O
the	O
nuclear	B-protein
transcription	I-protein
factors	I-protein
AP-1	B-protein
or	O
NFIL-2A	B-protein
.	O

Taken	O
together	O
,	O
cipro	O
inhibited	O
IFN-gamma	B-protein
synthesis	O
,	O
but	O
enhanced	O
IL-2	B-protein
production	O
in	O
murine	B-cell_type
lymphocytes	I-cell_type
by	O
means	O
of	O
influencing	O
NFAT-1	B-protein
and	O
causing	O
an	O
increased	O
IL-2	B-protein
transcription	O
.	O

Human	O
T-cell	O
leukemia	O
virus	O
type	O
I	O
Tax	B-protein
associates	O
with	O
and	O
is	O
negatively	O
regulated	O
by	O
the	O
NF-kappa	B-protein
B2	I-protein
p100	I-protein
gene	I-protein
product	I-protein
:	O
implications	O
for	O
viral	O
latency	O
.	O

Human	O
T-cell	O
leukemia	O
virus	O
type	O
I	O
(	O
HTLV-I	O
)	O
is	O
the	O
etiologic	O
agent	O
of	O
the	O
adult	O
T-cell	O
leukemia	O
,	O
an	O
aggressive	O
and	O
often	O
fatal	O
malignancy	O
of	O
activated	B-cell_line
human	I-cell_line
CD4	I-cell_line
T	I-cell_line
cells	I-cell_line
.	O

HTLV-I	O
encodes	O
an	O
essential	O
40-kDa	B-protein
protein	I-protein
termed	O
Tax	B-protein
that	O
not	O
only	O
transactivates	O
the	O
long	O
terminal	O
repeat	O
of	O
this	O
retrovirus	O
but	O
also	O
induces	O
an	O
array	O
of	O
cellular	B-DNA
genes	I-DNA
.	O

Tax	B-protein
-mediated	O
transformation	O
of	O
T	B-cell_type
cells	I-cell_type
likely	O
involves	O
the	O
deregulated	O
expression	O
of	O
various	O
cellular	B-DNA
genes	I-DNA
that	O
normally	O
regulate	O
lymphocyte	B-cell_type
growth	O
produced	O
by	O
altered	O
activity	O
of	O
various	O
endogenous	O
host	O
transcription	B-protein
factors	I-protein
.	O

In	O
particular	O
,	O
Tax	B-protein
is	O
capable	O
of	O
modulating	O
the	O
expression	O
or	O
activity	O
of	O
various	O
host	O
transcription	B-protein
factors	I-protein
,	O
including	O
members	O
of	O
the	O
NF-kappa	B-protein
B/Rel	I-protein
and	O
CREB/ATF	B-protein
families	I-protein
,	O
as	O
well	O
as	O
the	O
cellular	B-protein
factors	I-protein
HEB-1	B-protein
and	O
p67SRF	B-protein
.	O

An	O
additional	O
distinguishing	O
characteristic	O
of	O
HTLV-I	O
infection	O
is	O
the	O
profound	O
state	O
of	O
viral	O
latency	O
that	O
is	O
present	O
in	O
circulating	O
primary	B-cell_type
leukemic	I-cell_type
T	I-cell_type
cells	I-cell_type
.	O

In	O
this	O
study	O
,	O
we	O
demonstrate	O
that	O
HTLV-I	O
Tax	B-protein
can	O
physically	O
associate	O
with	O
p100	B-protein
,	O
the	O
product	O
of	O
the	O
Rel-related	B-DNA
NF-kappa	I-DNA
B2	I-DNA
gene	I-DNA
,	O
both	O
in	O
transfected	B-cell_line
cells	I-cell_line
and	O
in	O
HTLV-I-infected	B-cell_line
leukemic	I-cell_line
T-cell	I-cell_line
lines	I-cell_line
.	O

Furthermore	O
,	O
the	O
physical	O
interaction	O
of	O
Tax	B-protein
with	O
p100	B-protein
leads	O
to	O
the	O
inhibition	O
of	O
Tax	B-protein
-induced	O
activation	O
of	O
the	O
HTLV-I	O
and	O
human	B-DNA
immunodeficiency	I-DNA
virus	I-DNA
type	I-DNA
1	I-DNA
long	I-DNA
terminal	I-DNA
repeats	I-DNA
,	O
reflecting	O
p100	B-protein
-mediated	O
cytoplasmic	O
sequestration	O
of	O
the	O
normally	O
nuclearly	O
expressed	O
Tax	B-protein
protein	I-protein
.	O

In	O
contrast	O
,	O
a	O
mutant	O
of	O
Tax	B-protein
that	O
selectively	O
fails	O
to	O
activate	O
nuclear	O
NF-kappa	B-protein
B	I-protein
expression	O
does	O
not	O
associate	O
with	O
p100	B-protein
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Rhabdomyosarcomas	O
do	O
not	O
contain	O
mutations	O
in	O
the	O
DNA	O
binding	O
domains	O
of	O
myogenic	O
transcription	B-protein
factors	I-protein
.	O

Skeletal	O
myogenesis	O
is	O
regulated	O
by	O
a	O
group	O
of	O
transcription	B-protein
factors	I-protein
(	O
MyoD	B-protein
,	O
myogenin	B-protein
,	O
myf5	B-protein
,	O
and	O
myf6	B-protein
)	O
that	O
are	O
``	B-protein
basic	I-protein
helix-loop-helix	I-protein
''	I-protein
proteins	I-protein
that	O
bind	O
to	O
the	O
promoters	B-DNA
of	O
muscle-specific	B-DNA
genes	I-DNA
and	O
promote	O
their	O
expression	O
.	O

We	O
have	O
previously	O
shown	O
that	O
after	O
a	O
mutation	O
of	O
Leu122	O
to	O
Arg	O
the	O
DNA	B-protein
binding	I-protein
basic	I-protein
domain	I-protein
of	O
MyoD	B-protein
confers	O
c-myc	B-DNA
-like	O
functional	O
characteristics	O
to	O
the	O
protein	O
.	O

In	O
this	O
study	O
we	O
used	O
single-strand	O
conformation	O
polymorphism	O
analysis	O
to	O
determine	O
whether	O
such	O
mutations	O
occur	O
naturally	O
in	O
rhabdomyosarcomas	O
.	O

We	O
have	O
found	O
that	O
the	O
basic	B-protein
domains	I-protein
of	O
all	O
the	O
myogenic	B-protein
factors	I-protein
remain	O
unaltered	O
in	O
rhabdomyosarcomas	O
.	O

Selection	O
against	O
such	O
mutations	O
may	O
be	O
the	O
result	O
of	O
functional	O
redundancy	O
of	O
these	O
myogenic	B-protein
transcription	I-protein
factors	I-protein
.	O

Function	O
and	O
activation	O
of	O
NF-kappa	B-protein
B	I-protein
in	O
the	O
immune	O
system	O
.	O

NF-kappa	B-protein
B	I-protein
is	O
a	O
ubiquitous	B-protein
transcription	I-protein
factor	I-protein
.	O

Nevertheless	O
,	O
its	O
properties	O
seem	O
to	O
be	O
most	O
extensively	O
exploited	O
in	O
cells	O
of	O
the	O
immune	O
system	O
.	O

Among	O
these	O
properties	O
are	O
NF-kappa	B-protein
B	I-protein
's	O
rapid	O
posttranslational	O
activation	O
in	O
response	O
to	O
many	O
pathogenic	O
signals	O
,	O
its	O
direct	O
participation	O
in	O
cytoplasmic/nuclear	O
signaling	O
,	O
and	O
its	O
potency	O
to	O
activate	O
transcription	O
of	O
a	O
great	O
variety	O
of	O
genes	O
encoding	O
immunologically	B-protein
relevant	I-protein
proteins	I-protein
.	O

In	O
vertebrates	O
,	O
five	O
distinct	O
DNA	B-protein
binding	I-protein
subunits	I-protein
are	O
currently	O
known	O
which	O
might	O
extensively	O
heterodimerize	O
,	O
thereby	O
forming	O
complexes	O
with	O
distinct	O
transcriptional	O
activity	O
,	O
DNA	O
sequence	O
specificity	O
,	O
and	O
cell	O
type-	O
and	O
cell	O
stage-specific	O
distribution	O
.	O

The	O
activity	O
of	O
DNA	B-protein
binding	I-protein
NF-kappa	I-protein
B	I-protein
dimers	I-protein
is	O
tightly	O
controlled	O
by	O
accessory	B-protein
proteins	I-protein
called	O
I	B-protein
kappa	I-protein
B	I-protein
subunits	I-protein
of	O
which	O
there	O
are	O
also	O
five	O
different	O
species	O
currently	O
known	O
in	O
vertebrates	O
.	O

I	B-protein
kappa	I-protein
B	I-protein
proteins	I-protein
inhibit	O
DNA	O
binding	O
and	O
prevent	O
nuclear	O
uptake	O
of	O
NF-kappa	B-protein
B	I-protein
complexes	I-protein
.	O

An	O
exception	O
is	O
the	O
Bcl-3	B-protein
protein	I-protein
which	O
in	O
addition	O
can	O
function	O
as	O
a	O
transcription	B-protein
activating	I-protein
subunit	I-protein
in	O
th	O
nucleus	O
.	O

Other	O
I	B-protein
kappa	I-protein
B	I-protein
proteins	I-protein
are	O
rather	O
involved	O
in	O
terminating	O
NF-kappa	B-protein
B	I-protein
's	O
activity	O
in	O
the	O
nucleus	O
.	O

The	O
intracellular	O
events	O
that	O
lead	O
to	O
the	O
inactivation	O
of	O
I	B-protein
kappa	I-protein
B	I-protein
,	O
i.e.	O
the	O
activation	O
of	O
NF-kappa	B-protein
B	I-protein
,	O
are	O
complex	O
.	O

They	O
involve	O
phosphorylation	O
and	O
proteolytic	O
reactions	O
and	O
seem	O
to	O
be	O
controlled	O
by	O
the	O
cells	O
'	O
redox	O
status	O
.	O

Interference	O
with	O
the	O
activation	O
or	O
activity	O
of	O
NF-kappa	B-protein
B	I-protein
may	O
be	O
beneficial	O
in	O
suppressing	O
toxic/septic	O
shock	O
,	O
graft-vs-host	O
reactions	O
,	O
acute	O
inflammatory	O
reactions	O
,	O
acute	O
phase	O
response	O
,	O
and	O
radiation	O
damage	O
.	O

The	O
inhibition	O
of	O
NF-kappa	B-protein
B	I-protein
activation	O
by	O
antioxidants	O
and	O
specific	O
protease	O
inhibitors	O
may	O
provide	O
a	O
pharmacological	O
basis	O
for	O
interfering	O
with	O
these	O
acute	O
processes	O
.	O

Lack	O
of	O
T-cell-mediated	O
recognition	O
of	O
the	O
fusion	O
region	O
of	O
the	O
pml/RAR-alpha	B-protein
hybrid	I-protein
protein	I-protein
by	O
lymphocytes	B-cell_type
of	O
acute	O
promyelocytic	O
leukemia	O
patients	O
.	O

In	O
previous	O
studies	O
,	O
it	O
was	O
shown	O
that	O
the	O
fusion	O
region	O
of	O
the	O
pml/RAR-alpha	B-protein
protein	I-protein
,	O
expressed	O
by	O
acute	B-cell_line
promyelocytic	I-cell_line
leukemia	I-cell_line
(	I-cell_line
APL	I-cell_line
)	I-cell_line
cells	I-cell_line
,	O
can	O
be	O
specifically	O
recognized	O
in	O
vitro	O
by	O
donor	O
(	O
D.	O
E.	O
)	O
CD4	B-cell_line
T	I-cell_line
cells	I-cell_line
in	O
a	O
HLA	B-protein
class	I-protein
II	I-protein
DR11-restricted	O
fashion	O
.	O

We	O
present	O
here	O
the	O
results	O
on	O
the	O
recognition	O
of	O
several	O
pml/RAR-alpha	O
peptides	O
by	O
APL	O
patients	O
expressing	O
HLA	B-protein
DR11	I-protein
.	O

The	O
in	O
vitro	O
immunization	O
of	O
peripheral	B-cell_type
blood	I-cell_type
lymphocytes	I-cell_type
from	O
four	O
patients	O
in	O
remission	O
(	O
S.R.	O
,	O
F.R.	O
,	O
M.M.	O
,	O
P.	O
G.	O
)	O
with	O
BCR1/25	O
,	O
a	O
25-mer	O
pml/	O
RAR-alpha	B-protein
,	O
did	O
not	O
elicit	O
either	O
a	O
polyclonal	O
or	O
a	O
clonal	O
immune	O
response	O
specific	O
to	O
the	O
peptide	O
.	O

We	O
then	O
generated	O
new	O
donor	O
anti-pml/RAR-alpha	B-cell_line
CD4	I-cell_line
(	I-cell_line
+	I-cell_line
)	I-cell_line
T-cell	I-cell_line
clones	I-cell_line
.	O

These	O
clones	O
were	O
tested	O
for	O
their	O
recognition	O
of	O
BCR1/25	O
.	O

One	O
clone	O
(	O
C3/5	B-cell_line
,	I-cell_line
CD3	I-cell_line
(	I-cell_line
+	I-cell_line
)	I-cell_line
,	I-cell_line
CD4	I-cell_line
(	I-cell_line
+	I-cell_line
)	I-cell_line
,	I-cell_line
CD8	I-cell_line
(	I-cell_line
-	I-cell_line
)	I-cell_line
)	O
was	O
selected	O
for	O
further	O
analysis	O
.	O

Clone	B-cell_line
C3/5	I-cell_line
showed	O
specific	O
proliferation	O
,	O
cytotoxicity	O
,	O
and	O
cytokine	O
(	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
alpha	I-protein
,	O
granulocyte-macrophage	B-protein
colony-stimulating	I-protein
factor	I-protein
)	O
production	O
when	O
challenged	O
with	O
autologous	B-cell_line
lymphoblastic	I-cell_line
cell	I-cell_line
lines	I-cell_line
pulsed	O
with	O
peptide	O
BCR1/25	O
.	O

C3/5	B-cell_line
cells	I-cell_line
developed	O
specific	O
proliferation	O
and	O
cytotoxicity	O
when	O
challenged	O
with	O
peptide-pulsed	B-cell_line
lymphoblastic	I-cell_line
cell	I-cell_line
lines	I-cell_line
and	O
peripheral	B-cell_type
blood	I-cell_type
lymphocytes	I-cell_type
from	O
the	O
four	O
DR11	O
(	O
+	O
)	O
APL	O
patients	O
.	O

APL	B-cell_type
blasts	I-cell_type
,	O
available	O
only	O
from	O
patients	O
F.R.	O
and	O
P.G.	O
,	O
were	O
not	O
lysed	O
by	O
C3/5	B-cell_line
and	O
were	O
unable	O
to	O
present	O
peptide	O
BCR1/25	O
.	O

Incubation	O
of	O
APL	B-cell_line
cells	I-cell_line
with	O
IFN-gamma	B-protein
failed	O
to	O
induce	O
HLA	B-protein
class	I-protein
II	I-protein
molecules	I-protein
and	O
recognition	O
by	O
the	O
C3/5	B-cell_line
clone	I-cell_line
.	O

Since	O
APL	B-cell_line
cells	I-cell_line
do	O
not	O
express	O
HLA	B-protein
class	I-protein
II	I-protein
molecules	I-protein
,	O
we	O
tested	O
in	O
two	O
donors	O
(	O
D.E.	O
and	O
C.H.R.	O
)	O
and	O
in	O
patients	O
S.R.and	O
P.G.whether	O
the	O
use	O
of	O
9-mer	O
peptides	O
(	O
BCR1/9	O
)	O
would	O
generate	O
a	O
CD8	B-protein
/HLA	B-protein
class	I-protein
I	I-protein
-restricted	O
response	O
.	O

No	O
peptide-specific	B-cell_line
T-cell	I-cell_line
line	I-cell_line
or	O
clone	O
could	O
be	O
generated	O
from	O
both	O
donors	O
and	O
patients	O
.	O

These	O
findings	O
are	O
discussed	O
in	O
relation	O
to	O
possible	O
therapeutic	O
approaches	O
to	O
the	O
immunotherapy	O
of	O
APL	O
.	O

The	O
proximal	O
regulatory	O
element	O
of	O
the	O
interferon-gamma	B-DNA
promoter	I-DNA
mediates	O
selective	O
expression	O
in	O
T	B-cell_type
cells	I-cell_type
.	O

Interferon-gamma	B-protein
(	O
IFN-gamma	B-protein
)	O
is	O
produced	O
by	O
natural	B-cell_type
killer	I-cell_type
cells	I-cell_type
and	O
certain	O
subsets	O
of	O
T	B-cell_type
cells	I-cell_type
,	O
but	O
the	O
basis	O
for	O
its	O
selective	O
expression	O
is	O
unknown	O
.	O

Within	O
the	O
region	O
between	O
-108	O
and	O
-40	O
base	O
pairs	O
of	O
the	O
IFN-gamma	B-protein
promoter	O
are	O
two	O
conserved	O
and	O
essential	O
regulatory	B-DNA
elements	I-DNA
,	O
which	O
confer	O
activation-specific	O
expression	O
in	O
T	B-cell_type
cells	I-cell_type
.	O

This	O
report	O
describes	O
studies	O
indicating	O
that	O
the	O
most	O
proximal	O
of	O
these	O
two	O
regulatory	B-DNA
elements	I-DNA
is	O
an	O
important	O
determinant	O
of	O
its	O
restricted	O
expression	O
.	O

The	O
proximal	O
element	O
is	O
a	O
composite	O
site	O
that	O
binds	O
members	O
of	O
the	O
CREB/ATF	B-protein
,	O
AP-1	B-protein
,	O
and	O
octamer	B-protein
families	I-protein
of	O
transcription	B-protein
factors	I-protein
.	O

Jun	B-protein
is	O
essential	O
for	O
activation-induced	O
transcription	O
and	O
binds	O
preferably	O
as	O
a	O
heterodimer	O
with	O
ATF-2	B-protein
.	O

In	O
contrast	O
,	O
CREB	B-protein
appears	O
to	O
dampen	O
transcription	O
from	O
this	O
element	O
.	O

The	O
CpG	O
dinucleotide	O
in	O
this	O
element	B-DNA
is	O
selectively	O
methylated	O
in	O
Th2	B-cell_type
T	I-cell_type
cells	I-cell_type
and	O
other	O
cells	O
that	O
do	O
not	O
express	O
IFN-gamma	B-protein
,	O
and	O
methylation	O
markedly	O
reduces	O
transcription	B-protein
factor	I-protein
binding	O
.	O

As	O
a	O
target	O
for	O
DNA	O
methylation	O
and	O
for	O
binding	O
of	O
transcription	B-protein
factors	I-protein
that	O
mediate	O
or	O
impede	O
transcription	O
,	O
this	O
element	O
appears	O
to	O
play	O
a	O
central	O
role	O
in	O
controlling	O
IFN-gamma	B-protein
expression	O
.	O

CD40	B-protein
,	O
but	O
not	O
lipopolysaccharide	O
and	O
anti-IgM	B-protein
stimulation	O
of	O
primary	B-cell_type
B	I-cell_type
lymphocytes	I-cell_type
,	O
leads	O
to	O
a	O
persistent	O
nuclear	O
accumulation	O
of	O
RelB	B-protein
.	O

In	O
this	O
study	O
we	O
analyzed	O
the	O
effect	O
of	O
CD40	B-protein
stimulation	O
on	O
the	O
activity	O
and	O
nuclear	O
appearance	O
of	O
Rel/nuclear	B-protein
factor	I-protein
kappaB	I-protein
(	I-protein
NF-kappaB	I-protein
)	I-protein
factors	I-protein
in	O
primary	B-cell_type
murine	I-cell_type
B	I-cell_type
lymphocytes	I-cell_type
.	O

We	O
show	O
that	O
triggering	O
of	O
CD40	B-protein
signaling	O
pathway	O
(	O
s	O
)	O
by	O
CD40	B-protein
ligands	I-protein
expressed	O
on	O
L	B-cell_type
cells	I-cell_type
led	O
to	O
strong	O
activation	O
of	O
an	O
NF-kappaB-controlled	B-DNA
beta-globin	I-DNA
reporter	I-DNA
gene	I-DNA
in	O
primary	B-cell_type
B	I-cell_type
lymphocytes	I-cell_type
from	O
transgenic	O
mice	O
.	O

Analyses	O
of	O
nuclear	O
translocation	O
of	O
individual	O
members	O
of	O
Rel	B-protein
proteins	I-protein
after	O
CD40	B-protein
induction	O
of	O
primary	B-cell_type
B	I-cell_type
cells	I-cell_type
showed	O
a	O
strong	O
and	O
long-lasting	O
accumulation	O
of	O
RelB	B-protein
and	O
,	O
less	O
pronounced	O
,	O
of	O
c-Rel	B-protein
.	O

LPS	O
stimulation	O
did	O
not	O
give	O
rise	O
to	O
a	O
persistent	O
nuclear	O
accumulation	O
of	O
RelB	B-protein
and	O
c-Rel	B-protein
,	O
whereas	O
nuclear	O
c-Rel	B-protein
,	O
but	O
not	O
RelB	B-protein
,	O
accumulated	O
after	O
B	O
cell	O
receptor	O
stimulation	O
.	O

CD40	B-protein
induced	O
not	O
only	O
nuclear	O
translocation	O
but	O
also	O
de	O
novo	O
synthesis	O
of	O
RelB	B-RNA
RNA	I-RNA
and	O
protein	O
.	O

S107	B-cell_line
plasmacytoma	I-cell_line
cells	I-cell_line
,	O
which	O
express	O
CD40	B-protein
but	O
are	O
defective	O
for	O
the	O
nuclear	O
appearance	O
of	O
p50/p65-NF-kappaB	B-protein
,	O
do	O
not	O
express	O
RelB	B-protein
after	O
CD40	B-protein
stimulation	O
.	O

In	O
S107	B-cell_line
cells	I-cell_line
stably	O
transfected	O
with	O
relB	B-DNA
genes	I-DNA
,	O
stimulation	O
of	O
nuclear	O
RelB	B-protein
translocation	O
by	O
CD40	B-protein
was	O
observed	O
.	O

These	O
results	O
indicate	O
that	O
stimulation	O
of	O
CD40	B-protein
signaling	O
pathways	O
exerts	O
a	O
long-lasting	O
stimulatory	O
effect	O
on	O
both	O
the	O
transcription	O
and	O
nuclear	O
translocation	O
of	O
RelB	B-protein
.	O

Since	O
LPS	O
and	O
anti-IgM	B-protein
were	O
unable	O
to	O
activate	O
RelB	B-protein
,	O
CD40	B-protein
appears	O
to	O
trigger	O
a	O
special	O
program	O
of	O
gene	O
expression	O
involved	O
in	O
the	O
proliferation	O
and/or	O
differentiation	O
of	O
B	B-cell_type
lymphocytes	I-cell_type
.	O

Identification	O
and	O
characterization	O
of	O
a	O
leukocyte-specific	O
component	O
of	O
the	O
nuclear	O
body	O
.	O

The	O
nuclear	O
body	O
(	O
NB	O
)	O
is	O
a	O
cellular	O
organelle	O
that	O
is	O
involved	O
in	O
the	O
pathogenesis	O
of	O
acute	O
promyelocytic	O
leukemia	O
and	O
viral	O
infection	O
.	O

The	O
NB	O
is	O
also	O
a	O
target	O
of	O
antibodies	B-protein
in	O
the	O
serum	O
of	O
patients	O
with	O
the	O
autoimmune	O
disease	O
primary	O
biliary	O
cirrhosis	O
.	O

In	O
this	O
study	O
,	O
serum	O
from	O
a	O
patient	O
with	O
primary	O
biliary	O
cirrhosis	O
was	O
used	O
to	O
identify	O
a	O
cDNA	O
encoding	O
a	O
novel	O
component	O
of	O
the	O
NB	O
,	O
a	O
140-kDa	B-protein
protein	I-protein
designated	O
Sp140	B-protein
.	O

The	O
predicted	O
amino	O
acid	O
sequence	O
of	O
the	O
amino-terminal	B-protein
portion	I-protein
of	O
Sp140	B-protein
was	O
similar	O
to	O
Sp100	B-protein
,	O
a	O
previously	O
identified	O
NB	B-protein
protein	I-protein
.	O

The	O
carboxyl	B-protein
portion	I-protein
of	O
Sp140	B-protein
contained	O
a	O
zinc-finger	B-protein
domain	I-protein
and	O
a	O
bromodomain	B-protein
,	O
motifs	O
that	O
are	O
present	O
in	O
proteins	O
regulating	O
gene	O
transcription	O
.	O

High	O
levels	O
of	O
Sp140	B-RNA
mRNA	I-RNA
were	O
detected	O
in	O
human	O
spleen	O
and	O
peripheral	B-cell_type
blood	I-cell_type
leukocytes	I-cell_type
,	O
but	O
not	O
other	O
human	O
tissues	O
.	O

The	O
level	O
of	O
SP140	B-RNA
mRNA	I-RNA
in	O
myeloid	B-cell_line
precursor	I-cell_line
cell	I-cell_line
lines	I-cell_line
HL60	B-cell_line
and	O
NB4	B-cell_line
markedly	O
increased	O
in	O
response	O
to	O
chemically	O
induced	O
cellular	O
differentiation	O
.	O

Immunohistochemical	O
techniques	O
were	O
used	O
to	O
demonstrate	O
that	O
SP140	B-protein
localized	O
to	O
the	O
NB	O
in	O
differentiated	O
HL60	B-cell_line
and	O
NB4	B-cell_line
cells	I-cell_line
.	O

The	O
location	O
of	O
Sp140	B-protein
in	O
the	O
NB	O
,	O
and	O
expression	O
of	O
this	O
gene	O
in	O
cells	O
involved	O
in	O
host	O
defense	O
,	O
suggest	O
that	O
Sp140	B-protein
may	O
be	O
involved	O
in	O
the	O
pathogenesis	O
of	O
acute	O
promyelocytic	O
leukemia	O
and	O
viral	O
infection	O
.	O

Regulation	O
of	O
cytokine	B-protein
and	O
cytokine	B-protein
receptor	I-protein
expression	O
by	O
glucocorticoids	O
.	O

Glucocorticoids	O
(	O
GCS	O
)	O
profoundly	O
inhibit	O
several	O
aspects	O
of	O
T	O
cell	O
immunity	O
largely	O
through	O
inhibition	O
of	O
cytokine	B-protein
expression	O
at	O
the	O
transcriptional	O
and	O
posttranscriptional	O
levels	O
.	O

GCS	O
were	O
also	O
reported	O
to	O
act	O
indirectly	O
by	O
inducing	O
transforming	O
growth	B-protein
factor-beta	I-protein
expression	O
,	O
which	O
in	O
turn	O
blocks	O
T	O
cell	O
immunity	O
.	O

In	O
exerting	O
their	O
antiproliferative	O
effects	O
,	O
GCS	O
diffuse	O
into	O
target	B-cell_type
cells	I-cell_type
where	O
they	O
bind	O
their	O
cytoplasmic	B-protein
receptor	I-protein
,	O
which	O
in	O
turn	O
translocates	O
to	O
the	O
nucleus	O
where	O
it	O
inhibits	O
transcription	O
of	O
cytokine	B-DNA
genes	I-DNA
through	O
direct	O
binding	O
to	O
the	O
glucocorticoid	B-DNA
response	I-DNA
elements	I-DNA
(	O
GRE	B-DNA
)	O
,	O
which	O
are	O
located	O
in	O
the	O
promoter	O
region	O
of	O
cytokine	B-DNA
genes	I-DNA
or	O
,	O
alternatively	O
,	O
through	O
antagonism	O
of	O
the	O
action	O
of	O
transcription	B-protein
factors	I-protein
required	O
for	O
optimal	O
transcriptional	O
activation	O
.	O

In	O
contrast	O
to	O
their	O
inhibitory	O
effects	O
on	O
cytokine	B-protein
expression	O
,	O
GCS	O
up-regulate	O
cytokine	B-protein
receptor	I-protein
expression	O
that	O
correlates	O
with	O
enhanced	O
cytokine	B-protein
effects	O
on	O
target	B-cell_type
cells	I-cell_type
.	O

In	O
this	O
review	O
,	O
we	O
summarize	O
the	O
current	O
state	O
of	O
knowledge	O
of	O
the	O
mechanism	O
of	O
action	O
of	O
GCS	O
,	O
including	O
the	O
phenomenon	O
of	O
steroid-induced	O
rebound	O
,	O
which	O
ensues	O
upon	O
GCS	O
withdrawal	O
.	O

Isolation	O
and	O
characterization	O
of	O
murine	B-DNA
fra-1	I-DNA
:	O
induction	O
mediated	O
by	O
CD40	B-protein
and	O
surface	B-protein
Ig	I-protein
is	O
protein	B-protein
kinase	I-protein
C	I-protein
dependent	O
.	O

The	O
murine	B-DNA
fra-1	I-DNA
gene	I-DNA
,	O
encoding	O
Fos-related	B-protein
Ag	I-protein
1	I-protein
,	O
was	O
isolated	O
from	O
a	O
splenic	B-DNA
cDNA	I-DNA
library	I-DNA
and	O
sequenced	O
.	O

Murine	B-DNA
fra-1	I-DNA
was	O
highly	O
homologous	O
to	O
rat	B-DNA
and	I-DNA
human	I-DNA
fra-1	I-DNA
.	O

Oligonucleotide	O
primers	O
based	O
on	O
the	O
murine	B-DNA
sequence	I-DNA
were	O
used	O
to	O
construct	O
a	O
quantitative	O
reverse	O
transcription-PCR	O
assay	O
for	O
gene	O
expression	O
.	O

B	B-cell_type
lymphocyte	I-cell_type
stimulation	O
via	O
both	O
CD40	B-protein
and	O
surface	B-protein
Ig	I-protein
(	I-protein
sIg	I-protein
)	I-protein
receptors	I-protein
substantially	O
induced	O
fra-1	B-DNA
expression	O
,	O
and	O
for	O
both	O
receptors	O
,	O
induction	O
was	O
protein	B-protein
kinase	I-protein
C	I-protein
(	O
PKC	B-protein
)	O
dependent	O
.	O

This	O
contrasts	O
with	O
induction	O
of	O
c-fos	B-DNA
by	O
both	O
CD40	B-protein
and	O
sIg	B-protein
,	O
which	O
is	O
PKC	B-protein
independent	O
and	O
indicates	O
that	O
CD40	B-protein
is	O
capable	O
of	O
signaling	O
through	O
PKC	B-protein
or	O
a	O
closely	O
related	O
kinase	B-protein
.	O

Induction	O
of	O
fra-1	B-DNA
following	O
engagement	O
of	O
CD40	B-protein
did	O
not	O
require	O
protein	O
synthesis	O
,	O
suggesting	O
that	O
the	O
PKC	B-protein
-dependent	O
linkage	O
between	O
CD40	B-protein
and	O
fra-1	B-DNA
is	O
direct	O
.	O

CD40	B-protein
-mediated	O
fra-1	B-DNA
induction	O
did	O
require	O
tyrosine	B-protein
kinase	I-protein
activity	O
.	O

These	O
results	O
demonstrate	O
that	O
CD40	B-protein
,	O
like	O
sIg	B-protein
,	O
may	O
employ	O
PKC	B-protein
in	O
producing	O
select	O
outcomes	O
,	O
that	O
individual	O
B	B-protein
cell	I-protein
receptors	I-protein
may	O
signal	O
downstream	O
events	O
via	O
both	O
PKC-dependent	O
and	O
PKC-independent	O
pathways	O
,	O
and	O
that	O
multiple	O
signal	O
transduction	O
pathways	O
may	O
be	O
used	O
to	O
activate	O
the	O
expression	O
of	O
closely	O
related	O
genes	B-DNA
.	O

Pentoxifylline	O
for	O
the	O
treatment	O
of	O
infection	O
with	O
human	O
immunodeficiency	O
virus	O
.	O

Cytokine	O
dysregulation	O
in	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
infection	O
has	O
been	O
documented	O
in	O
numerous	O
studies	O
and	O
has	O
been	O
cited	O
as	O
an	O
important	O
component	O
in	O
the	O
pathogenesis	O
of	O
this	O
retroviral	O
infection	O
.	O

Pharmacological	O
modification	O
of	O
cytokine	B-protein
dysregulation	O
,	O
therefore	O
,	O
has	O
been	O
suggested	O
as	O
a	O
therapeutic	O
modality	O
for	O
HIV-1	O
infection	O
.	O

Dr.	O
Dezube	O
of	O
Beth	O
Israel	O
Hospital	O
(	O
Boston	O
)	O
concisely	O
reviews	O
the	O
state	O
of	O
our	O
knowledge	O
regarding	O
the	O
effects	O
of	O
pentoxifylline	O
on	O
expression	O
of	O
tumor	B-protein
necrosis	I-protein
factor-alpha	I-protein
,	O
a	O
cytokine	B-protein
known	O
to	O
influence	O
HIV-1	O
replication	O
and	O
to	O
play	O
a	O
possible	O
role	O
in	O
the	O
clinical	O
manifestations	O
of	O
advanced	O
infection	O
with	O
this	O
virus	O
.	O

Pentoxifylline	O
,	O
a	O
trisubstituted	O
xanthine	O
derivative	O
,	O
has	O
been	O
used	O
to	O
decrease	O
blood	O
viscosity	O
and	O
is	O
reasonably	O
well	O
tolerated	O
by	O
most	O
recipients	O
of	O
the	O
drug	O
.	O

Results	O
of	O
preliminary	O
studies	O
,	O
many	O
of	O
which	O
were	O
conducted	O
by	O
Dr.	O
Dezube	O
,	O
suggest	O
that	O
use	O
of	O
this	O
agent	O
in	O
combination	O
with	O
antiretroviral	O
compounds	O
may	O
prove	O
useful	O
in	O
the	O
treatment	O
of	O
patients	O
with	O
HIV-1	O
infection	O
.	O

Activation	O
of	O
the	O
granulocyte-macrophage	B-DNA
colony-stimulating	I-DNA
factor	I-DNA
promoter	I-DNA
in	O
T	B-cell_type
cells	I-cell_type
requires	O
cooperative	O
binding	O
of	O
Elf-1	B-protein
and	O
AP-1	B-protein
transcription	B-protein
factors	I-protein
.	O

The	O
granulocyte-macrophage	B-DNA
colony-stimulating	I-DNA
factor	I-DNA
(	I-DNA
GM-CSF	I-DNA
)	I-DNA
gene	I-DNA
has	O
been	O
studied	O
extensively	O
as	O
a	O
model	O
system	O
of	O
transcriptional	O
induction	O
during	O
T-lymphocyte	O
activation	O
.	O

The	O
GM-CSF	B-DNA
gene	I-DNA
is	O
not	O
expressed	O
in	O
resting	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
T	I-cell_type
cells	I-cell_type
but	O
is	O
rapidly	O
induced	O
at	O
the	O
transcriptional	O
level	O
following	O
activation	O
through	O
the	O
cell	B-protein
surface	I-protein
T-cell	I-protein
receptor	I-protein
.	O

A	O
highly	O
conserved	O
19-bp	O
element	O
located	O
immediately	O
5	O
'	O
of	O
the	O
human	B-DNA
GM-CSF	I-DNA
TATA	I-DNA
box	I-DNA
(	O
bp	B-DNA
-34	I-DNA
to	I-DNA
-52	I-DNA
)	O
,	O
herein	O
called	O
purine	B-DNA
box	I-DNA
1	I-DNA
(	O
PB1	B-DNA
)	O
,	O
has	O
been	O
shown	O
to	O
bind	O
a	O
T-cell	B-protein
nuclear	I-protein
protein	I-protein
complex	I-protein
and	O
to	O
be	O
required	O
for	O
transcriptional	O
induction	O
of	O
the	O
GM-CSF	B-DNA
gene	I-DNA
following	O
T-cell	O
activation	O
.	O

The	O
PB1	B-DNA
sequence	O
motif	O
is	O
highly	O
conserved	O
in	O
both	O
human	B-DNA
and	I-DNA
murine	I-DNA
GM-CSF	I-DNA
genes	I-DNA
.	O

In	O
this	O
report	O
,	O
we	O
demonstrate	O
that	O
the	O
PB1	B-DNA
element	I-DNA
alone	O
confers	O
inducibility	O
on	O
a	O
heterologous	O
promoter	O
following	O
transfection	O
into	O
human	B-cell_line
Jurkat	I-cell_line
T	I-cell_line
cells	I-cell_line
.	O

In	O
addition	O
,	O
we	O
identify	O
a	O
major	O
PB1	B-protein
nuclear	I-protein
protein-binding	I-protein
complex	I-protein
that	O
is	O
not	O
present	O
in	O
resting	B-cell_type
peripheral	I-cell_type
blood	I-cell_type
T	I-cell_type
cells	I-cell_type
but	O
is	O
rapidly	O
induced	O
following	O
T-cell	O
activation	O
.	O

Sequence	O
analysis	O
revealed	O
that	O
PB1	B-DNA
is	O
composed	O
of	O
adjacent	B-DNA
binding	I-DNA
sites	I-DNA
for	O
Ets	B-protein
and	O
AP-1	B-protein
transcription	B-protein
factors	I-protein
.	O

In	O
vitro	O
mutagenesis	O
experiments	O
demonstrated	O
that	O
both	O
the	O
Ets	B-DNA
and	I-DNA
AP-1	I-DNA
sites	I-DNA
are	O
required	O
for	O
binding	O
of	O
the	O
inducible	O
PB1	B-protein
nuclear	I-protein
protein	I-protein
complex	I-protein
and	O
for	O
the	O
transcriptional	O
activity	O
of	O
this	O
element	O
and	O
the	O
GM-CSF	B-DNA
promoter	I-DNA
in	O
activated	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Steroid-resistant	O
asthma	O
.	O

Cellular	O
mechanisms	O
contributing	O
to	O
inadequate	O
response	O
to	O
glucocorticoid	O
therapy	O
.	O

The	O
current	O
study	O
examined	O
whether	O
alterations	O
in	O
glucocorticoid	B-protein
receptor	I-protein
(	O
GR	B-protein
)	O
binding	O
contribute	O
to	O
poor	O
response	O
to	O
glucocorticoid	O
therapy	O
in	O
asthma	O
.	O

29	O
asthma	O
patients	O
with	O
forced	O
expiratory	O
volume	O
in	O
1	O
s	O
(	O
FEV1	O
)	O
<	O
70	O
%	O
predicted	O
were	O
studied	O
.	O

Patients	O
were	O
classified	O
as	O
steroid	O
sensitive	O
(	O
SS	O
)	O
if	O
their	O
morning	O
FEV1	O
increased	O
>	O
30	O
%	O
after	O
a	O
1-wk	O
course	O
of	O
oral	O
prednisone	O
20	O
mg	O
twice	O
daily	O
and	O
steroid	O
resistant	O
(	O
SR	O
)	O
if	O
they	O
failed	O
to	O
increase	O
>	O
15	O
%	O
.	O

PBMC	O
obtained	O
from	O
these	O
two	O
groups	O
,	O
17	O
SR	O
and	O
12	O
SS	O
,	O
as	O
well	O
as	O
12	O
normal	O
controls	O
were	O
analyzed.	O
SR	O
patients	O
had	O
two	O
distinguishable	O
GR	B-protein
binding	O
abnormalities	O
:	O
15	O
of	O
the	O
17	O
SR	O
patients	O
demonstrated	O
a	O
significantly	O
reduced	O
GR	B-protein
binding	O
affinity	O
,	O
as	O
compared	O
with	O
SS	O
patients	O
(	O
P	O
=	O
0.0001	O
)	O
and	O
normal	O
controls	O
(	O
P	O
=	O
0.0001	O
)	O
.	O

This	O
defect	O
was	O
localized	O
to	O
T	B-cell_type
cells	I-cell_type
and	O
reverted	O
to	O
normal	O
after	O
48	O
h	O
in	O
culture	O
media	O
.	O

However	O
,	O
incubation	O
with	O
a	O
combination	O
of	O
IL-2	B-protein
and	O
IL-4	B-protein
sustained	O
this	O
abnormality	O
.	O

The	O
other	O
two	O
SR	O
patients	O
had	O
an	O
abnormally	O
low	O
GR	B-protein
number	O
with	O
normal	O
binding	O
affinity	O
that	O
was	O
not	O
limited	O
to	O
T	B-cell_type
cells	I-cell_type
.	O

Furthermore	O
,	O
GR	B-protein
number	O
failed	O
to	O
normalize	O
after	O
incubation	O
in	O
media	O
alone	O
or	O
IL-2	B-protein
and	O
IL-4	B-protein
.	O

Therefore	O
,	O
SR	O
asthma	O
may	O
be	O
due	O
to	O
more	O
than	O
one	O
abnormality	O
,	O
the	O
majority	O
related	O
to	O
a	O
reversible	O
cytokine	B-protein
-induced	O
reduction	O
in	O
GR	B-protein
binding	O
affinity	O
and	O
the	O
second	O
related	O
to	O
an	O
irreversible	O
reduction	O
in	O
GR	B-protein
number	O
.	O

These	O
findings	O
may	O
have	O
important	O
implications	O
for	O
the	O
design	O
of	O
alternative	O
treatment	O
approaches	O
for	O
recalcitrant	O
asthma	O
.	O

Prevalence	O
of	O
aneuploidy	O
,	O
overexpressed	O
ER	B-protein
,	O
and	O
overexpressed	O
EGFR	B-protein
in	O
random	O
breast	O
aspirates	O
of	O
women	O
at	O
high	O
and	O
low	O
risk	O
for	O
breast	O
cancer	O
.	O

Breast	O
tissue	O
biomarkers	O
which	O
accurately	O
predict	O
breast	O
cancer	O
development	O
within	O
a	O
10	O
year	O
period	O
in	O
high	O
risk	O
women	O
are	O
needed	O
but	O
currently	O
not	O
available	O
.	O

We	O
initiated	O
this	O
study	O
to	O
determine	O
1	O
)	O
the	O
prevalence	O
of	O
one	O
or	O
more	O
breast	O
tissue	O
abnormalities	O
in	O
a	O
group	O
of	O
women	O
at	O
high	O
risk	O
for	O
breast	O
cancer	O
,	O
and	O
2	O
)	O
if	O
the	O
prevalence	O
of	O
biomarker	O
abnormalities	O
is	O
greater	O
in	O
high	O
risk	O
than	O
in	O
low	O
risk	O
women	O
.	O

Eligible	O
high	O
risk	O
women	O
were	O
those	O
with	O
a	O
first	O
degree	O
relative	O
with	O
breast	O
cancer	O
,	O
prior	O
breast	O
cancer	O
,	O
or	O
precancerous	O
mastopathy	O
.	O

Low	O
risk	O
women	O
were	O
those	O
without	O
these	O
or	O
other	O
major	O
identifiable	O
risk	O
factors	O
.	O

Ductal	B-cell_type
cells	I-cell_type
were	O
obtained	O
via	O
random	O
fine	O
needle	O
aspirations	O
and	O
cytologically	O
classified	O
.	O

Biomarkers	O
included	O
DNA	O
ploidy	O
,	O
estrogen	B-protein
receptor	I-protein
(	O
ER	B-protein
)	O
,	O
and	O
epidermal	B-protein
growth	I-protein
factor	I-protein
receptor	I-protein
(	O
EGFR	B-protein
)	O
.	O

The	O
prevalence	O
of	O
DNA	O
aneuploidy	O
was	O
30	O
%	O
,	O
overexpression	O
of	O
ER	B-protein
10	O
%	O
,	O
and	O
overexpression	O
of	O
EGFR	B-protein
35	O
%	O
,	O
in	O
the	O
206	O
high	O
risk	O
women	O
whose	O
median	O
10	O
year	O
Gail	O
risk	O
(	O
projected	O
probability	O
)	O
of	O
developing	O
breast	O
cancer	O
was	O
4.5	O
%	O
.	O

The	O
prevalence	O
of	O
aneuploidy	O
and	O
overexpressed	O
EGFR	B-protein
was	O
significantly	O
higher	O
in	O
the	O
high	O
risk	O
women	O
than	O
in	O
the	O
25	O
low	O
risk	O
controls	O
(	O
p	O
<	O
0.002	O
)	O
,	O
whose	O
median	O
10	O
year	O
Gail	O
risk	O
was	O
0.7	O
%	O
.	O

The	O
difference	O
in	O
the	O
prevalence	O
of	O
ER	B-protein
overexpression	O
between	O
high	O
and	O
low	O
risk	O
groups	O
was	O
not	O
statistically	O
significant	O
(	O
p	O
=	O
0.095	O
)	O
.	O

This	O
may	O
be	O
due	O
to	O
the	O
low	O
prevalence	O
of	O
overexpressed	O
ER	B-protein
and	O
the	O
small	O
number	O
of	O
controls	O
.	O

A	O
significant	O
difference	O
was	O
noted	O
in	O
the	O
prevalence	O
of	O
one	O
or	O
more	O
abnormal	O
biomarkers	O
between	O
the	O
high	O
risk	O
and	O
low	O
risk	O
women	O
(	O
p	O
<	O
0.001	O
)	O
.	O

A	O
large	O
prospective	O
trial	O
is	O
needed	O
to	O
determine	O
if	O
one	O
or	O
more	O
of	O
these	O
biomarkers	O
,	O
is	O
predictive	O
of	O
breast	O
cancer	O
development	O
.	O

Inhibition	O
of	O
nuclear	B-RNA
factor	I-RNA
kappa	I-RNA
B	I-RNA
subunit	I-RNA
p65	I-RNA
mRNA	I-RNA
accumulation	O
in	O
lipopolysaccharide-stimulated	B-cell_line
human	I-cell_line
monocytic	I-cell_line
cells	I-cell_line
treated	O
with	O
sodium	O
salicylate	O
.	O

Lipopolysaccharide	O
is	O
one	O
of	O
the	O
most	O
potent	O
trigger	O
substances	O
for	O
monocytes	O
and	O
macrophages	O
causing	O
secretion	O
of	O
inflammatory	B-protein
mediators	I-protein
such	O
as	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
and	O
interleukin-1	B-protein
.	O

The	O
nature	O
of	O
the	O
nuclear	O
factors	O
involved	O
in	O
regulation	O
of	O
these	O
cytokine	B-DNA
genes	I-DNA
is	O
still	O
unknown	O
.	O

Nuclear	B-protein
factor	I-protein
kappa	I-protein
B	I-protein
(	I-protein
NF-kappa	I-protein
B	I-protein
;	I-protein
heterodimer	I-protein
of	I-protein
p50	I-protein
and	I-protein
p65	I-protein
)	I-protein
proteins	I-protein
have	O
been	O
suggested	O
to	O
play	O
an	O
important	O
role	O
in	O
gene	O
transcription	O
of	O
inflammatory	B-protein
mediators	I-protein
when	O
monocytes	B-cell_type
are	O
stimulated	O
with	O
lipopolysaccharide	O
.	O

Nonsteroidal	O
anti-inflammatory	O
drugs	O
such	O
as	O
salicylates	O
have	O
been	O
used	O
to	O
treat	O
symptoms	O
of	O
inflammation	O
,	O
and	O
a	O
new	O
mechanism	O
of	O
drug	O
action	O
was	O
suggested	O
recently	O
.	O

Salicylates	O
have	O
been	O
shown	O
to	O
inhibit	O
lipopolysaccharide-induced	O
gene	O
transcription	O
via	O
inhibition	O
of	O
NF-kappa	B-protein
B	I-protein
activation	O
by	O
preventing	O
the	O
degradation	O
of	O
NF-kappa	B-protein
B	I-protein
inhibitor	I-protein
``	O
I	B-protein
kappa	I-protein
B	I-protein
``	O
,	O
blocking	O
the	O
translocation	O
of	O
NF-kappa	B-protein
B	I-protein
into	O
the	O
nuclear	O
compartment	O
.	O

However	O
,	O
the	O
nature	O
of	O
the	O
subunit	O
involved	O
in	O
this	O
mechanism	O
has	O
not	O
been	O
defined	O
.	O

To	O
examine	O
the	O
mechanisms	O
by	O
which	O
salicylates	O
affect	O
cytokine	B-protein
gene	O
transcription	O
,	O
the	O
amount	O
of	O
active	O
and	O
inactive	O
NF-kappa	B-protein
B	I-protein
and	O
NF-kappa	B-RNA
B	I-RNA
mRNA	I-RNA
,	O
in	O
Porphyromonas	O
gingivalis	O
lipopolysaccharide-stimulated	B-cell_line
human	I-cell_line
monocytic	I-cell_line
cells	I-cell_line
was	O
assessed	O
.	O

High	O
doses	O
of	O
sodium	O
salicylate	O
suppressed	O
NF-kappa	B-protein
B	I-protein
p65	B-RNA
mRNA	I-RNA
accumulation	O
,	O
resulting	O
in	O
suppression	O
of	O
total	O
NF-kappa	B-protein
B	I-protein
,	O
p50	B-protein
on	O
tissue	O
oligonucleotide	O
had	O
no	O
effects	O
on	O
lipopolysaccharide-induced	O
NF-kappa	B-protein
B	I-protein
activation	O
.	O

The	O
data	O
demonstrate	O
that	O
the	O
p65	B-protein
subunit	O
of	O
NF-kappa	B-protein
B	I-protein
is	O
inhibited	O
by	O
salicylate	O
treatment	O
and	O
highlight	O
the	O
role	O
of	O
salicylate	O
in	O
the	O
control	O
of	O
gene	O
expression	O
of	O
inflammatory	B-protein
mediators	I-protein
.	O

Glucocorticoid-mediated	O
inhibition	O
of	O
RANTES	B-protein
expression	O
in	O
human	B-cell_type
T	I-cell_type
lymphocytes	I-cell_type
.	O

The	O
chemokine	B-protein
RANTES	B-protein
has	O
been	O
implicated	O
in	O
the	O
pathogenesis	O
of	O
allergic	O
inflammatory	O
diseases	O
including	O
asthma	O
and	O
rhinitis	O
which	O
are	O
frequently	O
treated	O
with	O
glucocorticoids	O
.	O

We	O
observed	O
that	O
dexamethasone	O
dramatically	O
inhibited	O
RANTES	B-RNA
mRNA	I-RNA
expression	O
dose	O
dependently	O
in	O
anti-CD3	B-cell_line
activated	I-cell_line
Hut-78	I-cell_line
T	I-cell_line
cells	I-cell_line
and	O
human	B-cell_type
PBMCs	I-cell_type
.	O

Inhibition	O
of	O
RANTES	B-protein
expression	O
did	O
not	O
appear	O
to	O
be	O
secondary	O
to	O
IL-2	B-protein
inhibition	O
and	O
required	O
binding	O
to	O
the	O
intracellular	O
glucocorticoid	B-protein
receptor	I-protein
.	O

The	O
down-regulation	O
of	O
RANTES	B-protein
expression	O
by	O
glucocorticoids	O
in	O
T	B-cell_type
cells	I-cell_type
may	O
directly	O
contribute	O
to	O
the	O
efficacy	O
of	O
these	O
agents	O
in	O
suppressing	O
cellular	O
infiltration	O
and	O
to	O
their	O
anti-inflammatory	O
properties	O
.	O

Association	O
of	O
TRAF1	B-protein
,	O
TRAF2	B-protein
,	O
and	O
TRAF3	B-protein
with	O
an	O
Epstein-Barr	B-DNA
virus	I-DNA
LMP1	I-DNA
domain	I-DNA
important	O
for	O
B-lymphocyte	B-cell_type
transformation	O
:	O
role	O
in	O
NF-kappaB	B-protein
activation	O
.	O

The	O
Epstein-Barr	B-protein
virus	I-protein
(	I-protein
EBV	I-protein
)	I-protein
transforming	I-protein
protein	I-protein
LMP1	I-protein
appears	O
to	O
be	O
a	O
constitutively	B-protein
activated	I-protein
tumor	I-protein
necrosis	I-protein
factor	I-protein
receptor	I-protein
(	O
TNFR	B-protein
)	O
on	O
the	O
basis	O
of	O
an	O
intrinsic	O
ability	O
to	O
aggregate	O
in	O
the	O
plasma	O
membrane	O
and	O
an	O
association	O
of	O
its	O
cytoplasmic	B-protein
carboxyl	I-protein
terminus	I-protein
(	O
CT	B-protein
)	O
with	O
TNFR-associated	B-protein
factors	I-protein
(	O
TRAFs	B-protein
)	O
.	O

We	O
now	O
show	O
that	O
in	O
EBV-transformed	B-cell_line
B	I-cell_line
lymphocytes	I-cell_line
most	O
of	O
TRAF1	B-protein
or	O
TRAF3	B-protein
and	O
5	O
%	O
of	O
TRAF2	B-protein
are	O
associated	O
with	O
LMP1	B-protein
and	O
that	O
most	O
of	O
LMP1	B-protein
is	O
associated	O
with	O
TRAF1	B-protein
or	O
TRAF3	B-protein
.	O

TRAF1	B-protein
,	O
TRAF2	B-protein
,	O
and	O
TRAF3	B-protein
bind	O
to	O
a	O
single	O
site	O
in	O
the	O
LMP1	B-protein
CT	I-protein
corresponding	O
to	O
amino	O
acids	O
(	O
aa	O
)	O
199	O
to	O
214	O
,	O
within	O
a	O
domain	O
which	O
is	O
important	O
for	O
B-lymphocyte	O
growth	O
transformation	O
(	O
aa	O
187	O
to	O
231	O
)	O
.	O

Further	O
deletional	O
and	O
alanine	O
mutagenesis	O
analyses	O
and	O
comparison	O
with	O
TRAF	B-DNA
binding	I-DNA
sequences	I-DNA
in	O
CD40	O
,	O
in	O
CD30	O
,	O
and	O
in	O
the	O
LMP1	B-protein
of	O
other	O
lymphycryptoviruses	O
provide	O
the	O
first	O
evidence	O
that	O
PXQXT/S	B-DNA
is	O
a	O
core	O
TRAF	B-DNA
binding	I-DNA
motif	I-DNA
.	O

The	O
negative	O
effects	O
of	O
point	O
mutations	O
in	O
the	O
LMP1	B-DNA
(	I-DNA
1-231	I-DNA
)	I-DNA
core	I-DNA
TRAF	I-DNA
binding	I-DNA
motif	I-DNA
on	O
TRAF	O
binding	O
and	O
NF-kappaB	B-protein
activation	O
genetically	O
link	O
the	O
TRAFs	B-protein
to	O
LMP1	B-protein
(	O
1-231	O
)	O
-mediated	O
NF-kappaB	B-protein
activation	O
.	O

NF-kappaB	B-protein
activation	O
by	O
LMP1	B-protein
(	O
1-231	O
)	O
is	O
likely	O
to	O
be	O
mediated	O
by	O
TRAF1	B-protein
/TRAF2	B-protein
heteroaggregates	O
since	O
TRAF1	B-protein
is	O
unique	O
among	O
the	O
TRAFs	B-protein
in	O
coactivating	O
NF-kappaB	B-protein
with	O
LMP1	B-protein
(	O
1-231	O
)	O
,	O
a	O
TRAF2	B-protein
dominant-negative	O
mutant	O
can	O
block	O
LMP1	B-protein
(	O
1-231	O
)	O
-mediated	O
NF-kappaB	B-protein
activation	O
as	O
well	O
as	O
TRAF1	B-protein
coactivation	O
,	O
and	O
30	O
%	O
of	O
TRAF2	B-protein
is	O
associated	O
with	O
TRAF1	B-protein
in	O
EBV-transformed	O
B	O
cells	O
.	O

TRAF3	B-protein
is	O
a	O
negative	O
modulator	O
of	O
LMP1	B-protein
(	O
1-231	O
)	O
-mediated	O
NF-kappaB	B-protein
activation	O
.	O

Surprisingly	O
,	O
TRAF1	B-protein
,	I-protein
-2	I-protein
,	I-protein
or	I-protein
-3	I-protein
does	O
not	O
interact	O
with	O
the	O
terminal	B-protein
LMP1	I-protein
CT	I-protein
aa	O
333	O
to	O
386	O
which	O
can	O
independently	O
mediate	O
NF-kappaB	B-protein
activation	O
.	O

The	O
constitutive	O
association	O
of	O
TRAFs	B-protein
with	O
LMP1	B-protein
through	O
the	O
aa	B-protein
187	I-protein
to	I-protein
231	I-protein
domain	I-protein
which	O
is	O
important	O
in	O
NF-kappaB	B-protein
activation	O
and	O
primary	O
B-lymphocyte	B-cell_type
growth	O
transformation	O
implicates	O
TRAF	B-protein
aggregation	O
in	O
LMP1	B-protein
signaling	O
.	O

Lack	O
of	O
IL-12	B-protein
signaling	O
in	O
human	B-cell_line
allergen-specific	I-cell_line
Th2	I-cell_line
cells	I-cell_line
.	O

IL-12	B-protein
is	O
a	O
powerful	O
skewer	O
of	O
CD4+	B-cell_type
T	I-cell_type
cell	I-cell_type
responses	O
toward	O
the	O
Th1	O
phenotype	O
by	O
inducing	O
IFN-gamma	B-protein
production	O
in	O
naive	B-cell_line
Th	I-cell_line
cells	I-cell_line
.	O

In	O
the	O
present	O
study	O
we	O
addressed	O
the	O
question	O
of	O
whether	O
IL-12	B-protein
can	O
reverse	O
established	O
Th2	O
responses	O
into	O
Th1/Th0	O
responses	O
by	O
inducing	O
IFN-gamma	B-protein
production	O
in	O
memory	B-cell_line
Th2	I-cell_line
cells	I-cell_line
.	O

To	O
this	O
aim	O
,	O
allergen-specific	B-cell_line
CD4+	I-cell_line
T	I-cell_line
cell	I-cell_line
clones	I-cell_line
(	O
TCC	B-cell_line
)	O
were	O
generated	O
from	O
the	O
peripheral	O
blood	O
of	O
three	O
atopic	O
patients	O
,	O
and	O
their	O
cytokine	B-protein
profiles	O
were	O
analyzed	O
.	O

The	O
majority	O
of	O
these	O
TCC	B-cell_line
exhibited	O
a	O
strongly	O
polarized	O
Th2	O
cytokine	B-protein
profile	O
,	O
and	O
the	O
production	O
of	O
IFN-gamma	B-protein
could	O
not	O
be	O
induced	O
by	O
exogenous	O
IL-12	B-protein
.	O

Only	O
those	O
TCC	B-cell_line
with	O
low	O
IFN-gamma	B-protein
levels	O
in	O
the	O
absence	O
of	O
IL-12	B-protein
responded	O
to	O
IL-12	B-protein
by	O
additional	O
enhancement	O
of	O
IFN-gamma	B-protein
production	O
.	O

The	O
IL-12	B-protein
nonresponsiveness	O
of	O
the	O
Th2	B-cell_line
clones	I-cell_line
was	O
further	O
evident	O
by	O
the	O
total	O
lack	O
of	O
IL-12	B-protein
-induced	O
phosphorylation	O
of	O
STAT4	B-protein
(	O
signal	B-protein
transducer	I-protein
and	I-protein
activator	I-protein
of	I-protein
transcription-4	I-protein
)	O
,	O
a	O
transcription	B-protein
factor	I-protein
that	O
is	O
typically	O
involved	O
in	O
IL-12	B-protein
signaling	O
.	O

Consequently	O
,	O
IL-12	B-protein
also	O
failed	O
to	O
induce	O
the	O
DNA-binding	O
activity	O
of	O
STAT4-containing	B-protein
complexes	I-protein
in	O
the	O
nuclei	O
of	O
these	O
Th2	B-cell_line
clones	I-cell_line
.	O

All	O
TCC	B-cell_line
expressed	O
equal	O
levels	O
of	O
the	O
low-affinity	B-protein
IL-12R	I-protein
beta1	I-protein
subunit	I-protein
.	O

Our	O
results	O
indicate	O
that	O
human	O
allergen-specific	O
Th	O
cells	O
with	O
strongly	O
polarized	O
Th2	O
cytokine	B-protein
profiles	O
do	O
not	O
respond	O
to	O
IL-12	B-protein
and	O
,	O
therefore	O
,	O
can	O
not	O
be	O
induced	O
to	O
produce	O
IFN-gamma	B-protein
.	O

The	O
apparent	O
high	O
frequency	O
of	O
IL-12-nonresponsive	B-cell_line
Th	I-cell_line
cells	I-cell_line
within	O
the	O
allergen-specific	O
populations	O
in	O
atopic	O
patients	O
predicts	O
a	O
limited	O
skewing	O
potential	O
of	O
IL-12	B-protein
in	O
the	O
case	O
of	O
established	O
Th2	O
responses	O
,	O
but	O
only	O
affecting	O
newly	O
recruited	O
naive	O
Th	B-cell_line
cells	I-cell_line
.	O

Cloning	O
and	O
expression	O
of	O
the	O
Epstein-Barr	B-protein
virus-encoded	I-protein
dUTPase	I-protein
:	O
patients	O
with	O
acute	O
,	O
reactivated	O
or	O
chronic	O
virus	O
infection	O
develop	O
antibodies	B-protein
against	O
the	O
enzyme	B-protein
.	O

The	O
gene	O
encoding	O
the	O
Epstein-Barr	B-protein
virus	I-protein
(	I-protein
EBV	I-protein
)	I-protein
-specific	I-protein
dUTPase	I-protein
was	O
amplified	O
from	O
virus	B-DNA
DNA	I-DNA
by	O
PCR	O
.	O

The	O
active	O
enzyme	O
was	O
expressed	O
in	O
Escherichia	O
coli	O
and	O
in	O
insect	B-cell_type
cells	I-cell_type
as	O
a	O
non-fusion	B-protein
protein	I-protein
.	O

The	O
protein	O
from	O
E.	O
coli	O
specifically	O
converted	O
dUTP	O
to	O
dUMP	O
and	O
did	O
not	O
react	O
with	O
other	O
dNTPs	O
or	O
NTPs	O
.	O

Preliminary	O
experiments	O
yielded	O
a	O
Km	O
value	O
of	O
about	O
0.8	O
microM	O
for	O
dUTP	O
.	O

MAbs	O
against	O
the	O
dUTPase	B-protein
reacted	O
with	O
a	O
protein	O
of	O
approximately	O
31	O
kDa	O
in	O
12-O-tetradecanoyl-phorbol-13-acetate	B-cell_line
(	I-cell_line
TPA	I-cell_line
)	I-cell_line
-stimulated	I-cell_line
B	I-cell_line
cells	I-cell_line
harbouring	O
either	O
type	O
1	O
or	O
type	O
2	O
EBV	O
.	O

The	O
protein	O
was	O
found	O
in	O
untreated	B-cell_type
cells	I-cell_type
at	O
low	O
levels	O
,	O
whereas	O
induction	O
of	O
the	O
lytic	O
replication	O
cycle	O
by	O
TPA	O
treatment	O
or	O
by	O
providing	O
the	O
immediate	B-protein
early	I-protein
transactivator	I-protein
BZLF1	B-protein
in	O
trans	O
resulted	O
in	O
increased	O
expression	O
.	O

We	O
demonstrated	O
that	O
the	O
virus	B-protein
dUTPase	I-protein
isolated	O
from	O
EBV-infected	B-cell_type
cells	I-cell_type
is	O
a	O
phosphoprotein	B-protein
.	O

The	O
protein	O
expressed	O
in	O
insect	B-cell_type
cells	I-cell_type
was	O
used	O
to	O
test	O
for	O
the	O
presence	O
of	O
specific	B-protein
antibodies	I-protein
in	O
sera	O
from	O
normal	O
,	O
healthy	O
carriers	O
and	O
from	O
patients	O
with	O
various	O
diseases	O
.	O

While	O
the	O
sera	O
of	O
EBV-negative	O
individuals	O
(	O
0/3	O
)	O
or	O
healthy	O
carriers	O
(	O
0/33	O
)	O
did	O
not	O
contain	O
detectable	O
levels	O
of	O
antibodies	O
,	O
patients	O
with	O
mononucleosis	O
(	O
5/18	O
)	O
,	O
chronic	O
EBV	O
infection	O
(	O
2/7	O
)	O
,	O
EBV	O
reactivation	O
(	O
7/20	O
)	O
and	O
human	O
immunodeficiency	O
virus	O
infection	O
(	O
5/24	O
)	O
showed	O
elevated	O
antibody	O
titres	O
against	O
the	O
enzyme	O
.	O

This	O
indicated	O
that	O
the	O
dUTPase	O
is	O
expressed	O
during	O
EBV	O
replication	O
and	O
reactivation	O
.	O

The	O
enzyme	O
might	O
therefore	O
be	O
a	O
potential	O
target	O
for	O
drug	O
therapy	O
under	O
conditions	O
of	O
active	O
DNA	O
replication	O
.	O

The	O
catalytic	B-protein
domain	I-protein
of	O
pp56	B-protein
(	I-protein
lck	I-protein
)	I-protein
,	O
but	O
not	O
its	O
regulatory	B-protein
domain	I-protein
,	O
is	O
sufficient	O
for	O
inducing	O
IL-2	B-protein
production	O
.	O

The	O
lymphoid	B-protein
src	I-protein
kinase	I-protein
pp56	B-protein
(	I-protein
lck	I-protein
)	I-protein
has	O
been	O
shown	O
to	O
be	O
essential	O
for	O
the	O
induction	O
of	O
different	O
T	B-cell_type
lymphocyte	I-cell_type
responses	O
,	O
including	O
CD4	B-protein
-mediated	O
enhancement	O
of	O
Ag-induced	O
T	O
cell	O
activation	O
,	O
early	O
T	O
cell	O
differentiation	O
,	O
induction	O
of	O
IL-2	B-protein
production	O
,	O
and	O
cytotoxicity	O
.	O

It	O
is	O
assumed	O
that	O
pp56	B-protein
(	I-protein
lck	I-protein
)	I-protein
acts	O
on	O
these	O
processes	O
by	O
phosphorylating	O
substrates	O
.	O

However	O
,	O
it	O
has	O
been	O
recently	O
reported	O
that	O
the	O
NH2	B-protein
regulatory	B-protein
domain	I-protein
is	O
sufficient	O
to	O
mediate	O
CD4	B-protein
accessory	O
function	O
.	O

In	O
this	O
report	O
we	O
address	O
the	O
contribution	O
of	O
the	O
regulatory	B-protein
and	I-protein
catalytic	I-protein
domains	I-protein
of	O
pp56	B-protein
(	I-protein
lck	I-protein
)	I-protein
to	O
another	O
function	O
of	O
this	O
enzyme	O
independent	O
of	O
CD4	B-protein
:	O
TCR-induced	O
IL-2	B-protein
production	O
.	O

Two	O
pp56	B-protein
(	I-protein
lck	I-protein
)	I-protein
mutants	I-protein
lacking	O
either	O
the	O
entire	O
catalytic	B-protein
domain	I-protein
or	O
the	O
entire	O
NH2	B-protein
regulatory	B-protein
domain	I-protein
were	O
generated	O
,	O
and	O
their	O
abilities	O
to	O
trigger	O
transactivation	O
of	O
the	O
TCR-regulated	B-DNA
nuclear	I-DNA
factor	I-DNA
of	I-DNA
activated	I-DNA
T	I-DNA
cells	I-DNA
(	I-DNA
NF-AT	I-DNA
)	I-DNA
region	I-DNA
of	O
the	O
IL-2	B-DNA
promoter	I-DNA
were	O
compared	O
.	O

Only	O
the	O
catalytic	O
,	O
but	O
not	O
the	O
NH2	B-protein
regulatory	O
,	O
domain	O
of	O
pp56	B-protein
(	I-protein
lck	I-protein
)	I-protein
was	O
able	O
to	O
induce	O
NF-AT	B-protein
region	O
transactivation	O
on	O
its	O
own	O
and	O
to	O
cooperate	O
with	O
other	O
intracellular	O
signals	O
to	O
trigger	O
this	O
response	O
.	O

Moreover	O
,	O
the	O
catalytic	B-protein
domain	I-protein
of	O
pp56	B-protein
(	I-protein
lck	I-protein
)	I-protein
was	O
able	O
to	O
induce	O
IL-2	B-protein
cytokine	B-protein
production	O
to	O
an	O
extent	O
similar	O
to	O
that	O
of	O
wild-type	O
pp56	B-protein
(	I-protein
lck	I-protein
)	I-protein
.	O

We	O
conclude	O
that	O
different	O
domains	O
of	O
the	O
pp56	B-protein
(	I-protein
lck	I-protein
)	I-protein
molecule	O
contribute	O
to	O
regulate	O
distinct	O
biologic	O
functions	O
.	O

In	O
fact	O
,	O
while	O
the	O
NH2	B-protein
regulatory	B-protein
domain	I-protein
is	O
sufficient	O
to	O
mediate	O
CD4	B-protein
accessory	O
function	O
,	O
we	O
show	O
here	O
that	O
the	O
catalytic	B-protein
domain	I-protein
of	O
pp56	B-protein
(	I-protein
lck	I-protein
)	I-protein
is	O
sufficient	O
for	O
induction	O
of	O
IL-2	B-protein
production	O
,	O
mimicking	O
TCR	B-protein
ligation	O
.	O

[	O
The	O
changes	O
in	O
glucocorticoid	O
receptors	O
in	O
peripheral	B-cell_type
leukocytes	I-cell_type
in	O
asthmatic	O
subjects	O
]	O

The	O
number	O
of	O
glucocorticoid	B-protein
receptors	I-protein
(	O
GCR	B-protein
)	O
in	O
peripheral	B-cell_type
leukocytes	I-cell_type
was	O
determined	O
by	O
radioligand-binding	O
assay	O
in	O
extrinsic	O
and	O
intrinsic	O
asthmatics	O
.	O

Their	O
corresponding	O
plasma	O
cortisol	O
levels	O
were	O
assessed	O
.	O

The	O
results	O
showed	O
that	O
the	O
average	O
number	O
of	O
GCR	B-protein
in	O
asthmatics	O
was	O
significantly	O
lower	O
than	O
that	O
in	O
healthy	O
subjects	O
(	O
P	O
<	O
0.01	O
)	O
,	O
and	O
there	O
was	O
a	O
linear	O
correlation	O
between	O
the	O
number	O
of	O
GCR	B-protein
and	O
the	O
course	O
of	O
asthma	O
.	O

Besides	O
,	O
there	O
was	O
also	O
a	O
linear	O
correlation	O
between	O
the	O
number	O
of	O
GCR	B-protein
and	O
the	O
age	O
of	O
the	O
initial	O
attack	O
of	O
asthma	O
.	O

No	O
difference	O
in	O
plasma	O
cortisol	O
level	O
was	O
found	O
between	O
asthmatics	O
and	O
healthy	O
subjects	O
.	O

These	O
findings	O
suggest	O
that	O
there	O
is	O
no	O
primary	O
and	O
general	O
impairment	O
of	O
glucocorticoid	O
metabolism	O
in	O
the	O
asthmatics	O
,	O
but	O
the	O
number	O
of	O
GCR	B-protein
in	O
the	O
asthmatics	O
is	O
lower	O
than	O
that	O
in	O
healthy	O
controls	O
.	O

The	O
decrease	O
of	O
the	O
number	O
of	O
GCR	B-protein
in	O
asthmatics	O
,	O
we	O
think	O
,	O
is	O
related	O
to	O
heredity	O
and	O
repeated	O
attacks	O
of	O
asthma	O
.	O

Novel	O
aldosterone	B-protein
receptors	I-protein
:	O
specificity-conferring	O
mechanism	O
at	O
the	O
level	O
of	O
the	O
cell	O
membrane	O
.	O

Functional	O
studies	O
in	O
extra-renal	B-cell_type
,	I-cell_type
nonepithelial	I-cell_type
cells	I-cell_type
such	O
as	O
smooth	B-cell_type
muscle	I-cell_type
cells	I-cell_type
and	O
more	O
recently	O
circulating	O
human	B-cell_type
lymphocytes	I-cell_type
have	O
provided	O
increasing	O
evidence	O
that	O
aldosterone	O
produces	O
not	O
only	O
classical	O
genomic	O
effects	O
,	O
but	O
also	O
rapid	O
non-genomic	O
effects	O
on	O
transmembrane	O
electrolyte	O
movements	O
.	O

These	O
involve	O
activation	O
of	O
the	O
sodium/proton-exchanger	B-protein
of	O
the	O
cell	O
membrane	O
at	O
very	O
low	O
,	O
physiological	O
concentrations	O
of	O
aldosterone	O
with	O
an	O
acute	O
onset	O
within	O
1-2	O
minutes	O
.	O

A	O
second	O
messenger	O
cascade	O
involved	O
is	O
the	O
inositol-1	O
,	O
4	O
,	O
5-trisphosphate/calcium	O
pathway	O
which	O
responds	O
over	O
the	O
same	O
rapid	O
time	O
course	O
.	O

Such	O
changes	O
clearly	O
can	O
not	O
be	O
explained	O
by	O
genomic	O
mechanisms	O
,	O
which	O
are	O
responsible	O
for	O
later	O
effects	O
than	O
the	O
membrane-related	O
rapid	O
responses	O
.	O

In	O
addition	O
to	O
its	O
rapid	O
time	O
course	O
the	O
unique	O
characteristics	O
of	O
this	O
new	O
pathway	O
for	O
steroid	O
action	O
include	O
a	O
10000-fold	O
selectivity	O
for	O
aldosterone	O
over	O
cortisol	O
and	O
the	O
ineffectiveness	O
of	O
spironolactones	O
,	O
classical	O
mineralocorticoid	O
antagonists	O
,	O
as	O
antagonists	O
of	O
the	O
response	O
.	O

Subsequently	O
binding	O
sites	O
have	O
been	O
demonstrated	O
in	O
the	O
plasma	O
membrane	O
of	O
human	B-cell_type
lymphocytes	I-cell_type
which	O
show	O
pharmacological	O
(	O
aldosterone	O
specificity	O
)	O
and	O
kinetic	O
(	O
high	O
turnover	O
)	O
properties	O
identical	O
with	O
those	O
of	O
the	O
rapid	O
aldosterone	O
effects	O
in	O
the	O
same	O
cells	O
.	O

SDS-PAGE	O
analysis	O
of	O
the	O
receptor	B-protein
protein	I-protein
has	O
shown	O
a	O
molecular	O
weight	O
of	O
approximately	O
50	O
kD	O
.	O

The	O
present	O
paper	O
reviews	O
the	O
data	O
supporting	O
a	O
new	O
,	O
two-step	O
model	O
for	O
non-genomic	O
and	O
genomic	O
aldosterone	O
effects	O
.	O

It	O
also	O
suggests	O
a	O
novel	O
specificity-conferring	O
mechanism	O
for	O
mineralocorticoid	O
action	O
at	O
the	O
membrane	O
level	O
.	O

The	O
macrophage	B-protein
transcription	I-protein
factor	I-protein
PU.1	B-protein
directs	O
tissue-specific	O
expression	O
of	O
the	O
macrophage	B-protein
colony-stimulating	I-protein
factor	I-protein
receptor	I-protein
.	O

The	O
macrophage	B-protein
colony-stimulating	I-protein
factor	I-protein
(	I-protein
M-CSF	I-protein
)	I-protein
receptor	I-protein
is	O
expressed	O
in	O
a	O
tissue-specific	O
fashion	O
from	O
two	O
distinct	O
promoters	B-DNA
in	O
monocytes/macrophages	B-cell_type
and	O
the	O
placenta	O
.	O

In	O
order	O
to	O
further	O
understand	O
the	O
transcription	O
factors	O
which	O
play	O
a	O
role	O
in	O
the	O
commitment	O
of	O
multipotential	B-cell_type
progenitors	I-cell_type
to	O
the	O
monocyte/macrophage	O
lineage	O
,	O
we	O
have	O
initiated	O
an	O
investigation	O
of	O
the	O
factors	O
which	O
activate	O
the	O
M-CSF	B-protein
receptor	I-protein
very	O
early	O
during	O
the	O
monocyte	O
differentiation	O
process	O
.	O

Here	O
we	O
demonstrate	O
that	O
the	O
human	B-DNA
monocytic	I-DNA
M-CSF	I-DNA
receptor	I-DNA
promoter	I-DNA
directs	O
reporter	O
gene	O
activity	O
in	O
a	O
tissue-specific	O
fashion	O
.	O

Since	O
one	O
of	O
the	O
few	O
transcription	B-protein
factors	I-protein
which	O
have	O
been	O
implicated	O
in	O
the	O
regulation	O
of	O
monocyte	B-DNA
genes	I-DNA
is	O
the	O
macrophage-	B-protein
and	I-protein
B-cell-specific	I-protein
PU.1	I-protein
transcription	B-protein
factor	I-protein
,	O
we	O
investigated	O
whether	O
PU.1	B-protein
binds	O
and	O
activates	O
the	O
M-CSF	B-DNA
receptor	I-DNA
promoter	I-DNA
.	O

Here	O
we	O
demonstrate	O
that	O
both	O
in	O
vitro-translated	B-protein
PU.1	I-protein
and	O
PU.1	B-protein
from	O
nuclear	O
extracts	O
bind	O
to	O
a	O
specific	O
site	O
in	O
the	O
M-CSF	B-DNA
receptor	I-DNA
promoter	I-DNA
just	O
upstream	O
from	O
the	O
major	B-DNA
transcription	I-DNA
initiation	I-DNA
site	I-DNA
.	O

Mutations	O
in	O
this	O
site	O
which	O
eliminate	O
PU.1	B-protein
binding	O
decrease	O
M-CSF	B-protein
receptor	I-protein
promoter	O
activity	O
significantly	O
in	O
macrophage	B-cell_line
cell	I-cell_line
lines	I-cell_line
only	O
.	O

Furthermore	O
,	O
PU.1	B-protein
transactivates	O
the	O
M-CSF	B-DNA
receptor	I-DNA
promoter	I-DNA
in	O
nonmacrophage	B-cell_type
cells	I-cell_type
.	O

These	O
results	O
suggest	O
that	O
PU.1	B-protein
plays	O
a	O
major	O
role	O
in	O
macrophage	O
gene	O
regulation	O
and	O
development	O
by	O
directing	O
the	O
expression	O
of	O
a	O
receptor	O
for	O
a	O
key	B-protein
macrophage	I-protein
growth	I-protein
factor	I-protein
.	O

Increased	O
natural	O
killer	O
cell	O
activity	O
correlates	O
with	O
low	O
or	O
negative	O
expression	O
of	O
the	O
HER-2/neu	B-DNA
oncogene	I-DNA
in	O
patients	O
with	O
breast	O
cancer	O
.	O

BACKGROUND	O
.	O

Increased	O
expression	O
of	O
the	O
HER-2/neu	B-DNA
oncogene	I-DNA
in	O
breast	O
cancer	O
correlates	O
with	O
decreased	O
estrogen	B-protein
receptor	I-protein
concentration	O
and	O
seems	O
to	O
be	O
an	O
important	O
prognostic	O
factor	O
.	O

The	O
authors	O
investigated	O
whether	O
there	O
is	O
a	O
correlation	O
between	O
HER-2/neu	B-protein
expression	O
and	O
immunologic	O
parameters	O
representing	O
tumor	O
defense	O
in	O
patients	O
with	O
breast	O
cancer	O
.	O

METHOD	O
.	O

A	O
Western	O
blot	O
analysis	O
was	O
used	O
to	O
investigate	O
HER-2/neu	B-protein
expression	O
,	O
whereas	O
a	O
chromium-release	O
assay	O
using	O
the	O
K562	B-cell_line
cell	I-cell_line
line	I-cell_line
as	O
target	O
was	O
used	O
to	O
measure	O
natural	B-cell_type
killer	I-cell_type
(	I-cell_type
NK	I-cell_type
)	I-cell_type
cell	I-cell_type
activity	O
.	O

RESULTS	O
.	O

In	O
patients	O
with	O
breast	O
cancer	O
,	O
NK	B-cell_type
cell	I-cell_type
activity	O
was	O
significantly	O
higher	O
compared	O
with	O
patients	O
with	O
benign	B-cell_type
tumors	I-cell_type
(	O
P	O
=	O
0.006	O
)	O
or	O
healthy	O
control	O
subjects	O
(	O
P	O
=	O
0.002	O
)	O
.	O

Moreover	O
,	O
23.3	O
%	O
of	O
patients	O
with	O
breast	O
cancer	O
showed	O
an	O
overexpression	O
of	O
HER-2/neu	B-protein
protein	I-protein
.	O

Within	O
this	O
group	O
of	O
patients	O
,	O
NK	B-cell_type
cell	I-cell_type
activity	O
was	O
significantly	O
lower	O
(	O
45.6	O
+/-	O
16.1	O
%	O
)	O
compared	O
with	O
the	O
group	O
with	O
no	O
HER-2/neu	B-protein
overexpression	O
(	O
57.3	O
+/-	O
11.0	O
%	O
)	O
.	O

NK	B-cell_type
cell	I-cell_type
activity	O
did	O
not	O
increase	O
in	O
patients	O
with	O
HER-2/neu	B-protein
overexpression	O
.	O

Thus	O
,	O
there	O
was	O
a	O
statistically	O
significant	O
correlation	O
of	O
cytolytic	O
effector	O
cell	O
function	O
with	O
HER-2/neu	B-protein
expression	O
of	O
the	O
tumor	O
(	O
P	O
=	O
0.003	O
)	O
,	O
and	O
HER-2/neu	B-protein
overexpression	O
correlated	O
with	O
a	O
negative	O
estrogen	B-protein
receptor	I-protein
status	O
(	O
P	O
=	O
0.005	O
)	O
.	O

CONCLUSION	O
.	O

These	O
data	O
add	O
further	O
evidence	O
to	O
previous	O
observations	O
from	O
the	O
authors	O
'	O
laboratory	O
that	O
certain	O
tumor	O
characteristics	O
may	O
be	O
associated	O
with	O
reactions	O
of	O
the	O
host	O
with	O
breast	O
cancer	O
.	O

[	O
The	O
value	O
of	O
the	O
clinical	O
test	O
of	O
glucocorticoid	B-protein
receptors	I-protein
of	O
peripheral	B-cell_type
blood	I-cell_type
leukocytes	I-cell_type
in	O
patients	O
with	O
chronic	O
pulmonary	O
heart	O
disease	O
]	O

In	O
order	O
to	O
inquire	O
into	O
the	O
functional	O
state	O
of	O
adrenal	O
cortex	O
in	O
patients	O
with	O
pulmonary	O
heart	O
disease	O
,	O
the	O
number	O
of	O
glucocorticoid	B-protein
receptors	I-protein
(	O
GCR	B-protein
)	O
of	O
peripheral	B-cell_type
blood	I-cell_type
leukocytes	I-cell_type
in	O
patients	O
with	O
chronic	O
pulmonary	O
heart	O
disease	O
was	O
determined	O
with	O
radioligand-binding	O
assay	O
and	O
the	O
corresponding	O
plasma	O
cortisol	O
levels	O
were	O
assessed	O
with	O
radioimmune	O
assays	O
.	O

The	O
results	O
showed	O
that	O
the	O
number	O
of	O
GCR	B-protein
in	O
the	O
patients	O
was	O
significantly	O
reduced	O
(	O
P	O
<	O
0.01	O
)	O
and	O
it	O
was	O
increased	O
when	O
their	O
health	O
state	O
was	O
improved	O
.	O

However	O
,	O
it	O
was	O
still	O
lower	O
than	O
that	O
in	O
healthy	O
subjects	O
(	O
P	O
<	O
0.01	O
)	O
.	O

The	O
number	O
of	O
GCR	B-protein
in	O
the	O
patients	O
was	O
greatly	O
increased	O
when	O
these	O
patients	O
were	O
treated	O
with	O
oxygen	O
(	O
P	O
<	O
0.01	O
)	O
.	O

No	O
difference	O
in	O
plasma	O
cortisol	O
was	O
found	O
between	O
the	O
patients	O
and	O
the	O
healthy	O
subjects	O
(	O
P	O
>	O
0.05	O
)	O
.	O

These	O
results	O
indicate	O
that	O
the	O
function	O
of	O
adrenal	O
cortex	O
may	O
be	O
improved	O
by	O
the	O
compensation	O
mechanism	O
of	O
the	O
patients	O
,	O
but	O
the	O
lower	O
GCR	B-protein
number	O
was	O
the	O
result	O
of	O
lacking	O
of	O
oxygen	O
in	O
the	O
patients	O
.	O

The	O
number	O
of	O
GCR	B-protein
may	O
be	O
improved	O
by	O
inhalation	O
of	O
oxygen	O
.	O

Therefore	O
oxygen	O
therapy	O
is	O
helpful	O
in	O
raising	O
the	O
activity	O
of	O
glucocorticoid	B-protein
receptors	I-protein
and	O
controlling	O
the	O
development	O
of	O
the	O
disease	O
.	O

Signaling	O
via	O
IL-2	B-protein
and	O
IL-4	B-protein
in	O
JAK3-deficient	B-cell_line
severe	I-cell_line
combined	I-cell_line
immunodeficiency	I-cell_line
lymphocytes	I-cell_line
:	O
JAK3	B-protein
-dependent	O
and	O
independent	O
pathways	O
.	O

Both	O
IL-2	B-protein
and	O
IL-4	B-protein
bind	O
to	O
receptors	O
containing	O
the	O
common	B-protein
gamma	I-protein
chain	I-protein
and	O
JAK3	B-protein
.	O

Although	O
JAK3	B-protein
is	O
required	O
for	O
proper	O
lymphoid	O
development	O
,	O
the	O
precise	O
roles	O
of	O
this	O
kinase	O
in	O
IL-2	B-protein
and	O
IL-4	B-protein
signaling	O
in	O
lymphocytes	B-cell_type
have	O
not	O
been	O
defined	O
.	O

Here	O
,	O
we	O
have	O
studied	O
IL-2	B-protein
and	O
IL-4	B-protein
signaling	O
in	O
B	B-cell_line
cell	I-cell_line
lines	I-cell_line
lacking	O
JAK3	B-protein
.	O

Although	O
IL-2	B-protein
-induced	O
phosphorylation	O
of	O
IL-2R	B-protein
beta	I-protein
,	O
JAK1	B-protein
,	O
and	O
STAT5	B-protein
all	O
required	O
the	O
presence	O
of	O
JAK3	B-protein
,	O
IL-4	B-protein
-mediated	O
phosphorylation	O
of	O
JAK1	B-protein
,	O
STAT6	B-protein
,	O
and	O
insulin	B-protein
receptor	I-protein
substrates	O
1	O
and	O
2	O
did	O
not	O
.	O

However	O
,	O
IL-4	B-protein
-induced	O
effects	O
were	O
clearly	O
improved	O
following	O
JAK3	B-protein
expression	O
.	O

These	O
data	O
indicate	O
that	O
IL-4	B-protein
signaling	O
occurs	O
in	O
the	O
absence	O
of	O
of	O
JAK3	B-protein
,	O
but	O
is	O
comparatively	O
inefficient	O
.	O

These	O
findings	O
may	O
help	O
in	O
understanding	O
the	O
pathogenesis	O
of	O
the	O
immunodeficiency	O
that	O
occurs	O
with	O
mutations	O
of	O
JAK3	B-protein
and	O
may	O
suggest	O
a	O
mechanism	O
for	O
the	O
pleiotropic	O
effects	O
of	O
IL-4	B-protein
.	O

Elf-1	B-protein
and	O
Stat5	B-protein
bind	O
to	O
a	O
critical	O
element	O
in	O
a	O
new	O
enhancer	O
of	O
the	O
human	B-DNA
interleukin-2	I-DNA
receptor	I-DNA
alpha	I-DNA
gene	I-DNA
[	O
published	O
erratum	O
appears	O
in	O
Mol	O
Cell	O
Biol	O
1997	O
Apr	O
;	O
17	O
(	O
4	O
)	O
:	O
2351	O
]	O

The	O
interleukin	B-DNA
2	I-DNA
receptor	I-DNA
alpha-chain	I-DNA
(	I-DNA
IL-2R	I-DNA
alpha	I-DNA
)	I-DNA
gene	I-DNA
is	O
a	O
key	O
regulator	O
of	O
lymphocyte	O
proliferation	O
.	O

IL-2R	B-protein
alpha	I-protein
is	O
rapidly	O
and	O
potently	O
induced	O
in	O
T	B-cell_type
cells	I-cell_type
in	O
response	O
to	O
mitogenic	O
stimuli	O
.	O

Interleukin	B-protein
2	I-protein
(	O
IL-2	B-protein
)	O
stimulates	O
IL-2R	B-protein
alpha	I-protein
.	O

transcription	O
,	O
thereby	O
amplifying	O
expression	O
of	O
its	O
own	O
high-affinity	B-protein
receptor	I-protein
.	O

IL-2R	B-protein
alpha	I-protein
transcription	O
is	O
at	O
least	O
in	O
part	O
controlled	O
by	O
two	O
positive	B-protein
regulatory	I-protein
regions	I-protein
,	O
PRRI	B-DNA
and	O
PRRII	B-DNA
.	O

PRRI	B-DNA
is	O
an	O
inducible	B-DNA
proximal	I-DNA
enhancer	I-DNA
,	O
located	O
between	B-DNA
nucleotides	I-DNA
-276	I-DNA
and	I-DNA
-244	I-DNA
,	O
which	O
contains	O
NF-kappaB	B-DNA
and	I-DNA
SRE/CArG	I-DNA
motifs	I-DNA
.	O

PRRII	B-DNA
is	O
a	O
T-cell-specific	B-DNA
enhancer	I-DNA
,	O
located	O
between	O
nucleotides	O
-137	O
and	O
-64	O
,	O
which	O
binds	O
the	O
T-cell-specific	B-protein
Ets	I-protein
protein	I-protein
Elf-1	B-protein
and	O
HMG-I	B-protein
(	I-protein
Y	I-protein
)	I-protein
proteins	I-protein
.	O

However	O
,	O
none	O
of	O
these	O
proximal	O
regions	O
account	O
for	O
the	O
induction	O
of	O
IL-2R	O
alpha	O
transcription	O
by	O
IL-2	B-protein
.	O

To	O
find	O
new	O
regulatory	B-DNA
regions	I-DNA
of	O
the	O
IL-2R	B-DNA
alpha	I-DNA
gene	I-DNA
,	O
8.5	O
kb	O
of	O
the	O
5	O
'	O
end	O
noncoding	O
sequence	O
of	O
the	O
IL-2R	B-DNA
alpha	I-DNA
gene	I-DNA
have	O
been	O
sequenced	O
.	O

We	O
identified	O
an	O
86-nucleotide	O
fragment	O
that	O
is	O
90	O
%	O
identical	O
to	O
the	O
recently	O
characterized	O
murine	B-DNA
IL-2-responsive	I-DNA
element	I-DNA
(	O
mIL-2rE	B-DNA
)	O
.	O

This	O
putative	O
human	B-DNA
IL-2rE	I-DNA
,	O
designated	O
PRRIII	B-DNA
,	O
confers	O
IL-2	B-protein
responsiveness	O
on	O
a	O
heterologous	B-DNA
promoter	I-DNA
.	O

PRRIII	B-DNA
contains	O
a	O
Stat	B-DNA
protein	I-DNA
binding	I-DNA
site	I-DNA
that	O
overlaps	O
with	O
an	O
EBS	B-DNA
motif	I-DNA
(	O
GASd/EBSd	B-DNA
)	O
.	O

These	O
are	O
essential	O
for	O
IL-2	B-protein
inducibility	O
of	O
PRRIII/CAT	B-DNA
reporter	I-DNA
constructs	I-DNA
.	O

IL-2	B-protein
induced	O
the	O
binding	O
of	O
Stat5a	B-protein
and	I-protein
b	I-protein
proteins	I-protein
to	O
the	O
human	B-DNA
GASd	I-DNA
element	I-DNA
.	O

To	O
confirm	O
the	O
physiological	O
relevance	O
of	O
these	O
findings	O
,	O
we	O
carried	O
out	O
in	O
vivo	O
footprinting	O
experiments	O
which	O
showed	O
that	O
stimulation	O
of	O
IL-2R	B-protein
alpha	I-protein
expression	O
correlated	O
with	O
occupancy	O
of	O
the	O
GASd	B-DNA
element	I-DNA
.	O

Our	O
data	O
demonstrate	O
a	O
major	O
role	O
of	O
the	O
GASd/EBSd	B-DNA
element	I-DNA
in	O
IL-2R	B-protein
alpha	I-protein
regulation	O
and	O
suggest	O
that	O
the	O
T-cell-specific	B-protein
Elf-1	I-protein
factor	I-protein
can	O
serve	O
as	O
a	O
transcriptional	B-protein
repressor	I-protein
.	O

Signal	O
transduction	O
by	O
DR3	B-protein
,	O
a	O
death	B-protein
domain-containing	I-protein
receptor	I-protein
related	O
to	O
TNFR-1	B-protein
and	O
CD95	B-protein
.	O

Tumor	B-protein
necrosis	I-protein
factor	I-protein
receptor-1	I-protein
(	O
TNFR-1	B-protein
)	O
and	O
CD95	B-protein
(	O
also	O
called	O
Fas	B-protein
or	O
APO-1	B-protein
)	O
are	O
cytokine	B-protein
receptors	I-protein
that	O
engage	O
the	O
apoptosis	O
pathway	O
through	O
a	O
region	O
of	O
intracellular	O
homology	O
,	O
designated	O
the	O
``	O
death	B-protein
domain	I-protein
.	O
''	O
Another	O
death	B-protein
domain-containing	I-protein
member	I-protein
of	O
the	O
TNFR	B-protein
family	I-protein
,	O
death	B-protein
receptor	I-protein
3	I-protein
(	O
DR3	B-protein
)	O
,	O
was	O
identified	O
and	O
was	O
shown	O
to	O
induce	O
both	O
apoptosis	O
and	O
activation	O
of	O
nuclear	B-protein
factor	I-protein
kappaB	I-protein
.	O

Expression	O
of	O
DR3	B-protein
appears	O
to	O
be	O
restricted	O
to	O
tissues	O
enriched	O
in	O
lymphocytes	B-cell_type
.	O

DR3	B-protein
signal	O
transduction	O
is	O
mediated	O
by	O
a	O
complex	O
of	O
intracellular	B-protein
signaling	I-protein
molecules	I-protein
including	O
TRADD	B-protein
,	O
TRAF2	B-protein
,	O
FADD	B-protein
,	O
and	O
FLICE	B-protein
.	O

Thus	O
,	O
DR3	B-protein
likely	O
plays	O
a	O
role	O
in	O
regulating	O
lymphocyte	O
homeostasis	O
.	O

Differential	O
nuclear	O
localization	O
of	O
p50	B-protein
,	O
p52	B-protein
,	O
and	O
RelB	B-protein
proteins	O
in	O
human	B-cell_type
accessory	I-cell_type
cells	I-cell_type
of	O
the	O
immune	O
response	O
in	O
situ	O
.	O

The	O
Rel/NF-kappa	B-protein
B	I-protein
proteins	I-protein
,	O
p50	B-protein
,	O
p52	B-protein
,	O
p65	B-protein
,	O
c-Rel	B-protein
,	O
and	O
RelB	B-protein
,	O
constitute	O
a	O
family	O
of	O
transcription	B-protein
factors	I-protein
involved	O
in	O
the	O
positive	O
regulation	O
of	O
a	O
variety	O
of	O
genes	O
during	O
the	O
immune	O
response	O
.	O

Recently	O
,	O
it	O
has	O
been	O
shown	O
that	O
RelB	B-protein
knockout	O
mice	O
have	O
no	O
dendritic	B-cell_type
cells	I-cell_type
(	O
DC	B-cell_type
)	O
.	O

An	O
overexpression	O
of	O
p50	B-protein
has	O
been	O
described	O
in	O
follicular	B-cell_type
dendritic	I-cell_type
cells	I-cell_type
(	O
FDC	B-cell_type
)	O
.	O

A	O
constitutive	O
NF-kappa	B-protein
B	I-protein
activity	O
has	O
been	O
reported	O
in	O
mature	B-cell_type
macrophages	I-cell_type
.	O

This	O
led	O
to	O
the	O
hypothesis	O
that	O
some	O
of	O
the	O
Rel/NF-kappa	B-protein
B	I-protein
proteins	I-protein
were	O
key	O
nuclear	B-protein
factors	I-protein
in	O
functions	O
of	O
accessory	B-cell_type
cells	I-cell_type
of	O
the	O
immune	O
response	O
.	O

Therefore	O
,	O
we	O
investigated	O
in	O
situ	O
the	O
nuclear	O
localization	O
of	O
Rel/NF-kappa	B-protein
B	I-protein
proteins	I-protein
in	O
accessory	B-cell_type
cells	I-cell_type
of	O
the	O
immune	O
system	O
by	O
immunohistochemistry	O
and	O
double	O
labeling	O
by	O
immunofluorescence	O
from	O
five	O
normal	O
human	O
tonsils	O
and	O
five	O
lymph	O
nodes	O
with	O
follicular	O
hyperplasia	O
.	O

Nuclear	O
p65	B-protein
and	O
c-Rel	B-protein
proteins	O
were	O
found	O
in	O
all	O
cell	O
types	O
including	O
lymphocytes	B-cell_type
.	O

In	O
germinal	O
centers	O
GC	O
,	O
p50	B-protein
,	O
p52	B-protein
,	O
and	O
RelB	B-protein
were	O
found	O
in	O
the	O
nuclei	O
of	O
FDC	B-cell_type
only	O
and	O
were	O
not	O
detected	O
in	O
the	O
nuclei	O
of	O
CD68+	B-cell_line
cells	I-cell_line
.	O

In	O
T	O
cell	O
areas	O
,	O
p50	B-protein
,	O
p52	B-protein
,	O
and	O
RelB	B-protein
were	O
found	O
in	O
the	O
nuclei	O
of	O
HLA-DR+	B-cell_line
cells	I-cell_line
with	O
an	O
antigen-presenting	O
cell	O
(	O
APC	O
)	O
morphology	O
.	O

p52	B-protein
and	O
RelB	B-protein
were	O
detected	O
in	O
the	O
nuclei	O
in	O
both	O
CD1a+	B-cell_line
and	O
CD68+	B-cell_line
cells	I-cell_line
from	O
the	O
T	O
cell	O
area	O
,	O
whereas	O
p50	B-protein
was	O
found	O
only	O
in	O
CD68-	B-cell_line
and	I-cell_line
CD1a-	I-cell_line
cells	I-cell_line
.	O

Cells	O
with	O
nuclear	O
p50	B-protein
were	O
negative	O
for	O
the	O
CD38	B-protein
,	O
CD20	B-protein
and	O
CD2	B-protein
markers	I-protein
.	O

These	O
results	O
show	O
that	O
,	O
physiologically	O
,	O
high	O
levels	O
of	O
nuclear	O
of	O
p50	B-protein
,	O
p52	B-protein
and	O
RelB	B-protein
are	O
restricted	O
to	O
accessory	B-cell_type
cells	I-cell_type
of	O
the	O
immune	O
system	O
,	O
which	O
include	O
FDC	B-cell_type
in	O
GC	O
,	O
and	O
DC	B-cell_type
and	O
macrophages	O
in	O
the	O
T	O
cell	O
zone	O
,	O
that	O
specialized	O
scavenger	B-cell_type
macrophages	I-cell_type
from	O
GC	B-cell_type
do	O
not	O
have	O
detectable	O
levels	O
of	O
p52	B-protein
and	O
RelB	B-protein
,	O
whereas	O
macrophages	B-cell_type
from	O
the	O
T	O
cell	O
area	O
,	O
known	O
to	O
present	O
the	O
antigen	O
to	O
T	B-cell_type
cells	I-cell_type
,	O
do	O
have	O
both	O
nuclear	O
p52	B-protein
and	O
RelB	B-protein
,	O
and	O
that	O
in	O
the	O
T	O
cell	O
zone	O
,	O
p52	B-protein
and	O
RelB	B-protein
are	O
located	O
in	O
nuclei	O
of	O
both	O
CD1a+	B-cell_line
,	O
CD68+	B-cell_line
or	O
both	O
,	O
cells	O
APC	B-cell_type
,	O
whereas	O
p50	B-protein
is	O
restricted	O
to	O
CD1a-	B-cell_type
and	O
CD68-	B-cell_type
APC	I-cell_type
.	O

The	O
different	O
patterns	O
of	O
p50	B-protein
,	O
p52	B-protein
and	O
RelB	B-protein
protein	O
nuclear	O
localization	O
may	O
provide	O
insight	O
into	O
their	O
different	O
roles	O
during	O
the	O
immune	O
response	O
in	O
vivo	O
.	O

Tyrosines	O
113	O
,	O
128	O
,	O
and	O
145	O
of	O
SLP-76	B-protein
are	O
required	O
for	O
optimal	O
augmentation	O
of	O
NFAT	B-DNA
promoter	I-DNA
activity	O
.	O

SLP-76	B-protein
(	O
SH2	B-protein
domain	I-protein
leukocyte	I-protein
protein	I-protein
of	O
76	O
kDa	O
)	O
is	O
a	O
recently	O
identified	O
substrate	O
of	O
the	O
TCR-stimulated	B-protein
protein	I-protein
tyrosine	B-protein
kinases	I-protein
that	O
functions	O
in	O
the	O
signal	O
transduction	O
cascade	O
linking	O
the	O
TCR	B-protein
with	O
IL-2	B-protein
gene	O
expression	O
.	O

In	O
this	O
report	O
,	O
we	O
demonstrate	O
that	O
engagement	O
of	O
the	O
TCR	B-protein
results	O
in	O
tyrosine	O
phosphorylation	O
of	O
SLP-76	B-protein
in	O
its	O
amino-terminal	B-protein
acidic	I-protein
region	I-protein
.	O

Two	O
tyrosines	O
(	O
Y113	O
and	O
Y128	O
)	O
fall	O
within	O
an	O
identical	O
five	O
amino-acid	O
motif	O
and	O
are	O
shown	O
to	O
be	O
phosphorylated	O
upon	O
TCR	B-protein
ligation	O
.	O

Although	O
mutation	O
of	O
either	O
Y113	O
and	O
Y128	O
has	O
a	O
minimal	O
effect	O
on	O
SLP-76	B-protein
function	O
,	O
mutation	O
of	O
both	O
residues	O
decreases	O
significantly	O
the	O
ability	O
of	O
SLP-76	B-protein
to	O
promote	O
T	O
cell	O
activation	O
.	O

A	O
third	O
tyrosine	O
within	O
the	O
amino-terminal	B-protein
region	I-protein
(	O
Y145	O
)	O
appears	O
to	O
be	O
the	O
most	O
important	O
for	O
optimal	O
SLP-76	B-protein
function	O
,	O
as	O
altering	O
it	O
alone	O
to	O
phenylalanine	O
has	O
a	O
potent	O
impact	O
on	O
SLP-76	B-protein
augmentation	O
of	O
NFAT	B-DNA
promoter	I-DNA
activity	O
.	O

Human	B-DNA
interferon	I-DNA
regulatory	I-DNA
factor	I-DNA
2	I-DNA
gene	I-DNA
.	O

Intron-exon	O
organization	O
and	O
functional	O
analysis	O
of	O
5'-flanking	B-DNA
region	I-DNA
.	O

Interferon	B-protein
regulatory	I-protein
factor	I-protein
2	I-protein
(	O
IRF-2	B-protein
)	O
is	O
a	O
transcriptional	B-protein
regulatory	I-protein
protein	I-protein
that	O
terminates	O
interferon	B-protein
beta	I-protein
expression	O
initiated	O
by	O
interferon	B-protein
regulatory	I-protein
factor	I-protein
1	I-protein
.	O

In	O
this	O
study	O
,	O
we	O
isolated	O
the	O
genomic	B-DNA
DNA	I-DNA
for	O
human	B-DNA
IRF-2	I-DNA
gene	I-DNA
,	O
determined	O
the	O
intron-exon	O
structure	O
of	O
the	O
human	B-DNA
IRF-2	I-DNA
gene	I-DNA
,	O
mapped	O
the	O
major	B-DNA
transcription	I-DNA
initiation	I-DNA
site	I-DNA
,	O
identified	O
a	O
number	O
of	O
potential	O
regulatory	O
elements	O
in	O
the	O
5'-flanking	B-DNA
region	I-DNA
,	O
and	O
localized	O
the	O
IRF-2	B-DNA
gene	I-DNA
on	O
human	B-DNA
chromosome	I-DNA
4	I-DNA
.	O

The	O
IRF-2	B-protein
promoter	B-DNA
region	I-DNA
contains	O
a	O
CpG	O
island	O
,	O
with	O
several	O
GC	B-DNA
boxes	I-DNA
,	O
a	O
putative	O
NF-kappa	B-DNA
B-binding	I-DNA
site	I-DNA
,	O
and	O
a	O
CAAT	B-DNA
box	I-DNA
,	O
but	O
no	O
TATA	B-DNA
box	I-DNA
.	O

When	O
the	O
promoter	B-DNA
region	I-DNA
was	O
linked	O
with	O
a	O
heterologous	B-DNA
reporter	I-DNA
gene	I-DNA
,	O
we	O
found	O
that	O
the	O
promoter	B-DNA
region	I-DNA
is	O
inducible	O
by	O
both	O
interferons	B-protein
(	O
interferon-alpha	B-protein
and	I-protein
-gamma	I-protein
)	O
and	O
interferon	B-protein
regulatory	I-protein
factor	I-protein
1	I-protein
.	O

The	O
region	O
which	O
induced	O
these	O
inductions	O
was	O
identified	O
as	O
being	O
confined	O
to	O
40	B-DNA
nucleotides	I-DNA
5	I-DNA
'	I-DNA
to	O
the	O
major	B-DNA
transcriptional	I-DNA
initiation	I-DNA
site	I-DNA
by	O
testing	O
a	O
series	O
of	O
clones	O
with	O
truncated	B-DNA
promoter	I-DNA
of	O
IRF-2	B-protein
.	O

This	O
region	O
contains	O
elements	O
which	O
are	O
shared	O
with	O
the	O
transcriptional	B-DNA
enhancers	I-DNA
of	O
other	O
genes	O
including	O
interferon	B-protein
regulatory	I-protein
factor	I-protein
1	I-protein
,	O
interferon	B-protein
beta	I-protein
,	O
and	O
interferon-inducible	B-DNA
genes	I-DNA
.	O

These	O
data	O
suggest	O
that	O
interferon	B-protein
regulatory	I-protein
factor	I-protein
1	I-protein
not	O
only	O
triggers	O
the	O
activation	O
of	O
the	O
interferon	B-protein
signal	O
transduction	O
pathway	O
,	O
but	O
also	O
may	O
play	O
a	O
role	O
in	O
limiting	O
the	O
duration	O
of	O
this	O
response	O
by	O
activating	O
the	O
transcription	O
of	O
IRF-2	B-protein
.	O

Interferon	B-protein
alpha	I-protein
selectively	O
affects	O
expression	O
of	O
the	O
human	B-protein
myeloid	I-protein
cell	I-protein
nuclear	I-protein
differentiation	I-protein
antigen	I-protein
in	O
late	B-cell_type
stage	I-cell_type
cells	I-cell_type
in	O
the	O
monocytic	B-cell_type
but	O
not	O
the	O
granulocytic	B-cell_type
lineage	I-cell_type
.	O

The	O
human	B-protein
myeloid	I-protein
cell	I-protein
nuclear	I-protein
differentiation	I-protein
antigen	I-protein
(	O
MNDA	B-protein
)	O
is	O
expressed	O
constitutively	O
in	O
cells	O
of	O
the	O
myeloid	B-cell_type
lineage	I-cell_type
,	O
appearing	O
in	O
myeloblast	B-cell_type
cells	I-cell_type
in	O
some	O
cases	O
of	O
acute	O
myeloid	O
leukemia	O
and	O
consistently	O
being	O
detected	O
in	O
promyelocyte	B-cell_type
stage	I-cell_type
cells	I-cell_type
as	O
well	O
as	O
in	O
all	O
later	B-cell_type
stage	I-cell_type
cells	I-cell_type
including	O
peripheral	B-cell_type
blood	I-cell_type
monocytes	I-cell_type
and	O
granulocytes	B-cell_type
.	O

The	O
human	B-cell_line
myeloid	I-cell_line
leukemia	I-cell_line
cell	I-cell_line
lines	I-cell_line
,	O
HL-60	B-cell_line
,	O
U937	B-cell_line
,	O
and	O
THP-1	B-cell_line
,	O
express	O
similar	O
levels	O
of	O
immunochemically	O
detectable	O
MNDA	B-protein
.	O

Although	O
,	O
the	O
level	O
of	O
MNDA	B-RNA
mRNA	I-RNA
in	O
primary	B-cell_type
monocytes	I-cell_type
is	O
very	O
low	O
it	O
was	O
up-regulated	O
at	O
6	O
h	O
following	O
the	O
addition	O
of	O
interferon	B-protein
alpha	I-protein
.	O

The	O
effect	O
of	O
interferon	B-protein
alpha	I-protein
on	O
the	O
MNDA	B-RNA
mRNA	I-RNA
is	O
also	O
observed	O
in	O
the	O
cell	B-cell_line
lines	I-cell_line
HL-60	B-cell_line
,	O
U937	B-cell_line
,	O
and	O
THP-1	B-cell_line
.	O

The	O
MNDA	B-RNA
mRNA	I-RNA
level	O
in	O
primary	B-cell_type
granulocytes	I-cell_type
was	O
unaffected	O
by	O
addition	O
of	O
interferon	B-protein
alpha	I-protein
and	O
other	O
agents	O
including	O
interferon	B-protein
gamma	I-protein
,	O
endotoxin	B-protein
,	O
poly	B-protein
(	I-protein
I	I-protein
)	I-protein
.poly	I-protein
(	I-protein
C	I-protein
)	I-protein
,	O
and	O
FMLP	B-protein
.	O

The	O
MNDA	B-RNA
mRNA	I-RNA
level	O
in	O
the	O
myeloid	B-cell_line
cell	I-cell_line
lines	I-cell_line
was	O
also	O
unaffected	O
by	O
the	O
latter	O
four	O
agents	O
.	O

Induction	O
of	O
differentiation	O
in	O
the	O
myeloid	B-cell_line
cell	I-cell_line
lines	I-cell_line
with	O
phorbol	O
ester	O
induces	O
monocyte	O
differentiation	O
which	O
was	O
accompanied	O
by	O
a	O
decrease	O
in	O
MNDA	B-RNA
mRNA	I-RNA
level	O
.	O

This	O
reduced	O
level	O
of	O
mRNA	B-RNA
could	O
then	O
be	O
elevated	O
with	O
subsequent	O
interferon	B-protein
alpha	I-protein
treatment	O
.	O

The	O
effects	O
of	O
phorbol	O
ester	O
on	O
MNDA	B-RNA
mRNA	I-RNA
appeared	O
to	O
be	O
associated	O
with	O
induced	O
differentiation	O
since	O
inhibiting	O
cell	O
proliferation	O
did	O
not	O
alter	O
the	O
level	O
of	O
MNDA	B-RNA
mRNA	I-RNA
and	O
cell	O
cycle	O
variation	O
in	O
MNDA	B-RNA
mRNA	I-RNA
levels	O
were	O
not	O
observed	O
.	O

The	O
ability	O
of	O
interferon	B-protein
alpha	I-protein
to	O
up-regulate	O
MNDA	B-RNA
mRNA	I-RNA
in	O
phorbol	O
ester	O
treated	O
myeloid	B-cell_line
cell	I-cell_line
lines	I-cell_line
is	O
consistent	O
with	O
the	O
observations	O
made	O
in	O
primary	B-cell_type
monocytes	I-cell_type
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Involvement	O
of	O
transcription	B-protein
factor	I-protein
YB-1	B-protein
in	O
human	O
T-cell	O
lymphotropic	O
virus	O
type	O
I	O
basal	O
gene	O
expression	O
.	O

Sequences	O
which	O
control	O
basal	O
human	O
T-cell	O
lymphotropic	O
virus	O
type	O
I	O
(	O
HTLV-I	O
)	O
transcription	O
likely	O
play	O
an	O
important	O
role	O
in	O
initiation	O
and	O
maintenance	O
of	O
virus	O
replication	O
.	O

We	O
previously	O
identified	O
and	O
analyzed	O
a	O
45-nucleotide	B-DNA
sequence	I-DNA
(	O
downstream	B-DNA
regulatory	I-DNA
element	I-DNA
1	I-DNA
[	O
DRE	B-DNA
1	I-DNA
]	O
)	O
,	O
+195	B-DNA
to	I-DNA
+240	I-DNA
,	O
at	O
the	O
boundary	O
of	O
the	O
R/U5	B-DNA
region	I-DNA
of	O
the	O
long	B-DNA
terminal	I-DNA
repeat	I-DNA
which	O
is	O
required	O
for	O
HTLV-I	O
basal	O
transcription	O
.	O

We	O
identified	O
a	O
protein	O
,	O
p37	O
,	O
which	O
specifically	O
bound	O
to	O
DRE	B-DNA
1	I-DNA
.	O

An	O
affinity	O
column	O
fraction	O
,	O
containing	O
p37	B-protein
,	O
stimulated	O
HTLV-I	O
transcription	O
approximately	O
12-fold	O
in	O
vitro	O
.	O

We	O
now	O
report	O
the	O
identification	O
of	O
a	O
cDNA	B-DNA
clone	I-DNA
(	O
15B-7	B-DNA
)	O
,	O
from	O
a	O
Jurkat	B-DNA
expression	I-DNA
library	I-DNA
,	O
that	O
binds	O
specifically	O
to	O
the	O
DRE	B-DNA
1	I-DNA
regulatory	I-DNA
sequence	I-DNA
.	O

Binding	O
of	O
the	O
cDNA	B-protein
fusion	I-protein
protein	I-protein
,	O
similarly	O
to	O
the	O
results	O
obtained	O
with	O
purified	O
Jurkat	O
protein	O
,	O
was	O
decreased	O
by	O
introduction	O
of	O
site-specific	O
mutations	O
in	O
the	O
DRE	B-DNA
1	I-DNA
regulatory	I-DNA
sequence	I-DNA
.	O

In	O
vitro	O
transcription	O
and	O
translation	O
of	O
15B-7	B-DNA
cDNA	I-DNA
produced	O
a	O
fusion	B-protein
protein	I-protein
which	O
bound	O
specifically	O
to	O
the	O
HTLV-I	O
+195	O
to	O
+240	O
oligonucleotide	O
.	O

The	O
partial	B-DNA
cDNA	I-DNA
encodes	O
a	O
protein	O
which	O
is	O
homologous	O
to	O
the	O
C-terminal	B-protein
196	I-protein
amino	I-protein
acids	I-protein
of	O
the	O
36-kDa	B-protein
transcription	I-protein
factor	I-protein
,	O
YB-1	B-protein
.	O

Cotransfection	O
of	O
a	O
YB-1	B-DNA
expression	I-DNA
plasmid	I-DNA
increases	O
HTLV-I	O
basal	O
transcription	O
approximately	O
14-fold	O
in	O
Jurkat	B-cell_line
T	I-cell_line
lymphocytes	I-cell_line
.	O

On	O
the	O
basis	O
of	O
the	O
molecular	O
weight	O
,	O
DNA-binding	O
characteristics	O
,	O
and	O
in	O
vivo	O
transactivation	O
activity	O
,	O
we	O
suggest	O
that	O
the	O
previously	O
identified	O
DRE	B-DNA
1	I-DNA
-binding	O
protein	O
,	O
p37	B-protein
,	O
is	O
YB-1	B-protein
.	O

Changes	O
in	O
triiodothyronine	O
(	O
T3	O
)	O
mononuclear	O
leukocyte	O
receptor	O
kinetics	O
after	O
T3	O
administration	O
and	O
multiple	O
cold-air	O
exposures	O
.	O

Repeated	O
cold-air	O
exposures	O
increase	O
human	O
triiodothyronine	O
(	O
T3	O
)	O
plasma	O
clearance	O
rates	O
.	O

To	O
study	O
the	O
response	O
of	O
the	O
nuclear	B-protein
T3	I-protein
receptor	I-protein
(	O
NT3R	B-protein
)	O
in	O
this	O
condition	O
,	O
binding	O
characteristics	O
were	O
analyzed	O
in	O
human	B-cell_type
mononuclear	I-cell_type
leukocytes	I-cell_type
(	O
MNL	B-cell_type
)	O
.	O

In	O
addition	O
,	O
we	O
supplemented	O
one	O
group	O
of	O
individuals	O
with	O
a	O
daily	O
oral	O
replacement	O
dose	O
of	O
T3	O
to	O
isolate	O
the	O
influence	O
of	O
serum	O
thyroxine	O
(	O
T4	O
)	O
and	O
thyrotropin	O
(	O
TSH	O
)	O
levels	O
on	O
receptor	O
kinetics	O
.	O

The	O
subjects	O
were	O
exposed	O
to	O
cold	O
air	O
(	O
4	O
degrees	O
C	O
)	O
twice/d	O
,	O
30	O
min/exposure	O
,	O
for	O
a	O
total	O
of	O
80	O
exposures	O
.	O

The	O
T3-subjects	O
received	O
placebo	O
[	O
n	O
=	O
8	O
]	O
and	O
the	O
T3	O
+	O
subjects	O
received	O
T3	O
(	O
30	O
micrograms/d	O
)	O
[	O
n	O
=	O
8	O
]	O
in	O
a	O
double-blind	O
fashion	O
.	O

Mononuclear	B-cell_type
leukocytes	I-cell_type
were	O
isolated	O
from	O
peripheral	O
blood	O
before	O
the	O
cold	O
exposure	O
and	O
drug	O
regimen	O
began	O
,	O
and	O
then	O
after	O
every	O
20	O
exposures	O
.	O

The	O
dissociation	O
constant	O
(	O
Kd	O
)	O
and	O
maximum	O
binding	O
capacity	O
(	O
MBC	O
)	O
of	O
the	O
NT3R	B-protein
values	O
were	O
log	O
transformed	O
to	O
minimize	O
between-subject	O
variability	O
.	O

In	O
the	O
T3+	O
group	O
,	O
serum	O
total	O
thyroxine	O
(	O
TT4	O
)	O
,	O
free	O
T4	O
(	O
FT4	O
)	O
,	O
and	O
TSH	O
were	O
approx	O
50	O
%	O
lower	O
than	O
both	O
basal	O
and	O
T3-values	O
.	O

The	O
log10Kd	O
increased	O
0.304	O
+/-	O
0.139	O
(	O
p	O
<	O
0.04	O
)	O
and	O
the	O
log10MBC	O
increased	O
0.49	O
+/-	O
0.10	O
(	O
p	O
<	O
0.001	O
)	O
in	O
the	O
T3+	O
subjects	O
compared	O
to	O
baseline	O
.	O

This	O
change	O
in	O
MBC	O
represents	O
a	O
311	O
%	O
increase	O
in	O
the	O
MBC	O
over	O
baseline	O
and	O
a	O
fivefold	O
increase	O
over	O
placebo-treated	O
subjects	O
.	O

The	O
T3	O
-group	O
showed	O
no	O
change	O
in	O
MBC	O
over	O
the	O
study	O
.	O

These	O
results	O
describe	O
for	O
the	O
first	O
time	O
the	O
rapid	O
modulation	O
of	O
the	O
NT3R	B-protein
in	O
response	O
to	O
the	O
combined	O
influence	O
of	O
cold	O
exposure	O
and	O
reduced	O
circulating	O
T4	O
and	O
TSH	O
.	O

HIV-1	B-DNA
LTR	I-DNA
activity	O
in	O
human	B-cell_line
CD40-activated	I-cell_line
B	I-cell_line
lymphocytes	I-cell_line
is	O
dependent	O
on	O
NF-kappaB	B-protein
.	O

CD40-stimulated	B-cell_line
human	I-cell_line
B	I-cell_line
lymphocytes	I-cell_line
are	O
highly	O
permissive	O
to	O
a	O
productive	O
infection	O
by	O
the	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
.	O

In	O
these	O
cells	O
,	O
nuclear	B-protein
factors	I-protein
involved	O
in	O
activation	O
of	O
the	O
HIV-1	B-DNA
LTR	I-DNA
,	O
which	O
contains	O
the	O
transcriptional	B-DNA
control	I-DNA
elements	I-DNA
of	O
the	O
virus	O
,	O
are	O
unknown	O
.	O

Transient	O
expression	O
assays	O
with	O
plasmids	O
containing	O
deleted	O
parts	O
of	O
the	O
LTR	B-DNA
region	I-DNA
linked	O
to	O
a	O
reporter	O
gene	O
showed	O
that	O
the	O
NF-kappaB	B-DNA
binding	I-DNA
site	I-DNA
was	O
essential	O
for	O
HIV-1	B-DNA
LTR	I-DNA
activity	O
in	O
CD40-stimulated	B-cell_line
B	I-cell_line
lymphocytes	I-cell_line
.	O

In	O
addition	O
,	O
electrophoretic	O
mobility	O
shift	O
and	O
supershift	O
assays	O
revealed	O
that	O
important	O
NF-kappaB	B-protein
binding	O
activity	O
composed	O
of	O
at	O
least	O
p50	B-protein
,	O
p65	B-protein
,	O
and	O
c-Rel	B-protein
NF-kappaB	B-protein
subunits	I-protein
was	O
present	O
in	O
nuclei	O
of	O
CD40-stimulated	B-cell_line
B	I-cell_line
cells	I-cell_line
.	O

These	O
results	O
confirm	O
at	O
a	O
molecular	O
level	O
the	O
ability	O
of	O
HIV-1	O
to	O
replicate	O
in	O
B	B-cell_type
cells	I-cell_type
and	O
that	O
this	O
activity	O
is	O
strongly	O
associated	O
with	O
NF-kappaB	B-protein
.	O

Sequence	O
analysis	O
and	O
expression	O
in	O
cultured	B-cell_type
lymphocytes	I-cell_type
of	O
the	O
human	O
FOSB	B-DNA
gene	I-DNA
(	O
G0S3	B-DNA
)	O
.	O

G0S3	B-DNA
is	O
a	O
member	O
of	O
a	O
set	O
of	O
putative	B-DNA
G0/G1	I-DNA
switch	I-DNA
regulatory	I-DNA
genes	I-DNA
(	O
G0S	B-DNA
genes	I-DNA
)	O
selected	O
by	O
screening	O
cDNA	B-DNA
libraries	I-DNA
prepared	O
from	O
human	B-cell_type
blood	I-cell_type
mononuclear	I-cell_type
cells	I-cell_type
cultured	O
for	O
2	O
hr	O
with	O
lectin	B-protein
and	O
cycloheximide	O
.	O

The	O
sequence	O
shows	O
high	O
homology	O
with	O
the	O
murine	B-DNA
FOSB	I-DNA
gene	I-DNA
,	O
which	O
encodes	O
a	O
component	O
of	O
the	O
AP1	B-protein
transcriptional	I-protein
regulator	I-protein
.	O

Comparison	O
of	O
cDNA	B-DNA
and	O
genomic	O
sequences	O
reveals	O
a	O
4-exon	B-DNA
structure	I-DNA
characteristic	O
of	O
the	O
FOS	B-DNA
family	I-DNA
of	I-DNA
genes	I-DNA
.	O

Freshly	O
isolated	O
cells	O
show	O
high	O
levels	O
of	O
FOSB/G0S3	B-RNA
and	I-RNA
FOS/G0S7	I-RNA
mRNAs	I-RNA
,	O
which	O
decline	O
rapidly	O
during	O
incubation	O
in	O
culture	O
medium	O
.	O

The	O
kinetics	O
of	O
expression	O
suggest	O
that	O
the	O
high	O
initial	O
levels	O
are	O
caused	O
by	O
the	O
isolation	O
procedure	O
,	O
and	O
do	O
not	O
reflect	O
constitutive	O
expression	O
.	O

In	O
cells	O
preincubated	O
for	O
a	O
day	O
,	O
levels	O
of	O
FOS	B-RNA
mRNA	I-RNA
reach	O
a	O
maximum	O
20	O
min	O
after	O
the	O
addition	O
of	O
lectin	B-protein
and	O
decline	O
to	O
control	O
levels	O
over	O
the	O
next	O
3	O
hr	O
.	O

Levels	O
of	O
FOSB	B-RNA
mRNA	I-RNA
reach	O
a	O
maximum	O
40	O
min	O
after	O
the	O
addition	O
of	O
lectin	B-protein
and	O
decline	O
to	O
control	O
levels	O
over	O
the	O
next	O
6	O
hr	O
.	O

In	O
freshly	O
isolated	O
cells	O
,	O
both	O
FOS	B-RNA
and	I-RNA
FOSB	I-RNA
mRNAs	I-RNA
increase	O
dramatically	O
in	O
response	O
to	O
the	O
protein	O
synthesis	O
inhibitor	O
cycloheximide	O
.	O

In	O
preincubated	O
cells	O
,	O
the	O
cycloheximide	O
response	O
is	O
decreased	O
,	O
especially	O
in	O
the	O
case	O
of	O
FOSB	B-DNA
.	O

These	O
differences	O
in	O
expression	O
of	O
FOS	B-DNA
and	O
FOSB	B-DNA
suggest	O
different	O
roles	O
and	O
regulation	O
.	O

Regions	O
of	O
low	O
base	O
order-dependent	O
stem-loop	O
potential	O
in	O
the	O
region	O
of	O
the	O
gene	O
are	O
defined	O
.	O

These	O
indicate	O
where	O
base	O
order	O
has	O
been	O
adapted	O
for	O
purposes	O
other	O
than	O
stem-loop	O
stability	O
(	O
e.g.	O
,	O
encoding	O
proteins	O
or	O
gene	O
regulation	O
)	O
.	O

Regions	O
of	O
low	O
potential	O
in	O
a	O
68.5-kb	O
genomic	O
segment	O
containing	O
the	O
FOSB	B-DNA
gene	I-DNA
suggest	O
that	O
the	O
potential	O
may	O
help	O
locate	O
genes	O
in	O
uncharted	B-DNA
DNA	I-DNA
sequences	I-DNA
.	O

Susceptibility	O
to	O
natural	B-cell_type
killer	I-cell_type
cells	I-cell_type
and	O
down	O
regulation	O
of	O
MHC	B-protein
class	O
I	O
expression	O
in	O
adenovirus	B-cell_line
12	I-cell_line
transformed	I-cell_line
cells	I-cell_line
are	O
regulated	O
by	O
different	O
E1A	B-DNA
domains	I-DNA
.	O

All	O
human	O
adenoviruses	O
transform	O
rodent	B-cell_type
cells	I-cell_type
in	O
vitro	O
,	O
but	O
only	O
cells	O
transformed	O
by	O
serotypes	O
belonging	O
to	O
subgroups	O
A	O
(	O
Ad12	O
)	O
and	O
B	O
(	O
Ad3	O
)	O
are	O
tumorigenic	O
for	O
immunocompetent	O
animals	O
.	O

In	O
these	O
cells	O
,	O
the	O
expression	O
of	O
MHC-class	B-protein
I	I-protein
antigens	I-protein
is	O
repressed	O
and	O
might	O
allow	O
them	O
to	O
escape	O
from	O
recognition	O
by	O
cytotoxic	B-cell_type
T	I-cell_type
lymphocytes	I-cell_type
(	O
CTL	B-cell_type
)	O
and	O
to	O
develop	O
in	O
tumor	O
.	O

Furthermore	O
,	O
these	O
cell	B-cell_line
lines	I-cell_line
appear	O
resistant	O
to	O
lysis	O
by	O
natural	B-cell_type
killer	I-cell_type
(	I-cell_type
NK	I-cell_type
)	I-cell_type
cells	I-cell_type
.	O

To	O
determine	O
the	O
E1A	B-DNA
domain	I-DNA
(	O
s	O
)	O
responsible	O
for	O
these	O
properties	O
several	O
cell	B-cell_line
lines	I-cell_line
were	O
created	O
by	O
transforming	O
baby	B-cell_line
rat	I-cell_line
kidney	I-cell_line
(	I-cell_line
BRK	I-cell_line
)	I-cell_line
cells	I-cell_line
with	O
a	O
set	O
of	O
plasmids	B-DNA
expressing	O
different	O
Ad2/Ad12	B-protein
hybrid	I-protein
E1A	I-protein
gene	I-protein
products	I-protein
.	O

The	O
MHC	B-DNA
class	I-DNA
1	I-DNA
gene	I-DNA
expression	O
was	O
inhibited	O
in	O
cells	O
expressing	O
the	O
Ad12	B-protein
13S	I-protein
mRNA	I-protein
product	I-protein
and	O
in	O
cells	O
transformed	O
with	O
Ad2/Ad12	B-protein
hybrid	I-protein
E1A	I-protein
gene	I-protein
product	I-protein
harboring	O
the	O
C-terminal	B-protein
part	I-protein
of	O
the	O
conserved	B-DNA
region	I-DNA
(	I-DNA
CR	I-DNA
)	I-DNA
3	I-DNA
of	O
Ad12	O
.	O

Susceptibility	O
of	O
these	O
transformed	O
cell	B-cell_line
lines	I-cell_line
to	O
NK	B-cell_type
cells	I-cell_type
was	O
determined	O
by	O
cytolytic	O
assays	O
.	O

The	O
results	O
obtained	O
suggest	O
that	O
two	O
Ad12	B-DNA
E1A	I-DNA
domains	I-DNA
are	O
required	O
to	O
induce	O
resistance	O
of	O
the	O
cell	B-cell_line
lines	I-cell_line
to	O
NK	B-cell_type
cells	I-cell_type
.	O

Cell	O
specific	O
expression	O
of	O
human	B-DNA
Bruton	I-DNA
's	I-DNA
agammaglobulinemia	I-DNA
tyrosine	I-DNA
kinase	I-DNA
gene	I-DNA
(	O
Btk	B-protein
)	O
is	O
regulated	O
by	O
Sp1-	B-protein
and	O
Spi-1/PU.1-family	B-protein
members	I-protein
.	O

Bruton	B-protein
's	I-protein
agammaglobulinemia	I-protein
tyrosine	I-protein
kinase	I-protein
(	O
Btk	B-protein
)	O
is	O
a	O
cytoplasmic	B-protein
tyrosine	I-protein
kinase	I-protein
involved	O
in	O
the	O
human	O
disease	O
X-linked	O
agammaglobulinemia	O
(	O
XLA	O
)	O
.	O

The	O
gene	O
is	O
expressed	O
in	O
all	O
hematopoietic	B-cell_type
cells	I-cell_type
with	O
the	O
exception	O
of	O
T-cells	B-cell_type
and	O
plasma	B-cell_type
cells	I-cell_type
.	O

For	O
this	O
expression	O
pattern	O
the	O
first	O
280	B-DNA
bp	I-DNA
upstream	I-DNA
of	O
the	O
major	B-DNA
transcriptional	I-DNA
start	I-DNA
site	I-DNA
seems	O
to	O
be	O
sufficient	O
.	O

In	O
vitro	O
footprinting	O
analysis	O
within	O
this	O
part	O
of	O
the	O
promoter	B-DNA
revealed	O
two	O
Sp1	B-DNA
binding	I-DNA
sites	I-DNA
as	O
well	O
as	O
a	O
PU-box	B-DNA
.	O

The	O
transcription	B-protein
factor	I-protein
Spi-1/PU.1	B-protein
as	O
well	O
as	O
the	O
closely	O
related	O
factor	O
Spi-B	B-protein
bound	O
to	O
the	O
PU-box	B-DNA
in	O
B-cells	O
.	O

In	O
the	O
erythroleukemia	B-cell_line
cell	I-cell_line
line	I-cell_line
K562	I-cell_line
,	O
due	O
to	O
the	O
absence	O
of	O
Spi-B	B-protein
,	O
only	O
PU.1	B-protein
bound	O
to	O
the	O
Btk	B-DNA
promoter	I-DNA
.	O

Mutation	O
of	O
either	O
site	O
reduced	O
the	O
expression	O
in	O
transient	O
transfection	O
experiments	O
.	O

However	O
,	O
mutation	O
of	O
the	O
PU	B-DNA
box	I-DNA
had	O
no	O
effect	O
in	O
the	O
T-cell	B-cell_line
line	I-cell_line
Jurkat	I-cell_line
,	O
where	O
none	O
of	O
the	O
Spi-1	B-protein
family	I-protein
members	I-protein
is	O
expressed	O
.	O

In	O
addition	O
Spi-B	B-protein
as	O
well	O
as	O
PU.1	B-protein
were	O
able	O
to	O
transactivate	O
Btk	B-protein
expression	O
.	O

In	O
fetal	O
liver	O
of	O
PU.1-/-	O
mice	O
,	O
which	O
lack	O
lymphoid	B-cell_type
and	I-cell_type
myeloid	I-cell_type
cells	I-cell_type
,	O
expression	O
of	O
Btk	B-protein
was	O
reduced	O
two-	O
to	O
threefold	O
but	O
not	O
abolished	O
.	O

Collectively	O
this	O
study	O
shows	O
that	O
expression	O
of	O
the	O
Btk	B-DNA
gene	I-DNA
is	O
regulated	O
by	O
the	O
combined	O
action	O
of	O
Sp1-	B-protein
and	I-protein
PU.1-family	I-protein
members	I-protein
.	O

T	O
cell	O
response	O
to	O
Epstein-Barr	B-protein
virus	I-protein
transactivators	I-protein
in	O
chronic	O
rheumatoid	O
arthritis	O
.	O

Rheumatoid	O
arthritis	O
is	O
a	O
multistep	O
disorder	O
associated	O
with	O
autoimmune	O
features	O
of	O
yet	O
unknown	O
etiology	O
.	O

Implication	O
of	O
viruses	O
such	O
as	O
Epstein-Barr	O
virus	O
(	O
EBV	O
)	O
in	O
rheumatoid	O
arthritis	O
pathogenesis	O
has	O
been	O
suspected	O
on	O
the	O
basis	O
of	O
several	O
indirect	O
observations	O
,	O
but	O
thus	O
far	O
,	O
a	O
direct	O
link	O
between	O
EBV	O
and	O
rheumatoid	O
arthritis	O
has	O
not	O
been	O
provided	O
.	O

Here	O
we	O
show	O
that	O
a	O
large	O
fraction	O
of	O
T	B-cell_type
cells	I-cell_type
infiltrating	O
affected	O
joints	O
from	O
a	O
patient	O
with	O
chronic	O
rheumatoid	O
arthritis	O
recognizes	O
two	O
EBV	B-protein
transactivators	I-protein
(	O
BZLF1	B-protein
and	O
BMLF1	B-protein
)	O
in	O
a	O
major	B-protein
histocompatibility	I-protein
complex	I-protein
-restricted	O
fashion	O
.	O

Responses	O
to	O
these	O
EBV	B-protein
antigens	I-protein
by	O
synovial	O
lymphocytes	O
from	O
several	O
other	O
chronic	O
rheumatoid	O
arthritis	O
patients	O
were	O
readily	O
detectable	O
.	O

Thus	O
these	O
results	O
suggest	O
a	O
direct	O
contribution	O
of	O
EBV	O
to	O
chronic	O
rheumatoid	O
arthritis	O
pathogenesis	O
.	O

They	O
also	O
demonstrate	O
for	O
the	O
first	O
time	O
the	O
occurrence	O
of	O
T	O
cell	O
responses	O
against	O
EBV	B-protein
transactivating	I-protein
factors	I-protein
,	O
which	O
might	O
be	O
central	O
in	O
the	O
control	O
of	O
virus	O
reactivation	O
.	O

CD14	B-protein
-mediated	O
signal	O
pathway	O
of	O
Porphyromonas	O
gingivalis	O
lipopolysaccharide	O
in	O
human	B-cell_type
gingival	I-cell_type
fibroblasts	I-cell_type
.	O

Lipopolysaccharide	O
(	O
LPS	O
)	O
induces	O
expression	O
of	O
inflammatory	B-protein
cytokines	I-protein
in	O
monocytes/macrophages	B-cell_type
via	O
CD14	B-protein
,	O
one	O
of	O
the	O
LPS	B-protein
receptors	I-protein
,	O
which	O
is	O
expressed	O
predominantly	O
in	O
these	O
cells	O
.	O

It	O
has	O
been	O
demonstrated	O
that	O
Porphyromonas	O
gingivalis	O
LPS	O
(	O
P-LPS	O
)	O
also	O
is	O
able	O
to	O
induce	O
inflammatory	B-protein
cytokines	I-protein
in	O
human	B-cell_type
gingival	I-cell_type
fibroblasts	I-cell_type
.	O

Therefore	O
,	O
it	O
is	O
important	O
to	O
determine	O
whether	O
CD14	B-protein
is	O
expressed	O
in	O
gingival	B-cell_type
fibroblasts	I-cell_type
and	O
to	O
define	O
the	O
P-LPS-mediated	O
signal-transducing	B-protein
mechanism	O
in	O
the	O
cells	O
.	O

In	O
this	O
study	O
,	O
we	O
observed	O
unexpectedly	O
by	O
immunohistochemical	O
,	O
Western	O
blotting	O
(	O
immunoblotting	O
)	O
,	O
and	O
Northern	O
(	O
RNA	O
)	O
blotting	O
assays	O
that	O
CD14	B-protein
is	O
expressed	O
at	O
high	O
density	O
in	O
human	B-cell_type
gingival	I-cell_type
fibroblasts	I-cell_type
.	O

P-LPS-induced	O
expression	O
of	O
the	O
monocyte	B-DNA
chemoattractant	I-DNA
protein	I-DNA
1	I-DNA
(	I-DNA
MCP-1	I-DNA
)	I-DNA
gene	I-DNA
in	O
the	O
cells	O
was	O
inhibited	O
markedly	O
by	O
treatment	O
with	O
anti-human	O
CD14	B-protein
antibody	O
and	O
was	O
completely	O
inhibited	O
by	O
herbimycin	O
A	O
,	O
a	O
potent	O
inhibitor	O
of	O
tyrosine	B-protein
kinase	I-protein
.	O

The	O
inhibitor	O
also	O
dramatically	O
inhibited	O
monocyte	O
chemotactic	O
activity	O
of	O
and	O
MCP-1	B-protein
production	O
by	O
the	O
cells	O
.	O

Furthermore	O
,	O
P-LPS-induced	O
expression	O
of	O
the	O
MCP-1	B-DNA
gene	I-DNA
in	O
the	O
cells	O
also	O
was	O
blocked	O
by	O
inhibitors	O
of	O
two	O
transcription	B-protein
factors	I-protein
,	O
i.e.	O
,	O
curcumin	O
,	O
an	O
inhibitor	O
of	O
AP-1	B-protein
,	O
and	O
pyrolidine	O
dithiocarbamate	O
,	O
an	O
inhibitor	O
of	O
NF-kappaB	B-protein
.	O

Both	O
inhibitors	O
inhibited	O
monocyte	O
chemotactic	O
activity	O
in	O
the	O
culture	O
supernatant	O
of	O
P-LPS-treated	O
cells	O
.	O

Gel	O
shift	O
mobility	O
assay	O
showed	O
stimulation	O
of	O
the	O
AP-1	B-protein
and	O
NF-kappaB	B-protein
contents	O
in	O
P-LPS-treated	O
cells	O
.	O

This	O
study	O
is	O
the	O
first	O
to	O
demonstrate	O
the	O
expression	O
of	O
CD14	B-protein
in	O
human	B-cell_type
gingival	I-cell_type
fibroblasts	I-cell_type
and	O
to	O
show	O
that	O
the	O
signal-transducing	O
pathway	O
of	O
P-LPS	O
in	O
the	O
cells	O
is	O
mediated	O
by	O
CD14	B-protein
.	O

rel	B-protein
Is	O
rapidly	O
tyrosine-phosphorylated	O
following	O
granulocyte-colony	B-protein
stimulating	I-protein
factor	I-protein
treatment	O
of	O
human	O
neutrophils	O
.	O

Stimulation	O
of	O
neutrophils	B-cell_type
with	O
granulocyte-colony	B-protein
stimulating	I-protein
factor	I-protein
(	O
G-CSF	B-protein
)	O
results	O
in	O
an	O
enhanced	O
respiratory	O
burst	O
,	O
prolonged	O
survival	O
,	O
and	O
increased	O
tumor	O
cell	O
killing	O
.	O

The	O
effects	O
of	O
G-CSF	B-protein
are	O
mediated	O
by	O
binding	O
to	O
specific	O
,	O
high	O
affinity	B-protein
receptors	I-protein
.	O

G-CSF	B-protein
receptors	I-protein
lack	O
intrinsic	O
tyrosine	B-protein
kinase	I-protein
activity	O
,	O
but	O
activation	O
of	O
the	O
receptor	O
results	O
in	O
the	O
rapid	O
induction	O
of	O
tyrosine	O
kinase	O
activity	O
.	O

Antiphosphotyrosine	O
immunoblots	O
of	O
whole	O
cell	O
lysates	O
prepared	O
from	O
neutrophils	B-cell_type
show	O
that	O
the	O
G-CSF	B-protein
rapidly	O
induces	O
prominent	O
tyrosine	O
phosphorylation	O
of	O
a	O
protein	O
of	O
a	O
relative	O
molecular	O
mass	O
of	O
80	O
kDa	O
.	O

Using	O
monospecific	B-protein
antibodies	I-protein
,	O
the	O
80-kDa	O
tyrosine-phosphorylated	B-protein
protein	I-protein
has	O
been	O
shown	O
to	O
be	O
p80c-rel	B-protein
,	O
a	O
proto-oncogene	B-DNA
belonging	O
to	O
a	O
family	O
of	O
transcriptional	B-protein
regulators	I-protein
which	O
include	O
NF-kB	B-protein
.	O

The	O
induction	O
of	O
tyrosine	O
phosphorylation	O
of	O
p80c-rel	B-protein
was	O
unique	O
to	O
G-CSF	B-protein
in	O
that	O
granulocyte-macrophage	B-protein
colony	I-protein
stimulating	I-protein
factor	I-protein
which	O
also	O
stimulates	O
neutrophils	B-cell_type
and	O
induces	O
tyrosine	O
phosphorylation	O
does	O
not	O
result	O
in	O
tyrosine	O
phosphorylation	O
of	O
p80c-rel	B-protein
.	O

The	O
consequences	O
of	O
p80c-rel	B-protein
tyrosine	O
phosphorylation	O
are	O
not	O
yet	O
known	O
;	O
however	O
,	O
tyrosine-phosphorylated	O
p80c-rel	B-protein
is	O
capable	O
of	O
binding	O
to	O
DNA	O
,	O
and	O
G-CSF	B-protein
stimulation	O
results	O
in	O
an	O
increase	O
in	O
the	O
amount	O
of	O
p80c-rel	B-protein
which	O
binds	O
to	O
DNA	O
.	O

These	O
results	O
demonstrate	O
that	O
one	O
of	O
the	O
first	O
biochemical	O
events	O
which	O
occurs	O
in	O
neutrophils	B-cell_type
following	O
G-CSF	B-protein
stimulation	O
,	O
activation	O
of	O
a	O
tyrosine	B-protein
kinase	I-protein
,	O
leads	O
directly	O
to	O
the	O
tyrosine	O
phosphorylation	O
of	O
p80c-rel	B-protein
.	O

Thus	O
,	O
the	O
tyrosine	B-protein
kinase	I-protein
activated	O
by	O
G-CSF	B-protein
appears	O
to	O
directly	O
transduce	O
a	O
signal	O
to	O
a	O
protein	O
which	O
functions	O
as	O
a	O
transcriptional	B-protein
regulator	I-protein
.	O

Patterns	O
of	O
Pan	B-protein
expression	O
and	O
role	O
of	O
Pan	B-protein
proteins	I-protein
in	O
endocrine	O
cell	O
type-specific	O
complex	O
formation	O
.	O

The	O
Pan	B-DNA
gene	I-DNA
encodes	O
at	O
least	O
two	O
distinct	O
transcripts	O
,	O
Pan-1	B-protein
and	O
Pan-2	B-protein
(	O
also	O
known	O
as	O
E47	B-protein
and	O
E12	B-protein
,	O
respectively	O
)	O
,	O
by	O
the	O
mechanism	O
of	O
alternative	O
RNA	O
splicing	O
.	O

Northern	O
blot	O
analyses	O
performed	O
on	O
rat	O
and	O
mouse	O
tissues	O
have	O
detected	O
ubiquitously	O
expressed	O
Pan	O
transcripts	O
,	O
but	O
the	O
abundance	O
,	O
distribution	O
,	O
and	O
form	O
of	O
Pan	B-protein
proteins	I-protein
have	O
not	O
been	O
clearly	O
defined	O
.	O

Studies	O
of	O
cell	B-cell_line
lines	I-cell_line
representing	O
endocrine	B-cell_type
,	I-cell_type
fibroblast	I-cell_type
,	I-cell_type
and	I-cell_type
lymphoid	I-cell_type
lineages	I-cell_type
using	O
polyclonal	O
antisera	O
to	O
detect	O
E2A	B-protein
proteins	I-protein
have	O
suggested	O
that	O
significant	O
E2A	B-protein
protein	I-protein
expression	O
is	O
restricted	O
to	O
B-lymphocytes	B-cell_type
.	O

We	O
have	O
developed	O
a	O
monoclonal	B-protein
antibody	I-protein
,	O
Yae	B-protein
,	O
which	O
is	O
specific	O
for	O
Pan/E2A	B-protein
proteins	I-protein
,	O
and	O
have	O
used	O
the	O
Yae	B-protein
antibody	I-protein
to	O
examine	O
a	O
variety	O
of	O
endocrine	B-cell_type
and	I-cell_type
nonendocrine	I-cell_type
cell	I-cell_type
lineages	I-cell_type
for	O
differences	O
in	O
Pan/	O
E2A	B-protein
protein	I-protein
expression	O
,	O
subcellular	O
localization	O
,	O
and	O
heteromeric	O
complex	O
formation	O
.	O

In	O
contrast	O
to	O
previous	O
results	O
obtained	O
using	O
polyclonal	O
antiseras	O
to	O
detect	O
Pan/	O
E2A	B-protein
proteins	I-protein
,	O
we	O
report	O
comparable	O
levels	O
of	O
Pan	B-protein
proteins	I-protein
in	O
GH/PRL-	B-cell_line
and	I-cell_line
insulin-producing	I-cell_line
,	I-cell_line
B-	I-cell_line
and	I-cell_line
T-lymphocyte	I-cell_line
cells	I-cell_line
.	O

IEF-1	B-protein
,	O
a	O
pancreatic	O
beta-cell	O
type-specific	O
complex	O
believed	O
to	O
regulate	O
insulin	O
expression	O
,	O
is	O
demonstrated	O
to	O
consist	O
of	O
at	O
least	O
two	O
distinct	O
species	O
,	O
one	O
of	O
which	O
does	O
not	O
contain	O
Pan	B-protein
molecules	I-protein
.	O

Although	O
it	O
has	O
been	O
postulated	O
that	O
pituitary	B-cell_type
endocrine	I-cell_type
cells	I-cell_type
and	O
pancreatic	B-cell_type
endocrine	I-cell_type
beta-cells	I-cell_type
share	O
identical	O
Pan/E2A	B-protein
complexes	I-protein
,	O
native-Western	O
analyses	O
of	O
pituitary	O
and	O
endocrine	B-cell_type
beta-cells	I-cell_type
detect	O
Pan	B-protein
proteins	I-protein
in	O
distinct	O
cell	B-protein
type-specific	I-protein
complexes	I-protein
.	O

Visualization	O
of	O
the	O
endogenous	B-protein
NF-kappa	I-protein
B	I-protein
p50	I-protein
subunit	I-protein
in	O
the	O
nucleus	O
of	O
follicular	B-cell_type
dendritic	I-cell_type
cells	I-cell_type
in	O
germinal	O
centers	O
.	O

NF-kappa	B-protein
B	I-protein
,	O
a	O
50	B-protein
kDa/65	I-protein
kDa	I-protein
(	I-protein
p50/p65	I-protein
)	I-protein
heterodimer	I-protein
,	O
is	O
a	O
ubiquitous	B-protein
transcription	I-protein
factor	I-protein
involved	O
in	O
the	O
positive	O
regulation	O
of	O
various	O
immune	B-DNA
genes	I-DNA
.	O

